PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Foot, P				Foot, P			A new definition	BRITISH MEDICAL JOURNAL			English	Article											Foot, P (corresponding author), 6 Carlisle St, London W1D 3BN, England.								0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1576	1576		10.1136/bmj.321.7276.1576/a	http://dx.doi.org/10.1136/bmj.321.7276.1576/a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124185				2022-12-28	WOS:000166134500022
J	Michler, P; Kiraz, A; Becher, C; Schoenfeld, WV; Petroff, PM; Zhang, LD; Hu, E; Imamoglu, A				Michler, P; Kiraz, A; Becher, C; Schoenfeld, WV; Petroff, PM; Zhang, LD; Hu, E; Imamoglu, A			A quantum dot single-photon turnstile device	SCIENCE			English	Article							FLUORESCENCE; STATES	Quantum communication relies on the availability of Light pulses with strong quantum correlations among photons. An example of such an optical source is a single-photon pulse with a vanishing probability for detecting two or more photons. Using pulsed laser excitation of a single quantum dot, a single-photon turnstile device that generates a train of single-photon pulses was demonstrated. For a spectrally isolated quantum dot, nearly 100% of the excitation pulses Lead to emission of a single photon, yielding an ideal single-photon source.	Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Sabanci Univ, TR-81474 Istanbul, Turkey	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Sabanci University	Imamoglu, A (corresponding author), Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA.	atac@ece.ucsb.edu	Becker, Jonas/GZG-4234-2022; Kiraz, Alper/H-9608-2012; Becher, Christoph/AAE-8756-2020; Kiraz, Alper/O-1805-2019; Hu, Evelyn/AAD-8459-2019; Petroff, Pierre/M-9840-2019	Kiraz, Alper/0000-0001-7977-1286; Becher, Christoph/0000-0003-4645-6882; Kiraz, Alper/0000-0001-7977-1286; Schoenfeld, Winston/0000-0003-4008-0458; Michler, Peter/0000-0002-2949-2462				BASCHE T, 1992, PHYS REV LETT, V69, P1516, DOI 10.1103/PhysRevLett.69.1516; BECHER C, UNPUB; Bennett CH., 1984, P IEEE INT C COMP SY, P175; Brouri R, 2000, OPT LETT, V25, P1294, DOI 10.1364/OL.25.001294; Brunel C, 1999, PHYS REV LETT, V83, P2722, DOI 10.1103/PhysRevLett.83.2722; Dekel E, 2000, PHYS REV B, V62, P11038, DOI 10.1103/PhysRevB.62.11038; DIEDRICH F, 1987, PHYS REV LETT, V58, P203, DOI 10.1103/PhysRevLett.58.203; Garcia JM, 1998, APPL PHYS LETT, V72, P3172, DOI 10.1063/1.121583; Gerard JM, 1999, J LIGHTWAVE TECHNOL, V17, P2089, DOI 10.1109/50.802999; HANBURYBROWN R, 1956, NATURE, V178, P1447; IMAMOGLU A, 1994, PHYS REV LETT, V72, P210, DOI 10.1103/PhysRevLett.72.210; Imamoglu A, 1997, PHYS REV LETT, V79, P1467, DOI 10.1103/PhysRevLett.79.1467; Kim J, 1999, NATURE, V397, P500, DOI 10.1038/17295; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; Kurtsiefer C, 2000, PHYS REV LETT, V85, P290, DOI 10.1103/PhysRevLett.85.290; Lounis B, 2000, NATURE, V407, P491, DOI 10.1038/35035032; Michler P, 2000, NATURE, V406, P968, DOI 10.1038/35023100; Michler P, 2000, APPL PHYS LETT, V77, P184, DOI 10.1063/1.126918; PURCELL EM, 1946, PHYS REV, V69, P681; Raymond S, 1996, PHYS REV B, V54, P11548, DOI 10.1103/PhysRevB.54.11548; Walls D. F., 1994, QUANTUM OPT; [No title captured]	23	2051	2100	19	484	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	2000	290	5500					2282	2285		10.1126/science.290.5500.2282	http://dx.doi.org/10.1126/science.290.5500.2282			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125136				2022-12-28	WOS:000165995800036
J	Veenstra, GJC; Weeks, DL; Wolffe, AP				Veenstra, GJC; Weeks, DL; Wolffe, AP			Distinct roles for TBP and TBP-like factor in early embryonic gene transcription in Xenopus	SCIENCE			English	Article							MAJOR DEVELOPMENTAL TRANSITION; BOX-BINDING PROTEIN; MIDBLASTULA TRANSITION; EXPRESSION; EMBRYOGENESIS; LAEVIS	The TATA-binding protein (TBP) is believed to function as a key component of the general transcription machinery. We tested the role of TBP during the onset of embryonic transcription by antisense oligonucleotide-mediated turnover of maternal TBP messenger RNA. Embryos without detectable TBP initiated gastrulation but died before completing gastrulation. The expression of many genes transcribed by RNA polymerase II and III was reduced: however, some genes were transcribed with an efficiency identical to that of TBP-containing embryos. Using a similar antisense strategy, we found that the TBP-Like factor TLF/TRF2 is essential for development past the mid-blastula stage. Because TBP and a TLF factor play complementary roles in embryonic development, our results indicate that although similar mechanistic roles exist in common. TBP and TLF function differentially to control transcription of specific genes.	NICHHD, Mol Embryol Lab, Bethesda, MD 20892 USA; NICHHD, Mol Genet Lab, Bethesda, MD 20892 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Sangamo Biosci, Richmond, CA 94804 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Iowa; Sangamo Therapeutics, Inc.	Veenstra, GJC (corresponding author), NICHHD, Mol Embryol Lab, Bethesda, MD 20892 USA.		Weeks, Daniel/F-6216-2010; Veenstra, Gert Jan C./D-4963-2012	Veenstra, Gert Jan C./0000-0002-7787-4940; Weeks, Daniel/0000-0002-4977-2410				ALMOUZNI G, 1995, EMBO J, V14, P1752, DOI 10.1002/j.1460-2075.1995.tb07164.x; Bell P, 1999, EXP CELL RES, V248, P122, DOI 10.1006/excr.1999.4411; Dagle JM, 2000, NUCLEIC ACIDS RES, V28, P2153, DOI 10.1093/nar/28.10.2153; Dagle JM, 2000, METHOD ENZYMOL, V313, P420; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; Dantonel JC, 1999, TRENDS BIOCHEM SCI, V24, P335, DOI 10.1016/S0968-0004(99)01436-X; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; JAMRICH M, 1987, GENE DEV, V1, P124, DOI 10.1101/gad.1.2.124; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; KRIECHBAUM M, 1988, SUPERLATTICE MICROST, V5, P93, DOI 10.1016/0749-6036(89)90074-8; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; Moore PA, 1999, MOL CELL BIOL, V19, P7610; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Sible JC, 1997, DEV BIOL, V189, P335, DOI 10.1006/dbio.1997.8683; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; Takada S, 2000, CELL, V101, P459, DOI 10.1016/S0092-8674(00)80857-0; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; VEENSTRA GJC, UNPUB	25	109	113	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2312	+		10.1126/science.290.5500.2312	http://dx.doi.org/10.1126/science.290.5500.2312			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125147				2022-12-28	WOS:000165995800047
J	Kristensen, I; Aaby, P; Jensen, H				Kristensen, I; Aaby, P; Jensen, H			Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa	BRITISH MEDICAL JOURNAL			English	Article							CALMETTE-GUERIN THERAPY; MEASLES VACCINATION; EDMONSTON-ZAGREB; RANDOMIZED TRIAL; MORTALITY; BCG; IMMUNIZATION; PROTECTION; PERTUSSIS; VACCINES	Objective To examine the association between routine childhood vaccinations and survival among infants in Guinea-Bissau. Design Follow up study. Participants 15 351 women and their children born during 1990 and 1996. Setting Rural Guinea-Bissau. Main outcome measures Infant mortality over sh months (between age 0-6 months and 7-13 months for BCG; diphtheria, tetanus, and pertussis; and polio vaccines and between 7-13 months and 14-20 months for measles vaccine). Results Mortality was lower in the group vaccinated with any vaccine compared with those not vaccinated, the mortality ratio being 0.74 (95% confidence interval 0.53 to 1.03). After cluster, age, and other vaccines were adjusted for, BCG was associated with significantly lower mortality ratio (0.55 (0.36 to 0.85)). However, recipients of one dose of diphtheria, tetanus, and pertussis or polio vaccines had higher mortality than children who had received none of these vaccines (1.84 (1.10 to 3.10) for diphtheria, tetanus, and pertussis). Recipients of measles vaccine had a mortality ratio of 0.18 (0.27 to 0.87). When deaths from measles were excluded from the analysis the mortality ratio was 0.51 (0.28 to 0.95). Estimates were unchanged by controls for background factors. Conclusions These trends are unlikely to be explained exclusively by selection biases since different vaccines were associated with opposite tendencies. Measles and BCG vaccines may have beneficial effects in addition to protection against measles and tuberculosis.	Statens Serum Inst, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen, Denmark; Bandim Hlth Project, Bissau, Guinea Bissau	Aarhus University; Statens Serum Institut	Aaby, P (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen, Denmark.			Aaby, Peter/0000-0001-8331-1389				AABY P, 1993, BRIT MED J, V307, P1308, DOI 10.1136/bmj.307.6915.1308; Aaby P, 1996, T ROY SOC TROP MED H, V90, P326, DOI 10.1016/S0035-9203(96)90275-8; AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4; Cox D. R., 1984, ANAL SURVIVAL DATA; Diggle PJ, 1994, ANAL LONGITUDINAL DA; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347; HERR HW, 1995, J CLIN ONCOL, V13, P1404, DOI 10.1200/JCO.1995.13.6.1404; Hoj L, 1999, INT J EPIDEMIOL, V28, P70, DOI 10.1093/ije/28.1.70; Ivanoff B, 1997, DEV BIOL STAND, V89, P3; JAMISON DT, 1993, DIS CONTROL PRIORITI, P117; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; Lindblad EB, 1997, INFECT IMMUN, V65, P623, DOI 10.1128/IAI.65.2.623-629.1997; LUGOSI L, 1992, TUBERCLE LUNG DIS, V73, P252, DOI 10.1016/0962-8479(92)90129-8; Marchant A, 1999, J IMMUNOL, V163, P2249; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; NIOBEY FML, 1992, REV SAUDE PUBL, V26, P229, DOI 10.1590/S0034-89101992000400004; RAMSAY MEB, 1993, LANCET, V342, P203, DOI 10.1016/0140-6736(93)92298-8; RAVAUD A, 1990, J CLIN ONCOL, V8, P608, DOI 10.1200/JCO.1990.8.4.608; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; ROSENTHAL SR, 1988, AM J SURG, V156, P1, DOI 10.1016/S0002-9610(88)80158-2; United Nations Children's Fund, 1998, STAT WORLDS CHILDR 1; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474; *WHO, 1996, STAT WORLDS VACC IMM; Zochetti C, 1995, INT J EPIDEMIOL, V24, P1064	28	300	301	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1435	+		10.1136/bmj.321.7274.1435	http://dx.doi.org/10.1136/bmj.321.7274.1435			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110734	Green Published, Bronze			2022-12-28	WOS:000165852300023
J	Bennett, M; Ryall, N				Bennett, M; Ryall, N			Using the modified Barthel index to estimate survival in cancer patients in hospice: observational study	BRITISH MEDICAL JOURNAL			English	Article							KARNOFSKY		Rheumatol & Res Unit, Leeds LS2 9NZ, W Yorkshire, England; St Gemmas Hospice, Leeds LS17 6QD, W Yorkshire, England		Bennett, M (corresponding author), St Gemmas Hospice, Leeds LS17 6QD, W Yorkshire, England.		Bennett, Michael I/A-1620-2009	Bennett, Michael I/0000-0002-8369-8349				EVANS C, 1985, LANCET, V1, P1204; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Tennant A, 1996, CLIN REHABIL, V10, P301, DOI DOI 10.1177/026921559601000407; YATES JW, 1980, CANCER, V45, P2220, DOI 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q	4	42	44	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1381	1382		10.1136/bmj.321.7273.1381	http://dx.doi.org/10.1136/bmj.321.7273.1381			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099282	Green Published			2022-12-28	WOS:000165720100025
J	Lundgren, M; Chow, CM; Sabbattini, P; Georgiou, A; Minaee, S; Dillon, N				Lundgren, M; Chow, CM; Sabbattini, P; Georgiou, A; Minaee, S; Dillon, N			Transcription factor dosage affects changes in higher order chromatin structure associated with activation of a heterochromatic gene	CELL			English	Article							POSITION-EFFECT VARIEGATION; SURROGATE LIGHT-CHAIN; LOCUS-CONTROL REGION; B-CELL FACTOR; CENTROMERIC HETEROCHROMATIN; DROSOPHILA; EXPRESSION; EBF; ORGANIZATION; CHROMOSOMES	The mechanisms of transcriptional activation in heterochromatin were investigated by using FISH to directly visualize changes in chromatin organization during activation of a heterochromatic lambda5 transgene. A DNase I hypersensitive site was shown to relocate the transgene to the outside of the pericentromeric heterochromatin complex in the absence of transcription. Activation of transcription, which is dependent on the transcription factor EBF, occurs in a stochastic manner that resembles telomeric silencing in yeast, with the transcribed gene remaining closely associated with the heterochromatin complex. Reducing the dosage of EBF results in a reduced frequency of localization of the transgene to the outside of the heterochromatin complex and lower levels of transcription. These data provide evidence that transcription factors can initiate changes in higher order chromatin structure during the earliest stages of gene activation.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Clin Sci Ctr,Gene Regulat & Chromatin Grp,MRC, London W12 0NN, England	Imperial College London	Dillon, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Clin Sci Ctr,Gene Regulat & Chromatin Grp,MRC, London W12 0NN, England.	niall.dillon@csc.mrc.ac.uk						BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Belmont AS, 1999, CURR OPIN CELL BIOL, V11, P307, DOI 10.1016/S0955-0674(99)80041-6; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; Brockdorff N, 1998, CURR OPIN GENET DEV, V8, P328, DOI 10.1016/S0959-437X(98)80090-7; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; DILLON N, 1993, GENE TRANSCRIPTION P, P1523; EISSENBERG JC, 1995, CHROMATIN STRUCTURE, P147; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Heitz E., 1928, JAHRB WISS BOT, V69, P762; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; Henikoff S, 1996, BIOESSAYS, V18, P401, DOI 10.1002/bies.950180510; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; LOCKE J, 1988, GENETICS, V120, P181; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; Sabbattini P, 1999, MOL CELL BIOL, V19, P671; Schubeler D, 2000, GENE DEV, V14, P940; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Spector D. L., 1998, CELLS LAB MANUAL; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; Talbert PB, 2000, GENETICS, V154, P259; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239; Zucker-Franklin D, 1988, ATLAS BLOOD CELLS FU	48	109	111	1	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 22	2000	103	5					733	743		10.1016/S0092-8674(00)00177-X	http://dx.doi.org/10.1016/S0092-8674(00)00177-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114330	Bronze			2022-12-28	WOS:000165433100006
J	Haramburu, F; Miremont-Salame, G; Moore, K				Haramburu, F; Miremont-Salame, G; Moore, K			Good and bad drug prescription in pregnancy	LANCET			English	Editorial Material									Univ Victor Segalen, CHU Pellegrin Carriere, Dept Pharmacol, F-33076 Bordeaux, France	CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Moore, K (corresponding author), Univ Victor Segalen, CHU Pellegrin Carriere, Dept Pharmacol, F-33076 Bordeaux, France.		Miremont-Salame, Ghada/T-2055-2019					BERTHIER M, 1993, THERAPIE, V48, P43; BOETHIUS G, 1977, EUR J CLIN PHARMACOL, V12, P37, DOI 10.1007/BF00561403; BONATI M, 1990, EUR J CLIN PHARMACOL, V38, P325, DOI 10.1007/BF00315569; BROCKLEBANK JC, 1978, AM J OBSTET GYNECOL, V132, P235, DOI 10.1016/0002-9378(78)90887-6; HARAMBURU F, 1995, PHARMACOEPIDEM DR S, V4, pS74; PIPER JM, 1987, AM J OBSTET GYNECOL, V157, P148, DOI 10.1016/S0002-9378(87)80368-X; Wiebe S, 2000, BMJ-BRIT MED J, V320, P3, DOI 10.1136/bmj.320.7226.3; WOOLF SH, 1993, JAMA-J AM MED ASSOC, V270, P2846	8	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1704	1704		10.1016/S0140-6736(00)03202-5	http://dx.doi.org/10.1016/S0140-6736(00)03202-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095256				2022-12-28	WOS:000165462300007
J	Mogensen, CE; Neldam, S; Tikkanen, I; Oren, S; Viskoper, R; Watts, RW; Cooper, ME				Mogensen, CE; Neldam, S; Tikkanen, I; Oren, S; Viskoper, R; Watts, RW; Cooper, ME		CALM study grp	Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and Lisinopril microalbuminuria (CALM) study	BRITISH MEDICAL JOURNAL			English	Article							CONVERTING ENZYME-INHIBITION; NORMOTENSIVE PATIENTS; RECEPTOR BLOCKADE; BLOOD-PRESSURE; NEPHROPATHY; LOSARTAN; COMPLICATIONS; POLYMORPHISM; PREVENTION; MANAGEMENT	Objectives To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes. Design Prospective, randomised, parallel group, double blind study with four week placebo run in period and 12 weeks' monotherapy with candesartan or lisinopril followed by 12 weeks' monotherapy or combination treatment Setting Tertiary hospitals and primary care centres in four countries (37 centres). Participants 199 patients aged 30-75 years. Interventions Candesartan 16 mp; once daily, lisinopril 20 mg once daily. Main outcome measures Blood pressure and urinary albumin:creatinine ratio. Results At 12 creeks mean (95% confidence interval) reductions in diastolic blood pressure were 9.5 mm Hg (7.7 mm Hg to 11.2 mm Hg, P < 0.002) and 9.7 mm Hg (7.9 mm Hg to 115 mm Hg, P < 0.001), respectively, and in urinary albumin:creatinine ratio were 30% (15% to 42%, P < 0.001) and 46% (35% to 56%, P < 0.001) for candesartan and lisinopril, respectively. At 24 weeks the mean reduction in diastolic blood pressure with combination treatment (16.3 mm Hg, 13.6 mm Hg to 18.9 mm Hg, P < 0.001) was significantly greater than that with candesartan (10.4 mm Hg, 7.7 mm Hg to 13.1 mm Hg, P < 0.001) or lisinopril (mean 10.7 mm Hg. 8.0 nun Hg to 13.5 mm Hg, P < 0.001). Furthermore, the reduction in urinary albumin:creatinine ratio with combination treatment (50%, 36% to 61%, P<0.001) was greater than with candesartan (24%, 0% to 43%, P = 0.05) and lisinopril (39%, 20% to 54%, P < 0.001). All treatments were generally well tolerated. Conclusion Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes. Combination treatment is well tolerated and more effective in reducing blood pressure.	Aarhus Univ Hosp, Kommunehosp, Dept Med M, DK-8000 Aarhus C, Denmark; Univ Helsinki Hosp, Clin Internal Dis, FIN-00029 Hyks, Finland; Barzilai Med Ctr, Ashkelon, Israel; Univ Melbourne, Dept Med, W Heidelberg, Vic 3084, Australia	Aarhus University; University of Helsinki; Helsinki University Central Hospital; Ben Gurion University; Barzilai Medical Center; University of Melbourne	Mogensen, CE (corresponding author), Aarhus Univ Hosp, Kommunehosp, Dept Med M, DK-8000 Aarhus C, Denmark.		Cooper, Mark E/E-8680-2010; Cooper, Mark/AAC-5326-2020	Cooper, Mark E/0000-0002-5953-642X; 				Agardh CD, 1996, J HUM HYPERTENS, V10, P185; Allen TJ, 1997, DIABETES, V46, P1612, DOI 10.2337/diabetes.46.10.1612; Azizi M, 1997, HYPERTENSION, V29, P634, DOI 10.1161/01.HYP.29.2.634; AZIZI M, 1995, CIRCULATION, V92, P825, DOI 10.1161/01.CIR.92.4.825; BADENHOP RF, 1995, CIRCULATION, V91, P1655, DOI 10.1161/01.CIR.91.6.1655; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Black HR, 1997, ARCH INTERN MED, V157, P2413; Chalmers J, 1999, J HYPERTENS, V17, P151; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; Cooper ME, 1998, LANCET, V352, P213, DOI 10.1016/S0140-6736(98)01346-4; Demeilliers B, 1998, J HYPERTENS, V16, P1023, DOI 10.1097/00004872-199816070-00017; Gerstein HC, 2000, LANCET, V355, P253; Goa KL, 1997, DRUGS, V53, P1081, DOI 10.2165/00003495-199753060-00010; Hamroff G, 1999, CIRCULATION, V99, P990, DOI 10.1161/01.CIR.99.8.990; Hebert LA, 1999, AM J NEPHROL, V19, P1, DOI 10.1159/000013417; Hollenberg NK, 1998, HYPERTENSION, V32, P387, DOI 10.1161/01.HYP.32.3.387; JOHNSTON CI, 1995, LANCET, V346, P1403, DOI 10.1016/S0140-6736(95)92411-6; KOMERS R, 1995, AM J PHYSIOL-RENAL, V268, pF588, DOI 10.1152/ajprenal.1995.268.4.F588; Marre M, 1997, J CLIN INVEST, V99, P1585, DOI 10.1172/JCI119321; Mathiesen ER, 1999, BRIT MED J, V319, P24, DOI 10.1136/bmj.319.7201.24; McClellan KJ, 1998, DRUGS, V56, P847, DOI 10.2165/00003495-199856050-00013; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Parving HH, 1996, BRIT MED J, V313, P591; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; Ritz E, 1999, J INTERN MED, V245, P111, DOI 10.1046/j.1365-2796.1999.00411.x; Ruilope LM, 2000, J HYPERTENS, V18, P89, DOI 10.1097/00004872-200018010-00013; Russo D, 1999, AM J KIDNEY DIS, V33, P851, DOI 10.1016/S0272-6386(99)70416-6; Schmitt F, 1996, CLIN SCI, V90, P205, DOI 10.1042/cs0900205; Sever PS, 1997, J HYPERTENS, V15, pS9, DOI 10.1097/00004872-199715066-00003	30	716	766	0	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1440	1444		10.1136/bmj.321.7274.1440	http://dx.doi.org/10.1136/bmj.321.7274.1440			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110735	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000165852300025
J	Forte, AM; Perry, HKC				Forte, AM; Perry, HKC			Geodynamic evidence for a chemically depleted continental tectosphere	SCIENCE			English	Article							SEISMIC TOMOGRAPHY; THERMAL STRUCTURE; MANTLE; ROOTS; HETEROGENEITY; ANOMALIES; THICKNESS	The tectosphere, namely the portions of Earth's mantle Lying below cratons, has a thermochemical structure that differs from average suboceanic mantle. The tectosphere is thought to be depleted in its basaltic components and to have an intrinsic buoyancy that balances the mass increase associated with its colder temperature relative to suboceanic mantle. Inversions of a large set of geodynamic data related to mantle convection, using tomography-based mantle flow models, indicate that the tectosphere is chemically depleted and relatively cold to 250 kilometers depth below Earth's surface. The approximate equilibrium between thermal and chemical buoyancy contributes to cratonic stability over geological time.	Univ Western Ontario, Dept Earth Sci, London, ON N6A 5B7, Canada	Western University (University of Western Ontario)	Forte, AM (corresponding author), Univ Western Ontario, Dept Earth Sci, London, ON N6A 5B7, Canada.			Forte, Alessandro/0000-0002-3530-0455				ANDERSON DL, 1987, J GEOPHYS RES-SOLID, V92, P13968, DOI 10.1029/JB092iB13p13968; Bijwaard H, 1998, J GEOPHYS RES-SOL EA, V103, P30055, DOI 10.1029/98JB02467; CHOPELAS A, 1991, J GEOPHYS RES-SOLID, V96, P11817, DOI 10.1029/91JB00898; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; Doin MP, 1996, J GEOPHYS RES-SOL EA, V101, P16119, DOI 10.1029/96JB00640; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; Finnerty A.A., 1987, MANTLE XENOLITHS, P381; FORTE AM, 1995, PHYS EARTH PLANET IN, V92, P45, DOI 10.1016/0031-9201(95)03060-A; FORTE AM, 1993, GEOPHYS RES LETT, V20, P225, DOI 10.1029/93GL00249; FORTE AM, 2000, GEOPHYS MONOGR SER, V117, P3, DOI DOI 10.1029/GM117P0003; Grand SP., 1997, GSA TODAY, V7, P1; GWINN CR, 1986, J GEOPHYS RES-SOLID, V91, P4755, DOI 10.1029/JB091iB05p04755; HAGER BH, 1989, MANTLE CONVECTION, P657; Jaupart C, 1999, LITHOS, V48, P93, DOI 10.1016/S0024-4937(99)00023-7; Jordan T. H., 1979, MANTLE SAMPLE INCLUS, P1, DOI DOI 10.1029/SP016P0001; JORDAN TH, 1981, PHILOS T R SOC A, V301, P359, DOI 10.1098/rsta.1981.0117; JORDAN TH, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i003p00001; JORDAN TH, 1978, NATURE, V274, P544, DOI 10.1038/274544a0; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; MARSH JG, 1990, J GEOPHYS RES-SOLID, V95, P22043, DOI 10.1029/JB095iB13p22043; MATHEWS P, 1999, EOS S, V80, P19; Mooney WD, 1998, J GEOPHYS RES-SOL EA, V103, P727, DOI 10.1029/97JB02122; Pari G, 2000, J GEOPHYS RES-SOL EA, V105, P5635, DOI 10.1029/1999JB900349; Rohm AHE, 2000, EARTH PLANET SC LETT, V181, P395, DOI 10.1016/S0012-821X(00)00209-0; Rudnick RL, 1998, CHEM GEOL, V145, P395, DOI 10.1016/S0009-2541(97)00151-4; Shapiro SS, 1999, LITHOS, V48, P115, DOI 10.1016/S0024-4937(99)00025-0; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; Turcotte D., 2014, GEODYNAMICS, V3rd edn.; WOODHOUSE J, 1995, EOS T AM GEOPHYS UN, V76, P422	29	126	130	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1940	1944		10.1126/science.290.5498.1940	http://dx.doi.org/10.1126/science.290.5498.1940			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110656				2022-12-28	WOS:000165810000039
J	Berger, A				Berger, A			Doctors question new test for Down's syndrome	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1366	1366		10.1136/bmj.321.7273.1366/b	http://dx.doi.org/10.1136/bmj.321.7273.1366/b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099274				2022-12-28	WOS:000165720100009
J	Hernandez-Diaz, S; Werler, MM; Walker, AM; Mitchell, AA				Hernandez-Diaz, S; Werler, MM; Walker, AM; Mitchell, AA			Folic acid antagonists during pregnancy and the risk of birth defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERICONCEPTIONAL MULTIVITAMIN USE; CONOTRUNCAL HEART-DEFECTS; ANTICONVULSANT DRUGS; OROFACIAL CLEFTS; URINARY-TRACT; SUPPLEMENTATION	Background: Multivitamin supplementation in pregnant women may reduce the risks of cardiovascular defects, oral clefts, and urinary tract defects in their infants. We evaluated whether the folic acid component of multivitamins is responsible for the reduction in risk by examining the associations between maternal use of folic acid antagonists and these congenital malformations. Methods: We assessed exposure to folic acid antagonists that act as dihydrofolate reductase inhibitors and to certain antiepileptic drugs in 3870 infants with cardiovascular defects, 1962 infants with oral clefts, and 1100 infants with urinary tract defects and also in 8387 control infants with malformations the risk of which is not reduced after vitamin supplementation. Mothers were interviewed within six months after delivery about their medication use during pregnancy. Results: The relative risks of cardiovascular defects and oral clefts in infants whose mothers were exposed to dihydrofolate reductase inhibitors during the second or third month after the last menstrual period, as compared with infants whose mothers had no such exposure, were 3.4 (95 percent confidence interval, 1.8 to 6.4) and 2.6 (95 percent confidence interval, 1.1 to 6.1), respectively. The relative risks of cardiovascular defects, oral clefts, and urinary tract defects after maternal exposure to antiepileptic drugs were 2.2 (95 percent confidence interval, 1.4 to 3.5), 2.5 (95 percent confidence interval, 1.5 to 4.2), and 2.5 (95 percent confidence interval, 1.2 to 5.0), respectively. Use of multivitamin supplements containing folic acid diminished the adverse effects of dihydrofolate reductase inhibitors, but not that of antiepileptic drugs. Conclusions: Folic acid antagonists, which include such common drugs as trimethoprim, triamterene, carbamazepine, phenytoin, phenobarbital, and primidone, may increase the risk not only of neural-tube defects, but also of cardiovascular defects, oral clefts, and urinary tract defects. The folic acid component of multivitamins may reduce the risks of these defects. (N Engl J Med 2000;343:1608-14.) (C) 2000, Massachusetts Medical Society.	Boston Univ, Sch Publ Hlth, Slone Epidemiol Unit, Brookline, MA 02446 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Boston University; Harvard University; Harvard T.H. Chan School of Public Health	Hernandez-Diaz, S (corresponding author), Boston Univ, Sch Publ Hlth, Slone Epidemiol Unit, 1371 Beacon St, Brookline, MA 02446 USA.			Mitchell, Allen/0000-0003-0950-6799; Werler, Martha/0000-0003-3392-6814	NHLBI NIH HHS [HL50763] Funding Source: Medline; NICHD NIH HHS [HD27697] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027697] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Botto LD, 1996, PEDIATRICS, V98, P911; BRIGGS GG, 1998, DRUGS PREGNANCY LACT; CZEIZEL A, 1990, REPROD TOXICOL, V4, P305, DOI 10.1016/0890-6238(90)90042-T; Czeizel AE, 1996, TERATOLOGY, V53, P345, DOI 10.1002/(SICI)1096-9926(199606)53:6&lt;345::AID-TERA5&gt;3.0.CO;2-Z; Czeizel AE, 1996, AM J MED GENET, V62, P179, DOI 10.1002/(SICI)1096-8628(19960315)62:2<179::AID-AJMG12>3.0.CO;2-L; FINNELL RH, 1997, HANDB EXP PHARM II, V124, P121; HERNANDEZDIAZ S, IN PRESS AM J EPIDEM; KALLEN B, 1989, EUR J EPIDEMIOL, V5, P31, DOI 10.1007/BF00145041; LAMBIE DG, 1985, DRUGS, V30, P145, DOI 10.2165/00003495-198530020-00003; LI DK, 1995, EPIDEMIOLOGY, V6, P212, DOI 10.1097/00001648-199505000-00004; Mitchell A., 2002, PHARMACOEPIDEMIOLOGY, VThird Edition, P749, DOI [10.1002/0470842555.ch42, DOI 10.1002/0470842555.CH42]; MITCHELL AA, 1981, JAMA-J AM MED ASSOC, V245, P2311; MITCHELL AA, 1986, AM J EPIDEMIOL, V123, P670, DOI 10.1093/oxfordjournals.aje.a114286; ROSA FW, 1991, NEW ENGL J MED, V324, P674, DOI 10.1056/NEJM199103073241006; SHAW GM, 1995, LANCET, V346, P393, DOI 10.1016/S0140-6736(95)92778-6; SHAW GM, 1995, AM J MED GENET, V59, P536, DOI 10.1002/ajmg.1320590428; Smulders YM, 1999, LANCET, V353, P758; Smulders YM, 1998, LANCET, V352, P1827, DOI 10.1016/S0140-6736(05)79890-1; STEBBINS R, 1973, SEMIN HEMATOL, V10, P235; TOLAROVA M, 1995, TERATOLOGY, V51, P71, DOI 10.1002/tera.1420510205; Torchia, 1998, DEV HUMAN CLIN ORIEN; WALD N, 1991, LANCET, V338, P131; Werler MM, 1999, AM J EPIDEMIOL, V150, P675, DOI 10.1093/oxfordjournals.aje.a010070; Yang QH, 1997, EPIDEMIOLOGY, V8, P157, DOI 10.1097/00001648-199703000-00006	25	484	510	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1608	1614		10.1056/NEJM200011303432204	http://dx.doi.org/10.1056/NEJM200011303432204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096168				2022-12-28	WOS:000165511000004
J	Watanabe, Y; Martini, JEJ; Ohmoto, H				Watanabe, Y; Martini, JEJ; Ohmoto, H			Geochemical evidence for terrestrial ecosystems 2.6 billion years ago	NATURE			English	Article							SOUTH-AFRICA; PALEOSOLS; SEDIMENTS; GREENLAND; EVOLUTION; GRAPHITE; ROCKS; BIOTA; LAND; LIFE	Microorganisms have flourished in the oceans since at least 3.8 billion years (3.8 Gyr) ago(1,2), but it is not at present clear when they first colonized the land. Organic matter in some Au/U-rich conglomerates and ancient soils of 2.3-2.7 Gyr age has been suggested as remnants of terrestrial organisms(3-5). Some 2.7-Gyr-old stromatolites have also been suggested as structures created by terrestrial organisms(6-7). However, it has been disputed whether this organic matter is indigenous or exogenic, and whether these stromatolites formed in marine or fresh water. Consequently, the oldest undisputed remnants of terrestrial organisms are currently the 1.2-Gyr-old microfossils from Arizona, USA(8). Unusually carbonaceous ancient soils-palaeosols-have been found in the Mpumalanga Province (Eastern Transvaal) of South Africa(9). Here we report the occurrences, elemental ratios (C, H, N, P) and isotopic compositions of this organic matter and its host rocks. These data show that the organic matter very probably represents remnants of microbial mats that developed on the soil surface between 2.6 and 2.7 Gyr ago. This places the development of terrestrial biomass more than 1.4 billion years earlier than previously reported.	Penn State Univ, Astrobiol Res Ctr, University Pk, PA 16802 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Tohoku Univ, Fac Sci, Sendai, Miyagi 9808578, Japan; Geol Survey S Africa, Pretoria, South Africa	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Tohoku University	Watanabe, Y (corresponding author), Penn State Univ, Astrobiol Res Ctr, University Pk, PA 16802 USA.	yumiko@essc.psu.edu						Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; BUCK SG, 1980, PRECAMBRIAN RES, V12, P311, DOI 10.1016/0301-9268(80)90033-9; BUICK R, 1992, SCIENCE, V255, P74, DOI 10.1126/science.11536492; CAMPBELL SE, 1979, ORIGINS LIFE EVOL B, V9, P335, DOI 10.1007/BF00926826; Des Marais D.J., 1992, PROTEROZOIC BIOSPHER, P299; Des Marais DJ, 1997, ORG GEOCHEM, V27, P185, DOI 10.1016/S0146-6380(97)00061-2; GAY AL, 1980, PRECAMBRIAN RES, V12, P349, DOI 10.1016/0301-9268(80)90035-2; HALLBAUER D K, 1974, Precambrian Research, V1, P199, DOI 10.1016/0301-9268(74)90010-2; HORODYSKI RJ, 1994, SCIENCE, V263, P494, DOI 10.1126/science.263.5146.494; Luque FJ, 1998, AM J SCI, V298, P471, DOI 10.2475/ajs.298.6.471; MARTINI JEJ, 1994, PRECAMBRIAN RES, V67, P159, DOI 10.1016/0301-9268(94)90009-4; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; Mossman DJ, 1992, EARLY ORGANIC EVOLUT, P67; Naraoka H, 1996, CHEM GEOL, V133, P251, DOI 10.1016/S0009-2541(96)00076-9; NISBET EG, 1995, SPECIAL PUBLICATION, P27; Ohmoto H, 1996, GEOLOGY, V24, P1135, DOI 10.1130/0091-7613(1996)024<1135:EIPGPF>2.3.CO;2; Ohmoto H., 1997, GEOCHEMISTRY HYDROTH, P517; RETTALLACK GJ, 1990, SOILS PAST INTRO PAL; Rosing MT, 1999, SCIENCE, V283, P674, DOI 10.1126/science.283.5402.674; Ruttenberg KC, 1997, MAR GEOL, V139, P123, DOI 10.1016/S0025-3227(96)00107-7; Strauss H., 1992, PROTEROZOIC BIOSPHER, P709; Wright VP, 1994, NATO ADV SCI INST SE, V453, P95; [No title captured]	23	156	161	1	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					574	578		10.1038/35046052	http://dx.doi.org/10.1038/35046052			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117742				2022-12-28	WOS:000165548600115
J	Fischer, MB; Roeckl, C; Parizek, P; Schwarz, HP; Aguzzi, A				Fischer, MB; Roeckl, C; Parizek, P; Schwarz, HP; Aguzzi, A			Binding of disease-associated prion protein to plasminogen	NATURE			English	Article							MICE; PRP; ACTIVATOR; EPITOPE; DEATH	Transmissible spongiform encephalopathies are associated with accumulation of PrPSc, a conformer of a cellular protein called PrPC. PrPSc is thought to replicate by imparting its conformation onto PrPC (ref. 1), yet conformational discrimination between PrPC and PrPSc has remained elusive. Because deposition of PrPSc alone is not enough to cause neuropathology(2), PrPSc probably damages the brain by interacting with other cellular constituents. Here we rnd activities in human and mouse blood which bind PrPSc and prion infectivity, but not PrPC. We identify plasminogen, a pro-protease implicated in neuronal excitotoxicity(3,4), as a PrPSc-binding protein. Binding is abolished if the conformation of PrPSc is disrupted by 6M urea or guanidine. The isolated lysine binding site 1 of plasminogen (kringles I-III) retains this binding activity, and binding can be competed for with lysine. Therefore, plasminogen represents the first endogenous factor discriminating between normal and pathological prion protein. This unexpected property may be exploited for diagnostic purposes.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Baxter Hyland Immuno, A-1221 Vienna, Austria	University of Zurich; University Zurich Hospital	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; LEDESMA MD, IN PRESS EMBO REP; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Shibuya S, 1998, LANCET, V351, P419, DOI 10.1016/S0140-6736(05)78358-6; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Zulianello L, 2000, J VIROL, V74, P4351, DOI 10.1128/JVI.74.9.4351-4360.2000	20	183	210	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	2000	408	6811					479	483		10.1038/35044100	http://dx.doi.org/10.1038/35044100			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100730				2022-12-28	WOS:000165429800050
J	Henikoff, S; Vermaak, D				Henikoff, S; Vermaak, D			Bugs on drugs go GAGAA	CELL			English	Review							POSITION EFFECT VARIEGATION; BINDING PROTEINS; GENE-EXPRESSION; DROSOPHILA; DNA; HETEROCHROMATIN; CHROMOSOME		Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Henikoff, S (corresponding author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, 1100 Fairview Ave N, Seattle, WA 98109 USA.	steveh@fhcrc.org		Henikoff, Steven/0000-0002-7621-8685				Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; DIMITRI P, 1989, GENETICS, V122, P793; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; Girard F, 1998, EMBO J, V17, P2079, DOI 10.1093/emboj/17.7.2079; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Janssen S, 2000, MOL CELL, V6, P1013, DOI 10.1016/S1097-2765(00)00100-3; Janssen S, 2000, MOL CELL, V6, P999, DOI 10.1016/S1097-2765(00)00099-X; Platero JS, 1998, J CELL BIOL, V140, P1297; REEVES R, 1990, J BIOL CHEM, V265, P8573; Sachs RK, 2000, TRENDS GENET, V16, P143, DOI 10.1016/S0168-9525(99)01960-5; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wemmer DE, 2000, ANNU REV BIOPH BIOM, V29, P439, DOI 10.1146/annurev.biophys.29.1.439	15	16	16	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					695	698		10.1016/S0092-8674(00)00172-0	http://dx.doi.org/10.1016/S0092-8674(00)00172-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114325	Bronze			2022-12-28	WOS:000165433100002
J	Waddell, S; Armstrong, JD; Kitamoto, T; Kaiser, K; Quinn, WG				Waddell, S; Armstrong, JD; Kitamoto, T; Kaiser, K; Quinn, WG			The amnesiac gene product is expressed in two neurons in the Drosophila brain that are critical for memory	CELL			English	Article							SHORT-TERM-MEMORY; DEPENDENT PROTEIN-KINASE; MUSHROOM BODIES; PRESYNAPTIC FACILITATION; PREFERENTIAL EXPRESSION; CAMP; DOPAMINE; LOCALIZATION; HIPPOCAMPAL; SEROTONIN	Mutations in the amnesiac gene in Drosophila affect both memory retention and ethanol sensitivity. The predicted amnesiac gene product, AMN, is an apparent preproneuropeptide, and previous studies suggest that ii stimulates cAMP synthesis. Here we show that, unlike other learning-related Drosophila proteins, AMN is not preferentially expressed in mushroom bodies. Instead, it is strongly expressed in two large neurons that project over all the robes of the mushroom bodies, a finding that suggests a modulatory role for AMN in memory formation. Genetically engineered blockade of vesicle recycling in these cells abbreviates memory as in the amnesiac mutant. Moreover, restoration of amn gene expression to these cells reestablishes normal olfactory memory in an amn deletion background. These results indicate that AMN neuropeptide release onto the mushroom bodies is critical for normal olfactory memory.	MIT, Dept Brain & Cognit Sci, Ctr Learning & Memory, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Glasgow, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Glasgow; City of Hope; Beckman Research Institute of City of Hope	Waddell, S (corresponding author), MIT, Dept Brain & Cognit Sci, Ctr Learning & Memory, E25-618, Cambridge, MA 02139 USA.	waddell@mit.edu		Kitamoto, Toshihiro/0000-0003-0863-8466; Waddell, Scott/0000-0003-4503-6229; Armstrong, Douglas/0000-0002-5397-3864				ABRAMS TW, 1984, P NATL ACAD SCI-BIOL, V81, P7956, DOI 10.1073/pnas.81.24.7956; Armstrong JD, 1998, LEARN MEMORY, V5, P102; Bainton RJ, 2000, CURR BIOL, V10, P187, DOI 10.1016/S0960-9822(00)00336-5; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; Crittenden JR, 1998, LEARN MEMORY, V5, P38; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DeZazzo J, 1999, J NEUROSCI, V19, P8740, DOI 10.1523/JNEUROSCI.19-20-08740.1999; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; Fox LE, 2000, J NEUROPHYSIOL, V83, P1567, DOI 10.1152/jn.2000.83.3.1567; Fox LE, 1997, J NEUROSCI, V17, P6064; FREY U, 1990, BRAIN RES, V522, P69, DOI 10.1016/0006-8993(90)91578-5; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; HAMMER M, 1995, J NEUROSCI, V15, P1617, DOI 10.1523/JNEUROSCI.15-03-01617.1995; Hammer M, 1998, LEARN MEMORY, V5, P146; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; Harlow E., 1988, ANTIBODIES LAB MANUA; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; Hitier R, 1998, NEUROREPORT, V9, P2717, DOI 10.1097/00001756-199808240-00006; HOOPER SL, 1994, NEUROSCI LETT, V179, P167, DOI 10.1016/0304-3940(94)90960-1; HUANG YH, 1995, SEPAR TECHNOL, V5, P1, DOI 10.1016/0956-9618(94)00102-X; Ito K, 1998, LEARN MEMORY, V5, P52; Iversen L, 2000, MOL PSYCHIATR, V5, P357, DOI 10.1038/sj.mp.4000728; KANDEL E, 1995, SCIENCE, V268, P825, DOI 10.1126/science.7754367; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Li H, 2000, CURR BIOL, V10, P211, DOI 10.1016/S0960-9822(00)00340-7; Liu L, 1999, NATURE, V400, P753, DOI 10.1038/23456; MACKEY SL, 1989, J NEUROSCI, V9, P4227; Matthies H, 1997, NEUROREPORT, V8, P3533, DOI 10.1097/00001756-199711100-00023; McBride SMJ, 1999, NEURON, V24, P967, DOI 10.1016/S0896-6273(00)81043-0; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; MONTAGUE PR, 1995, NATURE, V377, P725, DOI 10.1038/377725a0; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; Otto C, 1999, MOL BRAIN RES, V66, P163, DOI 10.1016/S0169-328X(99)00010-8; Park SK, 2000, J BIOL CHEM, V275, P20588, DOI 10.1074/jbc.M002460200; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; Shioda S, 1997, NEUROSCI RES, V28, P345, DOI 10.1016/S0168-0102(97)00065-5; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAGHERT PH, 1990, J NEUROSCI, V10, P1929; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Vilim FS, 2000, J NEUROSCI, V20, P2036; Wolf R, 1998, LEARN MEMORY, V5, P166; YANG MY, 1995, NEURON, V15, P45; Zars T, 2000, SCIENCE, V288, P672, DOI 10.1126/science.288.5466.672	52	247	253	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					805	813		10.1016/S0092-8674(00)00183-5	http://dx.doi.org/10.1016/S0092-8674(00)00183-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114336	Bronze			2022-12-28	WOS:000165433100012
J	Ellis, W				Ellis, W			At the zoo	NATURE			English	Article																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					295	295		10.1038/35042645	http://dx.doi.org/10.1038/35042645			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099021	Bronze			2022-12-28	WOS:000165296000022
J	Smalley, W; Shatin, D; Wysowski, DK; Gurwitz, J; Andrade, SE; Goodman, M; Chan, KA; Platt, R; Schech, SD; Ray, WA				Smalley, W; Shatin, D; Wysowski, DK; Gurwitz, J; Andrade, SE; Goodman, M; Chan, KA; Platt, R; Schech, SD; Ray, WA			Contraindicated use of cisapride - Impact of food and drug administration regulatory action	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TORSADES-DE-POINTES; CLARITHROMYCIN	Context Cisapride, a gastrointestinal tract promotility agent, can cause life-threatening cardiac arrhythmias in patients susceptible either because of concurrent use of medications that interfere with cisapride metabolism or prolong the QT interval or because of the presence of other diseases that predispose to such arrhythmias. In June 1998, the US Food and Drug Administration (FDA) determined that use of cisapride was contraindicated in such patients and informed practitioners through additions to the boxed warning in the label and a "Dear Health Care Professional" letter sent by the drug's manufacturer. Objective To evaluate the impact of the FDA's 1998 regulatory action regarding contraindicated use of cisapride. Design and Setting Analysis of data for the 1-year periods before (July 1997-June 1998) and after (July 1998-June 1999) the regulatory action from the population-based, pharmacoepidemiology research databases of 2 managed care organizations (sites A and B) and a state Medicaid program (site C). Participants Patients with at least 180 days of prior enrollment in 1 of the 3 sites who were prescribed cisapride at least once in the period before (n = 24840) or after (n = 22459) regulatory action. Patients could be included in both cohorts. Main Outcome Measures Proportion of cisapride users in each period for whom cisapride use was contraindicated by the product label, based on computerized patient medical encounter records. Results In the year prior to regulatory action, cisapride use was contraindicated for 26%, 30%, and 60% of users in study sites A, B, and C, respectively. In the year after regulatory action, use was contraindicated for 24%, 28%, and 58% of users, a reduction in contraindicated use of approximately 2 per 100 cisapride users at each site. When the analysis was restricted to new users of cisapride after regulatory action, only minor reductions in contraindicated use were found. Conclusion The FDA's 1998 regulatory action regarding cisapride use had no material effect on contraindicated cisapride use. More effective ways to communicate new information about drug safety are needed.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; VA Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN USA; Unitedhlth Grp, Ctr Hlth Care Policy & Evaluat, Minnetonka, MN USA; US FDA, Off Postmkt Drug Risk Assessment, Rockville, MD 20857 USA; Univ Massachusetts, Sch Med, Fallon Healthcare Syst, Worcester, MA USA; Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Worcester, MA USA; Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA; Healthpartners Res Fdn, Bloomington, MN USA; Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; US Food & Drug Administration (FDA); University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Rhode Island; Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ray, WA (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Prevent Med, Med Ctr N,A-1124, Nashville, TN 37232 USA.			Chan, Kinwei/0000-0001-8161-1986				*IMS HLTH, 1995, NAT PRESCR AUD PLUS; KLAUSNER MA, 1998, DEAR HLTH CARE PROF; Piquette RK, 1999, ANN PHARMACOTHER, V33, P22, DOI 10.1345/aph.18107; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Sekkarie MA, 1997, AM J KIDNEY DIS, V30, P437, DOI 10.1016/S0272-6386(97)90291-2; SHATIN D, 2000, PHARMACOEPIDEMIOLOGY; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; van Haarst AD, 1998, CLIN PHARMACOL THER, V64, P542, DOI 10.1016/S0009-9236(98)90137-0; Vitola J, 1998, J CARDIOVASC ELECTR, V9, P1109, DOI 10.1111/j.1540-8167.1998.tb00888.x; WOOSLEY RL, 1994, CLIN PHARMACOL THER, V55, P249, DOI 10.1038/clpt.1994.24; Wysowski DK, 1996, NEW ENGL J MED, V335, P290, DOI 10.1056/NEJM199607253350416	12	200	206	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3036	3039		10.1001/jama.284.23.3036	http://dx.doi.org/10.1001/jama.284.23.3036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122591	Bronze			2022-12-28	WOS:000165847200029
J	Whiteman, S				Whiteman, S			Lost by degrees	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					2974	2975		10.1001/jama.284.23.2974	http://dx.doi.org/10.1001/jama.284.23.2974			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122563				2022-12-28	WOS:000165847200001
J	Rymer, J; Morris, EP				Rymer, J; Morris, EP			Menopausal symptoms	BMJ-BRITISH MEDICAL JOURNAL			English	Review							QUALITY-OF-LIFE; HORMONE REPLACEMENT THERAPY; MEDROXYPROGESTERONE ACETATE; VASOMOTOR SYMPTOMS; DOUBLE-BLIND; ORAL MEDROXYPROGESTERONE; POSTMENOPAUSAL WOMEN; ESTROGEN; TIBOLONE; PLACEBO	Definition Menopause begins one year after the last menstrual period. Symptoms often begin in the perimenopausal years. Incidence/prevalence In the United Kingdom the mean age for the menopause is 50 years 9 months. The median onset of the perimenopause is between 45.5 and 47.5 years. One Scottish survey (of 6096 women aged 45 to 54 years) found that 84% had experienced at least one of the classic menopausal symptoms, with 45% finding one or more symptoms a problem.(1) Aetiology/risk factors Urogenital symptoms of menopause are caused by decreased oestrogen concentrations, but the cause of vasomotor symptoms and psychological effects is complex and remains unclear. Prognosis Menopause is a physiological event. Its timing may be genetically determined. Although endocrine changes are permanent, menopausal symptoms such as hot flushes, which are experienced by about 70% of women, usually resolve with time.(2) However, some symptoms, such as genital atrophy, may remain the same or worsen. Aims To reduce or prevent menopausal symptoms, and to improve quality of life with minimum adverse effects. Outcomes Frequency and severity of vasomotor, urogenital, and psychological symptoms; quality of life. Methods Clinical Evidence search and appraisal December 1999. We included only randomised controlled trials (RCTs) and systematic reviews that met Clinical Evidence quality criteria.	Guys Hosp, HRT Res Unit, London SE1 9RT, England; Guys Kings & St Thomass Med Sch, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Morris, EP (corresponding author), Guys Hosp, HRT Res Unit, London SE1 9RT, England.	eddie.morris@virgin.net						Al-Azzawi F, 1999, OBSTET GYNECOL, V93, P258, DOI 10.1016/S0029-7844(98)00403-7; ASLAKSEN K, 1982, ACTA OBSTET GYN SCAN, V61, P423, DOI 10.3109/00016348209156584; Baber R J, 1999, Climacteric, V2, P85, DOI 10.3109/13697139909025571; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; BENEDEKJASZMANN LJ, 1987, MATURITAS, P25; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BULLOCK JL, 1975, OBSTET GYNECOL, V46, P165; Cardozo L, 1998, OBSTET GYNECOL, V92, P722, DOI 10.1016/S0029-7844(98)00175-6; Casper F, 1999, Int Urogynecol J Pelvic Floor Dysfunct, V10, P171, DOI 10.1007/s001920050040; DERMAN RJ, 1995, INT J FERTIL MENOP S, V40, P73; DOW MGT, 1983, BRIT J OBSTET GYNAEC, V90, P361, DOI 10.1111/j.1471-0528.1983.tb08924.x; EDINGTON RF, 1980, CAN MED ASSOC J, V123, P23; Eriksen BC, 1999, AM J OBSTET GYNECOL, V180, P1072, DOI 10.1016/S0002-9378(99)70597-1; GEDDES J, 2000, CLIN EVIDENCE, P434; Grady D, 1998, AM J MED, V105, P41, DOI 10.1016/S0002-9343(98)00136-3; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; HAGSTAD A, 1986, ACTA OBSTET GYN SCAN, P59; Hammar M, 1998, BRIT J OBSTET GYNAEC, V105, P904, DOI 10.1111/j.1471-0528.1998.tb10237.x; Haskell SG, 1997, J CLIN EPIDEMIOL, V50, P1249, DOI 10.1016/S0895-4356(97)00169-8; Hilditch JR, 1996, MATURITAS, V24, P177, DOI 10.1016/0378-5122(96)01037-7; KARLBERG J, 1995, ACTA OBSTET GYN SCAN, V74, P367, DOI 10.3109/00016349509024430; KICOVIC P M, 1982, Reproduccion, V6, P81; Leonetti HB, 1999, OBSTET GYNECOL, V94, P225, DOI 10.1016/S0029-7844(99)00266-5; LOBO RA, 1984, OBSTET GYNECOL, V63, P1; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MATTSSON LA, 1999, J MENOPAUSE, V6, P25; Moore RA, 1999, BRIT J OBSTET GYNAEC, V106, P1; Morris EP, 1999, BRIT J OBSTET GYNAEC, V106, P954, DOI 10.1111/j.1471-0528.1999.tb08436.x; MURKIES AL, 1995, MATURITAS, V21, P189, DOI 10.1016/0378-5122(95)00899-V; NAGAMANI M, 1987, AM J OBSTET GYNECOL, V156, P561, DOI 10.1016/0002-9378(87)90050-0; NathorstBoos J, 1997, MATURITAS, V26, P15, DOI 10.1016/S0378-5122(96)01069-9; Polo-Kantola P, 1999, FERTIL STERIL, V71, P873, DOI 10.1016/S0015-0282(99)00062-X; Porter M, 1996, BRIT J OBSTET GYNAEC, V103, P1025, DOI 10.1111/j.1471-0528.1996.tb09555.x; Reginster JY, 1996, CONTRACEPT FERTIL S, V24, P847; SCHIFF I, 1980, JAMA-J AM MED ASSOC, V244, P1443, DOI 10.1001/jama.244.13.1443; SHERWIN BB, 1985, PSYCHOSOM MED, V47, P339, DOI 10.1097/00006842-198507000-00004; Simon J, 1999, MENOPAUSE, V6, P138; SUDLOW C, 2000, CLIN EVIDENCE, P77; Utian WH, 1999, AM J OBSTET GYNECOL, V181, P71, DOI 10.1016/S0002-9378(99)70438-2; WALKER ID, 1985, THROMB HAEMOSTASIS, V53, P303; Washburn S, 1999, MENOPAUSE, V6, P7; WIKLUND I, 1993, AM J OBSTET GYNECOL, V168, P824, DOI 10.1016/S0002-9378(12)90828-5; Wilkes HC, 1996, BRIT MED J, V312, P473; Zweifel JE, 1997, PSYCHONEUROENDOCRINO, V22, P189, DOI 10.1016/S0306-4530(96)00034-0	44	51	54	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2000	321	7275					1516	1519		10.1136/bmj.321.7275.1516	http://dx.doi.org/10.1136/bmj.321.7275.1516			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118182	Green Published			2022-12-28	WOS:000165994700029
J	Ellison, J; Thomson, AJ; Greer, IA; Walker, ID				Ellison, J; Thomson, AJ; Greer, IA; Walker, ID			Drug points - Apparent interaction between warfarin and levonorgestrel used for emergency contraception	BRITISH MEDICAL JOURNAL			English	Letter																		Crowther NR, 1997, CAN FAM PHYSICIAN, V43, P1972; Grimes D, 1998, LANCET, V352, P428; Herve F, 1996, PHARMACOGENETICS, V6, P403, DOI 10.1097/00008571-199610000-00004; *ROYAL COLL OBSTET, 1995, JOINT STAT EM HORM C; 2000, BRIT NATL FORMULARY, V39, P614	5	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1382	1382		10.1136/bmj.321.7273.1382	http://dx.doi.org/10.1136/bmj.321.7273.1382			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099283	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000165720100026
J	Paiella, R; Capasso, F; Gmachl, C; Sivco, DL; Baillargeon, JN; Hutchinson, AL; Cho, AY; Liu, HC				Paiella, R; Capasso, F; Gmachl, C; Sivco, DL; Baillargeon, JN; Hutchinson, AL; Cho, AY; Liu, HC			Self-mode-locking of quantum cascade lasers with giant ultrafast optical nonlinearities	SCIENCE			English	Article							WELL INFRARED PHOTODETECTORS; PULSE GENERATION; CONTINUOUS-WAVE; PERFORMANCE; LIGHT	We report on the generation of picosecond self-mode-locked pulses from midinfrared quantum cascade Lasers, at wavelengths within the important molecular fingerprint region. These devices are based on intersubband electron transitions in semiconductor nanostructures, which are characterized by some of the largest optical nonlinearities observed in nature and by picosecond relaxation Lifetimes. Our results are interpreted with a model;in which one of these nonlinearities, the intensity-dependent refractive index of the Lasing transition, creates a nonlinear waveguide where the optical Losses decrease with increasing intensity. This favors the generation of ultrashort pulses, because of their Larger instantaneous intensity relative to continuous-wave emission.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Natl Res Council, Ottawa, ON, Canada	Alcatel-Lucent; Lucent Technologies; AT&T; National Research Council Canada	Paiella, R (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.							Agrawal G.P., 2006, NONLINEAR FIBER OPTI, V4th; Agrawal G.P., 1986, LONG WAVELENGTH SEMI, P287, DOI [10.1007/978-94-011-6994-3_7, DOI 10.1007/978-94-011-6994-3_7]; Boyd R. W., 2003, NONLINEAR OPTICS; Capasso F, 1999, OPT PHOTONICS NEWS, V10, P31, DOI 10.1364/OPN.10.10.000031; CAPASSO F, 1994, IEEE J QUANTUM ELECT, V30, P1313, DOI 10.1109/3.303697; Dunn MH, 1999, SCIENCE, V286, P1513, DOI 10.1126/science.286.5444.1513; ELSAESSER T, 1998, ULTRAFAST PHENOMENA, V11; FAIST J, 1994, SCIENCE, V264, P553, DOI 10.1126/science.264.5158.553; Faist J, 1998, IEEE J QUANTUM ELECT, V34, P336, DOI 10.1109/3.658728; FEJER MM, 1989, PHYS REV LETT, V62, P1041, DOI 10.1103/PhysRevLett.62.1041; Gmachl C, 1999, IEEE J SEL TOP QUANT, V5, P808, DOI 10.1109/2944.788454; GRIFFITHS PR, 1986, FOURIER TRANSFORM IN; KAISER W, 1993, ULTRASHORT LASER PUL, V60; LEVINE BF, 1993, J APPL PHYS, V74, pR1, DOI 10.1063/1.354252; LIN CH, 1972, IEEE J QUANTUM ELECT, VQE 8, P429, DOI 10.1109/JQE.1972.1076981; Liu HC, 1996, IEEE J QUANTUM ELECT, V32, P1024, DOI 10.1109/3.502380; MARTINS JF, 1995, IEEE J SEL TOP QUANT, V1, P539, DOI 10.1109/2944.401240; Neogi A, 1999, J APPL PHYS, V85, P3352, DOI 10.1063/1.369683; Paiella R, 2000, APPL PHYS LETT, V77, P169, DOI 10.1063/1.126913; Paiella R, 1999, APPL PHYS LETT, V75, P2536, DOI 10.1063/1.125069; POGORELSKY IV, 1995, IEEE J QUANTUM ELECT, V31, P556, DOI 10.1109/3.364413; Rosencher E, 1996, SCIENCE, V271, P168, DOI 10.1126/science.271.5246.168; SEGEV M, 1992, APPL PHYS LETT, V61, P2403, DOI 10.1063/1.108178; SPENCE DE, 1991, OPT LETT, V16, P42, DOI 10.1364/OL.16.000042; Steinmeyer G, 1999, SCIENCE, V286, P1507, DOI 10.1126/science.286.5444.1507; Yariv A., 1988, QUANTUM ELECT; Yeh P., 1988, OPTICAL WAVES LAYERE	27	152	158	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1739	1742		10.1126/science.290.5497.1739	http://dx.doi.org/10.1126/science.290.5497.1739			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099406				2022-12-28	WOS:000165632400034
J	Elser, JJ; Fagan, WF; Denno, RF; Dobberfuhl, DR; Folarin, A; Huberty, A; Interlandi, S; Kilham, SS; McCauley, E; Schulz, KL; Siemann, EH; Sterner, RW				Elser, JJ; Fagan, WF; Denno, RF; Dobberfuhl, DR; Folarin, A; Huberty, A; Interlandi, S; Kilham, SS; McCauley, E; Schulz, KL; Siemann, EH; Sterner, RW			Nutritional constraints in terrestrial and freshwater food webs	NATURE			English	Article							N-P STOICHIOMETRY; ECOSYSTEMS; PHOSPHORUS; GROWTH; PHYTOPLANKTON; ZOOPLANKTON; LIMITATION; PATTERNS; DAPHNIA; PLANTS	Biological and environmental contrasts between aquatic and terrestrial systems have hindered analyses of community and ecosystem structure across Earth's diverse habitats. Ecological stoichiometry(1,2) provides an integrative approach for such analyses, as all organisms are composed of the same major elements (C, N, P) whose balance affects production, nutrient cycling, and food-web dynamics(3,4). Here we show both similarities and differences in the C:N:P ratios of primary producers (autotrophs) and invertebrate primary consumers (herbivores) across habitats. Terrestrial food webs are built on an extremely nutrient-poor autotroph base with C:P and C:N ratios higher than in lake particulate matter, although the N:P ratios are nearly identical. Terrestrial herbivores (insects) and their freshwater counterparts (zooplankton) are nutrient-rich and indistinguishable in C:N:P stoichiometry. In both lakes and terrestrial systems, herbivores should have low growth efficiencies (10-30%) when consuming autotrophs with typical carbon-to-nutrient ratios. These stoichiometric constraints on herbivore growth appear to be qualitatively similar and widespread in both environments.	Arizona State Univ, Dept Biol, Tempe, AZ 85287 USA; Univ Maryland, Dept Entomol, College Pk, MD 20742 USA; Drexel Univ, Sch Environm Sci Engn & Policy, Philadelphia, PA 19104 USA; Univ Calgary, Dept Biol Sci, Div Ecol, Calgary, AB T2N 1N4, Canada; SUNY Syracuse, Dept Environm & Forest Biol, Syracuse, NY 13210 USA; Rice Univ, Dept Ecol & Evolutionary Biol, Houston, TX 77005 USA; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	Arizona State University; Arizona State University-Tempe; University System of Maryland; University of Maryland College Park; Drexel University; University of Calgary; State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; Rice University; University of Minnesota System; University of Minnesota Twin Cities	Elser, JJ (corresponding author), Arizona State Univ, Dept Biol, Tempe, AZ 85287 USA.		Elser, James/A-7082-2008	Elser, James/0000-0002-1460-2155; Sterner, Robert/0000-0003-2292-6122; Schulz, Kimberly/0000-0003-1506-5694				Andersen T., 1997, PELAGIC NUTR CYCLES; BUTLER NM, 1989, OECOLOGIA, V78, P368, DOI 10.1007/BF00379111; Cebrian J, 1999, AM NAT, V154, P449, DOI 10.1086/303244; Chapin FS, 1997, SCIENCE, V277, P500, DOI 10.1126/science.277.5325.500; CYR H, 1993, NATURE, V361, P148, DOI 10.1038/361148a0; DeMott WR, 1998, LIMNOL OCEANOGR, V43, P1147, DOI 10.4319/lo.1998.43.6.1147; ELSER JJ, 1995, MICROBIAL ECOL, V29, P145, DOI 10.1007/BF00167161; Elser JJ, 1996, BIOSCIENCE, V46, P674, DOI 10.2307/1312897; Elser JJ, 1999, ECOLOGY, V80, P735, DOI 10.2307/177013; ELSER JJ, 1990, CAN J FISH AQUAT SCI, V47, P1468, DOI 10.1139/f90-165; Elton C., 1927, ANIMAL ECOLOGY; FUTUYMA DJ, 1979, ECOL MONOGR, V49, P33, DOI 10.2307/1942571; LEIBOLD MA, 1989, AM NAT, V134, P922, DOI 10.1086/285022; Main TM, 1997, LIMNOL OCEANOGR, V42, P1474, DOI 10.4319/lo.1997.42.6.1474; McCauley E, 1999, NATURE, V402, P653, DOI 10.1038/45223; REINERS WA, 1986, AM NAT, V127, P59, DOI 10.1086/284467; Schlesinger WH., 1997, BIOGEOCHEMISTRY; SLANSKY F, 1977, ECOL MONOGR, V47, P209, DOI 10.2307/1942617; STERNER RW, 1994, ANNU REV ECOL SYST, V25, P1, DOI 10.1146/annurev.es.25.110194.000245; Sterner RW, 1997, FRESHWATER BIOL, V38, P473, DOI 10.1046/j.1365-2427.1997.00234.x; Strong D., 1984, INSECTS PLANTS COMMU; STRONG DR, 1992, ECOLOGY, V73, P747, DOI 10.2307/1940154; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Verhoeven JTA, 1996, TRENDS ECOL EVOL, V11, P494, DOI 10.1016/S0169-5347(96)10055-0; White T. C. R., 1993, INADEQUATE ENV NITRO	25	1056	1438	61	1251	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					578	580		10.1038/35046058	http://dx.doi.org/10.1038/35046058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117743				2022-12-28	WOS:000165548600116
J	Hyland, GJ				Hyland, GJ			Physics and biology of mobile telephony	LANCET			English	Review							FREQUENCY ELECTROMAGNETIC-FIELDS; CELLULAR PHONES; MICROWAVES; EXPOSURE; CELLS; RADIATION; LYMPHOCYTES; DENSITY; DAMAGE	Although safety guidelines-to which mobile telephones and their base-stations conform-do protect against excessive microwave heating, there is evidence that the low Intensity, pulsed radiation currently used can exert subtle non-thermal influences. If these influences entail adverse health consequences, current guidelines would be inadequate. This review will focus on this possibility. The radiation used is indeed of very low intensity, but an oscillatory similitude between this pulsed microwave radiation and certain electrochemical activities of the living human being should prompt concern. However, being so inherently dependent on aliveness, non-thermal effects cannot be expected to be as robust as thermal ones, as is indeed found; nor can everyone be expected to be affected in the same way by exposure to the same radiation. Notwithstanding uncertainty about whether the non-thermal influences reported do adversely affect health, there are consistencies between some of these effects and the neurological problems reported by some mobile-telephone users and people exposed longterm to base-station radiation. These should be pointers for future research.	Univ Warwick, Dept Phys, Coventry CV4 4AL, W Midlands, England; Int Inst Biophys, Neuss, Germany	University of Warwick	Hyland, GJ (corresponding author), Univ Warwick, Dept Phys, Coventry CV4 4AL, W Midlands, England.	G.J.Hyland@warwick.ac.uk						Ahlbom A, 1998, HEALTH PHYS, V74, P494; Andersen JB, 1997, RADIAT PROT DOSIM, V72, P249, DOI 10.1093/oxfordjournals.rpd.a032097; BALCERKUBICZEK EK, 1991, RADIAT RES, V126, P65, DOI 10.2307/3578172; Barbanti P, 1996, NEUROSCI LETT, V207, P73, DOI 10.1016/0304-3940(96)12491-5; Borbely AA, 1999, NEUROSCI LETT, V275, P207, DOI 10.1016/S0304-3940(99)00770-3; Braune S, 1998, LANCET, V351, P1857, DOI 10.1016/S0140-6736(98)24025-6; CARLO GL, 2000, FRENCH NAT ASS JUN 1; DUTTA SK, 1984, BIOELECTROMAGNETICS, V5, P71, DOI 10.1002/bem.2250050108; Freude G, 1998, BIOELECTROMAGNETICS, V19, P384, DOI 10.1002/(SICI)1521-186X(1998)19:6<384::AID-BEM6>3.0.CO;2-Y; FREY AH, 1994, NATURE ELECTROMAGNET; Frohlich H, 1988, BIOL COHERENCE RESPO; Frohlich H., 1980, ADV ELECTRON EL PHYS, V53, P85; Gandhi OP, 1996, IEEE T MICROW THEORY, V44, P1884, DOI 10.1109/22.539947; GARAJVRHOVAC V, 1992, MUTAT RES, V281, P181, DOI 10.1016/0165-7992(92)90006-4; Golant M. B., 1994, Radiophysics and Quantum Electronics, V37, P82, DOI 10.1007/BF01039307; Goldsmith, 1995, Int J Occup Environ Health, V1, P47; Gos P, 1997, BIOELECTROMAGNETICS, V18, P142, DOI 10.1002/(SICI)1521-186X(1997)18:2<142::AID-BEM7>3.0.CO;2-2; GRUNDLER W., 1992, NANOBIOLOGY, V1, P163; Harding G., 1994, PHOTOSENSITIVE EPILE; Hyland G. J., 1998, Engineering Science and Education Journal, V7, P261, DOI 10.1049/esej:19980606; HYLAND GJ, 1999, SCI ADVISORY SYSTEM, V2, P86; KAISER F, 1987, ENERGY TRANSFER DYNA, P224; Krause CM, 2000, NEUROREPORT, V11, P761, DOI 10.1097/00001756-200003200-00021; LAI H, 1987, IEEE ENG MED BIOL, V6, P31, DOI 10.1109/MEMB.1987.5006372; Lai H, 1996, INT J RADIAT BIOL, V69, P513, DOI 10.1080/095530096145814; Loscher W, 1998, PRAKT TIERARZT, V79, P437; LUKASHEVSKY K V, 1990, Medical Science Research, V18, P955; LYLE DB, 1983, BIOELECTROMAGNETICS, V4, P281, DOI 10.1002/bem.2250040308; Malyapa RS, 1998, RADIAT RES, V149, P637, DOI 10.2307/3579911; Mann K, 1996, NEUROPSYCHOBIOLOGY, V33, P41, DOI 10.1159/000119247; Marks P, 2000, NEW SCI, V166, P7; Penafiel LM, 1997, BIOELECTROMAGNETICS, V18, P132, DOI 10.1002/(SICI)1521-186X(1997)18:2<132::AID-BEM6>3.0.CO;2-3; Persson BRR, 1997, WIREL NETW, V3, P455, DOI 10.1023/A:1019150510840; Reiser H, 1995, Eur J Med Res, V1, P27; Repacholi MH, 1997, RADIAT RES, V147, P631, DOI 10.2307/3579630; Rothman KJ, 2000, LANCET, V356, P1837, DOI 10.1016/S0140-6736(00)03244-X; SAVOPOL T, 1995, ELECTRO MAGNETOBIOL, V14, P99, DOI 10.3109/15368379509022549; *SCI ADV SYST, 1999, MOB PHON HLTH, V1; Shcheglov VS, 1997, ELECTRO MAGNETOBIOL, V16, P69, DOI 10.3109/15368379709016174; SIDORENKO AV, 1999, P C EL FIELDS HUM HL, P283; SMITH CW, 1989, ELECTROMAGNETIC MAN; Smolyanskaya A.Z., 1974, SOV PHYS USPEKHI, V16, P571, DOI [10.1070/PU1974v016n04ABEH005311, DOI 10.1070/PU1974V016N04ABEH005311]; Stewart W., 2000, REPORT INDEPENDENT E, P1; TATTERSALL J, 1999, NEW HORIZONS     AUT, P11; WINKLER T, 1995, NEUROSCIENCE, V68, P1097, DOI 10.1016/0306-4522(95)00194-N; YOUBICIERSIMO BJ, 1999, RAD PROTECT, V1, P218	46	159	175	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 25	2000	356	9244					1833	1836		10.1016/S0140-6736(00)03243-8	http://dx.doi.org/10.1016/S0140-6736(00)03243-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117927				2022-12-28	WOS:000165545700040
J	Mrazek, MF; Mossialos, E				Mrazek, MF; Mossialos, E			Increasing demand while decreasing costs of generic medicines	LANCET			English	Editorial Material							PRESCRIPTION		Univ London London Sch Econ & Polit Sci, LSE Hlth, London WC2A 2AE, England	University of London; London School Economics & Political Science	Mossialos, E (corresponding author), Univ London London Sch Econ & Polit Sci, LSE Hlth, Houghton St, London WC2A 2AE, England.		Mossialos, Elias/ABE-1301-2021					Bussow R., 1996, Formal Methods for Industrial Applications. Specifying and Programming the Steam Boiler Control, P109, DOI 10.1007/BFb0027233; *DEP HLTH UK, 1998, STAT B DEP HLTH UK, V24; *DEP HLTH UK, 2000, GOV RESP HLTH SEL CO; *EUR OBS HLTH CAR, 1999, HLTH CAR SYST TRANS; Giuliani G, 1998, HEALTH POLICY, V44, P73, DOI 10.1016/S0168-8510(98)00012-8; Gosden T, 1997, HEALTH POLICY, V40, P103, DOI 10.1016/S0168-8510(96)00888-3; Hellerstein JK, 1998, RAND J ECON, V29, P108, DOI 10.2307/2555818; Hillman AL, 1999, HEALTH AFFAIR, V18, P189, DOI 10.1377/hlthaff.18.2.189; *HOECHST MAR ROUS, 1998, MAN CAR DIG SER; Hong SH, 1996, CLIN THER, V18, P528, DOI 10.1016/S0149-2918(96)80035-X; *PHARM PRIC REV, 1998, PHARMA PRICING REV, V3, P200; *US DEP HHS, 2000, PRESCR DRUG COV SPEN	12	9	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1784	1785		10.1016/S0140-6736(00)03225-6	http://dx.doi.org/10.1016/S0140-6736(00)03225-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	377UY	11117905				2022-12-28	WOS:000165545700004
J	Van den Bosch, F; Kruithof, E; De Vos, M; De Keyser, F; Mielants, H				Van den Bosch, F; Kruithof, E; De Vos, M; De Keyser, F; Mielants, H			Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms	LANCET			English	Article							ANTIBODY	Four patients with Crohn's disease and spondyloarthropathy were treated with infliximab for treatment-resistant gut inflammation. A substantial improvement in gastrointestinal signs and symptoms was noted, which was accompanied by a rapid reduction in C-reactive protein concentrations, Moreover, all four patients had a significant improvement of axial manifestations and/or peripheral arthritis, related to their spondyloarthropathy. This fast and substantial improvement of the articular manifestations of Crohn's disease after infliximab treatment warrants further investigation of the therapeutic potential of TNF-alpha blockade in other subtypes of spondyloarthropathies.	State Univ Ghent Hosp, Dept Rheumatol, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Gastroenterol, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Van den Bosch, F (corresponding author), State Univ Ghent Hosp, Dept Rheumatol, B-9000 Ghent, Belgium.							DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; MIELANTS H, 1995, J RHEUMATOL, V22, P2273; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502	5	162	174	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1821	1822		10.1016/S0140-6736(00)03239-6	http://dx.doi.org/10.1016/S0140-6736(00)03239-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117919				2022-12-28	WOS:000165545700018
J	Ward, H; Ison, CA; Day, SE; Martin, I; Ghani, AC; Garnett, GP; Bell, G; Kinghorn, G; Weber, JN				Ward, H; Ison, CA; Day, SE; Martin, I; Ghani, AC; Garnett, GP; Bell, G; Kinghorn, G; Weber, JN			A prospective social and molecular investigation of gonococcal transmission	LANCET			English	Article							NEISSERIA-GONORRHOEAE; DISCRIMINATORY POWER; EPIDEMIOLOGY; INFECTIONS; NETWORKS	Background Gonorrhoea is a common infectious disease, poorly controlled despite effective treatments. Tracing chains of transmission is difficult, because sexual partners are commonly difficult or impossible to identify. We assess the use of gonococcal opa-typing in identifying transmission links not revealed through interview. Methods Epidemiological data and gonococcal isolates were collected prospectively from patients at two UK clinics in London and Sheffield. Social and epidemiological data were combined with molecular typing of gonococcal isolates by a new methodology based on the polymorphisms of the opa gene. Findings In London, interview data and cpa-typing on samples from 215 cases showed a diverse population with few links. In Sheffield, interview data identified links between 51 (43%) of 120 cases, whereas cpa-typing suggested a more connected population: 95 (79%) of cases had shared profiles. There was a highly significant correlation between the two distributions with epidemiological clusters appearing as a subset of the cpa clusters. Two large cpa clusters, of 18 and 43 cases, accounted for 50% of local cases of gonorrhoea. Discordance between epidemiological and cpa-typing data was observed at highly connected points in the sexual network. Interpretation Opa-typing is a more powerful tool for epidemiological investigation of gonorrhoea transmission than earlier methods. Opa-typing can link infections that would otherwise remain unlinked, and may aid interventions to control endemic disease.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis & Microbiol, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Genitourinary Med & Communicable Dis, London W2 1PG, England; Royal Hallamshire Hosp, Dept Genitourinary Med, Sheffield S10 2JF, S Yorkshire, England; Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol, Oxford OX1 2JD, England	Imperial College London; Imperial College London; Imperial College London; University of Sheffield; University of Oxford	Ward, H (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, Norfolk Pl, London W2 1PG, England.		Ward, Helen/A-1836-2009; Ghani, Azra/B-8560-2009; Kinghorn, George/AAO-1425-2021; Garnett, Geoffrey P/A-9312-2008	Ward, Helen/0000-0001-8238-5036; Day, Sophie/0000-0002-9822-9094; Kinghorn, George/0000-0001-6608-5076; Ghani, Azra/0000-0002-0007-4910				Becker KM, 1998, AM J EPIDEMIOL, V147, P709, DOI 10.1093/oxfordjournals.aje.a009513; Bell G, 1998, SEX TRANSM INFECT, V74, P409, DOI 10.1136/sti.74.6.409; Blanchard JF, 1998, AM J PUBLIC HEALTH, V88, P1496, DOI 10.2105/AJPH.88.10.1496; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P1140, DOI 10.1164/ajrccm.155.3.9117000; CATLIN BW, 1973, J INFECT DIS, V128, P178, DOI 10.1093/infdis/128.2.178; Day S, 1998, SOC SCI MED, V47, P1981, DOI 10.1016/S0277-9536(98)00306-2; Day S, 1998, INT J STD AIDS, V9, P666, DOI 10.1258/0956462981921323; DAY S, 1994, BRIT MED ANTHR REV, V2, P20; DILLON JAR, 1993, J CLIN MICROBIOL, V31, P2831, DOI 10.1128/JCM.31.10.2831-2833.1993; Gerbase AC, 1998, SEX TRANSM INFECT, V74, pS12; GILL MJ, 1991, GENITOURIN MED, V67, P53; Hiltunen-Back E, 1998, SEX TRANSM DIS, V25, P181, DOI 10.1097/00007435-199804000-00001; Hobbs MM, 1999, J INFECT DIS, V179, P371, DOI 10.1086/314608; ISON CA, 1992, EPIDEMIOL INFECT, V109, P265, DOI 10.1017/S0950268800050214; Ison CA, 1998, CURR OPIN INFECT DIS, V11, P43, DOI 10.1097/00001432-199802000-00010; Klausner JD, 1998, J INFECT DIS, V177, P1766, DOI 10.1086/517442; KNAPP JS, 1984, J INFECT DIS, V150, P44, DOI 10.1093/infdis/150.1.44; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Low N, 1998, DERMATOL CLIN, V16, P713, DOI 10.1016/S0733-8635(05)70036-X; OROURKE M, 1995, MOL MICROBIOL, V17, P865, DOI 10.1111/j.1365-2958.1995.mmi_17050865.x; *PUBL HLTH LAB SER, 2000, NEW CAS AC SEX TRANS; Rothenberg R, 2000, SEX TRANSM DIS, V27, P12, DOI 10.1097/00007435-200001000-00003; van Looveren M, 1999, J CLIN MICROBIOL, V37, P2183, DOI 10.1128/JCM.37.7.2183-2188.1999; WOODFORD N, 1989, GENITOURIN MED, V65, P86	24	41	44	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1812	1817		10.1016/S0140-6736(00)03234-7	http://dx.doi.org/10.1016/S0140-6736(00)03234-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117914				2022-12-28	WOS:000165545700013
J	Solanki, SK; Schussler, M; Fligge, M				Solanki, SK; Schussler, M; Fligge, M			Evolution of the Sun's large-scale magnetic field since the Maunder minimum	NATURE			English	Article							SOLAR-ACTIVITY CYCLE; FLUX; CLIMATE; MODEL	The most striking feature of the Sun's magnetic field is its cyclic behaviour. The number of sunspots, which are dark regions of strong magnetic field on the Sun's surface, varies with a period of about 11 years. Superposed on this cycle are secular changes that occur on timescales of centuries and events like the Maunder minimum in the second half of the seventeenth century, when there were very few sunspots(1,2). A part of the Sun's magnetic field reaches out from the surface into interplanetary space, and it was recently discovered(3) that the average strength of this interplanetary field has doubled in the past 100 years. There has hitherto been no clear explanation for this doubling. Here we present a model describing the long-term evolution of the Sun's large-scale magnetic field, which reproduces the doubling of the interplanetary field. The model indicates that there is a direct connection between the length of the sunspot cycle and the secular variations.	Max Planck Inst Aeron, D-37191 Katlenburg Lindau, Germany; ETH Zentrum, Astron Inst, CH-8092 Zurich, Switzerland	Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich	Solanki, SK (corresponding author), Max Planck Inst Aeron, D-37191 Katlenburg Lindau, Germany.	solanki@linmpi.mpg.de	Solanki, Sami K/E-2487-2013	Solanki, Sami K/0000-0002-3418-8449				BEER J, 1990, NATURE, V347, P164, DOI 10.1038/347164a0; Chapman GA, 1997, ASTROPHYS J, V482, P541, DOI 10.1086/304138; DICKE RH, 1979, NATURE, V280, P24, DOI 10.1038/280024a0; Fligge M, 1998, ASTRON ASTROPHYS, V335, P709; FRIISCHRISTENSEN E, 1991, SCIENCE, V254, P698, DOI 10.1126/science.254.5032.698; HARVEY KL, 1992, ASTR SOC P, V27, P335; HARVEY KL, 1993, SOL PHYS, V148, P85, DOI 10.1007/BF00675537; HARVEY KL, 1994, NATO ADV SCI I C-MAT, V433, P347; HOWARD R, 1981, SOL PHYS, V74, P131, DOI 10.1007/BF00151283; Hoyng P, 1996, SOL PHYS, V169, P253, DOI 10.1007/BF00190603; LIVINGSTON WC, 1976, APPL OPTICS, V15, P40, DOI 10.1364/AO.15.000040; Lockwood M, 1999, NATURE, V399, P437, DOI 10.1038/20867; RIBES JC, 1993, ASTRON ASTROPHYS, V276, P549; Scherrer PH, 1995, SOL PHYS, V162, P129, DOI 10.1007/BF00733429; Schrijver CJ, 1998, NATURE, V394, P152, DOI 10.1038/28108; SCHRIJVER CJ, 1994, SOL PHYS, V150, P1, DOI 10.1007/BF00712873; SHEELEY NR, 1992, ASTR SOC P, V27, P1; Svensmark H, 1998, PHYS REV LETT, V81, P5027, DOI 10.1103/PhysRevLett.81.5027; Svensmark H, 1997, J ATMOS SOL-TERR PHY, V59, P1225, DOI 10.1016/S1364-6826(97)00001-1; WANG YM, 1995, ASTROPHYS J, V447, pL143, DOI 10.1086/309578; Wang YM, 2000, GEOPHYS RES LETT, V27, P621, DOI 10.1029/1999GL010759; Wang YM, 2000, GEOPHYS RES LETT, V27, P505, DOI 10.1029/1999GL010744; WANG YM, 1994, ASTROPHYS J, V430, P399, DOI 10.1086/174415; WILSON PR, 1988, NATURE, V333, P748, DOI 10.1038/333748a0	24	219	225	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					445	447		10.1038/35044027	http://dx.doi.org/10.1038/35044027			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100720				2022-12-28	WOS:000165429800040
J	Vogelauer, M; Wu, JS; Suka, N; Grunstein, M				Vogelauer, M; Wu, JS; Suka, N; Grunstein, M			Global histone acetylation and deacetylation in yeast	NATURE			English	Article							POLYMERASE-II HOLOENZYME; CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; IN-VIVO; PHO5 PROMOTER; ACETYLTRANSFERASE; CHROMATIN; TRANSCRIPTION; NUCLEOSOMES; ACTIVATION	Histone acetyltransferases and deacetylases can be targeted to promoters to activate or repress genes. For example, the histone acetyltransferase GCN5 is part of a yeast multiprotein complex that is recruited by the DNA-binding activator protein GCN4 (refs 1-3). The histone deacetylase RPD3 complex is recruited to DNA by the repressor UME6 (refs 4, 5); similar mechanisms exist in other eukaryotes(6). However, deletion of RPD3 also increases expression of the PHO5 gene(7) that is repressed by nucleosomes(8,9), and regulated by GCN5 (ref. 10) but not by UME6. We have determined whether acetylation and deacetylation are promoter specific at PHO5, by using antibodies against acetylated lysine residues and chromatin immunoprecipitation to examine the acetylation state of a 4.25-kilobase region surrounding the PHO5 gene. Here we show that this region is acetylated extensively by ESA1 and GCN5 and deacetylated by HDA1 and RPD3, and that widespread histone modification affects three separate chromosomal regions examined, which total 22 kb. Our data indicate that targeted modification occurs in a background of global acetylation and deacetylation that not only reduces basal transcription, but also allows a rapid return to the initial state of acetylation when targeting is removed.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Grunstein, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Boyer Hall, Los Angeles, CA 90095 USA.							ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LAMAN H, 1995, MOL CELL BIOL, V15, P3608; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Reifnyder C, 1997, NAT GENET, V16, P109, DOI 10.1038/ng0597-109b; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	29	342	362	1	24	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					495	498		10.1038/35044127	http://dx.doi.org/10.1038/35044127			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100734				2022-12-28	WOS:000165429800054
J	Vousden, KH				Vousden, KH			p53: Death star	CELL			English	Review							P53-MEDIATED APOPTOSIS		NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Vousden, KH (corresponding author), NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA.	vousden@ncifcrf.gov						Attardi LD, 2000, GENE DEV, V14, P704; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; DING HF, 2000, IN PRESS J BIOL CHEM; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Vousden KH, 2000, NAT CELL BIOL, V2, pE178, DOI 10.1038/35036427; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X	19	685	715	2	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					691	694		10.1016/S0092-8674(00)00171-9	http://dx.doi.org/10.1016/S0092-8674(00)00171-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114324	Bronze			2022-12-28	WOS:000165433100001
J	Loff, B; Gaze, B; Fairley, C				Loff, B; Gaze, B; Fairley, C			Prostitution, public health, and human-rights law	LANCET			English	Editorial Material									Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; Monash Univ, Fac Law, Melbourne, Vic 3004, Australia	Monash University; Monash University	Loff, B (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.		Loff, Bebe/G-9241-2014	Loff, Bebe/0000-0003-1963-6503; Christopher, Fairley/0000-0001-9081-1664					0	11	12	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1764	1764		10.1016/S0140-6736(00)03219-0	http://dx.doi.org/10.1016/S0140-6736(00)03219-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095276				2022-12-28	WOS:000165462300042
J	Bowman, AB; Kamal, A; Ritchings, BW; Philp, AV; McGrail, M; Gindhart, JG; Goldstein, LSB				Bowman, AB; Kamal, A; Ritchings, BW; Philp, AV; McGrail, M; Gindhart, JG; Goldstein, LSB			Kinesin-dependent axonal transport is mediated by the Sunday driver (SYD) protein	CELL			English	Article							FORMIMINOTRANSFERASE CYCLODEAMINASE; HEAVY-CHAIN; CYTOPLASMIC DYNEIN; TAIL DOMAIN; MOTOR; BINDING; MOTILITY; IDENTIFICATION; DROSOPHILA; KINECTIN	A broadly conserved membrane-associated protein required for the functional interaction of kinesin-1 with axonal cargo was identified. Mutations in sunday driver (syd) and the axonal transport motor kinesin-1 cause similar phenotypes in Drosophila, including aberrant accumulations of axonal cargoes. GFP-tagged mammalian SYD localizes to tubulovesicular structures that costain for kinesin-1 and a marker of the secretory pathway. Coimmunoprecipitation analysis indicates that mouse SYD forms a complex with kinesin-1 in vivo. Yeast two-hybrid analysis and in vitro interaction studies reveal that SYD directly binds kinesin-1 via the tetratricopeptide repeat (TPR) domain of kinesin light chain (KLC) with K-d approximate to 200 nM. We propose that SYD mediates the axonal transport of at least one class of vesicles by interacting directly with KLC.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Cellular & Mol Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Massachusetts, Dept Biol, Boston, MA 02125 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Massachusetts System; University of Massachusetts Boston	Goldstein, LSB (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Cellular & Mol Med, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		McGrail, Maura/AAA-5610-2021	McGrail, Maura/0000-0001-9308-6189; Bowman, Aaron/0000-0001-8728-3346	NIGMS NIH HHS [GM35252] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035252] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bashour AM, 1998, J BIOL CHEM, V273, P19612, DOI 10.1074/jbc.273.31.19612; Bowman AB, 1999, J CELL BIOL, V146, P165; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008; Gao YS, 1998, J BIOL CHEM, V273, P33825, DOI 10.1074/jbc.273.50.33825; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; GRASSO G, 1996, DIS, V77, P94; Hennig D, 1998, J BIOL CHEM, V273, P19602, DOI 10.1074/jbc.273.31.19602; Hurd DD, 1996, GENETICS, V144, P1075; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PARCHALIUK DL, 1999, YEAST 2 HYBRID SYS C; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheetz MP, 1999, EUR J BIOCHEM, V262, P19, DOI 10.1046/j.1432-1327.1999.00340.x; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; Toyoshima I, 1996, NEUROSCI LETT, V211, P171, DOI 10.1016/0304-3940(96)12752-X; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	38	261	269	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 10	2000	103	4					583	594		10.1016/S0092-8674(00)00162-8	http://dx.doi.org/10.1016/S0092-8674(00)00162-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106729	Bronze			2022-12-28	WOS:000165348000004
J	Ross, RS; Viazov, S; Gross, T; Hofmann, F; Seipp, H; Roggendorf, M				Ross, RS; Viazov, S; Gross, T; Hofmann, F; Seipp, H; Roggendorf, M			Transmission of hepatitis C virus from a patient to an anesthesiology assistant to five patients.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-TRANSMISSION; B-VIRUS; EPIDEMIOLOGY; INFECTION		Univ Essen Gesamthsch, Natl Reference Ctr Hepatitis C, Inst Virol, D-45122 Essen, Germany; Univ Gesamthsch Wuppertal, Dept Occupat Hlth, D-5600 Wuppertal, Germany; Dr Horst Schmidt Kliniken, Wiesbaden, Germany	University of Duisburg Essen; University of Wuppertal	Ross, RS (corresponding author), Univ Essen Gesamthsch, Natl Reference Ctr Hepatitis C, Inst Virol, Hufelandstr 55, D-45122 Essen, Germany.	ross@uni-essen.de						ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Brown P, 1999, BRIT MED J, V319, P1219, DOI 10.1136/bmj.319.7219.1219; Centers for Disease Control and Prevention, 1988, MMWR MORB MORTAL WKL, V37, P387; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Chouela E, 1996, INT J DERMATOL, V35, P797, DOI 10.1111/j.1365-4362.1996.tb02977.x; Cohen J, 1999, SCIENCE, V285, P26, DOI 10.1126/science.285.5424.26; COUTINHO RA, 1982, LANCET, V1, P345; Duckworth G J, 1999, Commun Dis Public Health, V2, P188; Esteban JI, 1998, CURR STUD HEMATOL BL, P102; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; Felsenstein J., 1993, PHYLIP PHYLOGENETIC; Katzenstein TL, 1999, AIDS, V13, P1737, DOI 10.1097/00002030-199909100-00018; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; MIZOKAMI M, 1998, METH MOLEC MED, V19, P147; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; POLAKOFF S, 1986, BRIT MED J, V293, P33, DOI 10.1136/bmj.293.6538.33; PRENTICE MB, 1992, BRIT MED J, V304, P761, DOI 10.1136/bmj.304.6829.761; Ross RS, 2000, J MED VIROL, V60, P122, DOI 10.1002/(SICI)1096-9071(200002)60:2&lt;122::AID-JMV3&gt;3.0.CO;2-#; SNYDMAN DR, 1976, ANN INTERN MED, V85, P573, DOI 10.7326/0003-4819-85-5-573; SUZUKI K, 1994, J INFECT DIS, V170, P1575, DOI 10.1093/infdis/170.6.1575; VIAZOV S, 1994, J VIROL METHODS, V48, P81, DOI 10.1016/0166-0934(94)90091-4; WEINER AJ, 1993, J VIROL, V67, P4365, DOI 10.1128/JVI.67.7.4365-4368.1993; Widell A, 1999, ANN INTERN MED, V130, P130, DOI 10.7326/0003-4819-130-2-199901190-00007; 1988, MMWR MORB MORTAL WKL, V37, P377	31	102	106	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1851	1854		10.1056/NEJM200012213432505	http://dx.doi.org/10.1056/NEJM200012213432505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117977				2022-12-28	WOS:000165940400005
J	Josefson, D				Josefson, D			University must tell patients that they were research "guinea pigs"	BRITISH MEDICAL JOURNAL			English	News Item																		Curtis JJ, 1996, INT J ANGIOL, V5, P212	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	2000	321	7275					1487	1487						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118166				2022-12-28	WOS:000165994700008
J	Rai, KR; Peterson, BL; Appelbaum, FR; Kolitz, J; Elias, L; Shepherd, L; Hines, J; Threatte, GA; Larson, RA; Cheson, BD; Schiffer, CA				Rai, KR; Peterson, BL; Appelbaum, FR; Kolitz, J; Elias, L; Shepherd, L; Hines, J; Threatte, GA; Larson, RA; Cheson, BD; Schiffer, CA			Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	38th Annual Meeting of the American-Society-of-Hematology	DEC 06-10, 1996	ORLANDO, FL	Amer Soc Hematol, US Dept Vet Affairs Merit Res Funds, NIH			TERM-FOLLOW-UP; PREDNISONE; REGIMENS; AGENT; CLL	Background: Fludarabine is an effective treatment for chronic lymphocytic leukemia that does not respond to initial treatment with chlorambucil. We compared the efficacy of fludarabine with that of chlorambucil in the primary treatment of chronic lymphocytic leukemia. Methods: Between 1990 and 1994, we randomly assigned 509 previously untreated patients with chronic lymphocytic leukemia to one of the following treatments: fludarabine (25 mg per square meter of body-surface area, administered intravenously daily for 5 days every 28 days), chlorambucil (40 mg per square meter, given orally every 28 days), or fludarabine (20 mg per square meter per day for 5 days every 28 days) plus chlorambucil (20 mg per square meter every 28 days). Patients with an additional response at each monthly evaluation continued to receive the assigned treatment for a maximum of 12 cycles. Results: Assignment of patients to the fludarabine-plus-chlorambucil group was stopped when a planned interim analysis revealed excessive toxicity and a response rate that was not better than the rate with fludarabine alone. Among the other two groups, the response rate was significantly higher for fludarabine alone than for chlorambucil alone. Among 170 patients treated with fludarabine, 20 percent had a complete remission, and 43 percent had a partial remission. The corresponding values for 181 patients treated with chlorambucil were 4 percent and 33 percent (P<0.001 for both comparisons). The median duration of remission and the median progression-free survival in the fludarabine group were 25 months and 20 months, respectively, whereas both values were 14 months in the chlorambucil group (P<0.001 for both comparisons). The median overall survival among patients treated with fludarabine was 66 months, which was not significantly different from the overall survival in the other two groups (56 months with chlorambucil and 55 months with combined treatment). Severe infections and neutropenia were more frequent with fludarabine than with chlorambucil (P=0.08), although, overall, toxic effects were tolerable with the two single-drug regimens. Conclusions: When used as the initial treatment for chronic lymphocytic leukemia, fludarabine yields higher response rates and a longer duration of remission and progression-free survival than chlorambucil; overall survival is not enhanced. (N Engl J Med 2000;343:1750-7.) (C) 2000, Massachusetts Medical Society.	Canc Leukemia Grp B, Chicago, IL USA; SW Oncol Grp, San Antonio, TX 78229 USA; Natl Canc Inst, Clin Trials Grp, Kingston, ON, Canada; Eastern Cooperat Oncol Grp, Brookline, MA USA; NCI, Rockville, MD USA	Southwest Oncology Group; Queens University - Canada; Canadian Cancer Trials Group; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rai, KR (corresponding author), Long Isl Jewish Med Ctr, 270-05 76th Ave, New Hyde Pk, NY 11040 USA.	rai@lij.edu		Larson, Richard/0000-0001-9168-3203	NATIONAL CANCER INSTITUTE [U10CA031946, U10CA021115, U10CA032102] Funding Source: NIH RePORTER; NCI NIH HHS [CA21115, CA31946, CA32102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; Dighiero G, 1998, NEW ENGL J MED, V338, P1506, DOI 10.1056/NEJM199805213382104; Fenaux P, 1996, LANCET, V347, P1432; *FRENCH COOP GROUP, 1993, SEMIN ONCOL       S7, V20, P21; GREVER MR, 1988, NOUV REV FR HEMATOL, V30, P457; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEATING MJ, 1993, BLOOD, V81, P2878; Keating MJ, 1998, BLOOD, V92, P1165, DOI 10.1182/blood.V92.4.1165.416k03_1165_1171; KEATING MJ, 1991, J CLIN ONCOL, V9, P44, DOI 10.1200/JCO.1991.9.1.44; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Leporrier M, 1999, BLOOD, V94, p603A; Morrison VA, 1998, BLOOD, V92, p490A; OBRIEN S, 1993, BLOOD, V82, P1695; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; RAI KR, 1987, CHRONIC LYMPHOCYTIC, P253; ROBERTSON LE, 1992, BLOOD, V80, P29	17	762	801	2	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1750	1757		10.1056/NEJM200012143432402	http://dx.doi.org/10.1056/NEJM200012143432402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	382FH	11114313				2022-12-28	WOS:000165812000002
J	Wortel, MJR; Spakman, W				Wortel, MJR; Spakman, W			Geophysics - Subduction and slab detachment in the Mediterranean-Carpathian region	SCIENCE			English	Review							FAULT-PLANE SOLUTIONS; WAVE VELOCITY IMAGE; TYRRHENIAN-SEA; UPPER-MANTLE; TRENCH MIGRATION; AEGEAN REGION; CONTINENTAL LITHOSPHERE; GEODYNAMIC EVOLUTION; STRUCTURAL-ANALYSIS; ACTIVE TECTONICS	Seismic tomography models of the three-dimensional upper mantle velocity structure of the Mediterranean-Carpathian region provide a better understanding of the lithospheric processes governing its geodynamical evolution. Slab detachment, in particular lateral migration of this process along the plate boundary, is a key element in the lithospheric dynamics of the region during the last 20 to 30 million years. It strongly affects arc and trench migration, and causes along-strike variations in vertical motions, stress fields, and magmatism. In a terminal-stage subduction zone, involving collision and suturing, slab detachment is the natural last stage in the gravitational settling of subducted lithosphere.	Univ Utrecht, Fac Earth Sci, Vening Meinesz Res Sch Geodynam, NL-3584 CD Utrecht, Netherlands	Utrecht University	Wortel, MJR (corresponding author), Univ Utrecht, Fac Earth Sci, Vening Meinesz Res Sch Geodynam, Budapestlaan 4, NL-3584 CD Utrecht, Netherlands.	wortel@geo.uu.nl; wims@geo.uu.nl		Spakman, Wim/0000-0002-9557-778X				Amato A., 1993, SEISMIC TOMOGRAPHY T, P361; ANDERSON H, 1987, GEOPHYS J INT, V91, P613, DOI 10.1111/j.1365-246X.1987.tb01661.x; [Anonymous], 13TH P INT GEOL C; Auzende J.M., 1973, J GEOL SOC LONDON, V129, P607, DOI 10.1144/gsjgs.129.6.0607; BADA G., 1999, THESIS VRIJE U AMSTE; Bijwaard H, 2000, GEOPHYS J INT, V141, P71, DOI 10.1046/j.1365-246X.2000.00053.x; Bijwaard H, 1998, J GEOPHYS RES-SOL EA, V103, P30055, DOI 10.1029/98JB02467; BLANCO MJ, 1993, TECTONOPHYSICS, V221, P13, DOI 10.1016/0040-1951(93)90025-F; BUFORN E, 1991, PURE APPL GEOPHYS, V136, P375, DOI 10.1007/BF00878576; BUITER SJH, 2000, THESIS UTRECHT U UTR; Caccamo D, 1996, GEOPHYS J INT, V125, P857, DOI 10.1111/j.1365-246X.1996.tb06029.x; Calvert A, 2000, J GEOPHYS RES-SOL EA, V105, P10871, DOI 10.1029/2000JB900024; Carminati E, 1998, EARTH PLANET SC LETT, V160, P651, DOI 10.1016/S0012-821X(98)00118-6; Carminati E, 1998, EARTH PLANET SC LETT, V160, P667, DOI 10.1016/S0012-821X(98)00119-8; Christensen UR, 1996, EARTH PLANET SC LETT, V140, P27, DOI 10.1016/0012-821X(96)00023-4; Cimini GB, 1999, GEOPHYS RES LETT, V26, P3709, DOI 10.1029/1999GL010907; Csontos L., 1995, ACTA VULCANOL, V7, P1, DOI DOI 10.1016/0040-1951(92)90346-8; DAVIES JH, 1995, EARTH PLANET SC LETT, V129, P85, DOI 10.1016/0012-821X(94)00237-S; de Boorder H, 1998, EARTH PLANET SC LETT, V164, P569, DOI 10.1016/S0012-821X(98)00247-7; DECOURT J, 1990, MEM SOC GEOL FR, V154, P159; DEJONGE MR, 1993, TECTONOPHYSICS, V223, P53, DOI 10.1016/0040-1951(93)90157-F; DEJONGE MR, 1994, J GEOPHYS RES-SOL EA, V99, P12091, DOI 10.1029/94JB00648; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; DERCOURT J, 1986, TECTONOPHYSICS, V123, P241, DOI 10.1016/0040-1951(86)90199-X; DEVOOGD B, 1992, GEOPHYS J INT, V109, P536, DOI 10.1111/j.1365-246X.1992.tb00116.x; Dewey J. F., 1989, GEOL SOC SPEC PUBL L, V45, P265, DOI DOI 10.1144/GSL.SP.1989.045.01.15; Duermeijer CE, 2000, EARTH PLANET SC LETT, V176, P509, DOI 10.1016/S0012-821X(00)00023-6; DURAND B, 1999, GEOL SOC LONDON SPEC, V156; ELSASSER WM, 1971, J GEOPHYS RES, V76, P1101, DOI 10.1029/JB076i005p01101; ERICKSON EJ, 1970, THESIS MIT CAMBRIDGE; Faccenna C, 1996, GEOPHYS J INT, V126, P781, DOI 10.1111/j.1365-246X.1996.tb04702.x; Frepoli A, 1996, GEOPHYS J INT, V125, P879, DOI 10.1111/j.1365-246X.1996.tb06031.x; GHISETTI F, 1981, J STRUCT GEOL, V3, P371, DOI 10.1016/0191-8141(81)90037-7; Girbacea R, 1998, GEOLOGY, V26, P611, DOI 10.1130/0091-7613(1998)026<0611:SITWPL>2.3.CO;2; Giunchi C, 1996, GEOPHYS J INT, V126, P555, DOI 10.1111/j.1365-246X.1996.tb05310.x; GRIFFITHS RW, 1995, EARTH PLANET SC LETT, V133, P1, DOI 10.1016/0012-821X(95)00027-A; Gvirtzman Z, 1999, NATURE, V401, P782, DOI 10.1038/44555; Hippolyte JC, 1999, TECTONICS, V18, P1120, DOI 10.1029/1999TC900027; Horvath F., 1982, AM GEOPHYS UNION GEO, V7, P141, DOI DOI 10.1029/GD007P0141; ISACKS B, 1971, REV GEOPHYS SPACE GE, V9, P103, DOI 10.1029/RG009i001p00103; Jolivet L, 1999, GEOL SOC SPEC PUBL, V156, P1, DOI 10.1144/GSL.SP.1999.156.01.02; Jolivet L, 1998, J GEOPHYS RES-SOL EA, V103, P12123, DOI 10.1029/97JB03616; JOLIVET L, 1994, B SOC GEOL FR, V165, P195; KASTENS K, 1988, GEOL SOC AM BULL, V100, P1140, DOI 10.1130/0016-7606(1988)100<1140:OLITTS>2.3.CO;2; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; LEPICHON X, 1982, MOUNTAIN BUILDING PR, P210; LIPS ALW, 1998, THESIS UTRECHT U UTR; Lucente FP, 1999, J GEOPHYS RES-SOL EA, V104, P20307, DOI 10.1029/1999JB900147; MALINVERNO A, 1986, TECTONICS, V5, P227, DOI 10.1029/TC005i002p00227; Mantovani E, 1996, J GEODYN, V21, P35, DOI 10.1016/0264-3707(95)00011-9; Mantovani E, 2000, J GEODYN, V30, P287, DOI 10.1016/S0264-3707(99)00067-8; Mantovani E., 1997, ANN GEOPHYS-ITALY, V40, P611; Mason PRD, 1998, TECTONOPHYSICS, V297, P157, DOI 10.1016/S0040-1951(98)00167-X; McClusky S, 2000, J GEOPHYS RES-SOL EA, V105, P5695, DOI 10.1029/1999JB900351; MCKENZIE D, 1972, GEOPHYS J ROY ASTR S, V30, P109, DOI 10.1111/j.1365-246X.1972.tb02351.x; MCKENZIE DP, 1970, NATURE, V226, P239, DOI 10.1038/226239a0; Meijer PT, 1997, TECTONICS, V16, P879, DOI 10.1029/97TC02004; Meijer PT, 1996, GEOPHYS RES LETT, V23, P439, DOI 10.1029/96GL00380; Mele G, 1998, GEOPHYS RES LETT, V25, P2877, DOI 10.1029/98GL02175; Mercier J.L, 1987, ANN TECTONICAE, V1, P20; Meulenkamp JE, 1996, TECTONOPHYSICS, V266, P301, DOI 10.1016/S0040-1951(96)00195-3; MUELLER S, 1993, AGU GEODYN SERIES 5, V23, P249; Nemcok M, 1998, TECTONOPHYSICS, V295, P307, DOI 10.1016/S0040-1951(98)00092-4; Noomen R, 1996, J GEODYN, V21, P73, DOI 10.1016/0264-3707(95)00015-1; Olbertz D, 1997, GEOPHYS RES LETT, V24, P221, DOI 10.1029/96GL03971; ONCESCU MC, 1984, TECTONOPHYSICS, V106, P305, DOI 10.1016/0040-1951(84)90182-3; PAYO G, 1969, B SEISMOL SOC AM, V59, P23; Peresson H, 1997, TECTONICS, V16, P38, DOI 10.1029/96TC02730; Piromallo C., 1997, ANN GEOFIS, VXL, P963; PLATT JP, 1989, GEOLOGY, V17, P540, DOI 10.1130/0091-7613(1989)017<0540:ECOTCL>2.3.CO;2; Radulian M, 2000, PURE APPL GEOPHYS, V157, P57, DOI 10.1007/PL00001100; RATSCHBACHER L, 1991, TECTONICS, V10, P257, DOI 10.1029/90TC02623; Rehault J. P., 1985, GEOLOGICAL EVOLUTION, P101; RITSEMA A. R., 1979, GEOL MIJNB, V58, P127; RITSEMA AR, 1969, VERH K NED GEOL MIJN, V26, P105; ROMAN C, 1970, NATURE, V228, P1176, DOI 10.1038/2281176a0; ROYDEN L, 1983, TECTONICS, V2, P63, DOI 10.1029/TC002i001p00063; Sanders CAE, 1999, J GEOPHYS RES-SOL EA, V104, P29095, DOI 10.1029/1998JB900046; Seghedi I, 1998, LITHOS, V45, P483, DOI 10.1016/S0024-4937(98)00046-2; SELVAGGI G, 1995, GEOPHYS J INT, V121, P818, DOI 10.1111/j.1365-246X.1995.tb06441.x; SERRI G, 1993, TECTONOPHYSICS, V223, P117, DOI 10.1016/0040-1951(93)90161-C; SPAKMAN W, 1988, GEOPHYS RES LETT, V15, P60, DOI 10.1029/GL015i001p00060; SPAKMAN W, 1991, GEOPHYS J INT, V107, P309, DOI 10.1111/j.1365-246X.1991.tb00828.x; SPAKMAN W, 1993, PHYS EARTH PLANET IN, V79, P3, DOI 10.1016/0031-9201(93)90142-V; SPAKMAN W, 1990, TERRA NOVA, V2, P542, DOI 10.1111/j.1365-3121.1990.tb00119.x; Spakman W., 1986, GEOL MIJNBOUW-N J G, V65, P145; Spakman W., 1988, MATH GEOPHYSICS, P155, DOI [10.1007/978-94-009-2857-2_8, DOI 10.1007/978-94-009-2857-2_8]; TAYMAZ T, 1991, GEOPHYS J INT, V106, P433, DOI 10.1111/j.1365-246X.1991.tb03906.x; TOMEK C, 1993, GEOLOGY, V21, P535, DOI 10.1130/0091-7613(1993)021<0535:SCMIIN>2.3.CO;2; Ton SYMWA, 1997, GEOPHYS RES LETT, V24, P2095, DOI 10.1029/97GL01939; van der Meulen MJ, 1999, TECTONOPHYSICS, V315, P319, DOI 10.1016/S0040-1951(99)00282-6; van der Meulen MJ, 1998, EARTH PLANET SC LETT, V154, P203, DOI 10.1016/S0012-821X(97)00166-0; van der Meulen MJ, 2000, TECTONICS, V19, P300, DOI 10.1029/1999TC900064; Van der Voo R, 1999, EARTH PLANET SC LETT, V171, P7, DOI 10.1016/S0012-821X(99)00131-4; Van der Voo R., 1993, PALEOMAGNETISM ATLAN, P411; Vandenberg J, 1982, GEODYNAMICS SER AM G, V7, P83; VANDERHILST R, 1991, NATURE, V353, P37, DOI 10.1038/353037a0; VANDERMEULEN MJ, 1999, THESIS UTRECHT U UTR; VLAAR NJ, 1975, PROGR GEODYNAMICS, P234; VON BLANCKENBURG F, 1995, TECTONICS, V14, P120, DOI 10.1029/94TC02051; von Blanckenburg F, 1998, SCHWEIZ MINER PETROG, V78, P55; WALCOTT CR, 1998, THESIS UTRECHT U UTR; WENZEL F, 1998, EOS, V79, P592, DOI DOI 10.1029/98E000427; WESTAWAY R, 1993, J GEOPHYS RES-SOL EA, V98, P21741, DOI 10.1029/93JB01566; WILLINGSHOFER E, THESIS VRIJE U AMSTE; Wilson M, 1999, GEOL SOC SPEC PUBL, V156, P141, DOI 10.1144/GSL.SP.1999.156.01.09; Wortel MJR, 1993, TERR ABSTR, V5, P97; WORTEL MJR, 1992, P K NED AKAD WETENSC, V95, P523; YOSHIOKA S, 1995, J GEOPHYS RES-SOL EA, V100, P20223, DOI 10.1029/94JB01258	109	1248	1259	8	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	2000	290	5498					1910	1917		10.1126/science.290.5498.1910	http://dx.doi.org/10.1126/science.290.5498.1910			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110653				2022-12-28	WOS:000165810000035
J	Heathcote, EJ; Shiffman, ML; Cooksley, WGE; Dusheiko, GM; Lee, SS; Balart, L; Reindollar, R; Reddy, RK; Wright, TL; Lin, A; Hoffman, J; De Pamphilis, J				Heathcote, EJ; Shiffman, ML; Cooksley, WGE; Dusheiko, GM; Lee, SS; Balart, L; Reindollar, R; Reddy, RK; Wright, TL; Lin, A; Hoffman, J; De Pamphilis, J			Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERFERON TREATMENT; RIBAVIRIN; VIRUS; EFFICACY; TRIAL	Background: Chronic hepatitis C virus (HCV) infection in patients with cirrhosis is difficult to treat. In patients with chronic hepatitis C but without cirrhosis, once-weekly administration of interferon modified by the attachment of a 40-kd branched-chain polyethylene glycol moiety (peginterferon alfa-2a) is more efficacious than a regimen of unmodified interferon. We examined the efficacy and safety of peginterferon alfa-2a in patients with HCV-related cirrhosis or bridging fibrosis. Methods: We randomly assigned 271 patients with cirrhosis or bridging fibrosis to receive subcutaneous treatment with 3 million units of interferon alfa-2a three times weekly (88 patients), 90 microg of peginterferon alfa-2a once weekly (96), or 180 microg of peginterferon alfa-2a once weekly (87). Treatment lasted 48 weeks and was followed by a 24-week follow-up period. We assessed efficacy by measuring HCV RNA and alanine aminotransferase and by evaluating liver-biopsy specimens. A histologic response was defined as a decrease of at least 2 points on the 22-point Histological Activity Index. Results: In an intention-to-treat analysis, HCV RNA was undetectable at week 72 in 8 percent, 15 percent, and 30 percent of the patients treated with interferon alfa-2a and with 90 microg and 180 microg of peginterferon alfa-2a, respectively (P=0.001 for the comparison between 180 microg of peginterferon alfa-2a and interferon alfa-2a). At week 72, alanine aminotransferase concentrations had normalized in 15 percent, 20 percent, and 34 percent of patients, respectively (P=0.004 for the comparison between 180 microg of peginterferon alfa-2a and interferon alfa-2a). In the subgroup of 184 patients with paired liver-biopsy specimens, the rates of histologic response at week 72 were 31 percent, 44 percent, and 54 percent, respectively (P=0.02 for the comparison between 180 microg of peginterferon alfa-2a and interferon alfa-2a). All three treatments were similarly tolerated. Conclusions: In patients with chronic hepatitis C and cirrhosis or bridging fibrosis, 180 microg of peginterferon alfa-2a administered once weekly is significantly more effective than 3 million units of standard interferon alfa-2a administered three times weekly. (N Engl J Med 2000;343:1673-80.) (C) 2000, Massachusetts Medical Society.	Toronto Western Hosp, Univ Hlth Network, Dept Med, Toronto, ON M5T 2S8, Canada; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Hepatol Sect, Richmond, VA 23298 USA; Royal Brisbane Hosp, Dept Med, Brisbane, Qld 4029, Australia; Royal Free Hosp, Dept Med, Dept Clin Res, London NW3 2QG, England; Heritage Med Res Clin, Dept Med, Calgary, AB, Canada; Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA USA; Carolinas Ctr Liver Dis, Dept Med, Charlotte, NC USA; Univ Miami, Sch Med, Dept Med, Ctr Liver Dis, Miami, FL USA; Vet Affairs Med Ctr, Dept Med, Gastroenterol Unit, San Francisco, CA 94121 USA; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Virginia Commonwealth University; Royal Brisbane & Women's Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding	Heathcote, EJ (corresponding author), Toronto Western Hosp, Univ Hlth Network, Dept Med, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		cooksley, william ge/G-7742-2011; Dusheiko, Geoffrey M/C-7677-2010					Algranati NE, 1999, HEPATOLOGY, V30, p190A; Ascione A, 1998, ITAL J GASTROENTEROL, V30, P517; Cooksley WGE, 1997, J VIRAL HEPATITIS, V4, P75, DOI 10.1111/j.1365-2893.1997.tb00182.x; Everson GT, 1999, HEPATOLOGY, V30, P271, DOI 10.1002/hep.510300116; Germer JJ, 1999, J CLIN MICROBIOL, V37, P2625, DOI 10.1128/JCM.37.8.2625-2630.1999; Idilman R, 1997, J VIRAL HEPATITIS, V4, P81, DOI 10.1111/j.1365-2893.1997.tb00209.x; *INT C HARM, 1998, FED REGISTER, V63, P31506; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lai MY, 1996, GASTROENTEROLOGY, V111, P1307, DOI 10.1053/gast.1996.v111.pm8898645; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Poynard T, 1998, ACTA GASTRO-ENT BELG, V61, P431; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Schalm SW, 1999, GASTROENTEROLOGY, V117, P408, DOI 10.1053/gast.1999.0029900408; SHIFFMAN M, 1999, GASTROENTEROLOGY, V116, P1275; Shiffman ML, 1997, HEPATOLOGY, V26, P780, DOI 10.1002/hep.510260335; Shiratori Y, 1999, HEPATOLOGY, V29, P1573, DOI 10.1002/hep.510290529; Sulkowski M, 1999, HEPATOLOGY, V30, p197A; Valla DC, 1999, HEPATOLOGY, V29, P1870, DOI 10.1002/hep.510290616; Xu ZX, 1998, HEPATOLOGY, V28, p702A; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	20	659	712	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2000	343	23					1673	1680		10.1056/NEJM200012073432302	http://dx.doi.org/10.1056/NEJM200012073432302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380PX	11106716	Green Published			2022-12-28	WOS:000165711900002
J	Sinclair, RC; Mark, MM; Moore, SE; Lavis, CA; Soldat, AS				Sinclair, RC; Mark, MM; Moore, SE; Lavis, CA; Soldat, AS			Psychology - An electoral butterfly effect	NATURE			English	Article									Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada; Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	University of Alberta; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Sinclair, RC (corresponding author), Univ Alberta, Dept Psychol, P-343 Biosci, Edmonton, AB T6G 2E9, Canada.			Moore, Sean/0000-0002-9668-4077					0	22	22	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					665	666		10.1038/35047160	http://dx.doi.org/10.1038/35047160			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130058				2022-12-28	WOS:000165815200032
J	Berge, KE; Tian, H; Graf, GA; Yu, LQ; Grishin, NV; Schultz, J; Kwiterovich, P; Shan, B; Barnes, R; Hobbs, HH				Berge, KE; Tian, H; Graf, GA; Yu, LQ; Grishin, NV; Schultz, J; Kwiterovich, P; Shan, B; Barnes, R; Hobbs, HH			Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; STEROL ABSORPTION; RECEPTOR; GENE; METABOLISM; PHYTOSTEROLEMIA; XANTHOMATOSIS; SEQUENCES; ELEMENTS; PATHWAY	In healthy individuals, acute changes in cholesterol intake produce modest changes in plasma cholesterol levels. A striking exception occurs in sitosterolemia, an autosomal recessive disorder characterized by increased intestinal absorption and decreased biliary excretion of dietary sterols, hypercholesterolemia, and premature coronary atherosclerosis. We identified seven different mutations in two adjacent, oppositely oriented genes that encode new members of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter family (six mutations in ABCG8 and one in ABCG5) in nine patients with sitosterolemia. The two genes are expressed at highest levels in Liver and intestine and, in mice, cholesterol feeding up-regulates expressions of both genes. These data suggest that ABCG5 and ABCG8 normally cooperate to Limit intestinal absorption and to promote biliary excretion of sterols, and that mutated forms of these transporters predispose to sterol accumulation and atherosclerosis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Tularik Inc, San Francisco, CA 94080 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21205 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Helen.Hobbs@UTSouthwestern.edu	Eckhardt, Erik/G-1567-2010	Graf, Gregory/0000-0002-0130-9929	NHLBI NIH HHS [HL07360, HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007360, P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATY TH, 1986, AM J HUM GENET, V38, P492; BERGE KE, UNPUB; BHATTACHARYYA AK, 1974, J CLIN INVEST, V53, P1033, DOI 10.1172/JCI107640; BINGHAM PM, 1981, CELL, V25, P693, DOI 10.1016/0092-8674(81)90176-8; Bjorkhem I., 1995, METABOLIC MOL BASES, P2073; EWART GD, 1994, J BIOL CHEM, V269, P10370; GREGG RE, 1986, J CLIN INVEST, V77, P1864, DOI 10.1172/JCI112513; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Ikeda S, 2000, BIOCHEM BIOPH RES CO, V273, P1063, DOI 10.1006/bbrc.2000.3071; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; KWITEROVICH PO, 1981, LANCET, V1, P466; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; LUTJOHANN D, 1995, J LIPID RES, V36, P1763; MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x; MORGANRO.J, 1974, J PEDIATR-US, V85, P639, DOI 10.1016/S0022-3476(74)80506-8; NYE ER, 1988, NEW ZEAL MED J, V101, P418; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Patel SB, 1998, J CLIN INVEST, V102, P1041, DOI 10.1172/JCI3963; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pollner R, 1997, FEBS LETT, V405, P31, DOI 10.1016/S0014-5793(97)00152-X; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SALEN G, 1970, J CLIN INVEST, V49, P952, DOI 10.1172/JCI106315; SALEN G, 1992, J LIPID RES, V33, P945; SALEN G, 1985, J LIPID RES, V26, P1126; SALEN G, 1985, J LIPID RES, V26, P203; STELL PS, 1990, TOP CLIN NUTR, V5, P63; SULLIVAN DT, 1974, J EXP ZOOL, V188, P225, DOI 10.1002/jez.1401880210; VENKATESWARAN, 2000, J BIOL CHEM, V275; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	36	1212	1272	3	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	2000	290	5497					1771	1775		10.1126/science.290.5497.1771	http://dx.doi.org/10.1126/science.290.5497.1771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099417				2022-12-28	WOS:000165632400045
J	Martin, JB; Kasper, DL				Martin, JB; Kasper, DL			In whose best interest? Breaching the academic-industrial wall	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Martin, JB (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; BEECHER HK, 1977, MED HARVARD 1 300 YE, P44; Blake John B, 1957, B WATERHOUSE INTRO V; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209; CASH P, 1999, AM NATL BIOGRAPHY, V22, P775; Cho MK, 2000, JAMA-J AM MED ASSOC, V284, P2203, DOI 10.1001/jama.284.17.2203; *HARV U, 2000, FAC POL INT SCI FAC; Lo B, 2000, NEW ENGL J MED, V343, P1616, DOI 10.1056/NEJM200011303432206; McCrary SV, 2000, NEW ENGL J MED, V343, P1621, DOI 10.1056/NEJM200011303432207; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; Weatherall D, 2000, LANCET, V355, P1574, DOI 10.1016/S0140-6736(00)02211-X	12	70	72	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1646	1649		10.1056/NEJM200011303432213	http://dx.doi.org/10.1056/NEJM200011303432213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096177				2022-12-28	WOS:000165511000013
J	Noad, MJ; Cato, DH; Bryden, MM; Jenner, MN; Jenner, KCS				Noad, MJ; Cato, DH; Bryden, MM; Jenner, MN; Jenner, KCS			Cultural revolution in whale songs	NATURE			English	Article							HUMPBACK WHALES; EVOLUTION		Univ Sydney, Dept Vet Anat & Pathol, Sydney, NSW 2006, Australia; Def Sci & Technol Org, Pyrmont, NSW 2009, Australia; Ctr Whale Res, Fremantle, WA 6959, Australia	University of Sydney; Defence Science & Technology	Noad, MJ (corresponding author), Univ Sydney, Dept Vet Anat & Pathol, Sydney, NSW 2006, Australia.		Noad, Michael/D-7975-2013	Noad, Michael/0000-0002-2799-8320				Baker CS, 1998, MAR MAMMAL SCI, V14, P721, DOI 10.1111/j.1748-7692.1998.tb00758.x; CATO D H, 1991, Memoirs of the Queensland Museum, V30, P277; CHITTLEBOROUGH R. G., 1965, AUSTRALIAN J MAR FRESHWATER RES, V16, P33; MUNDINGER PC, 1980, ETHOL SOCIOBIOL, V1, P183, DOI 10.1016/0162-3095(80)90008-4; Payne K., 1983, COMMUNICATION BEHAV, P9; PAYNE RB, 1985, Z TIERPSYCHOL, V70, P1; PAYNE RS, 1971, SCIENCE, V173, P585, DOI 10.1126/science.173.3997.585; TRAINER JM, 1989, ETHOLOGY, V80, P190; TYACK P, 1981, BEHAV ECOL SOCIOBIOL, V8, P105, DOI 10.1007/BF00300822; WINN HE, 1981, BEHAV ECOL SOCIOBIOL, V8, P41, DOI 10.1007/BF00302842; WINN HE, 1978, MAR BIOL, V47, P97, DOI 10.1007/BF00395631	11	251	259	4	97	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					537	537		10.1038/35046199	http://dx.doi.org/10.1038/35046199			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	377WE	11117730	Bronze			2022-12-28	WOS:000165548600102
J	Takayanagi, H; Ogasawara, K; Hida, S; Chiba, T; Murata, S; Sato, K; Takaoka, A; Yokochi, T; Oda, H; Tanaka, K; Nakamura, K; Taniguchi, T				Takayanagi, H; Ogasawara, K; Hida, S; Chiba, T; Murata, S; Sato, K; Takaoka, A; Yokochi, T; Oda, H; Tanaka, K; Nakamura, K; Taniguchi, T			T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma	NATURE			English	Article							COLLAGEN-INDUCED ARTHRITIS; INTERFERON-GAMMA; DEFECTIVE INTERLEUKIN-1; DIFFERENTIATION FACTOR; RHEUMATOID-ARTHRITIS; TARGETED DISRUPTION; MICE; RECEPTOR; LIGAND; GENE	Bone resorption is regulated by the immune system(1,2), where T-cell expression of RANKL (receptor activator of nuclear factor (NF)-kappaB ligand), a member of the tumour-necrosis factor family that is essential for osteoclastogenesis, may contribute to pathological conditions, such as autoimmune arthritis(3,4). However, whether activated T cells maintain bone homeostasis by counterbalancing the action of RANKL remains unknown. Here we show that T-cell production of interferon (IFN)-gamma strongly suppresses osteoclastogenesis by interfering with the RANKL-RANK signalling pathway. IFN-gamma induces rapid degradation of the RANK adapter protein, TRAF6 (tumour necrosis factor receptor-associated factor 6), which results in strong inhibition of the RANKL-induced activation of the transcription factor NF-kappaB and JNK. This inhibition of osteoclastogenesis is rescued by overexpressing TRAF6 in precursor cells, which indicates that TRAF6 is the target critical for the IFN-gamma action. Furthermore, we provide evidence that the accelerated degradation of TRAF6 requires both its ubiquitination, which is initiated by RANKL, and IFN-gamma -induced activation of the ubiquitin-proteasome system. Our study shows that there is cross-talk between the tumour necrosis factor and IFN families of cytokines, through which IFN-gamma provides a negative link between T-cell activation and bone resorption. Our results may offer a therapeutic approach to treat the inflammation-induced tissue breakdown.	Univ Tokyo, Fac Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Japan Technol Corp, CREST, Bunkyo Ku, Tokyo 1138613, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Taniguchi, T (corresponding author), Univ Tokyo, Fac Med, Dept Immunol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	tada@m.u-tokyo.ac.jp	Ogasawara, Kouetsu/G-9892-2011; Murata, Shigeo/A-1426-2010	Murata, Shigeo/0000-0002-3177-3503				Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231-4236.1999; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P; Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Kinne RW, 1997, BBA-MOL BASIS DIS, V1360, P109, DOI 10.1016/S0925-4439(96)00079-8; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; ManourySchwartz B, 1997, J IMMUNOL, V158, P5501; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1986, J IMMUNOL, V137, P3544; Takayanagi H, 2000, ARTHRITIS RHEUM-US, V43, P259, DOI 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W; Takayanagi H, 1999, J CLIN INVEST, V104, P137, DOI 10.1172/JCI6093; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Tanaka K, 1998, IMMUNOL REV, V163, P161; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Ukai T, 1996, J PERIODONTAL RES, V31, P414, DOI 10.1111/j.1600-0765.1996.tb00510.x; Vermeire K, 1997, J IMMUNOL, V158, P5507; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	30	992	1055	6	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					600	605		10.1038/35046102	http://dx.doi.org/10.1038/35046102			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117749				2022-12-28	WOS:000165548600122
J	Fujita, M; Miyamoto, S; Sekiguchi, H; Eiho, S; Sasayama, S				Fujita, M; Miyamoto, S; Sekiguchi, H; Eiho, S; Sasayama, S			Effects of posture on sympathetic nervous modulation in patients with chronic heart failure	LANCET			English	Article							RATE-VARIABILITY; DISEASE	We investigated which recumbent position is preferred by patients with chronic heart failure (CHF) and whether sympathetic nervous modulation differs in three recumbent positions. We assessed 12 patients with CHF by spectral analysis of heart-rate variability and measurement of plasma norepinephrine concentrations. The right lateral decubitus position was preferred for significantly longer periods than the left lateral decubitus and supine positions. Sympathetic nervous modulation was most attenuated in the right lateral decubitus position. The right lateral decubitus position preferred by patients with CHF may be a self-protective mechanism to control increased sympathetic nervous modulation.	Kyoto Univ, Coll Med Technol, Kyoto 6068507, Japan; Takeda Hosp, Div Cardiol, Kyoto, Japan; Kyoto Univ, Grad Sch Informat, Dept Syst Sci, Kyoto, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan	Kyoto University; Kyoto University; Kyoto University	Fujita, M (corresponding author), Kyoto Univ, Coll Med Technol, 53 Kawaharacho, Kyoto 6068507, Japan.							ECKBERG DL, 1971, NEW ENGL J MED, V285, P877, DOI 10.1056/NEJM197110142851602; Fauchier L, 1999, J AM COLL CARDIOL, V33, P1203, DOI 10.1016/S0735-1097(99)00021-2; HASKING GJ, 1986, CIRCULATION, V73, P615, DOI 10.1161/01.CIR.73.4.615; HUIKURI HV, 1994, CIRCULATION, V90, P121, DOI 10.1161/01.CIR.90.1.121; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178	5	36	37	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1822	1823		10.1016/S0140-6736(00)03240-2	http://dx.doi.org/10.1016/S0140-6736(00)03240-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117920				2022-12-28	WOS:000165545700019
J	Wang, JX; Davies, M; Norman, RJ				Wang, JX; Davies, M; Norman, RJ			Body mass and probability of pregnancy during assisted reproduction treatment: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Univ Adelaide, Queen Elizabeth Hosp, Dept Obstet & Gynaecol, Woodville, SA 5011, Australia	University of Adelaide	Wang, JX (corresponding author), Univ Adelaide, Queen Elizabeth Hosp, Dept Obstet & Gynaecol, Woodville, SA 5011, Australia.		Norman, Robert J/A-1155-2007; Davies, Michael/GWV-2527-2022; Davies, Michael John/Y-3542-2018	Norman, Robert J/0000-0002-3118-3896; Davies, Michael John/0000-0003-1526-0801				CORREA H, 1978, AM J CLIN NUTR, V31, P1431, DOI 10.1093/ajcn/31.8.1431; FRISCH RE, 1989, SCIENCE, V246, P432, DOI 10.1126/science.2814472; Lake JK, 1997, INT J OBESITY, V21, P432, DOI 10.1038/sj.ijo.0800424; NORMAN RJ, 1995, FERTIL STERIL, V63, P329; NORMAN RJ, 1991, HUM REPROD, V6, P206, DOI 10.1093/oxfordjournals.humrep.a137307	5	222	232	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1320	1321		10.1136/bmj.321.7272.1320	http://dx.doi.org/10.1136/bmj.321.7272.1320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090515	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000165561600026
J	Pavesi, L; Dal Negro, L; Mazzoleni, C; Franzo, G; Priolo, F				Pavesi, L; Dal Negro, L; Mazzoleni, C; Franzo, G; Priolo, F			Optical gain in silicon nanocrystals	NATURE			English	Article							SI NANOCRYSTALS; QUANTUM CONFINEMENT; POROUS SILICON; LIGHT-EMISSION; CRYSTALLINE SILICON; LUMINESCENCE; ABSORPTION; PHOTOLUMINESCENCE; OPTOELECTRONICS; WAVELENGTH	Adding optical functionality to a silicon microelectronic chip is one of the most challenging problems of materials research. Silicon is an indirect-bandgap semiconductor and so is an inefficient emitter of light. For this reason, integration of optically functional elements with silicon microelectronic circuitry has largely been achieved through the use of direct-bandgap compound semiconductors. For optoelectronic applications, the key device is the light source-a laser. Compound semiconductor lasers exploit low-dimensional electronic systems, such as quantum wells and quantum dots, as the active optical amplifying medium. Here we demonstrate that light amplification is possible using silicon itself, in the form of quantum dots dispersed in a silicon dioxide matrix. Net optical gain is seen in both waveguide and transmission configurations, with the material gain being of the same order as that of direct-bandgap quantum dots. We explain the observations using a model based on population inversion of radiative states associated with the Si/SiO2 interface. These findings open a route to the fabrication of a silicon laser.	Univ Trent, INFM, I-38050 Trento, Italy; Univ Catania, INFM, I-95129 Catania, Italy; Univ Catania, Dipartimento Fis & Astron, I-95129 Catania, Italy; Univ Trent, Dipartimento Fis, I-38050 Trento, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Trento; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Catania; University of Catania; University of Trento	Pavesi, L (corresponding author), Univ Trent, INFM, Via Sommar 14, I-38050 Trento, Italy.	pavesi@science.unitn.it	Mazzoleni, Claudio/E-5615-2011; pavesi, lorenzo/F-2631-2011; Franzo, Giorgia/B-7524-2015; pavesi, lorenzo/ACW-4934-2022	Mazzoleni, Claudio/0000-0002-2398-0721; pavesi, lorenzo/0000-0001-7316-6034; Franzo, Giorgia/0000-0003-3630-0315; pavesi, lorenzo/0000-0001-7316-6034; Priolo, Francesco/0000-0003-1218-2289				Bisi O, 2000, SURF SCI REP, V38, P1, DOI 10.1016/S0167-5729(99)00012-6; Blood P, 2000, IEEE J QUANTUM ELECT, V36, P354, DOI 10.1109/3.825883; Canham LT, 2000, NATO SCI SER II-MATH, V6, P85; CANHAM LT, 1990, APPL PHYS LETT, V57, P1045; CULLIS AG, 1991, NATURE, V353, P335, DOI 10.1038/353335a0; DEGOLI E, IN PRESS SURF SCI; Fauchet PM, 1998, J LUMIN, V80, P53, DOI 10.1016/S0022-2313(98)00070-2; FRANZO G, 1994, APPL PHYS LETT, V64, P2235, DOI 10.1063/1.111655; Hirschman KD, 1996, NATURE, V384, P338, DOI 10.1038/384338a0; HVAM JM, 1978, J APPL PHYS, V49, P3124, DOI 10.1063/1.325304; Iacona F, 2000, J APPL PHYS, V87, P1295, DOI 10.1063/1.372013; IYER SS, 1993, SCIENCE, V260, P40, DOI 10.1126/science.260.5104.40; JORDAN V, 1994, IEE P-OPTOELECTRON, V141, P13, DOI 10.1049/ip-opt:19949912; Kanemitsu Y, 1998, PHYS REV B, V58, P9652, DOI 10.1103/PhysRevB.58.9652; Kirstaedter N, 1996, APPL PHYS LETT, V69, P1226, DOI 10.1063/1.117419; Klimov VI, 1998, APPL PHYS LETT, V73, P2603, DOI 10.1063/1.122519; Kovalev D, 1999, PHYS STATUS SOLIDI B, V215, P871, DOI 10.1002/(SICI)1521-3951(199910)215:2<871::AID-PSSB871>3.0.CO;2-9; Kovalev D, 2000, PHYS REV B, V61, P4485, DOI 10.1103/PhysRevB.61.4485; Leong D, 1997, NATURE, V387, P686, DOI 10.1038/42667; Lingk C, 2000, APPL PHYS LETT, V76, P3507, DOI 10.1063/1.126689; Linnros J, 1997, THIN SOLID FILMS, V297, P167, DOI 10.1016/S0040-6090(96)09359-5; LU ZH, 1995, NATURE, V378, P258, DOI 10.1038/378258a0; MILLER DAB, 1995, NATURE, V378, P238, DOI 10.1038/378238a0; Nassiopoulos AG, 1996, APPL PHYS LETT, V69, P2267, DOI 10.1063/1.117529; Okamoto S, 1997, SOLID STATE COMMUN, V103, P573, DOI 10.1016/S0038-1098(97)00227-5; Shaklee K. L., 1973, Journal of Luminescence, V7, P284, DOI 10.1016/0022-2313(73)90072-0; vonBehren J, 1996, J NON-CRYST SOLIDS, V198, P957, DOI 10.1016/0022-3093(96)00095-6; WILSON WL, 1993, SCIENCE, V262, P1242, DOI 10.1126/science.262.5137.1242; Wolkin MV, 1999, PHYS REV LETT, V82, P197, DOI 10.1103/PhysRevLett.82.197; YARIV A, 1974, QUANTUM ELECT; 1998, MAT RES B, V23	31	2206	2328	6	648	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					440	444		10.1038/35044012	http://dx.doi.org/10.1038/35044012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100719				2022-12-28	WOS:000165429800039
J	Agalioti, T; Lomvardas, S; Parekh, B; Yie, JM; Maniatis, T; Thanos, D				Agalioti, T; Lomvardas, S; Parekh, B; Yie, JM; Maniatis, T; Thanos, D			Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter	CELL			English	Article							RNA-POLYMERASE-II; NUCLEOSOME DISRUPTION; HUMAN SWI/SNF; HMG I(Y); IN-VITRO; ENHANCEOSOME; HISTONE; HOLOENZYME; COMPLEX; BINDING	Here, we show that the IFN-beta enhanceosome activates transcription by directing the ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter. The enhanceosome is assembled in the nucleosome-free enhancer region of the IFN-beta gene, leading to the modification and remodeling of a strategically positioned nucleosome that masks the TATA box and the start site of transcription. Initially, the GCN5 complex is recruited, which acetylates the nucleosome, and this is followed by recruitment of the CBP-PoIII holoenzyme complex. Nucleosome acetylation in turn facilitates SWI/SNF recruitment by CBP, resulting in chromatin remodeling. This program of recruitment culminates in the binding of TFIID to the promoter and the activation of transcription.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA	Columbia University; Harvard University	Thanos, D (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.		Thanos, Dimitris/AAE-5720-2019	Lomvardas, Stavros/0000-0002-7668-3026; Agalioti, Theodora/0000-0002-5898-2751	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kim DS, 1997, POLYM ADVAN TECHNOL, V8, P1, DOI 10.1002/(SICI)1099-1581(199701)8:1<1::AID-PAT601>3.0.CO;2-G; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; KINGSTONR E, 1999, GENE DEV, V15, P2339; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Lowary PT, 1997, P NATL ACAD SCI USA, V94, P1183, DOI 10.1073/pnas.94.4.1183; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Munshi N, 1999, COLD SPRING HARB SYM, V64, P149, DOI 10.1101/sqb.1999.64.149; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Utley RT, 1996, METHOD ENZYMOL, V274, P276; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; ZINN K, 1986, CELL, V45, P611, DOI 10.1016/0092-8674(86)90293-X	34	591	606	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 10	2000	103	4					667	678		10.1016/S0092-8674(00)00169-0	http://dx.doi.org/10.1016/S0092-8674(00)00169-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106736	Bronze			2022-12-28	WOS:000165348000011
J	Stern, V				Stern, V			Operations: spinal versus general anaesthetics - a patient's view	BRITISH MEDICAL JOURNAL			English	Article											Stern, V (corresponding author), 30 Goldhurst Terrace, London NW6 3HU, England.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1606	1607		10.1136/bmj.321.7276.1606	http://dx.doi.org/10.1136/bmj.321.7276.1606			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124198	Green Published			2022-12-28	WOS:000166134500034
J	von Gunten, CF; Ferris, FD; Emanuel, LL				von Gunten, CF; Ferris, FD; Emanuel, LL			Ensuring competency in end-of-life care - Communication and relational skills	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; ADVANCE DIRECTIVES; EUTHANASIA; DEATH; ATTITUDES; FUTILITY; REQUESTS	Physician competence in end-of-life care requires skill in communication, decision making, and building relationships, yet these skills were not taught to the majority of physicians during their training. This article presents a 7-step approach for physicians for structuring communication regarding care at the end of life. Physicians should prepare for discussions by confirming medical facts and establishing an appropriate environment; establish what the patient (and family) knows by using open-ended questions; determine how information is to be handled at the beginning of the patient-physician relationship; deliver the information in a sensitive but straightforward manner; respond to emotions of the patients, parents, and families; establish goals for care and treatment priorities when possible; and establish an overall plan. These 7 steps can be used in situations such as breaking bad news, setting treatment goals, advance care planning, withholding or withdrawing therapy, making decisions in sudden life-threatening illness, resolving conflict around medical futility, responding to a request for physician-assisted suicide, and guiding patients and families through the last hours of living and early stages after death. Effective application as part of core end-of-life care competencies is likely to improve patients' and families' experiences of care. It may also enhance physicians' professional fulfillment from satisfactory relationships with their patients and patients' families.	Northwestern Univ, Sch Med, Interdisciplinary Program Professionalism & Human, EPEC Project, Chicago, IL 60611 USA; San Diego Hospice, Ctr Palliat Studies, San Diego, CA USA	Northwestern University	Emanuel, LL (corresponding author), Northwestern Univ, Sch Med, Interdisciplinary Program Professionalism & Human, EPEC Project, 750 N Lake Shore Dr,Suite 601, Chicago, IL 60611 USA.	lemanuel@epec.net						[Anonymous], 1989, Ann Intern Med, V110, P734; [Anonymous], 1991, JAMA, V265, P1868; *ASP REF GROUP, 1999, PALL CAR PAT FAM COU; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BREITBART W, 1998, TXB PSYCHOONCOLOGY, P437; Buckman R, 1992, BREAK BAD NEWS GUIDE, P65, DOI 10.3138/9781487596989; CASSEM NH, 1976, ACUTE GRIEF FUNERAL; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; CHOCHINOV HM, 1998, PSYCHO-ONCOLOGY, P1016; *COUN ETH JUD AFF, 1998, COUNC ETH JUD AFF RE, P41; *COUNC ETH JUD AFF, 1998, COUNC ETH JUD AFF RE, P46; *COUNC ETH JUD AFF, 1998, COUNC ETH JUD AFF RE, P30; *COUNC ETH JUD AFF, 1998, REP END LIF CAR, P52; COUSINS N, 1985, NEW ENGL J MED, V313, P1422, DOI 10.1056/NEJM198511283132227; Doyle D., 1998, OXFORD TXB PALLIATIV, P957; ELLERSHAW JE, 1995, J PAIN SYMPTOM MANAG, V10, P192, DOI 10.1016/0885-3924(94)00123-3; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL L, 1993, J CLIN ETHIC, V4, P8; Emanuel L. L., 1998, REGULATING WE DIE ET; Emanuel LL, 1998, JAMA-J AM MED ASSOC, V280, P643, DOI 10.1001/jama.280.7.643; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 2000, EPEC CURRICULUM ED P; Emanuel LL, 1998, PRINCIPLES PRACTICE, P791; Evans Alison, 1994, Palliative Medicine, V8, P159, DOI 10.1177/026921639400800211; Field MJ, 1997, APPROACHING DEATH IM; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; GUTHEIL TG, 1984, NEW ENGL J MED, V311, P49, DOI 10.1056/NEJM198407053110110; Halevy A, 1996, JAMA-J AM MED ASSOC, V276, P571, DOI 10.1001/jama.276.7.571; HINOHARA S, 1993, ANN INTERN MED, V118, P638, DOI 10.7326/0003-4819-118-8-199304150-00012; *HOSP I FLOR SUNC, 1996, CAR TIM DEATH HOSP R; *HOSP I FLOR SUNC, 1996, GRIEF BER HOSP TRAIN; HUDSON T, 1994, HOSP HEALTH NETWORK, V68, P26; HUDSON T, 1994, HOSP HEALTH NETWORK, V68, P32; IRVINE P, 1985, NEW ENGL J MED, V312, P1704, DOI 10.1056/NEJM198506273122608; Janson L J, 1991, J Palliat Care, V7, P51; Laine C, 1996, ANN INTERN MED, V125, P640, DOI 10.7326/0003-4819-125-8-199610150-00003; MARTINEZ J, 1997, CANC NURSING PRINCIP; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; O'Gorman SM, 1998, J ADV NURS, V27, P1127, DOI 10.1046/j.1365-2648.1998.00659.x; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PEARLMAN R, 1992, YOUR LIFE YOUR CHOIC; Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; ROY DJ, 1998, OXFORD TXB PALLIATIV, P112; SHELDON F, 1993, MANAGEMENT TERMINAL, P29; TENO JM, 1994, J AM GERIATR SOC, V42, P1202, DOI 10.1111/j.1532-5415.1994.tb06990.x; Teno JM, 1996, J CLIN ETHIC, V7, P205; The Council for Environmental Education, 1998, COUNCIL ENV ED AGEND, P1; TODRES ID, 1994, PEDIATR CLIN N AM, V41, P1395; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; *U TOR JOINT CTR B, 1999, JOINT CTR BIOETH CAN; VACHON MLS, 1982, AM J PSYCHIAT, V139, P998; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; Vincent JL, 1998, INTENS CARE MED, V24, P1251, DOI 10.1007/s001340050758; von Gunten C F, 2000, J Palliat Med, V3, P157, DOI 10.1089/10966210050085223; Weber M, 1998, J PALLIATIVE CARE, V14, P34, DOI 10.1177/082585979801400406; Yancey D, 1990, J Palliat Care, V6, P24; YOUNGNER SJ, 1994, J AM GERIATR SOC, V42, P887, DOI 10.1111/j.1532-5415.1994.tb06565.x	62	166	167	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3051	3057		10.1001/jama.284.23.3051	http://dx.doi.org/10.1001/jama.284.23.3051			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	382VC	11122596	Bronze			2022-12-28	WOS:000165847200034
J	Wenneras, C; Wold, N				Wenneras, C; Wold, N			A chair of one's own - The upper reaches of academe remain stubbornly inaccessible to women.	NATURE			English	Editorial Material									Sahlgrens Univ Hosp, Dept Clin Bacteriol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Immunol, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital	Wenneras, C (corresponding author), Sahlgrens Univ Hosp, Dept Clin Bacteriol, S-41345 Gothenburg, Sweden.			Wold, Agnes/0000-0001-9196-5040					0	19	19	0	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					647	647		10.1038/35047182	http://dx.doi.org/10.1038/35047182			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130048				2022-12-28	WOS:000165815200021
J	Chung-Faye, GA; Kerr, DJ				Chung-Faye, GA; Kerr, DJ			ABC of colorectal cancer - Innovative treatment for colon cancer	BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED TRIAL; THERAPY		Univ Birmingham, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Chung-Faye, GA (corresponding author), Univ Birmingham, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.							Chung-Faye GA, 2000, MOL MED TODAY, V6, P82, DOI 10.1016/S1357-4310(99)01598-1; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; Langman M, 1998, GUT, V43, P578, DOI 10.1136/gut.43.4.578; Riethmuller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Vermorken JB, 1999, LANCET, V353, P345, DOI 10.1016/S0140-6736(98)07186-4	6	15	15	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1397	1399		10.1136/bmj.321.7273.1397	http://dx.doi.org/10.1136/bmj.321.7273.1397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099287	Green Published			2022-12-28	WOS:000165720100032
J	Kopp, A; Duncan, I; Carroll, SB				Kopp, A; Duncan, I; Carroll, SB			Genetic control and evolution of sexually dimorphic characters in Drosophila	NATURE			English	Article							MELANOGASTER SPECIES-GROUP; MOLECULAR PHYLOGENY; SEX DETERMINATION; HOX GENES; DIFFERENTIATION; PROTEIN; DIVERGENCE; SELECTION; MUTATIONS; COURTSHIP	Sexually dimorphic abdominal pigmentation and segment morphology evolved recently in the melanogaster species group of the fruitfly Drosophila. Here we show that these traits are controlled by the bric-a-brac (bab) gene, which integrates regulatory inputs from the homeotic and sex-determination pathways. bab expression is modulated segment- and sex-specifically in sexually dimorphic species, but is uniform in sexually monomorphic species. We suggest that bab has an ancestral homeotic function, and that regulatory changes at the bab locus played a key role in the evolution of sexual dimorphism. Pigmentation patterns specified by bab affect mating preferences, suggesting that sexual selection has contributed to the evolution of bab regulation.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL)	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@facstaff.wisc.edu						Anderson M., 1994, SEXUAL SELECTION, DOI 10.1515/9780691207278; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; BAKER BS, 1980, GENETICS, V94, P383; Bender W, 2000, DEVELOPMENT, V127, P3981; BOCK IR, 1980, SYST ENTOMOL, V5, P341, DOI 10.1111/j.1365-3113.1980.tb00420.x; Bock IR, 1971, U TEXAS PUBL, V7103, P273; Bock IR., 1972, U TEXAS PUBLS, V7, P1; Brakefield PM, 1996, NATURE, V384, P236, DOI 10.1038/384236a0; BURKE AC, 1995, DEVELOPMENT, V121, P333; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; Carson H.L., 1978, ECOLOGICAL GENETICS, P93; CARSON HI, 1999, EVOL GENET, P495; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Cordts R, 1996, ANIM BEHAV, V52, P269, DOI 10.1006/anbe.1996.0172; COSCHIGANO KT, 1993, GENE DEV, V7, P42, DOI 10.1101/gad.7.1.42; CROSBY MA, 1993, GENETICS, V134, P809; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; EBERHARD WG, 1991, BIOL REV, V66, P1, DOI 10.1111/j.1469-185X.1991.tb01133.x; Fisher, 1958, GENETICAL THEORY NAT; GODT D, 1993, DEVELOPMENT, V119, P799; Gurganus MC, 1999, GENETICS, V152, P1585; Holland B, 1998, EVOLUTION, V52, P1, DOI 10.1111/j.1558-5646.1998.tb05132.x; HOPMANN R, 1995, GENETICS, V139, P815; JURSNICH VA, 1993, DEV BIOL, V155, P235, DOI 10.1006/dbio.1993.1021; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KIRKPATRICK M, 1982, EVOLUTION, V36, P1, DOI [10.2307/2407961, 10.1111/j.1558-5646.1982.tb05003.x]; Kopp A, 1997, DEVELOPMENT, V124, P3703; KOPP A, IN PRESS DROS INFO S; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; Lyman RF, 1999, GENET RES, V74, P303, DOI 10.1017/S001667239900419X; McKeown M, 1992, CURR OPIN GENET DEV, V2, P299, DOI 10.1016/S0959-437X(05)80288-6; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; OHNISHI S, 1985, JPN J GENET, V60, P355, DOI 10.1266/jjg.60.355; PELANDAKIS M, 1993, J MOL EVOL, V37, P525, DOI 10.1007/BF00160433; POINTUD JC, 1998, COMMUNICATION; ROBERTSON A, 1977, GENETICA, V47, P73, DOI 10.1007/BF00122443; RUSSO CAM, 1995, MOL BIOL EVOL, V12, P391; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; Stern DL, 1998, NATURE, V396, P463, DOI 10.1038/24863; Sucena E, 2000, P NATL ACAD SCI USA, V97, P4530, DOI 10.1073/pnas.97.9.4530; TODA MJ, 1991, ORIENT INSECTS, V25, P69, DOI 10.1080/00305316.1991.10432216; True JR, 1997, EVOLUTION, V51, P816, DOI [10.2307/2411157, 10.1111/j.1558-5646.1997.tb03664.x]; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; Waterbury JA, 1999, GENETICS, V152, P1653	47	274	280	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					553	559		10.1038/35046017	http://dx.doi.org/10.1038/35046017			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117736				2022-12-28	WOS:000165548600109
J	Lunde, C; Jensen, PE; Haldrup, A; Knoetzel, J; Scheller, HV				Lunde, C; Jensen, PE; Haldrup, A; Knoetzel, J; Scheller, HV			The PSI-H subunit of photosystem I is essential for state transitions in plant photosynthesis	NATURE			English	Article							PROTEIN-PHOSPHORYLATION; CHLAMYDOMONAS-REINHARDTII; CHLOROPHYLL-PROTEINS; ARABIDOPSIS-THALIANA; EXCITATION-ENERGY; THYLAKOIDS; EXPRESSION; MUTANTS; MAIZE	Photosynthesis in plants involves two photosystems responsible for converting light energy into redox processes. The photosystems, PSI and PSII, operate largely in series, and therefore their excitation must be balanced in order to optimize photosynthetic performance(1). When plants are exposed to illumination favouring either PSII or PSI they can redistribute excitation towards the light-limited photosystem. Long-term changes in illumination lead to changes in photosystem stoichiometry(2,3). In contrast, state transition is a dynamic mechanism that enables plants to respond rapidly to changes in illumination. When PSII is favoured (state 2), the redox conditions in the thylakoids change and result in activation of a protein kinase(4-6). The kinase phosphorylates the main light-harvesting complex (LHCII) and the mobile antenna complex is detached from PSII. It has not been clear if attachment of LHCII to PSI in state 2 is important in state transitions. Here we show that in the absence of a specific PSI subunit, PSI-H, LHCII cannot transfer energy to PSI, and state transitions are impaired.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Copenhagen C, Denmark	University of Copenhagen	Scheller, HV (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, 40 Thorvaldsensvej, DK-1871 Copenhagen C, Denmark.		Scheller, Henrik/AAH-4770-2020; Jensen, Poul Erik/A-4862-2014; Scheller, Henrik V/A-8106-2008	Scheller, Henrik/0000-0002-6702-3560; Jensen, Poul Erik/0000-0001-6524-7723; Scheller, Henrik V/0000-0002-6702-3560; Haldrup, Anna/0000-0002-2348-7072				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; Allen JF, 1997, PHYSIOL PLANTARUM, V100, P863, DOI 10.1034/j.1399-3054.1997.1000412.x; BASSI R, 1985, CARLSBERG RES COMMUN, V50, P145, DOI 10.1007/BF02907142; BASSI R, 1985, CARLSBERG RES COMMUN, V50, P127, DOI 10.1007/BF02907141; BOEKEMA EJ, IN PRESS BIOCHEMISTR; Fleischmann MM, 1999, J BIOL CHEM, V274, P30987, DOI 10.1074/jbc.274.43.30987; Fromme P, 1996, CURR OPIN STRUC BIOL, V6, P473, DOI 10.1016/S0959-440X(96)80112-6; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; Horton P, 1999, AUST J PLANT PHYSIOL, V26, P659, DOI 10.1071/PP99095; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Kjaer B, 1996, PHOTOSYNTH RES, V47, P33, DOI 10.1007/BF00017751; KNOETZEL J, 1991, PLANTA, V185, P111, DOI 10.1007/BF00194522; Kruse O, 1999, PHOTOSYNTH RES, V61, P43, DOI 10.1023/A:1006229308606; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; SAMSON G, 1995, BBA-BIOENERGETICS, V1232, P21, DOI 10.1016/0005-2728(95)00104-6; Scheller HV, 1997, PHYSIOL PLANTARUM, V100, P842, DOI 10.1034/j.1399-3054.1997.1000410.x; STEINBACK KE, 1982, ARCH BIOCHEM BIOPHYS, V216, P356, DOI 10.1016/0003-9861(82)90221-1; WALTERS RG, 1994, PLANTA, V195, P248, DOI 10.1007/BF00199685; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961	24	282	306	0	52	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					613	615		10.1038/35046121	http://dx.doi.org/10.1038/35046121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117752				2022-12-28	WOS:000165548600125
J	Spurgeon, D				Spurgeon, D			Canada tries to limit nanotech brain drain	NATURE			English	Article																			0	2	2	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					623	623		10.1038/35046291	http://dx.doi.org/10.1038/35046291			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117756	Bronze			2022-12-28	WOS:000165548600135
J	Hellstrom, AL				Hellstrom, AL			Influence of potty training habits on dysfunctional bladder in children	LANCET			English	Editorial Material							INFANTS		Queen Silvia Childrens Hosp, Urotherapeut Unit, S-41685 Gothenburg, Sweden; Gothenburg Univ, Inst Nursing, Div Hlth & Caring Sci, S-41685 Gothenburg, Sweden	Queen Silvia Children's Hospital; University of Gothenburg	Hellstrom, AL (corresponding author), Queen Silvia Childrens Hosp, Urotherapeut Unit, S-41685 Gothenburg, Sweden.							Bachelard M, 1999, J UROLOGY, V162, P1733, DOI 10.1016/S0022-5347(05)68226-2; Bakker E, 2000, BJU INT, V86, P248, DOI 10.1046/j.1464-410x.2000.00737.x; GOELLNER MH, 1981, NEPHRON, V28, P174, DOI 10.1159/000182168; Holmdahl G, 1996, J UROLOGY, V156, P1809, DOI 10.1016/S0022-5347(01)65543-5; JANSSON UB, IN PRESS J UROL; MUELLNER SR, 1960, JAMA-J AM MED ASSOC, V172, P1256, DOI 10.1001/jama.1960.03020120034007; Sillen U, 2000, J UROLOGY, V163, P278, DOI 10.1016/S0022-5347(05)68036-6; SILLEN U, 2000, BJU INT S, V85, P13; YEUNG CK, 1995, BRIT J UROL, V75, P531, DOI 10.1111/j.1464-410X.1995.tb07278.x; YEUNG CK, 1995, BRIT J UROL, V76, P235, DOI 10.1111/j.1464-410X.1995.tb07682.x	10	30	36	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1787	1787		10.1016/S0140-6736(00)03228-1	http://dx.doi.org/10.1016/S0140-6736(00)03228-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117908				2022-12-28	WOS:000165545700007
J	Adams, KL; Daley, DO; Qiu, YL; Whelan, J; Palmer, JD				Adams, KL; Daley, DO; Qiu, YL; Whelan, J; Palmer, JD			Repeated, recent and diverse transfers of a mitochondrial gene to the nucleus in flowering plants	NATURE			English	Article							MOLECULAR-CLONING; SWEET-POTATO; EVOLUTION; GENOMES; SUBUNIT; IMPORT; PRESEQUENCE; PROTEIN; SIGNALS; OXIDASE	A central component of the endosymbiotic theory for the bacterial origin of the mitochondrion is that many of its genes were transferred to the nucleus. Most of this transfer occurred early in mitochondrial evolution(1); functional transfer of mitochondrial genes has ceased in animals(2). Although mitochondrial gene transfer continues to occur in plants(3), no comprehensive study of the frequency and timing of transfers during plant evolution has been conducted. Here we report frequent loss (26 times) and transfer to the nucleus of the mitochondrial gene rps10 among 277 diverse angiosperms. Characterization of nuclear rps10 genes from 16 out of 26 loss lineages implies that many independent, RNA-mediated rps10 transfers occurred during recent angiosperm evolution; each of the genes may represent a separate functional gene transfer. Thus, rps10 has been transferred to the nucleus at a surprisingly high rate during angiosperm evolution. The structures of several nuclear rps10 genes reveal diverse mechanisms by which transferred genes become activated, including parasitism of pre-existing nuclear genes for mitochondrial or cytoplasmic proteins, and activation without gain of a mitochondrial targeting sequence.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia	Indiana University System; Indiana University Bloomington; University of Western Australia	Palmer, JD (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		Whelan, James/F-6402-2011; Palmer, Jeffrey/P-6747-2014	Whelan, James/0000-0001-5754-025X; Palmer, Jeffrey/0000-0002-4626-2220; Daley, Daniel/0000-0002-6425-5059				Adams KL, 1999, P NATL ACAD SCI USA, V96, P13863, DOI 10.1073/pnas.96.24.13863; BENASSON D, 2000, MOL BIOL EVOL, V17, P406; Boore JL, 1999, NUCLEIC ACIDS RES, V27, P1767, DOI 10.1093/nar/27.8.1767; BRAUN HP, 1994, FEBS LETT, V347, P90, DOI 10.1016/0014-5793(94)00515-X; DAY DA, 1985, AUST J PLANT PHYSIOL, V12, P219, DOI 10.1071/PP9850219; Figueroa P, 1999, MOL GEN GENET, V262, P139, DOI 10.1007/s004380051068; Figueroa P, 1999, PLANT J, V18, P601, DOI 10.1046/j.1365-313x.1999.00485.x; Gray MW, 1999, CURR OPIN GENET DEV, V9, P678, DOI 10.1016/S0959-437X(99)00030-1; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; Herrmann RG, 1997, EUKARYOTISM SYMBIOSI, P73, DOI [10.1007/978-3-642-60885-8_7, DOI 10.1007/978-3-642-60885-8_7]; Kadowaki KI, 1996, EMBO J, V15, P6652, DOI 10.1002/j.1460-2075.1996.tb01055.x; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Kubo N, 1999, P NATL ACAD SCI USA, V96, P9207, DOI 10.1073/pnas.96.16.9207; Kubo N, 2000, MOL GEN GENET, V263, P733, DOI 10.1007/s004380051222; Laroche J, 1997, P NATL ACAD SCI USA, V94, P5722, DOI 10.1073/pnas.94.11.5722; Long MY, 1996, P NATL ACAD SCI USA, V93, P7727, DOI 10.1073/pnas.93.15.7727; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; MORIKAMI A, 1993, J BIOL CHEM, V268, P17205; NAKAGAWA T, 1990, EUR J BIOCHEM, V191, P557, DOI 10.1111/j.1432-1033.1990.tb19157.x; NEUBURGER M, 1982, ARCH BIOCHEM BIOPHYS, V217, P312, DOI 10.1016/0003-9861(82)90507-0; Palmer JD, 1997, SCIENCE, V275, P790, DOI 10.1126/science.275.5301.790; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 2000, PAUP PHYLOGENETIC AN; Tanudji M, 1999, J BIOL CHEM, V274, P1286, DOI 10.1074/jbc.274.3.1286; WISCHMANN C, 1995, FEBS LETT, V374, P152, DOI 10.1016/0014-5793(95)01100-S; WOLFE KH, 1987, P NATL ACAD SCI USA, V84, P9054, DOI 10.1073/pnas.84.24.9054	27	160	166	2	32	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					354	357		10.1038/35042567	http://dx.doi.org/10.1038/35042567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099041				2022-12-28	WOS:000165296000044
J	Wardlaw, MJ				Wardlaw, MJ			Three lessons for a better cycling future	BRITISH MEDICAL JOURNAL			English	Article							HELMET				Wardlaw, MJ (corresponding author), 92 Drymen Rd, Glasgow G61 2SY, Lanark, Scotland.							ATTEWELL RG, 1992, CR105 FED OFF ROAD S; *AUSTR ROAD ACC PR, 1999, EC EV MAND HELM LEG; BURDETT A, CYCLIST FATALITIES C; Carnall D, 2000, BRIT MED J, V320, P888, DOI 10.1136/bmj.320.7239.888; *DEP ENV TRANSP RE, 1998, ROAD ACC GREAT BRIT; *DEP ENV TRANSP RE, 1998, NAT TRAV SURV; FORESTER J, 1986, EFFECTIVE CYCLING; FRANKLIN J, 1999, VEL CIT C GRAZ APR; FRANKLIN J, 2000, COMMUNICATION    JUN; FRANKLIN J, 1999, CAMBR CYCL CAMP AGM; GILBERT K, 1994, BRIT MED J, V308, P1534, DOI 10.1136/bmj.308.6943.1534; GILLHAM C, COMPULSORY BICYCLE H; HALLIDAY, 1996, 154 TRRL; HENDERSON D, 1995, EFFECTIVENESS BICYCL; Hillman M, 1994, CYCLING HLTH SAFETY; KIFER K, IS CYCLING DANGEROUS; Mills N J, 1990, Br J Sports Med, V24, P55; MORGAN JM, 1988, RISK CYCLING; Mullins J., 2000, NEW SCI, P16; *NAT STAT OFF, 1997, DEATH INJ POIS; ROBINSON B, 1996, P VEL AUSTR C PERTH; ROBINSON D, 1996, P VEL AUSTR C PERTH; Robinson DL, 1996, ACCIDENT ANAL PREV, V28, P463, DOI 10.1016/0001-4575(96)00016-4; ROGERS GB, 1988, J PRODUCT LIABILITY, V11, P307; Scuffham P, 2000, ACCIDENT ANAL PREV, V32, P565, DOI 10.1016/S0001-4575(99)00081-0; Scuffham PA, 1997, ACCIDENT ANAL PREV, V29, P1, DOI 10.1016/S0001-4575(96)00054-1; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	27	16	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1582	1585		10.1136/bmj.321.7276.1582	http://dx.doi.org/10.1136/bmj.321.7276.1582			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124188	Green Published			2022-12-28	WOS:000166134500025
J	Naureckiene, S; Sleat, DE; Lackland, H; Fensom, A; Vanier, MT; Wattiaux, R; Jadot, M; Lobel, P				Naureckiene, S; Sleat, DE; Lackland, H; Fensom, A; Vanier, MT; Wattiaux, R; Jadot, M; Lobel, P			Identification of HE1 as the second gene of Niemann-Pick C disease	SCIENCE			English	Article							MAJOR SECRETORY PROTEIN; MOLECULAR-CLONING; HUMAN EPIDIDYMIS; EXPRESSION; COMPLEMENTATION; GLYCOPROTEINS; HYBRIDIZATION; LYSOSOMES; CELLS; FLUID	Niemann-Pick type C2 disease (NP-C2) is a fatal hereditary disorder of unknown etiology characterized by defective egress of cholesterol from lysosomes. Here we show that the disease is caused by a deficiency in HE1, a ubiquitously expressed lysosomal protein identified previously as a cholesterol-binding protein. HE1 was undetectable in fibroblasts from NP-C2 patients but present in fibroblasts from unaffected controls and NP-C1 patients. Mutations in the HE1 gene, which maps to chromosome 14q24.3, were found in NP-C2 patients but not in controls. Treatment of NP-C2 fibroblasts with exogenous recombinant HE1 protein ameliorated lysosomal accumulation of low density lipoprotein-derived cholesterol.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Guys Hosp, Guys Kings & St Thomas Sch Med, Div Med & Mol Genet, London SE1 9RT, England; Lyon Sud Med Sch, INSERM 189, Oullins, France; Lyon Sud Hosp, Fdn Gillet Merieux, Pierre Benite, France; Fac Univ Notre Dame Paix, Physiol Chem Lab, B-5000 Namur, Belgium	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; University of Namur	Lobel, P (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.	lobel@cabm.rutgers.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054317, R01DK045992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037918] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54317, DK45992] Funding Source: Medline; NINDS NIH HHS [NS37918] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADY RO, 1989, NEUROL CLIN, V7, P75, DOI 10.1016/S0733-8619(18)30829-6; Brown D, 2000, J EXP BIOL, V203, P137; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ELLERBROCK K, 1994, INT J ANDROL, V17, P314, DOI 10.1111/j.1365-2605.1994.tb01262.x; Fouchecourt S, 2000, BIOL REPROD, V62, P1790, DOI 10.1095/biolreprod62.6.1790; Frohlich O, 1996, BIOL REPROD, V54, P857, DOI 10.1095/biolreprod54.4.857; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; JADOT M, 1985, EUR J BIOCHEM, V151, P485, DOI 10.1111/j.1432-1033.1985.tb09127.x; Kirchhoff C, 1998, ANDROLOGIA, V30, P225; Kirchhoff C, 1996, BIOL REPROD, V54, P847, DOI 10.1095/biolreprod54.4.847; KORNFELD S, 2001, METABOLIC MOL BASES, V2, P3469; KRULL N, 1993, MOL REPROD DEV, V34, P16, DOI 10.1002/mrd.1080340104; Larsen LB, 1997, EUR J BIOCHEM, V243, P437, DOI 10.1111/j.1432-1033.1997.0437a.x; Nakamura Y, 2000, GENE, V251, P55, DOI 10.1016/S0378-1119(00)00189-X; NAURECKIENE S, UNPUB; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; NISHIYAMA C, 1993, INT ARCH ALLERGY IMM, V101, P159, DOI 10.1159/000236514; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; Patterson M., 2001, METABOLIC MOL BASES, VII, P3611; RACZEK S, 1995, CELL TISSUE RES, V280, P415, DOI 10.1007/s004410050370; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Sohar I, 2000, CLIN CHEM, V46, P1005; Steinberg SJ, 1996, J INHERIT METAB DIS, V19, P769, DOI 10.1007/BF01799171; STEINBERG SJ, 1994, J MED GENET, V31, P317, DOI 10.1136/jmg.31.4.317; TOMOMASA H, 1994, J HISTOCHEM CYTOCHEM, V42, P417, DOI 10.1177/42.3.8308258; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; VANIER MT, 1991, BIOCHIM BIOPHYS ACTA, V1096, P328, DOI 10.1016/0925-4439(91)90069-L; Vanier MT, 1996, AM J HUM GENET, V58, P118; Vanier MT, 1998, BRAIN PATHOL, V8, P163; WATTIAUX R, 1963, CIBA F S LYSOSOMES, P176; Xiang X, 2000, CURR BIOL, V10, P603, DOI 10.1016/S0960-9822(00)00488-7	33	637	656	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	2000	290	5500					2298	+		10.1126/science.290.5500.2298	http://dx.doi.org/10.1126/science.290.5500.2298			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125141				2022-12-28	WOS:000165995800041
J	Cnattingius, S; Signorello, LB; Anneren, G; Clausson, B; Ekbom, A; Ljunger, E; Blot, WJ; McLaughlin, JK; Petersson, G; Rane, A; Granath, F				Cnattingius, S; Signorello, LB; Anneren, G; Clausson, B; Ekbom, A; Ljunger, E; Blot, WJ; McLaughlin, JK; Petersson, G; Rane, A; Granath, F			Caffeine intake and the risk of first-trimester spontaneous abortion.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL GROWTH; COFFEE CONSUMPTION; BIRTH-WEIGHT; PREGNANCY; CIGARETTE; KARYOTYPE; MODERATE	Background: Some epidemiologic studies have suggested that the ingestion of caffeine increases the risk of spontaneous abortion, but the results have been inconsistent. Methods: We performed a population-based, case-control study of early spontaneous abortion in Uppsala County, Sweden. The subjects were 562 women who had spontaneous abortion at 6 to 12 completed weeks of gestation (the case patients) and 953 women who did not have spontaneous abortion and were matched to the case patients according to the week of gestation (controls). Information on the ingestion of caffeine was obtained from in-person interviews. Plasma cotinine was measured as an indicator of cigarette smoking, and fetal karyotypes were determined from tissue samples. Multivariate analysis was used to estimate the relative risks associated with caffeine ingestion after adjustment for smoking and symptoms of pregnancy such as nausea, vomiting, and tiredness. Results: Among nonsmokers, more spontaneous abortions occurred in women who ingested at least 100 mg of caffeine per day than in women who ingested less than 100 mg per day, with the increase in risk related to the amount ingested (100 to 299 mg per day: odds ratio, 1.3; 95 percent confidence interval, 0.9 to 1.8; 300 to 499 mg per day: odds ratio, 1.4; 95 percent confidence interval, 0.9 to 2.0; and 500 mg or more per day: odds ratio, 2.2; 95 percent confidence interval, 1.3 to 3.8). Among smokers, caffeine ingestion was not associated with an excess risk of spontaneous abortion. When the analyses were stratified according to the results of karyotyping, the ingestion of moderate or high levels of caffeine was found to be associated with an excess risk of spontaneous abortion when the fetus had a normal or unknown karyotype but not when the fetal karyotype was abnormal. Conclusions: The ingestion of caffeine may increase the risk of an early spontaneous abortion among nonsmoking women carrying fetuses with normal karyotypes. (N Engl J Med 2000;343:1839-45.) (C) 2000, Massachusetts Medical Society.	Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Lab Sci & Tech, Stockholm, Sweden; Int Epidemiol Inst, Rockville, MD USA; Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Uppsala University; Uppsala University	Cnattingius, S (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, SE-17177 Stockholm, Sweden.		Rane, Anders/L-2675-2013					ARMSTRONG BG, 1992, AM J PUBLIC HEALTH, V82, P85, DOI 10.2105/AJPH.82.1.85; ARMSTRONG EG, 1984, J CLIN ENDOCR METAB, V59, P867, DOI 10.1210/jcem-59-5-867; Barone JJ, 1996, FOOD CHEM TOXICOL, V34, P119, DOI 10.1016/0278-6915(95)00093-3; BEAULACBAILLARGEON L, 1987, AM J OBSTET GYNECOL, V157, P1236, DOI 10.1016/S0002-9378(87)80301-0; BROWN CR, 1988, CLIN PHARMACOL THER, V43, P488, DOI 10.1038/clpt.1988.63; Cook DG, 1996, BRIT MED J, V313, P1358, DOI 10.1136/bmj.313.7069.1358; Dlugosz L, 1996, EPIDEMIOLOGY, V7, P250, DOI 10.1097/00001648-199605000-00006; DLUGOSZ L, 1992, EPIDEMIOL REV, V14, P83, DOI 10.1093/oxfordjournals.epirev.a036093; Eskenazi B, 1999, NEW ENGL J MED, V341, P1688, DOI 10.1056/NEJM199911253412210; Fenster L, 1991, Epidemiology, V2, P168, DOI 10.1097/00001648-199105000-00002; Fenster L, 1997, EPIDEMIOLOGY, V8, P515, DOI 10.1097/00001648-199709000-00008; Fernandes O, 1998, REPROD TOXICOL, V12, P435, DOI 10.1016/S0890-6238(98)00024-0; GIBAS LM, 1987, PRENATAL DIAG, V7, P323, DOI 10.1002/pd.1970070505; INFANTERIVARD C, 1993, JAMA-J AM MED ASSOC, V270, P2940, DOI 10.1001/jama.270.24.2940; *INT AG RES CANC, 1991, IARC MON EV CARC RIS, V51, P41; Klebanoff MA, 1999, NEW ENGL J MED, V341, P1639, DOI 10.1056/NEJM199911253412202; KLINE J, 1995, AM J EPIDEMIOL, V141, P417, DOI 10.1093/oxfordjournals.aje.a117444; KLINE J, 1991, EPIDEMIOLOGY, V2, P409, DOI 10.1097/00001648-199111000-00004; Knutti R, 1982, Arch Toxicol Suppl, V5, P187; MILLS JL, 1993, JAMA-J AM MED ASSOC, V269, P593, DOI 10.1001/jama.269.5.593; Ness RB, 1999, NEW ENGL J MED, V340, P333, DOI 10.1056/NEJM199902043400501; OLSSON P, 1991, ADV PHAR SC, P57; Parazzini F, 1998, HUM REPROD, V13, P2286, DOI 10.1093/humrep/13.8.2286; Peacock JL, 1998, INT J EPIDEMIOL, V27, P647, DOI 10.1093/ije/27.4.647; SRISUPHAN W, 1986, AM J OBSTET GYNECOL, V154, P14, DOI 10.1016/0002-9378(86)90385-6; Stanton CK, 1995, AM J EPIDEMIOL, V142, P1322, DOI 10.1093/oxfordjournals.aje.a117600; STEIN H, 1991, ANN ONCOL, V2, P163, DOI 10.1093/annonc/2.suppl_2.163; Vlajinac HD, 1997, AM J EPIDEMIOL, V145, P335, DOI 10.1093/oxfordjournals.aje.a009110; WEATHERSBEE PS, 1977, J REPROD MED, V19, P55	29	164	170	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1839	1845		10.1056/NEJM200012213432503	http://dx.doi.org/10.1056/NEJM200012213432503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117975				2022-12-28	WOS:000165940400003
J	Sorensen, HT; Mellemkjaer, L; Olsen, JH; Baron, JA				Sorensen, HT; Mellemkjaer, L; Olsen, JH; Baron, JA			Prognosis of cancers associated with venous thromboembolism.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; CLINICAL COURSE; MALIGNANCY; DIAGNOSIS; WARFARIN; RISK; LUNG	Background: Little is known about the prognosis of cancer discovered during or after an episode of venous thromboembolism. Methods: We linked the Danish National Registry of Patients, the Danish Cancer Registry, and the Danish Mortality Files to obtain data on the survival of patients who received a diagnosis of cancer at the same time as or after an episode of venous thromboembolism. Their survival was compared with that of patients with cancer who did not have venous thromboembolism (control patients), who were matched in terms of type of cancer, age, sex, and year of diagnosis. Results: Of 668 patients who had cancer at the time of an episode of deep venous thromboembolism, 44.0 percent of those with data on the spread of disease (563 patients) had distant metastasis, as compared with 35.1 percent of 5371 control patients with data on spread (prevalence ratio, 1.26; 95 percent confidence interval, 1.13 to 1.40). In the group with cancer at the time of venous thromboembolism, the one-year survival rate was 12 percent, as compared with 36 percent in the control group (P<0.001), and the mortality ratio for the entire follow-up period was 2.20 (95 percent confidence interval, 2.05 to 2.40). Patients in whom cancer was diagnosed within one year after an episode of venous thromboembolism had a slightly increased risk of distant metastasis at the time of the diagnosis (prevalence ratio, 1.23 [95 percent confidence interval, 1.08 to 1.40]) and a relatively low rate of survival at one year (38 percent, vs. 47 percent in the control group; P<0.001). Conclusions: Cancer diagnosed at the same time as or within one year after an episode of venous thromboembolism is associated with an advanced stage of cancer and a poor prognosis. (N Engl J Med 2000;343:1846-50.) (C) 2000, Massachusetts Medical Society.	Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Med 5, DK-8000 Aarhus, Denmark; Aalborg Hosp, Aarhus, Denmark; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA	Aarhus University; Aarhus University; Aalborg University; Aalborg University Hospital; Danish Cancer Society; Dartmouth College; Dartmouth College	Sorensen, HT (corresponding author), Aarhus Univ Hosp, Dept Clin Epidemiol, Vennelyst Bldg 6,Bldg 260, DK-8000 Aarhus, Denmark.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Olsen, Jorgen Helge/0000-0001-9633-5662				Andersen TF, 1999, DAN MED BULL, V46, P263; Baron JA, 1998, LANCET, V351, P1077, DOI 10.1016/S0140-6736(97)10018-6; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; Cornuz J, 1996, ANN INTERN MED, V125, P785, DOI 10.7326/0003-4819-125-10-199611150-00001; Francis JL, 1998, SEMIN THROMB HEMOST, V24, P93, DOI 10.1055/s-2007-995829; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GREEN D, 1992, LANCET, V339, P1476, DOI 10.1016/0140-6736(92)92064-M; Hettiarachchi RJK, 1998, CANCER, V83, P180, DOI 10.1002/(SICI)1097-0142(19980701)83:1<180::AID-CNCR24>3.0.CO;2-S; Maurer LH, 1997, J CLIN ONCOL, V15, P3378, DOI 10.1200/JCO.1997.15.11.3378; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; *NAT BOARD HLTH, 1999, CANC INC DENM 1996; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; Piccioli A, 1996, AM HEART J, V132, P850, DOI 10.1016/S0002-8703(96)90321-X; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Schulman S, 2000, NEW ENGL J MED, V342, P1953, DOI 10.1056/NEJM200006293422604; Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056/NEJM199804233381701; Storm HH, 1997, DAN MED BULL, V44, P535; *SUNDH, 1976, KLASS SYGD; TROUSSEAU A, 1977, LECT CLIN MED, P281; ZACHARSKI LR, 1981, JAMA-J AM MED ASSOC, V245, P831, DOI 10.1001/jama.245.8.831; ZACHARSKI LR, 1992, SEMIN THROMB HEMOST, V18, P104, DOI 10.1055/s-2007-1002415	22	1147	1198	2	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1846	1850		10.1056/NEJM200012213432504	http://dx.doi.org/10.1056/NEJM200012213432504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117976				2022-12-28	WOS:000165940400004
J	Grodstein, F; Manson, JE; Colditz, GA; Willett, WC; Speizer, FE; Stampfer, MJ				Grodstein, F; Manson, JE; Colditz, GA; Willett, WC; Speizer, FE; Stampfer, MJ			A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; ESTROGEN REPLACEMENT THERAPY; MYOCARDIAL-INFARCTION; FOLLOW-UP; RISK; STROKE; USERS; PROGESTIN; WOMEN	Background: Most primary prevention studies have found that long-term users of postmenopausal hormone therapy are at lower risk for coronary events, but numerous questions remain. An adverse influence of hormone therapy on cardiovascular risk has been suggested during the initial year of use; however, few data are available on short-term hormone therapy. In addition, the cardiovascular effects of daily doses of oral conjugated estrogen lower than 0.625 mg are unknown, and few studies have examined estrogen plus progestin in this regard. Objective: To investigate duration, dose, and type of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Design: Prospective, observational cohort study. Setting: Nurses' Health Study, with follow-up from 1976 to 1996. Patients: 70 533 postmenopausal women, in whom 1258 major coronary events (nonfatal myocardial infarction or fatal coronary disease) and 767 strokes were identified. Measurements: Details of postmenopausal hormone use were ascertained by using biennial questionnaires. Cardiovascular disease was established by using a questionnaire and was confirmed by medical record review. Logistic regression models were used to calculate relative risks and 95% Cls, adjusted for confounders. Results: When all cardiovascular risk factors were considered, the risk for major coronary events was lower among current users of hormone therapy, including short-term users, compared with never-users (relative risk, 0.61 [95% CI, 0.52 to 0.71]). Among women taking oral conjugated estrogen, the risk for coronary events was similarly reduced in those currently taking 0.625 mg daily (relative risk, 0.54 [CI, 0.44 to 0.67]) and those taking 0.3 mg daily (relative risk, 0.58 [CI, 0.37 to 0.92]) compared with never-users. However, the risk for stroke was statistically significantly increased among women taking 0.625 mg or more of oral conjugated estrogen daily (relative risk, 1.35 [CI, 1.08 to 1.68] for 0.625 mg/d and 1.63 [CI, 1.18 to 2.26] for greater than or equal to1.25 mg/d) and those taking estrogen plus progestin (relative risk, 1.45 [CI, 1.10 to 1.92]). Overall, little relation was observed between combination hormone therapy and risk for cardiovascular disease (major coronary heart disease plus stroke) (relative risk, 0.91 [CI, 0.75 to 1.11]). Conclusions: Postmenopausal hormone use appears to decrease risk for major coronary events in women without previous heart disease. Furthermore, 0.3 mg of oral conjugated estrogen daily is associated with a reduction similar to that seen with the standard dose of 0.625 mg. However, estrogen at daily doses of 0.625 mg or greater and in combination with progestin may increase risk for stroke.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline; NIA NIH HHS [AG13482] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; GANGAR KF, 1996, EUR MENOPAUSE J, V3, P147; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; GRODSTEIN F, 2000, CIRCULATION S, V100, P18; Heckbert SR, 1997, ARCH INTERN MED, V157, P1330, DOI 10.1001/archinte.157.12.1330; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HERNANDEZ AM, 1990, EPIDEMIOLOGY, V1, P128; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; PFEFFER RI, 1978, J CHRON DIS, V31, P389, DOI 10.1016/0021-9681(78)90003-6; ROSENBERG L, 1980, JAMA-J AM MED ASSOC, V244, P339, DOI 10.1001/jama.244.4.339; Rothman K, 1979, NIH PUBL; Rothman K, 1986, MODERN EPIDEMIOLOGY; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SARREL PM, 1992, AM J OBSTET GYNECOL, V167, P467, DOI 10.1016/S0002-9378(11)91431-8; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; Walker AE, 1981, STROKE S1, V12, P13; *WHO, 1971, IHD REGISTER REPORT; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598	37	760	789	2	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					933	941		10.7326/0003-4819-133-12-200012190-00008	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119394				2022-12-28	WOS:000165952300001
J	Kronzon, I				Kronzon, I			The department of card tricks and close magic	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									NYU Med Ctr, New York, NY 10016 USA	New York University	Kronzon, I (corresponding author), NYU Med Ctr, 560 1st Ave, New York, NY 10016 USA.	Itzhak.Kronzon@med.nyu.edu							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					1005	1007		10.7326/0003-4819-133-12-200012190-00018	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00018			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119404				2022-12-28	WOS:000165952300011
J	Rollins, G				Rollins, G			Developments in cervical and ovarian cancer screening: Implications for current practice	ANNALS OF INTERNAL MEDICINE			English	Article																			0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					1021	1024		10.7326/0003-4819-133-12-200012190-00101	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119415				2022-12-28	WOS:000165952300019
J	Chen, HT; Bhandoola, A; Difilippantonio, MJ; Zhu, J; Brown, MJ; Tai, XG; Rogakou, EP; Brotz, TM; Bonner, WM; Ried, T; Nussenzweig, A				Chen, HT; Bhandoola, A; Difilippantonio, MJ; Zhu, J; Brown, MJ; Tai, XG; Rogakou, EP; Brotz, TM; Bonner, WM; Ried, T; Nussenzweig, A			Response to RAG-mediated V(D)J cleavage by NBS1 and gamma-H2AX	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; T-CELL; MICE DEFICIENT; RECOMBINATION; DNA; THYMOCYTES; COMPLEX; REPAIR; REARRANGEMENT; EXPRESSION	Genetic disorders affecting cellular responses to DNA damage are characterized by high rates of translocations involving antigen receptor loci and increased susceptibility to lymphoid malignancies. We report that the Nijmegen breakage syndrome protein (NBS1) and histone gamma -H2AX, which associate with irradiation-induced DNA double-strand breaks (DSBs), are also found at sites of V(D)J (variable, diversity, joining) recombination-induced DSBs. In developing thymocytes, NBS1 and gamma -H2AX form nuclear foci that colocalize with the T cell receptor alpha locus in response to recombination activating gene (RAG) protein-mediated V(D)J cleavage. Our results suggest that surveillance of T cell receptor recombination intermediates by NBS1 and gamma -H2AX may be important for preventing oncogenic translocations.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Genet, NIH, Bethesda, MD 20892 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nussenzweig, A (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.		Difilippantonio, Michael/AAF-2839-2021; Brotz, Tilmann M/R-6599-2016	Difilippantonio, Michael/0000-0002-4676-7034; Brotz, Tilmann M/0000-0001-8212-459X	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010299, Z01SC010298] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Danska J S, 1997, Semin Immunol, V9, P199, DOI 10.1006/smim.1997.0072; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Livak F, 1996, MOL CELL BIOL, V16, P609; Livak F, 1997, J MOL BIOL, V267, P1, DOI 10.1006/jmbi.1996.0834; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schlissel MS, 1998, MOL CELL BIOL, V18, P2029, DOI 10.1128/MCB.18.4.2029; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	25	260	268	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1962	1964		10.1126/science.290.5498.1962	http://dx.doi.org/10.1126/science.290.5498.1962			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110662	Green Accepted			2022-12-28	WOS:000165810000045
J	Chen, T; Hiroko, T; Chaudhuri, A; Inose, F; Lord, M; Tanaka, S; Chant, J; Fujita, A				Chen, T; Hiroko, T; Chaudhuri, A; Inose, F; Lord, M; Tanaka, S; Chant, J; Fujita, A			Multigenerational cortical inheritance of the Rax2 protein in orienting polarity and division in yeast	SCIENCE			English	Article							BUD-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PATTERN; GENE	Diploid yeast cells repeatedly polarize and bud from their poles, probably because of highly stable marks of unknown composition. Here, Rax2, a membrane protein, was shown to behave as such a mark. The Rax2 protein itself was inherited immutably at the cell cortex for multiple generations, and Rax2 was shown to have a half-life exceeding several generations. The persistent inheritance of cortical protein markers would provide a means to couple a cell's history to the future development of a precise morphogenetic form.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	National Institute of Advanced Industrial Science & Technology (AIST); Harvard University	Chant, J (corresponding author), Natl Inst Biosci & Human Technol, AIST 1-1 Higahsi, Tsukuba, Ibaraki 3058566, Japan.	chant@fas.harvard.edu; atsushi@nibh.go.jp			NIGMS NIH HHS [GM49782] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049782] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEISSON J, 1965, P NATL ACAD SCI USA, V53, P275, DOI 10.1073/pnas.53.2.275; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Chen T., UNPUB; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; Halme A, 1996, CURR BIOL, V6, P570, DOI 10.1016/S0960-9822(02)00543-2; HICKS JB, 1977, GENETICS, V85, P373; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Roemer T, 1996, GENE DEV, V10, P777, DOI 10.1101/gad.10.7.777; Sanders SL, 1996, J CELL BIOL, V134, P413, DOI 10.1083/jcb.134.2.413; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	17	62	65	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	2000	290	5498					1975	1978		10.1126/science.290.5498.1975	http://dx.doi.org/10.1126/science.290.5498.1975			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110666				2022-12-28	WOS:000165810000049
J	Galy, A; Young, ED; Ash, RD; O'Nions, RK				Galy, A; Young, ED; Ash, RD; O'Nions, RK			The formation of chondrules at high gas pressures in the solar nebula	SCIENCE			English	Article							EVAPORATION; INCLUSIONS; SYSTEM; AL-26; FRACTIONATION; ORIGIN	High-precision magnesium isotope measurements of whole chondrules from the Allende carbonaceous chondrite meteorite show that some aluminum-rich Allende chondrules formed at or near the time of formation of calcium-aluminum-rich intrusions and that some others formed later and incorporated precursors previously enriched in magnesium-26. Chondrule magnesium-25/ magnesium-24 correlates with [magnesium]/[aluminum] and size, the aluminum-rich, smaller chondrules being the most enriched in the heavy isotopes of magnesium. These relations imply that high gas pressures prevailed during chondrule formation in the solar nebula.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	University of Oxford	Galy, A (corresponding author), Univ Cambridge, Dept Earth Sci, Downing St, Cambridge CB2 3EQ, England.		Ash, Richard/AAD-4888-2021; Galy, Albert/M-3101-2019; Galy, Albert/A-8518-2011	Ash, Richard/0000-0003-2144-5917; Galy, Albert/0000-0001-9978-4287; Galy, Albert/0000-0001-9978-4287; Young, Edward/0000-0002-1299-0801				Alexander CMO, 2000, METEORIT PLANET SCI, V35, P859, DOI 10.1111/j.1945-5100.2000.tb01469.x; ARDEN JW, 1983, EARTH PLANET SC LETT, V62, P395, DOI 10.1016/0012-821X(83)90010-9; Ash RD, 2000, METEORIT PLANET SCI, V35, pA21; Boss A. P., 1996, CHONDRULES PROTOPLAN, V27, P257; CATANZAR.EJ, 1966, J RES NBS A PHYS CH, VA 70, P453, DOI 10.6028/jres.070A.037; CLAYTON DD, 1995, ASTROPHYS J, V451, pL87, DOI 10.1086/309684; DAVIS AM, 1990, NATURE, V347, P655, DOI 10.1038/347655a0; Ebel DS, 2000, GEOCHIM COSMOCHIM AC, V64, P339, DOI 10.1016/S0016-7037(99)00284-7; Floss C, 1996, GEOCHIM COSMOCHIM AC, V60, P1975, DOI 10.1016/0016-7037(96)00068-3; GALY A, LUNAR PLANET, V31; Georges P, 2000, METEORIT PLANET SCI, V35, P1183, DOI 10.1111/j.1945-5100.2000.tb01507.x; Halicz L, 1999, J ANAL ATOM SPECTROM, V14, P1835, DOI 10.1039/a906422b; Hewins R. H., 1996, CHONDRULES PROTOPLAN, P3; Hsu WB, 2000, EARTH PLANET SC LETT, V182, P15, DOI 10.1016/S0012-821X(00)00233-8; LaTourrette T, 1998, EARTH PLANET SC LETT, V158, P91, DOI 10.1016/S0012-821X(98)00048-X; LEE T, 1977, ASTROPHYS J, V211, pL107, DOI 10.1086/182351; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; McKeegan KD, 2000, SCIENCE, V289, P1334, DOI 10.1126/science.289.5483.1334; Misawa K., 1996, CHONDRULES PROTOPLAN, P99; Nagahara H, 1996, GEOCHIM COSMOCHIM AC, V60, P1445, DOI 10.1016/0016-7037(96)00014-2; PODOSEK FA, 1991, GEOCHIM COSMOCHIM AC, V55, P1083, DOI 10.1016/0016-7037(91)90165-2; RICHTER FM, 1999, LUNAR PLANET SCI, V30; Russell SS, 1996, SCIENCE, V273, P757, DOI 10.1126/science.273.5276.757; SHENG YJ, 1991, GEOCHIM COSMOCHIM AC, V55, P581, DOI 10.1016/0016-7037(91)90014-V; Wood J. A., 1988, METEORITES EARLY SOL, P329; Young ED, 1998, GEOCHIM COSMOCHIM AC, V62, P3109, DOI 10.1016/S0016-7037(98)00213-0	26	143	149	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1751	1753		10.1126/science.290.5497.1751	http://dx.doi.org/10.1126/science.290.5497.1751			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099410				2022-12-28	WOS:000165632400038
J	Muscheler, R; Beer, J; Wagner, G; Finkel, RC				Muscheler, R; Beer, J; Wagner, G; Finkel, RC			Changes in deep-water formation during the Younger Dryas event inferred from Be-10 and C-14 records	NATURE			English	Article							GREENLAND ICE CORE; OCEAN CIRCULATION; ATMOSPHERIC C-14; RADIOCARBON; CLIMATE; DEGLACIATION; CALIBRATION; ATLANTIC; MODEL; CYCLE	Variations in atmospheric radiocarbon (C-14) concentrations can be attributed either to changes in the carbon cycle(1)-through the rate of radiocarbon removal from the atmosphere-or to variations in the production rate of C-14 due to changes in solar activity or the Earth's magnetic field(2). The production rates of Be-10 and C-14 vary in the same way, but whereas atmospheric radiocarbon concentrations are additionally affected by the carbon cycle, Be-10 concentrations reflect production rates more directly. A record of the Be-10 production-rate variations can therefore be used to separate the two influences-production rates and the carbon cycle-on radiocarbon concentrations. Here we present such an analysis of the large fluctuations in atmospheric C-14 concentrations, of unclear origin(3), that occurred during the Younger Dryas cold period(6). We use the Be-10 record from the GISP2 ice core(5) to model past production rates of radionuclides, and rnd that the largest part of the fluctuations in atmospheric radiocarbon concentrations can be attributed to variations in production rate. The residual difference between measured C-14 concentrations and those modelled using the Be-10 record can be explained with an additional change in the carbon cycle, most probably in the amount of deep-water formation.	EAWAG, Dept Surface Waters, CH-8600 Dubendorf, Switzerland; Univ Calif Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94550 USA; Univ Calif Lawrence Livermore Natl Lab, Geosci & Environm Technol Div, Livermore, CA 94550 USA	Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Muscheler, R (corresponding author), EAWAG, Dept Surface Waters, CH-8600 Dubendorf, Switzerland.			Muscheler, Raimund/0000-0003-2772-3631				ALLEY RB, 1995, J GLACIOL, V41, P503, DOI 10.3189/S0022143000034845; Alley RB, 1997, J GEOPHYS RES-OCEANS, V102, P26367, DOI 10.1029/96JC03837; BEER J, 1988, NATURE, V331, P675, DOI 10.1038/331675a0; Bjorck S, 1996, SCIENCE, V274, P1155, DOI 10.1126/science.274.5290.1155; BJORCK S, UNPUB GEOLOGY; BROECKER WS, 1985, NATURE, V315, P21, DOI 10.1038/315021a0; CHARLES CD, 1994, SCIENCE, V263, P508, DOI 10.1126/science.263.5146.508; Finkel RC, 1997, J GEOPHYS RES-OCEANS, V102, P26699, DOI 10.1029/97JC01282; Goslar T, 2000, NATURE, V403, P877, DOI 10.1038/35002547; GOSLAR T, 1995, NATURE, V377, P414, DOI 10.1038/377414a0; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; Johnsen SJ, 1989, TELLUS B, V41, P452, DOI 10.1111/j.1600-0889.1989.tb00321.x; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Johnsen SJ, 1997, J GEOPHYS RES-OCEANS, V102, P26397, DOI 10.1029/97JC00167; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; Lal D., 1967, HANDBUCH PHYSIK    2, V46, P551, DOI [DOI 10.1007/978-3-642-46079-1_7, 10.1007/978-3-642-46079-1_7]; Marchal O, 1999, CLIM DYNAM, V15, P341, DOI 10.1007/s003820050286; Masarik J, 1999, J GEOPHYS RES-ATMOS, V104, P12099, DOI 10.1029/1998JD200091; MCHARGUE LR, 1991, REV GEOPHYS, V29, P141, DOI 10.1029/91RG00072; SIEGENTHALER U, 1980, RADIOCARBON, V22, P177, DOI 10.1017/S0033822200009449; SIEGENTHALER U, 1983, J GEOPHYS RES-OCEANS, V88, P3599, DOI 10.1029/JC088iC06p03599; Stocker TF, 1996, PALEOCEANOGRAPHY, V11, P773, DOI 10.1029/96PA02640; STUIVER M, 1980, SCIENCE, V207, P11, DOI 10.1126/science.207.4426.11; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; TAUXE L, 1993, REV GEOPHYS, V31, P319, DOI 10.1029/93RG01771; Wagner G, 2000, EARTH PLANET SC LETT, V181, P1, DOI 10.1016/S0012-821X(00)00196-5; WAGNER G, 1998, THESIS ETH ZURICH	30	95	101	0	28	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					567	570		10.1038/35046041	http://dx.doi.org/10.1038/35046041			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117740				2022-12-28	WOS:000165548600113
J	Nishida, M; Maruyama, Y; Tanaka, R; Kontani, K; Nagao, T; Kurose, H				Nishida, M; Maruyama, Y; Tanaka, R; Kontani, K; Nagao, T; Kurose, H			G alpha(i) and G alpha(o) are target proteins of reactive oxygen species	NATURE			English	Article							BETA-GAMMA-SUBUNITS; RECOMBINANT ADENOVIRUSES; REOXYGENATION INJURY; OXIDATIVE STRESS; CARDIAC MYOCYTES; RECEPTOR KINASE; FREE-RADICALS; ACTIVATION; PATHWAY; BINDING	Reactive oxygen species (ROS) have been identified as central mediators in certain signalling events(1-4). In the heart, ROS have important functions in ischaemia/reperfusion-induced cardiac injury(5,6) and in cytokine-stimulated hypertrophy(7). Extracellular signal-regulated kinase (ERK) is one of the ROS-responsive serine/threonine kinases. Previous studies showed that tyrosine kinases and small G proteins are involved in the activation of ERK by ROS4,8; however, the initial target protein of ROS that leads to ERK activation remains unknown. Here we show that inhibition of the beta gamma -subunit of G protein (G beta gamma) attenuates hydrogen peroxide (H2O2)-induced ERK activation in rat neonatal cardiomyocytes. The G beta gamma -responsive ERK activation induced by H2O2 is independent of ligands binding to G(i)-coupled receptors, but requires phosphatidylinositol-3-kinase and Src activation. In in vitro studies, however, treatment with H2O2 increases [S-35]GTP-gammaS binding to cardiac membranes and directly activates purified heterotrimeric G(i) and G(o) but not G(s). Analysis using heterotrimeric G(o) and its individual subunits indicates that H2O2 modifies G alpha (o) but not G beta gamma, which leads to subunit dissociation. We conclude that G alpha (i) and G alpha (o) are critical targets of oxidative stress for activation of ERK.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Physiol Chem Lab, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Kurose, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kurose@mol.f.u-tokyo.ac.jp						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ALBAS J, 1993, J BIOL CHEM, V268, P19196; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Coffer PJ, 1998, BIOCHEM J, V335, P1; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; DOWNEY JM, 1990, ANNU REV PHYSIOL, V52, P487, DOI 10.1146/annurev.ph.52.030190.002415; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Isogaya M, 1998, MOL PHARMACOL, V54, P616; KATADA T, 1986, J BIOL CHEM, V261, P8182; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KUROSE H, 2000, CRC METH SIG TRANS, P185; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Yamashita N, 1997, J MOL CELL CARDIOL, V29, P1805, DOI 10.1006/jmcc.1997.0415; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	28	215	222	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	2000	408	6811					492	495		10.1038/35044120	http://dx.doi.org/10.1038/35044120			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100733				2022-12-28	WOS:000165429800053
J	Stevenson, S; Fowler, PW; Heine, T; Duchamp, JC; Rice, G; Glass, T; Harich, K; Hajdu, E; Bible, R; Dorn, HC				Stevenson, S; Fowler, PW; Heine, T; Duchamp, JC; Rice, G; Glass, T; Harich, K; Hajdu, E; Bible, R; Dorn, HC			Materials science - A stable non-classical metallofullerene family	NATURE			English	Article							ENDOHEDRAL METALLOFULLERENES; STABILITY; C-60		Virginia Tech, Dept Chem, Blacksburg, VA 24061 USA; Univ Exeter, Sch Chem, Exeter EX4 4QD, Devon, England; Univ Bologna, Dipartimento Chim G Ciamician, I-40126 Bologna, Italy; Emory & Henry Coll, Dept Chem, Emory, VA 24327 USA; GD Searle & Co, Skokie, IL 60077 USA	Virginia Polytechnic Institute & State University; University of Exeter; University of Bologna; Pfizer	Stevenson, S (corresponding author), Virginia Tech, Dept Chem, Blacksburg, VA 24061 USA.		Dorn, Harry/K-6830-2013; Heine, Thomas/H-5446-2011	Heine, Thomas/0000-0003-2379-6251; Stevenson, Steven/0000-0003-3576-4062; Duchamp, James/0000-0001-7619-3353				Albertazzi E, 1999, PHYS CHEM CHEM PHYS, V1, P2913, DOI 10.1039/a901600g; Butenschon H, 1997, ANGEW CHEM INT EDIT, V36, P1695, DOI 10.1002/anie.199716951; DORN HC, 1998, FULLERENES RECENT AD, P990; Fowler P. W., 1995, ATLAS FULLERENES; Kobayashi K, 1997, J AM CHEM SOC, V119, P12693, DOI 10.1021/ja9733088; KRATSCHMER W, 1990, CHEM PHYS LETT, V170, P167, DOI 10.1016/0009-2614(90)87109-5; KROTO HW, 1987, NATURE, V329, P529, DOI 10.1038/329529a0; Seifert G, 1996, INT J QUANTUM CHEM, V58, P185, DOI 10.1002/(SICI)1097-461X(1996)58:2<185::AID-QUA7>3.0.CO;2-U; Stevenson S, 1999, NATURE, V401, P55, DOI 10.1038/43415	9	330	335	4	66	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					427	428		10.1038/35044199	http://dx.doi.org/10.1038/35044199			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100715				2022-12-28	WOS:000165429800034
J	Katzen, F; Beckwith, J				Katzen, F; Beckwith, J			Transmembrane electron transfer by the membrane protein DsbD occurs via a disulfide bond cascade	CELL			English	Article							CYTOCHROME-C MATURATION; ISOMERASE-LIKE PROTEIN; ESCHERICHIA-COLI; IN-VIVO; RESPIRATORY-CHAIN; FORMATION INVIVO; PATHWAY; THIOREDOXIN; IDENTIFICATION; BIOGENESIS	The cytoplasmic membrane protein DsbD transfers electrons from the cytoplasm to the periplasm of E. coli, where its reducing power is used to maintain cysteines in certain proteins in the reduced state. We split DsbD into three structural domains, each containing two essential cysteines. Remarkably, when coexpressed, these truncated proteins restore DsbD function. Utilizing this three piece system, we were able to determine a pathway of the electrons through DsbD. Our findings strongly suggest that the pathway is based on a series of multistep redox reactions that include direct interactions between thioredoxin end DsbD, and between DsbD and its periplasmic substrates. A thioredoxin-fold domain in DsbD appears to have the novel role of intramolecular electron shuttle.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Beckwith, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	jbeckwith@hms.harvard.edu			NIGMS NIH HHS [GM-55090] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055090] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Chung J, 2000, MOL MICROBIOL, V35, P1099, DOI 10.1046/j.1365-2958.2000.01778.x; CROOKE H, 1995, MOL MICROBIOL, V15, P1139, DOI 10.1111/j.1365-2958.1995.tb02287.x; Darby NJ, 1998, BIOCHEMISTRY-US, V37, P783, DOI 10.1021/bi971888f; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; Debarbieux L, 2000, J BACTERIOL, V182, P723, DOI 10.1128/JB.182.3.723-727.2000; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Deshmukh M, 2000, MOL MICROBIOL, V35, P123, DOI 10.1046/j.1365-2958.2000.01683.x; Fabianek RA, 1999, ARCH MICROBIOL, V171, P92, DOI 10.1007/s002030050683; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frishman D, 1996, BIOCHEM BIOPH RES CO, V219, P686, DOI 10.1006/bbrc.1996.0295; Gordon EHJ, 2000, MOL MICROBIOL, V35, P1360, DOI 10.1046/j.1365-2958.2000.01796.x; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Guzman LM, 1997, J BACTERIOL, V179, P5094, DOI 10.1128/jb.179.16.5094-5103.1997; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Page MD, 1997, MICROBIOL-SGM, V143, P3111, DOI 10.1099/00221287-143-10-3111; POOIE LB, 2000, BIOCHEMISTRY-US, V39, P6602; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SAMBONGI Y, 1994, FEBS LETT, V353, P235, DOI 10.1016/0014-5793(94)01053-6; Schiott T, 1997, J BACTERIOL, V179, P1962, DOI 10.1128/jb.179.6.1962-1973.1997; SINGER M, 1989, MICROBIOL REV, V53, P1; Sone M, 1997, J BIOL CHEM, V272, P10349; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Walker KW, 1997, J BIOL CHEM, V272, P8845; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; WIELES B, 1995, J BIOL CHEM, V270, P25604, DOI 10.1074/jbc.270.43.25604; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	43	166	172	0	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 22	2000	103	5					769	779		10.1016/S0092-8674(00)00180-X	http://dx.doi.org/10.1016/S0092-8674(00)00180-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114333	Bronze			2022-12-28	WOS:000165433100009
J	Brotman, DJ; Fotuhi, M				Brotman, DJ; Fotuhi, M			Syphilis and orthostatic shaking limbs	LANCET			English	Article									Cleveland Clin Fdn, Dept Gen Internal Med E13, Cleveland, OH 44195 USA; Johns Hopkins Hosp, Dept Neurol, Baltimore, MD 21205 USA	Cleveland Clinic Foundation; Johns Hopkins University; Johns Hopkins Medicine	Brotman, DJ (corresponding author), Cleveland Clin Fdn, Dept Gen Internal Med E13, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Fotuhi, Majid/0000-0002-0980-1176				BAQUIS GD, 1985, STROKE, V16, P444, DOI 10.1161/01.STR.16.3.444; BAUGMGARTNER RW, 1997, J NEUROL NEUROSUR PS, V65, P561; Firlik AD, 1996, NEUROSURGERY, V39, P607, DOI 10.1097/00006123-199609000-00037; MCMANIS PG, 1993, MUSCLE NERVE, V16, P1254, DOI 10.1002/mus.880161117	4	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1734	1734		10.1016/S0140-6736(00)03208-6	http://dx.doi.org/10.1016/S0140-6736(00)03208-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095262				2022-12-28	WOS:000165462300013
J	Piwon, N; Gunther, W; Schwake, M; Bosl, MR; Jentsch, TJ				Piwon, N; Gunther, W; Schwake, M; Bosl, MR; Jentsch, TJ			CIC-5Cl(-)-channel disruption impairs endocytosis in a mouse model for Dent's disease	NATURE			English	Article							MOLECULAR-WEIGHT PROTEINURIA; CHLORIDE CHANNEL GENE; P-I; KIDNEY; CLC-5; RECEPTOR; MEGALIN; MICE; HYPERCALCIURIA; EXPRESSION	Dent's disease is an X-linked disorder associated with the urinary loss of low-molecular-weight proteins, phosphate and calcium, which often leads to kidney stones(1,2). It is caused by mutations(3) in ClC-5, a renal chloride channel(4,5) that is expressed in endosomes of the proximal tubule(6,7). Here we show that disruption of the mouse clcn5 gene causes proteinuria by strongly reducing apical proximal tubular endocytosis. Both receptor-mediated and fluid-phase endocytosis are affected, and the internalization of the apical transporters NaPi-2 and NHE3 is slowed. At steady state, however, both proteins are redistributed from the plasma membrane to intracellular vesicles. This may be caused by an increased stimulation of luminal parathyroid hormone (PTH) receptors owing to the observed decreased tubular endocytosis of PTH. The rise in luminal PTH concentration should also stimulate the hydroxylation of 25(OH) vitamin D-3 to the active hormone. However, this is counteracted by a urinary loss of the precursor 25(OH) vitamin D-3. The balance between these opposing effects, both of which are secondary to the defect in proximal tubular endocytosis, probably determines whether there will be hypercalciuria and kidney stones.	Univ Hamburg, ZMNH, D-20246 Hamburg, Germany	University of Hamburg	Jentsch, TJ (corresponding author), Univ Hamburg, ZMNH, Martinistr 85, D-20246 Hamburg, Germany.		Schwake, Michael/F-5381-2010	Jentsch, Thomas/0000-0002-3509-2553; Piwon, Nils/0000-0002-1225-5794; Schwake, Michael/0000-0002-4173-2166				Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; Bosio M, 1999, PEDIATR NEPHROL, V13, P278, DOI 10.1007/s004670050608; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; FISHER SE, 1994, HUM MOL GENET, V3, P2053; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Gekle M, 1999, J PHYSIOL-LONDON, V520, P709, DOI 10.1111/j.1469-7793.1999.00709.x; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hilpert J, 1999, J BIOL CHEM, V274, P5620, DOI 10.1074/jbc.274.9.5620; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KAUFMANN M, 1994, ENDOCRINOLOGY, V134, P1173, DOI 10.1210/en.134.3.1173; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Luyckx VA, 1999, P NATL ACAD SCI USA, V96, P12174, DOI 10.1073/pnas.96.21.12174; Morimoto T, 1998, J AM SOC NEPHROL, V9, P811; Murer H, 1999, AM J PHYSIOL-RENAL, V277, pF676, DOI 10.1152/ajprenal.1999.277.5.F676; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Orlando RA, 1998, J AM SOC NEPHROL, V9, P1759; Sakamoto H, 1999, AM J PHYSIOL-RENAL, V277, pF957, DOI 10.1152/ajprenal.1999.277.6.F957; Scheinman SJ, 1998, KIDNEY INT, V53, P3, DOI 10.1046/j.1523-1755.1998.00718.x; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Traebert M, 2000, AM J PHYSIOL-RENAL, V278, pF792, DOI 10.1152/ajprenal.2000.278.5.F792; Traebert M, 2000, AM J PHYSIOL-RENAL, V278, pF148, DOI 10.1152/ajprenal.2000.278.1.F148; WRONG OM, 1994, Q J MED, V87, P473; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	30	432	439	0	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					369	373		10.1038/35042597	http://dx.doi.org/10.1038/35042597			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099045				2022-12-28	WOS:000165296000048
J	Whorton, J				Whorton, J			Civilisation and the colon: constipation as the "disease of diseases"	BRITISH MEDICAL JOURNAL			English	Article									Univ Washington, Sch Med, Dept Med Hist & Eth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Whorton, J (corresponding author), Univ Washington, Sch Med, Dept Med Hist & Eth, Box 357120, Seattle, WA 98195 USA.							Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; BILIK SE, 1928, TRAINERS BIBLE, P88; BOUCHARD C, 1906, LECT AUTOINTOXICATIO, P15; BURKITT DP, 1960, W DIS THEIR EMERGENC, P427; Byers T, 2000, NEW ENGL J MED, V342, P1206, DOI 10.1056/NEJM200004203421609; COOPER AP, 1831, LECT A COOPER, P56; Ebbell B., 1937, PAPYRUS EBERS GREATE, P30; FERGUSSON A, 1993, BRIT MED J, V306, P996; FOLTZ K, 1984, NEWSWEEK        1126, P75; GILMAN M, 1989, PSYCHOL TODAY    DEC, P33; Kim YI, 2000, GASTROENTEROLOGY, V118, P1235, DOI 10.1016/S0016-5085(00)70377-5; LANE WA, 1913, BRIT MED J, V2, P1126; LANE WA, 1929, BLAZING HLTH TRAIL, P74; LANE WA, 1924, JAMA-J AM MED ASSOC, V83, P1179; LANE WA, 1909, OPERATIVE TREATMENT, P36; LIEUTAUD J, 1816, SYNOPSIS PRACTICE ME, P21; ROOT HK, 1856, PEOPLES MED LIGHTHOU, P114; STEMMERMAN W, 1928, INTESTINAL MANAGEMEN, P25	18	11	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1586	1589		10.1136/bmj.321.7276.1586	http://dx.doi.org/10.1136/bmj.321.7276.1586			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124189	Green Published			2022-12-28	WOS:000166134500026
J	de Urquiza, AM; Liu, SY; Sjoberg, M; Zetterstrom, RH; Griffiths, W; Sjovall, J; Perlmann, T				de Urquiza, AM; Liu, SY; Sjoberg, M; Zetterstrom, RH; Griffiths, W; Sjovall, J; Perlmann, T			Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain	SCIENCE			English	Article							POLYUNSATURATED FATTY-ACIDS; NUCLEAR RECEPTOR; RXR-ALPHA; RAR; ESSENTIALITY; ACTIVATION; PATHWAYS; GENE; RATS	The retinoid X receptor (RXR) is a nuclear receptor that functions as a ligand-activated transcription factor. Little is known about the Ligands that activate RXR in vivo. Here, we identified a factor in brain tissue from adult mice that activates RXR in cell-based assays. Purification and analysis of the factor by mass spectrometry revealed that it is docosahexaenoic acid (DHA), a long-chain polyunsaturated fatty acid that is highly enriched in the adult mammalian brain. Previous work has shown that DHA is essential for brain maturation, and deficiency of DHA in both rodents and humans Leads to impaired spatial Learning and other abnormalities. These data suggest that DHA may influence neural function through activation of an RXR signaling pathway.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research; Karolinska Institutet	Perlmann, T (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.	thomas.perlmann@licr.ki.se	Griffiths, William/N-4641-2016	Griffiths, William/0000-0002-4129-6616; Zetterstrom, Rolf/0000-0002-3016-0019				Bischoff ED, 1998, CANCER RES, V58, P479; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Botling J, 1997, J BIOL CHEM, V272, P9443; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; Fernstrom JD, 1999, LIPIDS, V34, P161, DOI 10.1007/s11745-999-0350-3; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4; Garcia MC, 1997, BRAIN RES, V768, P43, DOI 10.1016/S0006-8993(97)00583-0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Greiner RS, 1999, LIPIDS, V34, pS239, DOI 10.1007/BF02562305; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Kitareewan S, 1996, MOL BIOL CELL, V7, P1153, DOI 10.1091/mbc.7.8.1153; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Lu HC, 1997, DEVELOPMENT, V124, P195; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mascrez B, 1998, DEVELOPMENT, V125, P4691; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; ONATE SA, 1995, SCIENCE, V270, P1354; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CHEM BIOL, V5, P13, DOI 10.1016/S1074-5521(98)90083-7; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rose DP, 1999, PHARMACOL THERAPEUT, V83, P217, DOI 10.1016/S0163-7258(99)00026-1; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Salem N. Jr., 1986, Health effects of polyunsaturated fatty acids in seafoods, P263; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Storlien L H, 1998, Curr Opin Clin Nutr Metab Care, V1, P559, DOI 10.1097/00075197-199811000-00014; Wang S, 1999, NEURAL COMPUT APPL, V8, P3, DOI 10.1007/s005210050002; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	41	588	615	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	2000	290	5499					2140	2144						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118147				2022-12-28	WOS:000165870600055
J	Samet, JM; Dominici, F; Curriero, FC; Coursac, I; Zeger, SL				Samet, JM; Dominici, F; Curriero, FC; Coursac, I; Zeger, SL			Fine particulate air pollution and mortality in 20 US Cities, 1987-1994.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPOSURE; HEALTH	Background: Air pollution in cities has been linked to increased rates of mortality and morbidity in developed and developing countries. Although these findings have helped lead to a tightening of air-quality standards, their validity with respect to public health has been questioned. Methods: We assessed the effects of five major outdoor-air pollutants on daily mortality rates in 20 of the largest cities and metropolitan areas in the United States from 1987 to 1994. The pollutants were particulate matter that is less than 10 mum in aerodynamic diameter (PM10), ozone, carbon monoxide, sulfur dioxide, and nitrogen dioxide. We used a two-stage analytic approach that pooled data from multiple locations. Results: After taking into account potential confounding by other pollutants, we found consistent evidence that the level of PM(sub 10) is associated with the rate of death from all causes and from cardiovascular and respiratory illnesses. The estimated increase in the relative rate of death from all causes was 0.51 percent (95 percent posterior interval, 0.07 to 0.93 percent) for each increase in the PM10 level of 10 mug per cubic meter. The estimated increase in the relative rate of death from cardiovascular and respiratory causes was 0.68 percent (95 percent posterior interval, 0.20 to 1.16 percent) for each increase in the PM10 level of 10 mug per cubic meter. There was weaker evidence that increases in ozone levels increased the relative rates of death during the summer, when ozone levels are highest, but not during the winter. Levels of the other pollutants were not significantly related to the mortality rate. Conclusions: There is consistent evidence that the levels of fine particulate matter in the air are associated with the risk of death from all causes and from cardiovascular and respiratory illnesses. These findings strengthen the rationale for controlling the levels of respirable particles in outdoor air. (N Engl J Med 2000;343:1742-9.) (C) 2000, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Samet, JM (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, 615 N Wolfe St,Suite 6041, Baltimore, MD 21205 USA.	jsamet@jhsph.edu		Zeger, Scott/0000-0001-8907-1603	NIEHS NIH HHS [P30 ES0 3819-12] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bascom R, 1996, AM J RESP CRIT CARE, V153, P477, DOI 10.1164/ajrccm.153.2.8564086; *BUR CENS, 1990, STAT ABSTR US; Dockery D., 1996, PARTICLES OUR AIR CO, P123; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DOMINICI F, 2000, J R STAT SOC A, V152, P397; *ENV PROT AG, 1996, REV NAT AMB AIR QUAL; Gamble JF, 1996, ENVIRON HEALTH PERSP, V104, P838, DOI 10.2307/3432938; Gamble JF, 1998, ENVIRON HEALTH PERSP, V106, P535, DOI 10.1289/ehp.98106535; Gelman Andrew, 1995, BAYESIAN DATA ANAL; HASTIC TJ, 1990, GEN ADDITIVE MODELS; Kaiser J, 1997, SCIENCE, V277, P466, DOI 10.1126/science.277.5325.466; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658, DOI 10.1136/bmj.314.7095.1658; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; LINDLEY DV, 1972, J ROY STAT SOC B, V34, P1; Lipfert FW, 1997, J AIR WASTE MANAGE, V47, P517, DOI 10.1080/10473289.1997.10464417; *MATHS, 1998, S PLUS VERS 3 4; Mc Clellan R. O., 1997, CIIT ACTIVITIES CHEM, P1; Moolgavkar SH, 1996, EPIDEMIOLOGY, V7, P420, DOI 10.1097/00001648-199607000-00014; Morris CN, 1992, BAYESIAN STATISTICS, P321; *NAT CLIM DAT CTR, 1994, TD3280 NAT CLIM DAT; *OFF AIR QUAL PLAN, 1999, ACR INF RETR SYST; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; Samet J, 1997, PARTICULATE AIR POLL; SAMET JM, 2000, NATL MORBIDITY MORTA, V1; Samet JM, 1995, PARTICULATE AIR POLL; SAMET JM, 2000, NATL MORBIDITY MORTA, V2; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 2000, AM J EPIDEMIOL, V151, P440, DOI 10.1093/oxfordjournals.aje.a010228; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; Thurston G.D., 1999, AIR POLLUT HLTH, P485, DOI DOI 10.1016/B978-012352335-8/50097-1; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177, DOI 10.1093/oxfordjournals.aje.a009249; U.S. Environmental Protection Agency, 1997, FED REGISTER, V62, P138; Zeger SL, 1999, EPIDEMIOLOGY, V10, P171, DOI 10.1097/00001648-199903000-00015	34	1816	1930	10	440	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1742	1749		10.1056/NEJM200012143432401	http://dx.doi.org/10.1056/NEJM200012143432401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11114312				2022-12-28	WOS:000165812000001
J	Dixon, M				Dixon, M			Charity spice	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1479	1479		10.1136/bmj.321.7274.1479	http://dx.doi.org/10.1136/bmj.321.7274.1479			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110748	Green Published			2022-12-28	WOS:000165852300070
J	Lekstrom-Himes, JA; Gallin, JI				Lekstrom-Himes, JA; Gallin, JI			Immunodeficiency diseases caused by defects in phagocytes	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC GRANULOMATOUS-DISEASE; CHEDIAK-HIGASHI-SYNDROME; INTERFERON-GAMMA-RECEPTOR; BACILLE CALMETTE-GUERIN; BINDING-PROTEIN-EPSILON; ACUTE MYELOID-LEUKEMIA; NEUTROPHIL ADHESION; NADPH OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; CYTOSOLIC COMPONENTS		NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gallin, JI (corresponding author), Bldg 10,Rm 2C146,10 Ctr Dr,MSC 1504, Bethesda, MD 20892 USA.	jgallin@cc.nih.gov						Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; Anderson-Cohen M, 1999, BLOOD, V94, p208A; BACHNER RL, 1968, NEW ENGL J MED, V278, P971; BAEHNER RL, 1968, SCIENCE, V162, P1277, DOI 10.1126/science.162.3859.1277; BAEHNER RL, 1967, SCIENCE, V155, P835, DOI 10.1126/science.155.3764.835; BAEHNER RL, 1972, J RETICULOENDOTH SOC, V12, P150; Barbosa MDFS, 1997, NATURE, V385, P97, DOI 10.1038/385097a0; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; BERENDES H, 1957, Minn Med, V40, P309; Bernini JC, 1996, PEDIATR CLIN N AM, V43, P773, DOI 10.1016/S0031-3955(05)70432-6; BLUME RS, 1972, MEDICINE, V51, P247, DOI 10.1097/00005792-197207000-00001; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BRETONGORIUS J, 1980, AM J PATHOL, V99, P413; Brown E, 1997, SEMIN HEMATOL, V34, P319; Brown PK, 1902, AM MED, V3, P649; BUESCHER ES, 1985, J CLIN INVEST, V76, P1581, DOI 10.1172/JCI112140; CHEDIAK M M, 1952, Rev Hematol, V7, P362; CHIN TW, 1987, J PEDIATR-US, V111, P349, DOI 10.1016/S0022-3476(87)80452-3; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1971, J CLIN INVEST, V50, P2645, DOI 10.1172/JCI106765; CROWLEY CA, 1980, NEW ENGL J MED, V302, P1163, DOI 10.1056/NEJM198005223022102; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; DALE DC, 1979, MEDICINE, V58, P128, DOI 10.1097/00005792-197903000-00002; de Jong R, 1998, SCIENCE, V280, P1435; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; Doan CA, 1932, J AMER MED ASSOC, V99, P194, DOI 10.1001/jama.1932.02740550008003; Dokal I, 1997, BRIT J HAEMATOL, V99, P171, DOI 10.1046/j.1365-2141.1997.3673181.x; DONOWITZ GR, 1983, ADV HOST DEFENSE MEC, V3, P55; Dorman SE, 2000, CYTOKINE GROWTH F R, V11, P321, DOI 10.1016/S1359-6101(00)00010-1; Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Etzioni A, 1999, BLOOD, V94, P3281, DOI 10.1182/blood.V94.10.3281.422k37_3281_3288; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; Freedman M H, 1997, Curr Opin Hematol, V4, P217; Gagro A, 1999, EUR J IMMUNOL, V29, P3369, DOI 10.1002/(SICI)1521-4141(199910)29:10<3369::AID-IMMU3369>3.0.CO;2-#; GALLIN JI, 1985, ANNU REV MED, V36, P263; GALLIN JI, 1995, ANN INTERN MED, V123, P216, DOI 10.7326/0003-4819-123-3-199508010-00009; GALLIN JI, 1985, J INFECT DIS, V152, P661, DOI 10.1093/infdis/152.4.661; GALLIN JI, 1975, BLOOD, V45, P863; GALLIN JI, 1991, REV INFECT DIS, V13, P973; GANZ T, 1988, J CLIN INVEST, V82, P552, DOI 10.1172/JCI113631; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; HAMERS MN, 1984, NATURE, V307, P553, DOI 10.1038/307553a0; Haurie C, 1998, BLOOD, V92, P2629, DOI 10.1182/blood.V92.8.2629.420a35_2629_2640; HIGASHI O, 1954, Tohoku J Exp Med, V59, P315; HOLMES B, 1967, J CLIN INVEST, V46, P1422, DOI 10.1172/JCI105634; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Horwitz ME, 1999, BLOOD, V94, p710A; Introne W, 1999, MOL GENET METAB, V68, P283, DOI 10.1006/mgme.1999.2927; Jacob CMA, 1996, J INVEST ALLERG CLIN, V6, P202; JANEWAY CA, 1954, AMA AM J DIS CHILD, V88, P388; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Jouanguy E, 1999, NAT GENET, V21, P370, DOI 10.1038/7701; KLEBANOFF SJ, 1968, J BACTERIOL, V95, P2131, DOI 10.1128/JB.95.6.2131-2138.1968; KLEBANOFF SJ, 1969, NEW ENGL J MED, V280, P460, DOI 10.1056/NEJM196902272800902; Knight K R, 1997, Respirology, V2, P91, DOI 10.1111/j.1440-1843.1997.tb00060.x; KOMIYAMA A, 1979, J PEDIATR-US, V94, P19, DOI 10.1016/S0022-3476(79)80343-1; Kuijpers TW, 1999, J IMMUNOL METHODS, V232, P211, DOI 10.1016/S0022-1759(99)00178-7; Lamhamedi-Cherradi S, 1999, J IMMUNOL METHODS, V225, P75, DOI 10.1016/S0022-1759(99)00030-7; Lanza F, 1998, J MOL MED-JMM, V76, P676, DOI 10.1007/s001090050267; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes J, 1999, BLOOD, V93, P3096; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; Leung TF, 1999, BONE MARROW TRANSPL, V24, P567, DOI 10.1038/sj.bmt.1701932; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; Malech HL, 1997, SEMIN HEMATOL, V34, P279; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; MARGOLIS DM, 1990, J INFECT DIS, V162, P723, DOI 10.1093/infdis/162.3.723; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; McDowell G, 1997, P SOC EXP BIOL MED, V215, P145; Meyaard L, 1996, J IMMUNOL, V156, P2776; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; NATHAN DG, 1998, NATHAN OSKIS HEMATOL, V1, P276; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; NAUSEEF WM, 1994, J BIOL CHEM, V269, P1212; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; Palmer SE, 1996, AM J MED GENET, V66, P413, DOI 10.1002/(SICI)1096-8628(19961230)66:4<413::AID-AJMG5>3.0.CO;2-L; Phillips ML, 1995, J CLIN INVEST, V96, P2898, DOI 10.1172/JCI118361; QUIE PG, 1967, J CLIN INVEST, V46, P668, DOI 10.1172/JCI105568; RAUSCH PG, 1978, NEW ENGL J MED, V298, P693, DOI 10.1056/NEJM197803302981301; Roberts SR, 1930, J AMER MED ASSOC, V95, P780, DOI 10.1001/jama.1930.02720110016006; Roos D, 1999, BLOOD, V94, P2955; ROOT RK, 1972, J CLIN INVEST, V51, P649, DOI 10.1172/JCI106854; ROSENBERG EB, 1974, ARCH INTERN MED, V134, P769, DOI 10.1001/archinte.134.4.769; ROSENBERG HF, 1993, BLOOD, V82, P268, DOI 10.1182/blood.V82.1.268.bloodjournal821268; ROTROSEN D, 1987, ANNU REV IMMUNOL, V5, P127, DOI 10.1146/annurev.immunol.5.1.127; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SATO A, 1955, Tohoku J Exp Med, V61, P201; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; Smith OP, 1996, BRIT J HAEMATOL, V94, P279, DOI 10.1046/j.1365-2141.1996.d01-1788.x; SPITZNAGEL JK, 1972, J CLIN INVEST, V51, pA93; STRAUSS RG, 1974, NEW ENGL J MED, V290, P478, DOI 10.1056/NEJM197402282900903; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; Touw IP, 1996, LEUKEMIA RES, V20, P629, DOI 10.1016/0145-2126(96)00017-3; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; WALTHER MM, 1992, J UROLOGY, V147, P1314, DOI 10.1016/S0022-5347(17)37552-3; Welte K, 1996, ANN HEMATOL, V72, P158, DOI 10.1007/s002770050156; Welte K, 1997, SEMIN HEMATOL, V34, P267; WHITE JG, 1980, AM J PATHOL, V98, P151; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; WOLFF SM, 1972, ANN INTERN MED, V76, P293, DOI 10.7326/0003-4819-76-2-293; WRIGHT DG, 1979, J IMMUNOL, V123, P285; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187	116	269	278	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2000	343	23					1703	1714		10.1056/NEJM200012073432307	http://dx.doi.org/10.1056/NEJM200012073432307			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380PX	11106721				2022-12-28	WOS:000165711900007
J	Kerlikowske, K; Carney, PA; Geller, B; Mandelson, MT; Taplin, SH; Malvin, K; Ernster, V; Urban, N; Cutter, G; Rosenberg, R; Ballard-Barbash, R				Kerlikowske, K; Carney, PA; Geller, B; Mandelson, MT; Taplin, SH; Malvin, K; Ernster, V; Urban, N; Cutter, G; Rosenberg, R; Ballard-Barbash, R			Performance of screening mammography among women with and without a first-degree relative with breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article							POSITIVE PREDICTIVE VALUE; CARCINOMA IN-SITU; FAMILY-HISTORY; FOLLOW-UP; GROWTH-RATES; AGE; RISK; INTERVAL; SENSITIVITY; DENSITY	Background: Although it is recommended that women with a family history of breast cancer begin screening mammography at a younger age than average-risk women, few studies have evaluated the performance of mammography in this group. Objective: To compare the performance of screening mammography in women with a first-degree family history of breast cancer and women of similar age without such history. Design: Cross-sectional. Setting: Mammography registries in California (n = 1) New Hampshire (n = 1), New Mexico (n = 1), Vermont (n = 1) Washington State (n = 2), and Colorado (n = 1). Measurements: Risk factors for breast cancer; results of first screening examination captured for a woman by a registry; and any invasive cancer or ductal carcinoma in situ identified by linkage to a pathology database, the Surveillance, Epidemiology, and End Results program, or a state tumor registry. Results: The number of cancer cases per 1000 examinations increased with age and was higher in women with a family history of breast cancer than in those without (3.2 vs. 1.6 for ages 30 to 39 years, 4.7 vs. 2.7 for ages 40 to 49 years, 6.6 vs. 4.6 for ages 50 to 59 years, and 9.3 vs. 6.9 for ages 60 to 69 years). The sensitivity of mammography increased significantly with age (P = 0.001 [chi-square test for trend]) in women with a family history and in those without (63.2% [95% CI, 41.5% to 84.8%] vs. 69.5% [Ct, 57.7% to 81.2%] for ages 30 to 39 years, 70.2% [CI, 61.0% to 79.5%] vs. 77.5% [CI, 73.3% to 81.8%] for ages 40 to 49 years, 81.3% [CI, 73.3% to 89.3%] vs. 80.2% [CI, 76.5% to 83.9%] for ages 50 to 59 years, and 83.8% [CI, 76.8% to 90.9%] vs. 87.7% [Cf, 84.8% to 90.7%] for ages 60 to 69 years). Sensitivity was similar for each decade of age regardless of family history. The positive predictive value of mammography was higher in women with a family history than in those without (3.7% vs. 2.9%; P = 0.001). Conclusions: Cancer detection rates in women who had a first-degree relative with a history of breast cancer were similar to those in women a decade older without such a history. The sensitivity of screening mammography was influenced primarily by age.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Dartmouth Med Sch, Lebanon, NH USA; Univ Vermont, Coll Med, Burlington, VT USA; Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Ctr Canc Res, AMC, Denver, CO USA; Univ New Mexico, Med Ctr, New Mexico Tumor Registry, Albuquerque, NM 87131 USA; Natl Canc Inst, Bethesda, MD USA	University of California System; University of California San Francisco; Dartmouth College; University of Vermont; Group Health Cooperative; Fred Hutchinson Cancer Center; AMC Cancer Research Center; University of New Mexico; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kerlikowske, K (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.		Cutter, Gary/AAY-5392-2021	Cutter, Gary/0000-0002-8455-980X	NCI NIH HHS [1 U01 CA 63740, K07CA71869, CA63146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063146, K07CA071869, U01CA063740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1993, BREAST IMAGING REPOR; BallardBarbash R, 1997, AM J ROENTGENOL, V169, P1001, DOI 10.2214/ajr.169.4.9308451; BREKELMANS CTM, 1992, EUR J CANCER, V28A, P893, DOI 10.1016/0959-8049(92)90144-Q; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; Burman ML, 1999, ANN INTERN MED, V131, P1, DOI 10.7326/0003-4819-131-1-199907060-00002; CALLE EE, 1993, AM J EPIDEMIOL, V138, P675, DOI 10.1093/oxfordjournals.aje.a116904; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; Elmore JG, 1997, JAMA-J AM MED ASSOC, V277, P49, DOI 10.1001/jama.277.1.49; Gilbert FJ, 1998, EUR J CANCER, V34, P2010, DOI 10.1016/S0959-8049(98)00294-9; Gilliland FD, 2000, J NATL CANCER I, V92, P743, DOI 10.1093/jnci/92.9.743; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Kerlikowske K, 1997, JNCI-J NATL CANCER I, V89, P76, DOI 10.1093/jnci/89.1.76; Kerlikowske K, 1997, J Natl Cancer Inst Monogr, P105; Kollias J, 1998, EUR J CANCER, V34, P878, DOI 10.1016/S0959-8049(97)00365-1; Lalloo F, 1998, EUR J CANCER, V34, P937, DOI 10.1016/S0959-8049(98)00005-7; LEE JRJ, 1995, CANCER EPIDEM BIOMAR, V4, P901; Lippert MT, 1999, CANCER DETECT PREV, V23, P265, DOI 10.1046/j.1525-1500.1999.99023.x; May DS, 1998, AM J ROENTGENOL, V170, P97, DOI 10.2214/ajr.170.1.9423608; MONTICCIOLO DL, 1990, AM J ROENTGENOL, V155, P751, DOI 10.2214/ajr.155.4.2119104; MOSKOWITZ M, 1986, RADIOLOGY, V161, P37, DOI 10.1148/radiology.161.1.3532183; *NAT CANC ADV BOAR, 1997, CANC LETT, V23, P4; PEER PGM, 1993, CANCER, V71, P3547, DOI 10.1002/1097-0142(19930601)71:11<3547::AID-CNCR2820711114>3.0.CO;2-C; Porter PL, 1999, J NATL CANCER I, V91, P2020, DOI 10.1093/jnci/91.23.2020; RENNERT G, 1999, PROGR BREAST CANC SC; Rosenberg RD, 1998, RADIOLOGY, V209, P511, DOI 10.1148/radiology.209.2.9807581; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; SLATTERY ML, 1993, EPIDEMIOLOGY, V4, P543, DOI 10.1097/00001648-199311000-00011; SPRATT JS, 1986, CANCER RES, V46, P970; Tabar L, 1997, J Natl Cancer Inst Monogr, P43; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1995, CANCER, V75, P2507, DOI 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Yang QH, 1998, AM J EPIDEMIOL, V147, P652	39	170	177	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					855	863		10.7326/0003-4819-133-11-200012050-00009	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103055				2022-12-28	WOS:000165585800004
J	Lipsky, PE; van der Heijde, DMFM; St Clair, EW; Furst, DE; Breedveld, FC; Kalden, JR; Smolen, JS; Weisman, M; Emery, P; Feldmann, M; Harriman, GR; Maini, RN				Lipsky, PE; van der Heijde, DMFM; St Clair, EW; Furst, DE; Breedveld, FC; Kalden, JR; Smolen, JS; Weisman, M; Emery, P; Feldmann, M; Harriman, GR; Maini, RN		Anti-Tumor Necrosis Factor Trial	Infliximab and methotrexate in the treatment of rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; CHIMERIC MONOCLONAL-ANTIBODY; RADIOGRAPHIC PROGRESSION; RADIOLOGICAL PROGRESSION; FUSION PROTEIN; DOUBLE-BLIND; DISEASE; EFFICACY; PLACEBO; TRIAL	Background: Neutralization of tumor necrosis factor alpha (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known. Methods: We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-alpha, in intravenous doses of 3 or 10 mg per kilogram of body weight every 4 or 8 weeks in combination with oral methotrexate for 54 weeks. We assessed clinical responses with use of the criteria of the American College of Rheumatology, the quality of life with a health-status questionnaire, and the effect on joint damage radiographically. Results: The combination of infliximab and methotrexate was well tolerated and resulted in a sustained reduction in the symptoms and signs of rheumatoid arthritis that was significantly greater than the reduction associated with methotrexate therapy alone (clinical response, 51.8 percent vs. 17.0 percent; P<0.001). The quality of life was also significantly better with infliximab plus methotrexate than with methotrexate alone. Radiographic evidence of joint damage increased in the group given methotrexate, but not in the groups given infliximab and methotrexate (mean change in radiographic score, 7.0 vs. 0.6; P<0.001). Radiographic evidence of progression of joint damage was absent in infliximab-treated patients whether or not they had a clinical response. Conclusions: In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotrexate provided clinical benefit and halted the progression of joint damage. (N Engl J Med 2000;343:1594-602.) (C) 2000, Massachusetts Medical Society.	Univ Texas, SW Med Ctr, Dallas, TX USA; Univ Hosp Maastricht, Maastricht, Netherlands; Duke Univ, Med Ctr, Durham, NC USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Leiden Univ, Leiden, Netherlands; Inst Clin Immunol, Erlangen, Germany; Univ Vienna, Vienna, Austria; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Leeds, Res Sch Med, Leeds, W Yorkshire, England; Kennedy Inst Rheumatol, London, England; Charing Cross Hosp, Imperial Coll, Sch Med, London, England; Centocor Inc, Malvern, PA 19355 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Maastricht University; Maastricht University Medical Centre (MUMC); Duke University; Virginia Mason Medical Center; Leiden University; Leiden University - Excl LUMC; University of Erlangen Nuremberg; University of Vienna; University of California System; University of California San Diego; University of Leeds; University of Oxford; Imperial College London; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Lipsky, PE (corresponding author), NIAMSD, NIH, 9000 Rockville Pike,Bldg 10,Rm 9N228, Bethesda, MD 20892 USA.		van der Heijde, Désirée/I-6774-2019; emery, paul/B-3560-2013	van der Heijde, Désirée/0000-0002-5781-158X; 				BECKHAM JC, 1992, J CLIN IMMUNOL, V12, P353, DOI 10.1007/BF00920793; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BRENNAN FM, 1992, CURR OPIN IMMUNOL, V4, P754, DOI 10.1016/0952-7915(92)90057-L; Charles P, 1999, J IMMUNOL, V163, P1521; CROWE W, 1977, ARTHRITIS RHEUM, V20, P811, DOI 10.1002/art.1780200308; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Fries JF, 1996, ARTHRITIS RHEUM, V39, P616, DOI 10.1002/art.1780390412; Graudal NA, 1998, ARTHRITIS RHEUM, V41, P1470, DOI 10.1002/1529-0131(199808)41:8<1470::AID-ART18>3.0.CO;2-V; Kaarela K, 1997, J RHEUMATOL, V24, P1285; Kavanaugh A, 2000, J RHEUMATOL, V27, P841; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; Lassere M, 1999, J RHEUMATOL, V26, P731; LIPSKY PE, 1998, HARRISONS PRINCIPLES, V2, P1880; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MCCARTY GA, 1980, J RHEUMATOL, V7, P339; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Parker SL, 1997, CA-CANCER J CLIN, V47, P68; Plant MJ, 1998, J RHEUMATOL, V25, P417; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; SHARP JT, 1991, ARTHRITIS RHEUM, V34, P660, DOI 10.1002/art.1780340606; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; vanderHeide A, 1996, ANN INTERN MED, V124, P699, DOI 10.7326/0003-4819-124-8-199604150-00001; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VANDERHEIJDE DMF, 1991, ARTHRITIS RHEUM, V35, P26; VanderHeijde DMFM, 1996, BAILLIERE CLIN RHEUM, V10, P435, DOI 10.1016/S1521-6942(96)80007-6; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; WOLD RT, 1968, SCIENCE, V161, P806, DOI 10.1126/science.161.3843.806; Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1571, DOI 10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R	38	2546	2691	0	176	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1594	1602		10.1056/NEJM200011303432202	http://dx.doi.org/10.1056/NEJM200011303432202			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096166				2022-12-28	WOS:000165511000002
J	Fagerhol, MK				Fagerhol, MK			Calprotectin, a faecal marker of organic gastrointestinal abnormality	LANCET			English	Editorial Material							FECAL CALPROTECTIN; PROTEIN CALPROTECTIN; COLORECTAL-CANCER; DISEASE		Ullevaal Univ Hosp, Dept Immunol & Transfus Med, N-0407 Oslo, Norway	University of Oslo	Fagerhol, MK (corresponding author), Ullevaal Univ Hosp, Dept Immunol & Transfus Med, N-0407 Oslo, Norway.			Fagerhol, Magne Kristoffer/0000-0002-5103-6981				Campbell SS, 2000, GASTROENTEROLOGY, V118, pA103, DOI 10.1016/S0016-5085(00)82490-7; Fagerhol M. K., 1990, STIMULUS RESPONSE CO, P187; Fagerhol MK, 1996, J CLIN PATHOL-CL MOL, V49, pM74; FAGERHOL MK, 1980, SCAND J HAEMATOL, V24, P393; Gilbert JA, 1996, SCAND J GASTROENTERO, V31, P1001, DOI 10.3109/00365529609003120; Johne B, 1997, J CLIN PATHOL-MOL PA, V50, P113; Kristinsson J, 1998, DIS COLON RECTUM, V41, P316, DOI 10.1007/BF02237485; Kronborg O, 2000, GUT, V46, P795, DOI 10.1136/gut.46.6.795; Meling TR, 1996, SCAND J GASTROENTERO, V31, P339, DOI 10.3109/00365529609006407; Roseth AG, 1999, SCAND J GASTROENTERO, V34, P50; Roseth AG, 1997, DIGESTION, V58, P176, DOI 10.1159/000201441; ROSETH AG, 1992, SCAND J GASTROENTERO, V27, P793, DOI 10.3109/00365529209011186; ROSETH AG, 1993, SCAND J GASTROENTERO, V28, P1073, DOI 10.3109/00365529309098312; Tibble J, 2000, GUT, V47, P506, DOI 10.1136/gut.47.4.506; Tibble JA, 2000, GASTROENTEROLOGY, V119, P15, DOI 10.1053/gast.2000.8523; Tibble JA, 1999, GUT, V45, P362, DOI 10.1136/gut.45.3.362; Ton H, 2000, CLIN CHIM ACTA, V292, P41, DOI 10.1016/S0009-8981(99)00206-5; Yui S, 1995, J LEUKOCYTE BIOL, V58, P650, DOI 10.1002/jlb.58.6.650	18	113	118	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1783	1784		10.1016/S0140-6736(00)03224-4	http://dx.doi.org/10.1016/S0140-6736(00)03224-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117904				2022-12-28	WOS:000165545700003
J	Greub, G; Ledergerber, B; Battegay, M; Grob, P; Perrin, L; Furrer, H; Burgisser, P; Erb, P; Boggian, K; Piffaretti, JC; Hirschel, B; Janin, P; Francioli, P; Flepp, M; Telenti, A				Greub, G; Ledergerber, B; Battegay, M; Grob, P; Perrin, L; Furrer, H; Burgisser, P; Erb, P; Boggian, K; Piffaretti, JC; Hirschel, B; Janin, P; Francioli, P; Flepp, M; Telenti, A		Swiss HIV Cohort Study	Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED PATIENTS; MAINTENANCE TREATMENT; LIVER-DISEASE; DRUG-USERS; HEMOPHILIACS; PREVALENCE; AIDS; REPLICATION; REGRESSION	Background Hepatitis C virus (HCV) infection is highly prevalent among HIV-1-infected individuals, but its contribution to the morbidity and mortality of coinfected patients who receive potent antiretroviral therapy is controversial. We used data from the ongoing Swiss HIV Cohort Study to analyse clinical progression of HIV-1, and the virological and immunological response to potent antiretroviral therapy in HIV-1-infected patients with or without concurrent HCV infection. Methods We analysed prospective data on survival, clinical disease progression, suppression of HIV-1 replication, CD4-cell recovery, and frequency of changes in antiretroviral therapy according to HCV status in 3111 patients starting potent antiretroviral therapy. Results 1157 patients (37.2%) were coinfected with HCV, 1015 of whom (87.7%) had a history of intravenous drug use. In multivariate Cox's regression, the probability of progression to a new AIDS-defining clinical event or to death was independently associated with HCV seropositivity (hazard ratio 1.7 [95% CI 1.26-2.30]), and with active intravenous drug use (1.38 [1.02-1.88). Virological response to antiretroviral therapy and the probability of treatment change were not associated with HCV serostatus. In contrast, HCV seropositivity was associated with a smaller CD4-cell recovery (hazard ratio for a CD4-cell count increase of at least 50 cells/muL=0.79 [0.72-0.87]). Interpretation HCV and active intravenous drug use could be important factors in the morbidity and mortality among HIV-1-infected patients, possibly through impaired CD4-cell recovery in HCV seropositive patients receiving potent antiretroviral therapy. These findings are relevant for decisions about optimum timing for HCV treatment in the setting of HIV infection.	Univ Lausanne Hosp, Div Infect Dis, CH-1011 Lausanne, Switzerland; Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland; Univ Basel Hosp, Ctr HIV Res, CH-4031 Basel, Switzerland; Univ Zurich Hosp, Div Diagnost Immunol, CH-8091 Zurich, Switzerland; Univ Hosp, Virol Lab, Geneva, Switzerland; Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland; Univ Lausanne Hosp, Div Immunol, Lausanne, Switzerland; Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland; Cantonal Hosp, Dept Internal Med, St Gallen, Switzerland; Ist Cantonale Batteriosierol, Lugano, Switzerland; Univ Hosp, Div Infect Dis, Geneva, Switzerland; SHCS Data Ctr, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Zurich; University Zurich Hospital; University of Basel; University of Zurich; University Zurich Hospital; University of Geneva; University of Bern; University Hospital of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Basel; Kantonsspital St. Gallen; University of Geneva	Telenti, A (corresponding author), Univ Lausanne Hosp, Div Infect Dis, CH-1011 Lausanne, Switzerland.		Furrer, Hansjakob/G-6768-2013; Greub, Gilbert GG/K-5804-2017; Ledergerber, Bruno/B-5656-2009; VALLET, Yannick/F-9979-2011; Telenti, Amalio/AAY-1674-2021	Furrer, Hansjakob/0000-0002-1375-3146; Greub, Gilbert GG/0000-0001-9529-3317; Ledergerber, Bruno/0000-0002-6881-4401; 				Beld M, 1998, VIROLOGY, V244, P504, DOI 10.1006/viro.1998.9130; Broers B, 1998, AIDS, V12, P2059, DOI 10.1097/00002030-199815000-00018; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; CRIBIER B, 1995, AIDS, V9, P1131, DOI 10.1097/00002030-199510000-00003; Davis Gary L., 1999, American Journal of Medicine, V107, p21S; Dieterich Douglas T., 1999, American Journal of Medicine, V107, p79S; DORRUCCI M, 1995, J INFECT DIS, V172, P1503, DOI 10.1093/infdis/172.6.1503; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; GarciaSamaniego J, 1997, AM J GASTROENTEROL, V92, P1130; HESS KR, 1995, STAT MED, V14, P1707, DOI 10.1002/sim.4780141510; Laskus T, 1998, J INFECT DIS, V178, P1189, DOI 10.1086/515682; Laskus T, 2000, J INFECT DIS, V181, P442, DOI 10.1086/315283; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Lesens O, 1999, J INFECT DIS, V179, P1254, DOI 10.1086/314720; Liang T. Jake, 2000, Annals of Internal Medicine, V132, P296; LLIBRE JM, 1993, CLIN INFECT DIS, V17, P117; Macias J, 1998, EUR J CLIN MICROBIOL, V17, P167, DOI 10.1007/BF01691112; MANZIN A, 1994, CLIN DIAGN LAB IMMUN, V1, P160, DOI 10.1128/CDLI.1.2.160-163.1994; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Piroth L, 1998, AIDS, V12, P381, DOI 10.1097/00002030-199804000-00006; QUAN CM, 1993, CLIN INFECT DIS, V17, P117, DOI 10.1093/clinids/17.1.117; Ragni MV, 1999, J INFECT DIS, V180, P2027, DOI 10.1086/315143; Sabin CA, 1997, J INFECT DIS, V175, P164, DOI 10.1093/infdis/175.1.164; Sansonno D, 1998, BLOOD, V92, P3328, DOI 10.1182/blood.V92.9.3328.421k04_3328_3337; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SHERMAN KE, 1993, J CLIN MICROBIOL, V31, P2679, DOI 10.1128/JCM.31.10.2679-2682.1993; Soriano V, 1999, AIDS, V13, P539, DOI 10.1097/00002030-199904010-00002; Soriano V, 1996, CLIN INFECT DIS, V23, P585, DOI 10.1093/clinids/23.3.585; Soriano V, 1999, EUR J EPIDEMIOL, V15, P1, DOI 10.1023/A:1007506617734; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Thomas DL, 2000, J INFECT DIS, V181, P844, DOI 10.1086/315314; TROISI CL, 1993, BLOOD, V81, P412; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; WRIGHT TL, 1994, HEPATOLOGY, V20, P1152	35	678	708	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1800	1805		10.1016/S0140-6736(00)03232-3	http://dx.doi.org/10.1016/S0140-6736(00)03232-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117912				2022-12-28	WOS:000165545700011
J	Lee, HC; Kim, SJ; Kim, KS; Shin, HC; Yoon, JW				Lee, HC; Kim, SJ; Kim, KS; Shin, HC; Yoon, JW			RETRACTED: Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue (Retracted Article. See vol 458, pg 660, 2009)	NATURE			English	Article; Retracted Publication							PYRUVATE-KINASE GENE; ADENOASSOCIATED VIRUS; EXPRESSION; INTEGRATION; MELLITUS; PROMOTER; GLUCOSE; CELLS; SITE; DNA	A cure for diabetes has long been sought using several different approaches, including islet transplantation, regeneration of beta cells and insulin gene therapy(1). However, permanent remission of type 1 diabetes has not yet been satisfactorily achieved. The development of type 1 diabetes results from the almost total destruction of insulin-producing pancreatic beta cells by autoimmune responses specific to beta cells(2-6). Standard insulin therapy may not maintain blood glucose concentrations within the relatively narrow range that occurs in the presence of normal pancreatic beta cells(7). We used a recombinant adeno-associated virus (rAAV) that expresses a single-chain insulin analogue (SIA), which possesses biologically active insulin activity without enzymatic conversion, under the control of hepatocyte-specific L-type pyruvate kinase (LPK) promoter, which regulates SIA expression in response to blood glucose levels. Here we show that SIA produced from the gene construct rAAV-LPK-SIA caused remission of diabetes in streptozotocin-induced diabetic rats and autoimmune diabetic mice for a prolonged time without any apparent side effects. This new SIA gene therapy may have potential therapeutic value for the cure of autoimmune diabetes in humans.	Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Univ Calgary, Fac Med,Lab Viral & Immunopathogenesis Diabet, Dept Microbiol & Infect Dis, Julia McFarlane Diabet Res Ctr, Calgary, AB T2N 4N1, Canada	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; University of Calgary	Lee, HC (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol, Seoul 120752, South Korea.	endohclee@yumc.yonsei.ac.kr		Kim, Kyung-sup/0000-0001-8483-8537				BACH JF, 1995, J AUTOIMMUN, V8, P439, DOI 10.1016/0896-8411(95)90001-2; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CAMERON NE, 1991, AM J PHYSIOL, V261, pE1, DOI 10.1152/ajpendo.1991.261.1.E1; CHEN RH, 1995, FEBS LETT, V365, P223, DOI 10.1016/0014-5793(95)00472-L; Clark KR, 1999, HUM GENE THER, V10, P1031, DOI 10.1089/10430349950018427; Cuif MH, 1997, FEBS LETT, V417, P81, DOI 10.1016/S0014-5793(97)01260-X; CUIF MH, 1993, J BIOL CHEM, V268, P13769; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIRAUD C, 1994, P NATL ACAD SCI USA, V91, P10039, DOI 10.1073/pnas.91.21.10039; HEATH WF, 1992, J BIOL CHEM, V267, P419; Hirasawa K, 1997, J VIROL, V71, P4024, DOI 10.1128/JVI.71.5.4024-4031.1997; KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x; Levine F, 1999, MOL MED TODAY, V5, P165, DOI 10.1016/S1357-4310(98)01425-7; Ma ZM, 1997, CLIN CHEM, V43, P1732; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; POLLET RJ, 1977, J BIOL CHEM, V252, P5828; Rossini A.A., 1993, DIABETES REV ALEX, V1, P43; Roth J, 1975, Methods Enzymol, V37, P66; SAMULSKI RJ, 1993, CURR OPIN GENET DEV, V3, P74, DOI 10.1016/S0959-437X(05)80344-2; Schranz DB, 1998, DIABETES METAB REV, V14, P3, DOI 10.1002/(SICI)1099-0895(199803)14:1<3::AID-DMR206>3.0.CO;2-T; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; YOON JW, 1982, NATURE, V296, P566, DOI 10.1038/296566a0; YOON JW, 1976, NATURE, V264, P178, DOI 10.1038/264178a0; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183; YOON JW, 1998, ENCY IMMUNOLOGY, P1390	28	186	220	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	2000	408	6811					483	488		10.1038/35044106	http://dx.doi.org/10.1038/35044106			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100731				2022-12-28	WOS:000165429800051
J	Sakamoto, Y; Kaneda, M; Terasaki, O; Zhao, DY; Kim, JM; Stucky, G; Shim, HJ; Ryoo, R				Sakamoto, Y; Kaneda, M; Terasaki, O; Zhao, DY; Kim, JM; Stucky, G; Shim, HJ; Ryoo, R			Direct imaging of the pores and cages of three-dimensional mesoporous materials	NATURE			English	Article							ELECTRON-MICROSCOPY; COPOLYMER; TRIBLOCK; SILICA	Mesostructured composite materials, with features ranging from 20 to 500 Angstrom in size, are obtained by the kinetically controlled competitive assembly of organic and inorganic species into nanostructured domains. Short-range order is limited, and long-range order is determined by weak forces such as van der Waals or hydrogen-bonding. Three-dimensional mesoporous materials obtained by removing the organic phase are of particular interest for applications such as catalysis and chemical sensing or separation, for which structural features such as cavity shape, connectivity and ordered bimodal porosity are critical. But atomic-scale structural characterization by the usual diffraction techniques is challenging for these partially ordered materials because of the difficulty in obtaining large (>10 mum) single crystals, and because large repeat spacings cause diffraction intensities to fall off rapidly with scattering angle so that only limited small-angle data are available. Here we present a general approach for the direct determination of three-dimensional mesoporous structures by electron microscopy. The structure solutions are obtained uniquely without pre-assumed models or parametrization. We report high-resolution details of cage and pore structures of periodically ordered mesoporous materials(1,2), which reveal a highly ordered dual micro- and mesoscale pore structure.	Tohoku Univ, Dept Phys, Sendai, Miyagi 9808578, Japan; Tohoku Univ, CIR, Sendai, Miyagi 9808578, Japan; Tohoku Univ, Japan Sci & Technol Corp, CREST, Sendai, Miyagi 9808578, Japan; Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Korea Res Inst Chem Technol, Catalysis Ctr Mol Engn, Taejon 305600, South Korea; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Korea Adv Inst Sci & Technol, Sch Mol Sci BK21, Dept Chem, Mat Chem Lab, Taejon 305701, South Korea	Tohoku University; Tohoku University; Japan Science & Technology Agency (JST); Tohoku University; Fudan University; University of California System; University of California Santa Barbara; Korea Research Institute of Chemical Technology (KRICT); University of California System; University of California Santa Barbara; Korea Advanced Institute of Science & Technology (KAIST)	Sakamoto, Y (corresponding author), Tohoku Univ, Dept Phys, Sendai, Miyagi 9808578, Japan.	terasaki@msp.phys.tohoku.ac.jp; r.ryoo@mail.kaist.ac.kr	Ryoo, Ryong/B-1090-2009; , 赵东元/E-5796-2010; Sakamoto, Yasuhiro/G-8289-2012; Kim, Ji Man/A-4311-2013; Terasaki, Osamu/Y-1137-2018	, 赵东元/0000-0002-1642-2510; Kim, Ji Man/0000-0003-0860-4880; Terasaki, Osamu/0000-0001-5803-0817; Ryoo, Ryong/0000-0003-0047-3329				Alfredsson V, 1996, CHEM MATER, V8, P1141, DOI 10.1021/cm950568k; AUVRAY X, 1993, LANGMUIR, V9, P444, DOI 10.1021/la00026a014; CHARVOLIN J, 1988, J PHYS-PARIS, V49, P521, DOI 10.1051/jphys:01988004903052100; GEIS H, 1983, Z KRISTALLOGR, V164, P247; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; Nakanishi K, 1997, J POROUS MAT, V4, P67, DOI 10.1023/A:1009627216939; Ryoo R, 1998, STUD SURF SCI CATAL, V117, P151; Schacht S, 1998, MICROPOR MESOPOR MAT, V22, P485, DOI 10.1016/S1387-1811(98)00086-9; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i	12	762	786	2	338	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	2000	408	6811					449	453		10.1038/35044040	http://dx.doi.org/10.1038/35044040			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100722				2022-12-28	WOS:000165429800042
J	Yang, HQ; Wu, YJ; Tang, RH; Liu, DM; Liu, Y; Cashmore, AR				Yang, HQ; Wu, YJ; Tang, RH; Liu, DM; Liu, Y; Cashmore, AR			The C termini of Arabidopsis cryptochromes mediate a constitutive light response	CELL			English	Article							PHYTOCHROME-B; RECEPTOR CRYPTOCHROME-2; HYPOCOTYL ELONGATION; NUCLEAR-LOCALIZATION; SEEDLING DEVELOPMENT; GENE-EXPRESSION; CIRCADIAN CLOCK; FLOWERING TIME; DNA PHOTOLYASE; COP9 COMPLEX	Cryptochrome blue light photoreceptors share sequence similarity to photolyases, flavoproteins that mediate light-dependent DNA repair. However, cryptochromes lack photolyase activity and are characterized by distinguishing C-terminal domains. Here we show that the signaling mechanism of Arabidopsis cryptochrome is mediated through the C terminus. On fusion with beta -glucuronidase (GUS), both the Arabidopsis CRY1 C-terminal domain (CCT1) and the CRY2 C-terminal domain (CCT2) mediate a constitutive light response. This constitutive photomorphogenic (COP) phenotype was not observed for mutants of cct1 corresponding to previously described cry1 alleles. We propose that the C-terminal domain of Arabidopsis cryptochrome is maintained in an inactive state in the dark. Irradiation with blue light relieves this repression, presumably through an intra- or intermolecular redox reaction mediated through the flavin bound to the N-terminal photolyase-like domain.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Cashmore, AR (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	cashmore@sas.upenn.edu		wu, yingjie/0000-0002-2694-1971; Tang, Ruhang/0000-0003-4918-3525; Yang, Hong-Quan/0000-0001-6215-2665	NIGMS NIH HHS [GM38409, GM51956] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051956] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1995, PLANT J, V8, P653, DOI 10.1046/j.1365-313X.1995.08050653.x; Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1997, PLANT J, V11, P421, DOI 10.1046/j.1365-313X.1997.11030421.x; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Bagnall DJ, 1996, PLANTA, V200, P278, DOI 10.1007/BF00208319; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOYLAN M, 1994, PLANT CELL, V6, P449, DOI 10.1105/tpc.6.3.449; Bruggemann EP, 1998, GENETICS, V149, P1575; Casal JJ, 1998, PLANT PHYSIOL, V118, P19, DOI 10.1104/pp.118.1.19; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Cashmore AR, 1997, PLANT CELL ENVIRON, V20, P764, DOI 10.1046/j.1365-3040.1997.d01-125.x; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; CHORY J, 1992, DEVELOPMENT, V115, P337; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CHORY J, 1990, P NATL ACAD SCI USA, V87, P8776, DOI 10.1073/pnas.87.22.8776; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; Deng XW, 1999, SEMIN CELL DEV BIOL, V10, P121, DOI 10.1006/scdb.1999.0287; Devlin PF, 1999, PLANT PHYSIOL, V119, P909, DOI 10.1104/pp.119.3.909; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Fankhauser C, 2000, PLANT PHYSIOL, V124, P39, DOI 10.1104/pp.124.1.39; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Guo HW, 1999, PLANT J, V19, P279, DOI 10.1046/j.1365-313X.1999.00525.x; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Kircher S, 1999, PLANT CELL, V11, P1445, DOI 10.1105/tpc.11.8.1445; Kleiner O, 1999, PLANT J, V19, P289, DOI 10.1046/j.1365-313X.1999.00535.x; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; Lin CT, 1996, PLANT J, V10, P893, DOI 10.1046/j.1365-313X.1996.10050893.x; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Mockler TC, 1999, DEVELOPMENT, V126, P2073; Neff MM, 1998, PLANT PHYSIOL, V118, P27, DOI 10.1104/pp.118.1.27; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Poppe C, 1998, PLANT J, V16, P465, DOI 10.1046/j.1365-313x.1998.00322.x; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Sakamoto K, 1996, PLANT J, V10, P859, DOI 10.1046/j.1365-313X.1996.10050859.x; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Staub B, 1996, CD-ROM PROF, V9, P8; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wagner D, 1996, P NATL ACAD SCI USA, V93, P4011, DOI 10.1073/pnas.93.9.4011; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Whitelam GC, 1998, PLANT PHYSIOL BIOCH, V36, P125, DOI 10.1016/S0981-9428(98)80097-1	62	313	341	6	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					815	827		10.1016/S0092-8674(00)00184-7	http://dx.doi.org/10.1016/S0092-8674(00)00184-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114337	Bronze			2022-12-28	WOS:000165433100013
J	Fraser, AG; Kamath, RS; Zipperlen, P; Martinez-Campos, M; Sohrmann, M; Ahringer, J				Fraser, AG; Kamath, RS; Zipperlen, P; Martinez-Campos, M; Sohrmann, M; Ahringer, J			Functional genomic analysis of C-elegans chromosome I by systematic RNA interference	NATURE			English	Article							CAENORHABDITIS-ELEGANS; ZINC-FINGER; PROTEIN; KAKAPO; GENE; IDENTIFICATION; EXPRESSION; DROSOPHILA; ADHESION; SEQUENCE	Complete genomic sequence is known for two multicellular eukaryotes, the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster, and it will soon be known for humans. However, biological function has been assigned to only a small proportion of the predicted genes in any animal. Here we have used RNA-mediated interference (RNAi) to target nearly 90% of predicted genes on C. elegans chromosome I by feeding worms with bacteria that express double-stranded RNA. We have assigned function to 13.9% of the genes analysed, increasing the number of sequenced genes with known phenotypes on chromosome I from 70 to 378. Although most genes with sterile or embryonic lethal RNAi phenotypes are involved in basal cell metabolism, many genes giving post-embryonic phenotypes have conserved sequences but unknown function. In addition, conserved genes are significantly more likely to have an RNAi phenotype than are genes with no conservation. We have constructed a reusable library of bacterial clones that will permit unlimited RNAi screens in the future; this should help develop a more complete view of the relationships between the genome, gene function and the environment.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Sanger Ctr, Cambridge CB10 1SA, England	University of Cambridge; Wellcome Trust Sanger Institute	Ahringer, J (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	jaa@mole.bio.cam.ac.uk	Martínez Campos, Maruxa/F-5254-2015	Martínez Campos, Maruxa/0000-0001-7322-5268; Fraser, Andrew/0000-0001-9939-6014	Wellcome Trust [054523] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ahringer J, 1997, CURR OPIN GENET DEV, V7, P410, DOI 10.1016/S0959-437X(97)80157-8; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMSTRONG RC, 1995, GLIA, V14, P303, DOI 10.1002/glia.440140407; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARNES TM, 1995, GENETICS, V141, P159; Bowerman B, 1999, CURR OPIN GENET DEV, V9, P390, DOI 10.1016/S0959-437X(99)80059-8; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gregory SL, 1998, J CELL BIOL, V143, P1271, DOI 10.1083/jcb.143.5.1271; Hodgkin J, 1998, TRENDS GENET, V14, P352, DOI 10.1016/S0168-9525(98)01543-1; Hodgkin J, 1999, CELL, V98, P277, DOI 10.1016/S0092-8674(00)81956-X; KAMATH RS, IN PRESS GENOME BIOL; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; Lee S, 2000, J NEUROSCI, V20, P1096, DOI 10.1523/JNEUROSCI.20-03-01096.2000; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Prokop A, 1998, J CELL BIOL, V143, P1283, DOI 10.1083/jcb.143.5.1283; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; Srayko M, 2000, GENE DEV, V14, P1072; Strumpf D, 1998, J CELL BIOL, V143, P1259, DOI 10.1083/jcb.143.5.1259; Svetlov VV, 1995, YEAST, V11, P1439, DOI 10.1002/yea.320111502; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116	32	1291	1433	3	110	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 16	2000	408	6810					325	330		10.1038/35042517	http://dx.doi.org/10.1038/35042517			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099033				2022-12-28	WOS:000165296000036
J	Barone, JE				Barone, JE			Comparing apples and oranges: a randomised prospective study	BRITISH MEDICAL JOURNAL			English	Article									Stamford Hosp, Stamford, CT 06904 USA	Stamford Hospital	Barone, JE (corresponding author), Stamford Hosp, Stamford, CT 06904 USA.							Cummins RO, 1999, ANN EMERG MED, V33, P602, DOI 10.1016/S0196-0644(99)70357-4; Johnson W, 1998, ARCH INTERN MED, V158, P1591, DOI 10.1001/archinte.158.15.1591; LUBARSKY DA, 1995, ANESTH ANALG, V8, P428; Monahan CM, 1999, J HUM EVOL, V37, P789, DOI 10.1006/jhev.1999.0320; Petty TL, 1999, CHEST, V116, P1137, DOI 10.1378/chest.116.4.1137	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1569	1570		10.1136/bmj.321.7276.1569	http://dx.doi.org/10.1136/bmj.321.7276.1569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124178	Green Published			2022-12-28	WOS:000166134500016
J	Kinnell, HG				Kinnell, HG			Serial homicide by doctors: Shipman in perspective	BRITISH MEDICAL JOURNAL			English	Article											Kinnell, HG (corresponding author), 18 Cross St, Reading RG1 1SN, Berks, England.							BISHOP C, 1998, HITLERS 3 REICH, V1, P20; BLANDFORD N, 1985, WORLDS MOST EVIL MEN, P84; BURNABY E, 1990, MED MURDERS; CHAUDHARY V, 1992, BRIT MED J, V304, P1073; DUVALIER F, 1993, MICROSOFT ENCARTA 97; Dyer C, 2000, BRIT MED J, V321, P981; EATON H, 1990, MED MURDERS; EISENDRATH F, 1996, SPECTRUM FACTITIOUS, P161; FARRELL M, 1994, POISONS POISONERS, P80; GAUTE JHH, 1989, NEW MURDERERS WHOS W, P27; GAUTE JHH, 1989, NEW MURDERERS WHOS W, P201; GAUTE JHH, 1989, NEW MURDERERS WHOS W, P115; GEE J, 2000, DAILY EXPRESS   0711, P23; GOODMAN J, 1990, MED MURDERS; GORDON R, 1984, GREAT MED MYSTERIES, P104; GORDON R, 1984, GREAT MED MYSTERIES, P48; HALL A, 1987, CRIMES HOROR; HANAUSKEABEL HM, 1996, BRIT MED J, V313, P1464; HANAUSKEABEL HM, 1996, BRIT MED J, V313, P1459; HICKEY EW, 1997, SERIAL MURDERERS THE, P142; HUDSON C, 1999, DAILY MAIL      1231; LINEDECKER CL, 1990, NURSES WHO KILL; LUSTGARTEN E, 1976, ILLUSTRATED STORY CR, P210; MCDADE TM, 1990, MED MURDERS; NORRIS J, 1990, SERIAL KILLERS; RUMBELOW D, 1975, COMPLETE JACK RIPPER; SITPOND M, 2000, ADDICTED MURDER TRUE; SMITH EH, 1990, MED MURDERS; SMYTH F, 1992, CRIMES VICTIMS; STEWART JB, 1998, SUNDAY TELEGRAP 0125, P8; SURTEES J, 2000, STRANGE CASE B ADAMS; SWIFT G, 2000, DAILY EXPRESS   0201, P11; TENNYSON JF, 1990, MED MURDERS; WALBROOK HM, 1990, MED MURDERS; Whittle B., 2000, PRESCRIPTION MURDER; WILLIAMS P, 1989, UNIT 731 1; WILSON C, 1984, ENCY MURDER, P204; WILSON C, 1992, SERIAL KILLERS, P50; WILSON C, 1992, WORLD FAMOUS UNSOLVE; WILSON C, 1992, SERIAL KILLERS, P248; WILSON K, 1990, INVESTIGATING MURDER, P216; 1999, INT WHOS WHO 1999, P792; 1987, EUTHANESIEI ZENTRALE	43	27	27	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1594	1597		10.1136/bmj.321.7276.1594	http://dx.doi.org/10.1136/bmj.321.7276.1594			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124192	Green Published			2022-12-28	WOS:000166134500029
J	Furey, ML; Pietrini, P; Haxby, JV				Furey, ML; Pietrini, P; Haxby, JV			Cholinergic enhancement and increased selectivity of perceptual processing during working memory	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; PREFRONTAL CORTEX; ATTENTION; SYSTEMS; TASK; ORGANIZATION; SCOPOLAMINE; DEMENTIA; DISEASE; TESTS	Using functional magnetic resonance imaging, we investigated the mechanism by which cholinergic enhancement improves working memory. We studied the effect of the cholinesterase inhibitor physostigmine on subcomponents of this complex function. Cholinergic enhancement increased the selectivity of neural responses in extrastriate cortices during visual working memory, particularly during encoding, It also increased the participation of ventral extrastriate cortex during memory maintenance and decreased the participation of anterior prefrontal cortex. These results indicate that cholinergic enhancement improves memory performance by augmenting the selectivity of perceptual processing during encoding, thereby simplifying processing demands during memory maintenance and reducing the need for prefrontal participation.	NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA; Univ Pisa, Dept Human & Environm Sci, Pisa, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Pisa	Furey, ML (corresponding author), NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA.		Furey, Maura/H-5273-2013; Pietrini, Pietro/Z-4202-2019	Pietrini, Pietro/0000-0002-6768-5556				BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P603, DOI 10.1080/14640748608401616; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Baxter MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; CORBETTA M, 1991, J NEUROSCI, V11, P2383; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; DAWSON GR, 1993, BEHAV BRAIN RES, V57, P143, DOI 10.1016/0166-4328(93)90130-I; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Furey ML, 2000, BRAIN RES BULL, V51, P213, DOI 10.1016/S0361-9230(99)00219-1; Furey ML, 1997, P NATL ACAD SCI USA, V94, P6512, DOI 10.1073/pnas.94.12.6512; Furey ML, 2000, PHARMACOL BIOCHEM BE, V66, P475, DOI 10.1016/S0091-3057(00)00186-6; GLASKY AJ, 1994, PHARMACOL BIOCHEM BE, V47, P325, DOI 10.1016/0091-3057(94)90017-5; Grady CL, 1996, HUM BRAIN MAPP, V4, P227, DOI 10.1002/(SICI)1097-0193(1996)4:4<227::AID-HBM1>3.0.CO;2-5; HASSELMO ME, 1995, BEHAV BRAIN RES, V67, P1, DOI 10.1016/0166-4328(94)00113-T; Hasselmo ME, 1996, HIPPOCAMPUS, V6, P693, DOI 10.1002/(SICI)1098-1063(1996)6:6<693::AID-HIPO12>3.0.CO;2-W; Hasselmo ME, 2000, ANN NY ACAD SCI, V911, P418; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HAXBY JV, IN PRESS MAPPING MOD; Mesulam MM, 1996, PROG BRAIN RES, V109, P285; MEWALDT SP, 1979, PHARM BIOCH BEHAVIOR, V10, P1205; MURPHY PC, 1991, NEUROSCIENCE, V40, P13, DOI 10.1016/0306-4522(91)90170-S; Petrides M, 1996, PHILOS T ROY SOC B, V351, P1455, DOI 10.1098/rstb.1996.0130; Qizilbash N, 1998, JAMA-J AM MED ASSOC, V280, P1777, DOI 10.1001/jama.280.20.1777; Rainer G, 1998, P NATL ACAD SCI USA, V95, P15008, DOI 10.1073/pnas.95.25.15008; Robbins TW, 1997, PSYCHOPHARMACOLOGY, V134, P95, DOI 10.1007/s002130050430; Rosier A, 1998, NEUROPSYCHOBIOLOGY, V37, P98, DOI 10.1159/000026486; SATO H, 1987, J NEUROPHYSIOL, V58, P765, DOI 10.1152/jn.1987.58.4.765	30	242	246	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2315	+		10.1126/science.290.5500.2315	http://dx.doi.org/10.1126/science.290.5500.2315			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125148				2022-12-28	WOS:000165995800048
J	Tenenbaum, JB; de Silva, V; Langford, JC				Tenenbaum, JB; de Silva, V; Langford, JC			A global geometric framework for nonlinear dimensionality reduction	SCIENCE			English	Article							COMPONENT ANALYSIS	Scientists working with Large volumes of high-dimensional data, such as global climate patterns, stellar spectra, or human gene distributions, regularly confront the problem of dimensionality reduction: finding meaningful Low-dimensional structures hidden in their high-dimensional observations. The human brain confronts the same problem in everyday perception, extracting from its high-dimensional sensory inputs-30,000 auditory nerve fibers or 10(6) optic nerve fibers-a manageably small number of perceptually relevant features. Here we describe an approach to solving dimensionality reduction problems that uses easily measured local metric information to Learn the underlying global geometry of a data set. Unlike classical techniques such as principal component analysis (PCA) and multidimensional scaling (MDS), our approach is capable of discovering the nonlinear degrees of freedom that underlie complex natural observations, such as human handwriting or images of a face under different viewing conditions. In contrast to previous algorithms for nonlinear dimensionality reduction, ours efficiently computes a globally optimal solution, and, for an important class of data manifolds, is guaranteed to converge asymptotically to the true structure.	Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Math, Stanford, CA 94305 USA; Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15217 USA	Stanford University; Stanford University; Carnegie Mellon University	Tenenbaum, JB (corresponding author), Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.	jbt@psych.stanford.edu	cai, chao/C-4840-2009					Bailer-Jones CAL, 1998, MON NOT R ASTRON SOC, V298, P361, DOI 10.1046/j.1365-8711.1998.01596.x; Basri R, 1998, PROC CVPR IEEE, P414, DOI 10.1109/CVPR.1998.698639; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Beymer D, 1996, SCIENCE, V272, P1905, DOI 10.1126/science.272.5270.1905; Bishop CM, 1998, NEURAL COMPUT, V10, P215, DOI 10.1162/089976698300017953; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; Bregler C., 1995, Advances in Neural Information Processing Systems 7, P973; COMON P, 1994, SIGNAL PROCESS, V36, P287, DOI 10.1016/0165-1684(94)90029-9; DeMers D., 1993, ADV NEURAL INFORM PR, P580; DURBIN R, 1987, NATURE, V326, P689, DOI 10.1038/326689a0; ELMAN JL, 1988, J ACOUST SOC AM, V83, P1615, DOI 10.1121/1.395916; HASTIE T, 1989, J AM STAT ASSOC, V84, P502, DOI 10.2307/2289936; HECHTNIELSEN R, 1995, SCIENCE, V269, P1860, DOI 10.1126/science.269.5232.1860; Hinton G. E., 1995, ADV NEURAL INFORMATI, V7, P1015; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; KLEIN W, 1970, J ACOUST SOC AM, V48, P999, DOI 10.1121/1.1912239; KOHONEN T, 1988, SELF ORG ASS MEMORY, P119; KRAMER MA, 1991, AICHE J, V37, P233, DOI 10.1002/aic.690370209; KUMAR V, 1994, INTRO PARALLEL COMPU, P257; Mardia K., 1979, MULTIVARIATE ANAL, V15, P518; MARTINETZ T, 1994, NEURAL NETWORKS, V7, P507, DOI 10.1016/0893-6080(94)90109-0; MCCLURKIN JW, 1991, SCIENCE, V253, P675, DOI 10.1126/science.1908118; MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262; MONAHAN AH, IN PRESS J CLIM; MURASE H, 1995, INT J COMPUT VISION, V14, P5, DOI 10.1007/BF01421486; SANGER TD, 1995, ADV NEURAL INFO P SY, V7, P1023; SHEPARD RN, 1994, PSYCHON B REV, V1, P2, DOI 10.3758/BF03200759; SHEPARD RN, 1980, SCIENCE, V210, P390, DOI 10.1126/science.210.4468.390; SHEPARD RN, 1976, SCIENCE, V191, P952, DOI 10.1126/science.1251207; SHIFFRAR M, 1990, PSYCHOL SCI, V1, P257, DOI 10.1111/j.1467-9280.1990.tb00210.x; Simard P., 1993, ADV NEURAL INFORMATI, P50; Tenenbaum JB, 1998, ADV NEUR IN, V10, P682; TURK M, 1991, J COGNITIVE NEUROSCI, V3, P71, DOI 10.1162/jocn.1991.3.1.71; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	34	8091	8995	43	390	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	2000	290	5500					2319	+		10.1126/science.290.5500.2319	http://dx.doi.org/10.1126/science.290.5500.2319			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125149				2022-12-28	WOS:000165995800049
J	Berger, A				Berger, A			Gut cells engineered to produce insulin	BRITISH MEDICAL JOURNAL			English	News Item																		Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	2000	321	7275					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118169				2022-12-28	WOS:000165994700010
J	Rodgers, A; Walker, N; Schug, S; McKee, A; Kehlet, H; van Zundert, A; Sage, D; Futter, M; Saville, G; Clark, T; MacMahon, S				Rodgers, A; Walker, N; Schug, S; McKee, A; Kehlet, H; van Zundert, A; Sage, D; Futter, M; Saville, G; Clark, T; MacMahon, S			Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TOTAL HIP-REPLACEMENT; DEEP-VEIN THROMBOSIS; TRANS-URETHRAL RESECTION; AORTOCORONARY BYPASS-SURGERY; ABDOMINAL AORTIC-SURGERY; GENERAL-ANESTHESIA; REGIONAL ANESTHESIA; METABOLIC-RESPONSE; BLOOD-LOSS; PULMONARY COMPLICATIONS	Objectives To obtain reliable estimates of the effects of neuraxial blockade with epidural or spinal anaesthesia on postoperative morbidity and mortality. Design Systematic review of all trials with randomisation to intraoperative neuraxial blockade or not Studies 141 trials including 9559 patients for which data were available before 1 January 1997. Trials were eligible irrespective of their primary aims, concomitant use of general anaesthesia, publication status, or language. Trials were identified by extensive search methods, and substantial amounts of data were obtained or confirmed by correspondence with trialists. Main outcome measures. All cause mortality. deep vein thrombosis, pulmonary embolism, myocardial infarction, transfusion requirements, pneumonia, other infections, respiratory depression, and renal failure. Results Overall mortality was reduced by about a third in patients allocated to neuraxial blockade (103 deaths/4871 patients versus 144/4688 patients, odds ratio = 0.70, 95% confidence interval 0.54 to 0.90. P = 0.006). Neuraxial blockade reduced the odds of deep vein thrombosis by 44%, pulmonary embolism by 55%, transfusion requirements by 50%, pneumonia by 39%, and respiratory depression by 59% (all P < 0.001). There were also reductions in myocardial infarction and renal failure. Although there was limited power to assess subgroup effects, the proportional reductions in mortality did not clearly differ by surgical group, type of blockade (epidural or spinal), or in those trials in which neuraxial blockade was combined with general anaesthesia compared with trials in which neuraxial blockade was used alone. Conclusions Neuraxial blockade reduces postoperative mortality and other serious complications. The size of some of these benefits remains uncertain, and further research is required to determine whether these effects are due solely to benefits of neuraxial blockade or partly to avoidance of general anaesthesia. Nevertheless, these findings support more widespread use of neuraxial blockade.	Univ Auckland, Dept Med, Clin Trials Res Unit, Auckland, New Zealand; Univ Auckland, Div Anaesthesiol, Auckland 1, New Zealand; Green Lane Hosp, Dept Anaesthet, Auckland 1003, New Zealand; Hvidovre Univ Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark; Catharina Hosp, Dept Anesthesiol Intens Care & Pain Therapy, NL-5623 EJ Eindhoven, Netherlands; Auckland Hosp, Dept Anaesthesia, Auckland, New Zealand; Starship Hosp, Dept Anaesthesia, Auckland, New Zealand; Royal Cornwall Hosp, Dept Anaesthesia, Treliske TR1 3LJ, Truro, England; Univ Sydney, Inst Int Hlth, Sydney, NSW 1585, Australia	University of Auckland; University of Auckland; University of Copenhagen; Catharina Hospital; Auckland City Hospital; Starship Children's Hospital; Royal Cornwall Hospital; University of Sydney	Rodgers, A (corresponding author), Univ Auckland, Dept Med, Clin Trials Res Unit, Private Bag 92019, Auckland, New Zealand.	a.rodgers@ctru.auckland.ac.nz	Van Zundert, Andre A/G-2436-2015; van Zundert, Andre/D-6938-2012; Schug, Stephan/G-1432-2010; Clark, Taane G./AAM-2570-2020	Van Zundert, Andre A/0000-0001-5483-5941; Schug, Stephan/0000-0002-0302-2315; Clark, Taane G./0000-0001-8985-9265; Rodgers, Anthony/0000-0003-1282-1896; MacMahon, Stephen/0000-0003-2064-7699				ABBOUD TK, 1985, ANESTH ANALG, V64, P996; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ASBJORN J, 1989, ACTA ANAESTH SCAND, V33, P369, DOI 10.1111/j.1399-6576.1989.tb02925.x; ASOH T, 1983, ACTA ANAESTH SCAND, V27, P233, DOI 10.1111/j.1399-6576.1983.tb01942.x; ASOH T, UNPUB POSTOPERATIVE; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; BERGGREN D, 1987, ANESTH ANALG, V66, P497; BIGLER D, 1985, ANAESTHESIA, V40, P672, DOI 10.1111/j.1365-2044.1985.tb10949.x; BLUNNIE WP, 1983, BRIT J ANAESTH, V55, P611, DOI 10.1093/bja/55.7.611; Bode RH, 1996, ANESTHESIOLOGY, V84, P3, DOI 10.1097/00000542-199601000-00002; Bonnet F, 1989, Ann Vasc Surg, V3, P214, DOI 10.1016/S0890-5096(07)60026-0; BONNET F, 1982, BRIT J ANAESTH, V54, P29, DOI 10.1093/bja/54.1.29; BOROVSKIKH NA, 1990, VESTN KHIR IM GREKOV, V145, P95; BOTTIGLIERI T, 1992, REGION ANESTH S, V17, P95; BRANDT MR, 1978, BRIT MED J, V1, P1106, DOI 10.1136/bmj.1.6120.1106; BREDAHL C, 1991, ACTA ANAESTH SCAND, V35, P548, DOI 10.1111/j.1399-6576.1991.tb03346.x; BREDBACKA S, 1986, ACTA ANAESTH SCAND, V30, P204, DOI 10.1111/j.1399-6576.1986.tb02397.x; BRESLOW MJ, 1993, ANESTHESIOLOGY, V79, P1202, DOI 10.1097/00000542-199312000-00010; BRICHON PY, 1994, EUR J CARDIO-THORAC, V8, P482, DOI 10.1016/1010-7940(94)90019-1; BROMAGE PR, 1971, SURG GYNECOL OBSTETR, V132, P1051; BROWN AG, 1994, ANAESTH INTENS CARE, V22, P150, DOI 10.1177/0310057X9402200205; BUCKLEY FP, 1982, BRIT J ANAESTH, V54, P325, DOI 10.1093/bja/54.3.325; CHIN SP, 1982, BRIT J ANAESTH, V54, P491, DOI 10.1093/bja/54.5.491; CHRISTENSEN P, 1982, BRIT J ANAESTH, V54, P23, DOI 10.1093/bja/54.1.23; CHRISTENSEN T, 1986, ACTA CHIR SCAND, V152, P407; CHRISTOPHERSON R, 1993, ANESTHESIOLOGY, V79, P422, DOI 10.1097/00000542-199309000-00004; CHUNG F, 1987, ANESTHESIOLOGY, V67, P422, DOI 10.1097/00000542-198709000-00026; CHUNG FF, 1989, CAN J ANAESTH, V36, P382, DOI 10.1007/BF03005334; COOK PT, 1986, ANAESTH INTENS CARE, V14, P373, DOI 10.1177/0310057X8601400409; COUDERC E, 1977, ANESTH ANALG REANIM, V34, P987; COUSINS M, 1988, NEURAL BLOCKADE CLIN; CUSCHIERI RJ, 1985, BRIT J SURG, V72, P495, DOI 10.1002/bjs.1800720631; DAHL JB, 1990, BRIT J ANAESTH, V64, P178, DOI 10.1093/bja/64.2.178; Damask M C, 1990, J Clin Anesth, V2, P71, DOI 10.1016/0952-8180(90)90056-9; DARLING JR, 1994, ANESTH ANALG, V78, P706; DAVIES MJ, 1993, ANAESTH INTENS CARE, V21, P790, DOI 10.1177/0310057X9302100607; DAVIS FM, 1987, BRIT J ANAESTH, V59, P561, DOI 10.1093/bja/59.5.561; DAVIS FM, 1980, BRIT MED J, V281, P1528, DOI 10.1136/bmj.281.6254.1528; DAVIS FM, 1987, BRIT J ANAESTH, V59, P1080, DOI 10.1093/bja/59.9.1080; DAVIS FM, 1987, BRIT J ANAESTH, V59, P725, DOI 10.1093/bja/59.6.725; DAVIS FM, 1981, ANAESTH INTENS CARE, V9, P352, DOI 10.1177/0310057X8100900406; DAVIS FM, 1989, ANAESTH INTENS CARE, V17, P136, DOI 10.1177/0310057X8901700203; DAVIS FM, 1989, J BONE JOINT SURG BR, V71, P181, DOI 10.1302/0301-620X.71B2.2925731; DEKOCK M, 1993, ANESTHESIOLOGY, V79, P525, DOI 10.1097/00000542-199309000-00016; DICK W, 1992, EUR J ANAESTH, V9, P15; DICKERSIN K, 1995, ESTABLISHING MAINTAI; DOBSON PMS, 1994, BRIT J ANAESTH, V72, P267, DOI 10.1093/bja/72.3.267; DONADONI R, 1988, REGION ANESTH, V13, P55; EDWARDS ND, 1995, BRIT J ANAESTH, V74, P368, DOI 10.1093/bja/74.4.368; FLEISHER LA, 1994, ANESTH ANALG, V79, P165; FOATE JA, 1985, ANAESTH INTENS CARE, V13, P383, DOI 10.1177/0310057X8501300409; FRANK SM, 1994, ANESTHESIOLOGY, V80, P502, DOI 10.1097/00000542-199403000-00005; FRANK SM, 1992, ANESTHESIOLOGY, V77, P252, DOI 10.1097/00000542-199208000-00005; FREDIN H, 1986, EUR J ANAESTH, V3, P273; Garnett RL, 1996, CAN J ANAESTH, V43, P769, DOI 10.1007/BF03013027; GELMAN S, 1980, ANESTH ANALG, V59, P902; GHONEIM MM, 1988, ANESTHESIOLOGY, V69, P507, DOI 10.1097/00000542-198810000-00010; Go AS, 1996, ANESTHESIOLOGY, V84, P1, DOI 10.1097/00000542-199601000-00001; GODFREY PJ, 1981, BRIT J SURG, V68, P587, DOI 10.1002/bjs.1800680820; GOERTZ AW, 1993, ACTA ANAESTH SCAND, V37, P38, DOI 10.1111/j.1399-6576.1993.tb03595.x; GOLD MS, 1994, ANESTH ANALG, V78, P225, DOI 10.1213/00000539-199402000-00006; GOTTLIEB A, 1988, REGION ANESTH PAIN M, V13, P69; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P300, DOI 10.1093/oxfordjournals.aje.a117250; Gregoretti S M, 1985, Minerva Anestesiol, V51, P87; HAKANSSON E, 1983, ACTA ANAESTH SCAND, V27, P78; HALEVY S, 1978, BRIT J ANAESTH, V50, P1053, DOI 10.1093/bja/50.10.1053; Haljamae H, 1988, Eur J Vasc Surg, V2, P395, DOI 10.1016/S0950-821X(88)80018-5; HASENBOS M, 1985, ACTA ANAESTH SCAND, V29, P577, DOI 10.1111/j.1399-6576.1985.tb02257.x; HASENBOS M, 1985, ACTA ANAESTH SCAND, V29, P572, DOI 10.1111/j.1399-6576.1985.tb02256.x; HEDENSTIERNA G, 1985, ACTA ANAESTH SCAND, V29, P55, DOI 10.1111/j.1399-6576.1985.tb02159.x; HENDOLIN H, 1981, ACTA CHIR SCAND, V147, P425; HENDOLIN H, 1982, International Urology and Nephrology, V14, P399, DOI 10.1007/BF02081981; HENDOLIN H, 1987, ANN CHIR GYNAECOL FE, V76, P234; HENDOLIN H, 1982, ACTA CHIR SCAND, V148, P405; HENDOLIN H, 1982, ANN CLIN RES, V14, P181; HENDOLIN H, 1987, ACTA ANAESTH SCAND, V31, P645, DOI 10.1111/j.1399-6576.1987.tb02637.x; HENNY CP, 1986, BRIT J ANAESTH, V58, P301, DOI 10.1093/bja/58.3.301; HESSELVIK F, 1987, SCAND J CLIN LAB INV, V47, P435; HJORTSO NC, 1985, BRIT J ANAESTH, V57, P400, DOI 10.1093/bja/57.4.400; HJORTSO NC, 1985, ACTA ANAESTH SCAND, V29, P790, DOI 10.1111/j.1399-6576.1985.tb02302.x; HJORTSO NC, 1984, ACTA ANAESTH SCAND, V28, P128, DOI 10.1111/j.1399-6576.1984.tb02027.x; HOLDCROFT A, 1979, ANAESTHESIA, V34, P758, DOI 10.1111/j.1365-2044.1979.tb06408.x; HOLE A, 1980, ACTA ANAESTH SCAND, V24, P279, DOI 10.1111/j.1399-6576.1980.tb01549.x; HOLE A, 1983, ACTA ANAESTH SCAND, V27, P135, DOI 10.1111/j.1399-6576.1983.tb01923.x; HOLE A, 1984, ACTA ANAESTH SCAND, V28, P296, DOI 10.1111/j.1399-6576.1984.tb02064.x; HOLE A, 1984, ACTA ANAESTH SCAND, V28, P287, DOI 10.1111/j.1399-6576.1984.tb02062.x; HOLE A, 1982, ACTA ANAESTH SCAND, V26, P301, DOI 10.1111/j.1399-6576.1982.tb01771.x; HOMANN B, 1984, ANAESTHESIST, V33, P145; Horlocker TT, 1997, ANESTH ANALG, V84, P578, DOI 10.1097/00000539-199703000-00021; HOUWELING PL, 1993, EUR J ANAESTH, V10, P403; JAKOBSEN BW, 1986, ACTA ANAESTH SCAND, V30, P668, DOI 10.1111/j.1399-6576.1986.tb02498.x; JAYR C, 1993, ANESTHESIOLOGY, V78, P666, DOI 10.1097/00000542-199304000-00009; JAYR C, 1988, SURGERY, V104, P57; JAYR C, 1988, REGION ANESTH, V13, P6; JENKINS J, 1983, ANAESTHESIA, V38, P748, DOI 10.1111/j.1365-2044.1983.tb12197.x; JENSEN BH, 1977, ACTA ANAESTH SCAND, V21, P395, DOI 10.1111/j.1399-6576.1977.tb01238.x; JENSEN CH, 1980, ACTA ANAESTH SCAND, V24, P472, DOI 10.1111/j.1399-6576.1980.tb01586.x; JIA N, 1991, ACTA ACAD MED SIN, V13, P112; JIA N, 1985, CHIN MED J, V65, P30; JONES MJT, 1990, BRIT MED J, V300, P1683, DOI 10.1136/bmj.300.6741.1683; JORDANOV K, 1985, AKUSH GINEKOL SOFIA, V24, P31; JORGENSEN LN, 1991, BRIT J ANAESTH, V66, P8, DOI 10.1093/bja/66.1.8; KAUSALYA R, 1994, ANAESTH INTENS CARE, V22, P161, DOI 10.1177/0310057X9402200207; Kehlet H., 1988, NEURAL BLOCKADE CLIN, P145; KEITH I, 1977, ANAESTHESIA, V32, P444, DOI 10.1111/j.1365-2044.1977.tb09981.x; KOKHNOVER S, 1982, AKUSH GINEKOL SOFIA, V6, P48; KOSSMANN B, 1982, REGIONAL ANESTH, V7, P107; LEHTINEN AM, 1987, J IN VITRO FERTIL EM, V4, P23, DOI 10.1007/BF01555431; LICKER M, 1994, EUR J ANAESTH, V11, P193; MANN RAM, 1983, ANAESTHESIA, V38, P1185, DOI 10.1111/j.1365-2044.1983.tb12523.x; MAURETTE P, 1988, Annales Francaises d'Anesthesie et de Reanimation, V7, P305, DOI 10.1016/S0750-7658(88)80033-9; MCGOWAN SW, 1980, ANAESTHESIA, V35, P847, DOI 10.1111/j.1365-2044.1980.tb03941.x; MCKENZIE PJ, 1985, BRIT J ANAESTH, V57, P853, DOI 10.1093/bja/57.9.853; MCKENZIE PJ, 1984, BRIT J ANAESTH, V56, P581, DOI 10.1093/bja/56.6.581; MCKENZIE PJ, 1980, BRIT J ANAESTH, V52, P49, DOI 10.1093/bja/52.1.49; MCLAREN AD, 1978, ANAESTHESIA, V33, P10, DOI 10.1111/j.1365-2044.1978.tb08270.x; MCLAREN AD, 1982, REG ANAESTH S, V7, pS172; MELLBRING G, 1983, ACTA CHIR SCAND, V149, P263; MELSEN N C, 1987, Ugeskrift for Laeger, V149, P150; MERHAV H, 1993, INT SURG, V78, P257; MITCHELL D, 1991, CLIN ORTHOP RELAT R, V269, P109; MODIG J, 1983, ANESTH ANALG, V62, P174; MODIG J, 1980, ACTA ANAESTH SCAND, V24, P305, DOI 10.1111/j.1399-6576.1980.tb01553.x; MODIG J, 1980, Anesthesiology (Hagerstown), V53, pS34, DOI 10.1097/00000542-198009001-00034; MODIG J, 1987, EUR J ANAESTH, V4, P345; MODIG J, 1981, ACTA CHIR SCAND, V147, P125; MODIG J, 1988, ACTA CHIR SCAND    S, V550, P95; MODIG J, 1986, REGION ANESTH PAIN M, V11, P72; MOINICHE S, 1992, REGION ANESTH S, V17, P2; Murakami M, 1987, Masui, V36, P583; NAESH O, 1994, EUR J ANAESTH, V11, P169; NAESH O, 1994, ACTA ANAESTH SCAND, V38, P820, DOI 10.1111/j.1399-6576.1994.tb04012.x; NIELSEN K K, 1987, International Urology and Nephrology, V19, P287, DOI 10.1007/BF02549865; NIELSEN TH, 1989, EUR J ANAESTH, V6, P409; NIELSON WR, 1990, ANESTHESIOLOGY, V73, P1103, DOI 10.1097/00000542-199012000-00006; Ogata M, 1985, Masui, V34, P1358; Ogata M, 1988, Masui, V37, P163; PARKER MJ, 2000, COCHRANE LIB; Pedersen J, 1986, Ugeskr Laeger, V148, P1819; PEDERSEN J, 1987, Ugeskrift for Laeger, V149, P1463; PERHONIEMI V, 1986, EUR UROL, V12, P244; PLANES A, 1991, J BONE JOINT SURG BR, V73, P418, DOI 10.1302/0301-620X.73B3.1670442; POIKOLAINEN E, 1983, ACTA CHIR SCAND, V149, P361; POLL J, 1988, REGION ANESTH, V13, P4; RADE J, 1986, ANN FR ANESTH, V5, P24; RAVIN MB, 1971, ANESTHESIOLOGY, V35, P319, DOI 10.1097/00000542-197109000-00018; REINHART K, 1989, ANESTH ANALG, V69, P360; REM J, 1980, LANCET, V1, P283; RICKFORD JK, 1988, ANN ROY COLL SURG, V70, P69; Rigg JRA, 2000, CONTROL CLIN TRIALS, V21, P244, DOI 10.1016/S0197-2456(00)00045-3; RIIS J, 1983, ACTA ANAESTH SCAND, V27, P44, DOI 10.1111/j.1399-6576.1983.tb01903.x; Rodgers A, 1996, ANAESTH INTENS CARE, V24, P79, DOI 10.1177/0310057X9602400114; RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167; ROSBERG B, 1982, ACTA ANAESTH SCAND, V26, P189, DOI 10.1111/j.1399-6576.1982.tb01751.x; ROSENFELD BA, 1993, ANESTHESIOLOGY, V79, P435, DOI 10.1097/00000542-199309000-00005; ROSSEEL P, 1985, Acta Anaesthesiologica Belgica, V36, P345; RUTBERG H, 1984, BRIT J ANAESTH, V56, P233, DOI 10.1093/bja/56.3.233; RYAN P, 1992, EUR J SURG, V158, P45; SCHEININ B, 1982, ACTA ANAESTH SCAND, V26, P474, DOI 10.1111/j.1399-6576.1982.tb01802.x; SEELING W, 1990, ANAESTHESIST, V39, P33; SEELING W, 1986, ANAESTHESIST, V35, P80; SEELING W, 1985, ANAESTHESIST, V34, P217; SEELING W, 1991, ANAESTHESIST, V40, P614; SEELING W, 1985, ANAESTHESIST, V34, P417; SEITZ W, 1985, ANASTH INTENSIV NOTF, V20, P119, DOI 10.1055/s-2007-1003097; Sharrock NE, 1992, REGIONAL ANESTHES S3, V17, P94; SHIR Y, 1994, ANESTHESIOLOGY, V80, P49, DOI 10.1097/00000542-199401000-00011; SHIRASAKA C, 1986, BRIT J SURG, V73, P142, DOI 10.1002/bjs.1800730224; SIMPSON PJ, 1982, ANAESTHESIA, V37, P3, DOI 10.1111/j.1365-2044.1982.tb00985.x; SLINGER P, 1995, J CARDIOTHOR VASC AN, V9, P128, DOI 10.1016/S1053-0770(05)80182-X; SMEETS HJ, 1993, WORLD J SURG, V17, P601, DOI 10.1007/BF01659119; SORENSON RM, 1992, ANESTHESIOLOGY, V77, P1095, DOI 10.1097/00000542-199212000-00009; STATHOPOULOU T, 1992, REGION ANESTH S, V17, P181; STENSETH R, 1994, ACTA ANAESTH SCAND, V38, P834, DOI 10.1111/j.1399-6576.1994.tb04014.x; STENSETH R, 1994, ACTA ANAESTH SCAND, V38, P826, DOI 10.1111/j.1399-6576.1994.tb04013.x; STJERNSTROM H, 1985, ACTA ANAESTH SCAND, V29, P743, DOI 10.1111/j.1399-6576.1985.tb02293.x; TANAKA K, 1993, REGION ANESTH, V18, P34; TARKKILA PJ, 1991, REGION ANESTH, V16, P101; TRAYNOR C, 1982, BRIT J ANAESTH, V54, P319, DOI 10.1093/bja/54.3.319; TSUJI H, 1983, BRIT J SURG, V70, P437, DOI 10.1002/bjs.1800700716; TSUJI H, 1983, BRIT J SURG, V70, P122, DOI 10.1002/bjs.1800700223; TULLA H, 1992, ACTA ANAESTH SCAND, V36, P101, DOI 10.1111/j.1399-6576.1992.tb03431.x; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; UCHIDA I, 1988, BRIT J SURG, V75, P557, DOI 10.1002/bjs.1800750618; VALENTIN N, 1986, BRIT J ANAESTH, V58, P284, DOI 10.1093/bja/58.3.284; WALLACE DH, 1995, OBSTET GYNECOL, V86, P193, DOI 10.1016/0029-7844(95)00139-I; WATTERS JM, 1993, CAN J ANAESTH, V40, P314, DOI 10.1007/BF03009628; WATTWIL M, 1987, ACTA ANAESTH SCAND, V31, P529, DOI 10.1111/j.1399-6576.1987.tb02616.x; WESSEN A, 1994, J CLIN ANESTH, V6, P193, DOI 10.1016/0952-8180(94)90058-2; WHELAN P, 1982, CLIN EXP IMMUNOL, V48, P611; WHITE IWC, 1980, ANAESTHESIA, V35, P1107, DOI 10.1111/j.1365-2044.1980.tb05053.x; WICKSTROM I, 1982, ACTA ANAESTH SCAND, V26, P607, DOI 10.1111/j.1399-6576.1982.tb01825.x; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; WilliamsRusso P, 1996, CLIN ORTHOP RELAT R, P199, DOI 10.1097/00003086-199610000-00028; WORSLEY MH, 1988, BRIT J ANAESTH, V60, P836, DOI 10.1093/bja/60.7.836; Wust H J, 1980, Anasth Intensivther Notfallmed, V15, P87, DOI 10.1055/s-2007-1005128; XONISHI M, 1989, MASUI, V38, P329; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZWARTS SJ, 1989, REGION ANESTH, V14, P183	202	1173	1238	3	54	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2000	321	7275					1493	1497		10.1136/bmj.321.7275.1493	http://dx.doi.org/10.1136/bmj.321.7275.1493			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118174	Green Published, Bronze			2022-12-28	WOS:000165994700023
J	Sveinbjornsdottir, S; Hicks, AA; Jonsson, T; Petursson, H; Guomundsson, G; Frigge, ML; Kong, A; Gulcher, JR; Stefansson, K				Sveinbjornsdottir, S; Hicks, AA; Jonsson, T; Petursson, H; Guomundsson, G; Frigge, ML; Kong, A; Gulcher, JR; Stefansson, K			Familial aggregation of Parkinson's disease in Iceland.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECESSIVE JUVENILE PARKINSONISM; ALPHA-SYNUCLEIN; GENE; MUTATIONS; TWINS; LINKAGE; PAIRS	Background: The role of genetics in early-onset Parkinson's disease has been established, but whether there is a genetic contribution to the more common, late-onset form remains uncertain. Methods: We reviewed the medical records and confirmed the diagnosis of Parkinson's disease in 772 living and deceased patients in whom the disease had been diagnosed during the previous 50 years in Iceland. With the use of an extensive computerized data base containing genealogic information on 610,920 people in Iceland during the past 11 centuries, several analyses were conducted to determine whether the patients were more related to each other than random members of the population (control subjects). Results: Patients with Parkinson's disease, including a subgroup of 560 patients with late-onset disease (onset at >50 years of age), were significantly more related to each other than were subjects in matched groups of controls, and this relatedness extended beyond the nuclear family. The risk ratio for Parkinson's disease was 6.7 (95 percent confidence interval, 4.3 to 9.6) for siblings, 3.2 (95 percent confidence interval, 1.2 to 7.8) for offspring, and 2.7 (95 percent confidence interval, 1.6 to 3.9) for nephews and nieces of patients with late-onset Parkinson's disease. Conclusions: Late-onset Parkinson's disease has a genetic component as well as an environmental component. (N Engl J Med 2000;343:1765-70.) (C) 2000, Massachusetts Medical Society.	Natl Univ Hosp, Reykjavik, Iceland; deCODE Genet, Reykjavik, Iceland; Univ Chicago, Dept Human Genet, Chicago, IL USA	Landspitali National University Hospital; University of Chicago	Stefansson, K (corresponding author), Natl Univ Hosp, Reykjavik, Iceland.		Hicks, Andrew Anthony/E-9518-2017; Stefansson, Kari/AAE-7187-2019	Hicks, Andrew Anthony/0000-0001-6320-0411; Kong, Augustine/0000-0001-8193-5438				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; BHARUCHA NE, 1986, NEUROLOGY, V36, P284, DOI 10.1212/WNL.36.2.284; Duvoisin R C, 1987, Adv Neurol, V45, P307; DUVOISIN RC, 1981, NEUROLOGY, V31, P77, DOI 10.1212/WNL.31.1.77; Gasser T, 1998, ANN NEUROL, V44, pS53, DOI 10.1002/ana.410440708; Gudmundsson K. R., 1967, ACTA NEUROL SCAND  S, V43, P1; Gulcher J, 1998, CLIN CHEM LAB MED, V36, P523, DOI 10.1515/CCLM.1998.089; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; Guo SW, 1998, AM J HUM GENET, V63, P252, DOI 10.1086/301928; GUOMUNDSSON H, 2000, EUR J HUM GENET, V8, P743; Hattori N, 1998, BIOCHEM BIOPH RES CO, V251, P666, DOI 10.1006/bbrc.1998.9504; Hattori N, 1998, BIOCHEM BIOPH RES CO, V249, P754, DOI 10.1006/bbrc.1998.9134; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANGE K, 1997, MATH STAT METHODS AN, P70; Matsumine H, 1998, GENOMICS, V49, P143, DOI 10.1006/geno.1997.5196; Moceri VM, 2000, NEUROLOGY, V54, P415, DOI 10.1212/WNL.54.2.415; Piccini P, 1999, ANN NEUROL, V45, P577, DOI 10.1002/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; RISCH N, 1990, AM J HUM GENET, V46, P222; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Tassin J, 1998, AM J HUM GENET, V63, P88, DOI 10.1086/301934; WARD CD, 1983, NEUROLOGY, V33, P815, DOI 10.1212/WNL.33.7.815; Wood NW, 1998, ANN NEUROL, V44, pS58, DOI 10.1002/ana.410440709	26	212	216	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1765	1770		10.1056/NEJM200012143432404	http://dx.doi.org/10.1056/NEJM200012143432404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11114315				2022-12-28	WOS:000165812000004
J	Henney, JE				Henney, JE			Preventive use for ramipril	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2711	2711		10.1001/jama.284.21.2711-c	http://dx.doi.org/10.1001/jama.284.21.2711-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105160				2022-12-28	WOS:000165509500006
J	Hainer, MI; Tsai, N; Komura, ST; Chiu, CL				Hainer, MI; Tsai, N; Komura, ST; Chiu, CL			Fatal hepatorenal failure associated with hydrazine sulfate	ANNALS OF INTERNAL MEDICINE			English	Article							CELL LUNG-CANCER; MEDICAL PROGRESS; WEIGHT-LOSS; CACHEXIA; BIOLOGY	Background: The Internet has revolutionized the manner in which patients obtain information about health care. This technology has also allowed patients to obtain directly both prescription and nonprescription therapies. Objective: To report a case of fulminant hepatorenal failure associated with the use of hydrazine sulfate, an unregulated alternative remedy for cancer marketed on the Internet. Design: Case report. Setting: Academic medical center. Patient: A 55-year-old man with maxillary sinus cancer. Intervention: Self-medication with hydrazine sulfate. Measurements: serum liver and renal function tests; histologic evaluation of liver and kidney tissue. Results: The patient developed hepatic encephalopathy, renal failure, and profound coagulopathy. He died after severe gastrointestinal hemorrhage developed. Autopsy revealed autolysis of the kidneys and submassive bridging necrosis of the liver. Conclusion: Fatal hepatorenal failure may occur after the use of hydrazine sulfate. This fatal complication must be considered in anyone taking or contemplating the use of hydrazine sulfate.	Moncrief Army Community Hosp, Dept Internal Med, Ft Jackson, SC 29207 USA; St Francis Med Ctr, Honolulu, HI USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	University of Hawaii System	Hainer, MI (corresponding author), Moncrief Army Community Hosp, Dept Internal Med, Ft Jackson, SC 29207 USA.	mark.hainer@se.amedd.army.mil						CHLEBOWSKI RT, 1990, J CLIN ONCOL, V8, P9, DOI 10.1200/JCO.1990.8.1.9; CHLEBOWSKI RT, 1987, CANCER, V59, P406, DOI 10.1002/1097-0142(19870201)59:3<406::AID-CNCR2820590309>3.0.CO;2-W; CHLEBOWSKI RT, 1984, CANCER RES, V44, P857; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Gold J, 1998, J NATL CANCER I, V90, P1101, DOI 10.1093/jnci/90.14.1101; GOLD J, 1975, ONCOLOGY, V32, P1; GOLD J, 1987, Nutrition and Cancer, V9, P59; KOSTY MP, 1994, J CLIN ONCOL, V12, P1113, DOI 10.1200/JCO.1994.12.6.1113; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P1126, DOI 10.1200/JCO.1994.12.6.1126; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P1121, DOI 10.1200/JCO.1994.12.6.1121; MICHELOT D, 1989, J TOXICOL CLIN EXPER, V9, P83; SOTANIEMI E, 1971, ANN CLIN RES, V3, P30; *SYR CANC RES I, 2000, HYDR SULF GEN INF; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; Wheeler BM, 1998, J NATL CANCER I, V90, P628, DOI 10.1093/jnci/90.8.628; WOO J, 1992, J MED, V23, P51	19	46	47	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					877	880		10.7326/0003-4819-133-11-200012050-00011	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103057				2022-12-28	WOS:000165585800006
J	Joachim, C; Gimzewski, JK; Aviram, A				Joachim, C; Gimzewski, JK; Aviram, A			Electronics using hybrid-molecular and mono-molecular devices	NATURE			English	Review							CURRENT-VOLTAGE CHARACTERISTICS; SELF-ASSEMBLED MONOLAYERS; CARBON NANOTUBES; SWITCHING DEVICES; SINGLE MOLECULES; BEAM LITHOGRAPHY; COULOMB-BLOCKADE; ELECTRIC-FIELD; WIRES; CONDUCTANCE	The semiconductor industry has seen a remarkable miniaturization trend, driven by many scientific and technological innovations. But if this trend is to continue, and provide ever faster and cheaper computers, the size of microelectronic circuit components will soon need to reach the scale of atoms or molecules-a goal that will require conceptually new device structures. The idea that a few molecules, or even a single molecule, could be embedded between electrodes and perform the basic functions of digital electronics-rectification, amplification and storage-was first put forward in the mid-1970s. The concept is now realized for individual components, but the economic fabrication of complete circuits at the molecular level remains challenging because of the difficulty of connecting molecules to one another. A possible solution to this problem is 'mono-molecular' electronics, in which a single molecule will integrate the elementary functions and interconnections required for computation.	CNRS, Ctr Elaborat Mat & Etud Struct, F-31055 Toulouse, France; IBM Corp, Zurich Res Lab, Res, CH-8803 Ruschlikon, Switzerland; IBM Corp, Thomas J Watson Res Ctr, Res, Yorktown Heights, NY 10598 USA	Centre National de la Recherche Scientifique (CNRS); International Business Machines (IBM); International Business Machines (IBM)	Joachim, C (corresponding author), CNRS, Ctr Elaborat Mat & Etud Struct, 29 Rue J Marvig, F-31055 Toulouse, France.			gimzewski, james/0000-0003-4333-6957				Allara DL, 1998, ANN NY ACAD SCI, V852, P349, DOI 10.1111/j.1749-6632.1998.tb09884.x; AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; AVIRAM A, 1988, J AM CHEM SOC, V110, P5687, DOI 10.1021/ja00225a017; AVOURIS P, IN PRESS P NAN 1999; Bachtold A, 1998, APPL PHYS LETT, V73, P274, DOI 10.1063/1.121778; Bezryadin A, 1997, J VAC SCI TECHNOL B, V15, P793, DOI 10.1116/1.589411; Bezryadin A, 1997, APPL PHYS LETT, V71, P1273, DOI 10.1063/1.119871; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Brugger J, 1997, MICROELECTRON ENG, V35, P401, DOI 10.1016/S0167-9317(96)00210-9; CARTER FL, 1984, PHYSICA D, V10, P175, DOI 10.1016/0167-2789(84)90260-4; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Cholet S, 1999, EUR PHYS J-APPL PHYS, V8, P139, DOI 10.1051/epjap:1999239; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Collins PG, 1997, SCIENCE, V278, P100, DOI 10.1126/science.278.5335.100; COMPANO R, 1999, TECHNOLOGY ROADMAP E; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; Delamarche E, 1996, ADV MATER, V8, P719, DOI 10.1002/adma.19960080903; Di Ventra M, 2000, PHYS REV LETT, V84, P979, DOI 10.1103/PhysRevLett.84.979; DIERS JR, 1994, CHEM MATER, V6, P327, DOI 10.1021/cm00039a013; DIETZ TM, 1990, J CHEM SOC CHEM COMM, P367, DOI 10.1039/c39900000367; DiFabrizio E, 1997, JPN J APPL PHYS 2, V36, pL70, DOI 10.1143/JJAP.36.L70; DOROGI M, 1995, PHYS REV B, V52, P9071, DOI 10.1103/PhysRevB.52.9071; DRAIN CM, 1994, J CHEM SOC CHEM COMM, P2313, DOI 10.1039/c39940002313; Ebbesen TW, 1996, NATURE, V382, P54, DOI 10.1038/382054a0; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; FISCHER CM, 1994, EUROPHYS LETT, V28, P129, DOI 10.1209/0295-5075/28/2/009; FISCHER PB, 1993, APPL PHYS LETT, V62, P2989, DOI 10.1063/1.109166; Fraysse S, 2000, EUR J INORG CHEM, P1581; Gao HJ, 2000, PHYS REV LETT, V84, P1780, DOI 10.1103/PhysRevLett.84.1780; GEDDES NJ, 1990, APPL PHYS LETT, V56, P1916, DOI 10.1063/1.103043; Gerdes S, 1999, EUROPHYS LETT, V48, P292, DOI 10.1209/epl/i1999-00480-8; GILAT SL, 1993, J CHEM SOC CHEM COMM, P1439, DOI 10.1039/c39930001439; GIMZEWSKI JK, 1987, SURF SCI, V181, P267, DOI 10.1016/0039-6028(87)90167-1; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Girard C, 1998, EUROPHYS LETT, V44, P686, DOI 10.1209/epl/i1998-00526-5; Goldhaber-Gordon D, 1997, P IEEE, V85, P521, DOI 10.1109/5.573739; Guo LJ, 1997, APPL PHYS LETT, V71, P1881, DOI 10.1063/1.119426; Handschuh M, 1999, APPL SURF SCI, V137, P125, DOI 10.1016/S0169-4332(98)00379-1; HIGELIN D, 1983, CHEM PHYS, V77, P391, DOI 10.1016/0301-0104(83)85093-9; Hu JT, 1999, NATURE, V399, P48, DOI 10.1038/19941; Huang SL, 1999, J ORG CHEM, V64, P8898, DOI 10.1021/jo991201s; HUSH NS, 1990, J AM CHEM SOC, V112, P4192, DOI 10.1021/ja00167a014; JOACHIM C, 1986, CHEM PHYS, V109, P93, DOI 10.1016/0301-0104(86)80187-2; Joachim C, 1997, CHEM PHYS LETT, V265, P353, DOI 10.1016/S0009-2614(97)00014-6; Joachim C, 1998, PHYS REV B, V58, P16407, DOI 10.1103/PhysRevB.58.16407; Joachim C, 1996, EUROPHYS LETT, V33, P635, DOI 10.1209/epl/i1996-00391-2; JOACHIM C, 1995, PHYS REV LETT, V74, P2102, DOI 10.1103/PhysRevLett.74.2102; Kahn O., 1988, J P CHEMTRONICS, V3, P140; Kergueris C, 1999, PHYS REV B, V59, P12505, DOI 10.1103/PhysRevB.59.12505; KEYES RW, 1993, NATURE, V362, P289, DOI 10.1038/362289a0; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; Kratschmer E, 1995, J VAC SCI TECHNOL B, V13, P2498, DOI 10.1116/1.588381; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628; KWAN WSV, 1991, LANGMUIR, V7, P1419, DOI 10.1021/la00055a022; LANDAUER R, 1989, PHYS TODAY, P119; Lang ND, 1998, PHYS REV LETT, V81, P3515, DOI 10.1103/PhysRevLett.81.3515; LANG ND, 1995, PHYS REV B, V52, P5335, DOI 10.1103/PhysRevB.52.5335; Langlais VJ, 1999, PHYS REV LETT, V83, P2809, DOI 10.1103/PhysRevLett.83.2809; Lefebvre J, 1999, APPL PHYS LETT, V75, P3014, DOI 10.1063/1.125218; Leonard F, 1999, PHYS REV LETT, V83, P5174, DOI 10.1103/PhysRevLett.83.5174; LEWICKI G, 1966, PHYS REV LETT, V16, P939, DOI 10.1103/PhysRevLett.16.939; Luthi R, 1999, APPL PHYS LETT, V75, P1314, DOI 10.1063/1.124679; Magoga M, 1999, PHYS REV B, V59, P16011, DOI 10.1103/PhysRevB.59.16011; Magoga M, 1997, PHYS REV B, V56, P4722, DOI 10.1103/PhysRevB.56.4722; Magoga M, 1998, PHYS REV B, V57, P1820, DOI 10.1103/PhysRevB.57.1820; MANN B, 1971, J APPL PHYS, V42, P4398, DOI 10.1063/1.1659785; Manoharan HC, 2000, NATURE, V403, P512, DOI 10.1038/35000508; Mathews RH, 1999, P IEEE, V87, P596, DOI 10.1109/5.752517; Menon M, 1997, PHYS REV LETT, V79, P4453, DOI 10.1103/PhysRevLett.79.4453; Metzger RM, 1997, J AM CHEM SOC, V119, P10455, DOI 10.1021/ja971811e; Morpurgo AF, 1999, APPL PHYS LETT, V74, P2084, DOI 10.1063/1.123765; Mujica V, 1996, J CHEM PHYS, V104, P7296, DOI 10.1063/1.471396; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; NESS H, 1997, PHYS REV B, V56, P12462; Olson M, 1998, J PHYS CHEM B, V102, P941, DOI 10.1021/jp972940k; Patoux C, 1998, J AM CHEM SOC, V120, P3717, DOI 10.1021/ja974137+; Patoux C, 1997, INORG CHEM, V36, P5037, DOI 10.1021/ic970013m; PEARSON DL, 1994, MACROMOLECULES, V27, P2348, DOI 10.1021/ma00086a062; Philp D, 1996, ANGEW CHEM INT EDIT, V35, P1154, DOI 10.1002/anie.199611541; Porath D, 1997, J APPL PHYS, V81, P2241, DOI 10.1063/1.364275; Porath D, 2000, NATURE, V403, P635, DOI 10.1038/35001029; Reed MA, 1998, ANN NY ACAD SCI, V852, P133, DOI 10.1111/j.1749-6632.1998.tb09868.x; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; RIORDAN M, 1997, CRYSTAL FIRE BIRTH C; Rousset V, 1995, J PHYS III, V5, P1983, DOI 10.1051/jp3:1995243; Samanta MP, 1996, PHYS REV B, V53, pR7626, DOI 10.1103/PhysRevB.53.R7626; Sangregorio C, 1997, PHYS REV LETT, V78, P4645, DOI 10.1103/PhysRevLett.78.4645; SCHUMM JS, 1994, ANGEW CHEM INT EDIT, V33, P1360, DOI 10.1002/anie.199413601; SESSOLI R, 1993, NATURE, V365, P141, DOI 10.1038/365141a0; SIMMONS JG, 1963, J APPL PHYS, V34, P1793, DOI 10.1063/1.1702682; Stipe BC, 1998, SCIENCE, V279, P1907, DOI 10.1126/science.279.5358.1907; Sugiura K, 1999, CHEM LETT, P1193, DOI 10.1246/cl.1999.1193; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Tans SJ, 1998, NATURE, V394, P761, DOI 10.1038/29494; TAUBE H, 1984, SCIENCE, V226, P1028, DOI 10.1126/science.6494920; TOUR JM, 1991, J AM CHEM SOC, V113, P7064, DOI 10.1021/ja00018a069; Tour JM, 1998, J AM CHEM SOC, V120, P8486, DOI 10.1021/ja9808090; Treboux G, 1999, CHEM PHYS LETT, V306, P402, DOI 10.1016/S0009-2614(99)00445-5; Wada Y, 1998, ANN NY ACAD SCI, V852, P257, DOI 10.1111/j.1749-6632.1998.tb09878.x; WASHBURN S, 1987, PHYS REV LETT, V59, P1791, DOI 10.1103/PhysRevLett.59.1791; Yaliraki SN, 1999, J AM CHEM SOC, V121, P3428, DOI 10.1021/ja982918k; Yanson AI, 1999, NATURE, V400, P144, DOI 10.1038/22074; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241; YAZDANI A, 1996, SCIENCE, V272, P1912	106	2808	2876	6	782	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					541	548		10.1038/35046000	http://dx.doi.org/10.1038/35046000			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117734				2022-12-28	WOS:000165548600107
J	Sabatini, BL; Svoboda, K				Sabatini, BL; Svoboda, K			Analysis of calcium channels in single spines using optical fluctuation analysis	NATURE			English	Article							G-PROTEIN MODULATION; DENDRITIC SPINES; CA2+ CHANNELS; PYRAMIDAL NEURONS; VOLTAGE DEPENDENCE; NMDA RECEPTORS; TRANSIENTS; CURRENTS; RELEASE; INFLUX	Most synapses form on small, specialized postsynaptic structures known as dendritic spines(1). The influx of Ca2+ ions into such spines-through synaptic receptors and voltage-sensitive Ca2+ channels (VSCCs)-triggers diverse processes that underlie synaptic plasticity(2). Using two-photon laser scanning microscopy(3), we imaged action-potential-induced transient changes in Ca2+ concentration in spines and dendrites of CA1 pyramidal neurons in rat hippocampal slices(4). Through analysis of the large trial-to-trial fluctuations in these transients, we have determined the number and properties of VSCCs in single spines. Here we report that each spine contains 1-20 VSCCs, and that this number increases with spine volume. We are able to detect the opening of a single VSCC on a spine. In spines located on the proximal dendritic tree, VSCCs normally open with high probability (similar to0.5) following dendritic action potentials. Activation of GABA(B) receptors reduced this probability in apical spines to similar to0.3 but had no effect on VSCCs in dendrites or basal spines. Our studies show that the spatial distribution of VSCC subtypes and their modulatory potential is regulated with submicrometre precision.	Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Svoboda, K (corresponding author), Cold Spring Harbor Lab, Howard Hughes Med Inst, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.							BARAK SL, 1982, J CELL BIOL, V95, P846; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BOLAND LM, 1993, J NEUROSCI, V13, P516; CHRISTIE BR, 1995, J NEUROPHYSIOL, V73, P2553, DOI 10.1152/jn.1995.73.6.2553; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JONES R, 1970, APPL OPTICS, V10, P1673; KATZ B, 1970, NATURE, V226, P962, DOI 10.1038/226962a0; Kavalali ET, 1997, NEURON, V18, P651, DOI 10.1016/S0896-6273(00)80305-0; KOCH C, 1993, J NEUROSCI, V13, P413; KUO CC, 1993, NATURE, V365, P258, DOI 10.1038/365258a0; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; Mainen ZF, 1999, NATURE, V399, P151, DOI 10.1038/20187; Maravall M, 2000, BIOPHYS J, V78, P2655, DOI 10.1016/S0006-3495(00)76809-3; MARKRAM H, 1995, J PHYSIOL-LONDON, V485, P1; Page KM, 1998, J NEUROSCI, V18, P4815; Petersen CCH, 1998, P NATL ACAD SCI USA, V95, P4732, DOI 10.1073/pnas.95.8.4732; Rice S. O., 1954, NOISE STOCHASTIC PRO, P133; Schiller J, 1998, NAT NEUROSCI, V1, P114, DOI 10.1038/363; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Tottene A, 1996, J NEUROSCI, V16, P6353; TRIGGLE DJ, 1989, TRENDS PHARMACOL SCI, V10, P507, DOI 10.1016/0165-6147(89)90051-5; Wu LG, 1998, P NATL ACAD SCI USA, V95, P4720, DOI 10.1073/pnas.95.8.4720; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2	30	206	209	0	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					589	593		10.1038/35046076	http://dx.doi.org/10.1038/35046076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117746				2022-12-28	WOS:000165548600119
J	Jansen, B; Wacheck, V; Heere-Ress, E; Schlagbauer-Wadl, H; Hoeller, C; Lucas, T; Hoermann, M; Hollenstein, U; Wolff, K; Pehamberger, H				Jansen, B; Wacheck, V; Heere-Ress, E; Schlagbauer-Wadl, H; Hoeller, C; Lucas, T; Hoermann, M; Hollenstein, U; Wolff, K; Pehamberger, H			Chemosensitisation of malignant melanoma by BCL2 antisense therapy	LANCET			English	Article							CELL-DEATH; BCL-2-DEFICIENT MICE; CPG MOTIFS; EXPRESSION; OLIGODEOXYNUCLEOTIDES; DACARBAZINE; MELANOCYTES; APOPTOSIS; LYMPHOMA; PROTEIN	Background Chemoresistance of malignant melanoma has been linked to expression of the proto-oncogene BCL2. Antisense oligonucleotides (ASO) targeted against BCL2 mRNA decreased BCL2 protein concentrations, increased tumour-cell apoptosis, and led to tumour responses in a mouse xenotransplantation model when combined with systemic dacarbazine. This phase I-II clinical study investigated the combination of BCL2 ASO (augmerosen, Genasense, G3139) and dacarbazine in patients with advanced malignant melanoma expressing BCL2. Methods In a within-patient dose-escalation protocol, 14 patients with advanced malignant melanoma were given augmerosen intravenously or subcutaneously in daily doses of 0.6-6.5 mg/kg plus standard dacarbazine treatment (total doses up to 1000 mg/m(2) per cycle). Toxicity was scored by common toxicity criteria. Plasma augmerosen concentrations were assayed by high-performance liquid chromatography. In serial tumour biopsy samples, BCL2 protein concentrations were measured by western blotting and tumour-cell apoptosis was assessed. Findings The combination regimen was well tolerated, with no dose-limiting toxicity. Haematological abnormalities were mild to moderate. Lymphopenia was common, but no febrile neutropenia occurred. Higher doses of augmerosen were associated with transient fever. Four patients had liver-function abnormalities that resolved within 1 week. Steady-state plasma concentrations of augmerosen were attained within 24 h, and increased with administered dose. By day 5, daily doses of 1.7 mg/kg and higher led to a median 40% decrease in BCL2 protein in melanoma samples compared with baseline, concomitantly with increased tumour-cell apoptosis, which was greatly increased after dacarbazine treatment. Six patients have shown antitumour responses (one complete, two partial, three minor). The estimated median survival of ail patients now exceeds 12 months. Interpretation Systemic administration of augmerosen downregulated the target BCL2 protein in metastatic cancer. Such downregulation of BCL2, combined with standard anticancer therapy, offers a new approach to the treatment of patients with resistant neoplasms.	Univ Vienna, Vienna Gen Hosp, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Clin Pharmacol, Div Expt Oncol & Mol Pharmacol, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Internal Med 1, Div Chemotherapy & Infect Dis, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Radiol, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; University of Vienna	Jansen, B (corresponding author), Univ Vienna, Vienna Gen Hosp, Dept Dermatol, Div Gen Dermatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Wacheck, Volker/ABD-4893-2021	Lucas, Trevor/0000-0002-5114-8035				Ballas ZK, 1996, J IMMUNOL, V157, P1840; CERRONI L, 1995, AM J DERMATOPATH, V17, P7, DOI 10.1097/00000372-199502000-00002; Chapman PB, 1999, J CLIN ONCOL, V17, P2745, DOI 10.1200/JCO.1999.17.9.2745; Chen SH, 1997, J CHROMATOGR B, V692, P43, DOI 10.1016/S0378-4347(96)00499-9; Eton O, 1998, J CLIN ONCOL, V16, P1103, DOI 10.1200/JCO.1998.16.3.1103; Falkson CI, 1998, J CLIN ONCOL, V16, P1743, DOI 10.1200/JCO.1998.16.5.1743; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; KAMADA S, 1995, CANCER RES, V55, P354; Miayake H, 2000, J NATL CANCER I, V92, P34, DOI 10.1093/jnci/92.1.34; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; MORRIS MJ, 1999, P AN M AM SOC CLIN, V18, pA323; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NEUMUNATIS J, 1997, P AM SOC CLIN ONCOL, V16, pA246; ODWYER PJ, 1998, P AN M AM SOC CLIN, V17, pA210; PARK JR, 1995, BLOOD, V86, P686; Raynaud FI, 1997, J PHARMACOL EXP THER, V281, P420; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SCHER HI, 2000, P AN M AM SOC CLIN, V19, pA199; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wooldridge JE, 1997, BLOOD, V89, P2994, DOI 10.1182/blood.V89.8.2994; Yamamura K, 1996, CANCER RES, V56, P3546	26	420	452	0	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1728	1733		10.1016/S0140-6736(00)03207-4	http://dx.doi.org/10.1016/S0140-6736(00)03207-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095261				2022-12-28	WOS:000165462300012
J	Klopfenstein, DR; Vale, RD; Rogers, SL				Klopfenstein, DR; Vale, RD; Rogers, SL			Motor protein receptors: Moonlighting on other jobs	CELL			English	Review							MEMBRANE; TRANSPORT; COMPLEX; FAMILY; CELLS		Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.							ALLAN V, 1994, J CELL SCI, V107, P1885; Allan VJ, 1999, CURR OPIN CELL BIOL, V11, P476, DOI 10.1016/S0955-0674(99)80068-4; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; De Matteis MA, 2000, J CELL SCI, V113, P2331; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Hurd DD, 1996, GENETICS, V144, P1075; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797	18	41	43	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 10	2000	103	4					537	540		10.1016/S0092-8674(00)00144-6	http://dx.doi.org/10.1016/S0092-8674(00)00144-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106727	Bronze			2022-12-28	WOS:000165348000001
J	Wolfenbarger, LL; Phifer, PR				Wolfenbarger, LL; Phifer, PR			Biotechnology and ecology - The ecological risks and benefits of genetically engineered plants	SCIENCE			English	Review							THURINGIENSIS SUBSP KURSTAKI; COLEOMEGILLA-MACULATA COLEOPTERA; TRANSGENIC OILSEED RAPE; BACILLUS-THURINGIENSIS; BRASSICA-NAPUS; INSECTICIDAL TOXIN; DEVELOPMENT TIME; SNOWDROP LECTIN; GENE FLOW; RESISTANCE	Discussions of the environmental risks and benefits of adopting genetically engineered organisms are highly polarized between pro- and anti-biotechnology groups, but the current state of our knowledge is frequently overlooked in this debate. A review of existing scientific literature reveals that key experiments on both the environmental risks and benefits are lacking. The complexity of ecological systems presents considerable challenges for experiments to assess the risks and benefits and inevitable uncertainties of genetically engineered plants. Collectively, existing studies emphasize that these can vary spatially, temporally, and according to the trait and cultivar modified.	US EPA, Off Res & Dev, Natl Ctr Environm Assessment, Washington, DC 20460 USA; Bur Oceans Environm & Sci, US Dept State, Arlington, VA 22206 USA	United States Environmental Protection Agency	Wolfenbarger, LL (corresponding author), US EPA, Off Res & Dev, Natl Ctr Environm Assessment, 1200 Penn Ave NW 8601D, Washington, DC 20460 USA.	wolfenbarger.lareesa@epa.gov	Kesim, Haydar K/B-4662-2010					Bell HA, 1999, J INSECT PHYSIOL, V45, P983, DOI 10.1016/S0022-1910(99)00077-3; Bergelson J, 1998, NATURE, V395, P25, DOI 10.1038/25626; BERGELSON J, 1994, ECOLOGY, V75, P249, DOI 10.2307/1939399; Birch ANE, 1999, MOL BREEDING, V5, P75, DOI 10.1023/A:1009659316170; Bizily SP, 2000, NAT BIOTECHNOL, V18, P213, DOI 10.1038/72678; Bourguet D, 2000, P ROY SOC B-BIOL SCI, V267, P117, DOI 10.1098/rspb.2000.0975; CANNELL RQ, 1994, SOIL TILL RES, V30, P245, DOI 10.1016/0167-1987(94)90007-8; Carpenter J, 2000, SCIENCE, V287, P803; CHURCHER PB, 1987, J ZOOL, V212, P439, DOI 10.1111/j.1469-7998.1987.tb02915.x; Crawley M.J., 1989, BIOL INVASIONS GLOBA, P407; CRAWLEY MJ, 1993, NATURE, V363, P620, DOI 10.1038/363620a0; DERRICK ME, 1992, ENVIRON ENTOMOL, V21, P240, DOI 10.1093/ee/21.2.240; Dogan EB, 1996, J ECON ENTOMOL, V89, P1105, DOI 10.1093/jee/89.5.1105; Donegan KK, 1997, J APPL ECOL, V34, P767, DOI 10.2307/2404921; DONEGAN KK, 1995, APPL SOIL ECOL, V2, P111, DOI 10.1016/0929-1393(94)00043-7; ECHELLE AA, 1989, EVOLUTION, V43, P717, DOI 10.1111/j.1558-5646.1989.tb05171.x; Ellstrand NC, 1999, ANNU REV ECOL SYST, V30, P539, DOI 10.1146/annurev.ecolsys.30.1.539; FREDSHAVN JR, 1995, TRANSGENIC RES, V4, P142, DOI 10.1007/BF01969416; Gianessi L., 1999, AGR BIOTECHNOLOGY IN; Gleba D, 1999, P NATL ACAD SCI USA, V96, P5973, DOI 10.1073/pnas.96.11.5973; Gould F, 1998, ANNU REV ENTOMOL, V43, P701, DOI 10.1146/annurev.ento.43.1.701; GREENE AE, 1994, SCIENCE, V263, P1423, DOI 10.1126/science.8128222; Griffiths BS, 2000, J APPL ECOL, V37, P159, DOI 10.1046/j.1365-2664.2000.00481.x; GROETERS FR, 1993, J ECON ENTOMOL, V86, P1035, DOI 10.1093/jee/86.4.1035; HAILS RS, 1997, P ROY SOC LOND B BIO, V265, P1; HANSEN LC, 2000, OECOLOGIA; Hilbeck A, 1998, ENVIRON ENTOMOL, V27, P480, DOI 10.1093/ee/27.2.480; Hokanson SC, 1997, EUPHYTICA, V96, P397, DOI 10.1023/A:1003061501477; Jacquet C, 1998, J GEN VIROL, V79, P1509, DOI 10.1099/0022-1317-79-6-1509; KLINGER T, 1992, AM J BOT, V79, P1431, DOI 10.2307/2445143; LECOQ H, PHYTOPATHOLOGY, V81, P403; Lefol E, 1996, FIELD CROP RES, V45, P153, DOI 10.1016/0378-4290(95)00067-4; Levin SA., 1989, BIOL INVASIONS GLOBA, V37, P425; LINDER CR, 1995, ECOL APPL, V5, P1056, DOI 10.2307/2269354; Liu YB, 1999, NATURE, V400, P519, DOI 10.1038/22919; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; MACK RN, 2000, ISSUES ECOL, V5, P1; Marvier MA, 1999, METHODS FOR RISK ASSESSMENT OF TRANSGENIC PLANTS, VOL III, P109; Mikkelsen TR, 1996, NATURE, V380, P31, DOI 10.1038/380031a0; OMER AD, 1993, ENTOMOL EXP APPL, V67, P173, DOI 10.1007/BF02386523; Orr DB, 1997, J ECON ENTOMOL, V90, P905, DOI 10.1093/jee/90.4.905; Palm CJ, 1996, CAN J MICROBIOL, V42, P1258, DOI 10.1139/m96-163; Pilcher CD, 1997, ENVIRON ENTOMOL, V26, P446, DOI 10.1093/ee/26.2.446; Pilon-Smits EAH, 1999, PLANT PHYSIOL, V119, P123, DOI 10.1104/pp.119.1.123; Pimentel D, 2000, BIOSCIENCE, V50, P53, DOI 10.1641/0006-3568(2000)050[0053:EAECON]2.3.CO;2; Pohl-Orf M, 1999, EUPHYTICA, V108, P181, DOI 10.1023/A:1003680931766; Riddick EW, 1998, ANN ENTOMOL SOC AM, V91, P303, DOI 10.1093/aesa/91.3.303; Riddick EW, 1998, ANN ENTOMOL SOC AM, V91, P647, DOI 10.1093/aesa/91.5.647; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Saxena D, 1999, NATURE, V402, P480, DOI 10.1038/44997; SCHEFFLER JA, 1995, PLANT BREEDING, V114, P317, DOI 10.1111/j.1439-0523.1995.tb01241.x; Shelton AM, 2000, NAT BIOTECHNOL, V18, P339, DOI 10.1038/73804; Siciliano SD, 1998, CAN J MICROBIOL, V44, P844, DOI 10.1139/cjm-44-9-844; Siciliano SD, 1999, FEMS MICROBIOL ECOL, V29, P263, DOI 10.1111/j.1574-6941.1999.tb00617.x; Sims SR, 1996, ENVIRON ENTOMOL, V25, P659, DOI 10.1093/ee/25.3.659; Sims SR, 1997, J AGR FOOD CHEM, V45, P1502, DOI 10.1021/jf960647w; SKOGSMYR I, 1994, THEOR APPL GENET, V88, P770, DOI 10.1007/BF01253984; Snow AA, 1997, BIOSCIENCE, V47, P86, DOI 10.2307/1313019; Snow AA, 1999, MOL ECOL, V8, P605, DOI 10.1046/j.1365-294x.1999.00596.x; Stotzky G, 2000, J ENVIRON QUAL, V29, P691, DOI 10.2134/jeq2000.00472425002900030003x; TABASHNIK BE, 1994, ANNU REV ENTOMOL, V39, P47, DOI 10.1146/annurev.en.39.010194.000403; TABASHNIK BE, 1990, J ECON ENTOMOL, V83, P1177, DOI 10.1093/jee/83.4.1177; Tapp H, 1998, SOIL BIOL BIOCHEM, V30, P471, DOI 10.1016/S0038-0717(97)00148-X; TEPFER M, 1993, BIO-TECHNOL, V11, P1125, DOI 10.1038/nbt1093-1125; TIEDJE JM, 1989, ECOLOGY, V70, P298, DOI 10.2307/1937535; US Environmental Protection Agency (USEPA), 1998, GUIDELINES ECOLOGICA; *USDA, 2000, GEN ENG CROPS AD RED; *USDA, 2000, GEN ENG CROPS PEST M; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Watkinson AR, 2000, SCIENCE, V289, P1554, DOI 10.1126/science.289.5484.1554; WILHOIT L, 1999, PESTICIDE USE ANAL T; Wintermantel WM, 1996, VIROLOGY, V223, P156, DOI 10.1006/viro.1996.0464; WOOD M, 1989, SOIL BIOL; Wraight CL, 2000, P NATL ACAD SCI USA, V97, P7700, DOI 10.1073/pnas.130202097; Yu L, 1997, J ECON ENTOMOL, V90, P113, DOI 10.1093/jee/90.1.113; Zhu YL, 1999, PLANT PHYSIOL, V119, P73, DOI 10.1104/pp.119.1.73	76	396	483	4	413	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	2000	290	5499					2088	2093		10.1126/science.290.5499.2088	http://dx.doi.org/10.1126/science.290.5499.2088			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118136	Green Submitted			2022-12-28	WOS:000165870600039
J	Glantz, LH; Annas, GJ				Glantz, LH; Annas, GJ			Tobacco, the Food and Drug Administration, and Congress.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA	Boston University	Glantz, LH (corresponding author), Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.			Glantz, Leonard/0000-0003-4591-2305; Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V335, P1779, DOI 10.1056/NEJM199612053352322; [Anonymous], 1999, MMWR MORB MORTAL WKL, V48, P986; [Anonymous], 1998, MMWR-MORBID MORTAL W, V47, P229; *DEP HLTH HUM SERV, 1981, HLTH CONS SMOK CHANG; Food and Drug Administration FDA, 1996, FED REGISTER, V61, P44396; Ford H, 1914, CASE LITTLE WHITE SL, V3; Ford H, 1914, CASE LITTLE WHITE SL, V1; Ford H, 1914, CASE LITTLE WHITE SL, V2; KLUGER R, 1996, ASHES ASHES AM 100 Y; TATE C, 1989, SMITHSONIAN, V20, P107; Tate C., 1999, CIGARETTE WARS TRIUM; 2000, MMWR MORB MORTAL WKL, V49, P49	12	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1802	1806		10.1056/NEJM200012143432411	http://dx.doi.org/10.1056/NEJM200012143432411			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11114322	Green Published			2022-12-28	WOS:000165812000011
J	Myers, ML				Myers, ML			Protecting the public health by strengthening the Food and Drug Administration's authority over tobacco products.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Natl Ctr Tobacco Free Kids, Washington, DC 20036 USA		Myers, ML (corresponding author), Natl Ctr Tobacco Free Kids, Washington, DC 20036 USA.							ELLIS C, 1962, BATCO RES C; Food and Drug Administration FDA, 1996, FED REGISTER, V61, P44396; JOHNSTON LD, 2000, NIH PUBL; Kessler DA, 1996, NEW ENGL J MED, V335, P988, DOI 10.1056/NEJM199609263351321; KLUGER R, 1996, ASHES ASHES AM 100 Y; *LABST INT, 2000, CHAR 3 LOW ULTR LOW; National Cancer Institute, 1997, NIH PUBL; *OFF SMOK HLTH, 1988, DHHS PUBL; PEELER C, 1996, NIH PUBL; SHIFFMAN S, 2000, 11 WORLD C TOB HLTH; TURNERBOWKER D, 2000, CIGARETTE ADVERTISIN; WAKEFIELD M, 2000, CHANGES POINT OF PUR; YEAMAN A, 1963, IMPLICATION BATTELE	13	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1806	1809		10.1056/NEJM200012143432412	http://dx.doi.org/10.1056/NEJM200012143432412			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11114323				2022-12-28	WOS:000165812000012
J	Exner, K; Schleyer, PV				Exner, K; Schleyer, PV			Planar hexacoordinate carbon: A viable possibility	SCIENCE			English	Article							INDEPENDENT CHEMICAL-SHIFTS; TETRACOORDINATE CARBON; ORGANOMETALLIC CHEMISTRY; CRYSTAL-STRUCTURE; MOLECULES; AROMATICITY; CATION; SPECTROSCOPY; STABILITY; METHANE	The viability of molecules with planar hexacoordinate carbon atoms is demonstrated by density-functional theory (DFT) calculations for CB62-, a CB6H2 isomer, and three C3B4 minima. All of these species have six pi electrons and are aromatic. Although other C3B4 isomers are lower in energy, the activation barriers for the rearrangements of the three planar carbon C3B4 minima into more stable isomers are appreciable, and experimental observation should be possible. High-Level ab initio calculations confirm the DFT results. The planar hexacoordination in these species does not violate the octet rule because six partial bonds to the central carbons are involved.	Univ Georgia, Ctr Computat Quantum Chem, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Schleyer, PV (corresponding author), Univ Georgia, Ctr Computat Quantum Chem, Computat Chem Annex, Athens, GA 30602 USA.	schleyer@chem.uga.edu						ALBANO VG, 1973, J CHEM SOC DALTON, P651, DOI 10.1039/dt9730000651; Boldyrev AI, 1998, J AM CHEM SOC, V120, P7967, DOI 10.1021/ja981236u; Bondybey VE, 1996, CHEM REV, V96, P2113, DOI 10.1021/cr940262h; Choukroun R, 1999, ACCOUNTS CHEM RES, V32, P494, DOI 10.1021/ar970304z; COLLINS JB, 1976, J AM CHEM SOC, V98, P5419, DOI 10.1021/ja00434a001; Frisch M. J., 1998, GAUSSIAN 98; Gabbai FP, 1997, CHEM BER-RECL, V130, P111, DOI 10.1002/cber.19971300118; HOFFMANN R, 1970, J AM CHEM SOC, V92, P4992, DOI 10.1021/ja00719a044; HOGEVEEN H, 1975, ACCOUNTS CHEM RES, V8, P413, DOI 10.1021/ar50096a004; JEMMIS ED, 1982, J AM CHEM SOC, V104, P4275, DOI 10.1021/ja00379a051; LAMMERTSMA K, 1983, J AM CHEM SOC, V105, P5258, DOI 10.1021/ja00354a013; LEE TJ, 1989, INT J QUANTUM CHEM, P199, DOI 10.1002/qua.560360824; Li X, 1999, J AM CHEM SOC, V121, P6033, DOI 10.1021/ja9906204; Patchkovskii S, 2000, J MOL MODEL, V6, P67, DOI 10.1007/PL00010736; PERRY DS, 1995, TECHNIUES CHEM SERIE, V23, pCH3; Radom L, 1998, PURE APPL CHEM, V70, P1977, DOI 10.1351/pac199870101977; Rottger D, 1997, ANGEW CHEM INT EDIT, V36, P813; SCHERBAUM F, 1989, ANGEW CHEM INT EDIT, V28, P463, DOI 10.1002/anie.198904631; SCHLEYER PV, 1994, J AM CHEM SOC, V116, P10129, DOI 10.1021/ja00101a035; Schleyer PV, 1996, J AM CHEM SOC, V118, P6317, DOI 10.1021/ja960582d; SCHLEYER PV, 1983, J AM CHEM SOC, V105, P5930, DOI 10.1021/ja00356a045; Schleyer PV, 1996, CHEM PHYS LETT, V255, P363, DOI 10.1016/0009-2614(96)00391-0; SCHLEYER PV, 1991, J CHEM SOC CHEM COMM, P1536; Schleyer PV, 1997, J AM CHEM SOC, V119, P12669, DOI 10.1021/ja9719135; Siebert W, 1999, CHEM SOC REV, V28, P367, DOI 10.1039/a801225c; SIRIGU A, 1969, J CHEM SOC CHEM COMM, P596; SORGER K, 1995, J MOL STRUC-THEOCHEM, V338, P317, DOI 10.1016/0166-1280(95)04233-V; Wang LS, 2000, J AM CHEM SOC, V122, P7681, DOI 10.1021/ja993081b	28	263	268	0	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1937	1940		10.1126/science.290.5498.1937	http://dx.doi.org/10.1126/science.290.5498.1937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110655				2022-12-28	WOS:000165810000038
J	Zhang, FC; Zhou, ZH				Zhang, FC; Zhou, ZH			A primitive enantiornithine bird and the origin of feathers	SCIENCE			English	Article							YIXIAN FORMATION; EVOLUTION; DINOSAUR; SKULL; ARCHAEOPTERYX; SPAIN	A fossil enantiornithine bird, Protopteryx fengningensis gen. et sp. nov., was collected from the Early Cretaceous Yixian Formation of Northern China. it provides fossil evidence of a triosseal canal in early birds. The manus and the alular digit are long, as in Archaeopteryx and Confuciusornis, but are relatively short in other enantiornithines. The alula or bastard wing is attached to an unreduced alular digit. The two central tail feathers are scalelike without branching. This type of feather may suggest that modern feathers evolved through the following stages: (i) elongated scale, (ii) central shaft, (iii) barbs, and finally (iv) barbules and barbicel.	Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	Zhang, FC (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	fuchengzhang@yeah.net						Baumel Julian J., 1993, Publications of the Nuttall Ornithological Club, V23, P45; BOCK WJ, 1986, MEM CALIF ACAD SCI, V8, P57; Chen PJ, 1998, NATURE, V391, P147, DOI 10.1038/34356; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; Chiappe LM, 1999, B AM MUS NAT HIST, P3; Chiappe Luis M., 1996, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V30, P203; DYCK J, 1985, ZOOL SCR, V14, P137, DOI 10.1111/j.1463-6409.1985.tb00184.x; Feduccia A, 1999, ORIGIN EVOLUTION BIR, P1; GILL FB, 1994, ORNITHOLOGY, P65; Ginn H.B., 1983, BTO Guide, P1; Griffith Peter J., 1996, Archaeopteryx, V14, P1; Hou LH, 1999, NATURE, V399, P679, DOI 10.1038/21411; Hou Lian-Hai, 1999, Vertebrata Palasiatica, V37, P88; Ji Q, 1998, NATURE, V393, P753, DOI 10.1038/31635; Jones TD, 2000, SCIENCE, V288, P2202, DOI 10.1126/science.288.5474.2202; Jones TD, 2000, NATURE, V406, P716, DOI 10.1038/35021041; LUCAS AM, 1972, AGR HDB, V362, P1; Martin Larry D., 1995, Courier Forschungsinstitut Senckenberg, V181, P23; Martin LD, 1997, NATURE, V389, P556, DOI 10.1038/39228; MARTIN LD, 1980, AUK, V97, P86; Mayr E., 1960, EVOLUTION DARWIN, P349; Ostrom J.H., 1976, Smithsonian Contributions to Paleobiology, VNo. 27, P1; OSTROM JH, 1974, Q REV BIOL, V49, P27, DOI 10.1086/407902; Ostrom John H., 1997, P301; Padian K, 1998, BIOL REV, V73, P1, DOI 10.1111/j.1469-185X.1997.tb00024.x; REGAL PJ, 1975, Q REV BIOL, V50, P35, DOI 10.1086/408299; Sanz JL, 1996, NATURE, V382, P442, DOI 10.1038/382442a0; Sanz JL, 1997, SCIENCE, V276, P1543, DOI 10.1126/science.276.5318.1543; Sereno PC, 1999, SCIENCE, V284, P2137, DOI 10.1126/science.284.5423.2137; Storer R.W., 1960, P 12 INT ORN C, V2, P694; WALKER CA, 1981, NATURE, V292, P51, DOI 10.1038/292051a0; Wellnhofer P., 1974, Palaeontographica Abt A, V147, P169; WELLNHOFER P, 1992, PAPERS AVIAN PALEONT, P3; Xu X, 1999, NATURE, V401, P262, DOI 10.1038/45769; Xu X, 1999, NATURE, V399, P350, DOI 10.1038/20670; ZHOU Z, 1995, COUR FORSCHUNGSINST, V181, P9; Zhou Zhong-He, 2000, Vertebrata Palasiatica, V38, P111	37	186	224	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	2000	290	5498					1955	1959		10.1126/science.290.5498.1955	http://dx.doi.org/10.1126/science.290.5498.1955			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110660				2022-12-28	WOS:000165810000043
J	Vinge, JD				Vinge, JD			Murphy's cat - Take care who sits next to you at conferences...	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					649	649		10.1038/35047185	http://dx.doi.org/10.1038/35047185			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130049	Bronze			2022-12-28	WOS:000165815200022
J	Etkin, A				Etkin, A			Drugs and therapeutics in the age of the genome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROTEIN		Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Etkin, A (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.		Etkin, Amit/ABD-5761-2021					Abbott A, 1999, NATURE, V402, P715, DOI 10.1038/45350; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; CHEE M, 1996, SCIENCE, V274, P548; Cho MK, 2000, JAMA-J AM MED ASSOC, V284, P2203, DOI 10.1001/jama.284.17.2203; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Sander C, 2000, SCIENCE, V287, P1977, DOI 10.1126/science.287.5460.1977	10	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2786	2787		10.1001/jama.284.21.2786	http://dx.doi.org/10.1001/jama.284.21.2786			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105190	hybrid			2022-12-28	WOS:000165509500037
J	Walton, D; Farmer, P				Walton, D; Farmer, P			The new white plague	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TUBERCULOSIS		Harvard Univ, Boston, MA 02115 USA	Harvard University	Walton, D (corresponding author), Harvard Univ, Boston, MA 02115 USA.							Becerra MC, 2000, INT J TUBERC LUNG D, V4, P108; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P661; Cohn DL, 1997, CLIN INFECT DIS   S1, V24, P121; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; FARMER PE, 1999, TUBERCULOSIS COMPREH; Heifets LB, 1999, INT J TUBERC LUNG D, V3, P564; *WHO, 1997, TB TREATMENT OB 0324; World Health Organization, 1998, WHO PUBL, VMSA/MDN/98.2, P55	9	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2789	2789		10.1001/jama.284.21.2789	http://dx.doi.org/10.1001/jama.284.21.2789			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105192	hybrid			2022-12-28	WOS:000165509500039
J	Abrams, P; Wein, A				Abrams, P; Wein, A			Recent advances - Urology	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MANAGEMENT		Bristol Urol Inst, Bristol BS10 5NB, Avon, England		Abrams, P (corresponding author), Bristol Urol Inst, Bristol BS10 5NB, Avon, England.	p_abrams@bui.ac.uk						Abrams P, 2000, LANCET, V355, P2153; ABRAMS P, 1994, BRIT MED J, V308, P929, DOI 10.1136/bmj.308.6934.929; ABRAMS P, 1998, INC P 1 INT CONS INC; ABRAMS P, IN PRESS 5 WHO SPONS; Avanoglu A, 1999, BJU INT, V83, P91, DOI 10.1046/j.1464-410X.1999.00909.x; BELL R, 2000, EFFECTIVE MANAGEMENT, P79; Bulmer P, 2000, REV CONTEMP PHARMACO, V11, P1; de Jong Tom P. V. M., 1999, European Urology, V36, P1; de la Rosette JJMCH, 1999, EUR UROL, V35, P173, DOI 10.1159/000019839; Dearnaley DP, 1999, BJU INT, V83, P18; DELANCEY JOL, 1998, INC P 1 INT CONS INC, P280; *DEP HLTH, 2000, GOOD PRACT CONT SERV; Guillonneau B, 2000, J UROLOGY, V163, P1643, DOI 10.1016/S0022-5347(05)67512-X; MCCONNELL JD, N ENGL J MED, V338, P557; Murphy M, 1999, BJU INT, V83, P786; PARTIN AW, 1993, J UROLOGY, V150, P110, DOI 10.1016/S0022-5347(17)35410-1; RALPH D, 1999, UK MANAGEMENT GUIDEL, P3; Stone NN, 1999, J UROLOGY, V162, P421, DOI 10.1016/S0022-5347(05)68574-6; Whitfield HN, 1999, BJU INT, V84, P916; WILSON PD, 1998, INC P 1 INT CONS INC, P585	20	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	2000	321	7273					1393	1396		10.1136/bmj.321.7273.1393	http://dx.doi.org/10.1136/bmj.321.7273.1393			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099286	Green Published			2022-12-28	WOS:000165720100031
J	Briggs, A				Briggs, A			Economic evaluation and clinical trials: size matters - The need for greater power in cost analyses poses an ethical dilemma	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England	University of Oxford	Briggs, A (corresponding author), Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England.		Briggs, Andrew/ABA-9009-2020	Briggs, Andrew/0000-0002-0777-1997				ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Bower P, 2000, BMJ-BRIT MED J, V321, P1389, DOI 10.1136/bmj.321.7273.1389; Briggs A, 1998, J Health Serv Res Policy, V3, P233; Briggs AH, 1998, MED DECIS MAKING, V18, pS81, DOI 10.1177/0272989X98018002S10; Drummond M., 1994, EC ANAL ALONGSIDE CO; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; Gardner M. J., 1989, STAT CONFIDENCE; OBrien B, 1996, MED CARE, V34, pDS99; Ward E, 2000, BRIT MED J, V321, P1383, DOI 10.1136/bmj.321.7273.1383	9	138	138	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1362	1363		10.1136/bmj.321.7273.1362	http://dx.doi.org/10.1136/bmj.321.7273.1362			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099268	Green Published			2022-12-28	WOS:000165720100004
J	McCrary, SV; Anderson, CB; Jakovljevic, J; Khan, T; McCullough, LB; Wray, NP; Brody, BA				McCrary, SV; Anderson, CB; Jakovljevic, J; Khan, T; McCullough, LB; Wray, NP; Brody, BA			A national survey of policies on disclosure of conflicts of interest in biomedical research	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OF-INTEREST	Background: Conflicts of interest pose a threat to the integrity of scientific research. The current regulations of the U.S. Public Health Service and the National Science Foundation require that medical schools and other research institutions report the existence of conflicts of interest to the funding agency but allow the institutions to manage conflicts internally. The regulations do not specify how to do so. Methods: We surveyed all medical schools (127) and other research institutions (170) that received more than $5 million in total grants annually from the National Institutes of Health or the National Science Foundation; 48 journals in basic science and clinical medicine; and 17 federal agencies in order to analyze their policies on conflicts of interest. Results: Of the 297 institutions, 250 (84 percent) responded by March 2000, as did 47 of the 48 journals and 16 of the 17 federal agencies. Fifteen of the 250 institutions (6 percent) -- 5 medical schools and 10 other research institutions -- reported that they had no policy on conflicts of interest. Among the institutions that had policies, there was marked variation in the definition and management of conflicts. Ninety-one percent had policies that adhered to the federal threshold for disclosure ($10,000 in annual income or equity in a relevant company or 5 percent ownership), and 9 percent had policies that exceeded the federal guidelines. Only 8 percent had policies requiring disclosure to funding agencies, only 7 percent had such policies regarding journals, and only 1 percent had policies requiring the disclosure of information to the relevant institutional review boards or to research subjects. Twenty journals (43 percent) reported that they had policies requiring disclosure of conflicts of interest. Only four federal agencies had policies that explicitly addressed conflicts of interest in extramural research, and all but one of the agencies relied primarily on institutional discretion. Conclusions: There is substantial variation among policies on conflicts of interest at medical schools and other research institutions. This variation, combined with the fact that many scientific journals and funding agencies do not require disclosure of conflicts of interest, suggests that the current standards may not be adequate to maintain a high level of scientific integrity. (N Engl J Med 2000;343:1621-6.) (C) 2000, Massachusetts Medical Society.	Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McCrary, SV (corresponding author), Baylor Coll Med, Ctr Med Eth & Hlth Policy, 1 Baylor Plaza, Houston, TX 77030 USA.							ANDERSON C, 1994, SCIENCE, V265, P179, DOI 10.1126/science.8023137; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; Angell M, 2000, NEW ENGL J MED, V342, P586, DOI 10.1056/NEJM200002243420812; [Anonymous], 1991, FED REGISTER, V56, P28002; *ASS AM MED COLL, 1999, MED SCH US CAN GEOGR; Babbie E.R., 2015, PRACTICE SOCIAL RES, V14th; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; BRODY BA, 1996, CONFLICTS INTEREST C, P407; Clever LH, 1997, ANN INTERN MED, V126, P36, DOI 10.7326/0003-4819-126-1-199701010-00006; DEPALMA A, 1993, NY TIMES        0317, pB12; Donaldson M. S., 1991, PATIENT OUTCOMES RES, P61; EMANUEL EJ, 1995, NEW ENGL J MED, V332, P262, DOI 10.1056/NEJM199501263320412; *I SCI INF, 1997, J CIT REP CD ROM 199; KASSIRER JP, 1993, NEW ENGL J MED, V329, P570, DOI 10.1056/NEJM199308193290810; KORENMAN SG, 1993, ACAD MED, V68, pS18, DOI 10.1097/00001888-199309000-00029; Krimsky S, 1998, JAMA-J AM MED ASSOC, V280, P225, DOI 10.1001/jama.280.3.225; Nadis S, 2000, NATURE, V405, P497, DOI 10.1038/35014765; *NAT SCI FDN, 1999, AW SUMM TOP 200 I FY; *NIH, 1999, NIH SUPP ALL I FISC; *NIH, 1989, NIH GUID GRANTS CONT, V18, P3; *NIH, 2000, FIN CONFL INT RES OB; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; STOLBERG SG, 2000, NY TIMES        0524, pA21; Stolberg Sheryl Gay, 2000, NY TIMES 0215 NY TIMES 0215, P20; WITT MD, 1994, JAMA-J AM MED ASSOC, V271, P547, DOI 10.1001/jama.271.7.547; Zallen DT, 2000, TRENDS GENET, V16, P272, DOI 10.1016/S0168-9525(00)02025-4; 1994, FED REG, V59, P33242; 1994, FED REG, V59, P33308; 1999, N ENGL J MED, V341, P1618	29	122	125	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1621	1626		10.1056/NEJM200011303432207	http://dx.doi.org/10.1056/NEJM200011303432207			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096171	Bronze			2022-12-28	WOS:000165511000007
J	Poon, LLM; Leung, TN; Lau, TK; Lo, YMD				Poon, LLM; Leung, TN; Lau, TK; Lo, YMD			Prenatal detection of fetal Down's syndrome from maternal plasma	LANCET			English	Article							DNA	Fetal DNA is present in maternal plasma, and a proportion of such DNA is seen in intact fetal cells. We investigated the use of fluorescence in-situ hybridisation (FISH) techniques on maternal plasma samples, in plasma samples obtained from three women carrying fetuses affected by trisomy 21 (Down's syndrome), we identified fetal cells with three chromosome-21 signals. These results show the feasibility of non-invasive detection of fetal chromosomal aneuploidy by maternal plasma analysis.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Lo, YMD (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China.		Poon, Leo Lit Man/C-4382-2009; Lo, Yuk Ming Dennis/D-4468-2011; Poon, Leo/AAP-6887-2020	Poon, Leo Lit Man/0000-0002-9101-7953; Lo, Yuk Ming Dennis/0000-0001-8746-0293; Lau, Tze Kin/0000-0002-0242-1410				Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Lo YMD, 1998, NEW ENGL J MED, V339, P1734, DOI 10.1056/NEJM199812103392402; van Wijk IJ, 2000, CLIN CHEM, V46, P729	5	48	60	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1819	1820		10.1016/S0140-6736(00)03237-2	http://dx.doi.org/10.1016/S0140-6736(00)03237-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117917				2022-12-28	WOS:000165545700016
J	Roth, DB; Roth, SY				Roth, DB; Roth, SY			Unequal access: Regulating V(D)J recombination through chromatin remodeling	CELL			English	Review							HISTONE ACETYLATION; CLEAVAGE; DNA; STIMULATION		Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Roth, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA.	syr@odin.mda.uth.tmc.edu	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269				Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Golding A, 1999, EMBO J, V18, P3712, DOI 10.1093/emboj/18.13.3712; Hempel WM, 1998, GENE DEV, V12, P2305, DOI 10.1101/gad.12.15.2305; Kirch SA, 1998, EMBO J, V17, P4881, DOI 10.1093/emboj/17.16.4881; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; McBlane F, 2000, CURR BIOL, V10, P483, DOI 10.1016/S0960-9822(00)00449-8; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; Noordzij JG, 2000, BLOOD, V96, P203, DOI 10.1182/blood.V96.1.203.013k33_203_209; Oettinger MA, 1999, CURR OPIN CELL BIOL, V11, P325, DOI 10.1016/S0955-0674(99)80044-1; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schubeler D, 2000, GENE DEV, V14, P940; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	20	53	53	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					699	702		10.1016/S0092-8674(00)00173-2	http://dx.doi.org/10.1016/S0092-8674(00)00173-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114326	Bronze			2022-12-28	WOS:000165433100003
J	Warner, JT				Warner, JT			Reliability of indices of weight and height in assessment of nutritional state in children	LANCET			English	Editorial Material									John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England	University of Oxford	Warner, JT (corresponding author), John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.							FUNG KP, 1990, ARCH DIS CHILD, V65, P1516; Oguz A, 1999, PEDIATR HEMAT ONCOL, V16, P35, DOI 10.1080/088800199277579; Poustie VJ, 2000, ARCH DIS CHILD, V83, P183, DOI 10.1136/adc.83.2.183; Warner JT, 1997, ANN HUM BIOL, V24, P209, DOI 10.1080/03014469700004942	4	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1703	1704		10.1016/S0140-6736(00)03201-3	http://dx.doi.org/10.1016/S0140-6736(00)03201-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095255				2022-12-28	WOS:000165462300006
J	Dorling, D; Mitchell, R; Shaw, M; Orford, S; Smith, GD				Dorling, D; Mitchell, R; Shaw, M; Orford, S; Smith, GD			The Ghost of Christmas Past: health effects of poverty in London in 1896 and 1991	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL-CLASS; MORTALITY	Objectives To compare the extent to which late 20th century patterns of mortality in London are predicted by contemporary patterns of poverty and by late 19th century patterns of poverty. To test the hypothesis that the pattern of mortality from causes known to be related to deprivation in early life can be better predicted by the distribution of poverty in the late 19th century than by that in the late 20th century. Design Data from Charles Booth's survey of inner London in 1896 were digitised and matched to contemporary local government wards. Ward level indices of relative poverty were derived from Booth's survey and the 1991 UK census of population. AU deaths which took place within the surveyed area between 1991 and 1995 were identified and assigned to contemporary local government wards. Standardised mortality ratios for various causes of death were calculated for each ward for all ages, under age 65, and over age 65. Simple correlation and partial correlation analysis were used to estimate the contribution of the indices of poverty from 1896 and 1991 in predicting ward level mortality ratios in the early 1990s. Setting Inner London. Results For many causes of death in London, measures of deprivation made around 1896 and 1991 both contributed strongly to predicting the current spatial distribution. Contemporary mortality from diseases which are known to be related to deprivation in early life (stomach cancer, stroke, lung cancer) is predicted more strongly by the distribution of poverty in 1896 than that in 1991. In addition, all cause mortality among people aged over 65 was slightly more strongly related to the geography of poverty in the late 19th century than to its contemporary distribution. Conclusions Contemporary patterns of some diseases have their roots in the past. The fundamental relation between spatial patterns of social deprivation and spatial patterns of mortality is so robust that a century of change in inner London has failed to disrupt it.	Univ Leeds, Sch Geog, Leeds LS2 9JT, W Yorkshire, England; Univ Bristol, Sch Geog Sci, Bristol BS8 1SS, Avon, England; Cardiff Univ, Dept City & Reg Planning, Cardiff CF10 3WA, S Glam, Wales; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Leeds; University of Bristol; Cardiff University; University of Bristol	Dorling, D (corresponding author), Univ Leeds, Sch Geog, Leeds LS2 9JT, W Yorkshire, England.		Mitchell, Rich JL/E-8056-2011; Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				AVES E, 1916, ECON J, V26, P537; Bales K, 1999, SOCIOLOGY, V33, P153, DOI 10.1017/S0038038599000085; Bales K, 1996, J HIST SOCIOL, V9, P113, DOI 10.1111/j.1467-6443.1996.tb00180.x; BOOTH C, 1902, NOTES SOCIAL INFLUEN; BOOTH C, 1989, LIFE LABOUR PEOPLE; BOOTH C, 1969, LIFE LABOUR PEOPLE; Booth C., 1887, J ROY STAT SOC, V50, P326, DOI DOI 10.2307/2340191; CULLEN M, 1979, SEARCH WEALTH STABIL, P115; Davies Wayne KD, 1978, AREA, V10, P290; Dickens C., 1843, CHRISTMAS CAROL; Elman Richard E., 1969, C BOOTHS LONDON PORT; Gillie A, 1996, ECON HIST REV, V49, P715; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; Leon DA, 2000, BRIT MED J, V320, P1705, DOI 10.1136/bmj.320.7251.1705; ODay Rosemary, 1993, C BOOTHS INQUIRY LIF; PAMUK ER, 1985, POP STUD-J DEMOG, V39, P17, DOI 10.1080/0032472031000141256; PFAUTZ HW, 1967, CITY PHYSICAL PATTER; REEDER DA, 1984, LONDON TOPOGRAPHICAL, V130; SHAW M, 1999, WIDENING GAP HLTH IN; Simey Thomas Spensley, 1960, C BOOTH SOCIAL SCI; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P153; SPICKER P, 1990, SOC POLICY ADMIN, V24, P21, DOI 10.1111/j.1467-9515.1990.tb00322.x; Stevenson THC, 1928, J R STAT SOC, V91, P207, DOI 10.2307/2341530; Szreter S., 1986, WORLD WE HAVE GAINED, P337; SZRETER SRS, 1984, BRIT J SOCIOL, V35, P522, DOI 10.2307/590433; TOWNSEND P, 1987, SURVEY LONDONERS LIV, V1; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC	29	70	70	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1547	1551		10.1136/bmj.321.7276.1547	http://dx.doi.org/10.1136/bmj.321.7276.1547			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	387RA	11124169	Green Published, Bronze			2022-12-28	WOS:000166134500006
J	Kraemer, S				Kraemer, S			The fragile male	BRITISH MEDICAL JOURNAL			English	Article							GENDER DIFFERENCES; SEX; ALEXITHYMIA; BEHAVIOR; MEN		Tavistock & Portman NHS Trust, Child & Family Dept, London NW3 5BA, England		Kraemer, S (corresponding author), Tavistock & Portman NHS Trust, Child & Family Dept, London NW3 5BA, England.							ADAM K, 1995, ATTACHMENT THEORY SO, P327; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; BERRY JW, 1966, INT J PSYCHOL, V1, P207, DOI 10.1080/00207596608247156; Christensen K, 2000, BLOOD, V95, P2449, DOI 10.1182/blood.V95.7.2449.007k06_2449_2451; CICCHETTI D, 1994, DEV PSYCHOPATHOL, V6, P533, DOI 10.1017/S0954579400004673; Dabbs JM, 1998, EVOL HUM BEHAV, V19, P89, DOI 10.1016/S1090-5138(97)00107-4; Darwin C., 1871, P475; *DEP ED EMPL, 1999, STAT B DEP ED EMPL, V35; EARLS F, 1987, PSYCHIATRIC DEV, V1, P1; FABES RA, 1994, CHILD DEV, V65, P1678, DOI 10.2307/1131287; FEINGOLD A, 1988, AM PSYCHOL, V43, P95, DOI 10.1037/0003-066X.43.2.95; Fergusson DM, 1997, NEW ZEAL J EDUC STUD, V32, P83; Fischbein S., 1997, SCAND J EDUC RES, V41, P73, DOI 10.1080/0031383970410105; FIVUSH R, 1989, SEX ROLES, V20, P675, DOI 10.1007/BF00288079; Freeman RD, 2000, DEV MED CHILD NEUROL, V42, P436, DOI 10.1017/S0012162200000839; GUALTIERI T, 1985, BEHAV BRAIN SCI, V8, P427, DOI 10.1017/S0140525X00001023; Hansen D, 1999, BRIT MED J, V319, P548, DOI 10.1136/bmj.319.7209.548; HOPKINS WD, 1993, DEV PSYCHOBIOL, V26, P219, DOI 10.1002/dev.420260405; Kelleher MJ, 1998, BRIT J PSYCHIAT, V173, P196, DOI 10.1192/bjp.173.3.196; KINDLON D, 1999, RAISING CAIN PROTECT, V11; KONG MA, 1986, SOC SCI MED, V22, P15; KRAEMER S, 1991, FAM PROCESS, V30, P377, DOI 10.1111/j.1545-5300.1991.00377.x; Krugman S, 1995, NEW PSYCHOL MEN, P91; LABARTHE JC, 1977, ARCH DIS CHILD, V77, P140; Lavoie ME, 1998, PSYCHOPHYSIOLOGY, V35, P679; MALATESTA CZ, 1982, CHILD DEV, V53, P991, DOI 10.2307/1129139; MASTERS MS, 1993, BEHAV GENET, V23, P337, DOI 10.1007/BF01067434; McClure GMG, 2000, BRIT J PSYCHIAT, V176, P64, DOI 10.1192/bjp.176.1.64; MCCORMICK A, 1995, SER MB5, V3; Meltzer H., 2000, MENTAL HLTH CHILDREN; Mizuno R, 2000, LANCET, V356, P738, DOI 10.1016/S0140-6736(00)02637-4; MURRAY L, 1993, J CHILD PSYCHOL PSYC, V34, P1083, DOI 10.1111/j.1469-7610.1993.tb01775.x; *OFF NAT STAT, 1998, SER DH3, V29; OUNSTED C, 1972, GENDER DIFFERENCES T; Parker JDA, 1999, PSYCHOSOM MED, V61, P464, DOI 10.1097/00006842-199907000-00010; ROGERS LJ, 1999, SEXING BRAIN; Rout U, 1999, PSYCHOL HEALTH MED, V4, P345, DOI DOI 10.1080/135485099106081; RUTTER M, 1975, J CHILD PSYCHOL PSYC, V16, P181, DOI 10.1111/j.1469-7610.1975.tb01269.x; Rutter M, 1999, J CHILD PSYCHOL PSYC, V40, P19, DOI 10.1111/1469-7610.00423; Rutter M., 1998, ANTISOCIAL BEHAV YOU; SACKETT GP, 1972, DEV PSYCHOL, V6, P260, DOI 10.1037/h0032081; Scourfield J, 1999, BRIT J PSYCHIAT, V175, P559, DOI 10.1192/bjp.175.6.559; SHETTLES LB, 1961, OBSTET GYNECOL, V18, P122; Sinclair D, 1998, BRIT J PSYCHIAT, V172, P58, DOI 10.1192/bjp.172.1.58; SINGER JE, 1968, CHILD DEV, V39, P103, DOI 10.2307/1127362; Skuse DH, 1997, NATURE, V387, P705, DOI 10.1038/42706; TAYLOR DC, 1985, BEHAV BRAIN SCI, V8, P459, DOI 10.1017/S0140525X00001254; TAYLOR DC, 1985, HUMAN SEXUAL DIMORPH, P169; Taylor E., 1994, CHILD ADOLESCENT PSY, P285; Trevarthen C., 1999, IMITATION INFANCY PP, P127; TRONICK EZ, 1989, CHILD DEV, V60, P85, DOI 10.2307/1131074; TRONICK EZ, 1997, POSTPARTUM DEPRESSIO, P61; Tudiver F, 1999, J FAM PRACTICE, V48, P47; VERBRUGGE LM, 1985, J HEALTH SOC BEHAV, V26, P156, DOI 10.2307/2136750; Zaslow Martha J., 1986, ADV DEV PSYCHOL, P285; 2000, GUARDIAN        0101, P2	56	284	286	1	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1609	1612		10.1136/bmj.321.7276.1609	http://dx.doi.org/10.1136/bmj.321.7276.1609			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	387RA	11124200	Green Published			2022-12-28	WOS:000166134500036
J	Tournay, AE				Tournay, AE			Hostage	BRITISH MEDICAL JOURNAL			English	Article									Univ Calif Los Angeles, Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA	Children's Hospital Los Angeles; University of California System; University of California Los Angeles	Tournay, AE (corresponding author), Univ Calif Los Angeles, Childrens Hosp, Div Pediat Neurol, 22-474 MDCC Box 951752, Los Angeles, CA 90095 USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1603	1604		10.1136/bmj.321.7276.1603	http://dx.doi.org/10.1136/bmj.321.7276.1603			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124196	Green Published			2022-12-28	WOS:000166134500032
J	Maslin, MA; Burns, SJ				Maslin, MA; Burns, SJ			Reconstruction of the Amazon Basin effective moisture availability over the past 14,000 years	SCIENCE			English	Article							TROPICAL SOUTH-AMERICA; LAST GLACIAL MAXIMUM; NORTHEASTERN BRAZIL; ISOTOPE RECORDS; CLIMATE-CHANGE; ICE; HOLOCENE; FOREST; MODEL; TIME	Quantifying the moisture history of the Amazon Basin is essential for understanding the cause of rain forest diversity and its potential as a methane source. We reconstructed the Amazon River outflow history for the past 14,000 years to provide a moisture budget for the river drainage basin. The oxygen isotopic composition of planktonic foraminifera recovered from a marine sediment core in a region of Amazon River discharge shows that the Amazon Basin was extremely dry during the Younger Dryas, with the discharge reduced by at least 40% as compared with that of today. After the Younger Dryas, a meltwater-driven discharge event was followed by a steady increase in the Amazon Basin effective moisture throughout the Holocene.	UCL, Dept Geog, Environm Change Res Ctr, London WC1H 0AP, England; Univ Bern, Inst Geol, Stable Isotope Lab, CH-3012 Bern, Switzerland	University of London; University College London; University of Bern	Maslin, MA (corresponding author), UCL, Dept Geog, Environm Change Res Ctr, 26 Bedford Way, London WC1H 0AP, England.	mmaslin@geog.ucl.ac.uk	Burns, Stephen/H-9419-2013	Maslin, Mark/0000-0001-9957-3463				Arz HW, 1998, QUATERNARY RES, V50, P157, DOI 10.1006/qres.1998.1992; Arz HW, 1999, EARTH PLANET SC LETT, V167, P105, DOI 10.1016/S0012-821X(99)00025-4; BAKER P, 1999, OS S, V80, pF87; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; CLAPPERTON CM, 1998, QUAT P, V6, P65; Colinvaux PA, 1998, GLOBAL ECOL BIOGEOGR, V7, P95, DOI 10.2307/2997812; Colinvaux PA, 2000, QUATERNARY SCI REV, V19, P141, DOI 10.1016/S0277-3791(99)00059-1; Durham E., 1997, THESIS U COLL LONDON; Flood R.D., 1995, P OCEAN DRILLING PRO, V155; Grootes P. M., 1993, GEOPH MONOG SERIES, V78, P37; Haberle SG, 1999, QUATERNARY RES, V51, P27, DOI 10.1006/qres.1998.2020; HAFFER J, 1969, SCIENCE, V165, P131, DOI 10.1126/science.165.3889.131; Harris SE, 1999, QUATERNARY RES, V51, P14, DOI 10.1006/qres.1998.2008; Hooghiemstra H, 1998, EARTH-SCI REV, V44, P147, DOI 10.1016/S0012-8252(98)00027-0; Hostetler SW, 1999, NATURE, V399, P673, DOI 10.1038/21401; *INT AT EN AG, 1992, TECH REP SER INT AT, V331; Levitus S., 1994, WORLD OCEAN ATLAS 19, V3; Lorenz S, 1996, GEOL RUNDSCH, V85, P513, DOI 10.1007/s005310050092; Maslin M, 1998, GEOL SOC SPEC PUBL, V131, P111, DOI 10.1144/GSL.SP.1998.131.01.09; Mitsch W. J., 1993, WETLANDS; Mix AC, 1999, PALEOCEANOGRAPHY, V14, P350, DOI 10.1029/1999PA900012; Riehl H., 1979, CLIMATE WEATHER TROP; Schneider R.R., 1997, Proceedings of the Ocean Drilling Program Scientific Results, V155, P319; Seltzer G, 2000, GEOLOGY, V28, P35; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; Sylvestre F, 1999, QUATERNARY RES, V51, P54, DOI 10.1006/qres.1998.2017; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; Thompson LG, 2000, J QUATERNARY SCI, V15, P377, DOI 10.1002/1099-1417(200005)15:4<377::AID-JQS542>3.0.CO;2-L	30	141	145	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2285	+						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125137				2022-12-28	WOS:000165995800037
J	Ball, BG; Anderson, WF				Ball, BG; Anderson, WF			Bringing gene therapy to the clinic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ So Calif, Keck Sch Med, Gene Therapy Labs, Los Angeles, CA 90089 USA	University of Southern California	Ball, BG (corresponding author), Univ So Calif, Keck Sch Med, Gene Therapy Labs, Los Angeles, CA 90089 USA.							Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; TEMIN HM, 1990, HUM GENE THER, V1, P111, DOI 10.1089/hum.1990.1.2-111; 2000, HUMAN GENE THER, V11, P1745	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2788	2788		10.1001/jama.284.21.2788	http://dx.doi.org/10.1001/jama.284.21.2788			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105191	hybrid			2022-12-28	WOS:000165509500038
J	Wassell, JT; Gardner, LI; Landsittel, DP; Johnston, JJ; Johnston, JM				Wassell, JT; Gardner, LI; Landsittel, DP; Johnston, JJ; Johnston, JM			A prospective study of back belts for prevention of back pain and injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Despite scientific uncertainties about effectiveness, wearing back belts in the hopes of preventing costly and disabling low back injury in employees is becoming common in the workplace. Objective To evaluate the effectiveness of using back belts in reducing back injury claims and low back pain. Design and Setting Prospective cohort study. from April 1996 through April 1998, we identified material-handing employees in 160 new retail merchandise stores (89 required back belt use; 71 had voluntary back belt use) in 30 states (from New Hampshire to Michigan in the north and from Florida to Texas in the south); data collection ended December 1998, median follow-up was 6 1/2 months. Participants A referred sample of 13 873 material handling employees provided 9377 baseline interviews and 6311 (67%) follow-up interviews; 206 (1.4%) refused baseline interview. Main Outcome Measurer Incidence rate of material-handling back injury workers' compensation claims and 6-month incidence rate of self-reported low back pain. Results Neither frequent back belt use nor a belt-requirement store policy was significantly associated with back injury claim rates or self-reported back pain. Rate ratios comparing back injury claims of those who reported wearing back belts usually every day and once or twice a week vs those who reported wearing belts never or once or twice a month were 1.22 (95% confidence interval [CI], 0.87-1.70) and 0.95 (95% CI, 0.56-1.59), respectively. The respective odds ratios for low back pain incidence were 0.97 (95% CI, 0.83-1.13) and 0.92 (95% CI, 0.73-1.16). Conclusions In the largest prospective cohort study of back belt use, adjusted for multiple individual risk factors, neither frequent back belt use nor a store policy that required belt use was associated with reduced incidence of back injury claims or low back pain.	NIOSH, Ctr Dis Control & Prevent, Div Safety Res, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Wassell, JT (corresponding author), NIOSH, Ctr Dis Control & Prevent, Div Safety Res, 1095 Willowdale Rd, Morgantown, WV 26505 USA.			Johnston, Janet/0000-0001-8738-9677				BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14; *CYTEL SOFTW CORP, 1999, STATX 4 WIND STAT SO; GARDNER LI, 1997, INT J OCCUP ENV HEAL, V3, P236; KALLENBERG AL, 1986, AM WORK NATL SURVEYS; Kraus, 1996, Int J Occup Environ Health, V2, P264; LABAR G, 1996, OCCUP HAZARDS, V58, P33; Murphy PL, 1999, SPINE, V24, P691, DOI 10.1097/00007632-199904010-00015; Pan C S, 1999, Int J Occup Environ Health, V5, P79; REDDELL CR, 1992, APPL ERGON, V23, P319, DOI 10.1016/0003-6870(92)90293-5; *SAS I INC, 1998, STAT AN SYST VERS 7; *US BUR LAB STAT, 1998, NUMB NONF OCC INJ IL; van Poppel MNM, 1998, JAMA-J AM MED ASSOC, V279, P1789, DOI 10.1001/jama.279.22.1789; WALSH NE, 1990, AM J PHYS MED REHAB, V69, P245, DOI 10.1097/00002060-199010000-00004	13	49	50	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2727	2732		10.1001/jama.284.21.2727	http://dx.doi.org/10.1001/jama.284.21.2727			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105177				2022-12-28	WOS:000165509500026
J	Graziano, MSA; Cooke, DF; Taylor, CSR				Graziano, MSA; Cooke, DF; Taylor, CSR			Coding the location of the arm by sight	SCIENCE			English	Article							PARIETAL CORTEX; MOVEMENT; MONKEY; AREA-5; SHAPE; REPRESENTATIONS; PROPRIOCEPTION; PERCEPTION; NEURONS; VISION	Area 5 in the parietal Lobe of the primate brain is thought to be involved in monitoring the posture and movement of the body. In this study, neurons in monkey area 5 were found to encode the position of the monkey's arm while it was covered from view. The same neurons also responded to the position of a visible, realistic false arm. The neurons were not sensitive to the sight of unrealistic substitutes for the arm and were able to distinguish a right from a Left arm. These neurons appear to combine visual and somatosensory signals in order to monitor the configuration of the limbs. They could form the basis of the complex body schema that we constantly use to adjust posture and guide movement.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	Princeton University	Graziano, MSA (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.		Cooke, Dylan F./O-9954-2019	Cooke, Dylan F./0000-0002-5976-705X	PHS HHS [11347] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Balint R, 1909, MON PSYCHIATR NEUROL, V25, P51; BONDA E, 1995, P NATL ACAD SCI USA, V92, P11180, DOI 10.1073/pnas.92.24.11180; Botvinick M, 1998, NATURE, V391, P756, DOI 10.1038/35784; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P517, DOI 10.1016/0028-3932(91)90008-V; CRASKE B, 1984, J EXP PSYCHOL HUMAN, V10, P307, DOI 10.1037/0096-1523.10.2.307; Darian-Smith, 1984, HDB PHYSL 2 1, V3, P789; DUFFY FH, 1971, SCIENCE, V172, P273, DOI 10.1126/science.172.3980.273; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GEORGOPOULOS AP, 1985, BEHAV BRAIN RES, V18, P159, DOI 10.1016/0166-4328(85)90071-3; Ghez Claude, 1995, P549; GOODALE MA, 1994, CURR BIOL, V4, P604, DOI 10.1016/S0960-9822(00)00132-9; Graziano MSA, 1999, P NATL ACAD SCI USA, V96, P10418, DOI 10.1073/pnas.96.18.10418; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; HAY JC, 1965, PSYCHON SCI, V2, P215, DOI 10.3758/BF03343413; Iriki A, 1996, NEUROREPORT, V7, P2325; KALASKA JF, 1990, EXP BRAIN RES, V80, P351; Kolb B., 2015, FUNDAMENTALS HUMAN N; LACKNER JR, 1988, BRAIN, V111, P281, DOI 10.1093/brain/111.2.281; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; Moore T, 1999, SCIENCE, V285, P1914, DOI 10.1126/science.285.5435.1914; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; Murata A, 2000, J NEUROPHYSIOL, V83, P2580, DOI 10.1152/jn.2000.83.5.2580; PRABLANC C, 1979, BIOL CYBERN, V35, P183, DOI 10.1007/BF00337063; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; ROSSETTI Y, 1995, J NEUROPHYSIOL, V74, P457, DOI 10.1152/jn.1995.74.1.457; SAKATA H, 1973, BRAIN RES, V64, P85, DOI 10.1016/0006-8993(73)90172-8; SEKIYAMA K, 1982, PERCEPT PSYCHOPHYS, V32, P89, DOI 10.3758/BF03204268; Sereno AB, 1998, NATURE, V395, P500, DOI 10.1038/26752; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549	30	400	402	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1782	1786		10.1126/science.290.5497.1782	http://dx.doi.org/10.1126/science.290.5497.1782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099420				2022-12-28	WOS:000165632400048
J	Singer, PA; Martin, DK; Giacomini, M; Purdy, L				Singer, PA; Martin, DK; Giacomini, M; Purdy, L			Priority setting for new technologies in medicine: qualitative case study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; FAIR PROCEDURES; MANAGED CARE	Objective To describe priority setting for new technologies in medicine. Design Qualitative study using case studies and grounded theory. Setting Two committees advising on priorities for new technologies in cancer and cardiac care in Ontario, Canada. Participants The two committees and their 26 members. Main outcome measures Accounts of priority setting decision making gathered by reviewing documents, interviewing members, and observing meetings. Results Six interrelated domains were identified for priority setting for new technologies in medicine: the institution sin which the decision are made, the people who make the decisions, the factors they consider, the reasons for the decisions, the process of decision making,and the appeals mechanism for challenging the decisions. Conclusion These domains constitute a model of priority etting for new technologies in medicine. The next step will be to harmonise this description of how priority setting decisions are made with ethical accounts of how they should be made.	Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada; McMaster Univ, Hamilton, ON L8N 3Z5, Canada	University of Toronto; McMaster University	Singer, PA (corresponding author), Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada.	peter.singer@utoronto.ca	Giacomini, Mauro/D-3194-2013	Giacomini, Mauro/0000-0001-5646-2034				*CARD CAR NETW ONT, 1998, FIN REP REC; Daniels N, 1998, HASTINGS CENT REP, V28, P27, DOI 10.2307/3527569; Daniels N, 1997, PHILOS PUBLIC AFF, V26, P303, DOI 10.1111/j.1088-4963.1997.tb00082.x; Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Foy R, 1999, BRIT MED J, V318, P456, DOI 10.1136/bmj.318.7181.456; Green J, 1999, BRIT MED J, V319, P421; Ham C, 1999, BMJ-BRIT MED J, V319, P1258, DOI 10.1136/bmj.319.7219.1258; Ham C, 1997, HEALTH POLICY, V42, P49, DOI 10.1016/S0168-8510(97)00054-7; Holm S, 1998, BRIT MED J, V317, P1000, DOI 10.1136/bmj.317.7164.1000; Hope T, 1998, BRIT MED J, V317, P1067; Klein R, 1998, BMJ-BRIT MED J, V317, P959, DOI 10.1136/bmj.317.7164.959; Klein RDP, 1996, MANAGING SCARCITY PR; MARTIN DK, IN PRESS PRIORITIES; NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3; Singer P A, 1997, ACP J Club, V127, pA16; Strauss A., 1990, BASICS QUALITATIVE R; YIN RK, 1994, STUDY RES DESIGN MET, P13	17	94	95	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 25	2000	321	7272					1316	1319		10.1136/bmj.321.7272.1316	http://dx.doi.org/10.1136/bmj.321.7272.1316			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	378BK	11090513	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000165561600024
J	Coronado, E; Galan-Mascaros, JR; Gomez-Garcia, CJ; Laukhin, V				Coronado, E; Galan-Mascaros, JR; Gomez-Garcia, CJ; Laukhin, V			Coexistence of ferromagnetism and metallic conductivity in a molecule-based layered compound	NATURE			English	Article							DONOR MOLECULE; MAGNETS; FE	Crystal engineering-the planning and construction of crystalline supramolecular architectures from modular building blocks-permits the rational design of functional molecular materials that exhibit technologically useful behaviour such as conductivity and superconductivity(1), ferromagnetism(2) and nonlinear optical properties(3). Because the presence of two cooperative properties in the same crystal lattice might result in new physical phenomena and novel applications, a particularly attractive goal is the design of molecular materials with two properties that are difficult or impossible to combine in a conventional inorganic solid with a continuous lattice. A promising strategy for creating this type of 'bi-functionality' targets hybrid organic/inorganic crystals comprising two functional sub-lattices exhibiting distinct properties. In this way, the organic pi -electron donor bis(ethylenedithio)tetrathiafulvalene (BEDT-TTF) and its derivatives, which form the basis of most known molecular conductors and superconductors(1), have been combined with molecular magnetic anions, yielding predominantly materials with conventional semiconducting or conducting properties(4,5), but also systems that are both superconducting and paramagnetic(6,7). But interesting bulk magnetic properties fail to develop, owing to the discrete nature of the inorganic anions. Another strategy for achieving cooperative magnetism involves insertion of functional bulky cations into a polymeric magnetic anion, such as the bimetallic oxalato complex [(MnCrIII)-Cr-II (C2O4)(3)](-), but only insoluble powders have been obtained in most cases(8-12). Here we report the synthesis of single crystals formed by infinite sheets of this magnetic coordination polymer interleaved with layers of conducting BEDT-TTF cations, and show that this molecule-based compound displays ferromagnetism and metallic conductivity.	Univ Valencia, Inst Ciencia Mol, E-46100 Burjassot, Spain	University of Valencia	Coronado, E (corresponding author), Univ Valencia, Inst Ciencia Mol, Dr Moliner 50, E-46100 Burjassot, Spain.		Galan-Mascaros, Jose Ramon/O-7196-2014; Gomez-Garcia, Carlos Jose/A-5626-2009; Coronado, Eugenio/E-8960-2014	Galan-Mascaros, Jose Ramon/0000-0001-7983-9762; Gomez-Garcia, Carlos Jose/0000-0002-0015-577X; Coronado Miralles, Eugenio/0000-0002-1848-8791; Cador, Olivier/0000-0003-2064-6223				Antorrena G, 1999, J MAGN MAGN MATER, V196, P581, DOI 10.1016/S0304-8853(98)00840-3; BENO MA, 1990, INORG CHEM, V29, P1599, DOI 10.1021/ic00334a003; Coronado E, 1999, MOL CRYST LIQ CRYS A, V334, P679, DOI 10.1080/10587259908023361; Coronado E, 2000, CHEM-EUR J, V6, P552, DOI 10.1002/(SICI)1521-3765(20000204)6:3<552::AID-CHEM552>3.0.CO;2-U; Coronado E, 1997, ADV MATER, V9, P984, DOI 10.1002/adma.19970091213; DAY P, 1992, J AM CHEM SOC, V114, P10722, DOI 10.1021/ja00053a007; Decurtins S, 1996, NATO ADV SCI I C-MAT, V484, P487; Kobayashi H, 1996, J AM CHEM SOC, V118, P368, DOI 10.1021/ja9523350; KURMOO M, 1995, J AM CHEM SOC, V117, P12209, DOI 10.1021/ja00154a022; Mathoniere C, 1996, INORG CHEM, V35, P1201, DOI 10.1021/ic950703v; MILLER JS, 1994, ANGEW CHEM INT EDIT, V33, P385, DOI 10.1002/anie.199403851; Nuttall CJ, 1999, J SOLID STATE CHEM, V147, P3, DOI 10.1006/jssc.1999.8078; TAMAKI H, 1992, J AM CHEM SOC, V114, P6974, DOI 10.1021/ja00044a004; WILLIAMS JM, 1991, SCIENCE, V252, P1501, DOI 10.1126/science.252.5012.1501; Zyss J., 1994, MOL NONLINEAR OPTICS	15	1252	1266	176	1159	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					447	449		10.1038/35044035	http://dx.doi.org/10.1038/35044035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100721				2022-12-28	WOS:000165429800041
J	Zhou, BBS; Elledge, SJ				Zhou, BBS; Elledge, SJ			The DNA damage response: putting checkpoints in perspective	NATURE			English	Review							CELL-CYCLE CHECKPOINT; ATM-DEPENDENT PHOSPHORYLATION; NIJMEGEN BREAKAGE SYNDROME; S-PHASE CHECKPOINT; FACTOR C COMPLEX; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; MEC1-DEPENDENT PHOSPHORYLATION; SCHIZOSACCHAROMYCES-POMBE; IONIZING-RADIATION	The inability to repair DNA damage properly in mammals leads to various disorders and enhanced rates of tumour development. Organisms respond to chromosomal insults by activating a complex damage response pathway. This pathway regulates known responses such as cell-cycle arrest and apoptosis (programmed cell death), and has recently been shown to control additional processes including direct activation of DNA repair networks.	Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Dept Biochem & Mol Biol, Houston, TX 77030 USA; SmithKline Beecham Pharmaceut, Dept Oncol Res, King Of Prussia, PA 19406 USA	Baylor College of Medicine; Howard Hughes Medical Institute; GlaxoSmithKline	Elledge, SJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	selledge@bcm.tmc.edu						Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2000, GENE DEV, V14, P397; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GEORGE J, 1975, MOL GEN GENET, V140, P309, DOI 10.1007/BF00267322; Gong JG, 1999, NATURE, V399, P806; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Noskov VN, 1998, MOL CELL BIOL, V18, P4914, DOI 10.1128/MCB.18.8.4914; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Paciotti V, 2000, GENE DEV, V14, P2046; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shieh SY, 2000, GENE DEV, V14, P289; Shimada M, 1999, MOL BIOL CELL, V10, P3991, DOI 10.1091/mbc.10.12.3991; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Takai H, 2000, GENE DEV, V14, P1439; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TIBBETTS RS, IN PRESS GENES DEV; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang Y, 2000, GENE DEV, V14, P927; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Weiss RS, 2000, GENE DEV, V14, P1886; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	96	2548	2656	6	434	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	2000	408	6811					433	439		10.1038/35044005	http://dx.doi.org/10.1038/35044005			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100718				2022-12-28	WOS:000165429800038
J	Schulman, BA; Carrano, AC; Jeffrey, PD; Bowen, Z; Kinnucan, ERE; Finnin, MS; Elledge, SJ; Harper, JW; Pagano, M; Pavietich, NP				Schulman, BA; Carrano, AC; Jeffrey, PD; Bowen, Z; Kinnucan, ERE; Finnin, MS; Elledge, SJ; Harper, JW; Pagano, M; Pavietich, NP			Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex	NATURE			English	Article							LEUCINE-RICH REPEATS; F-BOX; CELL-CYCLE; PROTEOLYSIS MACHINERY; MEDIATED DEGRADATION; CRYSTAL-STRUCTURE; S-PHASE; PROTEIN; INHIBITOR; P45(SKP2)	F-box proteins are members of a large family that regulates the cell cycle, the immune response, signalling cascades and developmental programmes by targeting proteins, such as cyclins, cyclin-dependent kinase inhibitors, I kappaB alpha and beta -catenin, for ubiquitination (reviewed in refs 1-3). F-box proteins are the substrate-recognition components of SCF (Skp1-Cullin-F-box protein) ubiquitin-protein ligases(4,5). They bind the SCF constant catalytic core by means of the F-box motif interacting with Skp1, and they bind substrates through their variable protein-protein interaction domains(6). The large number of F-box proteins is thought to allow ubiquitination of numerous, diverse substrates(6). Most organisms have several Skp1 family members, but the function of these Skp1 homologues and the rules of recognition between different F-box and Skp1 proteins remain unknown. Here we describe the crystal structure of the human F-box protein Skp2 bound to Skp1. Skp1 recruits the F-box protein through a bipartite interface involving both the F-box and the substrate-recognition domain. The structure raises the possibility that different Skp1 family members evolved to function with different subsets of F-box proteins, and suggests that the F-box protein may not only recruit substrate, but may also position it optimally for the ubiquitination reaction.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; New York University; New York University; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Pavietich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	Nikola@xray2.mskcc.org		pagano, michele/0000-0003-3210-2442; Jeffrey, Philip/0000-0002-4351-5341; Finnin, Michael/0000-0003-2794-2703; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG011085] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Russell ID, 1999, J CELL BIOL, V145, P933, DOI 10.1083/jcb.145.5.933; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	30	452	484	4	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	2000	408	6810					381	386		10.1038/35042620	http://dx.doi.org/10.1038/35042620			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099048				2022-12-28	WOS:000165296000051
J	Amin, S; Zhang, YQ; Sawin, DT; Evans, SR; Hannan, MT; Kiel, DP; Wilson, PWF; Felson, DT				Amin, S; Zhang, YQ; Sawin, DT; Evans, SR; Hannan, MT; Kiel, DP; Wilson, PWF; Felson, DT			Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the framingham study	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; SEX STEROID-LEVELS; AROMATASE DEFICIENCY; RISK-FACTORS; OSTEOPOROTIC FRACTURES; PHYSICAL-ACTIVITY; ESTROGEN THERAPY; TESTICULAR AXIS; HIP-FRACTURES; HEALTHY-MEN	Background: Both hypogonadism and low estrogen levels adversely affect bone health in young men. In elderly men, who are at greatest risk for osteoporotic fracture, the influence of hypogonadism on bone mineral density remains unclear, as does the relative effect of estrogen status compared to hypogonadism. Objective: To examine the relation of hypogonadism and estrogen status to bone mineral density in elderly men. Design: Community-based, prospective cohort study. Setting: Framingham, Massachusetts. Patients: Male participants of the Framingham Study. Measurements: Total testosterone, total estradiol, and luteinizing hormone were measured in participants at all four biennial examinations from 1981 to 1989. Values from at least three of four examinations were averaged. Hypogonadism was defined as a mean testosterone level less than 10.4 nmol/L (<3.0 ng/mL) or a mean luteinizing hormone level of 20 IU/L or greater. An alternate definition of hypogonadism based only on a mean testosterone level less than 10.4 nmol/L (<3.0 ng/mL) was also used. In 1988-1989, bone mineral density was measured at the proximal femur (femoral neck, Ward triangle, and trochanter) and lumbar spine by using dual-photon absorptiometry and at the radial shaft by using single-photon absorptiometry. The association of hypogonadism with bone mineral density was examined with adjustment for confounders, including estradiol levels. A similar model that adjusted for hypogonadism was used to examine the association of estradiol level (ranked as quartiles) with bone mineral density. Results: of 448 men with bone mineral density measurements, 405 had evaluable hormone levels (mean age, 75.7 years [range, 68 to 96 years]); 71 (17.5%) of the 405 men were hypogonadal. Bone mineral density at any site did not significantly differ in hypogonadal men compared with eugonadal men (for example, bone mineral density at the femoral neck was 0.89 g/cm(2) vs. 0.87 g/cm(2), respectively; P > 0.2), even when alternate definitions of hypogonadism were used. In contrast, compared with the lowest estradiol quartile, men with higher estradiol levels had greater mean bone mineral density at all sites (for example, bone mineral density at the femoral neck was 0.84 g/cm(2), 0.88 g/cm(2), 0.86 g/cm(2), and 0.91 g/cm(2) from the lowest to the highest estradiol quartile; P for trend = 0.002). The difference in mean bone mineral density between men in the lowest and those in the highest estradiol quartile levels was similar to the effect of 10 years of aging on bone mineral density. Conclusions: In elderly men, hypogonadism related to aging has little influence on bone mineral density, but serum estradiol levels have a strong and positive association with bone mineral density.	Boston Univ, Sch Med, Multipurpose Arthrit & Musculoskeletal Dis Ctr, Boston, MA 02118 USA; Hebrew Rehabil Ctr Aged, Res & Training Inst, Boston, MA 02131 USA; Harvard Univ, Sch Med, Div Aging, Boston, MA 02115 USA; Vet Adm Headquarters, Washington, DC USA; NHLBI, Framingham Heart Study, Framingham, MA USA	Boston University; Harvard University; Harvard Medical School; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Amin, S (corresponding author), Mayo Clin, Div Rheumatol, 200 1st St SW, Rochester, MN 55905 USA.		Wilson, Peter W.F./J-2455-2016	Zhang, Yuqing/0000-0001-7954-1149; Felson, David/0000-0002-2668-2447; Kiel, Douglas/0000-0001-8474-0310	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIAMS NIH HHS [AR/AG41398, AR20613] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041398, P60AR020613] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson FH, 1997, J BONE MINER RES, V12, P472, DOI 10.1359/jbmr.1997.12.3.472; BAILLIE SP, 1992, AGE AGEING, V21, P139, DOI 10.1093/ageing/21.2.139; Bilezikian JP, 1998, NEW ENGL J MED, V339, P599, DOI 10.1056/NEJM199808273390905; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140-6736(98)09075-8; Center JR, 1999, J CLIN ENDOCR METAB, V84, P3626, DOI 10.1210/jc.84.10.3626; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Diamond TH, 1997, MED J AUSTRALIA, V167, P412, DOI 10.5694/j.1326-5377.1997.tb126646.x; DRINKA PJ, 1993, CALCIFIED TISSUE INT, V52, P67, DOI 10.1007/BF00675629; DRINKA PJ, 1993, SOUTHERN MED J, V86, P1264, DOI 10.1097/00007611-199311000-00017; Ettinger B, 1998, J CLIN ENDOCR METAB, V83, P2239, DOI 10.1210/jc.83.7.2239; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FELSON DT, 1995, AM J EPIDEMIOL, V142, P485, DOI 10.1093/oxfordjournals.aje.a117664; FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507; Ferrini RL, 1998, AM J EPIDEMIOL, V147, P750; FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003-4819-106-3; FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem-69-4-776; FORESTA C, 1984, HORM RES, V19, P18, DOI 10.1159/000179855; GRAY A, 1991, J CLIN ENDOCR METAB, V73, P1016, DOI 10.1210/jcem-73-5-1016; Greendale GA, 1997, J BONE MINER RES, V12, P1833, DOI 10.1359/jbmr.1997.12.11.1833; GRIFFIN JE, 1994, HARRISONS PRINCIPLES, V1, P2006; Hannan MT, 2000, J BONE MINER RES, V15, P710, DOI 10.1359/jbmr.2000.15.4.710; HANNAN MT, 1992, J BONE MINER RES, V7, P547; JACKSON JA, 1990, MEDICINE, V69, P137, DOI 10.1097/00005792-199005000-00002; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; Janssen JMMF, 1999, J CELL BIOCHEM, V75, P528; JONES G, 1994, BRIT MED J, V309, P691, DOI 10.1136/bmj.309.6956.691; KANNEL WB, 1985, AM HEART J, V109, P876, DOI 10.1016/0002-8703(85)90653-2; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266; MATSUMOTO AM, 1987, BAILLIERE CLIN ENDOC, V1, P71, DOI 10.1016/S0950-351X(87)80053-8; MEIER DE, 1987, J AM GERIATR SOC, V35, P189, DOI 10.1111/j.1532-5415.1987.tb02308.x; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; MURPHY S, 1993, BONE MINER, V20, P133, DOI 10.1016/S0169-6009(08)80022-0; MYERS AH, 1991, AM J EPIDEMIOL, V134, P1128, DOI 10.1093/oxfordjournals.aje.a116016; NEVITT MC, 1994, RHEUM DIS CLIN N AM, V20, P535; Orwoll ES, 1998, ENDOCRIN METAB CLIN, V27, P349, DOI 10.1016/S0889-8529(05)70009-8; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; Rapado A, 1999, CALCIFIED TISSUE INT, V65, P417, DOI 10.1007/s002239900726; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756-3282(95)00258-4; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; SCANE AC, 1993, CLIN ENDOCRINOL, V38, P15, DOI 10.1111/j.1365-2265.1993.tb00965.x; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; Shozu M, 1998, MOL CELL ENDOCRINOL, V139, P117, DOI 10.1016/S0303-7207(98)00069-0; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; SLEMENDA CW, 1992, ANN INTERN MED, V117, P286, DOI 10.7326/0003-4819-117-4-286; Slemenda CW, 1997, J CLIN INVEST, V100, P1755, DOI 10.1172/JCI119701; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P1966, DOI 10.1210/jc.84.6.1966; STANLEY HL, 1991, J AM GERIATR SOC, V39, P766, DOI 10.1111/j.1532-5415.1991.tb02698.x; STEPAN JJ, 1989, J CLIN ENDOCR METAB, V69, P523; Taaffe DR, 1999, AGING CLIN EXP RES, V11, P4, DOI 10.1007/BF03399630; TAXAL P, 1998, BONE, V23, pS178; TENOVER JL, 1995, PHARM BIOL CLILN APP, P310; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; TSITOURAS PD, 1982, J GERONTOL, V37, P288, DOI 10.1093/geronj/37.3.288; van Staa T, 1997, AM J MED, V103, P462, DOI 10.1016/S0002-9343(97)00242-8; VANDERSCHUEREN D, 1995, CALCIFIED TISSUE INT, V56, P341, DOI 10.1007/BF00301598; VERMEULEN A, 1995, HORM RES, V43, P25, DOI 10.1159/000184233; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	65	211	216	0	269	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					951	963		10.7326/0003-4819-133-12-200012190-00010	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119396				2022-12-28	WOS:000165952300003
J	[Anonymous]				[Anonymous]			Managing chronic disease - round 2	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		Davis RM, 1999, BRIT MED J, V318, P1090, DOI 10.1136/bmj.318.7191.1090	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2000	321	7275					1486	1486						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118164				2022-12-28	WOS:000165994700006
J	Zach, MP; Ng, KH; Penner, RM				Zach, MP; Ng, KH; Penner, RM			Molybdenum nanowires by electrodeposition	SCIENCE			English	Article							STEP DECORATION; FABRICATION; DEPOSITION; ARRAYS; PARTICLES; FILMS; GOLD	Metallic molybdenum (Mo-o) wires with diameters ranging from 15 nanometers to 1.0 micrometers and Lengths of up to 500 micrometers (0.5 millimeters) were prepared in a two-step procedure. Molybdenum oxide wires were electrodeposited selectively at step edges and then reduced in hydrogen gas at 500 degreesC to yield Mo-o. The hemicylindrical wires prepared by this technique were self-uniform, and the wires prepared in a particular electrodeposition tin batches of 10(5) to 10(7)) were narrowly distributed in diameter. Wires were obtained size selectively because the mean wire diameter was directly proportional to the square root of the electrolysis time. The metal nanowires could be embedded in a polystyrene film and lifted off the graphite electrode surface. The conductivity and mechanical resiliency of individual embedded wires were similar to those of bulk molybdenum.	Univ Calif Irvine, Dept Chem, Inst Surface & Interface Sci, Irvine, CA 92679 USA	University of California System; University of California Irvine	Penner, RM (corresponding author), Univ Calif Irvine, Dept Chem, Inst Surface & Interface Sci, Irvine, CA 92679 USA.		Zach, Michael/D-4160-2009; Penner, Reginald/AAR-1772-2021; Penner, Reginald M/D-1521-2009	Zach, Michael/0000-0002-4409-3419; Penner, Reginald M/0000-0003-2831-3028				Blanc M, 1998, SURF SCI, V414, pL964, DOI 10.1016/S0039-6028(98)00561-5; Davydov DN, 1998, PHYS REV B, V57, P13550, DOI 10.1103/PhysRevB.57.13550; Dekoster J, 1999, APPL PHYS LETT, V75, P938, DOI 10.1063/1.124560; ELMEGUID EAA, 1999, J ELECT CHEM, V467, P50; FOSS CA, 1992, J PHYS CHEM-US, V96, P9001, DOI 10.1021/j100201a057; Gambardella P, 2000, PHYS REV B, V61, P2254, DOI 10.1103/PhysRevB.61.2254; Himpsel FJ, 1999, MRS BULL, V24, P20, DOI 10.1557/S0883769400052854; LAMER VK, 1950, J AM CHEM SOC, V72, P4847, DOI 10.1021/ja01167a001; NICHOLS RJ, 1991, J ELECTROANAL CHEM, V313, P109, DOI 10.1016/0022-0728(91)85174-N; Petrovykh DY, 1998, SURF SCI, V407, P189, DOI 10.1016/S0039-6028(98)00175-7; PRESTON CK, 1993, J PHYS CHEM-US, V97, P8495, DOI 10.1021/j100134a019; REETZ MT, 1994, J AM CHEM SOC, V116, P7401, DOI 10.1021/ja00095a051; Routkevitch D, 1996, J PHYS CHEM-US, V100, P14037, DOI 10.1021/jp952910m; SUGIMOTO T, 1987, ADV COLLOID INTERFAC, V28, P65, DOI 10.1016/0001-8686(87)80009-X; Sun L, 2000, PHYS REV B, V61, pR6463, DOI 10.1103/PhysRevB.61.R6463; Sun L, 1999, APPL PHYS LETT, V74, P2803, DOI 10.1063/1.124019; WHITNEY TM, 1993, SCIENCE, V261, P1316, DOI 10.1126/science.261.5126.1316; Zach MP, 2000, ADV MATER, V12, P878, DOI 10.1002/1521-4095(200006)12:12<878::AID-ADMA878>3.0.CO;2-X	18	580	601	8	302	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2120	2123		10.1126/science.290.5499.2120	http://dx.doi.org/10.1126/science.290.5499.2120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118141				2022-12-28	WOS:000165870600049
J	Zeilinger, A				Zeilinger, A			The quantum centennial - One hundred years ago, a simple concept changed our world view forever.	NATURE			English	Editorial Material									Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria	University of Vienna	Zeilinger, A (corresponding author), Univ Vienna, Inst Expt Phys, Boltzmanngasse 5, A-1090 Vienna, Austria.		Zeilinger, Anton/A-1170-2011					Amelino-Camelia G, 2000, NATURE, V408, P661, DOI 10.1038/35047210; BEDERSON B, 1999, MORE THINDS HEAVEN E; Jammer M., 1974, PHILOS QUANTUM MECH; SCHILPP PA, 1949, A EINSTEIN PHILOS SC; Wheeler J. A., 1983, QUANTUM THEORY MEASU; [No title captured]	6	29	31	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					639	641		10.1038/35047177	http://dx.doi.org/10.1038/35047177			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130047				2022-12-28	WOS:000165815200017
J	Feagan, BG; Wong, CJ; Kirkley, A; Johnston, DWC; Smith, FC; Whitsitt, P; Wheeler, SL; Lau, CY; Johnston, W; Beaupre, L; Schaump, L; Bohonis, D; Greaves, K; Rorabeck, C; Bourne, R; Murkin, J; McCalden, R; MacDonald, S; McCabe, C; Smith, F; Dale, NI; Reynolds, L; Whitsitt, P; Rochon, N; Taylor, D; O'Farrell, TA; Boyce, D; Pisesky, W; O'Connor, G; LeNoble, E; Mantle, M; Bond, D; Turner, K; Bond, P; Swilzer, K; Laflamme, GH; Pynn, B; Dow, G; Steeves, J; Clark, A; Pavlatos-Jones, G; MacLoughlin, C; Laliberte, P; Grenier, A; Chabot, J; Lortie, M; Godin, C; Pynn, B; Waddell, J; Morton, J; Sandler, A; Kaszas, Z; Warriner, B; Werry, D; Metcalfe, C; Tile, M; Dubrovskis, V; Garnett, R; Krepski, B; Cicutti, N; Huk, O; Pynn, B; Wilson, J; Johnston, N; Mulock, R; Sarazin, B; Liddiard, E; Bergman, B; Johnson, W				Feagan, BG; Wong, CJ; Kirkley, A; Johnston, DWC; Smith, FC; Whitsitt, P; Wheeler, SL; Lau, CY; Johnston, W; Beaupre, L; Schaump, L; Bohonis, D; Greaves, K; Rorabeck, C; Bourne, R; Murkin, J; McCalden, R; MacDonald, S; McCabe, C; Smith, F; Dale, NI; Reynolds, L; Whitsitt, P; Rochon, N; Taylor, D; O'Farrell, TA; Boyce, D; Pisesky, W; O'Connor, G; LeNoble, E; Mantle, M; Bond, D; Turner, K; Bond, P; Swilzer, K; Laflamme, GH; Pynn, B; Dow, G; Steeves, J; Clark, A; Pavlatos-Jones, G; MacLoughlin, C; Laliberte, P; Grenier, A; Chabot, J; Lortie, M; Godin, C; Pynn, B; Waddell, J; Morton, J; Sandler, A; Kaszas, Z; Warriner, B; Werry, D; Metcalfe, C; Tile, M; Dubrovskis, V; Garnett, R; Krepski, B; Cicutti, N; Huk, O; Pynn, B; Wilson, J; Johnston, N; Mulock, R; Sarazin, B; Liddiard, E; Bergman, B; Johnson, W		London Clin Trials Res Grp	Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; AUTOLOGOUS BLOOD; VENOUS THROMBOSIS; ELECTIVE SURGERY; DONATION; KNEE; EFFICACY; RISK	Background: The optimum regimen of epoetin alfa for prevention of allogeneic blood transfusion is unknown. Objective: To determine whether a modified regimen of epoetin alfa reduces allogeneic blood transfusion in patients undergoing hip arthroplasty. Design: Randomized, double-blind, multicenter trial comparing two modified dose regimens of epoetin alfa with placebo. Setting: 13 teaching hospitals and 4 community hospitals in Canada. Patients: 201 patients undergoing primary hip arthroplasty who had a hemoglobin concentration of 98 to 137 g/L and did not predonate blood. Intervention: Patients were assigned in a 3:5:5 ratio to receive four weekly doses of epoetin alfa, 40 000 U (high-dose; n = 44) or 20 000 U (low-dose; n = 79), or placebo (n = 78), starting 4 weeks before surgery. All patients received oral iron supplementation, 450 mg/d, for 42 or more days before surgery. Measurements: The primary end point was allogeneic transfusion. Secondary end points were thromboembolic events and change in reticulocyte count and hemoglobin concentration. Results: Both modified epoetin alfa regimens significantly reduced the need for allogeneic transfusion: Five (11.4%) patients in the high-dose group (P = 0.001) and 18 (22.8%) patients in the low-dose group (P = 0.003) had transfusion, compared with 35 (44.9%) patients in the placebo group. The hematologic response was substantial in patients who received epoetin alfa. In the high-dose group, low-dose group, and placebo group, the preoperative increase in reticulocyte count was 58.8, 37.0 and 1.8 x 10(9) cells/L (P < 0.004), respectively, and the increase in hemoglobin concentration was 19.5, 17.2, and 1.2 g/L (P < 0.001). The incidence of thromboembolic events did not differ among groups. Conclusions: Both modified epoetin alfa regimens were effective compared with placebo in reducing allogeneic transfusion in patients undergoing hip arthroplasty. Patients who received high-dose epoetin alfa had the lowest transfusion rate.	John P Robarts Res Inst, London Clin Trials Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, London, ON N6A 3K7, Canada; Univ Alberta, Edmonton, AB T6G 2M7, Canada; Sir William Osler Hlth Inst, Hamilton, ON, Canada; LakeRidge Hlth Oshawa, Oshawa, ON, Canada; Janssen Ortho Inc, Toronto, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Alberta; Johnson & Johnson	Feagan, BG (corresponding author), John P Robarts Res Inst, London Clin Trials Res Grp, Box 5015,100 Perth Dr, London, ON N6A 5K8, Canada.		Feagan, Brian/G-3292-2011; Feagan, Brian G/M-4283-2015; MacDonald, Steven J/B-6173-2015					[Anonymous], 1993, Lancet, V341, P1227; AuBuchon JP, 1997, ANN INTERN MED, V127, P904, DOI 10.7326/0003-4819-127-10-199711150-00009; BARNES RW, 1989, J VASC SURG, V9, P251, DOI 10.1067/mva.1989.vs0090251; Bhandari S, 1998, J CLIN PHARM THER, V23, P73, DOI 10.1046/j.1365-2710.1998.00147.x; BIESMA DH, 1994, LANCET, V344, P367, DOI 10.1016/S0140-6736(94)91401-X; Cheung WK, 1998, CLIN PHARMACOL THER, V64, P412, DOI 10.1016/S0009-9236(98)90072-8; CHURCHILL DN, 1994, J AM SOC NEPHROL, V4, P1809; Churchill WH, 1998, TRANSFUSION, V38, P530, DOI 10.1046/j.1537-2995.1998.38698326332.x; de Andrade J R, 1996, Am J Orthop (Belle Mead NJ), V25, P533; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DUNN CJ, 1995, DRUG AGING, V7, P131, DOI 10.2165/00002512-199507020-00007; Dupuis JY, 1999, CAN MED ASSOC J, V160, P997; Forgie MA, 1998, ARCH INTERN MED, V158, P610, DOI 10.1001/archinte.158.6.610; Gandini G, 1999, TRANSFUSION, V39, P174, DOI 10.1046/j.1537-2995.1999.39299154732.x; Goldberg M A, 1996, Am J Orthop (Belle Mead NJ), V25, P544; Goldberg MA, 1995, AM J SURG, V170, pS37, DOI 10.1016/S0002-9610(99)80057-9; Goldman M, 1997, TRANSFUSION, V37, P523, DOI 10.1046/j.1537-2995.1997.37597293885.x; Goodnough LT, 1997, NEW ENGL J MED, V336, P933, DOI 10.1056/NEJM199703273361307; Goodnough LT, 1998, VOX SANG, V75, P128, DOI 10.1159/000030973; JOHNSON CA, 1992, ADV PERIT D, V8, P444; Klein HG, 1995, AM J SURG, V170, pS21, DOI 10.1016/S0002-9610(99)80054-3; LAINE LA, 1988, DIGEST DIS SCI, V33, P172, DOI 10.1007/BF01535729; Larocque BJ, 1998, TRANSFUSION, V38, P932, DOI 10.1046/j.1537-2995.1998.381098440857.x; Lee SJ, 1998, TRANSFUSION, V38, P757, DOI 10.1046/j.1537-2995.1998.38898375515.x; Leutz D W, 1994, J Arthroplasty, V9, P543, DOI 10.1016/0883-5403(94)90103-1; Linden JV, 1997, TRANSFUSION, V37, P455, DOI 10.1046/j.1537-2995.1997.37597293872.x; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; RHEIN R, 1992, BRIT MED J, V304, P465; RUTHERFORD CJ, 1994, AM J MED, V96, P139, DOI 10.1016/0002-9343(94)90134-1; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Stowell CP, 1999, ORTHOPEDICS, V22, pS105; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TOY PTCY, 1995, TRANSFUSION, V35, P703; Woronoff-Lemsi MC, 1999, TRANSFUSION, V39, P933, DOI 10.1046/j.1537-2995.1999.39090933.x	35	116	125	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					845	854		10.7326/0003-4819-133-11-200012050-00008	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103054				2022-12-28	WOS:000165585800003
J	Smith, R				Smith, R			US calls for research into research integrity	BRITISH MEDICAL JOURNAL			English	News Item																		BOYD, 2000, JAMA, V284, P2209	1	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1369	1369		10.1136/bmj.321.7273.1369/b	http://dx.doi.org/10.1136/bmj.321.7273.1369/b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099277				2022-12-28	WOS:000165720100020
J	Mezey, E; Chandross, KJ; Harta, G; Maki, RA; McKercher, SR				Mezey, E; Chandross, KJ; Harta, G; Maki, RA; McKercher, SR			Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; ADULT MAMMALIAN FOREBRAIN; IN-VIVO; RAT; DIFFERENTIATE; ASTROCYTES; MICE; NEUN; IDENTIFICATION	Bone marrow stern cells give rise to a variety of hematopoietic Lineages and repopulate the blood throughout adult Life. We show that, in a strain of mice incapable of developing colts of the myeloid and Lymphoid lineages,transplanted adult bone marrow cells migrated into the brain and differentiated into cells that expressed neuron-specific antigens. These findings raise the possibility that bone marrow-derived cells may provide an alternative source of neurons in patients with neurodegenerative diseases or central nervous system injury.	NINDS, Basic Neurosci Program, NIH, Bethesda, MD 20892 USA; NINDS, Lab Dev Neurogenet, NIH, Bethesda, MD 20892 USA; Burnham Inst, La Jolla, CA 92037 USA; Neurocrine Biosci, San Diego, CA 92121 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Sanford Burnham Prebys Medical Discovery Institute; Neurocrine Biosciences	Mezey, E (corresponding author), NINDS, Basic Neurosci Program, NIH, Bethesda, MD 20892 USA.		Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691	NIAID NIH HHS [AI30656] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002996, Z01NS002528, ZIANS002528] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts B., 1989, MOL BIOL CELL; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BARNETT SC, 1993, DEV BIOL, V155, P337, DOI 10.1006/dbio.1993.1033; Bjorklund A, 1999, NATURE, V397, P569, DOI 10.1038/17495; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Chandross KJ, 1999, J NEUROSCI, V19, P759, DOI 10.1523/jneurosci.19-02-00759.1999; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HEUMANN D, 1977, J HIRNFORSCH, V18, P483; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Knopf PM, 1998, J IMMUNOL, V161, P692; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; LING EA, 1973, J COMP NEUROL, V149, P73, DOI 10.1002/cne.901490105; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Luskin MB, 1998, J NEUROBIOL, V36, P221; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MORRISON SJ, 1995, P ASSOC AM PHYSICIAN, V107, P187; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Mujtaba T, 1998, DEV BIOL, V200, P1, DOI 10.1006/dbio.1998.8913; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nardi NB, 1999, BRAZ J MED BIOL RES, V32, P601, DOI 10.1590/S0100-879X1999000500014; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Schwanzel-Fukuda M, 1999, MICROSC RES TECHNIQ, V44, P2, DOI 10.1002/(SICI)1097-0029(19990101)44:1<2::AID-JEMT2>3.0.CO;2-4; THEELE DP, 1993, GLIA, V7, P5, DOI 10.1002/glia.440070104; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VINORES SA, 1984, J HISTOCHEM CYTOCHEM, V32, P1295, DOI 10.1177/32.12.6389693; Watson JD., 1976, MOL BIOL GENE, V3; Weiss S, 1996, J NEUROSCI, V16, P7599; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Weiss S, 1998, J NEUROBIOL, V36, P307, DOI 10.1002/(SICI)1097-4695(199808)36:2<307::AID-NEU14>3.0.CO;2-A; Williams KC, 1995, CURR TOP MICROBIOL, V202, P221; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C	43	1450	1694	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1779	1782		10.1126/science.290.5497.1779	http://dx.doi.org/10.1126/science.290.5497.1779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099419				2022-12-28	WOS:000165632400047
J	Adrian, L; Szewzyk, U; Wecke, J; Gorisch, H				Adrian, L; Szewzyk, U; Wecke, J; Gorisch, H			Bacterial dehalorespiration with chlorinated benzenes	NATURE			English	Article							REDUCTIVE DECHLORINATION; TRICHLOROBENZENE; ENRICHMENT; CONSORTIUM; CULTURE; WATER	Chlorobenzenes are toxic, highly persistent and ubiquitously distributed environmental contaminants that accumulate in the food chain(1). The only known microbial transformation of 1,2,3,5-tetrachlorobenzene (TeCB) and higher chlorinated benzenes is the reductive dechlorination to lower chlorinated benzenes under anaerobic conditions observed with mixed bacterial cultures(2-4). The lower chlorinated benzenes can subsequently be mineralized by aerobic bacteria. Here we describe the isolation of the oxygen-sensitive strain CBDB1, a pure culture capable of reductive dechlorination of chlorobenzenes. Strain CBDB1 is a highly specialized bacterium that stoichiometrically dechlorinates 1,2,3-trichlorobenzene (TCB), 1,2,4-TCB, 1,2,3,4-TeCB, 1,2,3,5-TeCB and 1,2,4,5-TeCB to dichlorobenzenes or 1,3,5-TCB. The presence of chlorobenzene as an electron acceptor and hydrogen as an electron donor is essential for growth, and indicates that strain CBDB1 meets its energy needs by a dehalorespiratory process. According to their 16S rRNA gene sequences, strain CBDB1, Dehalococcoides ethenogenes(5) and several uncultivated bacteria forma new bacterial cluster, of which strain CBDB1 is the first, so far, to thrive on a purely synthetic medium.	Tech Univ Berlin, Fachgebiet Tech Biochem, D-13353 Berlin, Germany; Tech Univ Berlin, Fachgebiet Okol Mikroorganismen, D-13353 Berlin, Germany; Robert Koch Inst, D-13353 Berlin, Germany	Technical University of Berlin; Technical University of Berlin; Robert Koch Institute	Adrian, L (corresponding author), Tech Univ Berlin, Fachgebiet Tech Biochem, D-13353 Berlin, Germany.	lorenz.adrian@tu-berlin.de	Adrian, Lorenz/A-4443-2012	Adrian, Lorenz/0000-0001-8205-0842				Adrian L, 1998, APPL ENVIRON MICROB, V64, P496; ADRIAN L, IN PRESS BIODEGRADAT; Bade K, 2000, FEMS MICROBIOL ECOL, V32, P215, DOI 10.1111/j.1574-6941.2000.tb00714.x; BEURSKENS JEM, 1994, ENVIRON SCI TECHNOL, V28, P701, DOI 10.1021/es00053a026; BOSMA TNP, 1988, FEMS MICROBIOL ECOL, V53, P223, DOI 10.1111/j.1574-6968.1988.tb02668.x; FATHEPURE BZ, 1988, APPL ENVIRON MICROB, V54, P327, DOI 10.1128/AEM.54.2.327-330.1988; Giesbrecht P, 1998, MICROBIOL MOL BIOL R, V62, P1371, DOI 10.1128/MMBR.62.4.1371-1414.1998; HOLLIGER C, 1992, APPL ENVIRON MICROB, V58, P1636, DOI 10.1128/AEM.58.5.1636-1644.1992; Holliger C, 1998, FEMS MICROBIOL REV, V22, P383, DOI 10.1016/S0168-6445(98)00030-8; Hugenholtz P, 1998, J BACTERIOL, V180, P366, DOI 10.1128/JB.180.2.366-376.1998; Kalmbach S, 1997, APPL ENVIRON MICROB, V63, P4164, DOI 10.1128/AEM.63.11.4164-4170.1997; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; Middeldorp PJM, 1997, APPL ENVIRON MICROB, V63, P1225, DOI 10.1128/AEM.63.4.1225-1229.1997; OLIVER BG, 1982, ENVIRON SCI TECHNOL, V16, P532, DOI 10.1021/es00102a019; PFENNIG N, 1978, INT J SYST BACTERIOL, V28, P283, DOI 10.1099/00207713-28-2-283; TIEDJE JM, 1987, DEV IND MICROBIOL, V27, P117; von Wintzingerode F, 1999, APPL ENVIRON MICROB, V65, P283; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	19	337	358	1	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					580	583		10.1038/35046063	http://dx.doi.org/10.1038/35046063			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117744				2022-12-28	WOS:000165548600117
J	Kilb, D; Gomberg, J; Bodin, P				Kilb, D; Gomberg, J; Bodin, P			Triggering of earthquake aftershocks by dynamic stresses	NATURE			English	Article							LINK CLUSTER-ANALYSIS; STATIC STRESS; 1992 LANDERS; STRAIN CHANGES; CALIFORNIA; SEISMICITY; TRANSIENT; SEQUENCE; FAULTS	It is thought that small 'static' stress changes due to permanent fault displacement can alter the likelihood of, or trigger, earthquakes on nearby faults(1). Many studies of triggering in the nearfield, particularly of aftershocks, rely on these static changes as the triggering agent(2-4) and consider them only in terms of equivalent changes in the applied load on the fault(3-6). Here we report a comparison of the aftershock pattern of the moment magnitude M-w = 7.3 Landers earthquake, not only with static stress changes but also with transient, oscillatory stress changes transmitted as seismic waves (that is, 'dynamic' stresses). Dynamic stresses do not permanently change the applied load and thus can trigger earthquakes only by altering the mechanical state or properties of the fault zone. These dynamically weakened faults may fail after the seismic waves have passed by, and might even cause earthquakes that would not otherwise have occurred. We rnd similar asymmetries in the aftershock and dynamic stress patterns, the latter being due to rupture propagation, whereas the static stress changes lack this asymmetry. Previous studies have shown that dynamic stresses can promote failure at remote distances(7-12), but here we show that they can also do so nearby.	US Geol Survey, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA; Ctr Earthquake Res & Informat, Memphis, TN 38152 USA	United States Department of the Interior; United States Geological Survey	Gomberg, J (corresponding author), US Geol Survey, Ctr Earthquake Res & Informat, 3876 Cent Ave,Suite 2, Memphis, TN 38152 USA.	gomberg@usgs.gov		Kilb, Debi/0000-0002-7252-4167				ANDERSON JG, 1994, B SEISMOL SOC AM, V84, P863; ATKINSON BK, 1984, J GEOPHYS RES, V89, P4077, DOI 10.1029/JB089iB06p04077; Boatwright J, 1996, J GEOPHYS RES-SOL EA, V101, P13895, DOI 10.1029/96JB00405; Cotton F, 1997, GEOPHYS J INT, V128, P676, DOI 10.1111/j.1365-246X.1997.tb05328.x; DAVIS SD, 1991, J GEOPHYS RES-SOLID, V96, P6335, DOI 10.1029/90JB02634; DIETERICH J, 1994, J GEOPHYS RES-SOL EA, V99, P2601, DOI 10.1029/93JB02581; DREGER DS, 1994, B SEISMOL SOC AM, V84, P713; FROHLICH C, 1990, GEOPHYS J INT, V100, P19, DOI 10.1111/j.1365-246X.1990.tb04564.x; GOMBERG J, 1994, B SEISMOL SOC AM, V84, P844; Gomberg J, 1996, J GEOPHYS RES-SOL EA, V101, P733, DOI 10.1029/95JB03250; Gomberg J, 1996, J GEOPHYS RES-SOL EA, V101, P751, DOI 10.1029/95JB03251; Gomberg J, 1997, B SEISMOL SOC AM, V87, P294; Gomberg J, 1998, J GEOPHYS RES-SOL EA, V103, P24411, DOI 10.1029/98JB01125; HARRIS RA, 1992, NATURE, V360, P251, DOI 10.1038/360251a0; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24347, DOI 10.1029/98JB01576; HAUKSSON E, 1993, J GEOPHYS RES-SOL EA, V98, P19835, DOI 10.1029/93JB02384; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; HILL DP, 1995, J GEOPHYS RES-SOL EA, V100, P12985, DOI 10.1029/95JB00860; JAUME SC, 1992, SCIENCE, V258, P1325, DOI 10.1126/science.258.5086.1325; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; MATTHEWS MV, 1988, PURE APPL GEOPHYS, V126, P357, DOI 10.1007/BF00879003; REASENBERG PA, 1992, SCIENCE, V255, P1687, DOI 10.1126/science.255.5052.1687; Richardson E, 1999, J GEOPHYS RES-SOL EA, V104, P28859, DOI 10.1029/1999JB900320; Toda S, 1998, J GEOPHYS RES-SOL EA, V103, P24543, DOI 10.1029/98JB00765; WALD DJ, 1994, B SEISMOL SOC AM, V84, P668	25	248	280	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					570	574		10.1038/35046046	http://dx.doi.org/10.1038/35046046			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117741				2022-12-28	WOS:000165548600114
J	Nishiyama, M; Hong, K; Mikoshiba, K; Poo, M; Kato, K				Nishiyama, M; Hong, K; Mikoshiba, K; Poo, M; Kato, K			Calcium stores regulate the polarity and input specificity of synaptic modfication	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL SLICES; DEPRESSION; MEMORY; CA2+; MECHANISM; INDUCTION; CHANNELS; RECEPTOR; NEURONS	Activity-induced synaptic modification is essential for the development and plasticity of the nervous system(1-3). Repetitive correlated activation of pre- and postsynaptic neurons can induce persistent enhancement or decrement of synaptic efficacy, commonly referred to as long-term potentiation or depression(2,3) (LTP or LTD). An important unresolved issue is whether and to what extent LTP and LTD are restricted to the activated synapses(4-8). Here we show that, in the CA1 region of the hippocampus, reduction of postsynaptic calcium influx by partial blockade of NMDA (N-methyl-D-aspartate) receptors results in a conversion of LTP to LTD and a loss of input specificity normally associated with LTP, with LTD appearing at heterosynaptic inputs. The induction of LTD at homo- and heterosynaptic sites requires functional ryanodine receptors and inositol triphosphate (InsP(3)) receptors, respectively. Functional blockade or genetic deletion of type 1 InsP(3) receptors led to a conversion of LTD to LTP and elimination of heterosynaptic LTD, whereas blocking ryanodine receptors eliminated only homosynaptic LTD. Thus, postsynaptic Ca2+, deriving from Ca2+ influx and differential release of Ca2+ from internal stores through ryanodine and InsP(3) receptors, regulates both the polarity and input specificity of activity-induced synaptic modification.	Japan Sci & Technol Corp, Exploratory Res Adv Technol, Mikoshiba Calciosignal Net Project, Tokyo 1130021, Japan; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Japan Science & Technology Agency (JST); University of California System; University of California San Diego	Poo, M (corresponding author), NYU, Sch Med, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.		Mikoshiba, Katsuhiko/N-7943-2015					ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BEAR MF, 1995, NEURON, V15, P1, DOI 10.1016/0896-6273(95)90056-X; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P31, DOI 10.1113/jphysiol.1971.sp009366; Cordoba-Rodriguez R, 1999, P NATL ACAD SCI USA, V96, P7650, DOI 10.1073/pnas.96.14.7650; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; Engert F, 1997, NATURE, V388, P279, DOI 10.1038/40870; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Fitzsimonds RM, 1997, NATURE, V388, P439, DOI 10.1038/41267; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Futatsugi A, 1999, NEURON, V24, P701, DOI 10.1016/S0896-6273(00)81123-X; KATO K, 1993, NEUROSCIENCE, V53, P39, DOI 10.1016/0306-4522(93)90282-K; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Nakamura T, 1999, NEURON, V24, P727, DOI 10.1016/S0896-6273(00)81125-3; Oliet SHR, 1997, NEURON, V18, P969, DOI 10.1016/S0896-6273(00)80336-0; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; Staubli UV, 1996, BRAIN RES, V714, P169, DOI 10.1016/0006-8993(95)01523-X; Tao HZW, 2000, J NEUROSCI, V20, P3233, DOI 10.1523/JNEUROSCI.20-09-03233.2000; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	30	473	482	2	20	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					584	588		10.1038/35046067	http://dx.doi.org/10.1038/35046067			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117745				2022-12-28	WOS:000165548600118
J	DiVincenzo, DP; Bacon, D; Kempe, J; Burkard, G; Whaley, KB				DiVincenzo, DP; Bacon, D; Kempe, J; Burkard, G; Whaley, KB			Universal quantum computation with the exchange interaction	NATURE			English	Article							DECOHERENCE-FREE SUBSPACES; ENVIRONMENT; COMPUTER; GATES; CODES; DOTS	Various physical implementations of quantum computers are being investigated, although the requirements(1) that must be met to make such devices a reality in the laboratory at present involve capabilities well beyond the state of the art. Recent solid-state approaches have used quantum dots(2), donor-atom nuclear spins(3) or electron spins(4); in these architectures, the basic two-qubit quantum gate is generated by a tunable exchange interaction between spins (a Heisenberg interaction), whereas the one-qubit gates require control over a local magnetic field. Compared to the Heisenberg operation, the one-qubit operations are significantly slower, requiring substantially greater materials and device complexity-potentially contributing to a detrimental increase in the decoherence rate. Here we introduced an explicit scheme in which the Heisenberg interaction alone suffices to implement exactly any quantum computer circuit. This capability comes at a price of a factor of three in additional qubits, and about a factor of ten in additional two-qubit operations. Even at this cost, the ability to eliminate the complexity of one-qubit operations should accelerate progress towards solid-state implementations of quantum computation(1).	IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Heights, NY 10598 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Math, Berkeley, CA 94720 USA; Ecole Natl Super Telecommun, F-75634 Paris 13, France; Univ Basel, Dept Phys & Astron, CH-4056 Basel, Switzerland	International Business Machines (IBM); University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; IMT - Institut Mines-Telecom; Institut Polytechnique de Paris; University of Basel	DiVincenzo, DP (corresponding author), IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Heights, NY 10598 USA.		Bacon, Dave/A-3112-2008; Burkard, Guido/ABB-9358-2021; Burkard, Guido/A-6949-2008; DiVincenzo, David P/H-5952-2013	Burkard, Guido/0000-0001-9053-2200; Burkard, Guido/0000-0001-9053-2200; DiVincenzo, David P/0000-0003-4332-645X				Bacon D, 2000, PHYS REV LETT, V85, P1758, DOI 10.1103/PhysRevLett.85.1758; BARENCO A, 1995, PHYS REV A, V52, P3457, DOI 10.1103/PhysRevA.52.3457; Burkard G, 1999, PHYS REV B, V59, P2070, DOI 10.1103/PhysRevB.59.2070; DIVINCENZO DP, IN PRESS NATO ASI; DIVINCENZO DP, IN PRESS FORTSCH PHY; DIVINCENZO DP, 2000, CONDMAT9911245; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; KEMPE J, UNPUB PHYS REV A; KEMPE J, 2000, QUANTPH0004064; Lidar DA, 1998, PHYS REV LETT, V81, P2594, DOI 10.1103/PhysRevLett.81.2594; Lidar DA, 1999, PHYS REV LETT, V82, P4556, DOI 10.1103/PhysRevLett.82.4556; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; MAKHLIN Y, 2000, QUANTPH0002045; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Palma GM, 1996, P ROY SOC A-MATH PHY, V452, P567, DOI 10.1098/rspa.1996.0029; Vrijen R, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.012306; Zanardi P, 1997, MOD PHYS LETT B, V11, P1085, DOI 10.1142/S0217984997001304; ZUREK WH, 1982, PHYS REV D, V26, P1862, DOI 10.1103/PhysRevD.26.1862	23	725	747	0	91	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					339	342		10.1038/35042541	http://dx.doi.org/10.1038/35042541			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099036	Green Submitted			2022-12-28	WOS:000165296000039
J	Witte, DR; Bots, ML; Hoes, AW; Grobbee, DE				Witte, DR; Bots, ML; Hoes, AW; Grobbee, DE			Cardiovascular mortality in Dutch men during 1996 European football championship: longitudinal population study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; CIRCADIAN VARIATION; SEXUAL-ACTIVITY; TRIGGERS; RISK; EARTHQUAKE; ONSET; CIVILIANS; STROKE; DEATH	Objective To investigate whether an important football match increases stress to such an extent that it triggers acute myocardial infarction and stroke. Design Longitudinal study of mortality around 22 June 1996 (the day the Dutch football team was eliminated from the European football championship). Mortality on 22 June was compared with the five days before and after the match and in the same period in 1995 and 1997. Setting Netherlands. Subjects Dutch population aged 45 years or over in June 1996. Main outcome measures All cause mortality and mortality due to coronary heart disease and stroke. Results Mortality from coronary heart disease and stroke was increased in men on the day of the match (relative risk 1.51, 95% confidence interval 1.08 to 2.09). No clear rise in mortality was observed for women (1.11, 0.80 to 1.56). Among men, about 14 excess cardiovascular deaths occurred on the day of the match. Conclusion Important sporting events may provoke a sufficient level of stress to trigger symptomatic cardiovascular disease. The difference between men and women requires further investigation.	Univ Med Ctr Utrecht, Julius Ctr Gen Practice & Patient Oriented Res, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Grobbee, DE (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Gen Practice & Patient Oriented Res, Huispostnummer D01-335, NL-3584 CX Utrecht, Netherlands.	D.E.Grobbee@jc.azu.nl	Witte, Daniel R/C-1722-2008; Grobbee, Diederick/C-7651-2014; Witte, Daniel/AAF-9535-2019	Witte, Daniel R/0000-0002-0769-2922; Grobbee, Diederick/0000-0003-4472-4468; Witte, Daniel/0000-0002-0769-2922				BEHAR S, 1993, AM J MED, V94, P395, DOI 10.1016/0002-9343(93)90150-N; BERGOVEC M, 1992, LANCET, V339, P303, DOI 10.1016/0140-6736(92)91370-N; Brown DL, 1999, AM HEART J, V137, P830, DOI 10.1016/S0002-8703(99)70406-0; Evans C, 2000, BRIT MED J, V320, P218, DOI 10.1136/bmj.320.7229.218; Haapaniemi H, 1996, STROKE, V27, P1023, DOI 10.1161/01.STR.27.6.1023; HILLBOM M, 1995, STROKE, V26, P40, DOI 10.1161/01.STR.26.1.40; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Leor J, 1996, AM J CARDIOL, V77, P1230, DOI 10.1016/S0002-9149(96)00169-5; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; Muller JE, 1996, JAMA-J AM MED ASSOC, V275, P1405, DOI 10.1001/jama.275.18.1405; Muller JE, 1999, AM J CARDIOL, V84, p2N; *NOS, 1996, MAAND KIJK LUIST TEL; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; Spencer FA, 1998, J AM COLL CARDIOL, V31, P1226, DOI 10.1016/S0735-1097(98)00098-9; SUZUKI S, 1995, LANCET, V345, P981, DOI 10.1016/S0140-6736(95)90727-0; TOFLER GH, 1990, AM J CARDIOL, V66, P22, DOI 10.1016/0002-9149(90)90729-K; TRICHOPOULOS D, 1983, LANCET, V1, P441; WILLICH SN, 1990, AM J CARDIOL, V66, pG15, DOI 10.1016/0002-9149(90)90387-G; WILLICH SN, 1989, CIRCULATION, V80, P853, DOI 10.1161/01.CIR.80.4.853; WILLICH SN, 1993, CIRCULATION, V87, P1442, DOI 10.1161/01.CIR.87.5.1442; WROE SJ, 1992, BRIT MED J, V304, P155, DOI 10.1136/bmj.304.6820.155	23	112	116	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2000	321	7276					1552	1554		10.1136/bmj.321.7276.1552	http://dx.doi.org/10.1136/bmj.321.7276.1552			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124170	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000166134500007
J	Gonzales, R; Sande, MA				Gonzales, R; Sande, MA			Uncomplicated acute bronchitis	ANNALS OF INTERNAL MEDICINE			English	Review							C-REACTIVE PROTEIN; RESPIRATORY-TRACT INFECTION; COMMUNITY-ACQUIRED PNEUMONIA; NEURAMINIDASE INHIBITOR ZANAMIVIR; RANDOMIZED CONTROLLED-TRIALS; ADULT-ONSET ASTHMA; DOUBLE-BLIND TRIAL; CHLAMYDIA-PNEUMONIAE; GENERAL-PRACTICE; PULMONARY-FUNCTION	Acute bronchitis is an acute cough illness in otherwise healthy adults that usually lasts 1 to 3 weeks. This review describes the pathophysiology of the condition and provides a practical approach to the evaluation and treatment of adults with uncomplicated acute bronchitis. practical points to be made are: 1. Respiratory viruses appear to cause the large majority of cases of uncomplicated acute bronchitis. 2. Pertussis infection is present in up to 10% to 20% of adults with cough illness of more than 2 to 3 weeks' duration. No clinical features distinguish pertussis from nonpertussis infection in adults who were immunized against pertussis as children. 3. Transient bronchial hyperresponsiveness appears to be the predominant mechanism of the bothersome cough of acute bronchitis. 4. Ruling out pneumonia is the primary objective in evaluating adults with acute cough illness in whom comorbid conditions and occult asthma are absent or unlikely. In the absence of abnormalities in vital signs (heart rate > 100 beats/min, respiratory rate > 24 breaths/min, and oral body temperature > 38 degreesC), the likelihood of pneumonia is very low. 5. Randomized, placebo-controlled trials do not support routine antibiotic treatment of uncomplicated acute bronchitis. 6. Randomized, placebo-controlled trials have shown that inhaled albuterol decreases the duration of cough in adults with uncomplicated acute bronchitis. 7. Intervention studies suggest that antibiotic treatment of acute bronchitis can be reduced by using a combination of patient and physician education. Decreased rates of antibiotic treatment are not associated with increased utilization, return visits, or dissatisfaction with care.	Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Univ Utah, Dept Med 4C104, Salt Lake City, UT 84132 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Gonzales, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Campus Box B-180,4200 E 9th Ave, Denver, CO 80262 USA.	ralph.gonzales@uchsc.edu						AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BASS JW, 1985, PEDIATR INFECT DIS J, V4, P614, DOI 10.1097/00006454-198511000-00003; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bent S, 1999, AM J MED, V107, P62, DOI 10.1016/S0002-9343(99)00167-9; BERGQUIST SO, 1987, PEDIATR INFECT DIS J, V6, P458, DOI 10.1097/00006454-198705000-00009; BLASI F, 1994, EUR RESPIR J, V7, P102, DOI 10.1183/09031936.94.07010102; BOLDY DAR, 1990, RESP MED, V84, P377, DOI 10.1016/S0954-6111(08)80072-8; BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; *COMM DIAGN STAND, 1970, AM REV RESPIR DIS, V101, P119; DahlerEriksen BS, 1997, SCAND J PRIM HEALTH, V15, P35, DOI 10.3109/02813439709043427; DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8; DUNLAY J, 1987, J FAM PRACTICE, V25, P137; EMERMAN CL, 1991, ANN EMERG MED, V20, P1215, DOI 10.1016/S0196-0644(05)81474-X; EVANS AS, 1967, MED CLIN N AM, V51, P803, DOI 10.1016/S0025-7125(16)33048-6; Fahey T, 1998, BRIT MED J, V316, P906, DOI 10.1136/bmj.316.7135.906; FALCK G, 1994, SCAND J INFECT DIS, V26, P179, DOI 10.3109/00365549409011782; FRANKS P, 1984, J FAM PRACTICE, V19, P185; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gennis P, 1989, J Emerg Med, V7, P263, DOI 10.1016/0736-4679(89)90358-2; Gonzales R, 1998, J GEN INTERN MED, V13, P541, DOI 10.1046/j.1525-1497.1998.00165.x; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; GRAYSTON JT, 1993, J INFECT DIS, V168, P1231, DOI 10.1093/infdis/168.5.1231; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; HALL CB, 1976, NEW ENGL J MED, V294, P414, DOI 10.1056/NEJM197602192940803; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; HALL WJ, 1979, CHEST, V76, P458, DOI 10.1378/chest.76.4.458; HALLETT JS, 1985, ANN ALLERGY, V55, P568; Hament JM, 1999, FEMS IMMUNOL MED MIC, V26, P189, DOI 10.1111/j.1574-695X.1999.tb01389.x; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; HECKERLING PS, 1990, ANN INTERN MED, V113, P664, DOI 10.7326/0003-4819-113-9-664; Hobbs FDR, 1996, BRIT J GEN PRACT, V46, P395; Houston MS, 1997, ARCH INTERN MED, V157, P2190, DOI 10.1001/archinte.157.19.2190; HOWIE JGR, 1970, LANCET, V2, P1099; HUESTON WJ, 1991, J FAM PRACTICE, V33, P476; HUESTON WJ, 1994, J FAM PRACTICE, V39, P437; Irwin RS, 1998, CHEST, V114, p133S, DOI 10.1378/chest.114.2_Supplement.133S; JANTOS C, 1993, EUR J CLIN MICROBIOL, V12, P33, DOI 10.1007/BF01997053; JEFFERSON T, 1999, COCHRANE ACUTE RESP, P2; JOHNSON D, 1991, J ASTHMA, V28, P85, DOI 10.3109/02770909109082732; Jonsson JS, 1997, SCAND J PRIM HEALTH, V15, P156, DOI 10.3109/02813439709018507; King DE, 1996, J FAM PRACTICE, V42, P601; Kornaar BGM, 1997, EUR RESPIR J, V10, P44; Lieberman D, 1998, EUR J CLIN MICROBIOL, V17, P685, DOI 10.1007/s100960050161; LINDBACK S, 1989, SCAND J INFECT DIS, V21, P543, DOI 10.3109/00365548909037883; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L; MacKay DN, 1996, J GEN INTERN MED, V11, P557, DOI 10.1007/BF02599608; MELBYE H, 1991, FAM PRACT, V8, P216, DOI 10.1093/fampra/8.3.216; MELBYE H, 1992, SCAND J INFECT DIS, V24, P647, DOI 10.3109/00365549209054652; MELBYE H, 1994, EUR RESPIR J, V7, P1239, DOI 10.1183/09031936.94.07071239; Melbye Hasse, 1994, Tidsskrift for den Norske Laegeforening, V114, P814; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; Metlay JP, 1997, JAMA-J AM MED ASSOC, V278, P1440, DOI 10.1001/jama.278.17.1440; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; MORDHORST CH, 1992, EUR J CLIN MICROBIOL, V11, P617, DOI 10.1007/BF01961668; Nennig ME, 1996, JAMA-J AM MED ASSOC, V275, P1672, DOI 10.1001/jama.275.21.1672; Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060; Oeffinger KC, 1997, J FAM PRACTICE, V45, P402; ORR PH, 1993, J FAM PRACTICE, V36, P507; PENDER E S, 1990, Journal of Emergency Medicine, V8, P727, DOI 10.1016/0736-4679(90)90287-6; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; RAMIREZRONDA CH, 1981, ARCH INTERN MED, V141, P1599, DOI 10.1001/archinte.141.12.1599; SCHAPPERT SM, 1997, DHHS PUBLICATION; SCHAPPERT SM, 1999, DHHS PUBL PHS; Scherl E R, 1987, J Ky Med Assoc, V85, P539; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; SINGAL BM, 1989, ANN EMERG MED, V18, P13, DOI 10.1016/S0196-0644(89)80304-X; SMITH RP, 1995, CHEST, V107, P1028, DOI 10.1378/chest.107.4.1028; Smucny JJ, 1998, J FAM PRACTICE, V47, P453; SODERSTROM M, 1991, SCAND J INFECT DIS, V23, P347, DOI 10.3109/00365549109024322; SPRAUER MA, 1992, AM J DIS CHILD, V146, P177, DOI 10.1001/archpedi.1992.02160140043018; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; TANNOCK GA, 1993, FAM PRACT, V10, P378, DOI 10.1093/fampra/10.4.378; THOM DH, 1994, EUR J CLIN MICROBIOL, V13, P785, DOI 10.1007/BF02111337; Toren K, 1999, INT J TUBERC LUNG D, V3, P192; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; von Konig CHW, 1998, EUR J PEDIATR, V157, P391, DOI 10.1007/s004310050836; WILLIAMSON HA, 1987, J FAM PRACTICE, V25, P251; WILLIAMSON HA, 1984, J FAM PRACTICE, V19, P481; WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; YOUNG B, 1991, PATHOLOGY, V23, P118, DOI 10.3109/00313029109060809	87	111	112	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					981	991		10.7326/0003-4819-133-12-200012190-00014	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00014			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119400				2022-12-28	WOS:000165952300007
J	Stott, PA; Tett, SFB; Jones, GS; Allen, MR; Mitchell, JFB; Jenkins, GJ				Stott, PA; Tett, SFB; Jones, GS; Allen, MR; Mitchell, JFB; Jenkins, GJ			External control of 20th century temperature by natural and anthropogenic forcings	SCIENCE			English	Article							FORCED CLIMATE-CHANGE; GREENHOUSE-GAS; SURFACE-TEMPERATURE; SOLAR IRRADIANCE; AEROSOLS; TRENDS; MODEL	A comparison of observations with simulations of a coupled ocean-atmosphere general circulation model shows that both natural and anthropogenic factors have contributed significantly to 20th century temperature changes. The model successfully simulates global mean and Large-scale Land temperature variations, indicating that the climate response on these scales is strongly influenced by external factors. More than 80% of observed multidecadal-scale global mean temperature variations and more than 60% of 10- to 50-year Land temperature variations are due to changes in external forcings, Anthropogenic global warming under a standard emissions scenario is predicted to continue at a rate similar to that observed in recent decades.	Hadley Ctr Climate Predict & Res, Met Off, Bracknell RG12 2SY, Berks, England; Rutherford Appleton Lab, Space Sci & Technol Dept, Didcot OX11 0QX, Oxon, England; Univ Oxford, Dept Phys, Oxford OX1 3PU, England	Met Office - UK; Hadley Centre; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; University of Oxford	Stott, PA (corresponding author), Hadley Ctr Climate Predict & Res, Met Off, Bracknell RG12 2SY, Berks, England.		Tett, Simon F. B./B-1504-2013; Scott, Peter/GYA-5335-2022; Jones, Gareth/H-8022-2013; Allen, Myles R/A-5172-2012; Stott, Peter/N-1228-2016	Tett, Simon F. B./0000-0001-7526-560X; Stott, Peter/0000-0003-4853-7686				ALBRECHT BA, 1989, SCIENCE, V245, P1227, DOI 10.1126/science.245.4923.1227; Allen MR, 2000, NATURE, V407, P617, DOI 10.1038/35036559; Allen MR, 1999, CLIM DYNAM, V15, P419, DOI 10.1007/s003820050291; Andronova NG, 2000, GEOPHYS RES LETT, V27, P2137, DOI 10.1029/2000GL006109; BEER JU, 1993, P IAU C, V143, P291; Boer GJ, 2000, CLIM DYNAM, V16, P469, DOI 10.1007/s003820050340; Cane MA, 1997, SCIENCE, V275, P957, DOI 10.1126/science.275.5302.957; COLLINS M, 2000, 21 HADL CTR CLIM PRE; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Crowley TJ, 1999, GEOPHYS RES LETT, V26, P1901, DOI 10.1029/1999GL900347; Delworth TL, 2000, SCIENCE, V287, P2246, DOI 10.1126/science.287.5461.2246; Gordon C, 2000, CLIM DYNAM, V16, P147, DOI 10.1007/s003820050010; Hegerl GC, 1996, J CLIMATE, V9, P2281, DOI 10.1175/1520-0442(1996)009<2281:DGGICC>2.0.CO;2; Hegerl GC, 1997, CLIM DYNAM, V13, P613, DOI 10.1007/s003820050186; HOYT DV, 1993, J GEOPHYS RES-SPACE, V98, P18895, DOI 10.1029/93JA01944; JONES A, 1999, 14 HADL CTR CLIM PRE; KELLY PM, 1992, NATURE, V360, P328, DOI 10.1038/360328a0; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; Lean J, 1998, J CLIMATE, V11, P3069, DOI 10.1175/1520-0442(1998)011<3069:CFBCSR>2.0.CO;2; Lockwood M, 1999, NATURE, V399, P437, DOI 10.1038/20867; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; NAKICENJOVIC N, 2000, IPCC SPECIAL REPORT; Osborn TJ, 1999, CLIM DYNAM, V15, P685, DOI 10.1007/s003820050310; PARKER DE, 1994, J GEOPHYS RES-ATMOS, V99, P14373, DOI 10.1029/94JD00548; Pope VD, 2000, CLIM DYNAM, V16, P123, DOI 10.1007/s003820050009; Santer BD, 1996, NATURE, V382, P39, DOI 10.1038/382039a0; SATO M, 1993, J GEOPHYS RES-ATMOS, V98, P22987, DOI 10.1029/93JD02553; Schimel D., 1996, CLIMATE CHANGE 1995, P65; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; Stott PA, 2001, CLIM DYNAM, V17, P1, DOI 10.1007/PL00007924; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164; TETT SFB, 2000, 19 HADL CTR CLIMK PR; TWOMEY S, 1974, ATMOS ENVIRON, V8, P1251, DOI 10.1016/0004-6981(74)90004-3	34	468	487	4	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2133	2137		10.1126/science.290.5499.2133	http://dx.doi.org/10.1126/science.290.5499.2133			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118145				2022-12-28	WOS:000165870600053
J	Henney, JE				Henney, JE			Shock wave for heel pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2711	2711		10.1001/jama.284.21.2711-c	http://dx.doi.org/10.1001/jama.284.21.2711-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105160				2022-12-28	WOS:000165509500005
J	Attaran, A; Maharaj, R				Attaran, A; Maharaj, R			DDT for malaria control should not be banned	BRITISH MEDICAL JOURNAL			English	Article									Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA; S Africa Dept Hlth, ZA-0001 Pretoria, South Africa	Harvard University	Attaran, A (corresponding author), Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA.							Attaran A, 2000, NAT MED, V6, P729, DOI 10.1038/77438; COLBORN T, 2000, OUR STOLEN FUTURE; GLADEN BC, 1995, AM J PUBLIC HEALTH, V85, P504, DOI 10.2105/AJPH.85.4.504; GRAMICCIA C, 1988, MALARIA PRINCIPLES P; *INT POPS EL NETW, 2000, BACKGR STAT POPS EL; *PHYS SOC RESP, 1999, MOD MAL CONTR HDB; Robertson L, 1997, J COGNITIVE NEUROSCI, V9, P295, DOI 10.1162/jocn.1997.9.3.295; Rothman N, 1997, LANCET, V350, P240, DOI 10.1016/S0140-6736(97)02088-6; Smith AG, 2000, LANCET, V356, P267, DOI 10.1016/S0140-6736(00)02497-1; *WHO, 1999, SDEPHDP02 WHO; *WHO, 2000, INT AG RES CANC; *WORLD WILDL FUND, 1998, RES DDT DIL	12	50	51	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1403	1404		10.1136/bmj.321.7273.1403	http://dx.doi.org/10.1136/bmj.321.7273.1403			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099289	Green Published			2022-12-28	WOS:000165720100034
J	Bower, P; Byford, S; Sibbald, B; Ward, E; King, M; Lloyd, R; Gabbay, M				Bower, P; Byford, S; Sibbald, B; Ward, E; King, M; Lloyd, R; Gabbay, M			Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: Cost effectiveness	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To compare the cost effectiveness of general practitioner care and two general practice based psychological therapies for depressed patients. Design Prospective, controlled trial with randomised and patient preference allocation arms. Setting General practices in London and greater Manchester. Participants 464 of 627 patients presenting with depression or mixed anxiety and depression were suitable for inclusion. Interventions Usual general practitioner care or up to 12 sessions of non-directive counselling or cognitive-behaviour therapy provided by therapists. Main outcome measures Beck depression inventory scores, EuroQol measure of health related quality of life, direct treatment and non-treatment costs, and cost of lost production. Results 197 patients were randomly assigned to treatment, 137 chose their treatment, and 130 were randomised only between the two psychological therapies. At four months, both non-directive counselling and cognitive-behaviour therapy reduced depressive symptoms to a significantly greater extent than usual general practitioner care. There was no significant difference in outcome between treatments at 12 months. There were no significant differences in direct costs, production losses, or societal costs between the three treatments at either four or 12 months. Sensitivity analyses did not suggest that the results depended on particular assumptions in the statistical analysis. Conclusions Within the constraints of available power, the data suggest that both brief psychological therapies may be significantly more cost effective than usual care in the short term, as benefit was gained with no significant difference in cost There are no significant differences between treatments in either outcomes or costs at 12 months.	UCL, Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England; Univ Liverpool, Dept Primary Care, Liverpool L69 3BX, Merseyside, England; Univ Manchester, NPCRDC, Manchester M13 9PL, Lancs, England; York Univ, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	University of London; University College London; University of Liverpool; University of Manchester; University of York - UK	King, M (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England.	m.king@rfc.ucl.ac.uk	Byford, Sarah/D-1699-2010; King, Michael B/D-7477-2011; Bower, Peter/A-1508-2011	Byford, Sarah/0000-0001-7084-1495; King, Michael B/0000-0003-4715-7171; Bower, Peter/0000-0001-9558-3349; Gabbay, Mark/0000-0002-0126-8485				ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; Beck A.T., 1987, BECK DEPRESSION INVE; BOOT D, 1994, PATIENT EDUC COUNS, V24, P79, DOI 10.1016/0738-3991(94)90028-0; *BRIT MED ASS, 1998, BRIT NATL FORM; *CHAR I PUBL FIN A, 1997, HLTH SERV FIN DAT 19; Efron B, 1993, INTRO BOTSTRAP; Fairhurst K, 1996, J Health Serv Res Policy, V1, P77; Friedli K, 2000, BRIT J GEN PRACT, V50, P276; GOURNAY K, 1995, J ADV NURS, V22, P769, DOI 10.1046/j.1365-2648.1995.22040769.x; Gray AM, 1999, HLTH TECHNOL ASSESS, V3; Harvey I, 1998, BRIT J GEN PRACT, V48, P1043; Johnston K, 1999, HLTH TECHNOL ASSESS, V3; Koopmanschap MA, 1996, PHARMACOECONOMICS, V10, P460, DOI 10.2165/00019053-199610050-00003; Netten A, 1998, UNIT COSTS HLTH SOCI; ROBSON MH, 1984, BRIT MED J, V288, P1805, DOI 10.1136/bmj.288.6433.1805; Roth A., 1996, WHAT WORKS WHOM CRIT; SCOTT AIF, 1992, BRIT MED J, V304, P883, DOI 10.1136/bmj.304.6831.883; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	19	68	68	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	2000	321	7273					1389	1392		10.1136/bmj.321.7273.1389	http://dx.doi.org/10.1136/bmj.321.7273.1389			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	380TT	11099285	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000165720100030
J	Savage, J				Savage, J			Ethnography and health care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITATIVE RESEARCH		Royal Coll Nursing UK, London W1M OAB, England		Savage, J (corresponding author), Royal Coll Nursing UK, London W1M OAB, England.	jan.savage@rcn.org.uk						Ahmed A., 1995, FUTURE ANTHR ITS REL; *ASS SOC ANTHR COM, 2000, ETH GUID PGOOD PRACT; Atkinson P, 1995, MED TALK MED WORK; Boyle J., 1994, CRITICAL ISSUES QUAL, P159; Gosbee J, 1998, BRIT MED J, V316, P642, DOI 10.1136/bmj.316.7132.642; HAMMERSLEY P, 1990, READING ETHNOGRAPHIC; HOLY L, 1984, ETHNOGRAPHIC RES GUI, P13; JONES R, 1995, BRIT MED J, V311, P2, DOI 10.1136/bmj.311.6996.2; Kingfisher CP, 1998, MED ANTHROPOL Q, V12, P447; Lincoln Y.S., 1994, HDB QUALITATIVE RES, P248; Marcus G., 1986, ANTHR CULTURAL CRITI; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Morse J. M., 1996, NURSING RES APPL QUA; Morse JM, 1999, QUAL HEALTH RES, V9, P5, DOI 10.1177/104973299129121622; Murphy E., 1998, HEALTH TECHNOL ASSES, V2, pI, DOI [DOI 10.3310/HTA2030, 10.3310/hta2030]; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Prout A, 1996, SOCIOL HEALTH ILL, V18, P198, DOI 10.1111/1467-9566.ep10934726; ROSE D, 1993, QUALITATIVE RES METH, V26; Said Edward W., 1994, CULTURE IMPERIALISM; Savage J, 2000, QUAL HEALTH RES, V10, P324, DOI 10.1177/104973200129118471; Ware NC, 2000, MED ANTHROPOL Q, V14, P3, DOI 10.1525/maq.2000.14.1.3; WRIGHT S, 1998, ANTHR ACTION, V5, P3	23	235	238	0	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	2000	321	7273					1400	1402		10.1136/bmj.321.7273.1400	http://dx.doi.org/10.1136/bmj.321.7273.1400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	380TT	11099288	Green Published			2022-12-28	WOS:000165720100033
J	Hoek, RM; Ruuls, SR; Murphy, CA; Wright, GJ; Goddard, R; Zurawski, SM; Blom, B; Homola, ME; Streit, WJ; Brown, MH; Barclay, AN; Sedgwick, JD				Hoek, RM; Ruuls, SR; Murphy, CA; Wright, GJ; Goddard, R; Zurawski, SM; Blom, B; Homola, ME; Streit, WJ; Brown, MH; Barclay, AN; Sedgwick, JD			Down-regulation of the macrophage lineage through interaction with OX2 (CD200)	SCIENCE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MICROGLIAL CELLS; GENE; MICE; LOCALIZATION; GLYCOPROTEIN; ARTHRITIS; MHC	OX2 (CD200) is a broadly expressed membrane glycoprotein, shown here to be important for regulation of the macrophage Lineage. In mice lacking CD200, macrophage lineage cells, including brain microglia, exhibited an activated phenotype and were more numerous. Upon facial nerve transection, damaged CD200-deficient neurons elicited an accelerated microglial response. Lack of CD200 resulted in a more rapid onset of experimental autoimmune encephalomyelitis (EAE). Outside the brain, disruption of CD200-CD200 receptor interaction precipitated susceptibility to collagen-induced arthritis(CIA) in mice normally resistant to this disease. Thus, in diverse tissues OX2 delivers an inhibitory signal for the macrophage Lineage.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Inst Brain, Gainesville, FL 32610 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Oxford; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Sedgwick, JD (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.			Wright, Gavin/0000-0003-0537-0863				Bakker ABH, 2000, IMMUNITY, V13, P345, DOI 10.1016/S1074-7613(00)00034-0; BARCLAY AN, 1981, IMMUNOLOGY, V44, P727; Bates EEM, 1998, MOL IMMUNOL, V35, P513, DOI 10.1016/S0161-5890(98)00045-5; Borriello F, 1998, MAMM GENOME, V9, P114, DOI 10.1007/s003359900700; Campbell IK, 1997, ANN RHEUM DIS, V56, P364, DOI 10.1136/ard.56.6.364; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; HOEK RM, UNPUB; JONSSON R, 1986, J IMMUNOL METHODS, V88, P109, DOI 10.1016/0022-1759(86)90058-X; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; KRAAL G, 1986, IMMUNOLOGY, V58, P665; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lemckert FA, 1997, NUCLEIC ACIDS RES, V25, P917, DOI 10.1093/nar/25.4.917; McColl SR, 1998, J IMMUNOL, V161, P6421; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; Preston S, 1997, EUR J IMMUNOL, V27, P1911, DOI 10.1002/eji.1830270814; RAINE CS, 1984, LAB INVEST, V50, P608; Riminton DS, 1998, J EXP MED, V187, P1517, DOI 10.1084/jem.187.9.1517; SEDGWICK JD, 1993, J EXP MED, V177, P1145, DOI 10.1084/jem.177.4.1145; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; WATSON WC, 1985, J EXP MED, V162, P1878, DOI 10.1084/jem.162.6.1878; WEBB M, 1984, J NEUROCHEM, V43, P1061, DOI 10.1111/j.1471-4159.1984.tb12844.x; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; 2000, 7 WORKSH C HUM LEUK	24	760	815	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1768	1771		10.1126/science.290.5497.1768	http://dx.doi.org/10.1126/science.290.5497.1768			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099416				2022-12-28	WOS:000165632400044
J	Lo, B; Wolf, LE; Berkeley, A				Lo, B; Wolf, LE; Berkeley, A			Conflict-of-interest policies for investigators in clinical trials.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINANCIAL CONFLICTS	Background: There is substantial concern that financial conflicts of interest on the part of investigators conducting clinical trials may compromise the well-being of research subjects. Methods: We analyzed policies governing conflicts of interest at the 10 medical schools in the United States that receive the largest amount of research funding from the National Institutes of Health. These institutions are Baylor College of Medicine, Columbia University College of Physicians and Surgeons, Harvard Medical School, Johns Hopkins University School of Medicine, the University of Pennsylvania School of Medicine, the University of California at Los Angeles School of Medicine, the University of California at San Francisco School of Medicine, the University of Washington School of Medicine, Washington University School of Medicine at St. Louis, and Yale University School of Medicine. Results: All 10 universities required that faculty members disclose financial interests to university officials. Only four required disclosure by all members of the research staff. Five universities required disclosure of all financial interests, even though federal regulations specify a threshold for disclosure. Six universities required disclosure to the institutional review board as well as to a committee on conflicts of interest or a university official. Four universities had stricter requirements for investigators conducting clinical trials than required by federal regulations. One university prohibited investigators from having stock, stock options, consulting agreements, or decision-making positions involving a company that sponsored the research. A second university prohibited researchers from trading stock or stock options in a company that sponsored the research or sold the product or device under study. Two universities ordinarily did not allow faculty members to participate in clinical research if they had what federal regulations refer to as a ``significant'' financial interest in the company owning the product or device being studied, but exceptions were allowed. Conclusions: Policies governing conflicts of interest at leading medical schools in the United States vary widely. We suggest that university-based investigators and research staff be prohibited from holding stock, stock options, or decision-making positions in a company that may reasonably appear to be affected by the results of their clinical research. Of the 10 medical schools we studied, only 1 had a policy that was close to this standard. (N Engl J Med 2000;343:1616-20.) (C) 2000, Massachusetts Medical Society.	Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Off Student Affairs, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lo, B (corresponding author), Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu		Wolf, Leslie/0000-0002-4660-8383	NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Agnew B, 2000, SCIENCE, V289, P1266, DOI 10.1126/science.289.5483.1266; American Federation for Clinical Research, 1990, CLIN RES, V38, P239; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Friedmann T, 2000, SCIENCE, V287, P2163, DOI 10.1126/science.287.5461.2163; HEALY B, 1989, NEW ENGL J MED, V320, P949, DOI 10.1056/NEJM198904063201432; KASSIRER JP, 1993, NEW ENGL J MED, V329, P570, DOI 10.1056/NEJM199308193290810; Lo B., 2000, RESOLVING ETHICAL DI, P231; Marshall E, 2000, SCIENCE, V288, P951, DOI 10.1126/science.288.5468.951; Overgaard CB, 2000, J INVEST MED, V48, P118; PITTA J, 1999, FORBES          0517, P210; RELMAN AS, 1989, NEW ENGL J MED, V320, P933, DOI 10.1056/NEJM198904063201410; SMITH K, 1999, MONEY            OCT, P116; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; Topol EJ, 1997, CIRCULATION, V95, P1072; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; TULLY S, 2000, FORTUNE         0626, P156; WOO SL, 2000, MOL THER, V1, P383; 2000, US NEWS WORLD R 0410, P82	19	146	147	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1616	1620		10.1056/NEJM200011303432206	http://dx.doi.org/10.1056/NEJM200011303432206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096170				2022-12-28	WOS:000165511000006
J	Patz, EF; Goodman, PC; Bepler, G				Patz, EF; Goodman, PC; Bepler, G			Current concepts - Screening for lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LYMPH-NODES; TUMOR-CELLS; BONE-MARROW; PREVALENCE; CARCINOMA; PROJECT; TRIALS; MICROMETASTASES; ANGIOGENESIS; LOCALIZATION		Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Duke University; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Patz, EF (corresponding author), Duke Univ, Med Ctr, Dept Radiol, Box 3808, Durham, NC 27710 USA.	patz0002@mc.duke.edu		Patz, Edward/0000-0003-3374-1596				Ahrendt SA, 1997, CLIN CANCER RES, V3, P1207; BERLIN NI, 1984, AM REV RESPIR DIS, V130, P545; Black WC, 1997, AM J ROENTGENOL, V168, P3, DOI 10.2214/ajr.168.1.8976910; BRETT GZ, 1968, THORAX, V23, P414, DOI 10.1136/thx.23.4.414; Canellos GP, 1997, J CLIN ONCOL, V15, P3169, DOI 10.1200/JCO.1997.15.10.3169; CHEN ZL, 1993, JNCI-J NATL CANCER I, V85, P493, DOI 10.1093/jnci/85.6.493; COTE RJ, 1995, ANN SURG, V222, P415; Crowell RE, 1996, CANCER EPIDEM BIOMAR, V5, P631; Flehinger B J, 1994, Chest Surg Clin N Am, V4, P1; FLEHINGER BJ, 1984, AM REV RESPIR DIS, V130, P555; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1975, CHEST, V67, P511, DOI 10.1378/chest.67.5.511; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; HAYATA Y, 1982, RECENT RES CANCER, V82, P163; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Hermanek P, 1999, CANCER-AM CANCER SOC, V86, P2668, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2668::AID-CNCR11>3.3.CO;2-I; Hillman BJ, 1999, RADIOLOGY, V213, P641, DOI 10.1148/radiology.213.3.r99dc38641; HULKA BS, 1988, CANCER, V62, P1776, DOI 10.1002/1097-0142(19881015)62:1+<1776::AID-CNCR2820621314>3.0.CO;2-V; Ikeda N, 1998, LUNG CANCER-J IASLC, V19, P161, DOI 10.1016/S0169-5002(97)00095-0; Jacobson D R, 1995, Ann Oncol, V6 Suppl 3, pS3; Kaneko M, 1996, RADIOLOGY, V201, P798, DOI 10.1148/radiology.201.3.8939234; KUBIK A, 1986, CANCER-AM CANCER SOC, V57, P2427, DOI 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M; Lam S, 1999, CLIN CHEST MED, V20, P53, DOI 10.1016/S0272-5231(05)70126-X; Lam S, 1998, CHEST, V113, P696, DOI 10.1378/chest.113.3.696; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P329; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; LILIENFE.A, 1966, CANCER RES, V26, P2083; LIOTTA LA, 1974, CANCER RES, V34, P997; MIDTHUN DE, 1998, J RESP DIS, V19, P59; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Mulshine JL, 1997, HEMATOL ONCOL CLIN N, V11, P235, DOI 10.1016/S0889-8588(05)70428-7; NASH FA, 1968, BRIT MED J, V2, P715, DOI 10.1136/bmj.2.5607.715; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; Passlick B, 1996, ANN THORAC SURG, V61, P177, DOI 10.1016/0003-4975(95)01012-2; Patz EF, 2000, CHEST, V117, P1568, DOI 10.1378/chest.117.6.1568; Peck K, 1998, CANCER RES, V58, P2761; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Spodick DH, 1999, CHEST, V115, P857, DOI 10.1378/chest.115.3.857; Strauss G M, 1999, Surg Oncol Clin N Am, V8, P371; Strauss GM, 1997, CHEST, V111, P754, DOI 10.1378/chest.111.3.754; Swartz MA, 1999, BRIT J CANCER, V81, P756, DOI 10.1038/sj.bjc.6690760; SZABO E, 1993, SEMIN ONCOL, V20, P374; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; TOCKMAN MS, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S-a; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; WEISS W, 1974, ARCH INTERN MED, V134, P306; WILDE J, 1989, EUR RESPIR J, V2, P656; Yang M, 1998, CANCER RES, V58, P4217	54	268	278	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1627	1633		10.1056/NEJM200011303432208	http://dx.doi.org/10.1056/NEJM200011303432208			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096172				2022-12-28	WOS:000165511000008
J	Primatesta, P; Poulter, NR				Primatesta, P; Poulter, NR			Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; CHOLESTEROL; PREVENTION; PRAVASTATIN; RISK; MEN	Objective To evaluate the prevalence of the use of lipid lowering agents and its relation to blood lipid concentrations in English adults. Design Cross sectional survey. Setting England, 1998. Participants Nationally representative sample of 13 586 adults (aged greater than or equal to 16 years) living in non-institutional households. Main outcome measures Mean blood concentrations of total cholesterol and high density lipoprotein (HDL) cholesterol, and the ratio of total cholesterol to HDL cholesterol, in participants classified by age and sex; prevalence of raised total cholesterol concentrations and increased ratio of total to HDL cholesterol; prevalence of use of lipid lowering agents and the lipid concentrations of people taking them. Results Mean total cholesterol concentrations were 5.47 (SE 0.02) mmol/l in men and 5.59 (0.02) mmol/l in women. Mean HDL cholesterol concentrations were 1.28 (0.01) mmol/l in men and 1.55 (0.01) mmol/l in women. Overall, of 10 569 adults who had a valid cholesterol measurement taken 7133 (67.5%; 95% confidence interval 66.5% to 68.4%) had a total cholesterol concentration greater than or equal to5 mmol/l, 2804 (26.5%; 25.7% to 27.4%) had a ratio of total cholesterol to HDL cholesterol greater than or equal to5 mmol/l, and 237 (2.2%; 1.9% to 2.5%) reported taking lipid lowering drugs. Of 117 participants with no history of cardiovascular disease but whose estimated 10 year risk of coronary heart disease was greater than or equal to 30% and whose total cholesterol concentration was greater than or equal to5 mmol/l, four (3%) were taking lipid lowering drugs. Of 385 adults aged 16-75 with a history of coronary heart disease and eligible for lipid lowering treatment, 114 (30%; 25%, to 34%) were taking lipid lowering drugs, of whom only 50 (44%; 35% to 53%) had a total cholesterol concentration <5 mmo/l. Conclusions Despite the high prevalence of dyslipidaemia in English adults, the proportion of adults taking lipid lowering drugs in 1998 was only 2.2%. Rates of treatment were low among high risk patients eligible for primary prevention with lipid lowering drugs, and less than one third of patients with established cardiovascular disease received such treatment.	UCL Royal Free & Univ Coll Med Sch, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; Imperial Coll Sch Med, Dept Clin Pharmacol, Cardiovasc Studies Unit, London W2 1PG, England	University of London; University College London; UCL Medical School; Imperial College London	Primatesta, P (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England.	paolap@public-health.uclac.uk						ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; *BRIT HEART FDN HL, 2000, EUR CARD DIS STAT; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; ERENS B, 1999, HLTH SURVEY ENGLAND, V1; Erens B, 1999, HLTH SURVEY ENGLAND, V2; Haq IU, 1999, HEART, V81, P40, DOI 10.1136/hrt.81.1.40; *NAT SERV FRAM COR, 2000, MOD STAND SERV MOD 2; *NHS EX, 1997, STAND MED ADV COMM U; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PEDERSEN TR, 1994, LANCET, V344, P1383; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIEDEL J, 1983, CLIN CHEM, V29, P1075; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Wood D, 1998, HEART, V80, pS1; World Health Organization, 1998, WORLD HLTH STAT ANN	20	113	115	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 25	2000	321	7272					1322	1325		10.1136/bmj.321.7272.1322	http://dx.doi.org/10.1136/bmj.321.7272.1322			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090516	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000165561600027
J	Holt, PG				Holt, PG			Parasites, atopy, and the hygiene hypothesis: resolution of a paradox?	LANCET			English	Editorial Material							SENSITIZATION; ALLERGENS		Univ Western Australia, TVW Telethon Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Holt, PG (corresponding author), Univ Western Australia, TVW Telethon Inst Child Hlth Res, Perth, WA 6872, Australia.		Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935				Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GERRARD JW, 1976, ANN ALLERGY, V37, P91; Holt PG, 1999, NATURE, V402, pB12; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; JULGE K, IN PRESS J ALLERGY C; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x	14	66	69	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 18	2000	356	9243					1699	1701		10.1016/S0140-6736(00)03198-6	http://dx.doi.org/10.1016/S0140-6736(00)03198-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095252				2022-12-28	WOS:000165462300003
J	Delamothe, T				Delamothe, T			O happy day	BRITISH MEDICAL JOURNAL			English	Article																		Frye N., 1953, SELECTED POETRY PROS; Hamlyn Robin, 2000, W BLAKE; MARSHALL P, 1994, W BLAKE VISIONARY AN; *TAT GALL, 1978, W BLAK 9 MARCH 21 MA	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1597	1598		10.1136/bmj.321.7276.1597	http://dx.doi.org/10.1136/bmj.321.7276.1597			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124193	Green Published			2022-12-28	WOS:000166134500030
J	Pager, CK				Pager, CK			Streptokinase versus alteplase and other treatments for acute and delayed thrombolysis of blood stains in clothing	BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the usefulness of heparin, alteplase, and streptokinase in removing blood stains. Design Randomised controlled trial. Setting Hospital laundry. Interventions Blood stains were allocated to treatment with alteplase, streptokinase, heparin, a commercial enzymatic stain remover, or no treatment at all after three or seven hours and then washed in hot or cold water two hours later. Results Both hot water and early treatment were strongly associated with improved stain removal. AU four treatments were associated with a worse outcome than no treatment at all, although for streptokinase this trend did not reach significance. The commercial stain remover gave the worst results of ail treatments tested. Conclusions Contrary to popular wisdom, hot water is much more effective than cold in removing blood stains. Methodologically rigorous research and evidence based principles are needed within the laundry industry, and the role of thrombolytic drugs should be assessed further.	Royal Prince Alfred Hosp, Sydney, NSW 2050, Australia	University of Sydney	Pager, CK (corresponding author), Royal Prince Alfred Hosp, Sydney, NSW 2050, Australia.							ASLETT D, 1990, D ASLETTS STAIN BUST; BARKER C, 1996, MENS HLTH, V11, P152; CHEVALLIER G, 1986, STAINS FABRICS 1000; FLIGOR A, 1937, SPOTTING MANUAL DRY; GERRY R, 1996, CHEM MARKET REPORTER, V251, P503; Hacke W, 1999, REV NEUROL, V155, P662; Hacke W, 1999, REV NEUROLOGIA, V29, P638, DOI 10.33588/rn.2907.99237; MCABBOT H, 1993, H MCABBOTS STAIN REM; Meneveau N, 1998, J AM COLL CARDIOL, V31, P1057, DOI 10.1016/S0735-1097(98)00068-0; MOORE AC, 1977, CLEAN EVERYTHING; PINKHAM ME, 1997, CLEAN HOUSE; SINGER, 1985, CLOTHING CARE REPAIR; 1974, GOOD HOUSEKEEPING MA; 1987, CLEANING MAINTENANCE	14	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1554	1556		10.1136/bmj.321.7276.1554	http://dx.doi.org/10.1136/bmj.321.7276.1554			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124171	Bronze, Green Published			2022-12-28	WOS:000166134500008
J	Ayus, JC; Arieff, AI				Ayus, JC; Arieff, AI			Noncardiogenic pulmonary edema in marathon runners - Response	ANNALS OF INTERNAL MEDICINE			English	Letter							HYPONATREMIA		Baylor Coll Med, Houston, TX 77024 USA; Univ Calif San Francisco, San Francisco, CA 94965 USA	Baylor College of Medicine; University of California System; University of California San Francisco	Ayus, JC (corresponding author), Baylor Coll Med, Houston, TX 77024 USA.							Ayus JC, 1999, JAMA-J AM MED ASSOC, V281, P2299, DOI 10.1001/jama.281.24.2299; Garigan TP, 1999, MIL MED, V164, P234, DOI 10.1093/milmed/164.3.234; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; Speedy DB, 1999, MED SCI SPORT EXER, V31, P809, DOI 10.1097/00005768-199906000-00008	4	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					1011	1011		10.7326/0003-4819-133-12-200012190-00025	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00025			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119411				2022-12-28	WOS:000165952300018
J	Fagon, JY; Chastre, J				Fagon, JY; Chastre, J			Management of suspected ventilator-associated pneumonia - Reply	ANNALS OF INTERNAL MEDICINE			English	Letter							INTENSIVE-CARE-UNIT		Hop Europeen Georges Pompidou, F-75015 Paris, France; Hop Bichat Claude Bernard, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Fagon, JY (corresponding author), Hop Europeen Georges Pompidou, F-75015 Paris, France.							AlvarezLerma F, 1996, INTENS CARE MED, V22, P387, DOI 10.1007/BF01712153; Cook D, 2000, INTENS CARE MED, V26, pS31, DOI 10.1007/s001340051116; JOLLIET P, 1992, INTENS CARE MED, V18, P160, DOI 10.1007/BF01709240; Singh N, 2000, AM J RESP CRIT CARE, V162, P505, DOI 10.1164/ajrccm.162.2.9909095	4	14	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					1009	1009		10.7326/0003-4819-133-12-200012190-00021	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00021			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119407				2022-12-28	WOS:000165952300014
J	Jones, A; Pill, R; Adams, S				Jones, A; Pill, R; Adams, S			Qualitative study of views of health professionals and patients on guided self management plans for asthma	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To explore the views held by general practitioners, practice nurses, and patients about the role of guided self management plans in asthma care. Design Qualitative study using nine focus groups that each met on two occasions. Setting South Wales. Subjects 13 asthma nurses, 11 general practitioners (six with an interest in asthma), and 32 patients (13 adults compliant with treatment, 12 non-compliant adults, and seven teenagers). Results Neither health professionals nor patients were enthusiastic about guided self management plans, and, although for different reasons, almost all participants were ambivalent about their usefulness or relevance. Most professionals opposed their use. Few patients reported sustained use, and most felt that plans were largely irrelevant to them. The attitudes associated with these views reflect the gulf between the professionals' concept of the "responsible asthma patient" and the patients' view. Conclusions Attempts to introduce self guided management plans in primary care are unlikely to be successful. A more patient centred, patient negotiated plan is needed for asthma care in the community.	Cardiff Univ, Ctr Hlth, Dept Gen Practice, Cardiff CF26 9PN, S Glam, Wales; Univ Swansea, Sch Social Sci & Int Dev, Swansea SA2 8PP, W Glam, Wales	Cardiff University; Swansea University	Jones, A (corresponding author), Princess St Surg, Swansea SA4 2US, W Glam, Wales.	research@gors.freeserve.co.uk						Adams S, 1997, SOC SCI MED, V45, P189, DOI 10.1016/S0277-9536(96)00333-4; [Anonymous], 1993, BRIT MED J, V306, P776; Ayres JG, 1996, EUR RESPIR J, V9, P886, DOI 10.1183/09031936.96.09050886; GIBSON PG, 2000, COCHRANE LIB; Guba E., 1989, 4 GENERATION EVALUAT; HAUGHNEY J, 1997, AIRWAYS, V4, P2; JONES KP, 1995, THORAX, V50, P851, DOI 10.1136/thx.50.8.851; Lahdensuo A, 1999, BMJ-BRIT MED J, V319, P759, DOI 10.1136/bmj.319.7212.759; LEVY M, 1999, ED SELF MANAGEMENT A, P63; Neville RG, 1999, THORAX, V54, P813, DOI 10.1136/thx.54.9.813; Partridge MR, 1990, RES CLIN FORUMS, V15, P65; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; YOON R, 1993, THORAX, V48, P1110, DOI 10.1136/thx.48.11.1110	13	103	104	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2000	321	7275					1507	1510		10.1136/bmj.321.7275.1507	http://dx.doi.org/10.1136/bmj.321.7275.1507			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118179	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000165994700027
J	Genzer, J; Efimenko, K				Genzer, J; Efimenko, K			Creating long-lived superhydrophobic polymer surfaces through mechanically assembled monolayers	SCIENCE			English	Article							ORIENTATION; ENERGY	We show that elastomeric surfaces can be tailored using "mechanically assembled monolayers" (MAMs), structures that are fabricated by combining self-assembly of surface grafting molecules with mechanical manipulation of the grafting points in the underlying elastic surface. The versatility of this surface modification method is demonstrated by fabricating MAMs with semifluorinated (SF) molecules. These SF-MAMs have superior nonwetting and barrier properties in that they are "superhydrophobic" and nonpermeable. We also establish that these material characteristics do not deteriorate even after prolonged exposure to water, which usually causes surface reconstruction in conventionally prepared SF self-assembled monolayers.	N Carolina State Univ, Dept Chem Engn, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Genzer, J (corresponding author), N Carolina State Univ, Dept Chem Engn, Raleigh, NC 27695 USA.	jan_genzer@ncsu.edu	Gentleman, Molly M/A-7137-2010; Efimenko, Kirill/AAC-9102-2019	Genzer, Jan/0000-0002-1633-238X				Andersson M, 1999, BIOFOULING, V14, P167, DOI 10.1080/08927019909378407; Bowden N, 1998, NATURE, V393, P146, DOI 10.1038/30193; CHAUDHURY MK, 1995, BIOSENS BIOELECTRON, V10, P785, DOI 10.1016/0956-5663(95)99216-8; Chaudhury MK, 1997, CURR OPIN COLLOID IN, V2, P65, DOI 10.1016/S1359-0294(97)80009-X; CHAUDHURY MK, 1992, SCIENCE, V255, P1230, DOI 10.1126/science.255.5049.1230; Chaudhury MK, 1996, MAT SCI ENG R, V16, P97, DOI 10.1016/0927-796X(95)00185-9; CHIDSEY CED, 1990, LANGMUIR, V6, P682, DOI 10.1021/la00093a026; EFIMENKO K, UNPUB; Fischer DA, 1998, APPL SURF SCI, V133, P58, DOI 10.1016/S0169-4332(98)00007-5; Genzer J, 2000, LANGMUIR, V16, P1993, DOI 10.1021/la9910327; Genzer J, 2000, MACROMOLECULES, V33, P1882, DOI 10.1021/ma991182o; Hillborg H, 1999, IEEE T DIELECT EL IN, V6, P703, DOI 10.1109/94.798127; Huck WTS, 2000, LANGMUIR, V16, P3497, DOI 10.1021/la991302l; Johnston E, 1999, MACROMOLECULES, V32, P8173, DOI 10.1021/ma990628y; Kennan JJ, 1997, J BIOMED MATER RES, V36, P487; Ouyang M, 2000, CHEM MATER, V12, P1591, DOI 10.1021/cm990770d; Silver JH, 1999, BIOMATERIALS, V20, P1533, DOI 10.1016/S0142-9612(98)00173-2; Stohr J, 2013, SPRINGE SER SURF SCI; SWALEN JD, 1987, LANGMUIR, V3, P932, DOI 10.1021/la00078a011; Ulman A., 1991, INTRO ULTRATHIN ORGA; Wang JG, 1997, MACROMOLECULES, V30, P1906, DOI 10.1021/ma961412o; WASSERMAN SR, 1989, LANGMUIR, V5, P1074, DOI 10.1021/la00088a035	22	523	558	13	351	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	2000	290	5499					2130	2133		10.1126/science.290.5499.2130	http://dx.doi.org/10.1126/science.290.5499.2130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118144				2022-12-28	WOS:000165870600052
J	Harmer, SL; Hogenesch, LB; Straume, M; Chang, HS; Han, B; Zhu, T; Wang, X; Kreps, JA; Kay, SA				Harmer, SL; Hogenesch, LB; Straume, M; Chang, HS; Han, B; Zhu, T; Wang, X; Kreps, JA; Kay, SA			Orchestrated transcription of key pathways in Arabidopsis by the circadian clock	SCIENCE			English	Article							HIGHER-PLANTS; GENE; THALIANA; METABOLISM; PROTEIN; MUTANTS; STARCH	Like most organisms, plants have endogenous biological clocks that coordinate internal events with the external environment. We used high-density oligonucleotide microarrays to examine gene expression in Arabidopsis and found that 6% of the more than 8000 genes on the array exhibited circadian changes in steady-state messenger RNA Levers. Clusters of circadian-regulated genes were found in pathways involved in plant responses to Light and other key metabolic pathways. Computational analysis of cycling genes allowed the identification of a highly conserved promoter motif that we found to be required for circadian control of gene expression. Our study presents a comprehensive view of the temporal compartmentalization of physiological pathways by the circadian clock in a eukaryote.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Univ Virginia, Dept Internal Med, Div Endocrinol & Metab, NSF Ctr Biol Timing,Ctr Biomath Technol, Charlottesville, VA 22904 USA; Novartis Agr Discovery Inst, San Diego, CA 92121 USA	Scripps Research Institute; Novartis; National Science Foundation (NSF); University of Virginia; Novartis	Kay, SA (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Harmer, Sarah/G-5572-2016; Rosa, Bruce/F-6393-2010; Kay, Steve A/F-6025-2011; Zhu, Tong/G-5202-2011	Harmer, Sarah/0000-0002-5627-5500; Kay, Steve A/0000-0002-0402-2878; Zhu, Tong/0000-0002-8732-3499; Harmer, Stacey/0000-0001-6813-6682	NIDDK NIH HHS [R01 DK51562] Funding Source: Medline; NIGMS NIH HHS [5F32GM20118-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020118] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beator J, 1996, CHRONOBIOL INT, V13, P319, DOI 10.3109/07420529609012657; BOREVITZ JO, IN PRESS PLANT CELL; CHATTERTON NJ, 1979, PLANT PHYSIOL, V64, P749, DOI 10.1104/pp.64.5.749; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cosgrove DJ, 1997, ANNU REV CELL DEV BI, V13, P171, DOI 10.1146/annurev.cellbio.13.1.171; Cutler S, 1997, CURR BIOL, V7, pR108, DOI 10.1016/S0960-9822(06)00050-9; Daniels MJ, 1996, PLANT CELL, V8, P587, DOI 10.1105/tpc.8.4.587; Darwin C, 1880, POWER MOVEMENT PLANT; Dowson-Day MJ, 1999, PLANT J, V17, P63, DOI 10.1046/j.1365-313X.1999.00353.x; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Gibson LCD, 1996, PLANT PHYSIOL, V111, P61, DOI 10.1104/pp.111.1.61; Goddijn OJM, 1999, TRENDS PLANT SCI, V4, P315, DOI 10.1016/S1360-1385(99)01446-6; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Koprivova A, 2000, PLANT PHYSIOL, V122, P737, DOI 10.1104/pp.122.3.737; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; Lam HM, 1996, ANNU REV PLANT PHYS, V47, P569, DOI 10.1146/annurev.arplant.47.1.569; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; LI JY, 1993, PLANT CELL, V5, P171, DOI 10.1105/tpc.5.2.171; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Lorberth R, 1998, NAT BIOTECHNOL, V16, P473, DOI 10.1038/nbt0598-473; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; PALME K, COMMUNICATION; RIKIN A, 1993, PLANT PHYSIOL, V101, P31, DOI 10.1104/pp.101.1.31; Samach A, 2000, BIOESSAYS, V22, P38, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;38::AID-BIES8&gt;3.0.CO;2-L; Shinozaki K, 2000, CURR OPIN PLANT BIOL, V3, P217, DOI 10.1016/S1369-5266(00)00067-4; Shirley BW, 1996, TRENDS PLANT SCI, V1, P377, DOI 10.1016/1360-1385(96)10040-6; Somers DE, 2000, CELL, V101, P319, DOI 10.1016/S0092-8674(00)80841-7; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Steponkus PL, 1998, P NATL ACAD SCI USA, V95, P14570, DOI 10.1073/pnas.95.24.14570; Strayer C, 2000, SCIENCE, V289, P768, DOI 10.1126/science.289.5480.768; Taiz L., 1998, PLANT PHYSIOL, P543; Yan OY, 1998, P NATL ACAD SCI USA, V95, P8660, DOI 10.1073/pnas.95.15.8660	34	1226	1293	3	228	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2110	2113		10.1126/science.290.5499.2110	http://dx.doi.org/10.1126/science.290.5499.2110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118138				2022-12-28	WOS:000165870600046
J	Couch, RB				Couch, RB			Drug therapy: Prevention and treatment of influenza.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GUILLAIN-BARRE-SYNDROME; LONG-TERM-CARE; NEURAMINIDASE INHIBITOR OSELTAMIVIR; VIRUS-VACCINE; INHALED ZANAMIVIR; ELDERLY PERSONS; UNITED-STATES; RESPIRATORY VIRUSES; CONTROLLED-TRIAL; WORKING ADULTS		Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Couch, RB (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.	rcouch@bcm.tmc.edu			NIAID NIH HHS [N01-AI-65298, N01-AI-32685, N01-AI-15103] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI065298, N01AI032685, N01AI015103] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], 1999, MMWR MORB MORTAL WKL, V48, P1139; Arden NH, 2000, INFECT CONT HOSP EP, V21, P59, DOI 10.1086/501702; Atmar RL, 1996, J CLIN MICROBIOL, V34, P2604, DOI 10.1128/JCM.34.10.2604-2606.1996; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; Belshe RB, 2000, J PEDIATR-US, V136, P168, DOI 10.1016/S0022-3476(00)70097-7; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Bradley SF, 1999, INFECT CONT HOSP EP, V20, P629, DOI 10.1086/501687; Bui M, 1996, J VIROL, V70, P8391, DOI 10.1128/JVI.70.12.8391-8401.1996; Capasso L, 1999, LANCET, V353, P504, DOI 10.1016/S0140-6736(05)75184-9; Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9; Cass LMR, 2000, RESP MED, V94, P166, DOI 10.1053/rmed.1999.0718; Cass LMR, 1999, CLIN PHARMACOKINET, V36, P21, DOI 10.2165/00003088-199936001-00003; Cass LMR, 1999, CLIN PHARMACOKINET, V36, P1, DOI 10.2165/00003088-199936001-00001; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P619; CLOVER RD, 1986, AM J DIS CHILD, V140, P706, DOI 10.1001/archpedi.1986.02140210104036; Couch R. B., 1986, UCLA S MOL CELLULAR, V36, P223; Couch RB, 1999, CLIN INFECT DIS, V28, P548, DOI 10.1086/515171; COUCH RB, 1986, J INFECT DIS, V153, P431, DOI 10.1093/infdis/153.3.431; COUCH RB, 1983, ANNU REV MICROBIOL, V37, P529, DOI 10.1146/annurev.mi.37.100183.002525; Couch RB, 1996, INT CONGR SER, V1123, P97; COUCH RB, 1984, MOL VIROLOGY EPIDEMI, P119; COUCH RB, 1986, ANTIVIRAL CHEMOTHERA, P50; Couch Robert B., 1997, Journal of Infectious Diseases, V176, pS38, DOI 10.1086/514173; Couch Robert B., 1997, P369; Demicheli V, 2000, VACCINE, V18, P957, DOI 10.1016/S0264-410X(99)00332-1; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; DOLIN R, 1983, 23 INT C ANT AG CHEM; Drinka PJ, 1997, J FAM PRACTICE, V45, P509; Drinka PJ, 1998, ARCH INTERN MED, V158, P2155, DOI 10.1001/archinte.158.19.2155; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P1133, DOI 10.1001/jama.272.14.1133; GLEZEN WP, 1978, NEW ENGL J MED, V298, P587, DOI 10.1056/NEJM197803162981103; GLEZEN WP, 1997, VIRAL INFECT HUMANS, P473; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; Hayden FG, 2000, NEW ENGL J MED, V343, P1282, DOI 10.1056/NEJM200011023431801; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; HAYDEN FG, 1992, REV MED VIROL, V2, P89, DOI 10.1002/rmv.1980020205; HAYDEN FG, 1996, ANTIVIRAL DRUG RESIS, P65; Hedrick JA, 2000, PEDIATR INFECT DIS J, V19, P410, DOI 10.1097/00006454-200005000-00005; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; HOFFMAN CE, 1973, SELECTIVE INHIBITORS, P199; HURWITZ ES, 1981, NEW ENGL J MED, V304, P1557, DOI 10.1056/NEJM198106253042601; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Kaiser L, 1999, ANTIVIR RES, V42, P149, DOI 10.1016/S0166-3542(99)00034-0; KAPLAN JE, 1982, JAMA-J AM MED ASSOC, V248, P698, DOI 10.1001/jama.248.6.698; Keitel WA, 1997, VACCINE, V15, P1114, DOI 10.1016/S0264-410X(97)00003-0; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008; LAMB RA, 1996, FIELDS VIROLOGY, V1, P1353; LAMONTAGNE JR, 1983, REV INFECT DIS, V5, P723; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; LEE C, 1999, 39 INT C ANT AG CHEM, P421; MAASSAB HF, 1985, VACCINE, V3, P355, DOI 10.1016/0264-410X(85)90124-0; MARGOLIS K, 1991, JAMA-J AM MED ASSOC, V265, P2810; MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139; MAST EE, 1991, AM J EPIDEMIOL, V134, P988, DOI 10.1093/oxfordjournals.aje.a116184; McKimm-Breschkin JL, 1998, J VIROL, V72, P2456, DOI 10.1128/JVI.72.3.2456-2462.1998; MEIKLEJOHN G, 1983, J INFECT DIS, V148, P775, DOI 10.1093/infdis/148.5.775; MIST Study Grp, 1999, LANCET, V353, P1104; Monto AS, 1999, J ANTIMICROB CHEMOTH, V44, P23, DOI 10.1093/jac/44.suppl_2.23; MONTO AS, 1975, AM J EPIDEMIOL, V102, P553, DOI 10.1093/oxfordjournals.aje.a112193; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; MONTO AS, 1985, AM J EPIDEMIOL, V121, P811, DOI 10.1093/oxfordjournals.aje.a114052; Munoz FM, 2000, ANTIVIR RES, V46, P91, DOI 10.1016/S0166-3542(00)00092-9; MURPHY BR, 1993, INFECT DIS CLIN PRAC, V2, P174, DOI 10.1097/00019048-199305000-00003; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nichol KL, 1996, ARCH INTERN MED, V156, P1546, DOI 10.1001/archinte.156.14.1546; Nichol KL, 1999, JAMA-J AM MED ASSOC, V282, P137, DOI 10.1001/jama.282.2.137; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Noyola DE, 2000, J CLIN MICROBIOL, V38, P1161, DOI 10.1128/JCM.38.3.1161-1165.2000; Ohmit SE, 1999, J AM GERIATR SOC, V47, P165, DOI 10.1111/j.1532-5415.1999.tb04574.x; OXFORD JS, 1980, PHARMACOL THERAPEUT, V11, P181, DOI 10.1016/0163-7258(80)90072-8; PARKMAN PD, 1977, J INFECT DIS, V136, pS722, DOI 10.1093/infdis/136.Supplement_3.S722; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; PIEDRA PA, 1991, SEMIN PEDIAT INFECT, V2, P140; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; Tai CY, 1998, ANTIMICROB AGENTS CH, V42, P3234, DOI 10.1128/AAC.42.12.3234; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VERNIER VG, 1969, TOXICOL APPL PHARM, V15, P642, DOI 10.1016/0041-008X(69)90066-0; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908; WRIGHT PF, 1977, J INFECT DIS, V136, pS731, DOI 10.1093/infdis/136.Supplement_3.S731; Ziegler T, 1999, J INFECT DIS, V180, P935, DOI 10.1086/314994; 1999, MED LETT DRUGS THER, V41, P113; 1989, MMWR MORB MORTAL WKL, V38, P124	103	124	136	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1778	1787		10.1056/NEJM200012143432407	http://dx.doi.org/10.1056/NEJM200012143432407			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11114318				2022-12-28	WOS:000165812000007
J	Berger, A				Berger, A			Science commentary: Renal function - and how to assess it	BRITISH MEDICAL JOURNAL			English	Article																		CAMERON JS, 1998, OXFORD TXB CLIN NEPH	1	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1444	1444		10.1136/bmj.321.7274.1444	http://dx.doi.org/10.1136/bmj.321.7274.1444			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110736	Green Published, Bronze			2022-12-28	WOS:000165852300026
J	Attaran, A; Maharaj, R				Attaran, A; Maharaj, R			Ethical debate - Doctoring malaria, badly: the global campaign to ban DDT	BRITISH MEDICAL JOURNAL			English	Editorial Material									Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA; S Africa Dept Hlth, ZA-0001 Pretoria, South Africa	Harvard University	Attaran, A (corresponding author), Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA.								0	50	51	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1403	1403		10.1136/bmj.321.7273.1403	http://dx.doi.org/10.1136/bmj.321.7273.1403			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099289	Green Published			2022-12-28	WOS:000165720100035
J	Mazzarello, P				Mazzarello, P			What dreams may come? The scientific benefits of eating cheese before bedtime.	NATURE			English	Editorial Material									CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR)	Mazzarello, P (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.			MAZZARELLO, PAOLO ANGELO/0000-0003-4130-5727				Maquet P, 2000, NAT NEUROSCI, V3, P831, DOI 10.1038/77744; STRATHERN P, 2000, MENDELEYEVS DREAM; 1960, PERSPECTIVES BIOL ME, V4, P1	3	32	32	0	26	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					523	523		10.1038/35046170	http://dx.doi.org/10.1038/35046170			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117722	Bronze			2022-12-28	WOS:000165548600093
J	Peng, CY; Manning, L; Albertson, R; Doe, CQ				Peng, CY; Manning, L; Albertson, R; Doe, CQ			The tumour-suppressor genes lgl and dlg regulate basal protein targeting in Drosophila neuroblasts	NATURE			English	Article							II HEAVY-CHAIN; ASYMMETRIC LOCALIZATION; CELL; PROSPERO; MITOSIS; MELANOGASTER; MECHANISM; DIVISIONS; TOMOSYN; MIRANDA	Drosophila neuroblasts are a model system for studying asymmetric cell division: they divide unequally to produce an apical neuroblast and a basal ganglion mother cell that differ in size, mitotic activity and developmental potential. During neuroblast mitosis, an apical protein complex orients the mitotic spindle and targets determinants of cell fate to the basal cortex(1), but the mechanism of each process is unknown. Here we show that the tumour-suppressor genes lethal giant larvae (lgl) and discs large (dlg) regulate basal protein targeting, but not apical complex formation or spindle orientation, in both embryonic and larval neuroblasts. Dlg protein is apically enriched and is required for maintaining cortical localization of Lgl protein. Basal protein targeting requires microfilament and myosin function, yet the lgl phenotype is strongly suppressed by reducing levels of myosin II. We conclude that Dlg and Lgl promote, and myosin II inhibits, actomyosin-dependent basal protein targeting in neuroblasts.	Univ Oregon, Howard Hughes Med Inst, Inst Neurosci, Inst Mol Biol, Eugene, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon	Doe, CQ (corresponding author), Univ Oregon, Howard Hughes Med Inst, Inst Neurosci, Inst Mol Biol, 1254, Eugene, OR 97403 USA.							Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Chou TB, 1996, GENETICS, V144, P1673; DOE CQ, IN PRESS CURR OPIN C; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; HAJJAR RJ, 1994, AM J PHYSIOL, V267, pH100, DOI 10.1152/ajpheart.1994.267.1.H100; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Jan YN, 1999, NAT CELL BIOL, V1, pE42, DOI 10.1038/10036; Kagami M, 1998, GENETICS, V149, P1717; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lu BW, 1999, MOL CELL, V4, P883, DOI 10.1016/S1097-2765(00)80218-X; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; Manning L, 1999, DEVELOPMENT, V126, P2063; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Skeath JB, 1998, DEVELOPMENT, V125, P1857; SPANA EP, 1995, DEVELOPMENT, V121, P3187; Stanley H, 1997, P NATL ACAD SCI USA, V94, P14467, DOI 10.1073/pnas.94.26.14467; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1995, ONCOGENE, V11, P291; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	25	284	292	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					596	600		10.1038/35046094	http://dx.doi.org/10.1038/35046094			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117748				2022-12-28	WOS:000165548600121
J	Slotow, R; van Dyk, G; Poole, J; Page, B; Klocke, A				Slotow, R; van Dyk, G; Poole, J; Page, B; Klocke, A			Older bull elephants control young males	NATURE			English	Article							LOXODONTA-AFRICANA; MUSTH; BEHAVIOR		Univ KwaZulu Natal, Sch Life & Environm Sci, ZA-4041 Durban, South Africa; North West Parks & Tourism Board, Mogwase, South Africa	University of Kwazulu Natal	Slotow, R (corresponding author), Univ KwaZulu Natal, Sch Life & Environm Sci, George Campbell Bldg, ZA-4041 Durban, South Africa.	slotow@biology.und.ac.za	Slotow, Rob/AAM-9053-2020; Page, Bruce R/G-1245-2010	Page, Bruce R/0000-0001-7979-5229; Slotow, Rob/0000-0001-9469-1508				PARKER GA, 1974, J THEOR BIOL, V47, P223, DOI 10.1016/0022-5193(74)90111-8; POOLE JH, 1981, NATURE, V292, P830, DOI 10.1038/292830a0; POOLE JH, 1989, ANIM BEHAV, V37, P140, DOI 10.1016/0003-3472(89)90014-6; POOLE JH, 1987, BEHAVIOUR, V102, P283, DOI 10.1163/156853986X00171; POOLE JH, 1984, J REPROD FERTIL, V70, P255; Rasmussen LEL, 1996, J MAMMAL, V77, P422, DOI 10.2307/1382819; SMITH JM, 1976, ANIM BEHAV, V24, P159, DOI 10.1016/S0003-3472(76)80110-8	7	103	109	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					425	426		10.1038/35044191	http://dx.doi.org/10.1038/35044191			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100713				2022-12-28	WOS:000165429800032
J	Denamur, E; Lecointre, G; Darlu, P; Tenaillon, O; Acquaviva, C; Sayada, C; Sunjevaric, I; Rothstein, R; Elion, J; Taddei, F; Radman, M; Matic, I				Denamur, E; Lecointre, G; Darlu, P; Tenaillon, O; Acquaviva, C; Sayada, C; Sunjevaric, I; Rothstein, R; Elion, J; Taddei, F; Radman, M; Matic, I			Evolutionary implications of the frequent horizontal transfer of mismatch repair genes	CELL			English	Article							ESCHERICHIA-COLI STRAINS; SALMONELLA-TYPHIMURIUM; MUTATION-RATES; PHYLOGENETIC ANALYSIS; ADAPTIVE EVOLUTION; RECOMBINATION; DNA; BACTERIA; POPULATIONS; MUTATORS	Mutation and subsequent recombination events create genetic diversity, which is subjected to natural selection. Bacterial mismatch repair (MMR) deficient mutants, exhibiting high mutation and homeologous recombination rates, are frequently found in natural populations. Therefore, we have explored the possibility that MMR deficiency emerging in nature has left some "imprint" in the sequence of bacterial genomes. Comparative molecular phylogeny of MMR genes from natural Escherichia coli isolates shows that, compared to housekeeping genes, individual functional MMR genes exhibit high sequence mosaicism derived from diverse phylogenetic lineages. This apparent horizontal gene transfer correlates with hyperrecombination phenotype of MMR-deficient mutators. The sequence mosaicism of MMR genes may be a hallmark of a mechanism of adaptive evolution that involves modulation of mutation and recombination rates by recurrent losses and reacquisitions of MMR gene functions.	Univ Paris 05, INSERM, Fac Med Necker Enfants Malad, F-75730 Paris 15, France; Hop Robert Debre, INSERM, U458, F-75935 Paris 19, France; Museum Natl Hist Nat, Serv Systemat Mol, GDR CNRS 1005, F-75231 Paris 05, France; INSERM, U155, F-94276 Le Kremlin Bicetre, France; Genopole, ACTGene Rech & Dev, F-91035 Evry, France; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm); Genopole; UDICE-French Research Universities; Universite Paris Saclay; Columbia University	Radman, M (corresponding author), Univ Paris 05, INSERM, Fac Med Necker Enfants Malad, 156 Rue Vaugirard, F-75730 Paris 15, France.	radman@necker.fr	Elion, Jacques/A-1048-2014; Tenaillon, Olivier/L-9857-2017; Radman, Miroslav/HDM-5955-2022	Elion, Jacques/0000-0002-8407-1783; Tenaillon, Olivier/0000-0002-3796-1601; Radman, Miroslav/0000-0002-7034-4365; Rothstein, Rodney/0000-0002-4107-9654; Radman, Miroslav/0000-0003-0216-3148				BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; Bingen E, 1998, J INFECT DIS, V177, P642, DOI 10.1086/514217; Boe L, 2000, MUTAT RES-FUND MOL M, V448, P47, DOI 10.1016/S0027-5107(99)00239-0; Boyd EF, 1998, J BACTERIOL, V180, P1159, DOI 10.1128/JB.180.5.1159-1165.1998; Bregeon D, 1999, J GENET, V78, P21, DOI 10.1007/BF02994699; BULL JJ, 1993, SYST BIOL, V42, P384, DOI 10.2307/2992473; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; DESJARDINS P, 1995, J MOL EVOL, V41, P440, DOI 10.1007/BF00160315; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; DYKHUIZEN DE, 1991, J BACTERIOL, V173, P7257, DOI 10.1128/jb.173.22.7257-7268.1991; FARRIS JS, 1994, CLADISTICS, V10, P315, DOI 10.1111/j.1096-0031.1996.tb00196.x; Fowler RG, 1997, FEMS MICROBIOL REV, V21, P43, DOI 10.1111/j.1574-6976.1997.tb00344.x; FUNCHAIN P, 2000, IN PRESS GENETICS; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; GUTTMAN DS, 1994, SCIENCE, V266, P1380, DOI 10.1126/science.7973728; HERZER PJ, 1990, J BACTERIOL, V172, P6175, DOI 10.1128/jb.172.11.6175-6181.1990; Horst JP, 1999, TRENDS MICROBIOL, V7, P29, DOI 10.1016/S0966-842X(98)01424-3; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; KAHN PL, 1968, J BACTERIOL, V96, P205; KALTENBOECK B, 1993, J BACTERIOL, V175, P487, DOI 10.1128/JB.175.2.487-502.1993; LeClerc JE, 1998, MUTAT RES-FUND MOL M, V400, P89; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; Lecointre G, 1998, MOL BIOL EVOL, V15, P1685, DOI 10.1093/oxfordjournals.molbev.a025895; LI J, 1994, P NATL ACAD SCI USA, V91, P2552, DOI 10.1073/pnas.91.7.2552; LICHTEN M, 1984, P NATL ACAD SCI-BIOL, V81, P7180, DOI 10.1073/pnas.81.22.7180; LOVETT ST, 1988, GENETICS, V120, P37; Maddison WP, 1997, SYST BIOL, V46, P523, DOI 10.2307/2413694; Majewski J, 2000, J BACTERIOL, V182, P1016, DOI 10.1128/JB.182.4.1016-1023.2000; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MATIC I, 1995, CELL, V80, P507, DOI 10.1016/0092-8674(95)90501-4; Matic I, 1997, SCIENCE, V277, P1833, DOI 10.1126/science.277.5333.1833; Matic I, 1996, TRENDS MICROBIOL, V4, P69, DOI 10.1016/0966-842X(96)81514-9; MAYNARDSMITH J, 1991, NATURE, V349, P29; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; Metzgar D, 2000, CELL, V101, P581, DOI 10.1016/S0092-8674(00)80869-7; MICKEVICH MF, 1981, SYST ZOOL, V30, P351, DOI 10.2307/2413255; MILKMAN R, 1993, GENETICS, V133, P455; MILKMAN R, 1995, SYMP SOC GEN MICROBI, V52, P127; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JF, 1991, METHODS ENZYMOLOGY, V204; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MYERS RS, 1994, ANNU REV GENET, V28, P49, DOI 10.1146/annurev.ge.28.120194.000405; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; Oliver A, 2000, SCIENCE, V288, P1251, DOI 10.1126/science.288.5469.1251; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; Otto SP, 1998, TRENDS ECOL EVOL, V13, P145, DOI 10.1016/S0169-5347(97)01260-3; PANG PP, 1985, J BACTERIOL, V163, P1007, DOI 10.1128/JB.163.3.1007-1015.1985; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; RADMAN M, 1993, CHROMOSOMA, V102, P369, DOI 10.1007/BF00360400; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; SANDERSON KE, 1972, BACTERIOL REV, V36, P608, DOI 10.1128/MMBR.36.4.608-637.1972; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SHEN P, 1986, GENETICS, V112, P441; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Swofford D.L., 1993, PHYLOGENETIC ANAL US; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; Tenaillon O, 1999, GENETICS, V152, P485; TSUI HCT, 1994, MOL MICROBIOL, V13, P35, DOI 10.1111/j.1365-2958.1994.tb00400.x; Vulic M, 1997, P NATL ACAD SCI USA, V94, P9763, DOI 10.1073/pnas.94.18.9763; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Zahrt TC, 1997, P NATL ACAD SCI USA, V94, P9786, DOI 10.1073/pnas.94.18.9786; ZAWADZKI P, 1995, GENETICS, V140, P917	67	192	198	1	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					711	721		10.1016/S0092-8674(00)00175-6	http://dx.doi.org/10.1016/S0092-8674(00)00175-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114328	Bronze			2022-12-28	WOS:000165433100004
J	van den Biggelaar, AHJ; van Ree, R; Rodrigues, LC; Lell, B; Deelder, AM; Kremsner, PG; Yazdanbakhsh, M				van den Biggelaar, AHJ; van Ree, R; Rodrigues, LC; Lell, B; Deelder, AM; Kremsner, PG; Yazdanbakhsh, M			Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10	LANCET			English	Article							HUMAN LYMPHATIC FILARIASIS; ALLERGIC REACTIVITY; CYTOKINE CONTROL; CELL RESPONSES; ASTHMA; MODULATION; ACTIVATION; INDUCTION; ANTIBODY; CD4(+)	Background Most of the effort directed at understanding the role infections have in preventing allergy has focused on bacteria and viruses and their ability to divert the immune system towards T-helper-1 responses and away from proallergic T-helper-2 responses. However, helminth infections, highly prevalent in large parts of the developing world, where allergy is uncommon, stimulate strong T-helper-2 responses. We investigated the influence of chronic helminth infections on the prevalence of atopy and aimed to understand the relation at a detailed immunological level. Methods 520 Gabonese schoolchildren were tested for shin reaction to house-dust mite and other allergens, for Schistosoma haematobium eggs In urine, and for microfilariae in blood samples. Total and mite-specific IgE antibodies were measured. A subsample selected on the basis of their skin test to house-dust mite received detailed immunological investigations. Findings Children with urinary schistosomiasis had a lower prevalence of a positive skin reaction to house-dust mite than those free of this infection (odds ratio 0.32 [95% CI 0.16-0.63]). The degree of sensitisation to house-dust mite could not explain this difference in skin-prick positivity. Schistosome-antigen-specific concentrations of interleukin-10 were significantly higher in infected children, and higher specific concentrations of this anti-inflammatory cytokine were negatively associated with the outcome of skin-test reactivity to mite (0.53 [0.30-0.96]). No association between polyclonal IgE antibodies and skin-test results was found. Interpretation The anti-inflammatory cytokine, interleukin-10, induced in chronic schistosomiasis, appears central to suppressing atopy in African children.	Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands; CLB, Dept Allergy, Amsterdam, Netherlands; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany; Albert Schweitzer Hosp, Res Unit, Lambarene, Gabon	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of London; London School of Hygiene & Tropical Medicine; Eberhard Karls University of Tubingen	Yazdanbakhsh, M (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, L4-Q,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.		RODRIGUES, LAURA CUNHA/AAO-4130-2021; Yazdanbakhsh, Maria/AAI-3996-2020	Yazdanbakhsh, Maria/0000-0002-7666-1441; Rodrigues, Laura Cunha/0000-0001-9008-660X				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Edwards-Smith CJ, 1999, HEPATOLOGY, V30, P526, DOI 10.1002/hep.510300207; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193; Holt PG, 1999, NATURE, V402, pB12; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; JARRETT E, 1980, NATURE, V283, P302, DOI 10.1038/283302a0; KING CL, 1993, J CLIN INVEST, V92, P1667, DOI 10.1172/JCI116752; King CL, 1996, J IMMUNOL, V156, P4715; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Oxenius A, 1998, IMMUNITY, V9, P449, DOI 10.1016/S1074-7613(00)80628-7; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STRACHAN DP, 1989, BRIT MED J, V351, P1225; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YAZDANBAKHSH M, 1993, EUR J IMMUNOL, V23, P3312, DOI 10.1002/eji.1830231238; YEMANEBERHAN H, 1997, LANCET, V350, P400	30	525	541	0	42	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1723	1727		10.1016/S0140-6736(00)03206-2	http://dx.doi.org/10.1016/S0140-6736(00)03206-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095260				2022-12-28	WOS:000165462300011
J	Hash, M				Hash, M			Medicare plus choice plans	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US Hlth Care Financing Adm, Baltimore, MD 21207 USA		Hash, M (corresponding author), US Hlth Care Financing Adm, Baltimore, MD 21207 USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					2988	2988		10.1001/jama.284.23.2988	http://dx.doi.org/10.1001/jama.284.23.2988			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122572				2022-12-28	WOS:000165847200007
J	Orth-Gomer, K; Wamala, SP; Horsten, M; Schenck-Gustafsson, K; Schneiderman, N; Mittleman, MA				Orth-Gomer, K; Wamala, SP; Horsten, M; Schenck-Gustafsson, K; Schneiderman, N; Mittleman, MA			Marital stress worsens prognosis in women with coronary heart disease - The Stockholm Female Coronary Risk Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; SOCIAL SUPPORT; PSYCHOLOGICAL STRESS; DECISION LATITUDE; JOB STRAIN; FOLLOW-UP; HOSTILITY; NEUROENDOCRINE; MORTALITY	Context Psychosocial stress has been associated with incidence of coronary heart disease (CHD) in men, but the prognostic impact of such stress rarely has been studied in women. Objective To investigate the prognostic impact of psychosocial work stress and marital stress among women with CHD. Design and setting Population-based, prospective follow-up study conducted in the city of Stockholm, Sweden. Participants A total of 292 consecutive female patients aged 30 to 65 years (n = 279 working or cohabiting with a male partner) who were hospitalized for acute myocardial infarction or unstable angina pectoris between February 1991 and February 1994. Patients were followed up from the date of clinical examination until August 1997 (median, 4.8 years). Main Outcome Measures Recurrent coronary events, including cardiac death, acute myocardial infarction, and revascularization procedures, by marital stress (assessed using the Stockholm Marital Stress Scale, a structured interview) and by work stress (assessed using the ratio of work demand to work control). Results Among women who were married or cohabiting with a male partner (n = 187), marital stress was associated with a 2.9-fold (95% confidence interval [CI], 1.3-6.5) increased risk of recurrent events after adjustment for age, estrogen status, education level, smoking, diagnosis at index event, diabetes mellitus, systolic blood pressure, smoking, triglyceride level, high-density lipoprotein cholesterol level, and left ventricular dysfunction, Among working women (n = 200), work stress did not significantly predict recurrent coronary events (hazard ratio, 1.6; 95% CI, 0.8-3.3). Conclusions Our results indicate that marital stress but not work stress predicts poor prognosis in women aged 30 to 65 years with CHD. These findings differ from previous findings in men and suggest that specific preventive measures be tailored to the needs of women with CHD.	Karolinska Inst, Dept Publ Hlth Sci, Div Prevent Med, SE-17176 Stockholm, Sweden; Karolinska Hosp, Dept Med, Div Cardiol, S-10401 Stockholm, Sweden; Univ Miami, Behav Med Res Ctr, Dept Psychol, Miami, FL 33152 USA; Harvard Univ, Sch Publ Hlth, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Miami; Harvard University; Beth Israel Deaconess Medical Center; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Orth-Gomer, K (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Div Prevent Med, Norrbacka Plan 7, SE-17176 Stockholm, Sweden.	K.Orth-Gomer@phs.ki.se	; Tanne, David/F-2560-2010	Mittleman, Murray/0000-0001-9788-7274; Tanne, David/0000-0002-6699-2220; Schenck-Gustafsson, Karin/0000-0002-3659-5101	NHLBI NIH HHS [HL45785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Khalili F, 2000, AM J CARDIOL, V86, P211, DOI 10.1016/S0002-9149(00)00858-4; ALFREDSSON L, 1985, INT J EPIDEMIOL, V14, P378, DOI 10.1093/ije/14.3.378; ALFREDSSON L, 1997, SOCIALSTYRELSEN, P84; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BLUMENTHAL JA, 1987, BRIT J MED PSYCHOL, V60, P349, DOI 10.1111/j.2044-8341.1987.tb02754.x; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; Brown PC, 1998, ANN BEHAV MED, V20, P286, DOI 10.1007/BF02886378; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; EAKER ED, 1992, AM J EPIDEMIOL, V135, P854, DOI 10.1093/oxfordjournals.aje.a116381; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; Eaker Elaine D., 1998, Cardiology Clinics, V16, P103, DOI 10.1016/S0733-8651(05)70387-8; FRANKENHAEUSER M, 1989, J ORGAN BEHAV, V10, P321, DOI 10.1002/job.4030100404; FUKUDO S, 1992, CIRCULATION, V85, P2045, DOI 10.1161/01.CIR.85.6.2045; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; HAMMAR N, 1991, INT J EPIDEMIOL, V20, P114, DOI 10.1093/ije/20.1.114; Horsten M, 2000, EUR HEART J, V21, P1072, DOI 10.1053/euhj.1999.2012; Horsten M, 1999, PSYCHOSOM MED, V61, P49, DOI 10.1097/00006842-199901000-00009; Horsten M, 1999, J CARDIOVASC RISK, V6, P391; ILFELD FW, 1980, J NERV MENT DIS, V168, P375, DOI 10.1097/00005053-198006000-00010; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; Kiecolt-Glaser JK, 1998, ANN NY ACAD SCI, V840, P656, DOI 10.1111/j.1749-6632.1998.tb09604.x; Knox SS, 1998, AM J CARDIOL, V82, P1192, DOI 10.1016/S0002-9149(98)00599-2; Luecken LJ, 1997, PSYCHOSOM MED, V59, P352, DOI 10.1097/00006842-199707000-00003; LUNDBERG U, 1994, SCAND J PSYCHOL, V35, P315, DOI 10.1111/j.1467-9450.1994.tb00956.x; LUNDBERG U, 1999, J OCCUP HEALTH, V4, P1; Markovitz JH, 1996, PSYCHOSOM MED, V58, P143, DOI 10.1097/00006842-199603000-00008; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; Moser V, 1996, 268 SWED NAT I PSYCH; Orth-Gomer K, 1998, EUR HEART J, V19, P1648, DOI 10.1053/euhj.1998.1190; Orth-Gomer K, 1997, Lakartidningen, V94, P635; Orth-Gomer K, 1997, WOMEN HEART DIS, P407; ORTHGOMER K, 1993, PSYCHOSOM MED, V55, P37, DOI 10.1097/00006842-199301000-00007; OrthGomer K, 1997, CIRCULATION, V95, P329; ORTHGOMER K, 1987, J CHRON DIS, V40, P949, DOI 10.1016/0021-9681(87)90145-7; ORTHGOMER K, 1979, J PSYCHOSOM RES, V23, P165, DOI 10.1016/0022-3999(79)90001-1; PEARLIN L, 1979, RES COMMUNITY MENTAL; Pike JL, 1997, PSYCHOSOM MED, V59, P447, DOI 10.1097/00006842-199707000-00015; POPE MK, 1991, PSYCHOSOM MED, V53, P386, DOI 10.1097/00006842-199107000-00004; Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; SHUMAKER SA, 1991, HEALTH PSYCHOL, V10, P102, DOI 10.1037/0278-6133.10.2.102; SLOAN RP, 1994, AM J CARDIOL, V74, P298, DOI 10.1016/0002-9149(94)90382-4; SMITH KE, 1999, 32 US BUR CENS POP D; Smith TW, 1999, PSYCHOSOM MED, V61, P436, DOI 10.1097/00006842-199907000-00005; SPANIER GB, 1996, J MARRIAGE FAM, P15; *STAT CORP, 1997, STAT STAT SOFTW; *STAT SWED, 1998, PA TAL KVINN MAN; Suarez EC, 1998, PSYCHOSOM MED, V60, P78, DOI 10.1097/00006842-199801000-00017; THEORELL T, 1991, INT J CARDIOL, V30, P61, DOI 10.1016/0167-5273(91)90125-9; Theorell T, 1998, AM J PUBLIC HEALTH, V88, P382, DOI 10.2105/AJPH.88.3.382; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401; vonDras DD, 1996, INT J AGING HUM DEV, V43, P199, DOI 10.2190/M0GP-7R75-AQJ6-Q17H; Wamala SP, 1999, AM J PUBLIC HEALTH, V89, P315, DOI 10.2105/AJPH.89.3.315; Wamala SP, 2000, SOC SCI MED, V51, P481, DOI 10.1016/S0277-9536(00)00006-X; *WHO REG OFF EUR, 1976, MYOC INF COMM REG RE; Williams Redford B., 1996, Cardiology Clinics, V14, P97; WOLK MJ, 1972, CIRCULATION, V45, P1125, DOI 10.1161/01.CIR.45.5.1125	60	382	392	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3008	3014		10.1001/jama.284.23.3008	http://dx.doi.org/10.1001/jama.284.23.3008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	382VC	11122587	Bronze			2022-12-28	WOS:000165847200025
J	Riechmann, JL; Heard, J; Martin, G; Reuber, L; Jiang, CZ; Keddie, J; Adam, L; Pineda, O; Ratcliffe, OJ; Samaha, RR; Creelman, R; Pilgrim, M; Broun, P; Zhang, JZ; Ghandehari, D; Sherman, BK; Yu, CL				Riechmann, JL; Heard, J; Martin, G; Reuber, L; Jiang, CZ; Keddie, J; Adam, L; Pineda, O; Ratcliffe, OJ; Samaha, RR; Creelman, R; Pilgrim, M; Broun, P; Zhang, JZ; Ghandehari, D; Sherman, BK; Yu, CL			Arabidopsis transcription factors: Genome-wide comparative analysis among eukaryotes	SCIENCE			English	Article							DNA-BINDING; PLANT; DOMAIN; FAMILY; GENES; PROTEINS; DUPLICATION; SEQUENCE; REGULATOR; EVOLUTION	The completion of the Arabidopsis thaliana genome sequence allows a comparative analysis of transcriptional regulators across the three eukaryotic kingdoms. Arabidopsis dedicates over 5% of its genome to code for more than 1500 transcription factors, about 45% of which are from families specific to plants. Arabidopsis transcription factors that belong to families common to all eukaryotes do not share significant similarity with those of the other kingdoms beyond the conserved DNA binding domains, many of which have been arranged in combinations specific to each lineage. The genome-wide comparison reveals the evolutionary generation of diversity in the regulation of transcription.	Mendel Biotechnol, Hayward, CA 94545 USA		Riechmann, JL (corresponding author), Mendel Biotechnol, 21375 Cabot Blvd, Hayward, CA 94545 USA.	jriechmann@mendelbio.com	Riechmann, José Luis/M-7005-2018	Riechmann, José Luis/0000-0003-1108-1945; Reuber, Lynne/0000-0001-7806-2437; Jiang, Cai-Zhong/0000-0002-5972-7963				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; Allen MD, 1998, EMBO J, V17, P5484, DOI 10.1093/emboj/17.18.5484; Alvarez-Buylla ER, 2000, P NATL ACAD SCI USA, V97, P5328, DOI 10.1073/pnas.97.10.5328; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Blanc G, 2000, PLANT CELL, V12, P1093, DOI 10.1105/tpc.12.7.1093; Boggon TJ, 1999, SCIENCE, V286, P2119, DOI 10.1126/science.286.5447.2119; Bowman JL, 2000, CURR OPIN PLANT BIOL, V3, P17, DOI 10.1016/S1369-5266(99)00035-7; Braun EL, 1999, PLANT PHYSIOL, V121, P21, DOI 10.1104/pp.121.1.21; Burglin TR, 1998, DEV GENES EVOL, V208, P113, DOI 10.1007/s004270050161; Burns CG, 1999, P NATL ACAD SCI USA, V96, P13789, DOI 10.1073/pnas.96.24.13789; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carroll SB, 2000, CELL, V101, P577, DOI 10.1016/S0092-8674(00)80868-5; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; Cvitanich C, 2000, P NATL ACAD SCI USA, V97, P8163, DOI 10.1073/pnas.090468497; Czarnecka-Verner E, 2000, PLANT MOL BIOL, V43, P459, DOI 10.1023/A:1006448607740; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Germain S, 2000, GENE DEV, V14, P435; Goffeau A, 1997, NATURE, V387, P5, DOI DOI 10.1038/387005B0.PUBMED:9169864; Guilfoyle T, 1998, PLANT PHYSIOL, V118, P341, DOI 10.1104/pp.118.2.341; Hall LN, 1998, PLANT CELL, V10, P925, DOI 10.1105/tpc.10.6.925; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; Jin HL, 1999, PLANT MOL BIOL, V41, P577, DOI 10.1023/A:1006319732410; KOTSCHAK RD, 2000, TRENDS BIOCHEM SCI, V25, P294; Kranz H, 2000, PLANT J, V21, P231, DOI 10.1046/j.1365-313x.2000.00666.x; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; Luo D, 1999, CELL, V99, P367, DOI 10.1016/S0092-8674(00)81523-8; Makino S, 2000, PLANT CELL PHYSIOL, V41, P791, DOI 10.1093/pcp/41.6.791; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; MEYEROWITZ EM, 1999, TRENDS GENET, V15, pM65; Nagano Y, 2000, PLANT PHYSIOL, V124, P491, DOI 10.1104/pp.124.2.491; Richards DE, 2000, BIOESSAYS, V22, P573, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;573::AID-BIES10&gt;3.0.CO;2-H; Riechmann JL, 1997, BIOL CHEM, V378, P1079; Riechmann JL, 1998, BIOL CHEM, V379, P633; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; Schauser L, 1999, NATURE, V402, P191, DOI 10.1038/46058; Schoffl F, 1998, PLANT PHYSIOL, V117, P1135, DOI 10.1104/pp.117.4.1135; Scott MP, 2000, CELL, V100, P27, DOI 10.1016/S0092-8674(00)81681-5; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Soullier S, 1999, J MOL EVOL, V48, P517, DOI 10.1007/PL00006495; Theissen G, 2000, PLANT MOL BIOL, V42, P115, DOI 10.1023/A:1006332105728; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wykoff DD, 1999, P NATL ACAD SCI USA, V96, P15336, DOI 10.1073/pnas.96.26.15336	48	1919	3661	30	558	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	2000	290	5499					2105	2110		10.1126/science.290.5499.2105	http://dx.doi.org/10.1126/science.290.5499.2105			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118137				2022-12-28	WOS:000165870600045
J	Dowrick, C; Dunn, G; Ayuso-Mateos, JL; Dalgard, OS; Page, H; Lehtinen, V; Casey, P; Wilkinson, C; Vazquez-Barquero, JL; Wilkinson, G				Dowrick, C; Dunn, G; Ayuso-Mateos, JL; Dalgard, OS; Page, H; Lehtinen, V; Casey, P; Wilkinson, C; Vazquez-Barquero, JL; Wilkinson, G		ODIN Grp	Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAJOR DEPRESSION; PRIMARY-CARE	Objectives To determine the acceptability of two psychological interventions for depressed adults in the community and their effect on caseness, symptoms, and subjective function. Design A pragmatic multicentre randomised controlled trial, stratified by centre. Setting Nine urban and rural communities in Finland, Republic of Ireland, Norway, Spain, and the United Kingdom. Participants 452 participants aged 18 to 65, identified through a community survey with depressive or adjustment disorders according to the international classification of diseases, 10th revision or Diagnostic and Statistical Manual of Mental Disorders, fourth edition. Interventions Six individual sessions of problem solving treatment (n = 128), eight group sessions of the course on prevention of depression (n = 108), and controls (n = 189). Main outcome measures Completion rates for each intervention, diagnosis of depression. and depressive symptoms and subjective function. Results 63% of participants assigned to problem solving and 44% assigned to prevention of depression completed their intervention. The proportion of problem solving participants depressed at six months was 17% less than that fur controls, giving a number needed to treat of 6: the mean difference in Beck depression inventory score was -2.63 (95% interval -4.95 to -0.32), and there were significant improvements in SF-36 scores. For depression prevention, die difference in proportions of depressed participants was 14% (number needed to treat of 7); the mean difference in Beck depression inventory score was -1.50 (-4.16 to 1.17), and there were significant improvements in SF-36 scores. Such differences were not observed at 12 months. Neither specific diagnosis nor treatment with antidepressants affected outcome. Conclusions When offered to adults with depressive disorders in the community, problem solving treatment was more acceptable than the course on prevention of depression. Both interventions reduced caseness and improved subjective function..	Univ Liverpool, Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Univ Manchester, Sch Epidemiol & Hlth Sci, Manchester M13 9PT, Lancs, England; Univ Hosp Marques de Valdecilla, Unit Res Social Psychiat, Santander 39008, Spain; Univ Oslo, Inst Gen Practice & Community Med, N-0317 Oslo, Norway; STAKES Mental Hlth Res & Dev Grp, FIN-20810 Turku, Finland; Univ Coll Dublin, Mater Misericordiae Hosp, Dublin 7, Ireland; Cardiff Univ, Div Gen Practice, Wrexham LL13 7YP, Wales; Univ Liverpool, Dept Psychiat, Liverpool L69 3BX, Merseyside, England	University of Liverpool; University of Manchester; Hospital Universitario Marques de Valdecilla (HUMV); University of Oslo; Mater Misericordiae University Hospital; University College Dublin; Cardiff University; University of Liverpool	Dowrick, C (corresponding author), Univ Liverpool, Dept Primary Care, Liverpool L69 3GB, Merseyside, England.	cfd@liv.ac.uk		Ayuso-Mateos, Jose Luis/0000-0002-7544-826X; Cuijpers, Pim/0000-0001-5497-2743				AYUSOMATEOS J, 2000, IN PRESS BR J PSYCHI; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Cuijpers P, 1998, BEHAV THER, V29, P521, DOI 10.1016/S0005-7894(98)80047-6; Dowrick C, 1998, BRIT J PSYCHIAT, V172, P359, DOI 10.1192/bjp.172.4.359; Dunn G, 1999, BRIT J PSYCHIAT, V174, P95, DOI 10.1192/bjp.174.2.95; Eccles M, 1999, FAM PRACT, V16, P103, DOI 10.1093/fampra/16.2.103; Frank E, 1997, J CLIN PSYCHIAT, V58, P11; FREEMANTLE N, 1993, TREATMENT DEPRESSION; Goldberg DP., 1992, COMMON MENTAL DISORD; Hawton K., 1989, COGNITIVE BEHAV THER, P406; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; LEWINSOHN PM, 1989, CAN J BEHAV SCI, V21, P470, DOI 10.1037/h0079846; Little R. J. A., 1987, STAT ANAL MISSING DA; MUNOZ RF, 1995, AM J COMMUN PSYCHOL, V23, P199, DOI 10.1007/BF02506936; MUNOZ RF, 1998, UNPUB DEPRESSION PRE; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; PAVKEL ES, 1992, BMJ-BRIT MED J, V161, P633; Paykel ES, 1998, BRIT J PSYCHIAT, V173, P519, DOI 10.1192/bjp.173.6.519; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; World Health Organization (WHO) Division of Mental Health, 1994, SCHED CLIN ASS NEUR	23	121	123	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	2000	321	7274					1450	1454		10.1136/bmj.321.7274.1450	http://dx.doi.org/10.1136/bmj.321.7274.1450			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	382XH	11110739	Bronze, Green Published			2022-12-28	WOS:000165852300029
J	Labrenz, M; Druschel, GK; Thomsen-Ebert, T; Gilbert, B; Welch, SA; Kemner, KM; Logan, GA; Summons, RE; De Stasio, G; Bond, PL; Lai, B; Kelly, SD; Banfield, JF				Labrenz, M; Druschel, GK; Thomsen-Ebert, T; Gilbert, B; Welch, SA; Kemner, KM; Logan, GA; Summons, RE; De Stasio, G; Bond, PL; Lai, B; Kelly, SD; Banfield, JF			Formation of sphalerite (ZnS) deposits in natural biofilms of sulfate-reducing bacteria	SCIENCE			English	Article								Abundant, micrometer-scale, spherical aggregates of 2- to 5-nanometer-diameter sphalerite (ZnS) particles formed within natural biofilms dominated by relatively aerotolerant sulfate-reducing bacteria of the family Desulfobacteriaceae. The biofilm zinc concentration is about 10(6) times that of associated groundwater (0.09 to 1.1 parts per million line). Sphalerite also concentrates arsenic (0.01 weight %) and selenium (0.004 weight %). The almost monomineralic product results from buffering of sulfide concentrations at Low values by sphalerite precipitation. These results show how microbes control metal concentrations in groundwater- and wetland-based remediation systems and suggest biological routes for formation of some Low-temperature ZnS deposits.	Oregon State Univ, Dept Geosci, US Geol Survey, Corvallis, OR 97331 USA	Oregon State University; United States Department of the Interior; United States Geological Survey	Banfield, JF (corresponding author), Oregon State Univ, Dept Geosci, US Geol Survey, Corvallis, OR 97331 USA.		Gilbert, Pupa/A-6299-2010; Gilbert, Benjamin/E-3182-2010; Summons, Roger Everett/AAL-3789-2020; Bond, Philip/N-6649-2017; Bond, Philip/C-6046-2009	Gilbert, Pupa/0000-0002-0139-2099; Bond, Philip/0000-0002-9025-4797; Gilbert, Benjamin/0000-0003-0853-0826; Banfield, Jill/0000-0001-8203-8771; Welch, Susan/0000-0002-2890-0065				Banfield JF, 2000, SCIENCE, V289, P751, DOI 10.1126/science.289.5480.751; BECKING LGM, 1961, ECON GEOL, V56, P259; Benning LG, 2000, CHEM GEOL, V167, P25, DOI 10.1016/S0009-2541(99)00198-9; DEGENS ET, 1972, MINER DEPOSITA, V7, P1; Drury WJ, 1999, WATER ENVIRON RES, V71, P1244, DOI 10.2175/106143096X122375; Ehrlich HL, 1999, GEOMICROBIOL J, V16, P135, DOI 10.1080/014904599270659; Hu MA, 1998, CAN J EARTH SCI, V35, P936, DOI 10.1139/e98-041; Ledin M, 1996, EARTH-SCI REV, V41, P67, DOI 10.1016/0012-8252(96)00016-5; LOGAN GA, 2000, IN PRESS COSMOCHIM A; LUTHER GW, 1980, J SEDIMENT PETROL, V50, P1117; MILLER LP, 1950, BOYCE THOMPSON I CON, V16, P85; Minz D, 1999, APPL ENVIRON MICROB, V65, P4666; Minz D, 1999, APPL ENVIRON MICROB, V65, P4659; Nelson DC, 1996, GEOCHIM COSMOCHIM AC, V60, P3531, DOI 10.1016/0016-7037(96)00221-9; Newman DK, 1998, GEOMICROBIOL J, V15, P255, DOI 10.1080/01490459809378082; Temple KL, 1964, ECON GEOL, V59, P647, DOI DOI 10.2113/GSEC0NGE0.59.4.647; Teske A, 1998, APPL ENVIRON MICROB, V64, P2943; US Environment Protection Agency, 2000, CURR DRINK WAT STAND; VAINSHTEIN M, 1992, APPL MICROBIOL, V125, P554; Widdel F., 1992, PROKARYOTES, DOI 10.1007/978-1-4757-2191-1_2	20	466	518	13	280	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1744	1747		10.1126/science.290.5497.1744	http://dx.doi.org/10.1126/science.290.5497.1744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099408				2022-12-28	WOS:000165632400036
J	Ehleringer, JR; Casale, JF; Lott, MJ; Ford, VL				Ehleringer, JR; Casale, JF; Lott, MJ; Ford, VL			Tracing the geographical origin of cocaine	NATURE			English	Article							DEPTH CHROMATOGRAPHIC ANALYSES; SOUTH-AMERICAN; LEAVES; ILLICIT		Univ Utah, Dept Biol, Stable Isotope Ratio Facil Environm Res, Salt Lake City, UT 84112 USA; US Dept Justice, Drug Enforcement Adm, Special Testing & Res Lab, Mclean, VA 22102 USA	Utah System of Higher Education; University of Utah	Ehleringer, JR (corresponding author), Univ Utah, Dept Biol, Stable Isotope Ratio Facil Environm Res, 257 S 1400 E, Salt Lake City, UT 84112 USA.		Ehleringer, James/G-1780-2010					Ehleringer JR, 1999, FORENSIC SCI INT, V106, P27, DOI 10.1016/S0379-0738(99)00139-5; FARQUHAR GD, 1989, ANNU REV PLANT PHYS, V40, P503, DOI 10.1146/annurev.pp.40.060189.002443; Giuliani G, 2000, SCIENCE, V287, P631, DOI 10.1126/science.287.5453.631; Martinelli LA, 1999, BIOGEOCHEMISTRY, V46, P45, DOI 10.1023/A:1006100128782; Moore J M, 1998, Forensic Sci Rev, V10, P13; Moore JM, 1996, J CHROMATOGR A, V756, P193, DOI 10.1016/S0021-9673(96)00651-6; MOORE JM, 1994, J CHROMATOGR A, V659, P163, DOI 10.1016/0021-9673(94)85018-6; MOORE JM, 1994, J CHROMATOGR A, V674, P165, DOI 10.1016/0021-9673(94)85224-3; Roden JS, 2000, GEOCHIM COSMOCHIM AC, V64, P21, DOI 10.1016/S0016-7037(99)00195-7; Vogel J., 1993, STABLE ISOTOPES PLAN, P26; Wassenaar LI, 1998, P NATL ACAD SCI USA, V95, P15436, DOI 10.1073/pnas.95.26.15436	11	118	123	4	50	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					311	312		10.1038/35042680	http://dx.doi.org/10.1038/35042680			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099029				2022-12-28	WOS:000165296000032
J	Sneader, W				Sneader, W			The discovery of aspirin: a reappraisal	BRITISH MEDICAL JOURNAL			English	Article									Univ Strathclyde, Dept Pharmaceut Sci, Glasgow G4 0NR, Lanark, Scotland	University of Strathclyde	Sneader, W (corresponding author), Univ Strathclyde, Dept Pharmaceut Sci, Glasgow G4 0NR, Lanark, Scotland.							BODENBENDER HG, 1948, ANGEW CHEM, V60, P111; BONHOEFFER O, 2000, Patent No. 656435; BONHOEFFER O, 2000, Patent No. 9123; DRESER, 1907, COMMUNICATION   0727, P6; DRESER H, 1918, GESCH ENTWICKLUNG FA, P419; Dreser M. H., 1970, PFLUGERS ARCH, V76, P306, DOI [10.1007/bf01662127, DOI 10.1007/BF01662127]; EICHENGRUN A, 1944, COMMUNICATION, P2; EICHENGRUN A, 1949, PHARMAZIE, V4, P582; EICHENGRUN A, 1918, GESCH ENTWICKLUNG FA, P409; ESCALES E, 1947, KUNSTOFFE, V37, P180; FISCHER F, 1918, GESCH ENTWICKLUNG FA, P427; Schmidt A., 1934, IND CHEM IHRER BEDEU, P775; Stadlinger H, 1947, PHARMAZIE, V2, P383; Witthauer Kurt, 1899, HEILKUNDE, V3, P396; ZUNDORF U, 1997, 100 YEARS ASPIRIN FU, P33	15	134	145	2	61	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1591	1594		10.1136/bmj.321.7276.1591	http://dx.doi.org/10.1136/bmj.321.7276.1591			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124191	Green Published, Green Accepted			2022-12-28	WOS:000166134500028
J	Riis, P				Riis, P			Perspectives on the fifth revision of the Declaration of Helsinki	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Minist Sci, Comm Sci Dishonesty, Copenhagen, Denmark		Riis, P (corresponding author), 7 Nerievej, DK-2900 Copenhagen, Denmark.							Council of Europa, 1997, CONV PROT HUM RIGHTS; RIIS P, 1996, HLTH SCI INFORMATION; *UNESCO, 2000, UN DECL HUM GEN HUM; *WORLD MED ASS, 2000, ETH PRINC MED RES IN	4	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3045	3046		10.1001/jama.284.23.3045	http://dx.doi.org/10.1001/jama.284.23.3045			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122594				2022-12-28	WOS:000165847200032
J	Couch, RB				Couch, RB			Influenza: Prospects for control	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							NEURAMINIDASE INHIBITOR OSELTAMIVIR; A VIRUS; ELDERLY PERSONS; VACCINE; EFFICACY; IMPACT; HEALTHY; PREVENTION; EPIDEMICS; MORTALITY	Influenza is a disease of antiquity that annually imposes a major burden of morbidity and mortality. The available inactivated vaccine is effective for preventing influenza and the serious disease and death that can accompany it. However, annual recommendations for vaccination among persons at risk have never been adequately implemented. This remains the most pressing current need for control of influenza. Amantadine, rimantadine, and the newly available drugs zanamivir and oseltamivir are effective for influenza prevention and treatment (the former two for influenza A only). The availability of four antiviral agents that effectively prevent and treat influenza provides the physician with considerable flexibility for their use in influenza control. Optimal application of the currently available vaccine and antiviral agents should substantially reduce the impact of influenza. Other methods for influenza treatment and control are under development, and a live attenuated vaccine with substantial potential for control is nearing approval. However, better inactivated vaccines, better rapid diagnostic tests, and an increased understanding of options for use of antiviral agents are still needed. When all of these things are available and optimally applied, effective control of influenza should result. The prospect is compelling. Full participation by the practicing physician will be necessary to achieve this goal.	Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Couch, RB (corresponding author), Baylor Coll Med, 280,1 Baylor Plaza, Houston, TX 77030 USA.	rcouch@bcm.cmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015103, N01AI032685, N01AI065298] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15103, N01-AI-32685, N01-AI-65298] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADA GL, 1981, IMMUNOL REV, V58, P5, DOI 10.1111/j.1600-065X.1981.tb00347.x; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; CLEMENTS ML, 1983, INFECT IMMUN, V40, P1044, DOI 10.1128/IAI.40.3.1044-1051.1983; COUCH RB, 1986, J INFECT DIS, V153, P431, DOI 10.1093/infdis/153.3.431; COUCH RB, 1984, MOL VIROLOGY EPIDEMI, P119; Couch Robert B., 1997, Journal of Infectious Diseases, V176, pS38, DOI 10.1086/514173; Couch Robert B., 1997, P369; Demicheli V, 2000, VACCINE, V18, P957, DOI 10.1016/S0264-410X(99)00332-1; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; KILBOURNE ED, 1991, MED VIROL, V10, P207; MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; Munoz FM, 2000, ANTIVIR RES, V46, P91, DOI 10.1016/S0166-3542(00)00092-9; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nichol KL, 1996, ARCH INTERN MED, V156, P1546, DOI 10.1001/archinte.156.14.1546; Noyola DE, 2000, J CLIN MICROBIOL, V38, P1161, DOI 10.1128/JCM.38.3.1161-1165.2000; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; POWERS DC, 1991, J CLIN MICROBIOL, V29, P498, DOI 10.1128/JCM.29.3.498-505.1991; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; SLEPUSHKIN VA, 1995, VACCINE, V13, P1399, DOI 10.1016/0264-410X(95)92777-Y; SULLIVAN KM, 1993, AM J PUBLIC HEALTH, V83, P1712, DOI 10.2105/AJPH.83.12.1712; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; *US DHHS, 1998, DHHS PUBL PHS; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128	37	27	29	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					992	998		10.7326/0003-4819-133-12-200012190-00015	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00015			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119401				2022-12-28	WOS:000165952300008
J	Griffiths, KM; Christensen, H				Griffiths, KM; Christensen, H			Quality of web based information on treatment of depression: cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE PRACTICE; WORLD-WIDE-WEB; PRACTICE GUIDELINES; HEALTH INFORMATION; MAJOR DEPRESSION; INTERNET	Objectives To evaluate quality of web based information on treatment of depression, to identify potential indicators of content quality, and to establish if accountability criteria are indicators of quality. Design Cross sectional survey. Data sources 21 frequently accessed websites about depression. Main outcome measures (i) Site characteristics; (ii) quality of content-concordance with evidence based depression guidelines (guideline score), appropriateness of other relevant site information (issues score), and subjective rating of site quality (global score); and (iii) accountability-conformity with core accountability standards (Silberg score) and quality of evidence cited in support of conclusions (level of evidence score). Results Although the sites contained useful information, their overall quality was poor: the mean guideline, issues, and global scores were only 4.7 (range 0-13) out of 43, 9.8 (6-14) out of 17, and 3 (0.5-7.5) out of 10 respectively. Sites typically did not cite scientific evidence in support of their conclusions. The guideline score correlated with the two other quality of content measures, but none of the content measures correlated with the Silberg accountability score. Content quality was superior for sites owned by organisations and sites with an editorial board. Conclusions There is a need for better evidence based information about depression on the web, and a need to reconsider the role of accountability criteria as indicators of site quality and to develop simple valid indicators of quality. Ownership by an organisation and the involvement of a professional editorial board may be useful indicators. The study methodology may be useful for exploring these issues in other health related subjects.	Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia	Australian National University	Griffiths, KM (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia.	kathy.griffiths@anu.edu.au	Griffiths, Kathleen/A-9872-2012; Christensen, Helen/F-5053-2012	Christensen, Helen/0000-0003-0435-2065				[Anonymous], 1996, GLOBAL BURDEN DIS CO; Bower H, 1996, BRIT MED J, V313, P381; CAMPBELL MJ, 1989, STAT CONFIDENCE CONF; Davison K, 1997, Clin Perform Qual Health Care, V5, P64; *DEPR GUID PAN, 1993, CLIN PRACT GUID US D, V5; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; Institute of Medicine, 1992, GUID CLIN PRACT DEV; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Kessler R. C., 2000, UNMET NEED PSYCHIAT, P59; McClung HJ, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.6.e2; *NAT HLTH MED RES, 1995, GUID DEV IMPL CLIN P; *NAT HLTH MED RES, 1997, CLIN PRACT GUID DEPR; O'Mahony B, 1999, IRISH MED J, V92, P334; Persons JB, 1996, ARCH GEN PSYCHIAT, V53, P283; SANDVIK H, 1993, BRIT MED J, V319, P29; Schulberg HC, 1998, ARCH GEN PSYCHIAT, V55, P1121, DOI 10.1001/archpsyc.55.12.1121; Schulberg HC, 1998, J CONSULT CLIN PSYCH, V66, P932, DOI 10.1037/0022-006X.66.6.932; Shon J, 1999, J AM MED INFORM ASSN, P945; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Soot LC, 1999, J VASC SURG, V30, P84, DOI 10.1016/S0741-5214(99)70179-5; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879	21	221	229	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2000	321	7275					1511	1515		10.1136/bmj.321.7275.1511	http://dx.doi.org/10.1136/bmj.321.7275.1511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118181	Green Published, Bronze			2022-12-28	WOS:000165994700028
J	Irwin, RS; Madison, JM				Irwin, RS; Madison, JM			The diagnosis and treatment of cough	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GASTROESOPHAGEAL REFLUX DISEASE; ACUTE MAXILLARY SINUSITIS; PLACEBO-CONTROLLED TRIAL; COMMON COLD; EOSINOPHILIC BRONCHITIS; PERTUSSIS INFECTION; CLINICAL-EVALUATION; PERSISTENT COUGH; KEY COMPONENTS; DOUBLE-BLIND		Univ Massachusetts, Sch Med, Dept Med,UMass Mem Hlth Care, Div Pulm Allergy & Crit Care Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Irwin, RS (corresponding author), Univ Massachusetts, Sch Med, Dept Med,UMass Mem Hlth Care, Div Pulm Allergy & Crit Care Med, Univ Campus,55 Lake Ave N, Worcester, MA 01655 USA.							BALTER MS, 1997, DIAGNOSIS TREATMENT, P155; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; CIPRANDI G, 1995, ANN ALLERG ASTHMA IM, V75, P115; CURLEY FJ, 1988, AM REV RESPIR DIS, V138, P305, DOI 10.1164/ajrccm/138.2.305; DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8; French CL, 1998, ARCH INTERN MED, V158, P1657, DOI 10.1001/archinte.158.15.1657; GIBSON PG, 1989, LANCET, V1, P1346; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; Hayden FG, 1996, ANN INTERN MED, V125, P89, DOI 10.7326/0003-4819-125-2-199607150-00002; HOFFSTEIN V, 1994, CAN RESPIR J, V1, P40; Irwin RS, 1997, ARCH INTERN MED, V157, P1981, DOI 10.1001/archinte.157.17.1981; Irwin RS, 1999, AM J GASTROENTEROL, V94, P3095, DOI 10.1111/j.1572-0241.1999.03095.x; IRWIN RS, 1993, DRUGS, V46, P80, DOI 10.2165/00003495-199346010-00006; IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; Irwin RS, 1998, CHEST, V114, p133S, DOI 10.1378/chest.114.2_Supplement.133S; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; IRWIN RS, 1997, DIAGNOSIS TREATMENT, P1; Jackson JL, 1997, ARCH INTERN MED, V157, P2373, DOI 10.1001/archinte.157.20.2373; KERR P, 1992, CHEST, V101, P1539, DOI 10.1378/chest.101.6.1539; Macknin ML, 1998, JAMA-J AM MED ASSOC, V279, P1962, DOI 10.1001/jama.279.24.1962; Madison JM, 1998, LANCET, V352, P467, DOI 10.1016/S0140-6736(97)11081-9; Marchesani F, 1998, Monaldi Arch Chest Dis, V53, P510; Markowitz D, 1997, J BRONCHOL, V4, P332, DOI 10.1097/00128594-199710000-00016; McGarvey LPA, 1998, THORAX, V53, P738, DOI 10.1136/thx.53.9.738; Mello CJ, 1996, ARCH INTERN MED, V156, P997, DOI 10.1001/archinte.156.9.997; Palombini BC, 1999, CHEST, V116, P279, DOI 10.1378/chest.116.2.279; Prasad AS, 2000, ANN INTERN MED, V133, P245, DOI 10.7326/0003-4819-133-4-200008150-00006; PRATTER MR, 1983, CHEST, V84, P42, DOI 10.1378/chest.84.1.42; PRATTER MR, 1993, ANN INTERN MED, V119, P977, DOI 10.7326/0003-4819-119-10-199311150-00003; Puhakka T, 1998, J ALLERGY CLIN IMMUN, V101, P726, DOI 10.1016/S0091-6749(98)70301-X; Schaefer OP, 1999, AM J RESP CRIT CARE, V159, pA830; SHOENUT JP, 1994, CHEST, V106, P738, DOI 10.1378/chest.106.3.738; SMYRNIOS NA, 1995, CHEST, V108, P991, DOI 10.1378/chest.108.4.991; SPERBER SJ, 1992, ANN INTERN MED, V117, P37, DOI 10.7326/0003-4819-117-1-37; Teramoto S, 1999, CHEST, V115, P602, DOI 10.1378/chest.115.2.602; vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; Yaari E, 1999, CHEST, V115, P1254, DOI 10.1378/chest.115.5.1254	44	228	248	1	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2000	343	23					1715	1721		10.1056/NEJM200012073432308	http://dx.doi.org/10.1056/NEJM200012073432308			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380PX	11106722				2022-12-28	WOS:000165711900008
J	Peterson, HB; Jeng, G; Folger, SG; Hillis, SA; Marchbanks, PA; Wilcox, LS				Peterson, HB; Jeng, G; Folger, SG; Hillis, SA; Marchbanks, PA; Wilcox, LS		US Collaborative Rev Sterlization	The risk of menstrual abnormalities after tubal sterilization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; HYSTERECTOMY; PREGNANCY	Background: The existence of a post-tubal-ligation syndrome of menstrual abnormalities has been debated for decades. We used data from the U.S. Collaborative Review of Sterilization to determine whether the likelihood of persistent menstrual abnormalities was greater among women who had undergone tubal sterilization than among women who had not. Methods: A total of 9514 women who underwent tubal sterilization and 573 women whose partners underwent vasectomy were followed in a multicenter, prospective cohort study for up to five years by means of annual telephone interviews. All women were asked the same questions about six characteristics of their menstrual cycles in the presterilization and follow-up interviews. Multiple logistic-regression analysis was used to assess the risk of persistent menstrual changes. Results: The women who had undergone sterilization were no more likely than those who had not undergone the procedure to report persistent changes in intermenstrual bleeding or the length of the menstrual cycle. They were more likely to have decreases in the number of days of bleeding (odds ratio, 2.4; 95 percent confidence interval, 1.1 to 5.2), the amount of bleeding (odds ratio, 1.5; 95 percent confidence interval, 1.1 to 2.0), and menstrual pain (odds ratio, 1.3; 95 percent confidence interval, 1.0 to 1.8) and to have an increase in cycle irregularity (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.3). Among women who had had very heavy bleeding at base line, women who had undergone sterilization were more likely than women who had not undergone the procedure to report decreased bleeding (45 percent vs. 33 percent, P=0.03). Conclusions: Women who have undergone tubal sterilization are no more likely than other women to have menstrual abnormalities. (N Engl J Med 2000;343:1681-7.) (C) 2000, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Peterson, HB (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-34,4770 Buford Hwy NE, Atlanta, GA 30341 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041075] Funding Source: NIH RePORTER; NICHD NIH HHS [3-Y02-HD41075-10] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CATTANACH JF, 1988, CONTRACEPTION, V38, P541, DOI 10.1016/0010-7824(88)90157-6; DESTEFANO F, 1983, OBSTET GYNECOL, V61, P153; DESTEFANO F, 1983, OBSTET GYNECOL, V62, P673; DESTEFANO F, 1985, AM J OBSTET GYNECOL, V152, P835, DOI 10.1016/S0002-9378(85)80073-9; ESCOBEDO LG, 1989, AM J OBSTET GYNECOL, V160, P147, DOI 10.1016/0002-9378(89)90108-7; Gentile GP, 1998, FERTIL STERIL, V69, P179, DOI 10.1016/S0015-0282(97)00229-X; Hillis SD, 1998, OBSTET GYNECOL, V91, P241, DOI 10.1016/S0029-7844(97)00648-0; LEE NC, 1984, AM J OBSTET GYNECOL, V150, P283, DOI 10.1016/S0002-9378(84)90366-1; Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0; Peterson HB, 1997, NEW ENGL J MED, V336, P762, DOI 10.1056/NEJM199703133361104; Piccinino LJ, 1998, FAM PLANN PERSPECT, V30, P4, DOI 10.2307/2991517; RULIN MC, 1993, OBSTET GYNECOL, V82, P118; SHAIN RN, 1989, FERTIL STERIL, V52, P192; THOMPSON JD, 1997, TELINDES OPERAPTIVE, P785; WILCOX LS, 1992, AM J EPIDEMIOL, V135, P1368, DOI 10.1093/oxfordjournals.aje.a116248; WILLIAMS EL, 1951, AM J OBSTET GYNECOL, V61, P423, DOI 10.1016/0002-9378(51)90262-1	16	62	64	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2000	343	23					1681	1687		10.1056/NEJM200012073432303	http://dx.doi.org/10.1056/NEJM200012073432303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380PX	11106717	Bronze			2022-12-28	WOS:000165711900003
J	Angus, DC; Kelley, MA; Schmitz, RJ; White, A; Popovich, J				Angus, DC; Kelley, MA; Schmitz, RJ; White, A; Popovich, J		Comm Manpower Pulm Critical Care	Current and projected workforce requirements for care of the critically ill and patients with pulmonary disease - Can we meet the requirements of an aging population?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; HEALTH-CARE; PHYSICIAN WORKFORCE; UNITED-STATES; INTERNATIONAL COMPARISONS; RESOURCE UTILIZATION; MEDICARE; OUTCOMES; SURGERY; SYSTEM	Context Two important areas of medicine, care of the critically ill and management of pulmonary disease, are likely to be influenced by the aging of the US population. Objective To estimate current and future requirements for adult critical care and pulmonary medicine physicians in the United States. Design, Setting, and Participants Analysis of existing population, patient, and hospital data sets and prospective, nationally representative surveys of intensive care unit (ICU) directors (n=393) and critical care specialists (intensivists) and pulmonary specialists (pulmonologists) (n=421), conducted from 1996 to 1999. Main Outcome Measures Influence of patient, physician, regional, hospital, and payer characteristics on current practice patterns; forecasted future supply of and demand for specialist care through 2030. Separate models for critical care and pulmonary disease. Base-case projections with sensitivity analyses to estimate the impact of future changes in training and retirement, disease prevalence and management, and health care reform initiatives. Results In 1997, intensivists provided care to 36.8% of all ICU patients, Care in the ICU was provided more commonly by intensivists in regions with high managed care penetration, The current ratio of supply to demand is forecast to remain in rough equilibrium until 2007, Subsequently, demand will grow rapidly while supply will remain near constant, yielding a shortfall of specialist hours equal to 22% of demand by 2020 and 35% by 2030, primarily because of the aging of the US population. Sensitivity analyses suggest that the spread of current health care reform initiatives will either have no effect or worsen this shortfall. A shortfall of pulmonologist time will also occur before 2007 and increase to 35% by 2020 and 46% by 2030, Conclusions We forecast that the proportion of care provided by intensivists and pulmonologists in the United States will decrease below current standards in less than 10 years. While current health care reform initiatives and modification of existing practice patterns may temporarily forestall this problem, most anticipated effects are minor in comparison with the growing disease burden created by the aging US population.	Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA; Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA; ABT Associates Inc, Math Policy Res, Cambridge, MA 02138 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Henry Ford Health System; Henry Ford Hospital; ABT Associates; Mathematica	Angus, DC (corresponding author), Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Room 604,Scaife Hall,200 Lothrop St, Pittsburgh, PA 15213 USA.	angusdc@anes.upmc.edu	Angus, Derek C/E-9671-2012					*AG HLTH CAR POL R, 1996, HEALTHC COST UT PROJ; Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; Angus DC, 1997, CRIT CARE CLIN, V13, P389, DOI 10.1016/S0749-0704(05)70317-1; Angus DC, 1996, JAMA-J AM MED ASSOC, V276, P1075, DOI 10.1001/jama.276.13.1075; Bion JF, 1998, INTENS CARE MED, V24, P372, DOI 10.1007/s001340050584; Butler Margaret A., 1993, RURAL URBAN CONTINUU; CALLAHAN D, 1998, FALSE HOPE WHY AM QU; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; CHELLURI L, 1995, ARCH INTERN MED, V155, P1013, DOI 10.1001/archinte.155.10.1013; Collett D., 1994, MODELING SURVIVAL DA; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; *COUNC GRAD MED ED, 1996, 8US DEP HHS COUNC GR; *COUNC GRAD MED ED, 1994, REC IMPR ACC HLTH CA; Cox D. R., 1984, ANAL SURVIVAL DATA; Draper N.R., 1998, APPL REGRESSION ANAL, P79; Fuchs VR, 1999, HEALTH AFFAIR, V18, P11, DOI 10.1377/hlthaff.18.1.11; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; Guntupalli KK, 1996, INTENS CARE MED, V22, P625, DOI 10.1007/BF01709737; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; Hart IG, 1997, HEALTH AFFAIR, V16, P55, DOI 10.1377/hlthaff.16.1.55; HINES FK, 1975, AER272 USDA EC RES S; *HLTH RES SERV ADM, 1991, HLTH PERS US; Iglehart JK, 1999, NEW ENGL J MED, V340, P327, DOI 10.1056/NEJM199901283400424; JONASSON O, 1995, JAMA-J AM MED ASSOC, V274, P731; KVETAN V, 1997, INT PERSPECTIVES CRI; LOHR KN, 1996, NATIONS PHYSICIAN WO; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P689, DOI 10.1001/jama.276.9.689; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; Neilson EG, 1997, J AM SOC NEPHROL, V8, pS1; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; RANDOLPH L, 1997, PHYSICIAN CHARACTERI; Reinhardt UE, 1999, JAMA-J AM MED ASSOC, V281, P462, DOI 10.1001/jama.281.5.462; Rivo ML, 1996, NEW ENGL J MED, V334, P892, DOI 10.1056/NEJM199604043341405; Rosenblatt RA, 1998, JAMA-J AM MED ASSOC, V279, P1364, DOI 10.1001/jama.279.17.1364; SCHROEDER SA, 1994, INQUIRY-J HEALTH CAR, V31, P266; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SCHWARTZ WB, 1988, NEW ENGL J MED, V318, P892, DOI 10.1056/NEJM198804073181405; STEINWACHS DM, 1986, NEW ENGL J MED, V314, P217, DOI 10.1056/NEJM198601233140406; TARLOV AR, 1995, JAMA-J AM MED ASSOC, V274, P1558, DOI 10.1001/jama.274.19.1558; Theil H., 1971, PRINCIPLES ECONOMETR; Vladeck BC, 1999, NEW ENGL J MED, V340, P1503, DOI 10.1056/NEJM199905133401911; Weiner DM, 1997, UROLOGY, V49, P335, DOI 10.1016/S0090-4295(96)00492-X; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; White J, 1999, HEALTH AFFAIR, V18, P63, DOI 10.1377/hlthaff.18.1.63; 1997, JAMA, V278, P775	49	716	737	2	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2762	2770		10.1001/jama.284.21.2762	http://dx.doi.org/10.1001/jama.284.21.2762			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105183	Bronze			2022-12-28	WOS:000165509500031
J	Henney, JE				Henney, JE			Drug product problem reports	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2711	2711		10.1001/jama.284.21.2711-c	http://dx.doi.org/10.1001/jama.284.21.2711-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105160				2022-12-28	WOS:000165509500007
J	Ohnishi, K; Yoshida, H; Shigeno, K; Nakamura, S; Fujisawa, S; Naito, K; Shinjo, K; Fujita, Y; Matsui, H; Takeshita, A; Sugiyama, S; Satoh, H; Terada, H; Ohno, R				Ohnishi, K; Yoshida, H; Shigeno, K; Nakamura, S; Fujisawa, S; Naito, K; Shinjo, K; Fujita, Y; Matsui, H; Takeshita, A; Sugiyama, S; Satoh, H; Terada, H; Ohno, R			Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia	ANNALS OF INTERNAL MEDICINE			English	Article							REMISSION	Background: Recently, arsenic trioxide has increasingly been used for relapsed acute promyelocytic leukemia, However, it is known to have several adverse effects, including acute cardiac toxicities. Objective: To determine cardiac toxicities resulting from arsenic trioxide therapy in patients with relapsed or refractory acute promyelocytic leukemia. Design: Phase II clinical prospective cohort study. Setting: A university hospital in Hamamatsu, Japan. Patients: 8 patients with relapsed acute promyelocytic leukemia Intervention: Arsenic trioxide, 0.15 mg/kg of body weight, administered daily by 2-hour infusion for a maximum of 60 days, Measurements: Continuous monitoring with ambulatory electrocardiography, Results: Five patients (63%) achieved complete remission. During induction therapy with arsenic trioxide, prolonged QT intervals were observed in all patients. Ventricular premature contractions were noticed during 8 of 12 courses of therapy. Four patients developed nonsustained ventricular tachycardia and required treatment with antiarrhythmic agents. Conclusions: Cardiac toxicity occurs during arsenic trioxide therapy in patients with acute promyelocytic leukemia. Such patients should be monitored for prolonged QT intervals and ventricular arrhythmia.	Hamamatsu Univ Sch Med, Dept Med 3, Hamamatsu, Shizuoka 4313192, Japan; Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan	Hamamatsu University School of Medicine; Aichi Cancer Center	Ohnishi, K (corresponding author), Hamamatsu Univ Sch Med, Dept Med 3, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.	kohnishi@hama-med.ac.jp	Matsui, Hirotaka/AED-6669-2022	Matsui, Hirotaka/0000-0002-6266-3227				Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; GOLDSMITH S, 1980, NEW ENGL J MED, V303, P1096, DOI 10.1056/NEJM198011063031905; Huang SY, 1998, BRIT J HAEMATOL, V103, P1092, DOI 10.1046/j.1365-2141.1998.01079.x; KLAASSEN CD, 1996, GOODMAN GILMANS PHAR, P1659; LITTLE RE, 1990, PACE, V13, P164, DOI 10.1111/j.1540-8159.1990.tb05066.x; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; STPETERY J, 1970, AM J DIS CHILD, V120, P367, DOI 10.1001/archpedi.1970.02100090141021	9	144	153	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					881	885		10.7326/0003-4819-133-11-200012050-00012	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103058				2022-12-28	WOS:000165585800007
J	Hasegawa, RP; Blitz, AM; Geller, NL; Goldberg, ME				Hasegawa, RP; Blitz, AM; Geller, NL; Goldberg, ME			Neurons in monkey prefrontal cortex that track past or predict future performance	SCIENCE			English	Article							DELAYED-RESPONSE TASK; WORKING-MEMORY; SINGLE NEURONS; DOPAMINE; PRIMATE; LESIONS; FIELDS	Although frontal cortex is thought to be important in controlling behavior across Long periods of time, most studies of this area concentrate on neuronal responses instantaneously relevant to the current task. In order to investigate the relationship of frontal activity to behavior over Longer time periods, we trained rhesus monkeys on a difficult oculomotor task. Their performance fluctuated during the day, and the activity of prefrontal neurons, even measured while the monkeys waited for the targets to appear at the beginning of each set of trials, correlated with performance in a probabilistic rather than a determinist manner: neurons reflected past or predicted future performance, much more than they reflected current performance. We suggest that this activity is related to processes such as arousal or motivation that set the tone for behavior rather than controlling it on a millisecond basis, and could result from ascending pathways that utilize slow, second-messenger synaptic processes.	NEI, Sensorimotor Res Lab, Bethesda, MD 20892 USA; NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA; NHLBI, Off Biostat Res, Bethesda, MD 20892 USA; Georgetown Univ, Sch Med, Dept Neurol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University	Hasegawa, RP (corresponding author), NEI, Sensorimotor Res Lab, Bldg 10, Bethesda, MD 20892 USA.		Hasegawa, Ryohei/Q-4296-2016	Hasegawa, Ryohei/0000-0001-9102-0434; Blitz, Ari/0000-0002-6763-2112				ARNSTEN AFT, 1984, BRAIN RES, V306, P9, DOI 10.1016/0006-8993(84)90351-2; Asaad WF, 2000, J NEUROPHYSIOL, V84, P451, DOI 10.1152/jn.2000.84.1.451; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Colby CL, 1996, J NEUROPHYSIOL, V76, P2841, DOI 10.1152/jn.1996.76.5.2841; Collins P, 1998, J COGNITIVE NEUROSCI, V10, P332, DOI 10.1162/089892998562771; Dorris MC, 2000, J NEUROSCI, V20; FUSTER JM, 1989, PREFONTAL CORTEX; Hasegawa Ryohei, 1999, Society for Neuroscience Abstracts, V25, P366; Levy R, 1999, J NEUROSCI, V19, P5149; *NAT EYE I AN CAR, 1996, GUID CAR US LAB AN; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; PETRIDES M, 1995, J NEUROSCI, V15, P359; Powell KD, 2000, J NEUROPHYSIOL, V84, P301, DOI 10.1152/jn.2000.84.1.301; Sawaguchi T, 1998, J NEUROPHYSIOL, V80, P2200, DOI 10.1152/jn.1998.80.4.2200; SAWAGUCHI T, 1994, J NEUROPHYSIOL, V71, P515, DOI 10.1152/jn.1994.71.2.515; SIEGELBAUM S, 1999, PRINCIPLES NEURAL SC, P229; Usher M, 1999, SCIENCE, V283, P549, DOI 10.1126/science.283.5401.549; Watanabe M, 1997, J NEUROPHYSIOL, V78, P2795, DOI 10.1152/jn.1997.78.5.2795; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0	19	52	53	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1786	1789		10.1126/science.290.5497.1786	http://dx.doi.org/10.1126/science.290.5497.1786			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099421				2022-12-28	WOS:000165632400049
J	Gavaghan, H				Gavaghan, H			Governments prime basic nanotech research, applied activity yet to soar	NATURE			English	Article																			0	1	1	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					619	620		10.1038/35046276	http://dx.doi.org/10.1038/35046276			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117753				2022-12-28	WOS:000165548600130
J	Wang, CR; Kai, T; Tomiyama, T; Yoshida, T; Kobayashi, Y; Nishibori, E; Takata, M; Sakata, M; Shinohara, H				Wang, CR; Kai, T; Tomiyama, T; Yoshida, T; Kobayashi, Y; Nishibori, E; Takata, M; Sakata, M; Shinohara, H			Materials science - C-66 fullerene encaging a scandium dimer	NATURE			English	Article							CAGES		Nagoya Univ, Dept Chem, Nagoya, Aichi 4648602, Japan; Osaka Univ, Dept Pharmacol, Suita, Osaka 5650871, Japan; Nagoya Univ, Dept Appl Phys, Nagoya, Aichi 4648603, Japan	Nagoya University; Osaka University; Nagoya University	Wang, CR (corresponding author), Nagoya Univ, Dept Chem, Nagoya, Aichi 4648602, Japan.		Takata, Masaki/M-1525-2014; Nishibori, Eiji/M-1362-2018	Nishibori, Eiji/0000-0002-4192-6577; Yoshida, Takuya/0000-0002-3491-9344				DORN HC, 1998, FULLERENES RECENT AD, P990; FOWLER PW, 1995, ATLAS FULLERENES, P27; Kobayashi K, 1997, J AM CHEM SOC, V119, P12693, DOI 10.1021/ja9733088; KROTO HW, 1987, NATURE, V329, P529, DOI 10.1038/329529a0; SCHMALZ TG, 1988, J AM CHEM SOC, V110, P1113, DOI 10.1021/ja00212a020; SHINOHARA H, 1992, NATURE, V357, P52, DOI 10.1038/357052a0; SHINOHARA H, 1993, J PHYS CHEM-US, V97, P4259, DOI 10.1021/j100119a004; Takata M, 1999, PHYS REV LETT, V83, P2214, DOI 10.1103/PhysRevLett.83.2214; TAKATA M, 1995, NATURE, V377, P46, DOI 10.1038/377046a0; YANNONI CS, 1992, SCIENCE, V256, P1191, DOI 10.1126/science.256.5060.1191	10	285	292	5	76	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					426	427		10.1038/35044195	http://dx.doi.org/10.1038/35044195			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100714				2022-12-28	WOS:000165429800033
J	Anderson, J; Baum, M; Bero, LA; Chalmers, I; Chapman, S; Deary, IJ; Ebrahim, S; Martyn, SOOLISS; Evans, M; Farrell, M; Greaves, D; Higginson, I; Hippisley-Cox, J; James, B; McKenzie, H; Macaulay, AC; Rabow, M; Smyth, RL; Stores, G; Wolpert, L				Anderson, J; Baum, M; Bero, LA; Chalmers, I; Chapman, S; Deary, IJ; Ebrahim, S; Martyn, SOOLISS; Evans, M; Farrell, M; Greaves, D; Higginson, I; Hippisley-Cox, J; James, B; McKenzie, H; Macaulay, AC; Rabow, M; Smyth, RL; Stores, G; Wolpert, L			Music to be born to, music to die to	BRITISH MEDICAL JOURNAL			English	Editorial Material									Monash Univ, So Healthcare Network, Ctr Clin Effectiveness, Melbourne, Vic, Australia; UCL, London WC1E 6BT, England; Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; UK Cochrane Ctr, Oxford, England; Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland; Univ Bristol, Dept Social Med, Bristol, Avon, England; Natl Addict Ctr, London, England; Kings Coll London, London WC2R 2LS, England; St Christophers Hospice, London, England; Univ Nottingham, Nottingham NG7 2RD, England; Inst Hlth Sector Dev, London, England; McGill Univ, Montreal, PQ H3A 2T5, Canada; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Liverpool, Royal Liverpool Childrens Hosp Alder Hey, Inst Child Hlth, Liverpool, Merseyside, England	Monash University; University of London; University College London; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cochrane Centre; University of Edinburgh; University of Bristol; University of London; King's College London; University of London; King's College London; University of Nottingham; McGill University; University of California System; University of California San Francisco; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool	Anderson, J (corresponding author), Monash Univ, So Healthcare Network, Ctr Clin Effectiveness, Melbourne, Vic, Australia.		Hippisley-Cox, Julia/AAY-2788-2020; Deary, Ian J/C-6297-2009; Higginson, Irene J/C-7309-2012	Hippisley-Cox, Julia/0000-0002-2479-7283; Deary, Ian J/0000-0002-1733-263X; Higginson, Irene J/0000-0002-3687-1313					0	1	1	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1577	1579		10.1136/bmj.321.7276.1577	http://dx.doi.org/10.1136/bmj.321.7276.1577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124186	Green Published			2022-12-28	WOS:000166134500023
J	Kutz, I				Kutz, I			Job and his "doctors": bedside wisdom in the book of Job	BRITISH MEDICAL JOURNAL			English	Article									Meir Gen Hosp, Consultat Liaison Serv, Kfar Saba, Israel; Shalvatah Psychiat Ctr, Consultat Liaison Serv, IL-44281 Kefar Sava, Israel	Tel Aviv University; Sackler Faculty of Medicine	Kutz, I (corresponding author), 56 Usishkin St, IL-62591 Tel Aviv, Israel.							ACHENBAUM WA, 1991, INT J AGING HUM DEV, V32, P21, DOI 10.2190/419R-X8FC-Q6NE-0M85; ANTONOVSKY H, 1986, J SOC PSYCHOL, V126, P213; Balint M, 1972, DOCTOR HIS PATIENT I; DeMasi F, 1997, INT J PSYCHOANAL, V78, P561; Gorman S, 1999, J AM ACAD DERMATOL, V40, P126, DOI 10.1016/S0190-9622(99)70546-3; HOLLAND JC, 1986, CLIN B, V11, P102; HOLUBAR K, 1985, AM J DERMATOPATH, V7, P437, DOI 10.1097/00000372-198510000-00007; James W., 1958, VARIETIES RELIG EXPE; KAPUSTA MA, 1977, ANN INTERN MED, V86, P667, DOI 10.7326/0003-4819-86-5-667; Kubler-Ross E., 1969, DEATH DYING; LEDERMAN MM, 1992, AM J MED, V92, P679, DOI 10.1016/0002-9343(92)90786-B; REID SA, 1973, PSYCHOANAL REV, V60, P373; RENIK O, 1991, PSYCHOANAL QUART, V60, P596, DOI 10.1080/21674086.1991.11927324; TOLSTOY L, 1901, DEATH I ILYICH; ZISOOK S, 1995, COMPREHENSIVE TXB PS, V4, P1713	15	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1613	1615		10.1136/bmj.321.7276.1613	http://dx.doi.org/10.1136/bmj.321.7276.1613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	387RA	11124201	Green Published			2022-12-28	WOS:000166134500037
J	Leavitt, F				Leavitt, F			Garages and hospitals, doctors and nurses	BRITISH MEDICAL JOURNAL			English	Article									Ben Gurion Univ Negev, Ctr Asian & Int Bioeth, Beer Sheva, Israel	Ben Gurion University	Leavitt, F (corresponding author), Ben Gurion Univ Negev, Ctr Asian & Int Bioeth, Beer Sheva, Israel.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1621	1621		10.1136/bmj.321.7276.1621	http://dx.doi.org/10.1136/bmj.321.7276.1621			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124205	Green Published			2022-12-28	WOS:000166134500041
J	Loxterkamp, D				Loxterkamp, D			Saving Fred: what family practice means to medicine	BRITISH MEDICAL JOURNAL			English	Article											Loxterkamp, D (corresponding author), 15 Salmond St, Belfast, ME 04915 USA.							Malcolm J., 1997, DIANA NIKON ESSAYS P; Merton Thomas, 1960, WISDOM DESERT	2	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1567	1568		10.1136/bmj.321.7276.1567	http://dx.doi.org/10.1136/bmj.321.7276.1567			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124177	Bronze, Green Published			2022-12-28	WOS:000166134500015
J	Myers, A; Holmans, P; Marshall, H; Kwon, J; Meyer, D; Ramic, D; Shears, S; Booth, J; DeVrieze, FW; Crook, R; Hamshere, M; Abraham, R; Tunstall, N; Rice, F; Carty, S; Lillystone, S; Kehoe, P; Rudrasingham, V; Jones, L; Lovestone, S; Perez-Tur, J; Williams, J; Owen, MJ; Hardy, J; Goate, AM				Myers, A; Holmans, P; Marshall, H; Kwon, J; Meyer, D; Ramic, D; Shears, S; Booth, J; DeVrieze, FW; Crook, R; Hamshere, M; Abraham, R; Tunstall, N; Rice, F; Carty, S; Lillystone, S; Kehoe, P; Rudrasingham, V; Jones, L; Lovestone, S; Perez-Tur, J; Williams, J; Owen, MJ; Hardy, J; Goate, AM			Susceptibility locus for Alzheimer's disease on chromosome 10	SCIENCE			English	Article							GENOME SCAN; LINKAGE	The apolipoprotein E (APOE) gene is the only genetic risk factor that has so far been Linked to risk for Late-onset Alzheimer's disease (LOAD), However, 50 percent of Alzheimer's disease cases do not carry an APOE4 allele, suggesting that other risk factors must exist. We performed a two-stage genome-wide screen in sibling pairs with LOAD to detect other susceptibility Loci. Here we report evidence for an Alzheimer's disease Locus on chromosome 10. Our stage one multipoint Lod score (Logarithm of the odds ratio for linkage/no Linkage) of 2.48 (266 sibling pairs) increased to 3.83 in stage 2 (429 sibling pairs) close to D10S1225 (79 centimorgans). This Locus modifies risk for Alzheimer's disease independent of APOE genotype.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Mayo Clin Jacksonville, Neurogenet Lab, Jacksonville, FL 32224 USA; Univ Wales Coll Med, Dept Psychol Med, Cardiff CF4 4XN, S Glam, Wales; Inst Psychiat, London SE5 8AF, England; CSIC, Inst Biomed Valencia, Unitat Genet Mol, E-46010 Valencia, Spain	Washington University (WUSTL); Mayo Clinic; Cardiff University; University of London; King's College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Goate, AM (corresponding author), Washington Univ, Sch Med, Dept Psychiat, 660 S Euclid, St Louis, MO 63110 USA.		Lovestone, Simon/E-8725-2010; Myers, Amanda J/B-1796-2010; Holmans, Peter/F-4518-2015; Perez-Tur, Jordi/A-2143-2010; Hardy, John/C-2451-2009; Kehoe, Patrick/P-8760-2018	Myers, Amanda J/0000-0002-3100-9396; Holmans, Peter/0000-0003-0870-9412; Perez-Tur, Jordi/0000-0002-9111-1712; Hardy, John/0000-0002-3122-0423; Lovestone, Simon/0000-0003-0473-4565; Goate, Alison/0000-0002-0576-2472; Kehoe, Patrick/0000-0002-7542-1139; Williams, Julie/0000-0002-4069-0259; Rice, Frances/0000-0002-9484-1729	NIA NIH HHS [AG16208, AG5681, U24 AG021886] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005681, R01AG016208, U24AG021886, Z01AG000950] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; HOLMANS P, 1995, AM J HUM GENET, V57, P1221; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Williams NM, 1999, HUM MOL GENET, V8, P1729, DOI 10.1093/hmg/8.9.1729	10	314	325	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2304	+		10.1126/science.290.5500.2304	http://dx.doi.org/10.1126/science.290.5500.2304			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125144				2022-12-28	WOS:000165995800044
J	Woosley, RL				Woosley, RL			Drug labeling revisions - Guaranteed to fail?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA	Georgetown University	Woosley, RL (corresponding author), Georgetown Univ, Med Ctr, Dept Med, 3900 Reservoir Rd NW, Washington, DC 20007 USA.		Woosley, Raymond/AAE-4874-2020	Woosley, Raymond/0000-0002-2588-328X				Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; *FOOD DRUG ADM, 2000, FDA TALK PAP JANSS P; *FOOD DRUG ADM, 2000, DEAR DOCT LETT IMP I; *FOOD DRUG ADM, 2000, FDA TALK PAP WYETH A; *FOOD DRUG ADM, 2000, FDA TALK PAP FDA UPT; *FOOD DRUG ADM, 2000, FDA TALK PAP FDA PRO; Honig P, 2000, JAMA-J AM MED ASSOC, V284, P2187; *I MED COMM QUAL H, 2000, ERR IS HUM BUILD SAF; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; *MED EC CO, 2000, PHYS DESK REF, P1451; Reidenberg MM, 2000, CLIN PHARMACOL THER, V68, P109, DOI 10.1067/mcp.2000.108505; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; Stein CM, 1997, CLIN PHARMACOL THER, V61, P1, DOI 10.1016/S0009-9236(97)90175-2; WOOSLEY RL, 1994, CLIN PHARMACOL THER, V55, P249, DOI 10.1038/clpt.1994.24; *WYETH AYERST, 1999, 28 WYETH AYERST	15	31	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3047	3049		10.1001/jama.284.23.3047	http://dx.doi.org/10.1001/jama.284.23.3047			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122595				2022-12-28	WOS:000165847200033
J	Sirringhaus, H; Kawase, T; Friend, RH; Shimoda, T; Inbasekaran, M; Wu, W; Woo, EP				Sirringhaus, H; Kawase, T; Friend, RH; Shimoda, T; Inbasekaran, M; Wu, W; Woo, EP			High-resolution inkjet printing of all-polymer transistor circuits	SCIENCE			English	Article							ORGANIC TRANSISTORS; CONJUGATED POLYMERS; FABRICATION; DEVICES	Direct printing of functional electronic materials may provide a new route to Low-cost fabrication of integrated circuits. However, to be useful it must allow continuous manufacturing of all circuit components by successive solution deposition and printing steps in the same environment. We demonstrate direct inkjet printing of complete transistor circuits, including via-hole interconnections based on solution-processed polymer conductors, insulators, and self-organizing semiconductors. We show that the use of substrate surface energy patterning to direct the flow of water-based conducting polymer inkjet droplets enables high-resolution definition of practical channel Lengths of 5 micrometers. High mobilities of 0.02 square centimeters per volt second and on-off current switching ratios of 10(5) were achieved.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; Seiko Epson Corp, Base Technol Res Ctr, Suwa, Nagano 392, Japan; Dow Chem Co, Midland, MI 48674 USA; Epson Cambridge Lab, Cambridge CB2 1SJ, England	University of Cambridge; Seiko Epson Corporation; Dow Chemical Company; University of Cambridge	Sirringhaus, H (corresponding author), Univ Cambridge, Cavendish Lab, Madingley Rd, Cambridge CB3 0HE, England.		Sirringhaus, Henning/ABD-1555-2021	Sirringhaus, Henning/0000-0001-9827-6061; Friend, Richard Henry/0000-0001-6565-6308				Bao ZN, 1997, CHEM MATER, V9, P1299, DOI 10.1021/cm9701163; Beh WS, 1999, ADV MATER, V11, P1038, DOI 10.1002/(SICI)1521-4095(199908)11:12<1038::AID-ADMA1038>3.0.CO;2-L; Brown TM, 1999, APPL PHYS LETT, V75, P1679, DOI 10.1063/1.124789; Campbell AJ, 2000, APPL PHYS LETT, V76, P1734, DOI 10.1063/1.126182; Darhuber AA, 2000, J APPL PHYS, V87, P7768, DOI 10.1063/1.373452; DEGENNES PG, 1989, LIQUIDS INTERFACES, V48, P273; DEMASSA TA, 1995, DIGITAL INTEGRATED C; Drury CJ, 1998, APPL PHYS LETT, V73, P108, DOI 10.1063/1.121783; Gau H, 1999, SCIENCE, V283, P46, DOI 10.1126/science.283.5398.46; Gelinck GH, 2000, APPL PHYS LETT, V77, P1487, DOI 10.1063/1.1290728; Hebner TR, 1998, APPL PHYS LETT, V72, P519, DOI 10.1063/1.120807; JAIN S, 1989, SOLID STATE ELECTRON, V32, P77, DOI 10.1016/0038-1101(89)90051-8; Katz HE, 2000, NATURE, V404, P478, DOI 10.1038/35006603; LUAN SW, 1992, J APPL PHYS, V72, P766, DOI 10.1063/1.351809; Rogers JA, 1999, ADV MATER, V11, P741, DOI 10.1002/(SICI)1521-4095(199906)11:9<741::AID-ADMA741>3.0.CO;2-L; Rogers JA, 1998, APPL PHYS LETT, V72, P2716, DOI 10.1063/1.121109; Service RF, 1997, SCIENCE, V278, P383, DOI 10.1126/science.278.5337.383; SHIMODA T, 1999, P SID, V99, P376; Sirringhaus H, 2000, APPL PHYS LETT, V77, P406, DOI 10.1063/1.126991; Sirringhaus H, 1999, NATURE, V401, P685, DOI 10.1038/44359; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; Sugimura H, 2000, LANGMUIR, V16, P885, DOI 10.1021/la990953e; Yang Y, 2000, J MATER SCI-MATER EL, V11, P89, DOI 10.1023/A:1008968511133	23	2830	2964	27	1219	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2123	2126		10.1126/science.290.5499.2123	http://dx.doi.org/10.1126/science.290.5499.2123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118142				2022-12-28	WOS:000165870600050
J	Keeling, MJ; Wilson, HB; Pacala, SW				Keeling, MJ; Wilson, HB; Pacala, SW			Reinterpreting space, time lags, and functional responses in ecological models	SCIENCE			English	Article							DELAYED DENSITY-DEPENDENCE; POPULATION-DYNAMICS; PATCHY ENVIRONMENTS; STABILITY; SYSTEMS	Natural enemy-victim interactions are of major applied importance and of fundamental interest to ecologists. A key question is what stabilizes these interactions, allowing the Long-term coexistence of the two species. Three main theoretical explanations have been proposed: behavioral responses, time-dependent factors such as delayed density dependence, and spatial heterogeneity. Here, using the powerful moment-closure technique, we show a fundamental equivalence between these three elements. Limited movement by organisms is a ubiquitous feature of ecological systems, allowing spatial structure to develop; we show that the effects of this can be naturally described in terms of time lags or within-generation functional responses.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol, Ascot SL5 7PY, Berks, England; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	University of Cambridge; Imperial College London; Princeton University	Keeling, MJ (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	matt@zoo.cam.ac.uk	Keeling, Matt J/J-9280-2012	Keeling, Matt J/0000-0003-4639-4765				Bjornstad ON, 1998, J ANIM ECOL, V67, P110, DOI 10.1046/j.1365-2656.1998.00168.x; Bolker BM, 1999, AM NAT, V153, P575, DOI 10.1086/303199; BROOMHEAD DS, 1986, PHYSICA D, V20, P217, DOI 10.1016/0167-2789(86)90031-X; Crone EE, 1997, THEOR POPUL BIOL, V51, P67, DOI 10.1006/tpbi.1997.1309; DURRETT R, 1994, THEOR POPUL BIOL, V46, P363, DOI 10.1006/tpbi.1994.1032; HANSKI I, 1983, ECOLOGY, V64, P493, DOI 10.2307/1939969; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; HASSELL MP, 1974, J ANIM ECOL, V43, P567, DOI 10.2307/3384; Hassell MP., 1978, DYNAMICS ARTHROPOD P; HASTINGS A, 1977, THEOR POPUL BIOL, V12, P37, DOI 10.1016/0040-5809(77)90034-X; HORNFELDT B, 1994, ECOLOGY, V75, P791, DOI 10.2307/1941735; HUFFAKER C. B., 1958, HILGARDIA, V27, P343; KAREIVA P, 1990, PHILOS T R SOC B, V330, P175, DOI 10.1098/rstb.1990.0191; KEELING M, 1999, ADV ECOLOGICAL THEOR, P64, DOI DOI 10.1002/9781444311501.CH3; Keeling MJ, 2000, J ANIM ECOL, V69, P725, DOI 10.1046/j.1365-2656.2000.00430.x; LOTKA AJ, 1925, ELEMENTS PHYSICAL BI; MAY RM, 1978, J ANIM ECOL, V47, P833, DOI 10.2307/3674; MCCAULEY E, 1993, AM NAT, V142, P412, DOI 10.1086/285547; Nicholson A. J., 1935, P ZOOL SOC LOND, V105, P551, DOI DOI 10.1111/J.1096-3642.1935.TB01680.X; Pacala SW, 1996, ECOL MONOGR, V66, P1, DOI 10.2307/2963479; PACALA SW, 1991, AM NAT, V138, P584, DOI 10.1086/285236; Renshaw E., 1991, MODELLING BIOL POPUL, DOI 10.1017/CBO9780511624094; Rodriguez DJ, 1998, J THEOR BIOL, V191, P95, DOI 10.1006/jtbi.1997.0569; Saitoh T, 1998, RES POPUL ECOL, V40, P61, DOI 10.1007/BF02765222; TURCHIN P, 1990, NATURE, V344, P660, DOI 10.1038/344660a0; Volterra V, 1926, NATURE, V118, P558, DOI 10.1038/118558a0; Wilson HB, 1997, P ROY SOC B-BIOL SCI, V264, P625, DOI 10.1098/rspb.1997.0088	27	79	81	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	2000	290	5497					1758	1761		10.1126/science.290.5497.1758	http://dx.doi.org/10.1126/science.290.5497.1758			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099413				2022-12-28	WOS:000165632400041
J	Echtay, KS; Winkler, E; Klingenberg, M				Echtay, KS; Winkler, E; Klingenberg, M			Coenzyme Q is an obligatory cofactor for uncoupling protein function	NATURE			English	Article							FATTY-ACIDS; BACTERIAL EXPRESSION; NUCLEOTIDE-BINDING; H+ TRANSPORT; MITOCHONDRIA; CARRIER; UCP1; RECONSTITUTION; MEMBRANE	Uncoupling proteins (UCPs) are thought to be intricately controlled uncouplers(1-3) that are responsible for the futile dissipation of mitochondrial chemiosmotic gradients, producing heat rather than ATP. They occur in many animal and plant cells(4-9) and forma subfamily of the mitochondrial carrier family(10). Physiological uncoupling of oxidative phosphorylation must be strongly regulated to avoid deterioration of the energy supply and cell death, which is caused by toxic uncouplers. However, an H+ transporting uncoupling function is well established only for UCP1 from brown adipose tissue(2,8,9,11), and the regulation of UCP1 by fatty acids, nucleotides and pH remains controversial(2,12-14). The failure of UCP1 expressed in Escherichia coli inclusion bodies to carry out fatty-acid-dependent H+ transport activity inclusion bodies(15) made us seek a native UCP cofactor. Here we report the identification of coenzyme Q (ubiquinone) as such a cofactor. On addition of CoQ(10) to reconstituted UCP1 from inclusion bodies, fatty-acid-dependent H+ transport reached the same rate as with native UCP1. The H+ transport was highly sensitive to purine nucleotides, and activated only by oxidized but not reduced CoQ. H+ transport of native UCP1 correlated with the endogenous CoQ content.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	University of Munich	Klingenberg, M (corresponding author), Univ Munich, Inst Physiol Chem, Schillerstr 44, D-80336 Munich, Germany.	klingenberg@pbm.med.uni-muenchen.de						AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; BATHGATE B, 1992, MOL MICROBIOL, V6, P363, DOI 10.1111/j.1365-2958.1992.tb01479.x; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; Echtay KS, 1997, BIOCHEMISTRY-US, V36, P8253, DOI 10.1021/bi970513r; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Kaplan RS, 1996, J BIOENERG BIOMEMBR, V28, P41; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; LIN CS, 1982, BIOCHEMISTRY-US, V21, P2950, DOI 10.1021/bi00541a023; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x	30	264	276	1	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					609	613		10.1038/35046114	http://dx.doi.org/10.1038/35046114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117751				2022-12-28	WOS:000165548600124
J	Ciccone, A; Citterio, A; Santilli, I; Sterzi, R				Ciccone, A; Citterio, A; Santilli, I; Sterzi, R			Subarachnoid haemorrhage treated with anticoagulants	LANCET			English	Article							VENOUS SINUS THROMBOSIS		Osped Niguarda Ca Granda, Dept Neurosci, Stroke Unit, Div Granda, I-20122 Milan, Italy; Osped Niguarda Ca Granda, Dept Neurosci, Serv Neuroradiol, I-20122 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda	Ciccone, A (corresponding author), Osped Niguarda Ca Granda, Dept Neurosci, Stroke Unit, Div Granda, Piazza Osped Maggiore 3, I-20122 Milan, Italy.		Ciccone, Alfonso/AAB-6942-2022; Citterio, Alberto/H-1596-2017	Ciccone, Alfonso/0000-0002-4590-3575; Citterio, Alberto/0000-0003-2198-1488				Allroggen H, 2000, POSTGRAD MED J, V76, P12, DOI 10.1136/pmj.76.891.12; de Bruijn SFTM, 1999, STROKE, V30, P484, DOI 10.1161/01.STR.30.3.484; de Bruijn SFTM, 1998, LANCET, V351, P1404, DOI 10.1016/S0140-6736(05)79442-3; deBruijn SFTM, 1996, LANCET, V348, P1623, DOI 10.1016/S0140-6736(96)07294-7; VILLRINGER A, 1994, J NEURORADIOLOGY, V21, P72	5	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1818	1818		10.1016/S0140-6736(00)03236-0	http://dx.doi.org/10.1016/S0140-6736(00)03236-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117916				2022-12-28	WOS:000165545700015
J	Goodwin, T				Goodwin, T			In-flight medical emergencies: an overview	BRITISH MEDICAL JOURNAL			English	Article									Airport Med Serv, Forte Posthouse Hotel, Surrey RH6 0BA, England		Goodwin, T (corresponding author), Airport Med Serv, Forte Posthouse Hotel, Surrey RH6 0BA, England.							*BRIT HEART FDN, 1996, FACTFILE         JAN; Cox GR, 1996, AVIAT SPACE ENVIR MD, V67, P976; CREWDSON J, 1996, CHICAGO TRIBUNE 0630, P9; CUMMINS RO, 1989, JAMA-J AM MED ASSOC, V261, P1295, DOI 10.1001/jama.261.9.1295; GARRETT JS, 1999, S CAL I 15 JAN; GORDON V, 2000, ROYAL AER SOC C PASS; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HORDINSKI JR, 1991, DOTFAAAM9 OFF AV MED; *INT C AV SPAC MED, 1998, MED EM AIR VIRG EXP; JOHNSON R, 2000, ROYAL AER SOC C PASS; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Rayman RB, 1998, AVIAT SPACE ENVIR MD, V69, P1007; *ROYAL AER SOC, 1998, CAR AIR; *ROYAL AER SOC HUM, 1999, C DISR PASS 12 OCT; SCHWARTZ GB, 1982, JAMA-J AM MED ASSOC, V247, P1007; WALLACE W, 1995, BRIT MED J, V311, P1508, DOI 10.1136/bmj.311.7018.1508; 2000, EM TEL CTR	17	45	46	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1338	1341		10.1136/bmj.321.7272.1338	http://dx.doi.org/10.1136/bmj.321.7272.1338			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090521	Green Published			2022-12-28	WOS:000165561600035
J	Tollervey, D; Caceres, JF				Tollervey, D; Caceres, JF			RNA processing marches on	CELL			English	Article							CYTIDINE DEAMINASE AID; SPLICING FACTOR SF1; MESSENGER-RNA; NUCLEAR EXPORT; BINDING PROTEIN; POLYMERASE-II; CAENORHABDITIS; POLYADENYLATION; TERMINATION; DROSOPHILA		Univ Edinburgh, Wellcome Trust Ctr Cell Biol, ICMB, Edinburgh EH9 3JR, Midlothian, Scotland; Western Gen Hosp, MCR, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Tollervey, D (corresponding author), Univ Edinburgh, Wellcome Trust Ctr Cell Biol, ICMB, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	d.tollervey@ed.ac.uk	Tollervey, David/AAR-6662-2020; Caceres, Javier F/D-5260-2013	Tollervey, David/0000-0003-2894-2772; Caceres, Javier F/0000-0001-8025-6169	MRC [MC_U127584479] Funding Source: UKRI; Medical Research Council [MC_U127584479] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams MD, 1997, GENE DEV, V11, P129, DOI 10.1101/gad.11.1.129; Aragon T, 2000, MOL CELL BIOL, V20, P6259, DOI 10.1128/MCB.20.17.6259-6268.2000; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chang WH, 2000, CELL, V102, P609, DOI 10.1016/S0092-8674(00)00083-0; de Vries H, 2000, EMBO J, V19, P5895, DOI 10.1093/emboj/19.21.5895; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hatton AR, 1998, MOL CELL, V2, P787, DOI 10.1016/S1097-2765(00)80293-2; Hurt E, 2000, J BIOL CHEM, V275, P8361, DOI 10.1074/jbc.275.12.8361; Kang YB, 2000, J VIROL, V74, P5863, DOI 10.1128/JVI.74.13.5863-5871.2000; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Luitjens C, 2000, GENE DEV, V14, P2596, DOI 10.1101/gad.831700; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Mazroui R, 1999, RNA, V5, P1615, DOI 10.1017/S1355838299991872; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Skuse GR, 1996, NUCLEIC ACIDS RES, V24, P478, DOI 10.1093/nar/24.3.478; Sleeman JE, 1999, CURR BIOL, V9, P1065, DOI 10.1016/S0960-9822(99)80475-8; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Subramaniam K, 1999, DEVELOPMENT, V126, P4861; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	40	18	20	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					703	709		10.1016/S0092-8674(00)00174-4	http://dx.doi.org/10.1016/S0092-8674(00)00174-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114327	Bronze			2022-12-28	WOS:000165433100014
J	Banks, RE; Dunn, MJ; Hochstrasser, DF; Sanchez, JC; Blackstock, W; Pappin, DJ; Selby, PJ				Banks, RE; Dunn, MJ; Hochstrasser, DF; Sanchez, JC; Blackstock, W; Pappin, DJ; Selby, PJ			Proteomics: new perspectives, new biomedical opportunities	LANCET			English	Review							CREUTZFELDT-JAKOB-DISEASE; MYCOBACTERIUM-TUBERCULOSIS INFECTION; LASER CAPTURE MICRODISSECTION; 2-DIMENSIONAL ELECTROPHORESIS; DILATED CARDIOMYOPATHY; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; GEL-ELECTROPHORESIS; MOLECULAR ANALYSIS; MASS-SPECTROMETRY	Proteomics-based approaches, which examine the expressed proteins of a tissue or cell type, complement the genome initiatives and are increasingly being used to address biomedical questions. Proteins are the main functional output, and the genetic code cannot always indicate which proteins are expressed, in what quantity, and in what form. For example, post-translational modifications of proteins, such as phosphorylation or glycosylation, are very important in determining protein function. Similarly, the effects of environmental factors or multigenic processes such as ageing or disease cannot be assessed simply by examination of the genome alone. This review describes the underlying technology and illustrates several areas of biomedical research, ranging from pathogenesis of neurological disorders to drug and vaccine design, in which potential clinical applications are being explored.	St Jamess Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Harefield Hosp, Imperial Coll Sch med, Natl Heart & Lung Inst, Dept Cardiothorac Surg, Harefield UB9 6JH, Middx, England; Univ Geneva, Geneva, Switzerland; Univ Hosp Geneva, Dept Biochem Med, Geneva, Switzerland; Univ Hosp Geneva, Cent Lab Clin Chem, Geneva, Switzerland; Glaxo Wellcome Res & Dev Ltd, Biomol Struct Unit, Cell Mapping Project, Stevenage SG1 2NY, Herts, England; Imperial Canc Res Fund, Prot Sequencing Lab, London WC2A 3PX, England	Saint James's University Hospital; University of Leeds; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; University of Geneva; University of Geneva; University of Geneva; GlaxoSmithKline; Cancer Research UK	Banks, RE (corresponding author), St Jamess Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England.			Pappin, Darryl/0000-0002-8981-8401; Banks, Rosamonde/0000-0002-0042-8715				Aicher L, 1998, ELECTROPHORESIS, V19, P1998, DOI 10.1002/elps.1150191118; Alaiya AA, 2000, ELECTROPHORESIS, V21, P1210, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1210::AID-ELPS1210>3.0.CO;2-S; ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; ANDERSEN P, 1995, J IMMUNOL, V154, P3359; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; ANDERSON NG, 1982, CLIN CHEM, V28, P739; ANDERSON NL, 1991, ELECTROPHORESIS, V12, P907, DOI 10.1002/elps.1150121110; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; Appel RD, 1997, ELECTROPHORESIS, V18, P2724, DOI 10.1002/elps.1150181506; Bairoch A, 1998, NUCLEIC ACIDS RES, V26, P38, DOI 10.1093/nar/26.1.38; Banks RE, 1999, ELECTROPHORESIS, V20, P689, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<689::AID-ELPS689>3.0.CO;2-J; Beaudry P, 1999, DEMENT GERIATR COGN, V10, P40, DOI 10.1159/000017095; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Cash P, 2000, ELECTROPHORESIS, V21, P1187, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1187::AID-ELPS1187>3.3.CO;2-6; Celis JE, 1999, CANCER RES, V59, P3003; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Corbett JM, 1998, ELECTROPHORESIS, V19, P2031, DOI 10.1002/elps.1150191123; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Eisenstein E, 2000, CURR OPIN BIOTECH, V11, P25, DOI 10.1016/S0958-1669(99)00063-4; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Field ML, 1997, CARDIOVASC RES, V33, P8, DOI 10.1016/S0008-6363(96)00141-1; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Griffiths AD, 1998, CURR OPIN BIOTECH, V9, P102, DOI 10.1016/S0958-1669(98)80092-X; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HARRINGTON MG, 1986, NEW ENGL J MED, V315, P279, DOI 10.1056/NEJM198607313150502; Heinke MY, 1998, ELECTROPHORESIS, V19, P2021, DOI 10.1002/elps.1150191122; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; HOCHSTRASSER DF, 1995, METHOD INFORM MED, V34, P75; Hochstrasser DF, 1998, CLIN CHEM LAB MED, V36, P825, DOI 10.1515/CCLM.1998.146; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; James P, 1997, Q REV BIOPHYS, V30, P279, DOI 10.1017/S0033583597003399; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KNECHT M, 1994, EUR HEART J, V15, P37, DOI 10.1093/eurheartj/15.suppl_D.37; Lamond AI, 1997, TRENDS CELL BIOL, V7, P139, DOI 10.1016/S0962-8924(97)01031-3; LATIF N, 1995, J HEART LUNG TRANSPL, V14, P119; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McKerrow JH, 2000, MOL MED, V6, P450, DOI 10.1007/BF03401787; Myers TG, 1997, ELECTROPHORESIS, V18, P647, DOI 10.1002/elps.1150180351; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Orme IM, 1999, INFECT DIS CLIN N AM, V13, P169, DOI 10.1016/S0891-5520(05)70049-0; Ostergaard M, 1997, CANCER RES, V57, P4111; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Pleissner KP, 1997, ELECTROPHORESIS, V18, P802, DOI 10.1002/elps.1150180525; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Samanich KM, 1998, J INFECT DIS, V178, P1534, DOI 10.1086/314438; Sanchez JC, 1997, ELECTROPHORESIS, V18, P638, DOI 10.1002/elps.1150180349; Schlaeppi JM, 1999, CANCER METAST REV, V18, P473, DOI 10.1023/A:1006358220123; SELL S, 1990, CLIN LAB MED, V10, P1; Senior K, 1999, MOL MED TODAY, V5, P326, DOI 10.1016/S1357-4310(99)01536-1; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; STROHMAN R, 1994, BIO-TECHNOL, V12, P156, DOI 10.1038/nbt0294-156; TAYLORPAPADIMITRIOU J, 1994, TRENDS BIOTECHNOL, V12, P227, DOI 10.1016/0167-7799(94)90121-X; Tolnay M, 1999, NEUROPATH APPL NEURO, V25, P171; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Walter G, 2000, CURR OPIN MICROBIOL, V3, P298, DOI 10.1016/S1369-5274(00)00093-X; WASINGER VC, 1995, ELECTROPHORESIS, V16, P1090, DOI 10.1002/elps.11501601185; Weekes J, 1999, ELECTROPHORESIS, V20, P898, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<898::AID-ELPS898>3.0.CO;2-B; Weldingh K, 1998, INFECT IMMUN, V66, P3492, DOI 10.1128/IAI.66.8.3492-3500.1998; Wheeler CH, 1995, J HEART LUNG TRANSPL, V14, pS188; Wilkins MR, 1996, BIOTECHNOL GENET ENG, V13, P19, DOI 10.1080/02648725.1996.10647923; Wilkins MR, 1996, ELECTROPHORESIS, V17, P830, DOI 10.1002/elps.1150170504; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2; Zerr I, 1998, ANN NEUROL, V43, P32, DOI 10.1002/ana.410430109	70	334	364	0	74	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1749	1756		10.1016/S0140-6736(00)03214-1	http://dx.doi.org/10.1016/S0140-6736(00)03214-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095271				2022-12-28	WOS:000165462300037
J	O'Doherty, MJ; Marsden, PK				O'Doherty, MJ; Marsden, PK			Being equipped for clinical PET	LANCET			English	Editorial Material							POSITRON-EMISSION-TOMOGRAPHY; HEAD GAMMA-CAMERA; WHOLE-BODY; FDG-PET; COST-EFFECTIVENESS; LUNG-CANCER; MANAGEMENT; FLUORODEOXYGLUCOSE		St Thomas Hosp, Guys Kings & St Thomas Sch Med, Dept Radiol Sci, London SE1 7EH, England; St Thomas Hosp, Clin PET Ctr, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	O'Doherty, MJ (corresponding author), St Thomas Hosp, Guys Kings & St Thomas Sch Med, Dept Radiol Sci, London SE1 7EH, England.							Ahuja V, 1998, CANCER, V83, P918, DOI 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y; Bakheet SM, 1998, SEMIN NUCL MED, V28, P352; Bangerter M, 1998, ANN ONCOL, V9, P1117, DOI 10.1023/A:1008486928190; Cook GJR, 1999, EUR J NUCL MED, V26, P1363, DOI 10.1007/s002590050597; Delbeke D, 1999, J NUCL MED, V40, P110; Dietlein M, 2000, EUR J NUCL MED, V27, P1441, DOI 10.1007/s002590000324; Gambhir SS, 1996, J NUCL MED, V37, P1428; Gambhir SS, 1998, J CLIN ONCOL, V16, P2113, DOI 10.1200/JCO.1998.16.6.2113; Huebner RH, 2000, J NUCL MED, V41, P1177; Mikhaeel NG, 2000, ANN ONCOL, V11, P147, DOI 10.1023/A:1008381115131; O'Doherty MJ, 2000, NUCL MED COMMUN, V21, P224, DOI 10.1097/00006231-200003000-00004; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; Romer W, 1998, BLOOD, V91, P4464; Saunders CAB, 1999, ANN THORAC SURG, V67, P790, DOI 10.1016/S0003-4975(98)01257-0; Warburg O, 1931, METABOLISM TUMORS, P129; Weber WA, 1999, EUR J NUCL MED, V26, P388, DOI 10.1007/s002590050402	16	17	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 18	2000	356	9243					1701	1703		10.1016/S0140-6736(00)03200-1	http://dx.doi.org/10.1016/S0140-6736(00)03200-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095254				2022-12-28	WOS:000165462300005
J	Craig, O; Mulville, J; Pearson, MP; Sokol, R; Gelsthorpe, K; Stacey, R; Collins, M				Craig, O; Mulville, J; Pearson, MP; Sokol, R; Gelsthorpe, K; Stacey, R; Collins, M			Archaeology - Detecting milk proteins in ancient pots	NATURE			English	Article									Univ Newcastle Upon Tyne, NRG, Fossil Fuels & Environm Geochem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Oxford Univ Museum, English Heritage, Oxford OX1 3PW, England; Univ Sheffield, Dept Archaeol & Prehist, Sheffield S1 4ET, S Yorkshire, England; Reg Blood Transfus Ctr, Sheffield S5 7JN, S Yorkshire, England; Univ Bradford, Dept Archaeol Sci, Bradford BD7 1DP, W Yorkshire, England	Newcastle University - UK; University of Sheffield; University of Bradford	Craig, O (corresponding author), Univ Newcastle Upon Tyne, NRG, Fossil Fuels & Environm Geochem, Drummond Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.		Stacey, Rebecca/AAW-7380-2021; Mulville, Jacqueline/AAC-6106-2020	Stacey, Rebecca/0000-0002-5074-6180; Collins, Matthew/0000-0003-4226-5501; Mulville, Jacqueline/0000-0002-9392-3693				Craig OE, 2000, J IMMUNOL METHODS, V236, P89, DOI 10.1016/S0022-1759(99)00242-2; Dudd SN, 1998, SCIENCE, V282, P1478, DOI 10.1126/science.282.5393.1478; EVERSHED RP, 1993, WORLD ARCHAEOL, V25, P74, DOI 10.1080/00438243.1993.9980229; Evershed RP, 1996, J ARCHAEOL SCI, V23, P429, DOI 10.1006/jasc.1996.0038; Gilmour S, 1998, ANTIQUITY, V72, P327, DOI 10.1017/S0003598X00086609; HALSTEAD P., 1998, ANTHROPOZOOLOGICA, V27, P3, DOI DOI 10.1080/00934690.2016.1201615; McCormick F., 1998, LIFE EDGE HUMAN SETT, V10, P49; PARKERPEARSON M, 1999, ANTIQUITY, V73, P146; PARKERPEARSON M, 1996, ANTIQUITY, V70, P57; ROTTLANDER RCA, 1986, P 24 INT S ARCH, P403; Tuross N, 1996, J ARCHAEOL SCI, V23, P289, DOI 10.1006/jasc.1996.0027	11	50	51	0	30	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					312	312		10.1038/35042684	http://dx.doi.org/10.1038/35042684			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	373NR	11099030	Green Accepted			2022-12-28	WOS:000165296000033
J	Brubaker, K; Cowley, SM; Huang, K; Loo, L; Yochum, GS; Ayer, DE; Eisenman, RN; Radhakrishnan, I				Brubaker, K; Cowley, SM; Huang, K; Loo, L; Yochum, GS; Ayer, DE; Eisenman, RN; Radhakrishnan, I			Solution structure of the interacting domains of the Mad-Sin3 complex: Implications for recruitment of a chromatin-modifying complex	CELL			English	Article							HISTONE DEACETYLASE COMPLEX; THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL REPRESSION; NMR-SPECTROSCOPY; J-COUPLINGS; N-COR; C-13-LABELED PROTEINS; MSIN3A; SIN3; MAD	Gene-specific targeting of the Sin3 corepressor complex by DNA-bound repressors is an important mechanism of gene silencing in eukaryotes. The Sin3 corepressor specifically associates with a diverse group of transcriptional repressors, including members of the Mad family, that play crucial roles in development. The NMR structure of the complex formed by the PAH2 domain of mammalian Sin3A with the transrepression domain (SID) of human Mad1 reveals that both domains undergo mutual folding transitions upon complex formation generating an unusual left-handed four-helix bundle structure and an amphipathic alpha helix, respectively. The SID helix is wedged within a deep hydrophobic pocket defined by two PAH2 helices. Structure-function analyses of the Mad-Sin3 complex provide a basis for understanding the underlying mechanism(s) that lead to gene silencing.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Struct Biol NMR Facil, Evanston, IL 60208 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Northwestern University; Northwestern University; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Fred Hutchinson Cancer Center	Radhakrishnan, I (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.		Radhakrishnan, Ishwar/R-8442-2018; Radhakrishnan, Ishwar/AHA-7392-2022	Radhakrishnan, Ishwar/0000-0002-0195-9710; Radhakrishnan, Ishwar/0000-0002-0195-9710; Ayer, Donald/0000-0002-5595-3269; Cowley, Shaun/0000-0002-2510-1305	NIGMS NIH HHS [R01 GM055668] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055668] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Eilers AL, 1999, J BIOL CHEM, V274, P32750, DOI 10.1074/jbc.274.46.32750; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fletcher CM, 1996, J BIOMOL NMR, V8, P292, DOI 10.1007/BF00410328; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lohr F, 1996, J MAGN RESON SER B, V112, P259, DOI 10.1006/jmrb.1996.0140; MATHEWS FS, 1972, J MOL BIOL, V64, P449, DOI 10.1016/0022-2836(72)90510-4; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; Yang Q, 2000, BIOCHEM J, V345, P335, DOI 10.1042/0264-6021:3450335; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	59	83	100	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 10	2000	103	4					655	665		10.1016/S0092-8674(00)00168-9	http://dx.doi.org/10.1016/S0092-8674(00)00168-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106735	Bronze			2022-12-28	WOS:000165348000010
J	Peppard, PE; Young, T; Palta, M; Dempsey, J; Skatrud, J				Peppard, PE; Young, T; Palta, M; Dempsey, J; Skatrud, J			Longitudinal study of moderate weight change and sleep-disordered breathing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR RISK-FACTORS; APNEA-SYNDROME; OBESE PATIENTS; NECK CIRCUMFERENCE; DAYTIME SLEEPINESS; NATURAL EVOLUTION; UNITED-STATES; POPULATION; MEN; HYPERTENSION	Context Excess body weight is positively associated with sleep-disordered breathing (SDB), a prevalent condition in the US general population. No large study has been conducted of the longitudinal association between SDB and change in weight. Objective To measure the independent longitudinal association between weight change and change in SDB severity. Design Population-based, prospective cohort study conducted from July 1989 to January 2000. Setting and Participants Six hundred ninety randomly selected employed Wisconsin residents (mean age at baseline, 46 years; 56% male) who were evaluated twice at 4-year intervals for SDB. Main Outcome Measures Percentage change in the apnea-hypopnea index (AHI; apnea events + hypopnea events per hour of sleep) and odds of developing moderate-to-severe SDB (defined by an AHI greater than or equal to 15 events per hour of sleep), with respect to change in weight. Results Relative to stable weight, a 10% weight gain predicted an approximate 32% (95% confidence interval [CI], 20%-45%) increase in the AHI, A 10% weight loss predicted a 26% (95% CI, 18%-34%) decrease in the AHI. A 10% increase in weight predicted a 6-fold (95% CI, 2.2-17.0) increase in the odds of developing moderate-to-severe SDB. Conclusions Our data indicate that clinical and public health programs that result in even modest weight control are likely to be effective in managing SDB and reducing new occurrence of SDB.	Univ Wisconsin, Sch Med, Dept Prevent Med, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Dept Biostat & Med Informat, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Peppard, PE (corresponding author), Univ Wisconsin, Sch Med, Dept Prevent Med, 502 N Walnut St, Madison, WI 53705 USA.				NCRR NIH HHS [RR03186] Funding Source: Medline; NHLBI NIH HHS [R01HL62252] Funding Source: Medline; NIA NIH HHS [AG14124-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014124] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEARPARK H, 1995, AM J RESP CRIT CARE, V151, P1459, DOI 10.1164/ajrccm.151.5.7735600; BEARPARK H, 1993, SLEEP, V16, pS3; CHARUZI I, 1985, SURGERY, V97, P535; DAVIES RJO, 1990, EUR RESPIR J, V3, P509; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; Engleman HM, 1997, THORAX, V52, P114, DOI 10.1136/thx.52.2.114; Enright PL, 1996, SLEEP, V19, P531, DOI 10.1093/sleep/19.7.531; FERINISTRAMBI L, 1994, CHEST, V105, P1759, DOI 10.1378/chest.105.6.1759; Finn L, 1998, SLEEP, V21, P701; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Gottlieb DJ, 1999, AM J RESP CRIT CARE, V159, P502, DOI 10.1164/ajrccm.159.2.9804051; GRUNSTEIN R, 1993, INT J OBESITY, V17, P533; GRUNSTEIN RR, 1995, INT J OBESITY, V19, P410; GUILLEMINAULT C, 1995, ANN INTERN MED, V122, P493, DOI 10.7326/0003-4819-122-7-199504010-00003; HARMAN EM, 1982, CHEST, V82, P291, DOI 10.1378/chest.82.3.291; HOFFSTEIN V, 1992, EUR RESPIR J, V5, P377; Hu FB, 1999, AM J EPIDEMIOL, V150, P806; Hu FB, 2000, J AM COLL CARDIOL, V35, P308, DOI 10.1016/S0735-1097(99)00540-9; JENNUM P, 1992, CHEST, V102, P1371, DOI 10.1378/chest.102.5.1371; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; KATZ I, 1990, AM REV RESPIR DIS, V141, P1228, DOI 10.1164/ajrccm/141.5_Pt_1.1228; Kim HC, 1997, AM J RESP CRIT CARE, V156, P1813, DOI 10.1164/ajrccm.156.6.9610026; KISELAK J, 1993, CHEST, V104, P775, DOI 10.1378/chest.104.3.775; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; KOSKENVUO M, 1985, LANCET, V1, P893; Kripke DF, 1997, SLEEP, V20, P65, DOI 10.1093/sleep/20.1.65; LEVINSON PD, 1993, CHEST, V103, P1336, DOI 10.1378/chest.103.5.1336; Lewis CE, 2000, AM J EPIDEMIOL, V151, P1172, DOI 10.1093/oxfordjournals.aje.a010167; Lindberg E, 1998, THORAX, V53, P631, DOI 10.1136/thx.53.8.631; LOHMAN TG, 1988, ANTHROPOMETRIC STAND, P1; MILLMAN RP, 1995, CHEST, V107, P362, DOI 10.1378/chest.107.2.362; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Mortimore IL, 1998, AM J RESP CRIT CARE, V157, P280, DOI 10.1164/ajrccm.157.1.9703018; Nahmias J, 1993, N J Med, V90, P48; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Noseda A, 1996, CHEST, V109, P138, DOI 10.1378/chest.109.1.138; OLSON LG, 1995, AM J RESP CRIT CARE, V152, P711, DOI 10.1164/ajrccm.152.2.7633731; PARTINEN M, 1988, CHEST, V94, P1200, DOI 10.1378/chest.94.6.1200; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; PASQUALI R, 1990, INT J OBESITY, V14, P207; PEISER J, 1984, ANN SURG, V199, P125; Pendlebury ST, 1997, THORAX, V52, P872, DOI 10.1136/thx.52.10.872; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; PILLAR G, 1994, CHEST, V106, P1702, DOI 10.1378/chest.106.6.1702; RAJALA R, 1991, J INTERN MED, V230, P125, DOI 10.1111/j.1365-2796.1991.tb00419.x; Rechtschaffen A, 1968, NIH PUBLICATION, V204; Redline S, 1997, SLEEP, V20, P160, DOI 10.1093/sleep/20.2.160; Rothman K., 1998, MODERN EPIDEMIOLOGY; RUBINSTEIN I, 1988, AM REV RESPIR DIS, V138, P1192, DOI 10.1164/ajrccm/138.5.1192; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; SCHWARTZ AR, 1991, AM REV RESPIR DIS, V144, P494, DOI 10.1164/ajrccm/144.3_Pt_1.494; SFORZA E, 1994, EUR RESPIR J, V7, P1765, DOI 10.1183/09031936.94.07101765; SHELTON KE, 1993, AM REV RESPIR DIS, V148, P462, DOI 10.1164/ajrccm/148.2.462; Shinohara E, 1997, J INTERN MED, V241, P11, DOI 10.1046/j.1365-2796.1997.63889000.x; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; Strobel RJ, 1996, SLEEP, V19, P104, DOI 10.1093/sleep/19.2.104; SURATT PM, 1987, CHEST, V92, P631, DOI 10.1378/chest.92.4.631; SURATT PM, 1992, AM J CLIN NUTR, V56, P1825; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; WETTER DW, 1994, ARCH INTERN MED, V154, P2219, DOI 10.1001/archinte.154.19.2219; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	65	1004	1066	2	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3015	3021		10.1001/jama.284.23.3015	http://dx.doi.org/10.1001/jama.284.23.3015			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122588	Bronze			2022-12-28	WOS:000165847200026
J	Laub, MT; McAdams, TH; Feldblyum, T; Fraser, CM; Shapiro, L				Laub, MT; McAdams, TH; Feldblyum, T; Fraser, CM; Shapiro, L			Global analysis of the genetic network controlling a bacterial cell cycle	SCIENCE			English	Article							DEPENDENT POLAR LOCALIZATION; CAULOBACTER-CRESCENTUS; DNA-REPLICATION; REGULATOR; PROTEIN	This report presents full-genome evidence that bacterial cells use discrete transcription patterns to control cell cycle progression. Global transcription analysis of synchronized Caulobacter crescentus cells was used to identify 553 genes (19% of the genome) whose messenger RNA Levels varied as a function of the cell cycle. We conclude that in bacteria, as in yeast, (i) genes involved in a given cell function are activated at the time of execution of that function, (ii) genes encoding proteins that function in complexes are coexpressed, and (iii) temporal cascades of gene expression control multiprotein structure biogenesis. A single regulatory factor, the CtrA member of the two-component signal transduction family, is directly or indirectly involved in the control of 26% of the cell cycle-regulated genes.	Stanford Univ, Sch Med, Dept Dev Biol, Beckman Ctr, Stanford, CA 94305 USA; Inst Genom Res, Rockville, MD 20850 USA	Stanford University; J. Craig Venter Institute	Shapiro, L (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Beckman Ctr, Stanford, CA 94305 USA.			Laub, Michael/0000-0002-8288-7607; Fraser, Claire/0000-0003-1462-2428	NIGMS NIH HHS [GM32506, GM51426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032506, R37GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Domian IJ, 1999, P NATL ACAD SCI USA, V96, P6648, DOI 10.1073/pnas.96.12.6648; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; DRAPER GC, 2000, INTERACTIONS GIDA CH; Gober JW, 2000, PROKARYOTIC DEVELOPMENT, P319; Hung D, 2000, PROKARYOTIC DEVELOPMENT, P361; IBA H, 1978, J BACTERIOL, V135, P647, DOI 10.1128/JB.135.2.647-655.1978; Jacobs C, 1999, CELL, V97, P111, DOI 10.1016/S0092-8674(00)80719-9; LAUB MT, UNPUB; Missiakas D, 1998, MOL MICROBIOL, V28, P1059, DOI 10.1046/j.1365-2958.1998.00865.x; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; NEWTON A, 1972, P NATL ACAD SCI USA, V69, P447, DOI 10.1073/pnas.69.2.447; Ohta N, 2000, PROKARYOTIC DEVELOPMENT, P341; ONEILL EA, 1987, J BACTERIOL, V169, P2618, DOI 10.1128/jb.169.6.2618-2623.1987; Quon KC, 1998, P NATL ACAD SCI USA, V95, P120, DOI 10.1073/pnas.95.1.120; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; Skerker JM, 2000, EMBO J, V19, P3223, DOI 10.1093/emboj/19.13.3223; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Wheeler RT, 1999, MOL CELL, V4, P683, DOI 10.1016/S1097-2765(00)80379-2	19	396	402	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2144	2148		10.1126/science.290.5499.2144	http://dx.doi.org/10.1126/science.290.5499.2144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118148				2022-12-28	WOS:000165870600056
J	Leung, WC				Leung, WC			Ethical debate - Results of genetic testing: when confidentiality conflicts with a duty to warn relatives	BRITISH MEDICAL JOURNAL			English	Editorial Material									Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital	Leung, WC (corresponding author), Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.								0	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1464	1465		10.1136/bmj.321.7274.1464	http://dx.doi.org/10.1136/bmj.321.7274.1464			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110744	Green Published			2022-12-28	WOS:000165852300035
J	Blight, KJ; Kolykhalov, AA; Rice, CM				Blight, KJ; Kolykhalov, AA; Rice, CM			Efficient initiation of HCV RNA replication in cell culture	SCIENCE			English	Article							HEPATITIS-C VIRUS; NONSTRUCTURAL PROTEIN 5A; NS5A; INTERFERON; HYPERPHOSPHORYLATION; PHOSPHORYLATION; REGION; LIVER; NS4A; NS3	Hepatitis C virus (HCV) infection is a global health problem affecting an estimated 170 million individuals worldwide. We report the identification of multiple independent adaptive mutations that cluster in the HCV nonstructural protein NS5A and confer increased replicative ability in vitro. Among these adaptive mutations were a single amino acid substitution that allowed HCV RNA replication in 10% of transfected hepatoma cells and a deletion of 47 amino acids encompassing the interferon (IFN) sensitivity determining region (ISDR). Independent of the ISDR, IFN-alpha rapidly inhibited HCV RNA replication in vitro. This work establishes a robust, cell-based system for genetic and functional analyses of HCV replication.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Rockefeller Univ, Ctr Study Hepatitis C, New York, NY 10021 USA	Washington University (WUSTL); Rockefeller University	Rice, CM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	ricec@rockvax.rockefeller.edu			NCI NIH HHS [CA57973] Funding Source: Medline; NIAID NIH HHS [AI40034] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; HAGEDORN CH, 1999, HEPATITIS C VIRUSES; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Koch JO, 1999, J VIROL, V73, P7138; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Noguchi M, 1996, IN VITRO CELL DEV-AN, V32, P135; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738	18	1192	1347	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	2000	290	5498					1972	1974		10.1126/science.290.5498.1972	http://dx.doi.org/10.1126/science.290.5498.1972			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110665				2022-12-28	WOS:000165810000048
J	Peterson, LC; Haug, GH; Hughen, KA; Rohl, U				Peterson, LC; Haug, GH; Hughen, KA; Rohl, U			Rapid changes in the hydrologic cycle of the tropical Atlantic during the last glacial	SCIENCE			English	Article							CARIACO BASIN; SEDIMENTS; VENEZUELA; RECORDS; BRAZIL; EVENTS; KYR; SEA	Sedimentary time series of color reflectance and major element chemistry from the anoxic Cariaco Basin off the coast of northern Venezuela record large and abrupt shifts in the hydrologic cycle of the tropical Atlantic during the past 90,000 years. Marine productivity maxima and increased precipitation and riverine discharge from northern South America are closely linked to interstadial (warm) climate events of marine isotope stage 3, as recorded in Greenland ice cores. Increased precipitation at this latitude during interstadials suggests the potential for greater moisture export from the Atlantic to Pacific, which could have affected the salinity balance of the Atlantic and increased thermohaline heat transport to high northern latitudes. This supports the notion that tropical feedbacks played an important role in modulating global climate during the last glacial period.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Swiss Fed Inst Technol ETH, Dept Earth Sci, CH-8092 Zurich, Switzerland; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Univ Bremen, Fachbereich Geowissensch, D-28334 Bremen, Germany	University of Miami; Swiss Federal Institutes of Technology Domain; ETH Zurich; Woods Hole Oceanographic Institution; University of Bremen	Peterson, LC (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.		Röhl, Ursula/G-5986-2011	Röhl, Ursula/0000-0001-9469-7053				Arz HW, 1998, QUATERNARY RES, V50, P157, DOI 10.1006/qres.1998.1992; BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; Behl RJ, 1996, NATURE, V379, P243, DOI 10.1038/379243a0; Black DE, 1999, SCIENCE, V286, P1709, DOI 10.1126/science.286.5445.1709; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; Broccoli AJ, 2000, J CLIMATE, V13, P951, DOI 10.1175/1520-0442(2000)013<0951:TCATLG>2.0.CO;2; Broecker WS, 1997, GLOBAL BIOGEOCHEM CY, V11, P589, DOI 10.1029/97GB02267; Cane M, 1999, GEOPH MONOG SERIES, V112, P373; CLARK PU, 1999, GEOPHYSICAL MONOGRAP, V112; Clayton T, 1999, MAR GEOL, V161, P191, DOI 10.1016/S0025-3227(99)00036-5; Fedorov AV, 2000, SCIENCE, V288, P1997, DOI 10.1126/science.288.5473.1997; Harris SE, 1999, QUATERNARY RES, V51, P14, DOI 10.1006/qres.1998.2008; HASTENRATH S, 1993, J GEOPHYS RES-ATMOS, V98, P5093, DOI 10.1029/92JD02646; Haug GH, 1998, PALEOCEANOGRAPHY, V13, P427, DOI 10.1029/98PA01976; Hostetler SW, 1999, J GEOPHYS RES-ATMOS, V104, P3947, DOI 10.1029/1998JD200067; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Jansen JHF, 1998, MAR GEOL, V151, P143, DOI 10.1016/S0025-3227(98)00074-7; Lin HL, 1997, PALEOCEANOGRAPHY, V12, P415, DOI 10.1029/97PA00230; MALONEY N., 1965, B I OCAENOGR, V4, P246; OHARA C, UNPUB; Peterson LC, 1991, PALEOCEANOGRAPHY, V6, P99, DOI 10.1029/90PA02497; Peterson L.C, 2000, P OCEAN DRILL PROGRA, V165, P85, DOI DOI 10.2973/ODP.PROC.SR.165.017.2000; SCHUBERT C, 1988, INTERCIENCIA, V13, P128; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750; STOCKER TF, 1991, NATURE, V351, P729, DOI 10.1038/351729a0; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; Weyl P. K., 1968, METEOROL MONOGR, V8, P37; Yarincik KM, 2000, PALEOCEANOGRAPHY, V15, P210	28	645	681	4	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1947	1951		10.1126/science.290.5498.1947	http://dx.doi.org/10.1126/science.290.5498.1947			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110658				2022-12-28	WOS:000165810000041
J	Spuler, A; Atkinson, JLD				Spuler, A; Atkinson, JLD			Astrocytoma following the pyramidal tract	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Klinikum Buch, D-13122 Berlin, Germany; Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Spuler, A (corresponding author), Klinikum Buch, D-13122 Berlin, Germany.			Spuler, Andreas/0000-0001-6031-179X					0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2000	343	23					1702	1702		10.1056/NEJM200012073432306	http://dx.doi.org/10.1056/NEJM200012073432306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380PX	11106720				2022-12-28	WOS:000165711900006
J	Bloche, MG; Jacobson, PD				Bloche, MG; Jacobson, PD			The Supreme Court and bedside rationing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Johns Hopkins Univ, Program Law & Publ Hlth, Washington, DC USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA	Johns Hopkins University; University of Michigan System; University of Michigan	Bloche, MG (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.							ARROW KJ, 1963, AM ECON REV, V53, P941; BECK J, 1998, CHICAGO TRIBUNE 1115, pC23; Bloche MG, 1999, JAMA-J AM MED ASSOC, V281, P268, DOI 10.1001/jama.281.3.268; BLOCHE MG, 2000, MED CARE ENGIMA EFFI; COOTER R, 1991, NEW YORK U LAW REV, V66, P1045; Davis A, 1999, Healthc Financ Manage, V53, P46; Jacobson PD, 2000, AM J LAW MED, V26, P155; Jacobson PD, 2000, JAMA-J AM MED ASSOC, V284, P1516, DOI 10.1001/jama.284.12.1516; JACOBSON PD, 1998, HOUSTON LAW REV, V35, P985; Langwell K M, 1990, Health Care Financ Rev, V12, P71; Mariner WK, 2000, NEW ENGL J MED, V343, P592, DOI 10.1056/NEJM200008243430823; OBRIEN B, 1994, BUFFALO NEWS    1024, P1; Pear Robert, 1994, N Y Times Web, pA12; RODWIN MA, 1995, NEW ENGL J MED, V332, P604, DOI 10.1056/NEJM199503023320913; Sulmasy DP, 2000, ARCH INTERN MED, V160, P649, DOI 10.1001/archinte.160.5.649	15	25	25	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2776	2779		10.1001/jama.284.21.2776	http://dx.doi.org/10.1001/jama.284.21.2776			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	377JB	11105185				2022-12-28	WOS:000165509500033
J	Brady, RO; Schiffmann, R				Brady, RO; Schiffmann, R			Clinical features of and recent advances in therapy for Fabry disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INHERITED ENZYME DEFICIENCY; REPLACEMENT THERAPY; ALPHA-GALACTOSIDASE; GENE-TRANSFER; CELLS; MICE; DEFECTS	Fabry disease is an X-linked recessive lysosomal storage disorder caused by a deficiency of alpha -galactosidase A. Intracellular accumulation of globotriaosylceramide, the glycolipid substrate of this enzyme, leads to severe painful neuropathy with progressive renal, cardiovascular, and cerebrovascular dysfunction and early death, Men are predominantly affected but many female carriers have similar clinical involvement, including increased risk of stroke. Physical stigmata, such as angiokeratomas in skin and mucous membranes and characteristic benign corneal abnormalities, facilitate identification of Fabry disease. The finding of a marked decreased activity of alpha -galactosidase A in white blood cells or cultured skin fibroblasts confirms the diagnosis. Treatment thus far has been symptomatic only, Etiology-based therapies are being developed that include enzyme replacement therapy, gene therapy, and substrate deprivation, Our recently completed double-blind, placebo-controlled trial of intravenous infusions of alpha -galactosidase A in patients with Fabry disease demonstrated the safety and efficacy of this treatment.	NINDS, Dev Metab Neurol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Schiffmann, R (corresponding author), NINDS, Dev Metab Neurol Branch, NIH, Bldg 10,Room 3D03,10 Ctr Dr,MSC 1260, Bethesda, MD 20892 USA.	rs4e@nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002984] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe A, 2000, J CLIN INVEST, V105, P1563, DOI 10.1172/JCI9711; Anderson W., 1898, BRIT J DERMATOL, V10, P113, DOI [10.1111/j.1365-2133.1898.tb16317.x, DOI 10.1111/J.1365-2133.1898.TB16317.X]; Argoff CE, 1998, NUCL MED COMMUN, V19, P887, DOI 10.1097/00006231-199809000-00009; BAO LL, 1990, CHINESE MED J-PEKING, V103, P134; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; BRADY RO, 1966, NEW ENGL J MED, V275, P312, DOI 10.1056/NEJM196608112750606; BRADY RO, 1973, NEW ENGL J MED, V289, P9, DOI 10.1056/NEJM197307052890103; Chimenti C, 1999, Cardiologia, V44, P469; Cox T, 2000, LANCET, V355, P1481, DOI 10.1016/S0140-6736(00)02161-9; Crutchfield KE, 1998, NEUROLOGY, V50, P1746, DOI 10.1212/WNL.50.6.1746; DeGraba T, 2000, ANN NEUROL, V47, P229, DOI 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.3.CO;2-K; Desnick RJ, 1996, METABOLIC MOL BASES, P2741; Fabry J., 1898, ARCH DERMATOL SYPHIL, V43, P187; Franceschetti A T, 1976, Birth Defects Orig Artic Ser, V12, P195; Jeyakumar M, 1999, P NATL ACAD SCI USA, V96, P6388, DOI 10.1073/pnas.96.11.6388; KINT J A, 1970, Science (Washington D C), V167, P1268, DOI 10.1126/science.167.3922.1268; KUSIAK JW, 1978, J BIOL CHEM, V253, P184; Ling GSF, 1999, NEUROLOGY, V52, pA362; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Meroni M, 1997, CONTRIB NEPHROL, V122, P178; Mitsias P, 1996, ANN NEUROL, V40, P8, DOI 10.1002/ana.410400105; MOORE DF, 2000, J NEUROIMAGING, V10, P60; NAKAO S, 1995, NEW ENGL J MED, V333, P288, DOI 10.1056/NEJM199508033330504; Ohshima T, 1999, P NATL ACAD SCI USA, V96, P6423, DOI 10.1073/pnas.96.11.6423; OPITZ JM, 1965, AM J HUM GENET, V17, P325; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; ROBERTS DH, 1984, J ROY SOC MED, V77, P430; SCHACHERN PA, 1989, ANN OTO RHINOL LARYN, V98, P359, DOI 10.1177/000348948909800509; Schiffmann R, 2000, AM J HUM GENET, V67, P38; Schiffmann R, 2000, P NATL ACAD SCI USA, V97, P365, DOI 10.1073/pnas.97.1.365; SWEELEY CC, 1963, J BIOL CHEM, V238, P3148; Takenaka T, 1999, EXP HEMATOL, V27, P1149, DOI 10.1016/S0301-472X(99)00050-8; Takenaka T, 1999, HUM GENE THER, V10, P1931, DOI 10.1089/10430349950017293; Topaloglu AK, 1999, MOL MED, V5, P806, DOI 10.1007/BF03401993; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; YAMAKAWA T, 1963, J BIOCHEM, V53, P28, DOI 10.1093/oxfordjournals.jbchem.a127654; Ziegler RJ, 1999, HUM GENE THER, V10, P1667, DOI 10.1089/10430349950017671	38	134	143	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2771	2775		10.1001/jama.284.21.2771	http://dx.doi.org/10.1001/jama.284.21.2771			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105184				2022-12-28	WOS:000165509500032
J	Josephson, ME; Callans, DJ; Buxton, AE				Josephson, ME; Callans, DJ; Buxton, AE			The role of the implantable cardioverter-defibrillator for prevention of sudden cardiac death	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-ARTERY-DISEASE; IDIOPATHIC DILATED CARDIOMYOPATHY; ANTIARRHYTHMIC-DRUG-THERAPY; VENTRICULAR-TACHYCARDIA; UNEXPLAINED SYNCOPE; ARRHYTHMIC DEATH; HEART-FAILURE; HIGH-RISK; MORTALITY; EFFICACY	Sudden cardiac death, which accounts for approximately 350 000 deaths each year, is a major health care problem. Antiarrhythmic drugs have not been reliable in preventing sudden cardiac death. Although p-blockers, angiotensin-converting enzyme inhibitors, and revascularization play a role in prevention of sudden cardiac death, the development and subsequent refinement of the implantable cardioverter-defibrillator has made the most important contribution to its management. Several randomized, controlled trials have demonstrated improved survival in patients resuscitated from cardiac arrest. Two recent trials also suggest a role for primary prevention in selected patients with coronary artery disease, ventricular dysfunction, and nonsustained ventricular tachycardia in whom sustained ventricular tachycardia is induced. Further technological refinements and development of new, more sensitive risk stratifiers with a higher positive predictive value for sudden cardiac death will expand the indications for this lifesaving therapy.	Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Univ Penn, Philadelphia, PA 19104 USA; Rhode Isl Hosp, Providence, RI USA	Harvard University; Beth Israel Deaconess Medical Center; University of Pennsylvania; Lifespan Health Rhode Island; Rhode Island Hospital	Josephson, ME (corresponding author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA.		Callans, David/ABH-2176-2021					Anderson JL, 1999, CIRCULATION, V99, P1692, DOI 10.1161/01.CIR.99.13.1692; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; BOCKER D, 1995, BRIT HEART J, V73, P158; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; BUXTON AE, 1993, PROG CARDIOVASC DIS, V36, P215, DOI 10.1016/0033-0620(93)90015-6; Caruso AC, 1997, CIRCULATION, V96, P1888, DOI 10.1161/01.CIR.96.6.1888; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; Domanski MJ, 1999, J AM COLL CARDIOL, V34, P1090, DOI 10.1016/S0735-1097(99)00327-7; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ECHT DS, 1985, CIRCULATION, V71, P289, DOI 10.1161/01.CIR.71.2.289; El-Shalakany A, 1999, CIRCULATION, V99, P2283, DOI 10.1161/01.CIR.99.17.2283; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; FOGOROS RN, 1990, J AM COLL CARDIOL, V16, P381, DOI 10.1016/0735-1097(90)90590-L; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; HOLMES DR, 1986, CIRCULATION, V73, P1254, DOI 10.1161/01.CIR.73.6.1254; Josephson ME, 1999, J AM COLL CARDIOL, V33, P1971; KIM SG, 1991, J AM COLL CARDIOL, V17, P1587, DOI 10.1016/0735-1097(91)90652-P; Knight BP, 1999, J AM COLL CARDIOL, V33, P1964, DOI 10.1016/S0735-1097(99)00148-5; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; Lechat P, 1997, CIRCULATION, V96, P2197; Link MS, 1997, J AM COLL CARDIOL, V29, P370, DOI 10.1016/S0735-1097(96)00477-9; MARCHLINSKI FE, 1986, ANN INTERN MED, V104, P481, DOI 10.7326/0003-4819-104-4-481; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MIROWSKI M, 1980, AM HEART J, V100, P1089, DOI 10.1016/0002-8703(80)90218-5; Moss A. J., 1999, Annals of Noninvasive Electrocardiology, V4, P83, DOI 10.1111/j.1542-474X.1999.tb00369.x; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; POLL DS, 1986, AM J CARDIOL, V58, P992, DOI 10.1016/S0002-9149(86)80025-X; Reddy RK, 1997, PACE, V20, P600, DOI 10.1111/j.1540-8159.1997.tb06213.x; *RES COLL GROUP, 1997, LANCET, V349, P375; RODRIGUEZ E, 1998, PACE, V21, P891; Rothman SA, 1997, CIRCULATION, V96, P3499; Sarter BH, 1996, J AM COLL CARDIOL, V28, P122, DOI 10.1016/0735-1097(96)00123-4; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WALLER TJ, 1987, J AM COLL CARDIOL, V10, P83, DOI 10.1016/S0735-1097(87)80164-X; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; ZADO ES, 1997, CIRCULATION, V96, P318; 1993, AM J CARDIOL, V72, P28	39	20	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					901	910		10.7326/0003-4819-133-11-200012050-00015	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00015			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103061				2022-12-28	WOS:000165585800009
J	Tsai, AP; Guo, JQ; Abe, E; Takakura, H; Sato, TJ				Tsai, AP; Guo, JQ; Abe, E; Takakura, H; Sato, TJ			Alloys - A stable binary quasicrystal	NATURE			English	Article							SYMMETRY		Japan Sci & Technol Corp, Natl Res Inst Met, Tsukuba, Ibaraki 3050047, Japan; Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki 3050047, Japan	Japan Science & Technology Agency (JST); National Institute for Materials Science; Japan Science & Technology Agency (JST)	Tsai, AP (corresponding author), Japan Sci & Technol Corp, Natl Res Inst Met, Tsukuba, Ibaraki 3050047, Japan.		Sato, Taku J/I-7664-2015; Abe, Eiji/AAE-7129-2020; Takakura, Hiroyuki/D-6146-2012	Sato, Taku J/0000-0003-2511-4998; Abe, Eiji/0000-0003-3999-4383				BALL MD, 1985, SCRIPTA METALL MATER, V19, P1065, DOI 10.1016/0036-9748(85)90010-9; ELSER V, 1985, PHYS REV LETT, V55, P2883, DOI 10.1103/PhysRevLett.55.2883; Guo J, 2000, JPN J APPL PHYS 2, V39, pL770, DOI 10.1143/JJAP.39.L770; GUO JQ, IN PRESS PHIL MAG LE; HENLEY CL, 1986, PHIL MAG LETT, V53, P59; MASSALSKI TB, 1990, BINARY ALLOY PHASE D, V2, P996; PALENZONA A, 1971, J LESS-COMMON MET, V25, P367, DOI 10.1016/0022-5088(71)90179-2; SHECHTMAN D, 1984, PHYS REV LETT, V53, P1951, DOI 10.1103/PhysRevLett.53.1951; TSAI AP, 1987, JPN J APPL PHYS 2, V26, pL1505, DOI 10.1143/JJAP.26.L1505; TSAI AP, 1990, MATER T JIM, V31, P98, DOI 10.2320/matertrans1989.31.98; TSAI AP, 1994, PHIL MAG LETT, V70, P169, DOI 10.1080/09500839408240971	11	403	406	1	137	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					537	538		10.1038/35046202	http://dx.doi.org/10.1038/35046202			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117731				2022-12-28	WOS:000165548600103
J	Hohnloser, SH; Kuck, KH; Lilienthal, J				Hohnloser, SH; Kuck, KH; Lilienthal, J		PIAF Investigators	Rhythm or rate control in atrial fibrillation - Pharmacological intervention in atrial fibrillation (PIAF): a randomised trial	LANCET			English	Article							QUALITY-OF-LIFE; ATRIOVENTRICULAR JUNCTION ABLATION; III ANTIARRHYTHMIC DRUGS; VENTRICULAR RATE CONTROL; SINUS RHYTHM; MAINTENANCE; THERAPY; CARDIOVERSION; TACHYCARDIA; PERFORMANCE	Background Atrial fibrillation is the most commonly encountered sustained cardiac arrhythmia. Restoration and maintenance of sinus rhythm is believed by many physicians to be superior to rate control only. However, there are no prospective data that compare both therapeutic strategies. Methods The Pharmacological Intervention in Atrial Fibrillation (PIAF) trial was a randomised trial in 252 patients with atrial fibrillation of between 7 days and 360 days duration, which compared rate (group A, 125 patients) with rhythm control (group B, 127 patients). In group A, diltiazem was used as first-line therapy and amiodarone was used in group B. The primary study endpoint was improvement in symptoms related to atrial fibrillation. Findings Over the entire observation period of 1 year, a similar proportion of patients reported improvement in symptoms in both groups (76 responders at 12 months in group A vs 70 responders in group B, p=0.317). Amiodarone administration resulted in pharmacological restoration of sinus rhythm in 23% of patients. Walking distance in a 6 min walk test was better in group B compared with group A, but assessment of quality of life showed no differences between groups. The incidence of hospital admission was higher in group B (87 [69%] out of 127 vs 30 [24%] out of 125 in group A, p=0.001). Adverse drug effects more frequently led to a change in therapy in group 3 (31 [25%] patients compared with 17 [14%] in group A, p=0.036). Interpretation With respect to symptomatic improvement in patients with atrial fibrillation, the therapeutic strategies of rate versus rhythm control yielded similar clinical results overall. However, exercise tolerance is better with rhythm control, although hospital admission is more frequent. These data may serve as a basis to select therapy in individual patients.	Univ Frankfurt, Dept Med, Div Cardiol, D-60590 Frankfurt, Germany; St Georges Hosp, Hamburg, Germany; Datamap, Freiburg, Germany	Goethe University Frankfurt; Asklepios Klinik St. Georg	Hohnloser, SH (corresponding author), Univ Frankfurt, Dept Med, Div Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.							ATWOOD JE, 1989, AM HEART J, V118, P913, DOI 10.1016/0002-8703(89)90223-8; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BHANDARI AK, 1992, AM HEART J, V124, P381, DOI 10.1016/0002-8703(92)90601-Q; BIALY D, 1992, Journal of the American College of Cardiology, V19, p41A; Brignole M, 1998, CIRCULATION, V98, P953, DOI 10.1161/01.CIR.98.10.953; Bubien RS, 1996, CIRCULATION, V94, P1585, DOI 10.1161/01.CIR.94.7.1585; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Golzari H, 1996, ANN INTERN MED, V125, P311, DOI 10.7326/0003-4819-125-4-199608150-00010; GOSSELINK ATM, 1994, BRIT HEART J, V72, P161; Hlatky MA, 1996, CIRCULATION, V94, P1491, DOI 10.1161/01.CIR.94.7.1491; Hohnloser SH, 1997, PACE, V20, P1989, DOI 10.1111/j.1540-8159.1997.tb03606.x; HOHNLOSER SH, 1994, PACE, V17, P1019, DOI 10.1111/j.1540-8159.1994.tb01456.x; HOHNLOSER SH, 1995, J CARDIOVASC ELECTR, V6, P920, DOI 10.1111/j.1540-8167.1995.tb00368.x; HOHNLOSER SH, 1994, ANN INTERN MED, V121, P529, DOI 10.7326/0003-4819-121-7-199410010-00009; JUNG W, 1993, J AM COLL CARDIOL, V33, pA104; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; Lee SH, 1998, J AM COLL CARDIOL, V31, P637, DOI 10.1016/S0735-1097(97)00530-5; Levy S, 1998, EUR HEART J, V19, P1294, DOI 10.1053/euhj.1998.1050; Levy S, 1999, CIRCULATION, V99, P3028, DOI 10.1161/01.CIR.99.23.3028; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; LUNDSTROM T, 1990, J AM COLL CARDIOL, V16, P86, DOI 10.1016/0735-1097(90)90461-W; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Myerburg RJ, 1999, J CARDIOVASC ELECTR, V10, P482, DOI 10.1111/j.1540-8167.1999.tb00702.x; PRYSTOWSKY EN, 1996, CIRCULATION, V94, P191; Roy D, 2000, NEW ENGL J MED, V342, P913, DOI 10.1056/NEJM200003303421302; Sopher SM, 1996, AM J CARDIOL, V77, pA24, DOI 10.1016/S0002-9149(97)89115-1; Wyse DG, 1997, AM J CARDIOL, V79, P1198	28	814	848	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1789	1794		10.1016/S0140-6736(00)03230-X	http://dx.doi.org/10.1016/S0140-6736(00)03230-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117910				2022-12-28	WOS:000165545700009
J	Pohl, F				Pohl, F			Brain drain - Why civilizations fall silent.	NATURE			English	Editorial Material																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					409	409		10.1038/35044153	http://dx.doi.org/10.1038/35044153			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100704	Bronze			2022-12-28	WOS:000165429800021
J	Shorey, L; Piertney, S; Stone, J; Hoglund, J				Shorey, L; Piertney, S; Stone, J; Hoglund, J			Fine-scale genetic structuring on Manacus manacus leks	NATURE			English	Article							KIN SELECTION; RELATEDNESS; MARKERS; SUCCESS; MALES; BIRDS	Leks have traditionally been considered as arenas where males compete to attract females and secure matings. Thus, direct fitness benefits mediated through competition between males to fertilize females have been considered to be the primary force driving the evolution of lekking behaviour(1,2). Inclusive fitness benefits mediated through kin selection(3) may also be involved in lek formation and evolution(4,5), but to date this theory has been largely ignored. According to kin-selection theory, both reproducing and non-reproducing males may gain indirect inclusive fitness benefits. If females are attracted to larger leks, non-reproducing males add attractiveness to a lek, and therefore, in a genetically structured population, boost the reproductive success of kin. Theory predicts that the attractiveness of leks is plastic, and that males establish themselves on a lek in which the top male, in terms of reproductive success, is a close relative(6). Here we show that in white-bearded manakins (Manacus manacus), for which larger leks are more attractive to females(7,8) and so secure the maximum number of matings, there is extraordinary fine-scale genetic structure, with leks being composed of clusters of related kin. We propose that males establish themselves where they rnd relatives to such an extent that they form groups within leks, and that such behaviour is consistent with kin-selection theory to maximize reproductive success of the group.	Uppsala Univ, Populat Biol EBC, SE-75236 Uppsala, Sweden; Univ Aberdeen, Dept Zool, NERC Mol Genet Ecol Initiat, Aberdeen AB24 2TZ, Scotland; Uppsala Univ, Anim Ecol EBC, SE-75236 Uppsala, Sweden	Uppsala University; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Aberdeen; Uppsala University	Shorey, L (corresponding author), Uppsala Univ, Populat Biol EBC, Norbyvagen 18D, SE-75236 Uppsala, Sweden.	lisa.shorey@ebc.uu.se	Piertney, Stuart/I-3144-2012	Hoglund, Jacob/0000-0002-5840-779X; Piertney, Stuart/0000-0001-6654-0569				HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hoglund J, 1999, P ROY SOC B-BIOL SCI, V266, P813; Hoglund J., 1995, LEKS, DOI DOI 10.1515/9781400864157; Kokko H, 1996, P ROY SOC B-BIOL SCI, V263, P919, DOI 10.1098/rspb.1996.0136; Kokko H, 1998, ANIM BEHAV, V56, P755, DOI 10.1006/anbe.1998.0815; LILL A, 1974, Zeitschrift fuer Tierpsychologie, V36, P1; LILL A, 1974, Zeitschrift fuer Tierpsychologie, V36, P513; Lynch M, 1999, GENETICS, V152, P1753; MCDONALD DB, 1994, SCIENCE, V266, P1030, DOI 10.1126/science.7973654; Petrie M, 1999, NATURE, V401, P155, DOI 10.1038/43651; Sherman Paul W., 1997, P69; Sherman PW, 1999, NATURE, V401, P119, DOI 10.1038/43574; SNOW D. W., 1962, ZOOLOGICA [NEW YORK], V47, P65; Wiley RH, 1991, ADV STUD BEHAV, V20, P201	14	92	92	0	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 16	2000	408	6810					352	353		10.1038/35042562	http://dx.doi.org/10.1038/35042562			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099040				2022-12-28	WOS:000165296000043
J	Mothes, W; Boerger, AL; Narayan, S; Cunningham, JM; Young, JAT				Mothes, W; Boerger, AL; Narayan, S; Cunningham, JM; Young, JAT			Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein	CELL			English	Article							ROUS-SARCOMA VIRUS; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; AVIAN-LEUKOSIS; CONFORMATIONAL-CHANGES; CELL-FUSION; HIV-1 ENTRY; PROTEIN; INFECTION; CLATHRIN	Avian leukosis virus (ALV) has been used as a model system to understand the mechanism of pH-independent viral entry involving receptor-induced conformational changes in the viral envelope (Env) glycoprotein that lead to membrane fusion. Here, we report the unexpected finding that ALV entry depends on a critical low pH step that was overlooked when this virus was directly compared to the classical pH-dependent influenza A virus. In contrast to influenza A virus, receptor interaction plays an essential role in priming ALV Env for subsequent low pH triggering. Our results reveal a novel principle in viral entry, namely that receptor interaction can convert a pH-insensitive viral glycoprotein to a form that is responsive to low pH.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison	Young, JAT (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.			Young, John/0000-0003-1824-2561	NCI NIH HHS [CA70810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adkins HB, 2000, J VIROL, V74, P3572, DOI 10.1128/JVI.74.8.3572-3578.2000; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ANDERSEN KB, 1983, VIROLOGY, V125, P85, DOI 10.1016/0042-6822(83)90065-X; Balliet JW, 1999, J VIROL, V73, P3054, DOI 10.1128/JVI.73.4.3054-3061.1999; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Boerger AL, 1999, P NATL ACAD SCI USA, V96, P9867, DOI 10.1073/pnas.96.17.9867; BOERKOEL CF, 1993, VIROLOGY, V195, P669, DOI 10.1006/viro.1993.1418; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Damico RL, 1998, P NATL ACAD SCI USA, V95, P2580, DOI 10.1073/pnas.95.5.2580; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; De Tulleo L, 1998, EMBO J, V17, P4585, DOI 10.1093/emboj/17.16.4585; Drose S, 1997, J EXP BIOL, V200, P1; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; DUVE CD, 1974, BIOCHEM PHARMACOL, V23, P2495; FAN H, 1974, J VIROL, V14, P421, DOI 10.1128/JVI.14.3.421-429.1974; GILBERT JM, 1990, J VIROL, V64, P5106, DOI 10.1128/JVI.64.10.5106-5113.1990; GILBERT JM, 1995, J VIROL, V69, P7410, DOI 10.1128/JVI.69.12.7410-7415.1995; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hernandez LD, 1997, J CELL BIOL, V139, P1455, DOI 10.1083/jcb.139.6.1455; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Marsh M, 1997, J CELL SCI, V110, P95; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; ORY DS, 1996, P NATL ACAD SCI USA, V93, P1140; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; REDMOND S, 1984, VIROLOGY, V133, P393, DOI 10.1016/0042-6822(84)90405-7; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Snitkovsky S, 1998, P NATL ACAD SCI USA, V95, P7063, DOI 10.1073/pnas.95.12.7063; Sodroski JG, 1999, CELL, V99, P243, DOI 10.1016/S0092-8674(00)81655-4; STEGMANN T, 1995, BIOCHEM J, V307, P875, DOI 10.1042/bj3070875; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; Telesnitsky A., 1997, P121; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	38	249	259	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 10	2000	103	4					679	689		10.1016/S0092-8674(00)00170-7	http://dx.doi.org/10.1016/S0092-8674(00)00170-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106737	Bronze			2022-12-28	WOS:000165348000012
J	Giannakakis, IA; Ioannidis, JPA				Giannakakis, IA; Ioannidis, JPA			Arabian nights-1001 tales of how pharmaceutical companies cater to the material needs of doctors: case report	BRITISH MEDICAL JOURNAL			English	Article								Objective To describe how pharmaceutical companies cater to the material needs of doctors. Design Case report of memoirs. Setting Facilities that have nothing to do with medicine, somewhere in the Arabian peninsula. Patient population Random sample of doctors. Interventions Promotion by the pharmaceutical industry. Main outcome measures Short term outcomes were travel, pleasure, amusement, and gifts, and long term outcomes were the market share of specific companies. Results Short term outcomes were heterogeneous, underlying the diversity of the means employed by the pharmaceutical industry to subvert, divert, and influence medical practice. Overall, 200 doctors were dressed in white gowns,a doctor in preventive medicine quoted Hippocrates in favour of smoking, a senior doctor became a poet, a doctor trying to understand the Methods section of a poster paper wondered whether he should have been sunbathing at the beach instead, and two women doctors were kidnapped by Bedouin warriors. Long term outcomes on the sales of the company drugs are pending but are likely to be most favourable. Conclusions Eat, drink, be merry, and boost prescriptions.	Univ Ioannina, Sch Med, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece; Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece	University of Ioannina; University of Ioannina	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece.		Ioannidis, John P. A./G-9836-2011						0	15	15	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1563	1564		10.1136/bmj.321.7276.1563	http://dx.doi.org/10.1136/bmj.321.7276.1563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124175	Green Published, Bronze			2022-12-28	WOS:000166134500013
J	Davies, JP; Chen, FW; Ioannou, YA				Davies, JP; Chen, FW; Ioannou, YA			Transmembrane molecular pump activity of Niemann-Pick C1 protein	SCIENCE			English	Article							TOPOLOGICAL ANALYSIS; EFFLUX; GENE; CHOLESTEROL; EXPRESSION; FAMILY; MUTANT	Niemann-Pick C1 (NPC1) disease is characterized by cholesterol accumulation in Lysosomes and aberrant feedback regulation of cellular cholesterol homeostasis, We provide evidence that the NPC1 protein has homology with the resistance-nodulation-division (RND) family of prokaryotic permeases and may normally function as a transmembrane efflux pump, Studies of acriflavine Loading in normal and NPC1 fibroblasts indicated that NPC1 uses a proton motive force to remove accumulated acriflavine from the endosomal/lysosomal system. Expression of NPC1 in Escherichia coli (i) facilitated the transport of acriflavine across the plasma membrane, causing cytosolic accumulation, and (ii) resulted in transport of oleic acid but not cholesterol or cholesterol-oleate across the plasma membrane. These studies establish NPC1 as a eukaryotic member of the RND permease family.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ioannou, YA (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, Box 1498,1 Gustave L Levy Pl, New York, NY 10029 USA.	Yiannis.Ioannou@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054736] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK54736] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beja O, 1996, P NATL ACAD SCI USA, V93, P5969, DOI 10.1073/pnas.93.12.5969; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; Davies JP, 2000, GENOMICS, V65, P137, DOI 10.1006/geno.2000.6151; Gotoh N, 1999, FEBS LETT, V458, P32, DOI 10.1016/S0014-5793(99)01116-3; Li XZ, 1998, J BACTERIOL, V180, P2987, DOI 10.1128/JB.180.11.2987-2991.1998; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; Millat G, 1999, AM J HUM GENET, V65, P1321, DOI 10.1086/302626; NAKAMURA K, 1982, EMBO J, V1, P771, DOI 10.1002/j.1460-2075.1982.tb01244.x; Nikaido H, 1998, J BACTERIOL, V180, P4686, DOI 10.1128/JB.180.17.4686-4692.1998; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Thanassi DG, 1997, J BACTERIOL, V179, P2512, DOI 10.1128/jb.179.8.2512-2518.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Ward A, 2000, PRACT APPROACH SER, P141	21	231	241	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	2000	290	5500					2295	+		10.1126/science.290.5500.2295	http://dx.doi.org/10.1126/science.290.5500.2295			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125140				2022-12-28	WOS:000165995800040
J	Kapoor, WN				Kapoor, WN			Primary care - Syncope	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; UNEXPLAINED SYNCOPE; TILT-TABLE; VASOVAGAL SYNCOPE; UPRIGHT TILT; DOUBLE-BLIND; NEUROCARDIOGENIC SYNCOPE; DIAGNOSING SYNCOPE; UNKNOWN ORIGIN; TRANSIENT LOSS		Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kapoor, WN (corresponding author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.							ABBOUD FM, 1993, NEW ENGL J MED, V328, P1117, DOI 10.1056/NEJM199304153281510; BANNISTER R, 1988, AUTONOMIC FAILURE TX, V1, P20; BASS EB, 1990, ARCH INTERN MED, V150, P1073, DOI 10.1001/archinte.150.5.1073; BENCHETRIT E, 1985, ISRAEL J MED SCI, V21, P950; Benditt DG, 1996, J AM COLL CARDIOL, V28, P263, DOI 10.1016/0735-1097(96)00236-7; BENDITT DG, 1991, PACE, V14, P1528, DOI 10.1111/j.1540-8159.1991.tb04074.x; BROWN AP, 1987, BRIT HEART J, V58, P251; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; Davies AJ, 1998, AM J CARDIOL, V81, P1256, DOI 10.1016/S0002-9149(98)00130-1; DAVIS TL, 1990, ARCH INTERN MED, V150, P2027, DOI 10.1001/archinte.150.10.2027; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; Di Girolamo E, 1999, J AM COLL CARDIOL, V33, P1227, DOI 10.1016/S0735-1097(98)00694-9; DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; DIMARCO JP, 1987, CIRCULATION, V75, P140; FUJIMURA O, 1989, NEW ENGL J MED, V321, P1703, DOI 10.1056/NEJM198912213212503; Grubb BP, 1996, CURR OPIN CARDIOL, V11, P32, DOI 10.1097/00001573-199601000-00006; GRUBB BP, 1991, ANN INTERN MED, V115, P871, DOI 10.7326/0003-4819-115-11-871; GRUBB BP, 1992, CLIN CARDIOL, V15, P839, DOI 10.1002/clc.4960151109; HOEFNAGELS WAJ, 1991, J NEUROL, V238, P39, DOI 10.1007/BF00319709; KAPOOR WN, 1989, AM J CARDIOL, V63, P730, DOI 10.1016/0002-9149(89)90260-9; Kapoor WN, 1999, AM J MED SCI, V317, P110, DOI 10.1097/00000441-199902000-00005; KAPOOR WN, 1982, JAMA-J AM MED ASSOC, V247, P2687, DOI 10.1001/jama.247.19.2687; KAPOOR WN, 1995, AM J MED, V99, P505, DOI 10.1016/S0002-9343(99)80227-7; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1987, AM J MED, V83, P700, DOI 10.1016/0002-9343(87)90901-6; KAPOOR WN, 1994, AM J MED, V97, P78, DOI 10.1016/0002-9343(94)90051-5; Kapoor WN, 1996, AM J MED, V100, P646, DOI 10.1016/S0002-9343(95)00052-6; Krahn AD, 1999, CIRCULATION, V99, P406, DOI 10.1161/01.CIR.99.3.406; LEMPERT T, 1994, ANN NEUROL, V36, P233, DOI 10.1002/ana.410360217; LINZER M, 1991, J CLIN EPIDEMIOL, V44, P1037, DOI 10.1016/0895-4356(91)90005-T; Linzer M, 1997, ANN INTERN MED, V127, P76, DOI 10.7326/0003-4819-127-1-199707010-00014; LINZER M, 1990, AM J CARDIOL, V66, P214, DOI 10.1016/0002-9149(90)90591-N; Linzer M, 1997, ANN INTERN MED, V126, P989, DOI 10.7326/0003-4819-126-12-199706150-00012; LIPSITZ LA, 1986, J CHRON DIS, V39, P619, DOI 10.1016/0021-9681(86)90187-6; MAHANONDA N, 1995, AM HEART J, V130, P1250, DOI 10.1016/0002-8703(95)90150-7; MARTIN GJ, 1984, ANN EMERG MED, V13, P499, DOI 10.1016/S0196-0644(84)80511-9; Martin TP, 1997, ANN EMERG MED, V29, P459, DOI 10.1016/S0196-0644(97)70217-8; MCANULTY JH, 1987, CIRCULATION, V75, P144; NATALE A, 1995, CIRCULATION, V92, P54, DOI 10.1161/01.CIR.92.1.54; Raviele A, 1999, CIRCULATION, V99, P1452, DOI 10.1161/01.CIR.99.11.1452; RAVIELE A, 1995, AM J CARDIOL, V76, P267, DOI 10.1016/S0002-9149(99)80079-4; RAVIELE A, 1994, AM HEART J, V127, P103, DOI 10.1016/0002-8703(94)90515-0; Recchia D, 1995, J GEN INTERN MED, V10, P649, DOI 10.1007/BF02602755; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; STRASBERG B, 1989, PROG CARDIOVASC DIS, V31, P379, DOI 10.1016/0033-0620(89)90032-7	45	253	271	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1856	1862		10.1056/NEJM200012213432507	http://dx.doi.org/10.1056/NEJM200012213432507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117979				2022-12-28	WOS:000165940400007
J	Sawaya, GF; Grady, D; Kerlikowske, K; La Valleur, J; Barnabei, VM; Bass, K; Snyder, TE; Pickar, JH; Agarwal, SK; Mandelblatt, J				Sawaya, GF; Grady, D; Kerlikowske, K; La Valleur, J; Barnabei, VM; Bass, K; Snyder, TE; Pickar, JH; Agarwal, SK; Mandelblatt, J		Heart Estrogen Progestin Replaceme	The positive predictive value of cervical smears in previously screened postmenopausal women: The Heart and Estrogen/progestin Replacement Study (HERS)	ANNALS OF INTERNAL MEDICINE			English	Article							INTRAEPITHELIAL NEOPLASIA; TRANSGENIC MICE; ESTROGEN; CANCER; THERAPY; RISK; MANAGEMENT; PROGESTIN; LESIONS	Background: The benefits and risks of performing annual cervical smears on postmenopausal women are not well defined. The independent effect of hormone replacement therapy on development of cytologic abnormalities is unknown. Objective: To determine the positive predictive value of cervical smears in previously screened postmenopausal women and to determine the effect of oral estrogen plus progestin on incident cervical cytologic abnormalities. Design: Prospective cohort study (incidence) and randomized, double-blind, placebo-controlled trial (hormone therapy). Setting: 20 U.S. outpatient and community clinical centers. Participants: 2561 women with a uterus and normal cytologic characteristics at baseline. Interventions: Annual smears; oral conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or identical placebo. Measurements: Incident cytologic abnormalities (atypical squamous cells of undetermined significance, atypical glandular cells of undetermined significance, low-grade squamous epithelial lesion, and high-grade squamous epithelial lesion) and final histologic diagnoses. Results: The incidence of new cytologic abnormalities in the 2 years following a normal smear was 110 per 4895 person-years (23 per 1000 person-years [95% CI, 18 to 27 per 1000 person-years]). Among the 103 women with known histologic diagnoses, one had mild to moderate dysplasia. The positive predictive value of any smear abnormality identified 1 year after a normal smear, therefore, was 0% (CI, 0% to 5.0%) (0 of 78 women); the positive predictive value of abnormalities found within 2 years was 0.9% (CI, 0.0% to 3.0%) (1 of 110 women). In hormone-treated compared with non-hormone-treated women, the incidence of cytologic abnormalities was nonsignificantly higher (relative hazard, 1.36 [CI, 0.93 to 1.99]), largely because of a nonsignificant 58% greater incidence of atypical squamous cells of undetermined significance (relative hazard, 1.58 [CI, 0.99 to 2.52]). Conclusions: Because of a poor positive predictive value, cervical smears should not be performed within 2 years of normal cytologic results in postmenopausal women. Therapy with oral estrogen plus progestin does not significantly affect the incidence of cytologic abnormalities.	Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Minnesota, Dept Obstet & Gynecol, Minneapolis, MN 55455 USA; Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; Johns Hopkins Univ, Baltimore, MD USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Obstet & Gynecol, Winston Salem, NC 27157 USA; Wyeth Ayerst Res, Radnor, PA USA; Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA; George Washington Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA	University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; Medical College of Wisconsin; Johns Hopkins University; Wake Forest University; Wake Forest Baptist Medical Center; Pfizer; Cedars Sinai Medical Center; George Washington University	Sawaya, GF (corresponding author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 3333 Calif St,Suite 335, San Francisco, CA 94143 USA.				AHRQ HHS [HS07373] Funding Source: Medline; NCI NIH HHS [K08 CA 74973-02] Funding Source: Medline; NIA NIH HHS [AG 15340] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA074973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015340] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; BELL S, 1995, PREV MED, V24, P610, DOI 10.1006/pmed.1995.1096; BRINTON LA, 1990, INT J EPIDEMIOL, V19, P4, DOI 10.1093/ije/19.1.4; BRISSON J, 1994, AM J EPIDEMIOL, V140, P700, DOI 10.1093/oxfordjournals.aje.a117318; Cruickshank ME, 1997, BRIT J OBSTET GYNAEC, V104, P586, DOI 10.1111/j.1471-0528.1997.tb11537.x; Ferenczy A, 1997, OBSTET GYNECOL, V90, P7, DOI 10.1016/S0029-7844(97)00217-2; Frame P S, 1998, J Am Board Fam Pract, V11, P87; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KASHIMURA M, 1987, DIAGN CYTOPATHOL, V3, P181, DOI 10.1002/dc.2840030302; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; Lawson HW, 1998, OBSTET GYNECOL, V92, P745, DOI 10.1016/S0029-7844(98)00257-9; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; MCDONALD TW, 1989, GYNECOL ONCOL, V34, P345, DOI 10.1016/0090-8258(89)90170-4; Michelin D, 1997, GYNECOL ONCOL, V66, P202, DOI 10.1006/gyno.1997.4745; Parazzini F, 1997, BRIT MED J, V315, P85, DOI 10.1136/bmj.315.7100.85; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T; Rader AE, 1999, ACTA CYTOL, V43, P357, DOI 10.1159/000331081; SHINGLETON HM, 1995, CA-CANCER J CLIN, V45, P305, DOI 10.3322/canjclin.45.5.305; Smith EM, 1997, GYNECOL ONCOL, V65, P441, DOI 10.1006/gyno.1997.4703; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; Weiss NS, 1996, MATURITAS, V23, P235, DOI 10.1016/0378-5122(95)00976-0	22	64	66	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					942	950		10.7326/0003-4819-133-12-200012190-00009	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119395				2022-12-28	WOS:000165952300002
J	Klionsky, DJ; Emr, SD				Klionsky, DJ; Emr, SD			Cell biology - Autophagy as a regulated pathway of cellular degradation	SCIENCE			English	Review							PROTEIN TARGETING PATHWAY; MITOCHONDRIAL PERMEABILITY TRANSITION; SACCHAROMYCES-CEREVISIAE; PEROXISOME DEGRADATION; SIGNAL-TRANSDUCTION; VACUOLE INHERITANCE; CONJUGATION SYSTEM; SYNTAXIN HOMOLOG; RAT HEPATOCYTES; ELEGANS UNC-51	Macroautophagy is a dynamic process involving the rearrangement of subcellular membranes to sequester cytoplasm and organelles for delivery to the lysosome or vacuole where the sequestered cargo is degraded and recycled. This profess takes place in ail eukaryotic cells. It is highly regulated through the action of various kinases, phosphatases, and guanosine triphosphatases (GTPases). The core protein machinery that is necessary to drive formation and consumption of intermediates in the macroautophagy pathway includes a ubiquitin-like protein conjugation system and a protein complex that directs membrane docking and fusion at the Lysosome or vacuole. Macroautophagy plays an important role in developmental processes, human disease, and cellular response to nutrient deprivation.	Univ Michigan, Dept Biol, North Univ 830, Ann Arbor, MI 48109 USA; Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, San Diego, CA 92093 USA; Howard Hughes Med Inst, San Diego, CA 92093 USA	University of Michigan System; University of Michigan; University of California System; University of California San Diego; Howard Hughes Medical Institute	Klionsky, DJ (corresponding author), Univ Michigan, Dept Biol, North Univ 830, Nat Sci Bldg, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [R01 GM053396, GM53396, R01 GM053396-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Bursch W, 2000, J CELL SCI, V113, P1189; Codogno P, 1997, CELL SIGNAL, V9, P125, DOI 10.1016/S0898-6568(96)00130-1; Coffer PJ, 1998, BIOCHEM J, V335, P1; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dawson G, 2000, J NEUROSCI RES, V60, P133, DOI 10.1002/(SICI)1097-4547(20000415)60:2<133::AID-JNR1>3.0.CO;2-3; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Graham LA, 2000, J EXP BIOL, V203, P61; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Hutchins MU, 1999, J CELL SCI, V112, P4079; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; LAMBORGHINI JE, 1987, J COMP NEUROL, V264, P47, DOI 10.1002/cne.902640105; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Mortimore G E, 1996, Subcell Biochem, V27, P93; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Nakamura N, 1997, J BIOCHEM, V121, P338; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SchulteHermann R, 1997, TOXICOL PATHOL, V25, P89, DOI 10.1177/019262339702500117; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Stromhaug PE, 1998, BIOCHEM J, V335, P217, DOI 10.1042/bj3350217; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; TETER SA, UNPUB; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; TUTTLE DL, 1995, J CELL SCI, V108, P25; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; VITRORINI S, 1999, BIOL SCI MED SCI, V54, pB318; Wada Y, 1997, J CELL SCI, V110, P1299; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	81	2848	3025	14	714	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1717	1721		10.1126/science.290.5497.1717	http://dx.doi.org/10.1126/science.290.5497.1717			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099404	Green Accepted			2022-12-28	WOS:000165632400032
J	Koga, K; Tanaka, H; Zeng, XC				Koga, K; Tanaka, H; Zeng, XC			First-order transition in confined water between high-density liquid and low-density amorphous phases	NATURE			English	Article							MELTING TEMPERATURE; SUPERCOOLED WATER; CRITICAL-POINT; X-RAY; ICE-I; DIFFUSION; DIAGRAM	Supercooled water and amorphous ice have a rich metastable phase behaviour. In addition to transitions between high- and low-density amorphous solids(1,2), and between high- and low-density liquids(3-8), a fragile-to-strong liquid transition has recently been proposed(9,10), and supported by evidence from the behaviour of deeply supercooled bilayer water confined in hydrophilic slit pores(11). Here we report evidence from molecular dynamics simulations for another type of first-order phase transition-a liquid-to-bilayer amorphous transition-above the freezing temperature of bulk water at atmospheric pressure. This transition occurs only when water is confined in a hydrophobic slit pore(12-14) with a width of less than one nanometre. On cooling, the confined water, which has an imperfect random hydrogen-bonded network, transforms into a bilayer amorphous phase with a perfect network (owing to the formation of various hydrogen-bonded polygons) but no long-range order. The transition shares some characteristics with those observed in tetrahedrally coordinated substances such as liquid silicon(15,16), liquid carbon(17) and liquid phosphorus(18).	Fukuoka Univ Educ, Dept Chem, Fukuoka 8114192, Japan; Okayama Univ, Dept Chem, Okayama 7008530, Japan; Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Univ Nebraska, Ctr Mat & Anal, Lincoln, NE 68588 USA	Fukuoka University Education; Okayama University; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Koga, K (corresponding author), Fukuoka Univ Educ, Dept Chem, Fukuoka 8114192, Japan.	kenkoga@fukuoka-edu.ac.jp	Zeng, Xiao Cheng/C-1590-2013; Tanaka, Hideki/B-1456-2011; Koga, Kenichiro/B-2635-2011	Zeng, Xiao Cheng/0000-0003-4672-8585; Koga, Kenichiro/0000-0002-1153-5831				ANGELL CA, 1993, J PHYS CHEM-US, V97, P6339, DOI 10.1021/j100126a005; Angell CA, 1996, J NON-CRYST SOLIDS, V207, P463, DOI 10.1016/S0022-3093(96)00261-X; Angell CA, 2000, PHYS CHEM CHEM PHYS, V2, P1559, DOI 10.1039/b000206m; BellissentFunel MC, 1996, J CHEM PHYS, V104, P10023, DOI 10.1063/1.471728; Bergman R, 2000, NATURE, V403, P283, DOI 10.1038/35002027; Gao GT, 2000, J CHEM PHYS, V112, P8534, DOI 10.1063/1.481457; GILLEN KT, 1972, J CHEM PHYS, V57, P5117, DOI 10.1063/1.1678198; Glosli JN, 1999, PHYS REV LETT, V82, P4659, DOI 10.1103/PhysRevLett.82.4659; GOTO K, 1986, JPN J APPL PHYS 1, V25, P351, DOI 10.1143/JJAP.25.351; Ito K, 1999, NATURE, V398, P492, DOI 10.1038/19042; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Katayama Y, 2000, NATURE, V403, P170, DOI 10.1038/35003143; Koga K, 1997, PHYS REV LETT, V79, P5262, DOI 10.1103/PhysRevLett.79.5262; Meyer M, 1999, J PHYS CHEM B, V103, P9728, DOI 10.1021/jp98412f; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; MISHIMA O, 1985, NATURE, V314, P76, DOI 10.1038/314076a0; MISHIMA O, 1984, NATURE, V310, P393, DOI 10.1038/310393a0; POOLE PH, 1992, NATURE, V360, P324, DOI 10.1038/360324a0; Scala A, 2000, NATURE, V406, P166, DOI 10.1038/35018034; Sciortino F, 1997, PHYS REV E, V55, P727, DOI 10.1103/PhysRevE.55.727; SMITH RS, 1999, NATURE, V403, P283; Soper AK, 2000, PHYS REV LETT, V84, P2881, DOI 10.1103/PhysRevLett.84.2881; STANLEY HE, 1994, PHYSICA A, V205, P122, DOI 10.1016/0378-4371(94)90495-2; STILLINGER FH, 1995, SCIENCE, V267, P1935, DOI 10.1126/science.267.5206.1935; Tanaka H, 1998, PHYS REV LETT, V80, P113, DOI 10.1103/PhysRevLett.80.113; Tanaka H, 1996, J CHEM PHYS, V105, P5099, DOI 10.1063/1.472354; Tanaka H, 1996, NATURE, V380, P328, DOI 10.1038/380328a0; THOMPSON MO, 1984, PHYS REV LETT, V52, P2360, DOI 10.1103/PhysRevLett.52.2360; Tse JS, 1999, NATURE, V400, P647, DOI 10.1038/23216; ZALLEN R, 1998, PHYSICS AMORPHOUS SO, P63	30	287	290	5	148	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					564	567		10.1038/35046035	http://dx.doi.org/10.1038/35046035			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117739				2022-12-28	WOS:000165548600112
J	Ohshiro, T; Yagami, T; Zhang, C; Matsuzaki, F				Ohshiro, T; Yagami, T; Zhang, C; Matsuzaki, F			Role of cortical tumour-suppressor proteins in asymmetric division of Drosophila neuroblast	NATURE			English	Article							CELL DIVISIONS; LOCALIZATION; GENE; PROSPERO; MYOSIN; POLARITY; PARTNER; MIRANDA; LINEAGE; FATES	Cellular diversity during development arises in part from asymmetric divisions, which generate two distinct cells by transmitting localized determinants from a progenitor cell into one daughter cell. In Drosophila, neuroblasts undergo typical asymmetric divisions to produce another neuroblast and a ganglion mother cell(1,2). At mitosis, neural fate determinants, including Prospero and Numb, localize to the basal cortex(3,4), from which the ganglion mother cell buds off; Inscuteable and Bazooka, which regulate spindle orientation, localize apically(5-8). Here we show that a tumour-suppressor protein, Lethal giant larvae (Lgl)(9), is essential for asymmetric cortical localization of all basal determinants in mitotic neuroblasts, and is therefore indispensable for neural fate decisions. Lgl, which itself is uniformly cortical, interacts with several types of Myosin to localize the determinants. Another tumour-suppressor protein, Lethal discs large (Dlg)(10), participates in this process by regulating the localization of Lgl. The localization of the apical components is unaffected in lgl or dlg mutants. Thus, Lgl and Dlg act in a common process that differentially mediates cortical protein targeting in mitotic neuroblasts, and that creates intrinsic differences between daughter cells.	Japan Sci & Technol Corp, CREST, Sendai, Miyagi, Japan; RIKEN, Ctr Dev Biol, Cell Asymmetry Grp, Sendai, Miyagi, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Dev Neurobiol, Aoba Ku, Sendai, Miyagi 9808575, Japan	Japan Science & Technology Agency (JST); RIKEN; Tohoku University	Matsuzaki, F (corresponding author), Japan Sci & Technol Corp, CREST, Sendai, Miyagi, Japan.	fumio@idac.tohoku.ac.jp						Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHOU TB, 1992, GENETICS, V131, P643; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; DAWSON IA, 1993, DEVELOPMENT, V117, P359; De Lorenzo C, 1999, INT J DEV BIOL, V43, P207; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Gho M, 1996, DEVELOPMENT, V122, P1673; Gho M, 1999, DEVELOPMENT, V126, P3573; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Kagami M, 1998, GENETICS, V149, P1717; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lu BW, 1999, MOL CELL, V4, P883, DOI 10.1016/S1097-2765(00)80218-X; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; Matsuzaki F, 2000, CURR OPIN NEUROBIOL, V10, P38, DOI 10.1016/S0959-4388(99)00052-5; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; Wang SW, 1997, DEVELOPMENT, V124, P4435; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	30	266	276	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					593	596		10.1038/35046087	http://dx.doi.org/10.1038/35046087			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117747				2022-12-28	WOS:000165548600120
J	Teotonio, H; Rose, MR				Teotonio, H; Rose, MR			Variation in the reversibility of evolution	NATURE			English	Article							DROSOPHILA-MELANOGASTER; POSTPONED SENESCENCE; LABORATORY EVOLUTION; PEPPERED MOTH; HISTORY; ENVIRONMENT; RESISTANCE; SELECTION	How reversible is adaptive evolution(1-6)? Studies of microbes give mixed answers to this question(6-11). Reverse evolution has been little studied in sexual populations(12-14), even though the population genetics of sexual populations may be quite different. In the present study, 25 diverged replicated populations of Drosophila melanogaster are returned to a common ancestral environment for 50 generations. Here we show that reverse evolution back to the ancestral state occurs, but is not universal, instead depending on previous evolutionary history and the character studied. Hybrid populations showed no greater tendency to undergo successful reverse evolution, suggesting that insufficient genetic variation was not the factor limiting reverse evolution. Adaptive reverse evolution is a contingent process which occurs with only 50 generations of sexual reproduction.	Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92612 USA	University of California System; University of California Irvine	Teotonio, H (corresponding author), Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92612 USA.			Teotonio, Henrique/0000-0003-1057-6882				BULL JJ, 1985, EVOLUTION, V39, P1149, DOI 10.2307/2408742; Burch CL, 1999, GENETICS, V151, P921; Chippindale AK, 1997, EVOLUTION, V51, P1536, DOI [10.2307/2411206, 10.1111/j.1558-5646.1997.tb01477.x]; CLARKE CA, 1985, BIOL J LINN SOC, V26, P189, DOI 10.1111/j.1095-8312.1985.tb01555.x; COHAN FM, 1989, AM NAT, V134, P613, DOI 10.1086/285000; Cook LM, 1999, P ROY SOC B-BIOL SCI, V266, P293, DOI 10.1098/rspb.1999.0636; Coyne JA, 1997, EVOLUTION, V51, P643, DOI [10.2307/2411143, 10.1111/j.1558-5646.1997.tb03650.x]; Crill WD, 2000, GENETICS, V154, P27; FLEMING JE, 1993, GENETICA, V91, P183, DOI 10.1007/BF01435997; GAYON J, 1998, DARWINISMS STRUGGLE; Glantz S., 1990, PRIMER APPL REGRESSI; GRAVES JL, 1992, PHYSIOL ZOOL, V65, P268, DOI 10.1086/physzool.65.2.30158253; LENSKI RE, 1988, EVOLUTION, V42, P433, DOI 10.1111/j.1558-5646.1988.tb04150.x; LEROI AM, 1994, EVOLUTION, V48, P1244, DOI [10.2307/2410382, 10.1111/j.1558-5646.1994.tb05309.x]; Levin BR, 2000, GENETICS, V154, P985; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; Moore FBG, 2000, P ROY SOC B-BIOL SCI, V267, P515, DOI 10.1098/rspb.2000.1030; Muller HJ, 1939, BIOL REV CAMB PHILOS, V14, P261, DOI 10.1111/j.1469-185X.1939.tb00934.x; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; REZNICK DA, 1990, NATURE, V346, P357, DOI 10.1038/346357a0; ROSE MR, 1992, EXP GERONTOL, V27, P241, DOI 10.1016/0531-5565(92)90048-5; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; SERVICE PM, 1988, EVOLUTION, V42, P708, DOI 10.1111/j.1558-5646.1988.tb02489.x; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; *SPSS, 1998, SIGM 5 0 PROGR GUID; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; TYLER RH, 1993, GENETICA, V91, P143, DOI 10.1007/BF01435994; Wright S., 1977, EVOLUTION GENETICS P, V3; Zar J. H., 1996, BIOSTATISTICAL ANAL	29	101	101	0	26	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					463	466		10.1038/35044070	http://dx.doi.org/10.1038/35044070			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100726				2022-12-28	WOS:000165429800046
J	Ngadiman, S; Vallejo, CE; Siegel, B; Axelrod, D				Ngadiman, S; Vallejo, CE; Siegel, B; Axelrod, D			Minimising discomfort with fine-needle aspiration cytology of the breast	LANCET			English	Editorial Material							TRIAL		St Vincents Comprehens Breast Ctr, New York, NY 10012 USA		Ngadiman, S (corresponding author), St Vincents Comprehens Breast Ctr, New York, NY 10012 USA.			Axelrod, Deborah/0000-0002-9929-3389				Cannon CR, 1999, OTOLARYNG HEAD NECK, V120, P458; Daltrey IR, 2000, BRIT J SURG, V87, P777, DOI 10.1046/j.1365-2168.2000.087006777.x; Florentine BD, 1997, DIAGN CYTOPATHOL, V17, P472, DOI 10.1002/(SICI)1097-0339(199712)17:6<472::AID-DC18>3.0.CO;2-J; KOSS LG, 1993, CANCER, V72, P1499, DOI 10.1002/1097-0142(19930901)72:5<1499::AID-CNCR2820720502>3.0.CO;2-#; Walker SR, 1998, J ROY COLL SURG EDIN, V43, P322	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 18	2000	356	9243					1701	1701		10.1016/S0140-6736(00)03199-8	http://dx.doi.org/10.1016/S0140-6736(00)03199-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095253				2022-12-28	WOS:000165462300004
J	Nakagawa, T; Setou, M; Seog, DH; Ogasawara, K; Dohmae, N; Takio, K; Hirokawa, N				Nakagawa, T; Setou, M; Seog, DH; Ogasawara, K; Dohmae, N; Takio, K; Hirokawa, N			A novel motor, KIF13A, transports mannose-6-phosphate receptor to plasma membrane through direct interaction with AP-1 complex	CELL			English	Article							SYNAPTIC VESICLE; MONOMERIC MOTOR; COATED VESICLES; BINDING PROTEIN; GOLGI MEMBRANES; CLATHRIN; ADAPTERS; CHAIN	Intracellular transport mediated by kinesin superfamily proteins (KIFs) is a highly regulated process. The molecular mechanism of KIFs binding to their respective cargoes remains unclear. We report that KIF13A is a novel plus end-directed microtubule-dependent motor protein and associates with beta1-adaptin, a subunit of the AP-1 adaptor complex. The cargo vesicles of KIF13A contained AP-1 and mannnose-6-phosphate receptor (M6PR). Overexpression of KIF13A resulted in mislocalization of the AP-1 and the M6PR. Functional blockade of KIF13A reduced cell surface expression of the M6PR. Thus, KIF13A transports M6PR-containing vesicles and targets the M6PR from TGN to the plasma membrane via direct interaction with the AP-1 adaptor complex.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Immunol, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	University of Tokyo; University of Tokyo; RIKEN	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, 7-3-1 Hongo, Tokyo 1130033, Japan.	hirokawa@m.u-tokyo.ac.jp	Ogasawara, Kouetsu/G-9892-2011; Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; KAWANO JI, 1994, J HISTOCHEM CYTOCHEM, V42, P363, DOI 10.1177/42.3.8308253; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OEILLY DR, 1992, BACULOVIRUS EXPRESSI; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SCLAKY N, 1997, J CELL BIOL, V139, P1137; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	38	209	223	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 10	2000	103	4					569	581		10.1016/S0092-8674(00)00161-6	http://dx.doi.org/10.1016/S0092-8674(00)00161-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106728	Bronze			2022-12-28	WOS:000165348000003
J	Chang, MH; Shau, WY; Chen, CJ; Wu, TC; Kong, MS; Liang, DC; Hsu, HM; Chen, HL; Hsu, HY; Chen, DS				Chang, MH; Shau, WY; Chen, CJ; Wu, TC; Kong, MS; Liang, DC; Hsu, HM; Chen, HL; Hsu, HY; Chen, DS		Taiwan Childhood Hepatoma Study Gr	Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS-INFECTION; MASS VACCINATION; TAIWAN; CHILDHOOD; CHILDREN	Context Hepatocellular carcinoma (HCC) has a male predominance and is closely related to hepatitis B Virus (HBV) infection. Hepatitis B virus vaccination was launched in 1984 in Taiwan for neonates of mothers carrying hepatitis B e antigen, resulting in a decreased incidence of HCC in children, The effect on boys vs girls is not known. Objective To evaluate the association between a HBV vaccination program with incidence of childhood HCC by sex. Design and Setting Analysis of data collected from Taiwan's National Cancer Registry System and the Taiwan Childhood Hepatoma Study Group between 1981 and 1996. Participants Children aged 6 to 14 years who were diagnosed as having HCC (201 boys and 70 girls). Main Outcome Measure Incidence of HCC in boys and girls before and after implementation of the vaccination program. Results The boy-girl incidence ratio decreased steadily from 4.5 in 1981-1984 (before the program's introduction) to 1.9 in 1990-1996 (6-12 years after the vaccination program was launched). The incidence of HCC in boys born after 1984 was significantly reduced in comparison with those born before 1978 (relative risk [RR], 0.72; P=.002). No significant decrease in HCC incidence was observed in girls born in the same periods (RR, 0.77; P=.20). The incidence of HCC in boys remained stable with increasing age, while an increase of HCC incidence with age in girls was observed. These age and sex effects remained the same regardless of birth before or after the vaccination program. Conclusion Our results suggest that boys may benefit more from HBV Vaccination than girls in the prevention of HCC.	Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan; Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 10764, Taiwan; Vet Gen Hosp, Dept Pediat, Taipei, Taiwan; Chang Gung Childrens Hosp, Lin Kou, Taiwan; Mackay Mem Hosp, Dept Pediat, Taipei, Taiwan; Execut Yuan, Ctr Dis Control, Dept Hlth, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Chang Gung Memorial Hospital; Mackay Memorial Hospital; Centers For Disease Control - Taiwan	Chang, MH (corresponding author), Natl Taiwan Univ Hosp, Dept Pediat, No 7 Chung Shan S Rd, Taipei 10016, Taiwan.		Chen, Chien-Jen/N-4723-2019; Chen, Chien-Jen/C-6976-2008	CHEN, DING-SHINN/0000-0001-7791-6154; Chang, Mei Hwei/0000-0002-3648-9261; Hsu, Hong-Yuan/0000-0002-5720-4835	NHLBI NIH HHS [DOH 88-HR-832, DOH 87-HR-518] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHANG MH, 1989, CANCER-AM CANCER SOC, V64, P2377, DOI 10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chen D-S, 1987, NEOPLASMS LIVER, P71; CHEN DS, 1987, JAMA-J AM MED ASSOC, V257, P2597; Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906; HSU HY, 1984, J MED VIROL, V18, P301; KEMP CJ, 1989, P NATL ACAD SCI USA, V86, P7505, DOI 10.1073/pnas.86.19.7505; KUO C-Y, 1991, Acta Paediatrica Sinica, V32, P79; MUNOZ N, 1987, NEOPLASMS LIVER, P1; NI YH, 1991, CANCER, V68, P1737, DOI 10.1002/1097-0142(19911015)68:8<1737::AID-CNCR2820680815>3.0.CO;2-G; RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122, DOI 10.1093/oxfordjournals.aje.a116578; Selvin S, 1995, PRACTICAL BIOSTATIST, P455; Tang JR, 1998, J PEDIATR-US, V133, P374, DOI 10.1016/S0022-3476(98)70272-0	13	141	147	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3040	3042		10.1001/jama.284.23.3040	http://dx.doi.org/10.1001/jama.284.23.3040			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122592				2022-12-28	WOS:000165847200030
J	Murray, SF				Murray, SF			Relation between private health insurance and high rates of caesarean section in Chile: qualitative and quantitative study	BRITISH MEDICAL JOURNAL			English	Article							TRENDS; BIRTHS; BRAZIL	Objectives To explore the circumstances and factors that explain the association between private health insurance cover and a high rate of caesarean sections in Chile. Design Qualitative analysis of audiotaped in-depth interviews with obstetricians and pregnant women; quantitative analysis of data from face to face semistructured interview survey conducted postnatally (with women who had given birth in the previous 24-72 hours), and of a review of medical notes at a public hospital, a university hospital, and a private clinic. Setting Santiago, Chile. Participants Qualitative arm: 22 obstetricians, 21 pregnant women; quantitative arm: 540 postnatal women. Main outcome measures Rates of caesarean section in different types of institutions; consultants' views on private practice; work patterns in private practice; women's reasons for choosing private care; women's preferences on method of delivery. Results Private health insurance cover requires the primary maternity care provider to be an obstetrician. In the postnatal survey, women with private obstetricians showed consistently higher rates of caesarean section (range 57-83%) than those cared for by midwives or doctors on duty in public or university hospitals (range 27-28%). Only a minority of women receiving private care reported that they had wanted this method of delivery (range 6-32%). With the diversification in the healthcare market, most obstetricians now have demanding peripatetic work schedules. Private maternity patients are a lucrative source of income. The obstetrician is committed to attend these private births in person, and the "programming" (or scheduling) of births is a common time management strategy The rate of elective caesarean sections was 30-68% in women with private obstetricians and 12-14% in women not attended by private obstetricians. Conclusions Policies on healthcare financing can influence maternity care management and outcomes in unforeseen ways. The prevailing business ethos in health care encourages such pragmatism among those doctors who do not have a moral objection to non-medical caesarean section.	UCL, Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England	University of London; University College London	Murray, SF (corresponding author), UCL, Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England.	s.murray@ich.ucl.ac.uk						Belizan JM, 1999, BMJ-BRIT MED J, V319, P1397, DOI 10.1136/bmj.319.7222.1397; Castro A, 1999, BRIT MED J, V319, P1401; FAUNDES A, 1993, HEALTH POLICY PLANN, V8, P33, DOI 10.1093/heapol/8.1.33; Hopkins K, 2000, SOC SCI MED, V51, P725, DOI 10.1016/S0277-9536(99)00480-3; Miranda E, 1995, HEALTH PLACE, V1, P51, DOI 10.1016/1353-8292(95)00006-8; Murray SF, 1997, BIRTH-ISS PERINAT C, V24, P258, DOI 10.1111/j.1523-536X.1997.tb00600.x; Schnapp C, 1997, LANCET, V349, P1029, DOI 10.1016/S0140-6736(05)62933-9; Seale C., 1999, QUALITY QUALITATIVE, P1; SOUZA CD, 1994, CAMB Q HEALTHC ETHIC, V3, P358, DOI 10.1017/S096318010000517X	9	147	156	0	20	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 16	2000	321	7275					1501	1505		10.1136/bmj.321.7275.1501	http://dx.doi.org/10.1136/bmj.321.7275.1501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	385GF	11118176	Green Published, Bronze			2022-12-28	WOS:000165994700025
J	White, RH; Gettner, S; Newman, JM; Trauner, KB; Romano, PS				White, RH; Gettner, S; Newman, JM; Trauner, KB; Romano, PS			Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; C-REACTIVE PROTEIN; ELECTIVE HIP; PNEUMATIC COMPRESSION; HOSPITAL DISCHARGE; KNEE ARTHROPLASTY; REPLACEMENT; SURGERY; PROPHYLAXIS	Background: Recent studies have shown that symptomatic venous thromboembolism after total hip arthroplasty most commonly develops after the patient is discharged from the hospital. Risk factors associated with these symptomatic thromboembolic events are not well defined. Methods: Using administrative data from the California Medicare records for 1993 through 1996, we identified 297 patients 65 years of age or older who were rehospitalized for thromboembolism within three months after total hip arthroplasty. We compared demographic, surgical, and medical variables potentially associated with the development of thromboembolism in these patients and 592 unmatched controls. Results: A total of 89.6 percent of patients with thromboembolism and 93.8 percent of control patients were treated with pneumatic compression, warfarin, enoxaparin, or unfractionated heparin, alone or in combination. In addition, 22.2 percent and 29.7 percent, respectively, received warfarin after discharge. A body-mass index (the weight in kilograms divided by the square of the height in meters) of 25 or greater was associated with rehospitalization for thromboembolism, with an odds ratio of 2.5 (95 percent confidence interval, 1.8 to 3.4). In a multivariate model, the only prophylactic regimens associated with a reduced risk of thromboembolism were pneumatic compression in patients with body-mass indexes of less than 25 (odds ratio, 0.3; 95 percent confidence interval, 0.2 to 0.6) and warfarin treatment after discharge (odds ratio, 0.6; 95 percent confidence interval, 0.4 to 1.0). Conclusions: In patients who underwent total hip arthroplasty, a body-mass index of 25 or greater was associated with subsequent hospitalization for thromboembolism. Pneumatic compression in patients with a body-mass index of less than 25 and prophylaxis with warfarin after discharge were independently protective against thromboembolism. (N Engl J Med 2000;343:1758-64.) (C) 2000, Massachusetts Medical Society.	Univ Calif Davis, Dept Med, Div Gen Med, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Orthopaed Surg, Sacramento, CA 95817 USA; Calif Med Review Inc, San Francisco, CA USA	University of California System; University of California Davis; University of California System; University of California Davis	White, RH (corresponding author), Univ Calif Davis, Dept Med, Div Gen Med, Suite 2400,PSSB,4150 V St, Sacramento, CA 95817 USA.		Romano, Patrick S/N-4225-2014	Romano, Patrick S/0000-0001-6749-3979				Anderson FA, 1996, ORTHOPEDICS, V19, P9; Bergqvist D, 1996, NEW ENGL J MED, V335, P696, DOI 10.1056/NEJM199609053351002; BUCHANAN RRC, 1980, J RHEUMATOL, V7, P551; BUCHLER KO, 1999, CLIN ORTHOPAEDICS, V361, P123; Caprini JA, 1999, J VASC SURG, V30, P813, DOI 10.1016/S0741-5214(99)70005-4; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Colwell CW, 1999, J BONE JOINT SURG AM, V81A, P932, DOI 10.2106/00004623-199907000-00005; Comerota AJ, 1997, ANN SURG, V226, P306, DOI 10.1097/00000658-199709000-00010; COVENTRY MB, 1974, J BONE JOINT SURG AM, VA 56, P273, DOI 10.2106/00004623-197456020-00005; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; GRADYBENSON JC, 1994, CLIN ORTHOP RELAT R, P130; Heit JA, 2000, ANN INTERN MED, V132, P853, DOI 10.7326/0003-4819-132-11-200006060-00002; Hirsh J, 1998, Chest, V114, p113S, DOI 10.1378/chest.114.2_Supplement.113S; Hooker JA, 1999, J BONE JOINT SURG AM, V81A, P690, DOI 10.2106/00004623-199905000-00010; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; IMPERIALE TF, 1995, JAMA-J AM MED ASSOC, V273, P288; JOHNSON R, 1977, CLIN ORTHOP RELAT R, P123; KAEMPFFE FA, 1991, CLIN ORTHOP RELAT R, P89; LASSEN MR, 1991, LANCET, V337, P618, DOI 10.1016/0140-6736(91)91686-O; LAWRENCE L, 1999, ADV DATA VITAL HLTH, V308, P13; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LIEBERMAN JR, 1994, J BONE JOINT SURG AM, V76A, P341, DOI 10.2106/00004623-199403000-00004; Lowe GDO, 1999, THROMB HAEMOSTASIS, V81, P879; Lundgren CH, 1996, CIRCULATION, V93, P106, DOI 10.1161/01.CIR.93.1.106; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Munin MC, 1998, JAMA-J AM MED ASSOC, V279, P847, DOI 10.1001/jama.279.11.847; National Heart Lung and Blood Institute, 1998, NIH PUBL, V98-4083; O'Brien J, 2000, LANCET, V355, P1295; Paiement G D, 1992, J Arthroplasty, V7, P471, DOI 10.1016/S0883-5403(05)80220-7; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; Robinson KS, 1997, ANN INTERN MED, V127, P439, DOI 10.7326/0003-4819-127-6-199709150-00004; Salvati EA, 2000, J BONE JOINT SURG AM, V82A, P252; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; White RH, 1998, ARCH INTERN MED, V158, P1525, DOI 10.1001/archinte.158.14.1525; Woolson ST, 1996, J BONE JOINT SURG AM, V78A, P1735, DOI 10.2106/00004623-199611000-00015; World Health Organization, 1980, INT CLASSIFICATION D	42	196	210	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1758	1764		10.1056/NEJM200012143432403	http://dx.doi.org/10.1056/NEJM200012143432403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11114314				2022-12-28	WOS:000165812000003
J	Burdick, JS; Chung, EK; Tanner, G; Sun, M; Paciga, JE; Cheng, JQ; Washington, K; Goldenring, JR; Coffey, RJ				Burdick, JS; Chung, EK; Tanner, G; Sun, M; Paciga, JE; Cheng, JQ; Washington, K; Goldenring, JR; Coffey, RJ			Treatment of Menetrier's disease with a monoclonal antibody against the epidermal growth factor receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY PULMONARY-HYPERTENSION; FACTOR-ALPHA; HYPERTROPHIC GASTROPATHY; EPITHELIAL-CELLS; TRANSGENIC MICE; DIFFERENTIATION; EPOPROSTENOL; SECRETION; RENEWAL; STOMACH		Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N CC2201, Nashville, TN 37232 USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA; Vet Affairs Med Ctr, Augusta, GA USA; Med Coll Georgia, Dept Med, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Inst Mol Med & Genet, Augusta, GA 30912 USA	Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Coffey, RJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N CC2201, 221 Kirkland Hall, Nashville, TN 37232 USA.	coffeyrj@ctrvax.vanderbilt.edu			NCI NIH HHS [CA-46413, CA-77935] Funding Source: Medline; NIDDK NIH HHS [DK-48370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413, R29CA077935, R01CA077935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD JA, 1995, GASTROENTEROLOGY, V108, P564, DOI 10.1016/0016-5085(95)90087-X; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BAYERDORFFER E, 1994, GUT, V35, P701, DOI 10.1136/gut.35.5.701; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BERRY EM, 1980, ARCH INTERN MED, V140, P99, DOI 10.1001/archinte.140.1.99; CHEN MC, 1991, J CLIN INVEST, V87, P1716, DOI 10.1172/JCI115189; Coffey RJ, 1995, J CLIN GASTROENTEROL, V21, pS36; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; FERRANS CE, 1985, ADV NURS SCI, V8, P15, DOI 10.1097/00012272-198510000-00005; Goldenring JR, 1996, DIGEST DIS SCI, V41, P773, DOI 10.1007/BF02213134; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; JARNUM S, 1972, GUT, V13, P128, DOI 10.1136/gut.13.2.128; JOHNSON LR, 1976, GASTROENTEROLOGY, V70, P278; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KOVACS AAS, 1993, PEDIATR INFECT DIS J, V12, P1011, DOI 10.1097/00006454-199312000-00010; Menetrier P, 1888, ARCH PHYSL NORM PATH, V1, P32; Menetrier P, 1888, ARCH PHYSL NORM PATH, V1, P236; MEUWISSEN SGM, 1992, SCAND J GASTROENTERO, V27, P1, DOI 10.3109/00365529209096018; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; RHODES JA, 1986, P NATL ACAD SCI USA, V83, P3844, DOI 10.1073/pnas.83.11.3844; Robbins IM, 1998, CHEST, V114, P1269, DOI 10.1378/chest.114.5.1269; ROMANO M, 1992, J CLIN INVEST, V90, P2409, DOI 10.1172/JCI116132; RUTTEN MJ, 1993, AM J PHYSIOL, V265, pG361, DOI 10.1152/ajpgi.1993.265.2.G361; SCHARSCHMIDT BF, 1977, AM J MED, V63, P644, DOI 10.1016/0002-9343(77)90210-8; SCOTT HW, 1975, ANN SURG, V181, P765, DOI 10.1097/00000658-197505000-00036; SEARCY RM, 1984, ANN INTERN MED, V100, P565, DOI 10.7326/0003-4819-100-4-565; SMOLKA A, 1983, AM J PHYSIOL, V245, pG589, DOI 10.1152/ajpgi.1983.245.4.G589; STRYGLER B, 1990, GASTROENTEROLOGY, V99, P1380, DOI 10.1016/0016-5085(90)91165-3; SUNDT TM, 1988, ANN SURG, V208, P694, DOI 10.1097/00000658-198812000-00004; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; WOLFSEN HC, 1993, GASTROENTEROLOGY, V104, P1310, DOI 10.1016/0016-5085(93)90339-E; YEATON P, 1993, AM J GASTROENTEROL, V88, P95	34	70	82	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2000	343	23					1697	1701		10.1056/NEJM200012073432305	http://dx.doi.org/10.1056/NEJM200012073432305			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380PX	11106719				2022-12-28	WOS:000165711900005
J	Schubert, G; Russell, CT; Moore, WB				Schubert, G; Russell, CT; Moore, WB			Geophysics - Timing of the Martian dynamo	NATURE			English	Article							THERMAL EVOLUTION; MAGNETIC-FIELD		Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Schubert, G (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.		Russell, Christopher T/E-7745-2012	Russell, Christopher T/0000-0003-1639-8298				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; Collinson DW, 1997, METEORIT PLANET SCI, V32, P803, DOI 10.1111/j.1945-5100.1997.tb01571.x; GUBBINS D, 1979, GEOPHYS J ROY ASTR S, V59, P57, DOI 10.1111/j.1365-246X.1979.tb02553.x; LOPER DE, 1978, J GEOPHYS RES, V83, P5961, DOI 10.1029/JB083iB12p05961; Nimmo F, 2000, J GEOPHYS RES-PLANET, V105, P11969, DOI 10.1029/1999JE001216; Purucker M, 2000, GEOPHYS RES LETT, V27, P2449, DOI 10.1029/2000GL000072; RUNCORN SK, 1994, PHILOS T R SOC A, V349, P181, DOI 10.1098/rsta.1994.0123; Russell C. T., 1977, P 8 LUN SCI C PERG N, P1171; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; STEVENSON DJ, 1983, ICARUS, V54, P466, DOI 10.1016/0019-1035(83)90241-5; STEVENSON DJ, 1983, REP PROG PHYS, V46, P555, DOI 10.1088/0034-4885/46/5/001; Strom R.G., 1992, MARS, P383, DOI DOI 10.1016/S0032-0633(99)00016-1	12	79	82	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					666	667		10.1038/35047163	http://dx.doi.org/10.1038/35047163			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130059				2022-12-28	WOS:000165815200033
J	Mandel, JS; Church, TR; Bond, JH; Ederer, F; Geisser, MS; Mongin, SJ; Snover, DC; Schuman, LM				Mandel, JS; Church, TR; Bond, JH; Ederer, F; Geisser, MS; Mongin, SJ; Snover, DC; Schuman, LM			The effect of fecal occult-blood screening on the incidence of colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MORTALITY; POPULATION; MINNESOTA; TESTS; SIGMOIDOSCOPY; SENSITIVITY; NEOPLASIA; POLYPS	Background: Both annual testing for fecal occult blood and biennial testing significantly reduce mortality from colorectal cancer. However, the effect of screening on the incidence of colorectal cancer remains uncertain, despite the diagnosis and removal of precancerous lesions in many persons who undergo screening. Methods: We have followed the participants in the Minnesota Colon Cancer Control Study for 18 years. A total of 46,551 people, most of whom were 50 to 80 years old, were enrolled between 1975 and 1978 and randomly assigned to annual screening, biennial screening, or usual care (the control group). Those assigned to the screening groups were asked to prepare and submit two samples from each of three consecutive stools for guaiac-based testing. Those with at least one positive slide in the set of six were offered a diagnostic examination that included colonoscopy. Screening was conducted between 1976 and 1982 and again between 1986 and 1992. Study participants have been followed with respect to newly diagnosed cases of colorectal cancer and deaths. Follow-up has been more than 90 percent complete. Results: During the 18-year follow-up period, we identified 1359 new cases of colorectal cancer: 417 in the annual-screening group, 435 in the biennial-screening group, and 507 in the control group. The cumulative incidence ratios for colorectal cancer in the screening groups as compared with the control group were 0.80 (95 percent confidence interval, 0.70 to 0.90) and 0.83 (95 percent confidence interval, 0.73 to 0.94) for the annual-screening and biennial-screening groups, respectively. For both screening groups, the number of positive slides was associated with the positive predictive value both for colorectal cancer and for adenomatous polyps at least 1 cm in diameter. Conclusions: The use of either annual or biennial fecal occult-blood testing significantly reduces the incidence of colorectal cancer. (N Engl J Med 2000;343:1603-7.) (C) 2000, Massachusetts Medical Society.	Exponent, Menlo Park, CA 94025 USA; Univ Minnesota, Sch Publ Hlth, Div Environm & Occupat Hlth, Minneapolis, MN USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Vet Affairs Hosp, Minneapolis, MN USA; Emmes Corp, Potomac, MD USA; Fairview Hosp, Minneapolis, MN USA	Exponent; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Emmes Corporation	Mandel, JS (corresponding author), Exponent, 149 Commonwealth Dr, Menlo Park, CA 94025 USA.		Church, Timothy/AAH-7017-2020	Church, Timothy/0000-0003-3292-5035	DIVISION OF CANCER BIOLOGY AND DIAGNOSIS [N01CB061005, N01CB095613, N01CB053862] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CB-61005, N01-CB-95613, N01-CB-53862] Funding Source: Medline	DIVISION OF CANCER BIOLOGY AND DIAGNOSIS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlquist DA, 1997, GASTROENTEROL CLIN N, V26, P41, DOI 10.1016/S0889-8553(05)70282-X; Bertario L, 1999, EUR J CANCER, V35, P973, DOI 10.1016/S0959-8049(99)00062-3; BUSHHOUSE S, 1999, OCCURRENCE CANC MINN; Church TR, 1997, JNCI-J NATL CANCER I, V89, P1440, DOI 10.1093/jnci/89.19.1440; CONOVER W. J, 1980, PRACTICAL NONPARAMET; CUTLER S J, 1958, J Chronic Dis, V8, P699, DOI 10.1016/0021-9681(58)90126-7; *DAT AN PROD DIV, 1998, S PLUS 5 UNIX GUID S; DEMERS RY, 1985, PREV MED, V14, P55, DOI 10.1016/0091-7435(85)90020-9; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; Ederer F, 1999, J CLIN EPIDEMIOL, V52, P447, DOI 10.1016/S0895-4356(99)00016-5; Ederer F, 1997, J NATL CANCER I, V89, P1423, DOI 10.1093/jnci/89.19.1423; Faivre J, 1999, BRIT J CANCER, V79, P680, DOI 10.1038/sj.bjc.6690107; GILBERTSEN VA, 1980, J CHRON DIS, V33, P107, DOI 10.1016/0021-9681(80)90034-X; Hope RL, 1996, GUT, V39, P722, DOI 10.1136/gut.39.5.722; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; Lazovich D, 1995, J Med Screen, V2, P84; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Mandel JS, 1999, J NATL CANCER I, V91, P434, DOI 10.1093/jnci/91.5.434; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; NAKAMA H, 1994, CLIN INVESTIGATOR, V72, P117; SAS Institute, 1997, SAS STAT SOFTW CHANG; SELBY JV, 1993, ANN INTERN MED, V118, P1, DOI 10.7326/0003-4819-118-1-199301010-00001; Simon JB, 1998, NEW ENGL J MED, V338, P1151; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; Wahrendorf J, 1993, Eur J Cancer Prev, V2, P221, DOI 10.1097/00008469-199305000-00005; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; Zappa M, 1997, INT J CANCER, V73, P208, DOI 10.1002/(SICI)1097-0215(19971009)73:2<208::AID-IJC8>3.0.CO;2-#; ZEGER SL, 1989, BIOMETRICS, V45, P347; ZHOU DY, 1993, CHINESE MED J-PEKING, V106, P739	34	1069	1103	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1603	1607		10.1056/NEJM200011303432203	http://dx.doi.org/10.1056/NEJM200011303432203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096167	Bronze			2022-12-28	WOS:000165511000003
J	Sullivan, NJ; Sanchez, A; Rollin, PE; Yang, ZY; Nabel, GJ				Sullivan, NJ; Sanchez, A; Rollin, PE; Yang, ZY; Nabel, GJ			Development of a preventive vaccine for Ebola virus infection in primates	NATURE			English	Article							T-CELL INDUCTION; PROTECTIVE EFFICACY; IMMUNE-RESPONSES; RECOMBINANT; IMMUNIZATION; ADENOVIRUS; PROTEIN; MALARIA; IMMUNOGENICITY; THERAPY	Outbreaks of haemorrhagic fever caused by the Ebola virus are associated with high mortality rates that are a distinguishing feature of this human pathogen. The highest lethality is associated with the Zaire subtype, one of four strains identified to date(1,2). Its rapid progression allows little opportunity to develop natural immunity, and there is currently no effective anti-viral therapy. Therefore, vaccination offers a promising intervention to prevent infection and limit spread. Here we describe a highly effective vaccine strategy for Ebola virus infection in non-human primates. A combination of DNA immunization and boosting with adenoviral vectors that encode viral proteins generated cellular and humoral immunity in cynomolgus macaques. Challenge with a lethal dose of the highly pathogenic, wild-type, 1976 Mayinga strain of Ebola Zaire virus resulted in uniform infection in controls, who progressed to a moribund state and death in less than one week. In contrast, all vaccinated animals were asymptomatic for more than six months, with no detectable virus after the initial challenge. These findings demonstrate that it is possible to develop a preventive vaccine against Ebola virus infection in primates.	NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA 30333 USA	National Institutes of Health (NIH) - USA; Centers for Disease Control & Prevention - USA	Nabel, GJ (corresponding author), NIH, Vaccine Res Ctr, 40 Convent Dr,MSC-3005, Bethesda, MD 20892 USA.			Rollin, Pierre/0000-0002-4608-2641	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005004] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; Bray M, 1998, J INFECT DIS, V178, P651, DOI 10.1086/515386; Connolly BM, 1999, J INFECT DIS, V179, pS203, DOI 10.1086/514305; DAVIS AR, 1985, P NATL ACAD SCI USA, V82, P7560, DOI 10.1073/pnas.82.22.7560; FELDMANN H, 1994, VIROLOGY, V199, P469, DOI 10.1006/viro.1994.1147; FISHERHOCH SP, 1985, J INFECT DIS, V152, P887, DOI 10.1093/infdis/152.5.887; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; KILEY MP, 1980, J GEN VIROL, V49, P333, DOI 10.1099/0022-1317-49-2-333; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; Maruyama T, 1999, J VIROL, V73, P6024, DOI 10.1128/JVI.73.7.6024-6030.1999; NATUK RJ, 1992, P NATL ACAD SCI USA, V89, P7777, DOI 10.1073/pnas.89.16.7777; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; Robinson HL, 1999, NAT MED, V5, P526, DOI 10.1038/8406; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Vanderzanden L, 1998, VIROLOGY, V246, P134, DOI 10.1006/viro.1998.9176; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; Wilson JA, 2000, SCIENCE, V287, P1664, DOI 10.1126/science.287.5458.1664; Xiang ZQ, 1999, J IMMUNOL, V162, P6716; Xiang ZQ, 1996, VIROLOGY, V219, P220, DOI 10.1006/viro.1996.0239; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037	29	532	582	0	513	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					605	609		10.1038/35046108	http://dx.doi.org/10.1038/35046108			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117750				2022-12-28	WOS:000165548600123
J	Astrup, A; Marckmann, P; Blundell, J				Astrup, A; Marckmann, P; Blundell, J			Oiling of health messages in marketing of food	LANCET			English	Editorial Material							DIETARY-FAT; METAANALYSIS		Danish Nutr Council, Soborg, Denmark; Royal Vet & Agr Univ, Res Dept Human Nutr, DK-1958 Frederiksberg C, Denmark; Univ Leeds, Sch Psychol, Leeds, W Yorkshire, England	University of Copenhagen; University of Leeds	Astrup, A (corresponding author), Danish Nutr Council, Soborg, Denmark.		Astrup, Arne/B-1407-2015	Astrup, Arne/0000-0001-8968-8996				ASSMANN G, 1997, OLIVE OIL MEDITERRAN; Astrup A, 2000, BRIT J NUTR, V83, pS25; Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Doucet E, 1998, EUR J CLIN NUTR, V52, P2, DOI 10.1038/sj.ejcn.1600500; *EUR COMM INT OL O, 2000, 2000 INT C MED DIET; Lawton GL, 2000, BRIT J NUTR, V83, P473; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Yu-Poth S, 1999, AM J CLIN NUTR, V69, P632	9	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 25	2000	356	9244					1786	1786		10.1016/S0140-6736(00)03227-X	http://dx.doi.org/10.1016/S0140-6736(00)03227-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117907				2022-12-28	WOS:000165545700006
J	Dendy, PP				Dendy, PP			Mobile phones and the illusory pursuit of safety	LANCET			English	Editorial Material											Dendy, PP (corresponding author), 1A Coppice Ave, Cambridge CB2 5AQ, England.							HUMPHRIES FH, 1937, EMANOTHERAPY; Malyapa RS, 1998, RADIAT RES, V149, P637, DOI 10.2307/3579911; Mould RF, 1993, CENTURY XRAYS RADIOA, V1st	3	2	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1782	1783		10.1016/S0140-6736(00)03223-2	http://dx.doi.org/10.1016/S0140-6736(00)03223-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117903				2022-12-28	WOS:000165545700002
J	Gilbert, D; Walley, T; New, B				Gilbert, D; Walley, T; New, B			Lifestyle medicines	BRITISH MEDICAL JOURNAL			English	Article							PROTON PUMP INHIBITORS; RESTRICTIONS; VIAGRA		Off Publ Management, London WC1X 8JT, England; Univ Liverpool, Dept Pharmacol, Liverpool L69 3GF, Merseyside, England	University of Liverpool	Gilbert, D (corresponding author), Off Publ Management, 252B Grays Inn Rd, London WC1X 8JT, England.							Bashford JNR, 1998, BRIT MED J, V317, P452; Beecham L, 1999, BRIT MED J, V318, P279, DOI 10.1136/bmj.318.7179.279; Dolan P, 1999, BRIT MED J, V318, P916, DOI 10.1136/bmj.318.7188.916; Ferriman A, 1999, BRIT MED J, V318, P1305, DOI 10.1136/bmj.318.7194.1305a; Freemantle N, 2000, BRIT MED J, V320, P1156, DOI 10.1136/bmj.320.7243.1156; GIBLERT D, 1999, LIFESTYLE DRUGS WHO; HADORN DC, 1997, RATIONING TALK ACTIO, P183; HALL C, 1998, DAILY TELEGRAPH 0708; Ham C, 1998, BRIT MED J, V316, P1965, DOI 10.1136/bmj.316.7149.1965; KLEIN R, 1997, RATIONING TALK ACTIO, P85; LABELLE R, 1994, J HEALTH ECON, V13, P347, DOI 10.1016/0167-6296(94)90036-1; LEUFKENS H, 1994, BRIT MED J, V309, P1137, DOI 10.1136/bmj.309.6962.1137; MCIVER S., 1998, HLTH DEBATE INDEPEND; McManus P, 1998, BRIT J CLIN PHARMACO, V46, P409, DOI 10.1046/j.1365-2125.1998.00791.x; *NAT I CLIN EXC, 1999, NICE GUID ZAN REL TR; NEW B, 1996, RATIONING NHS PRINCI, P31; *NHS EX, 1999, TREATM IMP; *NHS EX, 1999, TREATM IMP PAT SEV D; REISSMAN D, 1999, DIS MANAG HEALTH OUT, V6, P249; *ROYAL COLL PHYS L, 1999, CLIN MAN OV OB PAT P; Shakespeare J, 2000, BRIT MED J, V320, P291, DOI 10.1136/bmj.320.7230.291; Smith R, 1999, BRIT MED J, V318, P209; Swedish Parliamentary Priorities Commission, 1995, PRIOR HLTH CAR ETH E; Walley T, 1998, BRIT MED J, V317, P487; 2000, BMJ, V320, P204	25	45	45	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1341	1344		10.1136/bmj.321.7272.1341	http://dx.doi.org/10.1136/bmj.321.7272.1341			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090522	Green Published			2022-12-28	WOS:000165561600036
J	Kmietowicz, Z				Kmietowicz, Z			Parents "not told" of hospital errors	BRITISH MEDICAL JOURNAL			English	News Item																		Ross LM, 2000, ARCH DIS CHILD, V83, P492, DOI 10.1136/adc.83.6.492; Stephenson T, 2000, ARCH DIS CHILD, V83, P496	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1310	1310		10.1136/bmj.321.7272.1310/a	http://dx.doi.org/10.1136/bmj.321.7272.1310/a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090511				2022-12-28	WOS:000165561600022
J	Dieterich, J; Cayol, V; Okubo, P				Dieterich, J; Cayol, V; Okubo, P			The use of earthquake rate changes as a stress meter at Kilauea volcano	NATURE			English	Article							SOUTH FLANK; HAWAII; DEFORMATION; MAGMA; FAULT; SEISMICITY; FRICTION; BENEATH	Stress changes in the Earth's crust are generally estimated from model calculations that use near-surface deformation as an observational constraint. But the widespread correlation of changes of earthquake activity with stress(1-5) has led to suggestions that stress changes might be calculated from earthquake occurrence rates obtained from seismicity catalogues. Although this possibility has considerable appeal, because seismicity data are routinely collected and have good spatial and temporal resolution, the method has not yet proven successful, owing to the nonlinearity of earthquake rate changes with respect to both stress and time. Here, however, we present two methods for inverting earthquake rate data to infer stress changes, using a formulation for the stress- and time-dependence of earthquake rates(6). Application of these methods at Kilauea volcano, in Hawaii, yields good agreement with independent estimates, indicating that earthquake rates can provide a practical remote-sensing stress meter.	US Geol Survey, Menlo Park, CA 94025 USA; Univ Blaise Pascal, Clermont Ferrand, France; US Geol Survey, Hawaii Volcano Observ, Hawaii Natl Pk, HI 96718 USA	United States Department of the Interior; United States Geological Survey; Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); United States Department of the Interior; United States Geological Survey	Dieterich, J (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Park, CA 94025 USA.	jdieterich@usgs.gov	Cayol, Valerie/AGV-1316-2022; Cayol, Valerie/AAK-6394-2020	Cayol, Valerie/0000-0001-9225-7441				ANDO M, 1979, J GEOPHYS RES, V84, P7616, DOI 10.1029/JB084iB13p07616; Cayol V, 2000, SCIENCE, V288, P2343, DOI 10.1126/science.288.5475.2343; Cayol V, 1997, INT J ROCK MECH MIN, V34, P275, DOI 10.1016/S0148-9062(96)00035-6; DELANEY PT, 1990, SCIENCE, V247, P1311, DOI 10.1126/science.247.4948.1311; DELANEY PT, 1993, J GEOPHYS RES-SOL EA, V98, P17801, DOI 10.1029/93JB01819; DIETERICH J, 1994, J GEOPHYS RES-SOL EA, V99, P2601, DOI 10.1029/93JB02581; Dieterich JH, 1996, P NATL ACAD SCI USA, V93, P3787, DOI 10.1073/pnas.93.9.3787; DIETERICH JH, 1988, J GEOPHYS RES-SOLID, V93, P4258, DOI 10.1029/JB093iB05p04258; DVORAK JJ, 1986, TECTONOPHYSICS, V124, P193, DOI 10.1016/0040-1951(86)90200-3; Gillard D, 1996, NATURE, V384, P343, DOI 10.1038/384343a0; GOT JL, 1994, J GEOPHYS RES-SOL EA, V99, P15375, DOI 10.1029/94JB00577; HARRIS RA, 1995, NATURE, V375, P221, DOI 10.1038/375221a0; Jaume SC, 1996, J GEOPHYS RES-SOL EA, V101, P765, DOI 10.1029/95JB02393; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; Klein F.W., 1987, VOLCANISM HAWAII, P1019; LINKER MF, 1992, J GEOPHYS RES-SOL EA, V97, P4923, DOI 10.1029/92JB00017; OWEN S, 1995, SCIENCE, V267, P1328, DOI 10.1126/science.267.5202.1328; Scholz CH, 1998, NATURE, V391, P37, DOI 10.1038/34097; Simpson R. W, 1994, US GEOL SURV PROF F, P55; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; Stein RS, 1997, GEOPHYS J INT, V128, P594, DOI 10.1111/j.1365-246X.1997.tb05321.x	21	164	166	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	2000	408	6811					457	460		10.1038/35044054	http://dx.doi.org/10.1038/35044054			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100724				2022-12-28	WOS:000165429800044
J	Szabowski, A; Maas-Szabowski, N; Andrecht, S; Kolbus, A; Schorpp-Kistner, M; Fusenig, NE; Angel, P				Szabowski, A; Maas-Szabowski, N; Andrecht, S; Kolbus, A; Schorpp-Kistner, M; Fusenig, NE; Angel, P			c-jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin	CELL			English	Article							KERATINOCYTE GROWTH-FACTOR; SUPRABASAL INTEGRIN EXPRESSION; CELL-CYCLE PROGRESSION; TRANSGENIC MICE; GENE-EXPRESSION; GM-CSF; INDUCTION; AP-1; FOS; DIFFERENTIATION	Interactions between mesenchymal and epithelial cells are responsible for organogenesis and tissue homeostasis. This mutual cross-talk involves cell surface proteins and soluble factors, which are mostly the result of regulated transcription. To elucidate dimer-specific functions of the AP-1 family of transcription factors, we reconstituted skin by combining primary human keratinocytes and mouse wild-type, c-jun(-/-) and junB(-/-) fibroblasts. We have discovered an antagonistic function of these AP-1 subunits in the fibroblast-mediated paracrine control of keratinocyte proliferation and differentiation, and traced this effect to the IL-1-dependent regulation of KGF and GM-CSF. These data suggest that the relative activation state of these AP-1 subunits in a non-cell-autonomous, transregulatory fashion directs regeneration of the epidermis and maintenance of tissue homeostasis in skin.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Carcinogenesis & Differentiat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.angel@dkfz-heidelberg.de						ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Borden P, 1996, J BIOL CHEM, V271, P23577, DOI 10.1074/jbc.271.38.23577; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BRAUNSTEIN S, 1994, J INVEST DERMATOL, V103, P601, DOI 10.1111/1523-1747.ep12396936; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1995, J BIOL CHEM, V270, P11230, DOI 10.1074/jbc.270.19.11230; FUSENIG NE, 1994, KERATINOCYTE HDB, P71; FUSENIG NE, 1992, CULTURE EPITHELIAL C, P25; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Huffman JA, 1996, J CLIN INVEST, V97, P649, DOI 10.1172/JCI118461; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAUR P, 1992, J CELL SCI, V103, P755; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KUPPER TS, 1995, J INVEST DERMATOL, V105, P62; LEVER WF, 1984, HISTOPATHOLOGY SKIN; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LUGER TA, 1995, ALLERGY, V50, P292, DOI 10.1111/j.1398-9995.1995.tb01151.x; Maas-Szabowski N, 1999, J CELL SCI, V112, P1843; Maas-Szabowski N, 2000, J INVEST DERMATOL, V114, P1075, DOI 10.1046/j.1523-1747.2000.00987.x; Metcalf D, 1998, IMMUNOL CELL BIOL, V76, P441, DOI 10.1046/j.1440-1711.1998.00761.x; Metcalf D, 1998, LEUKEMIA, V12, P353, DOI 10.1038/sj.leu.2400926; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Ponec M, 1997, ARCH DERMATOL RES, V289, P317, DOI 10.1007/s004030050198; Rikimaru K, 1997, EXP DERMATOL, V6, P214, DOI 10.1111/j.1600-0625.1997.tb00165.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SAIAG P, 1985, SCIENCE, V230, P669, DOI 10.1126/science.2413549; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHRODER JM, 1995, J INVEST DERMATOL, V105, P20; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; Stefanidou MP, 1999, BRIT J DERMATOL, V141, P1040, DOI 10.1046/j.1365-2133.1999.03202.x; Takei T, 1998, J CELL BIOCHEM, V69, P95; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; Welter JF, 1995, ONCOGENE, V11, P2681; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xing Z, 1997, LAB INVEST, V77, P615; Ye JP, 1996, MOL CELL BIOL, V16, P157; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	62	332	347	1	19	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 22	2000	103	5					745	755		10.1016/S0092-8674(00)00178-1	http://dx.doi.org/10.1016/S0092-8674(00)00178-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114331	Bronze			2022-12-28	WOS:000165433100007
J	Lanzetti, L; Rybin, V; Malabarba, MG; Christoforidis, S; Scita, G; Zerial, M; Di Fiore, PP				Lanzetti, L; Rybin, V; Malabarba, MG; Christoforidis, S; Scita, G; Zerial, M; Di Fiore, PP			The Eps8 protein coordinates EGF receptor signalling through Rac and trafficking through Rab5	NATURE			English	Article							GTPASE-ACTIVATING PROTEINS; ENDOCYTIC PATHWAY; BINDING-PROTEIN; SH3 DOMAIN; GROWTH; KINASE; SUBSTRATE; FUSION; E3B1	How epidermal growth factor receptor (EGFR) signalling is linked to EGFR trafficking is largely unknown. Signalling and trafficking involve small GTPases of the Rho and Rab families, respectively. But it remains unknown whether the signalling relying on these two classes of GTPases is integrated, and, if it is, what molecular machinery is involved. Here we report that the protein Eps8 connects these signalling pathways. Eps8 is a substrate of the EGFR(1), which is held in a complex with Sos1 by the adaptor protein E3b1 (ref. 2), thereby mediating activation of Rac(2). Through its src homology-3 domain, Eps8 interacts with RN-tre(3). We show that RN-tre is a Rab5 GTPase-activating protein, whose activity is regulated by the EGFR. By entering in a complex with Eps8, RN-tre acts on Rab5 and inhibits internalization of the EGFR. Furthermore, RN-tre diverts Eps8 from its Rac-activating function, resulting in the attenuation of Rac signalling. Thus, depending on its state of association with E3b1 or RN-tre, Eps8 participates in both EGFR signalling through Rac, and trafficking through Rab5.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; FIRC Inst Mol Oncol, IFOM, I-20134 Milan, Italy	IRCCS European Institute of Oncology (IEO); European Molecular Biology Laboratory (EMBL); Max Planck Society; IFOM - FIRC Institute of Molecular Oncology	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Scita, Giorgio/J-9670-2012; Malabarba, Maria Grazia/L-4805-2015; Di Fiore, Pier Paolo/K-2130-2012	Malabarba, Maria Grazia/0000-0002-9457-2047; Di Fiore, Pier Paolo/0000-0002-2252-0950; Scita, Giorgio/0000-0001-7984-1889; Christoforidis, Savvas/0000-0002-0210-0713; LANZETTI, Letizia/0000-0001-7541-5524				Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Carbone R, 1997, CANCER RES, V57, P5498; CASTAGNINO P, 1995, ONCOGENE, V10, P723; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Matoskova B, 1996, ONCOGENE, V12, P2679; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P243, DOI 10.1016/S0968-0004(97)01073-6; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Simon I, 1996, J BIOL CHEM, V271, P20470, DOI 10.1074/jbc.271.34.20470; SORKIN A, 1993, ONCOGENE, V8, P3021	24	227	245	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					374	377		10.1038/35042605	http://dx.doi.org/10.1038/35042605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099046				2022-12-28	WOS:000165296000049
J	Bartsch, D; Ghirardi, M; Casadio, A; Giustetto, M; Karl, KA; Zhu, HX; Kandel, ER				Bartsch, D; Ghirardi, M; Casadio, A; Giustetto, M; Karl, KA; Zhu, HX; Kandel, ER			Enhancement of memory-related long-term facilitation by ApAF, a novel transcription factor that acts downstream from both CREB1 and CREB2	CELL			English	Article							APLYSIA SENSORY NEURONS; GLUTATHIONE-S-TRANSFERASE; CAMP-RESPONSIVE ELEMENT; STRUCTURAL-CHANGES; BINDING PROTEIN; SYNAPTIC FACILITATION; TRANSMITTER RELEASE; FUSION PROTEINS; SENSITIZATION; HABITUATION	The memory for sensitization of the gill withdrawal reflex in Aplysia is reflected in facilitation of the monosynaptic connection between the sensory and motor neurons of the reflex. The switch from short- to longterm facilitation requires activation of CREB1, derepression of ApCREB2, and induction of ApC/EBP. In search for genes that act downstream from CREB1, we have identified a transcription activator, ApAF, which is stimulated by protein kinase A and can dimerize with both ApC/EBP and ApCREB2. ApAF is necessary for long-term facilitation induced by five pulses of serotonin, by activation of CREB1, or by derepression of ApCREB2. Overexpression of ApAF enhances the long-term facilitation further. Thus, ApAF is a candidate memory enhancer gene downstream from both CREB1 and ApCREB2.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA; Univ Turin, Dipartimento Neurosci, I-10125 Turin, Italy	Columbia University; Howard Hughes Medical Institute; New York State Psychiatry Institute; University of Turin	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Howard Hughes Med Inst, Ctr Neurobiol & Behav, 722 W 168th St, New York, NY 10032 USA.		giustetto, maurizio/D-6606-2011; ghirardi, mirella/AEQ-0420-2022	giustetto, maurizio/0000-0003-1323-4060; 				Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P9356, DOI 10.1073/pnas.85.23.9356; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CAREW T J, 1971, International Journal of Neuroscience, V2, P79, DOI 10.3109/00207457109146995; CAREW TJ, 1973, SCIENCE, V182, P1158, DOI 10.1126/science.182.4117.1158; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEXNER JB, 1963, SCIENCE, V141, P57, DOI 10.1126/science.141.3575.57; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; Gass P, 1998, LEARN MEMORY, V5, P274; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NORBY PL, 1992, NUCLEIC ACIDS RES, V20, P6317, DOI 10.1093/nar/20.23.6317; Pinsker H, 1970, Adv Biochem Psychopharmacol, V2, P351; PINSKER HM, 1973, SCIENCE, V182, P1039, DOI 10.1126/science.182.4116.1039; RAYPORT SG, 1986, J NEUROSCI, V6, P759; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	47	51	51	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 10	2000	103	4					595	608		10.1016/S0092-8674(00)00163-X	http://dx.doi.org/10.1016/S0092-8674(00)00163-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106730	Bronze			2022-12-28	WOS:000165348000005
J	Bhattacharjee, C; Bradley, P; Smith, M; Scally, AJ; Wilson, BJ				Bhattacharjee, C; Bradley, P; Smith, M; Scally, AJ; Wilson, BJ			Do animals bite more during a full moon? Retrospective observational analysis	BRITISH MEDICAL JOURNAL			English	Article							LUNAR	Objective To test the hypothesis that the incidence of animal bites increases at the time of a full moon. Design Retrospective observational analysis. Setting Accident and emergency department at a general hospital in an English city Subjects 1621 consecutive patients, irrespective of age and sex. Main outcome measures Number of patients who attended an accident and emergency department during 1997 to 1999 after being bitten by an animal, The number of bites in each day was compared with the lunar phase in each month. Results The incidence of animal bites rose significantly at the time of a full moon. With the period of the full moon as the reference period, the incidence rate ratio of the bites for all other periods of the lunar cycle was significantly lower(P < 0.001). Conclusions The full moon is associated with a significant increase in animal bites to humans.	Bradford Royal Infirm, Dept Accid & Emergency, Bradford BD9 6RJ, W Yorkshire, England; Clayton Surg, Bradford BD14 6JA, W Yorkshire, England; Univ Bradford, Sch Hlth Studies, Bradford BD5 0BB, W Yorkshire, England	Bradford Royal Infirmary; University of Bradford	Bhattacharjee, C (corresponding author), Bradford Royal Infirm, Dept Accid & Emergency, Bradford BD9 6RJ, W Yorkshire, England.		Callahan, Charles D/L-1641-2013; Scally, Andrew/A-9021-2012	Scally, Andy/0000-0002-6189-2247				DECASTRO JM, 1995, PHYSIOL BEHAV, V57, P439, DOI 10.1016/0031-9384(94)00232-T; Ghiandoni G, 1997, Minerva Ginecol, V49, P91; Laverty WH, 1998, PERCEPT MOTOR SKILL, V86, P299, DOI 10.2466/pms.1998.86.1.299; MIKULECKY M, 1992, EXPERIENTIA, V48, P530, DOI 10.1007/BF01928182; Owen C, 1998, AUST NZ J PSYCHIAT, V32, P496, DOI 10.1046/j.1440-1614.1998.00442.x; Raison CL, 1999, J AFFECT DISORDERS, V53, P99, DOI 10.1016/S0165-0327(99)00016-6; SHARFMAN M, 1980, PERCEPT MOTOR SKILL, V50, P124, DOI 10.2466/pms.1980.50.1.124; Sitar J, 1994, Cas Lek Cesk, V133, P596; Sitar J, 1997, Cas Lek Cesk, V136, P174; SOYMAN P, 1980, J CLIN PSYCHOL, V36, P884; THAKUR CP, 1984, BRIT MED J, V289, P1789, DOI 10.1136/bmj.289.6460.1789; Thompson DA, 1996, AM J EMERG MED, V14, P161, DOI 10.1016/S0735-6757(96)90124-2	12	28	29	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1559	1561		10.1136/bmj.321.7276.1559	http://dx.doi.org/10.1136/bmj.321.7276.1559			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	387RA	11124173	Green Published, Bronze			2022-12-28	WOS:000166134500011
J	Mimouni, D; Mimouni, FB; Mimouni, M				Mimouni, D; Mimouni, FB; Mimouni, M			Polydactyly reported by Raphael	BRITISH MEDICAL JOURNAL			English	Article									Rabin Med Ctr, Petah Tiqva, Israel; Tel Aviv Sourasky Med Ctr, Lis Matern Hosp, Tel Aviv, Israel; Schneider Childrens Med Ctr Israel, Tel Aviv, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Mimouni, D (corresponding author), Rabin Med Ctr, Petah Tiqva, Israel.			Mimouni, Daniel/0000-0001-7158-2085				Temtamy SA., 1979, BIRTH DEFECTS COMPEN, P873	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1622	1622		10.1136/bmj.321.7276.1622	http://dx.doi.org/10.1136/bmj.321.7276.1622			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124206	Green Published			2022-12-28	WOS:000166134500042
J	Porter, R				Porter, R			Happy hedonists	BRITISH MEDICAL JOURNAL			English	Article									UCL, Wellcome Trust Ctr Hist Med, London NW1 1AD, England	University of London; University College London	Porter, R (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London NW1 1AD, England.			tester22, sciencv/0000-0002-2791-7842; Holland, Sherri/0000-0003-2860-0668					0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1572	1575		10.1136/bmj.321.7276.1572/a	http://dx.doi.org/10.1136/bmj.321.7276.1572/a			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124182				2022-12-28	WOS:000166134500019
J	Ertekin-Taner, N; Graff-Radford, N; Younkin, LH; Eckman, C; Baker, M; Adamson, J; Ronald, J; Blangero, J; Hutton, M; Younkin, SG				Ertekin-Taner, N; Graff-Radford, N; Younkin, LH; Eckman, C; Baker, M; Adamson, J; Ronald, J; Blangero, J; Hutton, M; Younkin, SG			Linkage of plasma A beta 42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees	SCIENCE			English	Article							AMYLOID-BETA-PROTEIN; TRAIT LOCUS; IN-VIVO; PRESENILIN-1; PRECURSOR	Plasma A beta 42 (amyloid beta 42 peptide) is invariably elevated in early-onset familial Alzheimer's disease (AD), and it is also increased in the first-degree relatives of patients with typical late-onset AD (LOAD), To detect LOAD Loci that increase A beta 42, we used plasma A beta 42 as a surrogate trait and performed Linkage analysis on extended AD pedigrees identified through a LOAD patient with extremely high plasma A beta. Here, we report linkage to chromosome 10 with a maximal Lod score of 3.93 at 81 centimorgans close to D10S1225, Remarkably, Linkage to the same region was obtained independently in a genome-wide screen of LOAD sibling pairs. These results provide strong evidence for a novel LOAD Locus on chromosome 10 that acts to increase A beta.	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; SW Fdn Biomed Res, San Antonio, TX 78245 USA	Mayo Clinic; Texas Biomedical Research Institute	Hutton, M (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Blangero, John/ABA-7175-2021		NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH059490, R01MH059490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006656, P50AG016574] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG16574, AG06656] Funding Source: Medline; NIMH NIH HHS [MH59490] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Blangero J, 2000, GENET EPIDEMIOL, V19, pS8, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI2>3.0.CO;2-Y; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; YOUNKIN SG, 2000, NEUROBIOL AGING, V21, pS136	15	311	318	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2303	+		10.1126/science.290.5500.2303	http://dx.doi.org/10.1126/science.290.5500.2303			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125143				2022-12-28	WOS:000165995800043
J	Roweis, ST; Saul, LK				Roweis, ST; Saul, LK			Nonlinear dimensionality reduction by locally linear embedding	SCIENCE			English	Article								Many areas of science depend on exploratory data analysis and visualization. The need to analyze Large amounts of multivariate data raises the fundamental problem of dimensionality reduction: how to discover compact representations of high-dimensional data. Here, we introduce Locally Linear embedding (LLE), an unsupervised Learning algorithm that computes Low-dimensional, neighborhood-preserving embeddings of high-dimensional inputs. Unlike clustering methods for Local dimensionality reduction, LLE maps its inputs into a single global coordinate system of lower dimensionality, and its optimizations do not involve Local minima. By exploiting the local symmetries of Linear reconstructions, LLE is able to Learn the global structure of nonlinear manifolds, such as those generated by images of faces or documents of text.	UCL, Gatsby Computat Neurosci Unit, London WC1N 3AR, England; AT&T Lab Res, Florham Pk, NJ 07932 USA	University of London; University College London; AT&T	Roweis, ST (corresponding author), UCL, Gatsby Computat Neurosci Unit, 17 Queen Sq, London WC1N 3AR, England.	roweis@gatsby.ucl.ac.uk; lsaul@research.att.com	cai, chao/C-4840-2009					Beymer D, 1996, SCIENCE, V272, P1905, DOI 10.1126/science.272.5270.1905; Bishop CM, 1998, NEURAL COMPUT, V10, P215, DOI 10.1162/089976698300017953; Cox T. F, 1994, MULTIDIMENSIONAL SCA; DeMers D., 1993, ADV NEURAL INFORM PR, P580; DONNELL DJ, 1994, ANN STAT, V22, P1635, DOI 10.1214/aos/1176325746; HASTIE T, 1989, J AM STAT ASSOC, V84, P502, DOI 10.2307/2289936; Horn R.A., 2013, MATRIX ANAL, P321; Jolliffe I., 1989, APPL OPTICS; Klock H, 2000, PATTERN RECOGN, V33, P651, DOI 10.1016/S0031-3203(99)00078-3; Kohonen T., 1988, SELF ORG ASS MEMORY; KRAMER MA, 1991, AICHE J, V37, P233, DOI 10.1002/aic.690370209; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; LITTMAN M, 1992, COMPUTING SCIENCE AND STATISTICS : VOL 24, P208; MARTINETZ T, 1994, NEURAL NETWORKS, V7, P507, DOI 10.1016/0893-6080(94)90109-0; TAKANE Y, 1977, PSYCHOMETRIKA, V42, P7, DOI 10.1007/BF02293745; Tarjan R., 1983, CBMS, V44; Tenenbaum JB, 1998, ADV NEUR IN, V10, P682; van der Vorst, 2000, TEMPLATES SOLUTION A	19	9353	10553	54	1162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	2000	290	5500					2323	+		10.1126/science.290.5500.2323	http://dx.doi.org/10.1126/science.290.5500.2323			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125150				2022-12-28	WOS:000165995800050
J	Fichtenberg, CM; Glantz, SA				Fichtenberg, CM; Glantz, SA			Association of the california tobacco control program with declines in cigarette consumption and mortality from heart disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAMPAIGNS; SMOKING	Background: The California Tobacco Control Program, a large, aggressive antitobacco program implemented in 1989 and funded by a voter-enacted cigarette surtax, accelerated the decline in cigarette consumption and in the prevalence of smoking in California. Since the excess risk of heart disease falls rapidly after the cessation of smoking, we tested the hypothesis that this program was associated with lower rates of death from heart disease. Methods: Data on per capita cigarette consumption and age-adjusted rates of death from heart disease in California and the United States from 1980 to 1997 were fitted in multiple regression analyses. The regression analyses included the rates in the rest of the United States and variables that allowed for changes in the rates after 1988, when the tobacco-control program was approved, and after 1992, when the program was cut back. Results: Between 1989 and 1992, the rates of decline in per capita cigarette consumption and mortality from heart disease in California, relative to the rest of the United States, were significantly greater than the pre-1989 rates, by 2.72 packs per year per year (P=0.001) and by 2.93 deaths per year per 100,000 population per year (P<0.001). These rates of decline were reduced (by 2.05 packs per year per year [P=0.04], and by 1.71 deaths per year per 100,000 population per year [P=0.03]) when the program was cut back, beginning in 1992. Despite these problems, the program was associated with 33,300 fewer deaths from heart disease between 1989 and 1997 than the number that would have been expected if the earlier trend in mortality from heart disease in California relative to the rest of the United States had continued. The diminished effectiveness of the program after 1992 was associated with 8300 more deaths than would have been expected had its initial effectiveness been maintained. Conclusions: A large and aggressive tobacco-control program is associated with a reduction in deaths from heart disease in the short run. (N Engl J Med 2000;343:1772-7.) (C) 2000, Massachusetts Medical Society.	Univ Calif San Francisco, Cardiovasc Res Inst, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Inst Hlth Policy Studies, Box 0130, San Francisco, CA 94143 USA.				NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAL DG, 1990, JAMA-J AM MED ASSOC, V264, P1570, DOI 10.1001/jama.264.12.1570; Balbach ED, 1998, TOB CONTROL, V7, P397, DOI 10.1136/tc.7.4.397; BAUER U, 2000, 1 FLOR DEP HLTH SURV; Biener L, 2000, BRIT MED J, V321, P351, DOI 10.1136/bmj.321.7257.351; BURNS DM, 1997, NIH PUBL; *CA DEP HLTH SERV, MOD CHANG CAL EXP TO; *CIG SMOK EXC TAX, 1990, MMWR-MORBID MORTAL W, V45, P966; *CTR H**CTR HLTH S, 1998, HEART DIS DEATHS CAL; *DECL CIG CONS FOL, 1999, MMWR MORTAL WKLY REP, V7, P140; *DEP HLTH HUM SERV, 1990, DHHS PUBL; *DEP HLTH HUM SERV, 1983, DHHS PUBL; Glantz S., 1993, TOB CONTROL, V2, P311, DOI DOI 10.1136/TC.2.4.311; Glantz SA, 2000, TOBACCO WAR INSIDE C; Goldman LK, 1998, JAMA-J AM MED ASSOC, V279, P772, DOI 10.1001/jama.279.10.772; KIEGEL M, 1978, AM J PUBLIC HEALTH, V90, P372; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; *NAT CANC POL BOAR, 2000, STAT PROGR RED TOB U; *NAT CTR HLTH STAT, 1995, HLTH US 1995; *NAT CTR HLTH STAT, 1999, HLTH US 199 HLTH AG; National Center for Health Statistics, 1999, HLTH US 1999 HLTH AG; ORZECHOWSKI W, 1999, TAX BURDEN TOBACCO; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Pierce JP, 1999, JAMA-J AM MED ASSOC, V281, P37; Pierce JP, 1998, JAMA-J AM MED ASSOC, V280, P893, DOI 10.1001/jama.280.10.893; Pierce JP., 1998, TOBACCO CONTROL CALI; *TOB ED RES OV COM, 1997, TOB FREE CAL REN COM	26	215	217	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1772	1777		10.1056/NEJM200012143432406	http://dx.doi.org/10.1056/NEJM200012143432406			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11114317				2022-12-28	WOS:000165812000006
J	Ripouteau, C; Conort, O; Lamas, JP; Auleley, GR; Hazebroucq, G; Durieux, P				Ripouteau, C; Conort, O; Lamas, JP; Auleley, GR; Hazebroucq, G; Durieux, P			Quality improvement report - Effect of multifaceted intervention promoting early switch from intravenous to oral acetaminophen for postoperative pain: controlled, prospective, before and after study	BRITISH MEDICAL JOURNAL			English	Article							CONTINUING MEDICAL-EDUCATION; HEALTH-CARE; PARACETAMOL; GUIDELINES; OUTCOMES	Problem Need to improve the efficiency of postoperative pain management by early switching from intravenous to oral acetaminophen. Design Implementation of local guidelines aimed at improving nurses' and doctors' behaviour. A controlled prospective, before lid after study evaluated its impact on appropriateness and costs. Background and setting Orthopaedic surgery department (intervention) and all other surgical departments (control) of a university hospital. Five departments (control) of a university hospital. Five anaesthetists and 30 nurses of a orthopaedic department participated in study. Key measures for improvement Reducing number of acetaminophen injections per patient, reducing consumption of acetaminophen injections; cost savings over a one year period. Strategies for improvement Multifaceted intervention included a local consensus process, short educational presentation, poster displayed in all nurses' offices, and feedback of practices six months after implementation of guidelines. Effects of change Mean number of acetaminophen injections per patient decreased from 6.81 before intervention to 2.36 six months after. Monthly consumption of acetaminophen injections per 100 patients decreased by 320.9 (95% confidence interval 192.4 to 449.4) in intervention department and remained unchanged in control departments. Annual cost reduction was projected to be pound 15 100. Lessons learnt Simple and locally implemented guidelines carl improve practices and cut costs. Educational interventions call improve professionals' behaviour when they are based on actual working practices, use interactive techniques such as discussion groups, and are associated with other effective implementation strategies.	Hop Cochin, Dept Pharm, F-75006 Paris, France; Hop Cochin, Dept Orthopaed, F-75674 Paris, France; Hop Cochin, Publ Hlth Unit, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Durieux, P (corresponding author), Broussais Hotel Dieu, Fac Med, 15 Rue Ecole Med, F-75006 Paris, France.							Auleley GR, 1997, JAMA-J AM MED ASSOC, V277, P1935; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Cantillon P, 1999, BMJ-BRIT MED J, V318, P1276; CARR DB, 1992, AHCPR PUBLICATION US; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; *DEL EV MED, 1994, DIR PROSP INF MED AS; DEPRE M, 1992, FUNDAM CLIN PHARM, V6, P259, DOI 10.1111/j.1472-8206.1992.tb00119.x; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAMMERMEISTER KE, 1994, ANN THORAC SURG, V58, P1815, DOI 10.1016/0003-4975(94)91720-5; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; McKee M, 1997, BRIT MED J, V315, P142, DOI 10.1136/bmj.315.7101.142; MCNALLY E, 1995, BRIT MED J, V310, P640, DOI 10.1136/bmj.310.6980.640; Nash R, 1999, J CLIN NURS, V8, P180, DOI 10.1046/j.1365-2702.1999.00228.x; NHS Centre for Reviews and Dissemination, 1994, EFFECTIVE HLTH CARE, V8, P1; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Po ALW, 1997, BRIT MED J, V315, P1565, DOI 10.1136/bmj.315.7122.1565; Reynolds J.E.F., 1996, MARTINDALE EXTRA PHA, V31st; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; THOMAS L, 1999, COCHRANE LIB; Waddell D L, 1991, J Contin Educ Nurs, V22, P113; *WHO, 1997, TREATM CANC PAIN, P18	24	20	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1460	1463		10.1136/bmj.321.7274.1460	http://dx.doi.org/10.1136/bmj.321.7274.1460			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110743	Green Published			2022-12-28	WOS:000165852300034
J	Sackey, AH				Sackey, AH			Drug points - Recurrent generalised urticaria at insulin injection sites	BRITISH MEDICAL JOURNAL			English	Letter							ALLERGY											Bollinger ME, 1999, J ALLERGY CLIN IMMUN, V104, P462, DOI 10.1016/S0091-6749(99)70394-5; FEINGLOS MN, 1979, LANCET, V1, P122; Jehle PM, 1999, LANCET, V354, P1604, DOI 10.1016/S0140-6736(98)12459-5	3	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1449	1449		10.1136/bmj.321.7274.1449	http://dx.doi.org/10.1136/bmj.321.7274.1449			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110738	Green Published, Bronze			2022-12-28	WOS:000165852300028
J	Petford, N; Cruden, AR; McCaffrey, KJW; Vigneresse, JL				Petford, N; Cruden, AR; McCaffrey, KJW; Vigneresse, JL			Granite magma formation, transport and emplacement in the Earth's crust	NATURE			English	Review							PLUTON EMPLACEMENT; CONTINENTAL-CRUST; SEGREGATION; MELT; DEFORMATION; GENERATION; INTRUSION; ASCENT; DISEQUILIBRIUM; TRANSPRESSION	The origin of granites was once a question solely for petrologists and geochemists. But in recent years a consensus has emerged that recognizes the essential role of deformation in the segregation, transport and emplacement of silica-rich melts in the continental crust. Accepted petrological models are being questioned, either because they require unrealistic rheological behaviours of rocks and magmas, or because they do not satisfactorily explain the available structural or geophysical data. Provided flow is continuous, mechanical considerations suggest that-far from being geologically sluggish-granite magmatism is a rapid, dynamic process operating at timescales of less than or equal to 100,000 years, irrespective of tectonic setting.	Kingston Univ, Ctr Earth & Environm Sci Res, Kingston upon Thames KT1 2EE, Surrey, England; Univ Toronto, Dept Geol, Toronto, ON M5S 3B1, Canada; Univ Durham, Dept Geol Sci, Durham DH1 3LE, England; CNRS, CREGU, UMR 7566, F-54501 Vandoeuvre Les Nancy, France	Kingston University; University of Toronto; Durham University; Centre National de la Recherche Scientifique (CNRS); Total SA; Centre de Reserches sur la Geologie des Matieres Premieres Minerales et Energetiques; Universite de Lorraine	Petford, N (corresponding author), Kingston Univ, Ctr Earth & Environm Sci Res, Kingston upon Thames KT1 2EE, Surrey, England.	n.pet@kingston.ac.uk	McCaffrey, Kenneth JW/F-2285-2014; vigneresse, jean louis/I-9556-2019; Wheldall, Kevin/A-6792-2008	McCaffrey, Kenneth JW/0000-0002-9882-1709; vigneresse, jean louis/0000-0001-7118-3500; Wheldall, Kevin/0000-0002-9449-4579; Cruden, Alexander/0000-0001-6367-8589				Ameglio L, 1999, GEOL SOC SPEC PUBL, V168, P39, DOI 10.1144/GSL.SP.1999.168.01.04; ARZI AA, 1978, TECTONOPHYSICS, V44, P173, DOI 10.1016/0040-1951(78)90069-0; ATHERTON MP, 1999, 4 INT S AND GEOD, P60; BATEMAN PC, 1992, US GEOL SURV PROF PA, V1483; Benn K, 1998, GEOLOGY, V26, P1079, DOI 10.1130/0091-7613(1998)026<1079:PEDTIB>2.3.CO;2; Bergantz G.W., 1989, SCIENCE, V254, P1039; BOUCHEZ JL, 1997, GRANITE SEGREGATION; Brandon AD, 1996, SCIENCE, V271, P1845, DOI 10.1126/science.271.5257.1845; Brown EH, 2000, GEOL SOC AM BULL, V112, P708, DOI 10.1130/0016-7606(2000)112<708:PEBSAV>2.0.CO;2; Brown M, 1999, TECTONOPHYSICS, V312, P1, DOI 10.1016/S0040-1951(99)00169-9; BROWN M, 1994, EARTH-SCI REV, V36, P83, DOI 10.1016/0012-8252(94)90009-4; Brown M., 1997, DEFORMATION ENHANCED, P111; Clemens J.D., 1997, DEFORMATION ENHANCED, P145; CLEMENS JD, 1992, TECTONOPHYSICS, V204, P339, DOI 10.1016/0040-1951(92)90316-X; Clemens JD, 1999, J GEOL SOC LONDON, V156, P1057, DOI 10.1144/gsjgs.156.6.1057; Collins WJ, 1996, J METAMORPH GEOL, V14, P565, DOI 10.1046/j.1525-1314.1996.00442.x; Cruden AR, 1998, J GEOL SOC LONDON, V155, P853, DOI 10.1144/gsjgs.155.5.0853; Cruden AR, 1999, J GEOPHYS RES-SOL EA, V104, P10511, DOI 10.1029/1998JB900093; DAVIDSON C, 1994, TERRA NOVA, V6, P133, DOI 10.1111/j.1365-3121.1994.tb00646.x; Davies GR, 2000, CHEM GEOL, V162, P169, DOI 10.1016/S0009-2541(99)00123-0; DINGWELL DB, 1993, MINERAL ASS CANADA S, V21, P131; DLEMOS RS, 1992, J GEOL SOC LONDON, V149, P487, DOI 10.1144/gsjgs.149.4.0487; Evans D.J., 1994, P YORKS GEOL SOC, V50, DOI [10.1144/pygs.50.1.11, DOI 10.1144/PYGS.50.1.11]; Fernandez C, 1999, J STRUCT GEOL, V21, P1143, DOI 10.1016/S0191-8141(99)00086-3; Grocott J, 1999, J GEOL SOC LONDON, V156, P15, DOI 10.1144/gsjgs.156.1.0015; Harris N, 2000, CHEM GEOL, V162, P155, DOI 10.1016/S0009-2541(99)00121-7; HOGAN JP, 1995, J GEOPHYS RES-SOL EA, V100, P15779, DOI 10.1029/94JB03258; HUPPERT HE, 1988, J PETROL, V29, P599, DOI 10.1093/petrology/29.3.599; Hutton D.H.W., 1988, T ROYAL SOC EDINBURG, V79, P245, DOI DOI 10.1017/S0263593300014255; KELEMEN PB, 1995, J GEOPHYS RES-SOL EA, V100, P423, DOI 10.1029/94JB02063; MARSH BD, 1982, AM J SCI, V282, P808, DOI 10.2475/ajs.282.6.808; McCaffrey KJW, 1997, J GEOL SOC LONDON, V154, P1, DOI 10.1144/gsjgs.154.1.0001; MCKENZIE D, 1984, J PETROL, V25, P713, DOI 10.1093/petrology/25.3.713; Miller RB, 1999, J STRUCT GEOL, V21, P1161, DOI 10.1016/S0191-8141(99)00033-4; Petford N, 1998, J GEOL SOC LONDON, V155, P873, DOI 10.1144/gsjgs.155.5.0873; PETFORD N, 1993, GEOLOGY, V21, P845, DOI 10.1130/0091-7613(1993)021<0845:DTOGM>2.3.CO;2; Petford N, 1998, J STRUCT GEOL, V20, P1425, DOI 10.1016/S0191-8141(98)00081-9; Petford N, 1997, PETR STRU G, V8, P3; PETFORD N, 1995, J GEOPHYS RES-SOL EA, V100, P15735, DOI 10.1029/94JB03259; Pitcher W.S, 1993, NATURE ORIGIN GRANIT; RomanBerdiel T, 1997, AM J SCI, V297, P651, DOI 10.2475/ajs.297.6.651; RUTTER EH, 1995, J GEOPHYS RES-SOL EA, V100, P15697, DOI 10.1029/94JB03388; SAWYER EW, 1991, J PETROL, V32, P701, DOI 10.1093/petrology/32.4.701; SCALLIET B, 1994, J GEOPHYS RES, V100, P585; TAYLOR SR, 1995, REV GEOPHYS, V33, P241, DOI 10.1029/95RG00262; THOMPSON AB, 1995, J GEOPHYS RES-SOL EA, V100, P15565, DOI 10.1029/95JB00191; Thompson AB, 1999, GEOL SOC SPEC PUBL, V168, P7, DOI 10.1144/GSL.SP.1999.168.01.02; Vigneresse JL, 1996, J PETROL, V37, P1579, DOI 10.1093/petrology/37.6.1579; Watt GR, 2000, GEOLOGY, V28, P327; WEINBERG RF, 1994, J GEOPHYS RES-SOL EA, V99, P9543, DOI 10.1029/93JB03461; Weinberg RF, 1999, LITHOS, V46, P393, DOI 10.1016/S0024-4937(98)00075-9; WICKHAM SM, 1987, J GEOL SOC LONDON, V144, P281, DOI 10.1144/gsjgs.144.2.0281	52	619	679	5	156	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					669	673		10.1038/35047000	http://dx.doi.org/10.1038/35047000			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130061				2022-12-28	WOS:000165815200037
J	Zeuzem, S; Feinman, SV; Rasenack, J; Heathcote, EJ; Lai, MY; Gane, E; O'Grady, J; Reichen, J; Diago, M; Lin, A; Hoffman, J; Brunda, MJ				Zeuzem, S; Feinman, SV; Rasenack, J; Heathcote, EJ; Lai, MY; Gane, E; O'Grady, J; Reichen, J; Diago, M; Lin, A; Hoffman, J; Brunda, MJ			Peginterferon alfa-2a in patients with chronic hepatitis C	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERFERON-ALPHA; IN-VIVO; RIBAVIRIN; THERAPY; VIRUS; METAANALYSIS; COMBINATION; EFFICACY; GENOTYPE; DYNAMICS	Background: Covalent attachment of a 40-kd branched-chain polyethylene glycol moiety to interferon alfa-2a results in a compound (peginterferon alfa-2a) that has sustained absorption, a slower rate of clearance, and a longer half-life than unmodified interferon alfa-2a. We compared the clinical effects of a regimen of peginterferon alfa-2a with those of a regimen of interferon alfa-2a in the initial treatment of patients with chronic hepatitis C. Methods: We randomly assigned 531 patients with chronic hepatitis C to receive either 180 microg of peginterferon alfa-2a subcutaneously once per week for 48 weeks (267 patients) or 6 million units of interferon alfa-2a subcutaneously three times per week for 12 weeks, followed by 3 million units three times per week for 36 weeks (264 patients). All the patients were assessed at week 72 for a sustained virologic response, defined as an undetectable level of hepatitis C virus RNA (<100 copies per milliliter). Results: In the peginterferon group, 223 of the 267 patients completed treatment and 206 completed follow-up. In the interferon group, 161 of the 264 patients completed treatment and 154 completed follow-up. In an intention-to-treat analysis in which patients who missed the examination at the end of treatment or follow-up were considered not to have had a response at that point, peginterferon alfa-2a was associated with a higher rate of virologic response than was interferon alfa-2a at week 48 (69 percent vs. 28 percent, P=0.001) and at week 72 (39 percent vs. 19 percent, P=0.001). Sustained normalization of serum alanine aminotransferase concentrations at week 72 was also more common in the peginterferon group than in the interferon group (45 percent vs. 25 percent, P=0.001). The two groups were similar with respect to the frequency and severity of adverse events, which were typical of those associated with interferon alfa. Conclusions: In patients with chronic hepatitis C, a regimen of peginterferon alfa-2a given once weekly is more effective than a regimen of interferon alfa-2a given three times weekly. (N Engl J Med 2000;343:1666-72.) (C) 2000, Massachusetts Medical Society.	Univ Frankfurt Klinikum, Zentrum Inneren Med, Med Klin 2, D-60590 Frankfurt, Germany; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Med Univ Klin, Freiburg, Germany; Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; Natl Taiwan Univ Hosp, Taipei, Taiwan; Middlemore Hosp, Auckland 6, New Zealand; Kings Coll Hosp London, London, England; Univ Inst Klin Pharmakol, Bern, Switzerland; Gen Univ, Valencia, Spain; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Taiwan University; National Taiwan University Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; Roche Holding	Zeuzem, S (corresponding author), Univ Frankfurt Klinikum, Zentrum Inneren Med, Med Klin 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	zeuzem@em.uni-frankfurt.de	DIAGO, MOISES/AAH-5364-2019; Zeuzem, Stefan/AAE-7435-2019					Algranati NE, 1999, HEPATOLOGY, V30, p190A; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Carithers RL, 1997, HEPATOLOGY, V26, pS83, DOI 10.1002/hep.510260715; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; Dunnett CW, 1996, STAT MED, V15, P1729; Farrell GC, 1997, HEPATOLOGY, V26, pS96, DOI 10.1002/hep.510260717; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lai MY, 1996, GASTROENTEROLOGY, V111, P1307, DOI 10.1053/gast.1996.v111.pm8898645; Lam NP, 1997, HEPATOLOGY, V26, P226; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Nieforth KA, 1996, CLIN PHARMACOL THER, V59, P636, DOI 10.1016/S0009-9236(96)90003-X; Poynard T, 1996, HEPATOLOGY, V24, P778; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; WILLS RJ, 1990, CLIN PHARMACOKINET, V19, P390, DOI 10.2165/00003088-199019050-00003; Xu ZX, 1998, HEPATOLOGY, V28, p702A; Zeuzem S, 1996, HEPATOLOGY, V23, P366	20	941	1038	0	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2000	343	23					1666	1672		10.1056/NEJM200012073432301	http://dx.doi.org/10.1056/NEJM200012073432301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380PX	11106715				2022-12-28	WOS:000165711900001
J	Voigt, C; Schreiner, J; Kohlmann, A; Zink, P; Mauersberger, K; Larsen, N; Deshler, T; Kroger, C; Rosen, J; Adriani, A; Cairo, F; Di Donfrancesco, G; Viterbini, M; Ovarlez, J; Ovarlez, H; David, C; Dornbrack, A				Voigt, C; Schreiner, J; Kohlmann, A; Zink, P; Mauersberger, K; Larsen, N; Deshler, T; Kroger, C; Rosen, J; Adriani, A; Cairo, F; Di Donfrancesco, G; Viterbini, M; Ovarlez, J; Ovarlez, H; David, C; Dornbrack, A			Nitric acid trihydrate (NAT) in polar stratospheric clouds	SCIENCE			English	Article							LIDAR OBSERVATIONS; OZONE DEPLETION; AEROSOL; PARTICLES; WINTER; GROWTH; WATER; TEMPERATURES; CHEMISTRY; HNO3	A comprehensive investigation of polar stratospheric clouds was performed on 25 January 2000 with instruments onboard a balloon gondola flown from Kiruna, Sweden. Cloud layers were repeatedly encountered at altitudes between 20 and 24 kilometers over a wide range of atmospheric temperatures (185 to 197 kelvin). Particle composition analysis showed that a large fraction of the cloud layers was composed of nitric acid trihydrate (NAT) particles, containing water and nitric acid at a molar ratio of 3:1; this confirmed that these long-sought solid crystals exist well above ice formation temperatures. The presence of NAT particles enhances the potential for chlorine activation with subsequent ozone destruction in polar regions, particularly in early and late winter.	Max Planck Inst Kernphys, Div Atmospher Phys, D-69029 Heidelberg, Germany; Danish Meteorol Inst, Div Middle Atmosphere Res, DK-2100 Copenhagen, Denmark; Univ Wyoming, Dept Atmospher Sci, Laramie, WY 82071 USA; CNR, Ist Fis Atmosfera, I-00133 Rome, Italy; Ecole Polytech, CNRS, Meteorol Dynam Lab, F-91128 Palaiseau, France; Univ Paris, Inst Pierre Simon Laplace, CNRS, Serv Aeron, F-75252 Paris, France; DLR Oberpfaffenhofen, Inst Phys Atmosphare, D-82234 Wessling, Germany	Max Planck Society; Danish Meteorological Institute DMI; University of Wyoming; Consiglio Nazionale delle Ricerche (CNR); Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; Helmholtz Association; German Aerospace Centre (DLR)	Mauersberger, K (corresponding author), Max Planck Inst Kernphys, Div Atmospher Phys, POB 103 980, D-69029 Heidelberg, Germany.		Larsen, Niels/G-3145-2014; Voigt, Christiane/G-3279-2010; cairo, francesco/C-7460-2015	Larsen, Niels/0000-0002-1582-661X; Voigt, Christiane/0000-0001-8925-7731; cairo, francesco/0000-0002-2886-2601; Adriani, Alberto/0000-0003-4998-8008				ADRIANI A, 1998, P 18 QUADR OZ S AQ 1, V2, P879; BEYERLE G, 1994, GEOPHYS RES LETT, V21, P57, DOI 10.1029/93GL02846; Carslaw KS, 1998, J GEOPHYS RES-ATMOS, V103, P5785, DOI 10.1029/97JD03626; Carslaw KS, 1998, NATURE, V391, P675, DOI 10.1038/35589; CARSLAW KS, 1994, GEOPHYS RES LETT, V21, P2479, DOI 10.1029/94GL02799; CRUTZEN PJ, 1986, NATURE, V324, P651, DOI 10.1038/324651a0; Deshler T, 1998, J ATMOS CHEM, V30, P11, DOI 10.1023/A:1006023729315; Deshler T, 2000, J GEOPHYS RES-ATMOS, V105, P3943, DOI 10.1029/1999JD900469; Dornbrack A, 1999, TELLUS A, V51, P951, DOI 10.1034/j.1600-0870.1999.00028.x; FAHEY DW, 1989, J GEOPHYS RES-ATMOS, V94, P11299, DOI 10.1029/JD094iD09p11299; HANSON D, 1988, GEOPHYS RES LETT, V15, P855, DOI 10.1029/GL015i008p00855; HOFMANN DJ, 1991, J GEOPHYS RES-ATMOS, V96, P2897, DOI 10.1029/90JD02494; Iraci LT, 1998, J GEOPHYS RES-ATMOS, V103, P8491, DOI 10.1029/98JD00281; Larsen N, 2000, J GEOPHYS RES-ATMOS, V105, P1491, DOI 10.1029/1999JD900910; Newman PA, 1997, GEOPHYS RES LETT, V24, P2689, DOI 10.1029/97GL52831; OVARLEZ J, 1994, GEOPHYS RES LETT, V21, P1235, DOI 10.1029/93GL02438; Pawson S, 1999, J GEOPHYS RES-ATMOS, V104, P14209, DOI 10.1029/1999JD900211; Peter T, 1997, ANNU REV PHYS CHEM, V48, P785, DOI 10.1146/annurev.physchem.48.1.785; POOLE LR, 1988, GEOPHYS RES LETT, V15, P867, DOI 10.1029/GL015i008p00867; POOLE LR, 1988, GEOPHYS RES LETT, V15, P21, DOI 10.1029/GL015i001p00021; ROSEN JM, 1991, APPL OPTICS, V30, P1552, DOI 10.1364/AO.30.001552; Schreiner J, 1999, AEROSOL SCI TECH, V31, P373, DOI 10.1080/027868299304093; Schreiner J, 1999, SCIENCE, V283, P968, DOI 10.1126/science.283.5404.968; Solomon S, 1999, REV GEOPHYS, V37, P275, DOI 10.1029/1999RG900008; Stolarski R, 1997, NATURE, V389, P788, DOI 10.1038/39737; TABAZADEH A, 1994, J GEOPHYS RES-ATMOS, V99, P12897, DOI 10.1029/94JD00820; TOON OB, 1986, GEOPHYS RES LETT, V13, P1284, DOI 10.1029/GL013i012p01284; VOIGT C, IN PRESS GEOPHYS RES; *WORLD MET ORG, 1999, 44 WMO GLOB OZ RES M	29	166	167	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1756	1758		10.1126/science.290.5497.1756	http://dx.doi.org/10.1126/science.290.5497.1756			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099412				2022-12-28	WOS:000165632400040
J	Freeman, M				Freeman, M			Feedback control of intercellular signalling in development	NATURE			English	Review							DROSOPHILA EGF RECEPTOR; BIOLOGICAL PATTERN-FORMATION; LEFT-RIGHT ASYMMETRY; LEFT-RIGHT AXIS; VERTEBRATE LIMB; GENE ENCODES; PATCHED GENE; CELL FATE; MEMBRANE-PROTEIN; VENTRAL ECTODERM	The intercellular communication that regulates cell fate during animal development must be precisely controlled to avoid dangerous errors. How is this achieved? Recent work has highlighted the importance of positive and negative feedback loops in the dynamic regulation of developmental signalling. These feedback interactions can impart precision, robustness and versatility to intercellular signals. Feedback failure can cause disease.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	MF1@mrc-lamb.cam.ac.uk		Freeman, Matthew/0000-0003-0410-5451				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Christian JL, 1999, BIOESSAYS, V21, P382, DOI 10.1002/(SICI)1521-1878(199905)21:5<382::AID-BIES5>3.0.CO;2-V; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Collier JR, 1996, J THEOR BIOL, V183, P429, DOI 10.1006/jtbi.1996.0233; DIMARCO E, 1989, ONCOGENE, V4, P831; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Esteban CR, 1999, NATURE, V401, P243, DOI 10.1038/45738; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Freeman M, 1997, DEVELOPMENT, V124, P261; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gaio U, 1999, CURR BIOL, V9, P1339, DOI 10.1016/S0960-9822(00)80059-7; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; Golembo M, 1999, GENE DEV, V13, P158, DOI 10.1101/gad.13.2.158; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GONZALEZREYES A, 1992, DEVELOPMENT, V116, P1059; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Jin MH, 2000, MOL CELL BIOL, V20, P2098, DOI 10.1128/MCB.20.6.2098-2107.2000; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Marigo V, 1996, DEVELOPMENT, V122, P1225; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MEINHARDT H, 1994, BIOESSAYS, V16, P627, DOI 10.1002/bies.950160906; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Moon AM, 2000, DEVELOPMENT, V127, P989; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nicola NA, 1999, COLD SPRING HARB SYM, V64, P397, DOI 10.1101/sqb.1999.64.397; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Smolen P, 2000, NEURON, V26, P567, DOI 10.1016/S0896-6273(00)81194-0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; TREMML G, 1992, DEVELOPMENT, V116, P447; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; WEISS P, 1957, J GEN PHYSIOL, V41, P1, DOI 10.1085/jgp.41.1.1; Wilkins AS, 1997, BIOESSAYS, V19, P257, DOI 10.1002/bies.950190312; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yokouchi Y, 1999, CELL, V98, P573, DOI 10.1016/S0092-8674(00)80045-8; ZECCA M, 1995, DEVELOPMENT, V121, P2265; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	84	399	409	3	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	2000	408	6810					313	319		10.1038/35042500	http://dx.doi.org/10.1038/35042500			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099031				2022-12-28	WOS:000165296000034
J	Suzuki, M; Youle, RJ; Tjandra, N				Suzuki, M; Youle, RJ; Tjandra, N			Structure of Bax: Coregulation of dimer formation and intracellular localization	CELL			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; ORIENTED MACROMOLECULES; BACKBONE DYNAMICS; DIPOLAR COUPLINGS; CHEMICAL-SHIFT; BCL-2 FAMILY; BH3 DOMAIN; APOPTOSIS; MITOCHONDRIA	Apoptosis is stimulated by the insertion of Bax from the cytosol into mitochondrial membranes. The solution structure of Bax, including the putative transmembrane domain at the C terminus, was determined in order to understand the regulation of its subcellular location. Bax consists of 9 alpha helices where the assembly of helices alpha1 through alpha8 resembles that of the apoptosis inhibitor, Bcl-x(L). The C-terminal alpha9 helix occupies the hydrophobic pocket proposed previously to mediate heterodimer formation and bioactivity of opposing members of the Bcl-2 family. The Bax structure shows that the orientation of helix alpha9 provides simultaneous control over its mitochondrial targeting and dimer formation.	NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA; NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Tjandra, N (corresponding author), NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA.			Suzuki, Motoshi/0000-0002-4346-7677	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002674, ZIANS002859, ZIANS002674, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BRUNGER AT, 1992, XPLOR VERSION 3 1; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ottiger M, 1998, J MAGN RESON, V134, P365, DOI 10.1006/jmre.1998.1546; Ottiger M, 1999, J BIOMOL NMR, V13, P187, DOI 10.1023/A:1008395916985; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281	41	867	920	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 10	2000	103	4					645	654		10.1016/S0092-8674(00)00167-7	http://dx.doi.org/10.1016/S0092-8674(00)00167-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106734	Bronze			2022-12-28	WOS:000165348000009
J	Ramanan, SV				Ramanan, SV			Three incidents	BRITISH MEDICAL JOURNAL			English	Article									Univ Connecticut, Sch Med, Hartford, CT 06105 USA	University of Connecticut	Ramanan, SV (corresponding author), St Francis Hosp & Med Ctr, 1000 Asylum Ave,Suite 1002, Hartford, CT 06105 USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1615	1616		10.1136/bmj.321.7276.1615	http://dx.doi.org/10.1136/bmj.321.7276.1615			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124202	Green Published			2022-12-28	WOS:000166134500038
J	Fromm, R; Guntupalli, K				Fromm, R; Guntupalli, K			Update in critical care medicine	ANNALS OF INTERNAL MEDICINE			English	Review							MECHANICAL VENTILATION; UNIT		Methodist Hosp, Houston, TX 77030 USA; Ben Taub Gen Hosp, Houston, TX 77030 USA	The Methodist Hospital System; The Methodist Hospital - Houston	Fromm, R (corresponding author), Methodist Hosp, 6565 Fannin St,Room 196, Houston, TX 77030 USA.							ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; WITEK TJ, 1985, ARCH INTERN MED, V145, P235, DOI 10.1001/archinte.145.2.235; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	6	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					974	980		10.7326/0003-4819-133-12-200012190-00013	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119399				2022-12-28	WOS:000165952300006
J	Berger, A				Berger, A			Statins could be useful in organ transplantation	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1430	1430		10.1136/bmj.321.7274.1430/b	http://dx.doi.org/10.1136/bmj.321.7274.1430/b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110728	Green Published			2022-12-28	WOS:000165852300009
J	Ishikawa, T; Maurizi, MR; Belnap, D; Steven, AC				Ishikawa, T; Maurizi, MR; Belnap, D; Steven, AC			ATP-dependent proteases - Docking of components in a bacterial complex	NATURE			English	Article							PROTEIN		NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ishikawa, T (corresponding author), NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA.	steven@calvin.niams.nih.gov	Song, Hyun Kyu/D-6763-2016; Ishikawa, Takashi/E-5023-2017	Song, Hyun Kyu/0000-0001-5684-4059; Ramachandran, Ravishankar/0000-0002-0723-9861; Ishikawa, Takashi/0000-0002-1976-7477	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027015, ZIAAR027015] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Belnap DM, 1999, J STRUCT BIOL, V125, P166, DOI 10.1006/jsbi.1999.4093; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Neuwald AF, 1999, GENOME RES, V9, P27; ORTEGA J, IN PRESS MOL CELL; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schmidt M, 1999, CURR OPIN CHEM BIOL, V3, P584, DOI 10.1016/S1367-5931(99)00013-7; Singh SK, 1999, BIOCHEMISTRY-US, V38, P14906, DOI 10.1021/bi991615f; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	11	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					667	668		10.1038/35047165	http://dx.doi.org/10.1038/35047165			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130060				2022-12-28	WOS:000165815200034
J	Hostetler, SW; Clark, PU				Hostetler, SW; Clark, PU			Tropical climate at the last glacial maximum inferred from glacier mass-balance modeling	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; CORDILLERA BLANCA; CARBON-DIOXIDE; PERU; PALEOCLIMATE; OCEAN; ATMOSPHERE; ANDES	Model-derived equilibrium line altitudes (ELAs) of former tropical glaciers support arguments, based on other paleoclimate data, for both the magnitude and spatial pattern of terrestrial cooling in the tropics at the last glacial maximum (LGM). Relative to the present, LGM ELAs were maintained by air temperatures that were 3.5 degrees to 6.6 degreesC Lower and precipitation that ranged from 63% wetter in Hawaii to 25% drier on Mt. Kenya, Africa. Our results imply the need for a similar to3 degreesC cooling of LGM sea surface temperatures in the western Pacific warm pool. Sensitivity tests suggest that LGM ELAs could have persisted until 16,000 years before the present in the Peruvian Andes and on Papua, New Guinea.	Oregon State Univ, Dept Geosci, US Geol Survey, Corvallis, OR 97331 USA	Oregon State University; United States Department of the Interior; United States Geological Survey	Hostetler, SW (corresponding author), Oregon State Univ, Dept Geosci, US Geol Survey, Corvallis, OR 97331 USA.							ALLISON I, 1976, EQUATORIAL GLACIERS, P27; Broecker WS, 1997, GLOBAL BIOGEOCHEM CY, V11, P589, DOI 10.1029/97GB02267; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; *CLIMAP MEMB, 1981, GEOL SOC AM MAP CHAR, V3; Crowley TJ, 2000, CLIM DYNAM, V16, P241, DOI 10.1007/s003820050325; Diaz HF, 1996, NATURE, V383, P152, DOI 10.1038/383152a0; DORMAN JL, 1989, J APPL METEOROL, V28, P833, DOI 10.1175/1520-0450(1989)028<0833:AGCOAR>2.0.CO;2; Downie C., 1972, GEOLOGY KILIMANJARO; Farrera I, 1999, CLIM DYNAM, V15, P823, DOI 10.1007/s003820050317; GALLOWAY RW, 1973, PALAEOECOL AFR, V8, P125; Ganopolski A, 1998, NATURE, V391, P351, DOI 10.1038/34839; Hastenrath S, 1997, J GLACIOL, V43, P455, DOI 10.3189/S0022143000035048; HASTENRATH S, 1995, J GEOPHYS RES-ATMOS, V100, P5105, DOI 10.1029/94JD03108; Hastenrath S., 1984, GLACIERS EQUATORIAL; HOFFMAN JAJ, 1975, CLIMATIC ATLAS S AM; Hostetler SW, 1999, NATURE, V399, P673, DOI 10.1038/21401; Hotchkiss S, 1999, QUATERNARY RES, V52, P115, DOI 10.1006/qres.1999.2052; JOHANNESSON T, 1995, J GLACIOL, V41, P345, DOI 10.3189/S0022143000016221; JOLEY D, 1997, SCIENCE, V276, P786; Kaser G, 1997, ANN GLACIOL-SER, V24, P344, DOI 10.1017/S0260305500012428; Klein AG, 1999, QUATERNARY SCI REV, V18, P63, DOI 10.1016/S0277-3791(98)00095-X; Kutzbach J, 1998, QUATERNARY SCI REV, V17, P473, DOI 10.1016/S0277-3791(98)00009-2; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Lee KE, 1999, NATURE, V397, P512, DOI 10.1038/17357; Lu┬ffer, 1972, Z GEOMORPHOL, V13, P32; Marshall SJ, 1999, CLIM DYNAM, V15, P533, DOI 10.1007/s003820050298; Mix AC, 1999, PALEOCEANOGRAPHY, V14, P350, DOI 10.1029/1999PA900012; NIX HA, 1972, BRIDGE BARRIER NATUR; Osmaston HA, 1989, QUATERNARY ENV RES E, V1, P31; Pinot S, 1999, CLIM DYNAM, V15, P857, DOI 10.1007/s003820050318; Pollard D, 2000, GLOBAL PLANET CHANGE, V24, P79, DOI 10.1016/S0921-8181(99)00071-5; PORTER SC, 1977, SCIENCE, V195, P61, DOI 10.1126/science.195.4273.61; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; SELTZER GO, 1990, QUATERNARY SCI REV, V9, P137, DOI 10.1016/0277-3791(90)90015-3; StreetPerrott FA, 1997, SCIENCE, V278, P1422, DOI 10.1126/science.278.5342.1422; THOMPSON LG, 1984, J GEOPHYS RES-ATMOS, V89, P4638, DOI 10.1029/JD089iD03p04638; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; Wagnon P, 1999, GLOBAL PLANET CHANGE, V22, P49, DOI 10.1016/S0921-8181(99)00025-9; Weaver AJ, 1998, NATURE, V394, P847, DOI 10.1038/29695	39	58	60	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1747	1750		10.1126/science.290.5497.1747	http://dx.doi.org/10.1126/science.290.5497.1747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099409				2022-12-28	WOS:000165632400037
J	Simons, K; Ikonen, E				Simons, K; Ikonen, E			Cell biology - How cells handle cholesterol	SCIENCE			English	Review							NIEMANN-PICK C1; BINDING CASSETTE TRANSPORTER-1; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; TANGIER-DISEASE; GOLGI-APPARATUS; PROTEIN; SECRETION; CAVEOLAE; TRAFFICKING	Cholesterol plays an indispensable role in regulating the properties of cell membranes in mammalian cells. Recent advances suggest that cholesterol exerts many of its actions mainly by maintaining sphingolipid rafts in a functional state. How rafts contribute to cholesterol metabolism and transport in the cell is still an open issue. It has Long been known that cellular cholesterol Levels are precisely controlled by biosynthesis, efflux from cells, and influx of Lipoprotein cholesterol into cells. The regulation of cholesterol homeostasis is now receiving a new focus, and this changed perspective may throw Light on diseases caused by cholesterol excess, the prime example being atherosclerosis.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Natl Publ Hlth Inst, Dept Biochem, Helsinki 00300, Finland	Max Planck Society; Finland National Institute for Health & Welfare	Simons, K (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr, D-01307 Dresden, Germany.			Simons, Kai/0000-0002-9231-9996				ALPY F, IN PRESS J BIOL CHEM; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRASAEMLE DL, 1988, J LIPID RES, V29, P481; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; BRUGGER B, IN PRESS J CELL BIOL; Cohen DE, 1999, CURR OPIN LIPIDOL, V10, P295, DOI 10.1097/00041433-199908000-00002; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Elferink RPJO, 1999, GASTROENTEROL CLIN N, V28, P59; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, J LIPID RES, V38, P1503; Fivaz M, 1999, TRENDS CELL BIOL, V9, P212, DOI 10.1016/S0962-8924(99)01567-6; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Keller P, 1997, J CELL SCI, V110, P3001; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Kuwabara PE, 2000, GENE DEV, V14, P1933; Laitinen S, 1999, J LIPID RES, V40, P2204; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 1999, J LIPID RES, V40, P2264; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Liscum L, 2000, TRAFFIC, V1, P218, DOI 10.1034/j.1600-0854.2000.010304.x; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PELKMANS L, COMMUNICATION; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Remaley AT, 1998, J LIPID RES, V39, P1231; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; SCHMITZ G, 1991, J LIPID RES, V32, P1539; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sturley SL, 1997, CURR OPIN LIPIDOL, V8, P167, DOI 10.1097/00041433-199706000-00007; Sym M, 2000, CURR BIOL, V10, P527, DOI 10.1016/S0960-9822(00)00468-1; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAZ WLC, 1993, CURR OPIN STRUC BIOL, V3, P482, DOI 10.1016/0959-440X(93)90071-R; Vogel U, 1998, J CELL SCI, V111, P825; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; Zimmerberg J, 2000, TRAFFIC, V1, P366, DOI 10.1034/j.1600-0854.2000.010409.x	86	1023	1049	2	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1721	1726		10.1126/science.290.5497.1721	http://dx.doi.org/10.1126/science.290.5497.1721			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099405				2022-12-28	WOS:000165632400033
J	Jha, A				Jha, A			Britain turns its attention to nanotech transfer	NATURE			English	Article									Res Fortnight, London, England		Jha, A (corresponding author), Res Fortnight, London, England.								0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					620	621		10.1038/35046280	http://dx.doi.org/10.1038/35046280			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117754				2022-12-28	WOS:000165548600131
J	Schneider, DJ; Reid, JS				Schneider, DJ; Reid, JS			Gas gangrene associated with occult cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Penn State Univ, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Schneider, DJ (corresponding author), Penn State Univ, Hershey, PA 17033 USA.								0	2	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1615	1615		10.1056/NEJM200011303432205	http://dx.doi.org/10.1056/NEJM200011303432205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096169				2022-12-28	WOS:000165511000005
J	Smaglik, P				Smaglik, P			US industry starts to think big by acting small	NATURE			English	Article																			0	0	0	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					621	622		10.1038/35046285	http://dx.doi.org/10.1038/35046285			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117755				2022-12-28	WOS:000165548600133
J	Stern, D; Eisenhardt, P; Spinrad, H; Dawson, S; van Breugel, W; Dey, A; de Vries, W; Stanford, SA				Stern, D; Eisenhardt, P; Spinrad, H; Dawson, S; van Breugel, W; Dey, A; de Vries, W; Stanford, SA			Evidence against a redshift z > 6 for the galaxy STIS123627+621755	NATURE			English	Article							LUMINOSITY DENSITY; WHITE-DWARF; FIELD; UNIVERSE	The identification of galaxies at extreme distances provides the most direct information about the earliest phases of galaxy formation. But at redshifts z>5 even the most luminous galaxies appear faint; the interpretation of low signal-to-noise ratio data is difficult and misidentifications do occur. Here we report optical and near-infrared observations of the source STIS123627+621755, which was previously suggested to be at a redshift of 6.68 (ref. 1). At that redshift, and with the reported 1 spectral energy distribution, the galaxy should be essentially invisible at wavelengths less than 9,300 Angstrom, because the intervening intergalactic medium absorbs almost all light energetic enough to ionize neutral hydrogen-that is, with wavelengths less than the redshifted Lyman limit of lambda = (1 + z) x 912 Angstrom. At near-infrared wavelengths, however, the galaxy should be relatively bright. Here we report a detection of the galaxy at 6,700 Angstrom and a non-detection at a wavelength of 1.2 mum, contrary to expectations for z approximate to 6.68. The data conservatively require that STIS123627+621755 has a redshift z< 6.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA; Kitt Peak Natl Observ, Natl Opt Astron Observ, Tucson, AZ 85726 USA; Univ Calif Davis, Dept Phys, Davis, CA 95616 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; National Optical Astronomy Observatory; University of California System; University of California Davis	Dawson, S (corresponding author), CALTECH, Jet Prop Lab, Mail Stop 169-327, Pasadena, CA 91109 USA.	stern@zwolfkinder.jpl.nasa.gov		Stern, Daniel/0000-0003-2686-9241; de Vries, Willem/0000-0003-2760-1669				ADELBERGER KL, IN PRESS ASTROPHYS J; ADELBERGER KL, 2000, ASTROPH0001126; Barger AJ, 1999, ASTRON J, V117, P102, DOI 10.1086/300675; Chen MC, 1999, TRANSPLANTATION, V68, P586, DOI 10.1097/00007890-199908270-00026; Harris HC, 1999, ASTROPHYS J, V524, P1000, DOI 10.1086/307856; Hogg DW, 1998, ASTROPHYS J, V504, P622, DOI 10.1086/306122; Leitherer C, 1999, ASTROPHYS J SUPPL S, V123, P3, DOI 10.1086/313233; MADAU P, 1995, ASTROPHYS J, V441, P18, DOI 10.1086/175332; MATTHEWS K, 1994, ASTROPHYS SPACE SC L, V190, P239; OKE JB, 1995, PUBL ASTRON SOC PAC, V107, P375, DOI 10.1086/133562; RUIZ MT, 1995, ASTROPHYS J, V455, pL159, DOI 10.1086/309845; Steidel CC, 1999, ASTROPHYS J, V519, P1, DOI 10.1086/307363; Steidel CC, 1996, ASTROPHYS J, V462, pL17, DOI 10.1088/1538-4357/462/1/L17; Stern D, 2000, ASTROPHYS J, V537, P73, DOI 10.1086/309001; Stern D, 2000, ASTROPHYS J, V533, pL75, DOI 10.1086/312614; Stockton A, 1998, ASTRON J, V115, P1340, DOI 10.1086/300298; Williams RE, 1996, ASTRON J, V112, P1335, DOI 10.1086/118105; [No title captured]	18	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					560	562		10.1038/35046027	http://dx.doi.org/10.1038/35046027			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117737	Green Submitted			2022-12-28	WOS:000165548600110
J	Deliens, L; Mortier, F; Bilsen, J; Cosyns, M; Vander Stichele, R; Vanoverloop, J; Ingels, K				Deliens, L; Mortier, F; Bilsen, J; Cosyns, M; Vander Stichele, R; Vanoverloop, J; Ingels, K			End-of-life decisions in medical practice in Flanders, Belgium: a nationwide survey	LANCET			English	Article							PHYSICIAN-ASSISTED SUICIDE; MAIL SURVEYS; EUTHANASIA; NETHERLANDS	Background Our study is a repeat of the Dutch death-certificate study on end-of-life decisions (ELDs). The main objective was to estimate the frequency of euthanasia (the administration of lethal drugs with the explicit intention of shortening the patient's life at the patient's explicit request), physician-assisted suicide (PAS), and other ELDs in medical practice in Flanders, Belgium. Methods A 20% random sample of 3999 deaths was selected from all deaths recorded between Jan 1 and April 30, 1998. The physicians who signed the corresponding death certificates received one questionnaire by post per death. Findings The physicians' response rate was 1355 (52%). 1925 deaths were described. The results were corrected for non-response bias, and extrapolated to estimated annual rates after seasonal adjustment for death causes, and we estimate that 705 (1.3%, 95% CI 1.0-1.6) deaths resulted from euthanasia or PAS. In 1796 (3.2%, 2.7-3.8) cases, lethal drugs were given without the explicit request of the patient. Alleviation of pain and symptoms with opioids in doses with a potential life-shortening effect preceded death in 10 416 (18.5%, 17.3-19.7) cases and non-treatment decisions in 9218 (16.4%, 15.3-17.5) cases, of which 3261 (5.8%, 5.1-6.5) with the explicit intention of ending the patient's life. Interpretation ELDs are prominent in medical practice in Flanders. The frequency of deaths preceded by an ELD is similar to that in the Netherlands, but lower than that in Australia. However, in Flanders the rate of administration of lethal drugs to patients without their explicit request is similar to Australia, and significantly higher than that in the Netherlands.	Free Univ Brussels, Dept Med Sociol & Hlth Sci, B-1090 Brussels, Belgium; State Univ Ghent, Ctr Environm Philosophy & Bioeth, B-9000 Ghent, Belgium; State Univ Ghent, Dept Gen Practice, B-9000 Ghent, Belgium; Flemish Inst Gen Practice, Antwerp, Belgium; Minist Flanders, Prevent & Social Hlth Care Div, Brussels, Belgium; Catholic Univ Nijmegen, Acad Hosp, Nijmegen, Netherlands	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Ghent University; Radboud University Nijmegen	Deliens, L (corresponding author), Free Univ Brussels, Dept Med Sociol & Hlth Sci, Laarbeeklaan 103, B-1090 Brussels, Belgium.		Stichele, Robert Vander/K-7203-2015; Ingels, K.J.A.O./L-4404-2015	Stichele, Robert Vander/0000-0001-9118-9651; Mortier, Freddy/0000-0002-5390-3508; Deliens, Luc/0000-0002-8158-2422				Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; BERNARD HR, 1984, ANNU REV ANTHROPOL, V13, P495, DOI 10.1146/annurev.an.13.100184.002431; DELIENS L, 1991, NUISARTS NU, V20, P113; DILLMAN DA, 1991, ANNU REV SOCIOL, V17, P225, DOI 10.1146/annurev.so.17.080191.001301; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Jochemsen H, 1999, J MED ETHICS, V25, P16, DOI 10.1136/jme.25.1.16; Kaner EF, 1998, BRIT J GEN PRACT, V48, P1067; KEOWN J, 1995, EUTHANASIA EXAMINED, P261; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; LEMESHOW S, 1992, ADEQUACY SAMPLE SIZE, P1; MCCULLAGH P, 1994, GEN LINEAR MODELS, P72; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Mortier F, 2000, BIOETHICS, V14, P254, DOI 10.1111/1467-8519.00195; *NAT RAAD ORD GEN, 1997, TIJDSCHR NAT RAAD OR, V7, P27; *RAADG COM BIOETH, 1998, BIOETHIC BELG    MAY, P2; SIBBALD B, 1998, BR J GE PRACT, V48, P1067; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; [No title captured]	19	225	227	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1806	1811		10.1016/S0140-6736(00)03233-5	http://dx.doi.org/10.1016/S0140-6736(00)03233-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	377UY	11117913				2022-12-28	WOS:000165545700012
J	Imai, K; Matsuyama, S; Miyake, S; Suga, K; Nakachi, K				Imai, K; Matsuyama, S; Miyake, S; Suga, K; Nakachi, K			Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population	LANCET			English	Article							KILLER-CELL-ACTIVITY; DRINKING GREEN TEA; NK CELLS; JAPANESE POPULATION; GROWTH; MICE	Background One of the most critical questions in immunosurveillance is whether differences between individuals with regards to natural immunological host defence can predict future development of cancer. Although this question has so far remained open, there are clear indications of significant roles of several naturally cytotoxic lymphocytes in preventing the development of cancer. We began a prospective cohort study among a Japanese general population in 1986, using various immunological and biochemical markers. Methods Natural cytotoxic activity of peripheral-blood mononuclear cells was assessed by isotope-release assay in 3625 residents of a Japanese population mostly older than 40 years of age, between 1986 and 1990. Immunological and biochemical markers were also measured, and participants were given a questionnaire on lifestyle. We did an Ii-year follow-up survey of the cohort members looking at cancer incidence and death from all causes, and analysed the association between cytotoxic activity of peripheral-blood lymphocytes assessed at baseline and cancer incidence found in the subsequent follow-up. Findings 154 cancer cases were used in the analysis. When we categorised the cytotoxic activity of peripheral-blood lymphocytes by tertiles, age-adjusted relative risk of cancer incidence (all sites) was 0.72 (95% CI 0.45-1.16) for men with high cytotoxic activity, and 0.62 (0.38-1.03) for men with medium cytotoxic activity, taking the risk of those with low cytotoxic activity as reference. For women with high cytotoxic activity relative risk was 0.52 (0.28-0.95), and for those with medium cytotoxic activity 0.56 (0.31-1.01). For both sexes with high and medium cytotoxic activity risk was 0.63 (0.43-0.92) and 0.59 (0.40-0.87), respectively. Interpretation Our results indicate that medium and high cytotoxic activity of peripheral-blood lymphocytes is associated with reduced cancer risk, whereas low activity is associated with increased cancer risk suggesting a role for natural immunological host defence mechanisms against cancer.	Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan		Nakachi, K (corresponding author), Saitama Canc Ctr, Res Inst, 818 Komuro, Ina, Saitama 3620806, Japan.		wang, edwin/G-5372-2010					Brittenden J, 1996, CANCER-AM CANCER SOC, V77, P1226, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1226::AID-CNCR2>3.0.CO;2-G; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; GORELIK E, 1982, INT J CANCER, V30, P107, DOI 10.1002/ijc.2910300118; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HERBERMAN RB, 1983, PROGR IMMUNOLOGY, V5, P1157; HERSEY P, 1979, BRIT J CANCER, V40, P113, DOI 10.1038/bjc.1979.147; IMAI K, 1995, BRIT MED J, V310, P693, DOI 10.1136/bmj.310.6981.693; Imai K, 1997, PREV MED, V26, P769, DOI 10.1006/pmed.1997.0242; Kawano T, 1998, P NATL ACAD SCI USA, V95, P5690, DOI 10.1073/pnas.95.10.5690; Moretta A, 1997, CELL, V90, P13, DOI 10.1016/S0092-8674(00)80309-8; Moretta A, 2000, IMMUNOL TODAY, V21, P228, DOI 10.1016/S0167-5699(00)01596-6; NAKACHI K, 1992, JPN J CANCER RES, V83, P798, DOI 10.1111/j.1349-7006.1992.tb01983.x; NAKACHI K, 1993, CANCER RES, V53, P2994; NAKAJIMA T, 1987, JPN J CLIN ONCOL, V17, P327; PENN I, 1977, TRANSPLANT P, V9, P1121; PROSS HF, 1982, INT J CANCER, V29, P383, DOI 10.1002/ijc.2910290404; PROSS HF, 1993, NAT IMMUN, V12, P279; RODER JC, 1980, NATURE, V284, P553, DOI 10.1038/284553a0; SCHANTZ SP, 1986, JNCI-J NATL CANCER I, V77, P869; STRAYER DR, 1984, CANCER RES, V44, P370; SULLIVAN JL, 1980, SCIENCE, V210, P543, DOI 10.1126/science.6158759; TALMADGE JE, 1980, NATURE, V284, P622, DOI 10.1038/284622a0	22	752	780	2	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1795	1799		10.1016/S0140-6736(00)03231-1	http://dx.doi.org/10.1016/S0140-6736(00)03231-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117911				2022-12-28	WOS:000165545700010
J	Bertram, L; Blacker, D; Mullin, K; Keeney, D; Jones, J; Basu, S; Yhu, S; McInnis, MG; Go, RCP; Vekrellis, K; Selkoe, DJ; Saunders, AJ; Tanzi, RE				Bertram, L; Blacker, D; Mullin, K; Keeney, D; Jones, J; Basu, S; Yhu, S; McInnis, MG; Go, RCP; Vekrellis, K; Selkoe, DJ; Saunders, AJ; Tanzi, RE			Evidence for genetic linkage of Alzheimer's disease to chromosome 10q	SCIENCE			English	Article							ONSET	Recent studies suggest that insulin-degrading enzyme (IDE) in neurons and microglia degrades A beta, the principal component of beta -amyloid and one of the neuropathological hallmarks of Alzheimer's disease (AD). We performed parametric and nonparametric linkage analyses of seven genetic markers on chromosome 10q, six of which map near the IDE gene, in 435 multiplex AD families. These analyses revealed significant evidence of linkage for adjacent markers (D10S1671, D10S583, D10S1710, and D10S566), which was most pronounced in late-onset families. Furthermore, we found evidence for allele-specific association between the putative disease locus and marker D10S583, which has recently been located within 195 kilobases of the IDE gene.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Genet & Aging Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Gerontol Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Johns Hopkins Univ, Inst Med, Dept Psychiat, Baltimore, MD 21287 USA; Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Tanzi, RE (corresponding author), Massachusetts Gen Hosp E, Genet & Aging Unit, 149 13th St, Charlestown, MA 02129 USA.		Bertram, Lars/K-3889-2015; McInnis, Melvin G/F-6963-2012; Tanzi, Rudolph/AAE-9622-2019	Bertram, Lars/0000-0002-0108-124X; McInnis, Melvin G/0000-0002-0375-6247; Tanzi, Rudolph/0000-0002-7032-1454; Saunders, Aleister/0000-0002-7298-7823				Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; *GENB, AL356128 GENB; Hauser ER, 1997, AM J HUM GENET, V61, pA278; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; MYERS AJ, 2000, NEUROBIOL AGING S, V21, pS103; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Roberts SB, 1999, AM J HUM GENET, V65, P876, DOI 10.1086/302528; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Vekrellis K, 2000, J NEUROSCI, V20, P1657	13	424	457	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2302	+		10.1126/science.290.5500.2302	http://dx.doi.org/10.1126/science.290.5500.2302			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125142				2022-12-28	WOS:000165995800042
J	Wohlschlegel, JA; Dwyer, BT; Dhar, SK; Cvetic, C; Walter, JC; Dutta, A				Wohlschlegel, JA; Dwyer, BT; Dhar, SK; Cvetic, C; Walter, JC; Dutta, A			Inhibition of eukaryotic DNA replication by geminin binding to Cdt1	SCIENCE			English	Article							S-PHASE; MITOSIS; PHOSPHORYLATION; YEAST; COMPLEX; NUCLEUS; CDC6; CDK	In all eukaryotic organisms, inappropriate firing of replication origins during the G(2) phase of the cell cycle is suppressed by cyclin-dependent kinases. Multicellular eukaryotes contain a second putative inhibitor of re-replication called geminin, Geminin is believed to block binding of the mini-chromosome maintenance (MCM) complex to origins of replication, but the mechanism of this inhibition is unclear. Here we show that geminin interacts tightly with Cdt1, a recently identified replication initiation factor necessary for MCM Loading. The inhibition of DNA replication by geminin that is observed in cell-free DNA replication extracts is reversed by the addition of excess Cdt1. In the normal cell cycle, Cdt1 is present only in G(1) and S, whereas geminin is present in S and G(2) phases of the cell cycle. Together, these results suggest that geminin inhibits inappropriate origin firing by targeting Cdt1.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Walter, Johannes/0000-0002-4186-7570	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; TADA S, IN PRESS NATURE CELL; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Whittaker AJ, 2000, GENE DEV, V14, P1765; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	20	575	590	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2309	+		10.1126/science.290.5500.2309	http://dx.doi.org/10.1126/science.290.5500.2309			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125146				2022-12-28	WOS:000165995800046
J	Marx, SJ				Marx, SJ			Medical progress - Hyperparathyroid and hypoparathyroid disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC-RENAL-FAILURE; HORMONE-RELATED PEPTIDE; TUMOR-SUPPRESSOR GENE; VITAMIN-D-RECEPTOR; FAMILIAL ISOLATED HYPERPARATHYROIDISM; EXTRACELLULAR CA2+-SENSING RECEPTOR; ENDOCRINE NEOPLASIA TYPE-1; BONE-MINERAL DENSITY; PARATHYROID-HORMONE; SECONDARY HYPERPARATHYROIDISM		NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Marx, SJ (corresponding author), NIDDKD, Metab Dis Branch, NIH, Bldg 10,Rm 9C-101,9000 Rockville Pike, Bethesda, MD 20892 USA.	StephenM@intra.niddk.nih.gov						Abdelhadi M, 1998, J CLIN ENDOCR METAB, V83, P3845, DOI 10.1210/jc.83.11.3845; Agarwal SK, 1998, CANCER GENET CYTOGEN, V106, P30, DOI 10.1016/S0165-4608(98)00049-1; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Antonsen JE, 1998, KIDNEY INT, V53, P223, DOI 10.1046/j.1523-1755.1998.00735.x; ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890; ARNOLD A, IN PRESS PARATHYROID; Bacchini G, 1997, NEPHRON, V77, P267, DOI 10.1159/000190286; Bendz H, 1996, J INTERN MED, V240, P357, DOI 10.1046/j.1365-2796.1996.28864000.x; BILEZIKIAN JP, PARATHYROIDS BASIC C; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Brown DL, 1999, J CLIN PHARMACOL, V39, P651, DOI 10.1177/00912709922008272; Brown EM, 1999, VITAM HORM, V55, P1; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; BROWN EM, 1981, J CLIN ENDOCR METAB, V52, P1046, DOI 10.1210/jcem-52-5-1046; Brown SB, 2000, J CLIN ENDOCR METAB, V85, P868, DOI 10.1210/jc.85.2.868; Burney RE, 1999, SURGERY, V125, P608, DOI 10.1067/msy.1999.98023; Carling T, 2000, J CLIN ENDOCR METAB, V85, P2042, DOI 10.1210/jc.85.5.2042; CHAN AK, 1995, ANN SURG, V222, P402, DOI 10.1097/00000658-199509000-00017; Chen H, 1998, WORLD J SURG, V22, P531, DOI 10.1007/s002689900431; CHOREV M, IN PRESS PARATHYROID; Christiansen P, 1999, BONE, V25, P589, DOI 10.1016/S8756-3282(99)00207-0; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; CRYNS VL, 1994, J CLIN ENDOCR METAB, V78, P1320, DOI 10.1210/jc.78.6.1320; DAVIES SJ, 1993, J MED GENET, V30, P101, DOI 10.1136/jmg.30.2.101; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; Dempster DW, 1999, J CLIN ENDOCR METAB, V84, P1562, DOI 10.1210/jc.84.5.1562; DING C, 2000, 82 ANN M END SOC TOR, P409; Farnebo F, 1999, J CLIN ENDOCR METAB, V84, P3775, DOI 10.1210/jc.84.10.3775; Grey AB, 1996, ANN INTERN MED, V125, P360, DOI 10.7326/0003-4819-125-5-199609010-00002; Hampl H, 1999, MINER ELECTROL METAB, V25, P161, DOI 10.1159/000057440; Hasnain M, 1999, ASAIO J, V45, P424, DOI 10.1097/00002480-199909000-00011; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Hoff AO, 2000, ANNU REV PHYSIOL, V62, P377, DOI 10.1146/annurev.physiol.62.1.377; Horandner HH, 1997, NIEREN HOCHDRUCK, V26, P319; HOSOKAWA Y, 1995, J CLIN ENDOCR METAB, V80, P3107, DOI 10.1210/jc.80.11.3107; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; Imanishi Y, 1999, J BONE MINER RES, V14, pS446; Indridason OS, 2000, KIDNEY INT, V57, P282, DOI 10.1046/j.1523-1755.2000.00819.x; Irvin GL, 1999, ANN SURG, V229, P874, DOI 10.1097/00000658-199906000-00015; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; Jaskowiak N, 1996, ANN SURG, V224, P308, DOI 10.1097/00000658-199609000-00007; John MR, 1999, J CLIN ENDOCR METAB, V84, P4287, DOI 10.1210/jc.84.11.4287; Juppner H, 1999, BONE, V25, P87, DOI 10.1016/S8756-3282(99)00110-6; JUPPNER H, IN PRESS ENDOCRINOLO; KAO PC, 1992, MAYO CLIN PROC, V67, P637, DOI 10.1016/S0025-6196(12)60717-4; Kassem M, 2000, J CLIN ENDOCR METAB, V85, P165, DOI 10.1210/jc.85.1.165; Kerby JD, 1998, ANN SURG, V227, P878, DOI 10.1097/00000658-199806000-00011; Khosla S, 1999, J BONE MINER RES, V14, P1700, DOI 10.1359/jbmr.1999.14.10.1700; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Lepage R, 1998, CLIN CHEM, V44, P805; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; Liu J, 2000, J CLIN INVEST, V106, P1167, DOI 10.1172/JCI10431; Loghman-Adham M, 1999, PEDIATR NEPHROL, V13, P701, DOI 10.1007/s004670050685; Low RA, 1998, HEAD NECK-J SCI SPEC, V20, P583, DOI 10.1002/(SICI)1097-0347(199810)20:7<583::AID-HED1>3.0.CO;2-X; Lundgren E, 1997, SURGERY, V121, P287, DOI 10.1016/S0039-6060(97)90357-3; Malberti F, 1999, NEPHROL DIAL TRANSPL, V14, P2398, DOI 10.1093/ndt/14.10.2398; MALKIN D, IN PRESS METABOLIC M, V10; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P447, DOI 10.1016/S0165-6147(99)01400-5; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; Marx SJ, 1999, J CLIN ENDOCR METAB, V84, P3001, DOI 10.1210/jc.84.9.3001; Masciullo V, 2000, INT J ONCOL, V17, P897; Michelangeli VP, 1997, ANN CLIN BIOCHEM, V34, P97, DOI 10.1177/000456329703400115; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mucsi I, 1999, AM J MED SCI, V317, P405, DOI 10.1097/00000441-199906000-00009; NAVEHMANY T, 1995, J CLIN INVEST, V96, P1786, DOI 10.1172/JCI118224; Norman J, 1998, AM SURGEON, V64, P391; Novelli A, 1999, MOL CELL PROBE, V13, P303, DOI 10.1006/mcpr.1999.0252; Parfitt AM, 1997, KIDNEY INT, V52, P3, DOI 10.1038/ki.1997.297; Pattou F, 1999, SURGERY, V126, P1123, DOI 10.1067/msy.2099.101579; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; POTTS JT, 1991, ANN INTERN MED, V114, P593, DOI 10.7326/0003-4819-114-7-593; Ryan JA, 1997, AM J SURG, V173, P441, DOI 10.1016/S0002-9610(97)00074-3; Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; SCHNEIDER AB, 1995, J CLIN ENDOCR METAB, V80, P254, DOI 10.1210/jc.80.1.254; Schuffenecker I, 1998, J CLIN ENDOCR METAB, V83, P487, DOI 10.1210/jc.83.2.487; Shan L, 1999, JPN J CANCER RES, V90, P965, DOI 10.1111/j.1349-7006.1999.tb00842.x; SHAWKER TH, 2000, ULTRASOUND Q, V16, P73; SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64; Silverberg SJ, 1996, J CLIN ENDOCR METAB, V81, P4007, DOI 10.1210/jc.81.11.4007; Silverberg SJ, 1997, NEW ENGL J MED, V337, P1506, DOI 10.1056/NEJM199711203372104; Silverberg SJ, 1999, NEW ENGL J MED, V341, P1249, DOI 10.1056/NEJM199910213411701; Silverberg SJ, 2000, NEW ENGL J MED, V342, P144; SOLAL MEC, 1991, J CLIN ENDOCR METAB, V73, P516, DOI 10.1210/jcem-73-3-516; Spiegel AM, 1996, J CLIN ENDOCR METAB, V81, P2434, DOI 10.1210/jc.81.7.2434; Stefenelli T, 1997, J CLIN ENDOCR METAB, V82, P106, DOI 10.1210/jc.82.1.106; STOCK JL, PARATHYROIDS BASIC C; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Sunthornthepvarakul T, 1999, J CLIN ENDOCR METAB, V84, P3792, DOI 10.1210/jc.84.10.3792; SZABO J, 1995, AM J HUM GENET, V56, P944; Tahara H, 1996, CANCER RES, V56, P599; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2114, DOI 10.1210/jc.83.6.2114; Tominaga Y, 1999, AM J MED SCI, V317, P390, DOI 10.1097/00000441-199906000-00007; Torres A, 1998, NEPHROL DIAL TRANSPL, V13, P94, DOI 10.1093/ndt/13.suppl_3.94; Usdin TB, 1999, NAT NEUROSCI, V2, P941, DOI 10.1038/14724; WANG M, 1995, AM J KIDNEY DIS, V26, P836, DOI 10.1016/0272-6386(95)90453-0; Wei JP, 1997, AM SURGEON, V63, P1097; Wermers RA, 1998, AM J MED, V104, P115, DOI 10.1016/S0002-9343(97)00270-2; Wermers RA, 1997, ANN INTERN MED, V126, P433, DOI 10.7326/0003-4819-126-6-199703150-00003; Williamson C, 1999, J BONE MINER RES, V14, P230, DOI 10.1359/jbmr.1999.14.2.230; Winer KK, 1996, JAMA-J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; Zhang P, 1998, J CLIN ENDOCR METAB, V83, P3365, DOI 10.1210/jc.83.9.3373	111	309	333	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1863	1875		10.1056/NEJM200012213432508	http://dx.doi.org/10.1056/NEJM200012213432508			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117980				2022-12-28	WOS:000165940400008
J	Schrag, D; Cramer, LD; Bach, PB; Cohen, AM; Warren, JL; Begg, CB				Schrag, D; Cramer, LD; Bach, PB; Cohen, AM; Warren, JL; Begg, CB			Influence of hospital procedure volume on outcomes following surgery for colon cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; COLORECTAL-CANCER; PATIENT OUTCOMES; ADMINISTRATIVE DATA; MEDICARE PATIENTS; BREAST-CANCER; RECTAL-CANCER; HEALTH-CARE; MORTALITY; QUALITY	Context Survival following high-risk cancer surgery, such as pancreatectomy and esophagectomy, is superior at hospitals where high volumes of these procedures are per formed. Conflicting evidence exists as to whether the association between hospital experience and favorable health outcomes also applies to more frequently performed operations, such as those for colon cancer. Objective To determine whether hospital procedure volume predicts survival following colon cancer surgery. Design, Setting, and Participants Retrospective cohort study of data from the Surveillance, Epidemiology and End Results-Medicare linked database on 27986 colon cancer patients aged 65 years and older who had surgical resection for primary adenocarcinoma diagnosed between 1991 and 1996. Main Outcome Measures Thirty-day postoperative mortality and overall and cancer-specific long-term survival, by hospital procedure volume. Results We found small differences in 30-day postoperative mortality for patients treated at low- vs high-volume hospitals (3.5% at hospitals in the top-volume quartile vs 5.5% at hospitals in the bottom-volume quartile). However, the correlation was statistically significant and persisted after adjusting for age at diagnosis, sex, race, cancer stage, comorbid illness, socioeconomic status, and acuity of hospitalization (P<.001). The association was evident for subgroups with stage I, II, and III disease. Hospital Volume directly correlated with survival beyond 30 days and also was not attributable to differences in case mix (P<.001). The association between hospital volume and long-term survival was concentrated among patients with stage II and III disease (P<.001 for both). Among stage III patients. Variation in use of adjuvant chemotherapy did not explain this finding. Conclusion Our data suggest that hospital procedure volume predicts clinical outcomes following surgery for colon cancer, although the absolute magnitudes of these differences are modest in comparison with the variation observed for higher-risk cancer surgeries.	Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Hlth Outcomes Res Grp, New York, NY 10021 USA; NCI, Appl Res Branch, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrag, D (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, 1275 York Ave, New York, NY 10021 USA.			Schrag, Deborah/0000-0002-4334-5717				Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Begg MD, 1999, BIOMETRICS, V55, P302, DOI 10.1111/j.0006-341X.1999.00302.x; Birkmeyer JD, 1999, SURGERY, V126, P178, DOI 10.1016/S0039-6060(99)70152-2; Birkmeyer JD, 2000, JAMA-J AM MED ASSOC, V283, P1191, DOI 10.1001/jama.283.9.1191; BURNS LR, 1991, MED CARE, V29, P251, DOI 10.1097/00005650-199103000-00007; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; Gordon TA, 1998, ANN SURG, V228, P71, DOI 10.1097/00000658-199807000-00011; Hannan EL, 1998, STROKE, V29, P2292, DOI 10.1161/01.STR.29.11.2292; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; Hannan EL, 1999, NEW ENGL J MED, V340, P1677, DOI 10.1056/NEJM199905273402112; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; Harmon JW, 1999, ANN SURG, V230, P404, DOI 10.1097/00000658-199909000-00013; Hermanek P, 1996, EUR J SURG ONCOL, V22, P213, DOI 10.1016/S0748-7983(96)80004-7; Hillner BE, 2000, J CLIN ONCOL, V18, P2327, DOI 10.1200/JCO.2000.18.11.2327; Hillner BE, 1998, JAMA-J AM MED ASSOC, V280, P1783, DOI 10.1001/jama.280.20.1783; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; HUGHES RG, 1988, MED CARE, V26, P1057, DOI 10.1097/00005650-198811000-00004; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; LLOYD SS, 1985, JAMA-J AM MED ASSOC, V254, P1330, DOI 10.1001/jama.254.10.1330; Merrill RM, 1999, MED CARE RES REV, V56, P177, DOI 10.1177/107755879905600204; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; Parry JM, 1999, BRIT J SURG, V86, P475, DOI 10.1046/j.1365-2168.1999.01064.x; Percy C., 1990, INT CLASSIFICATION D; Porter GA, 1998, ANN SURG, V227, P157, DOI 10.1097/00000658-199802000-00001; POTOSKY AL, 1993, MED CARE, V31, P732; Riley G, 1985, Health Care Financ Rev, V7, P37; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Roohan PJ, 1998, AM J PUBLIC HEALTH, V88, P454, DOI 10.2105/AJPH.88.3.454; Simons AJ, 1997, DIS COLON RECTUM, V40, P641, DOI 10.1007/BF02140891; Sosa JA, 1998, ANN SURG, V228, P429, DOI 10.1097/00000658-199809000-00016; Yao SL, 1999, J NATL CANCER I, V91, P1950, DOI 10.1093/jnci/91.22.1950	38	405	412	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3028	3035		10.1001/jama.284.23.3028	http://dx.doi.org/10.1001/jama.284.23.3028			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122590				2022-12-28	WOS:000165847200028
J	Reinus, JF; Persky, S; Burkiewicz, JS; Quan, D; Bass, NM; Davern, TJ				Reinus, JF; Persky, S; Burkiewicz, JS; Quan, D; Bass, NM; Davern, TJ			Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	64th Annual Meeting of the American-College-of-Gastroenterology	OCT 17-20, 1999	PHOENIX, AZ	Amer Coll Gastroenterol			ASTHMA; DRUGS	Background: In registration trials, zafirlukast, an asthma medication, caused asymptomatic elevated aminotransferase levels in up to 5% of participants. Until now, however, no cases of severe hepatitis attributed to zafirlukast have been reported. Objective: To report the clinical characteristics of three patients with severe hepatitis due to zafirlukast. Design: Case report. Setting: One community hospital and two university hospitals. Patients: Three middle-aged women taking zafirlukast, 20 mg twice per day. Intervention: Discontinuation of zafirlukast therapy in three patients, steroid therapy in two patients, and orthotopic liver transplantation in one patient. Measurements: Serum aminotransferase and bilirubin levels, standard blood tests for causes of hepatitis other than drug toxicity, and liver biopsy in two patients. Results: Patient 1 recovered spontaneously, had a severe relapse after inadvertent rechallenge with the medication, and ultimately made a complete recovery. Patient 2 developed subfulminant hepatic failure and required liver transplantation. Patient 3 developed severe hepatitis that improved after treatment with corticosteroids. Liver tissue was available from two patients and showed histologic changes commonly associated with drug reactions. Conclusion: Patients receiving zafirlukast may develop severe liver injury and should be observed for signs and symptoms of hepatitis.	Montefiore Med Ctr, Albert Einstein Coll Med, Div Gastroenterol & Hepatol, Bronx, NY 10467 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco	Reinus, JF (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Div Gastroenterol & Hepatol, 111 E 210th St, Bronx, NY 10467 USA.	jreinus@montefiore.org			NIDDK NIH HHS [R-O3 DK52827-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052827] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, pS238, DOI 10.1164/ajrccm.157.6.mar6; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Fish JE, 1997, CLIN THER, V19, P675, DOI 10.1016/S0149-2918(97)80092-6; Fontana RJ, 1999, LIVER TRANSPLANT SUR, V5, P480, DOI 10.1002/lt.500050607; Garcia-Marcos L, 1999, PEDIAT ALLERG IMM-UK, V10, P77, DOI 10.1034/j.1399-3038.1999.00006.x; *MED EC CO, 2000, PHYS DESK REF, P535; WATKINS PB, 1989, J CLIN INVEST, V83, P688, DOI 10.1172/JCI113933; Wechsler ME, 1999, DRUG SAFETY, V21, P241, DOI 10.2165/00002018-199921040-00001; Wenzel SE, 1998, AM J MED, V104, P287, DOI 10.1016/S0002-9343(98)00031-X; [No title captured]; 1999, AM DRUGGIST      FEB, P42	11	46	48	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					964	968		10.7326/0003-4819-133-12-200012190-00011	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	384NT	11119397				2022-12-28	WOS:000165952300004
J	[Anonymous]				[Anonymous]			Results of genetic testing: when confidentiality conflicts with a duty to warn relatives	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	15	15	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	2000	321	7274					1464	1464		10.1136/bmj.321.7274.1464	http://dx.doi.org/10.1136/bmj.321.7274.1464			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110744	Green Published			2022-12-28	WOS:000165852300036
J	The, AM; Hak, T; Koeter, G; van der Wal, G				The, AM; Hak, T; Koeter, G; van der Wal, G			Collusion in doctor-patient communication about imminent death: an ethnographic study	BRITISH MEDICAL JOURNAL			English	Article								Objective To discover and explore the factors that result in "false optimism about recovery" observed in patients with small cell lung cancer. Design A qualitative observational (ethnographic) study in two stages over four years. Setting Lung diseases ward and outpatient clinic in university hospital in the Netherlands. Participants 35 patients with small cell lung cancer. Results "False optimism about recovery" usually developed during the (first) course of chemotherapy and was most prevalent when the cancer could no longer be seen in the x ray pictures. This optimism tended to vanish when the tumour recurred, but it could develop again, though to a lesser extent, during further courses of chemotherapy. Patients gradually found out the facts about their poor prognosis, partly because of physical deterioration and partly through contact with fellow patients who were in a more advanced stage of the illness and were dying. "False optimism about recovery" was the result an association between doctors' activism and patients' adherence to the treatment calendar and to the "recovery plot," which allowed them not to acknowledge explicitly what they should and could know. The doctor did and did net want to pronounce a "death sentence" and the patient did and did not want to hear it. Conclusion Solutions to the problem of collusion between doctor and patient require an active, patient oriented approach from the doctor. Perhaps solutions have to be found outside the doctor-patient relationship itself-for example, by involving "treatment brokers."	Univ Groningen Hosp, Dept Lung Dis, NL-9700 RB Groningen, Netherlands; Vrije Univ Amsterdam, Dept Social Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands	University of Groningen; Vrije Universiteit Amsterdam	The, AM (corresponding author), Vrije Univ Amsterdam, Dept Social Med, Inst Res Extramural Med, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		The, Anne-Mei/AAE-3468-2020; Hak, Tony/A-2227-2009	Hak, Tony/0000-0002-7208-3795				Christakis Nicholas, 1999, DEATH FORETOLD PROPH; Frank AW., 2013, WOUNDED STORYTELLER; Geertz Clifford, 1973, INTERPRETATION CULTU; Leydon GM, 2000, BMJ-BRIT MED J, V320, P909, DOI 10.1136/bmj.320.7239.909; MAYS N, 1995, BRIT MED J, V311, P182, DOI 10.1136/bmj.311.6998.182; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; Nuland S.B., 1994, HOW WE DIE; SCHOU KC, 1999, EXPERIENCING CANC; Smith TJ, 1998, JAMA-J AM MED ASSOC, V279, P1746, DOI 10.1001/jama.279.21.1746; TEH AM, 1997, NURSING DILEMMAS EUT; THE AM, 1999, PALLIATIVE CARE COMM; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709	12	310	310	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1376	1381		10.1136/bmj.321.7273.1376	http://dx.doi.org/10.1136/bmj.321.7273.1376			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11099281	Green Published, Bronze			2022-12-28	WOS:000165720100024
J	Brazelton, TR; Rossi, FMV; Keshet, GI; Blau, HM				Brazelton, TR; Rossi, FMV; Keshet, GI; Blau, HM			From marrow to brain: Expression of neuronal phenotypes in adult mice	SCIENCE			English	Article							DIFFERENTIATION ANTIGENS; PROGENITOR CELLS; OLFACTORY-BULB; BONE-MARROW; IN-VIVO; HETEROKARYONS; ACTIVATION; PLASTICITY; ANTIBODIES; MICROGLIA	After intravascular delivery of genetically marked adult mouse bone marrow into Lethally irradiated normal adult hosts, donor-derived cells expressing neuronal proteins (neuronal phenotypes) developed in the central nervous system. Flow cytometry revealed a population of donor-derived cells in the brain with characteristics distinct from bone marrow. Confocal microscopy of individual cells showed that hundreds of marrow-derived cells in brain sections expressed gene products typical of neurons (NeuN, 200-kilodalton neurofilament, and class III beta -tubulin) and were able to activate the transcription factor CAMP response element-binding protein (CREB). The generation of neuronal phenotypes in the adult brain 1 to 6 months after an adult bone marrow transplant demonstrates a remarkable plasticity of adult tissues with potential clinical applications.	Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Blau, HM (corresponding author), Stanford Univ, Dept Mol Pharmacol, CCSR 4215,269 Campus Dr, Stanford, CA 94305 USA.		Rossi, Fabio MV/B-5587-2013	Rossi, Fabio MV/0000-0002-0368-2620; Keshet, Gilmor/0000-0002-1907-3029	NCI NIH HHS [CA59717] Funding Source: Medline; NIA NIH HHS [AG09521] Funding Source: Medline; NICHD NIH HHS [HD18179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA059717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009521, R37AG009521] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA H, 1990, J NEUROIMMUNOL, V30, P81, DOI 10.1016/0165-5728(90)90055-R; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; HINDS JW, 1968, J COMP NEUROL, V134, P287, DOI 10.1002/cne.901340304; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Liu N, 1999, J BIOL CHEM, V274, P3042, DOI 10.1074/jbc.274.5.3042; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHEPHERD GM, 1972, PHYSIOL REV, V52, P864, DOI 10.1152/physrev.1972.52.4.864; SPEAR BT, 1990, MOL CELL BIOL, V10, P5047, DOI 10.1128/MCB.10.10.5047; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; Vescovi AL, 1999, BRAIN PATHOL, V9, P569, DOI 10.1111/j.1750-3639.1999.tb00542.x; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; WRIGHT WE, 1984, EXP CELL RES, V151, P55, DOI 10.1016/0014-4827(84)90355-0	28	1372	1651	1	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1775	1779		10.1126/science.290.5497.1775	http://dx.doi.org/10.1126/science.290.5497.1775			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099418				2022-12-28	WOS:000165632400046
J	Lyko, F; Ramsahoye, BH; Jaenisch, R				Lyko, F; Ramsahoye, BH; Jaenisch, R			Development - DNA methylation in Drosophila melanogaster	NATURE			English	Article							METHYLTRANSFERASES; 5-METHYLCYTOSINE; ABSENCE; CELLS; RDNA		Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Edinburgh, Western Gen Hosp, Dept Oncol, John Hughes Bennett Lab, Edinburgh EH4 2XU, Midlothian, Scotland; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Edinburgh; Massachusetts Institute of Technology (MIT)	Lyko, F (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Hu, Ruogu/B-2203-2008					ACHWAL CW, 1984, EMBO J, V3, P263, DOI 10.1002/j.1460-2075.1984.tb01795.x; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1485, DOI 10.1093/nar/8.7.1485; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Lyko F, 2000, MECH DEVELOP, V95, P215, DOI 10.1016/S0925-4773(00)00325-7; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; PATEL CV, 1987, ANAL BIOCHEM, V164, P164, DOI 10.1016/0003-2697(87)90381-2; RAE PMM, 1979, NUCLEIC ACIDS RES, V6, P2987, DOI 10.1093/nar/6.9.2987; Ramsahoye BH, 1996, BLOOD, V87, P2065, DOI 10.1182/blood.V87.5.2065.bloodjournal8752065; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	15	338	360	3	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					538	540		10.1038/35046205	http://dx.doi.org/10.1038/35046205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117732				2022-12-28	WOS:000165548600104
J	Schon, JH; Kloc, C; Batlogg, B				Schon, JH; Kloc, C; Batlogg, B			RETRACTED: Superconductivity at 52 K in hole-doped C-60 (Retracted article. See vol 422 pg 93 2003)	NATURE			English	Article; Retracted Publication							ELECTRICAL-RESISTIVITY; VOLUME	Superconductivity in electron-doped C-60 was first observed almost ten years ago. The metallic state and superconductivity result from the transfer of electrons from alkaline or alkaline-earth ions to the C-60 molecule, which is known to be a strong electron acceptor. For this reason, it is very difficult to remove electrons from C-60-yet one might expect to see superconductivity at higher temperatures in hole-doped than in electron-doped C-60, because of the higher density of electronic states in the valence band than in the conduction band. We have used the technique of gate-induced doping in a reld-effect transistor conrguration to introduce signircant densities of holes into C-60. We observe superconductivity over an extended range of hole density, with a smoothly varying transition temperature T-c that peaks at 52 K. By comparison with the well established dependence of T-c on the lattice parameter in electron-doped C-60, we anticipate that T-c values signircantly in excess of 100 K should be achievable in a suitably expanded, hole-doped C-60 lattice.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Batlogg, B (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	batlogg@lucent.com	Kloc, Christian/A-2255-2011					CRESPI VH, 1992, PHYS REV B, V46, P12064, DOI 10.1103/PhysRevB.46.12064; DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270; ERWIN SC, 1992, BUCKMINSTERFULLERENE, P217; Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575; HADDON RC, 1993, PHILOS T ROY SOC A, V343, P53, DOI 10.1098/rsta.1993.0040; HADDON RC, 1995, J MATER CHEM, V5, P1719, DOI 10.1039/jm9950501719; Han JE, 2000, PHYS REV LETT, V84, P1276, DOI 10.1103/PhysRevLett.84.1276; HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0; HEINEY PA, 1992, PHYS REV B, V45, P4544, DOI 10.1103/PhysRevB.45.4544; Hesper R, 2000, PHYS REV LETT, V85, P1970, DOI 10.1103/PhysRevLett.85.1970; HIRSCH JE, 1989, PHYSICA C, V158, P326, DOI 10.1016/0921-4534(89)90225-6; KLEIN O, 1992, PHYS REV B, V46, P11247, DOI 10.1103/PhysRevB.46.11247; Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9; KOCHANSKI GP, 1992, SCIENCE, V255, P184, DOI 10.1126/science.255.5041.184; MAZIN II, 1992, PHYS REV B, V45, P5114, DOI 10.1103/PhysRevB.45.5114; Ramirez A. P., 1994, Superconductivity Review, V1, P1; Reed CA, 2000, SCIENCE, V289, P101, DOI 10.1126/science.289.5476.101; Rosseinsky MJ, 1998, CHEM MATER, V10, P2665, DOI 10.1021/cm980226p; Schon JH, 2000, NATURE, V406, P702, DOI 10.1038/35021011; Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656; SEITZ F, 1994, SOLID STATE PHYSICS, V48; SONG LW, 1993, SOLID STATE COMMUN, V87, P387, DOI 10.1016/0038-1098(93)90782-I; VAREKA WA, 1994, PHYS REV LETT, V72, P4121, DOI 10.1103/PhysRevLett.72.4121; VARMA CM, 1991, SCIENCE, V254, P989, DOI 10.1126/science.254.5034.989; Yildirim T, 1996, PHYS REV LETT, V77, P167, DOI 10.1103/PhysRevLett.77.167	25	223	231	2	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 30	2000	408	6812					549	552		10.1038/35046008	http://dx.doi.org/10.1038/35046008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117735				2022-12-28	WOS:000165548600108
J	Jiang, YJ; Aerne, BL; Smithers, L; Haddon, C; Ish-Horowicz, D; Lewis, J				Jiang, YJ; Aerne, BL; Smithers, L; Haddon, C; Ish-Horowicz, D; Lewis, J			Notch signalling and the synchronization of the somite segmentation clock	NATURE			English	Article							LUNATIC-FRINGE; VERTEBRATE SEGMENTATION; DANIO-RERIO; ZEBRAFISH; EXPRESSION; GENE; MESODERM; MOUSE; HOMOLOG; DIFFERENTIATION	In vertebrates with mutations in the Notch cell-cell communication pathway, segmentation fails: the boundaries demarcating somites, the segments of the embryonic body axis, are absent or irregular(1-8). This phenotype has prompted many investigations, but the role of Notch signalling in somitogenesis remains mysterious(1,9-12). Somite patterning is thought to be governed by a "clock-and-wavefront" mechanism(13) : a biochemical oscillator (the segmentation clock) operates in the cells of the presomitic mesoderm, the immature tissue from which the somites are sequentially produced, and a wavefront of maturation sweeps back through this tissue, arresting oscillation and initiating somite differentiation(14,15). Cells arrested in different phases of their cycle express different genes, defining the spatially periodic pattern of somites and controlling the physical process of segmentation(1,16-19). Notch signalling, one might think, must be necessary for oscillation, or to organize subsequent events that create the somite boundaries. Here we analyse a set of zebrafish mutants and arrive at a different interpretation: the essential function of Notch signalling in somite segmentation is to keep the oscillations of neighbouring presomitic mesoderm cells synchronized.	Imperial Canc Res Fund, Vertebrate Dev Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Dev Genet Lab, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Lewis, J (corresponding author), Imperial Canc Res Fund, Vertebrate Dev Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	j.lewis@icrf.icnet.uk	Jiang, Yun-Jin/E-3995-2010; Lewis, Julian H/E-8733-2010	Jiang, Yun-Jin/0000-0003-0499-7306; Ish-Horowicz, David/0000-0001-5684-7129				Aulehla A, 1999, DEV BIOL, V207, P49, DOI 10.1006/dbio.1998.9164; Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Durbin L, 1998, GENE DEV, V12, P3096, DOI 10.1101/gad.12.19.3096; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Haddon C, 1998, DEVELOPMENT, V125, P4637; Haddon C, 1998, DEVELOPMENT, V125, P359; Holley SA, 2000, GENE DEV, V14, P1678; Jen WC, 1999, GENE DEV, V13, P1486, DOI 10.1101/gad.13.11.1486; Jiang YJ, 1998, CURR BIOL, V8, pR868, DOI 10.1016/S0960-9822(07)00547-7; Jiang YJ, 1996, DEVELOPMENT, V123, P205; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; Muller M, 1996, DEVELOPMENT, V122, P2071; OKA C, 1995, DEVELOPMENT, V121, P3291; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Pourquie O, 1999, CURR OPIN GENET DEV, V9, P559, DOI 10.1016/S0959-437X(99)00011-8; Saga Y, 1997, GENE DEV, V11, P1827, DOI 10.1101/gad.11.14.1827; Sawada A, 2000, DEVELOPMENT, V127, P1691; Smithers L, 2000, MECH DEVELOP, V90, P119, DOI 10.1016/S0925-4773(99)00231-2; Takke C, 1999, DEVELOPMENT, V126, P3005; Van Eeden FJM, 1998, DEV GENET, V23, P65; vanEeden FJM, 1996, DEVELOPMENT, V123, P153; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yamamoto A, 1998, DEVELOPMENT, V125, P3389; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	30	416	423	0	36	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					475	479		10.1038/35044091	http://dx.doi.org/10.1038/35044091			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100729				2022-12-28	WOS:000165429800049
J	Luo, JY; Su, F; Chen, DL; Shiloh, A; Gu, W				Luo, JY; Su, F; Chen, DL; Shiloh, A; Gu, W			Deacetylation of p53 modulates its effect on cell growth and apoptosis	NATURE			English	Article							METASTASIS-ASSOCIATED GENE; HISTONE DEACETYLASE; TRANSCRIPTIONAL ACTIVATION; TERMINAL DOMAIN; DNA METHYLATION; COMPLEX; MTA1; OVEREXPRESSION; ACETYLATION; REPRESSION	The p53 tumour suppressor is a transcriptional factor whose activity is modulated by protein stability and post-translational modifications including acetylation(1-4). The mechanism by which acetylated p53 is maintained in vivo remains unclear. Here we show that the deacetylation of p53 is mediated by an histone deacetylase-1 (HDAC1)-containing complex. We have also purified a p53 target protein in the deacetylase complexes (designated PID; but identical to metastasis-associated protein 2 (MTA2)), which has been identified as a component of the NuRD complex(5-7). PID specifically interacts with p53 both in vitro and in vivo, and its expression reduces significantly the steady-state levels of acetylated p53. PID expression strongly represses p53-dependent transcriptional activation, and, notably, it modulates p53-mediated cell growth arrest and apoptosis. These results show that deacetylation and functional interactions by the PID/MTA2-associated NuRD complex may represent an important pathway to regulate p53 function.	Columbia Univ, Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Gu, W (corresponding author), Columbia Univ, Coll Phys & Surg, Inst Canc Genet, 1150 St Nicholas Ave, New York, NY 10032 USA.		Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Futamura M, 1999, J HUM GENET, V44, P52, DOI 10.1007/s100380050107; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Prives C, 1999, J PATHOL, V187, P112; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yu AD, 2000, MOL CELL, V5, P801, DOI 10.1016/S1097-2765(00)80320-2; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	30	656	684	0	47	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					377	381		10.1038/35042612	http://dx.doi.org/10.1038/35042612			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099047				2022-12-28	WOS:000165296000050
J	Wessberg, J; Stambaugh, CR; Kralik, JD; Beck, PD; Laubach, M; Chapin, JK; Kim, J; Biggs, J; Srinivasan, MA; Nicolelis, MAL				Wessberg, J; Stambaugh, CR; Kralik, JD; Beck, PD; Laubach, M; Chapin, JK; Kim, J; Biggs, J; Srinivasan, MA; Nicolelis, MAL			Real-time prediction of hand trajectory by ensembles of cortical neurons in primates	NATURE			English	Article							PREMOTOR CORTEX; CORTICOMOTONEURONAL CELLS; MOTOR CORTEX; OWL MONKEYS; REPRESENTATION; DIRECTION; MOVEMENTS; DORSAL; AREAS	Signals derived from the rat motor cortex can be used for controlling one-dimensional movements of a robot arm(1). It remains unknown, however, whether real-time processing of cortical signals can be employed to reproduce, in a robotic device, the kind of complex arm movements used by primates to reach objects in space. Here we recorded the simultaneous activity of large populations of neurons, distributed in the premotor, primary motor and posterior parietal cortical areas, as non-human primates performed two distinct motor tasks. Accurate real-time predictions of one- and three-dimensional arm movement trajectories were obtained by applying both linear and nonlinear algorithms to cortical neuronal ensemble activity recorded from each animal. In addition, cortically derived signals were successfully used for real-time control of robotic devices, both locally and through the Internet. These results suggest that long-term control of complex prosthetic robot arm movements can be achieved by simple real-time transformations of neuronal population signals derived from multiple cortical areas in primates.	Duke Univ, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA; Duke Univ, Dept Expt Psychol, Durham, NC 27710 USA; SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; MIT, Dept Mech Engn, Lab Human & Machine Hapt, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA	Duke University; Duke University; Duke University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Nicolelis, MAL (corresponding author), Duke Univ, Dept Neurobiol, Durham, NC 27710 USA.		Kim, Jung/C-1636-2011	Laubach, Mark/0000-0002-2403-4497				Batista AP, 1999, SCIENCE, V285, P257, DOI 10.1126/science.285.5425.257; Bendat J.S., 2000, RANDOM DATA ANAL MEA, V3rd; Brillinger D.R., 1981, TIME SERIES DATA ANA; Chapin JK, 1999, NAT NEUROSCI, V2, P664, DOI 10.1038/10223; EVARTS EV, 1966, J NEUROPHYSIOL, V29, P1011, DOI 10.1152/jn.1966.29.6.1011; Ferraina S, 1997, J NEUROPHYSIOL, V77, P1034, DOI 10.1152/jn.1997.77.2.1034; FETZ EE, 1978, J PHYSIOL-PARIS, V74, P239; FETZ EE, 1980, J NEUROPHYSIOL, V44, P751, DOI 10.1152/jn.1980.44.4.751; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; Ghazanfar AA, 2000, J NEUROSCI, V20, P3761, DOI 10.1523/JNEUROSCI.20-10-03761.2000; Halliday DM, 1995, PROG BIOPHYS MOL BIO, V64, P237, DOI 10.1016/S0079-6107(96)00009-0; HUMPHREY DR, 1970, SCIENCE, V170, P758, DOI 10.1126/science.170.3959.758; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Laubach M, 2000, NATURE, V405, P567, DOI 10.1038/35014604; MITZ AR, 1991, J NEUROSCI, V11, P1855; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; MUSSAIVALDI FA, 1988, NEUROSCI LETT, V91, P106, DOI 10.1016/0304-3940(88)90257-1; Nicolelis MAL, 1998, NAT NEUROSCI, V1, P621, DOI 10.1038/2855; Nicolelis MAL, 1997, NEURON, V18, P529, DOI 10.1016/S0896-6273(00)80295-0; NICOLELIS MAL, IN PRESS NATURE; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Preuss TM, 1996, J COMP NEUROL, V371, P649, DOI 10.1002/(SICI)1096-9861(19960805)371:4<649::AID-CNE12>3.0.CO;2-E; Salisbury JK, 1997, IEEE COMPUT GRAPH, V17, P6, DOI 10.1109/MCG.1997.1626171; SCHMIDT EM, 1980, ANN BIOMED ENG, V8, P339, DOI 10.1007/BF02363437; SCHWARTZ AB, 1994, SCIENCE, V265, P540, DOI 10.1126/science.8036499; Scott SH, 1997, J NEUROPHYSIOL, V78, P2413, DOI 10.1152/jn.1997.78.5.2413; STEPNIEWSKA I, 1993, J COMP NEUROL, V330, P238, DOI 10.1002/cne.903300207; WEINRICH M, 1982, J NEUROSCI, V2, P1329; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25	30	961	1028	12	202	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					361	365		10.1038/35042582	http://dx.doi.org/10.1038/35042582			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099043				2022-12-28	WOS:000165296000046
J	Ashton, J				Ashton, J			An elusive concept?	BRITISH MEDICAL JOURNAL			English	Article									Publ Hlth & Policy Directorate, NHS Execut, Warrington WA3 7QN, Cheshire, England		Ashton, J (corresponding author), Publ Hlth & Policy Directorate, NHS Execut, North West,Millennium Pk, Warrington WA3 7QN, Cheshire, England.							BENTALL RP, 1992, J MED ETHICS, V18, P94, DOI 10.1136/jme.18.2.94	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1575	1576		10.1136/bmj.321.7276.1575	http://dx.doi.org/10.1136/bmj.321.7276.1575			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124183	Green Published			2022-12-28	WOS:000166134500020
J	Chen, M; Daly, M; Natt; Susie; Candy; Williams, G				Chen, M; Daly, M; Natt; Susie; Candy; Williams, G			Non-invasive detection of hypoglycaemia using a novel, fully biocompatible and patient friendly alarm system	BRITISH MEDICAL JOURNAL			English	Article							TYPE-1		Univ Liverpool, Univ Hosp Aintree, Dept Med, Diabet & Endocrinol Res Grp, Liverpool L9 7AL, Merseyside, England; Wansbeck Gen Hosp, Dept Med, Ashington NE63 9JJ, England	University of Liverpool	Williams, G (corresponding author), Univ Liverpool, Univ Hosp Aintree, Dept Med, Diabet & Endocrinol Res Grp, Liverpool L9 7AL, Merseyside, England.							FRIER BM, 1997, TXB DIABETES; Lim K., 1992, DIABETIC MED, V9, pS3; Pickup J, 2000, LANCET, V355, P426; PRAMMING S, 1991, DIABETIC MED, V8, P217, DOI 10.1111/j.1464-5491.1991.tb01575.x; Rebrin K, 1999, AM J PHYSIOL-ENDOC M, V277, pE561, DOI 10.1152/ajpendo.1999.277.3.E561; Strong V, 1999, SEIZURE-EUR J EPILEP, V8, P62, DOI 10.1053/seiz.1998.0250; VORMBROCK JK, 1988, J BEHAV MED, V11, P509, DOI 10.1007/BF00844843; Weston PJ, 1999, DIABETIC MED, V16, P626, DOI 10.1046/j.1464-5491.1999.00121.x; *WHO INT FED SPORT, 1997, EX HLTH; Williams TM, 1995, BRIT MED J, V311, P1700, DOI 10.1136/bmj.311.7021.1700	10	36	36	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1565	1566		10.1136/bmj.321.7276.1565	http://dx.doi.org/10.1136/bmj.321.7276.1565			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124176	Green Published, Bronze			2022-12-28	WOS:000166134500014
J	Dehlinger, G; Diehl, L; Gennser, U; Sigg, H; Faist, J; Ensslin, K; Grutzmacher, D; Muller, E				Dehlinger, G; Diehl, L; Gennser, U; Sigg, H; Faist, J; Ensslin, K; Grutzmacher, D; Muller, E			Intersubband electroluminescence from silicon-based quantum cascade structures	SCIENCE			English	Article							WELLS; ABSORPTION; LASERS	The quantum cascade laser, which uses electronic transitions within a single band of a semiconductor, constitutes a possible way to integrate active optical components into silicon-based technology. This concept necessitates a transition with a narrow Linewidth and an upper state with a sufficiently Long Lifetime. We report the observation of intersubband electroluminescence from a p-type silicon/silicon-germanium quantum cascade structure, centered at 130 millielectron volts with a width of 22 millielectron volts, with the expected polarization, and discernible up to 180 kelvin. The nonradiative Lifetime is found to depend strongly on the design of the quantum well structure, and is shown to reach values comparable to that of an equivalent GaInAs/AlInAs Laser structure.	Paul Scherrer Inst, Lab Micro & Nanotechnol, CH-5232 Villigen, Switzerland; Univ Neuchatel, Inst Phys, CH-2000 Neuchatel, Switzerland; ETH Zurich, Solid State Phys Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Neuchatel; Swiss Federal Institutes of Technology Domain; ETH Zurich	Dehlinger, G (corresponding author), Paul Scherrer Inst, Lab Micro & Nanotechnol, CH-5232 Villigen, Switzerland.		Sigg, Hans/B-4323-2013; Faist, Jerome/A-7339-2013; Gennser, Ulf/F-2728-2019	Sigg, Hans/0000-0001-8649-7983; Faist, Jerome/0000-0003-4429-7988; 				BLASER S, UNPUB; Boucaud P, 1996, APPL PHYS LETT, V69, P3069, DOI 10.1063/1.116842; FAIST J, 1993, APPL PHYS LETT, V63, P1354, DOI 10.1063/1.109675; FAIST J, 1994, APPL PHYS LETT, V65, P94, DOI 10.1063/1.113086; FAIST J, 1994, SCIENCE, V264, P553, DOI 10.1126/science.264.5158.553; FAIST J, 2000, INTERSUBBAND TRANSIT, V66, pCH1; FROHERZ T, 1994, PHYS REV B, V50, P10573; Fromherz T, 1996, APPL PHYS LETT, V68, P3611, DOI 10.1063/1.115746; Graf S, 2000, PHYS REV LETT, V84, P2686, DOI 10.1103/PhysRevLett.84.2686; Kruck P, 2000, APPL PHYS LETT, V76, P3340, DOI 10.1063/1.126686; Schrenk W, 2000, APPL PHYS LETT, V76, P253, DOI 10.1063/1.125738; Sirtori C, 1998, APPL PHYS LETT, V73, P3486, DOI 10.1063/1.122812; SUN G, 1995, APPL PHYS LETT, V66, P3425, DOI 10.1063/1.113375; Yang RQ, 1997, APPL PHYS LETT, V71, P2409, DOI 10.1063/1.120076	14	258	261	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2277	+		10.1126/science.290.5500.2277	http://dx.doi.org/10.1126/science.290.5500.2277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125134				2022-12-28	WOS:000165995800034
J	Ren, B; Robert, F; Wyrick, JJ; Aparicio, O; Jennings, EG; Simon, I; Zeitlinger, J; Schreiber, J; Hannett, N; Kanin, E; Volkert, TL; Wilson, CJ; Bell, SP; Young, RA				Ren, B; Robert, F; Wyrick, JJ; Aparicio, O; Jennings, EG; Simon, I; Zeitlinger, J; Schreiber, J; Hannett, N; Kanin, E; Volkert, TL; Wilson, CJ; Bell, SP; Young, RA			Genome-wide location and function of DNA binding proteins	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; REGULATED GENES; IDENTIFICATION; GROWTH; FUSION; GIC1	Understanding how DNA binding proteins control global gene expression and chromosomal maintenance requires knowledge of the chromosomal Locations at which these proteins function in vivo. We developed a microarray method that reveals the genome-wide Location of DNA-bound proteins and used this method to monitor binding of gene-specific transcription activators in yeast. A combination of location and expression profiles was used to identify genes whose expression is directly controlled by Gal4 and Ste12 as cells respond to changes in carbon source and mating pheromone, respectively. The results identify pathways that are coordinately regulated by each of the two activators and reveal previously unknown functions for Gal4 and Ste12. Genome-wide Location analysis will facilitate investigation of gene regulatory networks, gene function, and genome maintenance.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ So Calif, Program Mol Biol, Los Angeles, CA 90089 USA; Corning Inc, Corning, NY 14834 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of Southern California; Corning Inc; State University of New York (SUNY) System; SUNY Community College	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Robert, Francois/D-2316-2012; Rosa, Bruce/F-6393-2010; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Bell, Stephen/0000-0002-2876-610X; Simon, Itamar/0000-0002-8517-1903; Wilson, Christopher/0000-0002-9146-522X; Aparicio, Oscar/0000-0002-5591-0277				Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; FUJIMURA H, 1990, CURR GENET, V18, P395, DOI 10.1007/BF00309907; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KONOPKA JB, 1993, MOL CELL BIOL, V13, P6876, DOI 10.1128/MCB.13.11.6876; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARSH L, 1997, MOL CELLULAR BIOL YE, V3, P827; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; Olson KA, 2000, MOL CELL BIOL, V20, P4199, DOI 10.1128/MCB.20.12.4199-4209.2000; ORLANDO, 2000, TRENDS BIOCH SCI, V25, P99; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; ROY A, 1991, MOL CELL BIOL, V11, P4196, DOI 10.1128/MCB.11.8.4196; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316	27	1487	1599	6	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2306	+		10.1126/science.290.5500.2306	http://dx.doi.org/10.1126/science.290.5500.2306			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125145				2022-12-28	WOS:000165995800045
J	Kernan, WN; Viscoli, CM; Brass, LM; Broderick, JP; Brott, T; Feldmann, E; Morgenstern, LB; Wilterdink, JL; Horwitz, RI				Kernan, WN; Viscoli, CM; Brass, LM; Broderick, JP; Brott, T; Feldmann, E; Morgenstern, LB; Wilterdink, JL; Horwitz, RI			Phenylpropanolamine and the risk of hemorrhagic stroke.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACEREBRAL HEMORRHAGE; CEREBRAL VASCULITIS	Background: Phenylpropanolamine is commonly found in appetite suppressants and cough or cold remedies. Case reports have linked the use of products containing phenylpropanolamine to hemorrhagic stroke, often after the first use of these products. To study the association, we designed a case-control study. Methods: Men and women 18 to 49 years of age were recruited from 43 U.S. hospitals. Eligibility criteria included the occurrence of a subarachnoid or intracerebral hemorrhage within 30 days before enrollment and the absence of a previously diagnosed brain lesion. Random-digit dialing identified two matched control subjects per patient. Results: There were 702 patients and 1376 control subjects. For women, the adjusted odds ratio was 16.58 (95 percent confidence interval, 1.51 to 182.21; P=0.02) for the association between the use of appetite suppressants containing phenylpropanolamine and the risk of a hemorrhagic stroke and 3.13 (95 percent confidence interval, 0.86 to 11.46; P=0.08) for the association with the first use of a product containing phenylpropanolamine. All first uses of phenylpropanolamine involved cough or cold remedies. For men and women combined, the adjusted odds ratio was 1.49 (95 percent confidence interval, 0.84 to 2.64; P=0.17) for the association between the use of a product containing phenylpropanolamine and the risk of a hemorrhagic stroke, 1.23 (95 percent confidence interval, 0.68 to 2.24; P=0.49) for the association with the use of cough or cold remedies that contained phenylpropanolamine, and 15.92 (95 percent confidence interval, 1.38 to 184.13; P=0.03) for the association with the use of appetite suppressants that contained phenylpropanolamine. An analysis in men showed no increased risk of a hemorrhagic stroke in association with the use of cough or cold remedies containing phenylpropanolamine. No men reported the use of appetite suppressants. Conclusions: The results suggest that phenylpropanolamine in appetite suppressants, and possibly in cough and cold remedies, is an independent risk factor for hemorrhagic stroke in women. (N Engl J Med 2000;343:1826-32.) (C) 2000, Massachusetts Medical Society.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Univ Cincinnati, Dept Neurol, Cincinnati, OH USA; Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA; Brown Univ, Sch Med, Dept Neurol, Providence, RI 02912 USA; Univ Texas, Dept Neurol, Houston, TX 77225 USA; Univ Texas, Sch Publ Hlth, Houston, TX USA	Yale University; Yale University; Yale University; University System of Ohio; University of Cincinnati; Mayo Clinic; Brown University; University of Texas System; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Kernan, WN (corresponding author), Yale Univ, Sch Med, Dept Med, POB 208025, New Haven, CT 06520 USA.							Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRODERICK JP, 1992, NEW ENGL J MED, V326, P733, DOI 10.1056/NEJM199203123261103; Chung Y. T., 1998, CHUNG HUA I HSUEH TS, V61, P432; Edlow JA, 2000, NEW ENGL J MED, V342, P29, DOI 10.1056/NEJM200001063420106; FALLIS RJ, 1985, NEUROLOGY, V35, P405, DOI 10.1212/WNL.35.3.405; FORMAN HP, 1989, PEDIATRICS, V83, P737; HORWITZ RI, 1984, ARCH INTERN MED, V144, P1257, DOI 10.1001/archinte.144.6.1257; JICK H, 1984, LANCET, V1, P1017; JICK H, 1978, AM J EPIDEMIOL, V107, P1; JOHNSON DA, 1983, LANCET, V2, P970; KASE CS, 1987, NEUROLOGY, V37, P399, DOI 10.1212/WNL.37.3.399; KIKTA DG, 1985, STROKE, V16, P510, DOI 10.1161/01.STR.16.3.510; KING J, 1979, MED J AUSTRALIA, V2, P258, DOI 10.5694/j.1326-5377.1979.tb127123.x; KNODEL LC, 1997, NONPRESCRIPTION PROD; LAKE CR, 1990, AM J MED, V89, P195, DOI 10.1016/0002-9343(90)90299-S; LINN FHH, 1994, LANCET, V344, P590, DOI 10.1016/S0140-6736(94)91970-4; MAHER LM, 1987, NEUROLOGY, V37, P1686, DOI 10.1212/WNL.37.10.1686; MAHER LM, 1987, NEUROLOGY, V37, P1890; Mayer PL, 1996, STROKE, V27, P1558, DOI 10.1161/01.STR.27.9.1558; MCDOWELL JR, 1985, WESTERN J MED, V142, P688; Medical Economics, 1999, PHYS DESK REF, V53rd; MORGAN J, 1986, PHENYLPROPANOLAMINE, P105; STOESSL AJ, 1985, STROKE, V16, P734, DOI 10.1161/01.STR.16.4.734; TRAYNELIS VC, 1986, NEUROLOGY, V36, P593, DOI 10.1212/WNL.36.4.593	24	419	435	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1826	1832		10.1056/NEJM200012213432501	http://dx.doi.org/10.1056/NEJM200012213432501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117973				2022-12-28	WOS:000165940400001
J	Hughen, KA; Southon, JR; Lehman, SJ; Overpeck, JT				Hughen, KA; Southon, JR; Lehman, SJ; Overpeck, JT			Synchronous radiocarbon and climate shifts during the last deglaciation	SCIENCE			English	Article							OCEAN CIRCULATION; YOUNGER DRYAS; ATMOSPHERIC C-14/C-12; TH-230 AGES; CALIBRATION; GREENLAND; CORALS; RECORD; SOLAR	Radiocarbon data from the Cariaco Basin provide calibration of the carbon-14 time scale across the period of deglaciation (15,000 to 10,000 years ago) with resolution available previously only from Holocene tree rings. Reconstructed changes in atmospheric carbon-14 are larger than previously thought, with the largest change occurring simultaneously with the sudden climatic cooling of the Younger Dryas event. Carbon-14 and published beryllium-10 data together suggest that concurrent climate and carbon-14 changes were predominantly the result of abrupt shifts in deep ocean ventilation.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94551 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Univ Arizona, Inst Planet Earth, Tucson, AZ 85721 USA	Woods Hole Oceanographic Institution; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Arizona; University of Arizona	Hughen, KA (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.	khughen@whoi.edu						ALLEY RB, 1995, J GLACIOL, V41, P503, DOI 10.3189/S0022143000034845; ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; Bjorck S, 1996, SCIENCE, V274, P1155, DOI 10.1126/science.274.5290.1155; Black DE, 1999, SCIENCE, V286, P1709, DOI 10.1126/science.286.5445.1709; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P119, DOI 10.1029/97PA03707; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Burr GS, 1998, RADIOCARBON, V40, P1093, DOI 10.1017/S0033822200019147; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; Finkel RC, 1997, J GEOPHYS RES-OCEANS, V102, P26699, DOI 10.1029/97JC01282; Friedrich M, 1999, QUATERN INT, V61, P27, DOI 10.1016/S1040-6182(99)00015-4; Goslar T, 2000, NATURE, V403, P877, DOI 10.1038/35002547; HOLMEN KJ, 1990, DEEP-SEA RES, V37, P203, DOI 10.1016/0198-0149(90)90124-E; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; KEIGWIN LD, 1991, J GEOPHYS RES-OCEANS, V96, P16811, DOI 10.1029/91JC01624; Kitagawa H, 1998, SCIENCE, V279, P1187, DOI 10.1126/science.279.5354.1187; Kromer B, 1998, RADIOCARBON, V40, P1117, DOI 10.1017/S0033822200019160; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; MARCHAL O, UNPUB EARTH PLAN SCI; MARCHAL O, COMMUNICATION; Marchitto TM, 1998, NATURE, V393, P557, DOI 10.1038/31197; MIKOLAJEWICZ U, 1996, 189 M PLANCK I MET; Peterson LC, 1991, PALEOCEANOGRAPHY, V6, P99, DOI 10.1029/90PA02497; RAHMSTORF S, 1994, NATURE, V372, P82, DOI 10.1038/372082a0; RIND D, 1993, QUATERNARY SCI REV, V12, P357, DOI 10.1016/S0277-3791(05)80002-2; Schiller A, 1997, CLIM DYNAM, V13, P325, DOI 10.1007/s003820050169; Stocker TF, 1996, PALEOCEANOGRAPHY, V11, P773, DOI 10.1029/96PA02640; STUIVER M, 1991, QUATERNARY RES, V35, P1, DOI 10.1016/0033-5894(91)90091-I; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; TINSLEY BA, 1991, J GEOPHYS RES-ATMOS, V96, P22283, DOI 10.1029/91JD02473; TRIC E, 1992, J GEOPHYS RES-SOL EA, V97, P9337, DOI 10.1029/91JB01620	34	296	311	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	2000	290	5498					1951	1954		10.1126/science.290.5498.1951	http://dx.doi.org/10.1126/science.290.5498.1951			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110659				2022-12-28	WOS:000165810000042
J	Zhang, KK; Schubert, G				Zhang, KK; Schubert, G			Teleconvection: Remotely driven thermal convection in rotating stratified spherical layers	SCIENCE			English	Article							FLUID SHELLS; ATMOSPHERE; CORE	We report the discovery of a convective phenomenon found to occur in a rotating spherical system in which an inner convectively unstable fluid layer is bounded by a corotating outer convectively stable fluid layer. Although convection is thermally driven in the unstable interior, the resulting convective motions concentrate primarily in the stable outer region. This phenomenon, which we term teleconvection, suggests that fluid motions observed at the "surface" of a planet (such as Jupiter's alternating zonal winds) may be driven by an energy source located deep inside the planet.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Schubert, G (corresponding author), Univ Exeter, Sch Math Sci, N Pk Rd, Exeter EX4 4QE, Devon, England.							Ardes M, 1997, PHYS EARTH PLANET IN, V99, P55, DOI 10.1016/S0031-9201(96)03200-1; Baker RD, 1998, J ATMOS SCI, V55, P3, DOI 10.1175/1520-0469(1998)055<0003:CLPCCI>2.0.CO;2; BUSSE FH, 1976, ICARUS, V29, P255, DOI 10.1016/0019-1035(76)90053-1; BUSSE FH, 1970, J FLUID MECH, V44, P441, DOI 10.1017/S0022112070001921; BUSSE FH, 1983, GEOPHYS ASTROPHYS FL, V23, P152; Chandrasekhar S, 2013, HYDRODYNAMIC HYDROMA; GUBBINS D, 1982, GEOPHYS J ROY ASTR S, V68, P241, DOI 10.1111/j.1365-246X.1982.tb06972.x; GUILLOT T, 1994, ICARUS, V112, P337, DOI 10.1006/icar.1994.1188; Jones CA, 2000, J FLUID MECH, V405, P157, DOI 10.1017/S0022112099007235; Manneville JB, 1996, ICARUS, V122, P242, DOI 10.1006/icar.1996.0123; Moffatt H. K., 1978, MAGNETIC FIELD GENER; Olson P, 1999, NATURE, V402, P170, DOI 10.1038/46017; ROBERTS PH, 1968, PHILOS TR R SOC S-A, V263, P93, DOI 10.1098/rsta.1968.0007; Seiff A, 2000, NATURE, V403, P603, DOI 10.1038/35001171; Straughan B., 1993, MATH ASPECTS PENETRA; SUN ZP, 1993, GEOPHYS ASTRO FLUID, V69, P95, DOI 10.1080/03091929308203576; Tilgner A, 1997, J FLUID MECH, V332, P359, DOI 10.1017/S0022112096004259; VERONIS G, 1963, ASTROPHYS J, V137, P641, DOI 10.1086/147538; ZHANG K, 1994, J FLUID MECH, V268, P211, DOI 10.1017/S0022112094001321; ZHANG K, 1992, J FLUID MECH, V236, P535, DOI 10.1017/S0022112092001526; ZHANG KK, 1987, GEOPHYS ASTRO FLUID, V39, P119, DOI 10.1080/03091928708208809; Zhang KK, 1996, SCIENCE, V273, P941, DOI 10.1126/science.273.5277.941	23	41	42	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1944	1947		10.1126/science.290.5498.1944	http://dx.doi.org/10.1126/science.290.5498.1944			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110657				2022-12-28	WOS:000165810000040
J	Wolf, G				Wolf, G			"Show your wound" medicine and the work of Joseph Beuys	ANNALS OF INTERNAL MEDICINE			English	Article							ART		Univ Hamburg, Hosp Eppendorf, Dept Med, Div Nephrol & Osteol, D-20246 Hamburg, Germany	University of Hamburg	Wolf, G (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Med, Div Nephrol & Osteol, Pavil 61,Martinistr 52, D-20246 Hamburg, Germany.							Adriani G., 1979, J BEUYS LIFE WORKS; BEAUYS E, 1997, J BEUYS BLOCK BEUYS; BORER A, 1996, J BEAUYS; Emery AEH, 1996, AM J MED GENET, V66, P334, DOI 10.1002/(SICI)1096-8628(19961218)66:3<334::AID-AJMG17>3.0.CO;2-N; Meakins JL, 1996, ARCH SURG-CHICAGO, V131, P1289; MURKEN AH, 1979, DTSCH ARZTEBLATT, V47, P3155; MURKEN AH, 1979, J BEUYS MED; SCHELLMANN B, 1983, PATHOLOGE, V4, P325; Schulz H, 1999, Mund Kiefer Gesichtschir, V3 Suppl 1, pS7, DOI 10.1007/PL00014521; SCHULZ H, 1997, PLAZENTAVORSTELLUNG; STACHELHAUS H, 1991, J BEAUYS	11	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					927	931		10.7326/0003-4819-133-11-200012050-00031	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00031			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103077				2022-12-28	WOS:000165585800022
J	Geddes, J; Freemantle, N; Harrison, P; Bebbington, P				Geddes, J; Freemantle, N; Harrison, P; Bebbington, P		Natl Schizophrenia Guideline Dev	Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIALS; TARDIVE-DYSKINESIA; METAANALYSIS; OLANZAPINE; RISPERIDONE; SCALE; CARE	Objective To develop an evidence base for recommendations on the use of atypical antipsychotics for patients with schizophrenia. Design Systematic overview and meta-regression analyses of randomised controlled trials, as a basis for formal development of guidelines. Subjects 12 649 patients in 52 randomised trials comparing atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole) with conventional antipsychotics (usually haloperidol or chlorpromazine) or alternative atypical antipsychotics. Main outcome measures Overall symptom scores. Rate of drop out las a proxy for tolerability) and of side effects, notably extrapyramidal side effects. Results For both symptom reduction and drop out, there was substantial heterogeneity between the results of trials, including those evaluating the same atypical antipsychotic and comparator drugs. Meta-regression suggested that dose of conventional antipsychotic explained the heterogeneity. When the dose was less than or equal to 12 mg/day of haloperidol (or equivalent), atypical antipsychotics had no benefits in terms of efficacy or overall tolerability, but they still caused fewer extrapyramidal side effects. Conclusions There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotics. Conventional antipsychotics should usually be used in the initial treatment of an episode of schizophrenia unless the patient has previously not responded to these drugs or has unacceptable extrapyramidal side effects.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ York, Ctr Hlth Econ, Med Evaluat Grp, York YO10 5DD, N Yorkshire, England; UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London W1N 8AA, England	University of Oxford; University of York - UK; University of London; University College London; UCL Medical School	Geddes, J (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	john.geddes@psych.ox.ac.uk	Bebbington, Paul Ernest/C-1939-2008	Bebbington, Paul Ernest/0000-0002-6030-7456				Allison DB, 1999, AM J PSYCHIAT, V156, P1686; American Psychiatric Association, 1997, PRACT GUID TREATM PA; Beasley CM, 1999, BRIT J PSYCHIAT, V174, P23, DOI 10.1192/bjp.174.1.23; Beasley CM, 1999, BRIT J PSYCHIAT, V175, P392, DOI 10.1192/S0007125000263113; BOLLINI P, 1994, PSYCHOL MED, V24, P307, DOI 10.1017/S003329170002729X; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUGGAN L, 1999, COCHRANE LIB; Eccles M, 1998, BRIT MED J, V316, P1232, DOI 10.1136/bmj.316.7139.1232; Hedges LV, 2014, STAT METHODS META AN; KANE JM, 1995, LANCET, V346, P820, DOI 10.1016/S0140-6736(95)91630-X; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; KENNEDY E, 1999, COCHRANE LIB; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P11, DOI 10.1093/oxfordjournals.schbul.a033303; Leucht S, 1999, SCHIZOPHR RES, V35, P51, DOI 10.1016/S0920-9964(98)00105-4; OVERALL JE, 1962, PSYCHOL REP, V10, P799; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; Song FJ, 1997, J PSYCHOPHARMACOL, V11, P65; SRISURAPANONT M, 1999, COCHRANE LIB; SUTTON AJ, 1998, HLTH SERVICES RES ME; WAHLBECK K, 1999, COCHRANE LIB	21	774	818	1	70	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1371	1376		10.1136/bmj.321.7273.1371	http://dx.doi.org/10.1136/bmj.321.7273.1371			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	380TT	11099280	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000165720100023
J	Bathon, JM; Martin, RW; Fleischmann, RM; Tesser, JR; Schiff, MH; Keystone, EC; Genovese, MC; Wasko, MC; Moreland, LW; Weaver, AL; Markenson, J; Finck, BK				Bathon, JM; Martin, RW; Fleischmann, RM; Tesser, JR; Schiff, MH; Keystone, EC; Genovese, MC; Wasko, MC; Moreland, LW; Weaver, AL; Markenson, J; Finck, BK			A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECROSIS FACTOR-ALPHA; LOW-DOSE METHOTREXATE; LONG-TERM; RADIOGRAPHIC PROGRESSION; FUSION PROTEIN; TRIAL; THERAPY; DISEASE; ABNORMALITIES; IMPROVEMENT	Background: Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease activity and preventing joint damage in patients with active early rheumatoid arthritis is unknown. Methods: We treated 632 patients with early rheumatoid arthritis with either twice-weekly subcutaneous etanercept (10 or 25 mg) or weekly oral methotrexate (mean, 19 mg per week) for 12 months. Clinical response was defined as the percent improvement in disease activity according to the criteria of the American College of Rheumatology. Bone erosion and joint-space narrowing were measured radiographically and scored with use of the Sharp scale. On this scale, an increase of 1 point represents one new erosion or minimal narrowing. Results: As compared with patients who received methotrexate, patients who received the 25-mg dose of etanercept had a more rapid rate of improvement, with significantly more patients having 20 percent, 50 percent, and 70 percent improvement in disease activity during the first six months (P<0.05). The mean increase in the erosion score during the first 6 months was 0.30 in the group assigned to receive 25 mg of etanercept and 0.68 in the methotrexate group (P=0.001), and the respective increases during the first 12 months were 0.47 and 1.03 (P=0.002). Among patients who received the 25-mg dose of etanercept, 72 percent had no increase in the erosion score, as compared with 60 percent of patients in the methotrexate group (P=0.007). This group of patients also had fewer adverse events (P=0.02) and fewer infections (P=0.006) than the group that was treated with methotrexate. Conclusions: As compared with oral methotrexate, intravenous etanercept acted more rapidly to decrease symptoms and slow joint damage in patients with early active rheumatoid arthritis. (N Engl J Med 2000;343:1586-93.) (C) 2000, Massachusetts Medical Society.	Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Michigan State Univ, Grand Rapids, MI USA; Metroplex Clin Res Ctr, Dallas, TX USA; Phoenix Ctr Clin Res, Phoenix, AZ USA; Denver Arthrit Clin, Denver, CO USA; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Stanford Univ, Stanford, CA 94305 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Univ Alabama Birmingham, Birmingham, AL USA; Arthrit Ctr Nebraska, Lincoln, NE USA; Hosp Special Surg, New York, NY 10021 USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA	Johns Hopkins University; Johns Hopkins Medicine; Michigan State University; Metroplex Clinical Research Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham	Bathon, JM (corresponding author), Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Cir,Rm 5A24, Baltimore, MD 21224 USA.			Moreland, Larry/0000-0003-4483-0359; Ticora Silva, Daiana Carolina/0000-0002-6347-8875; Martin, Richard/0000-0002-0411-7519				BENSEN WG, 1990, J RHEUMATOL, V17, P987; Braunstein J., 1994, Immunobiology, V191, P193; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1564, DOI 10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M; Finck B. K., 1997, Arthritis and Rheumatism, V40, pS288; JEURISSEN MEC, 1991, ARTHRITIS RHEUM-US, V34, P961, DOI 10.1002/art.1780340805; Kim JM, 2000, ARTHRITIS RHEUM, V43, P473, DOI 10.1002/1529-0131(200003)43:3<473::AID-ANR1>3.0.CO;2-A; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; LOPEZMENDEZ A, 1993, ARTHRITIS RHEUM, V36, P1364; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; Madhok R, 1999, LANCET, V353, P257, DOI 10.1016/S0140-6736(05)74938-2; MCKENDRY RJR, 1993, J RHEUMATOL, V20, P1850; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Paleolog EM, 1996, ARTHRITIS RHEUM-US, V39, P1082, DOI 10.1002/art.1780390703; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Parker SL, 1997, CA-CANCER J CLIN, V47, P68; PINCUS T, 1990, J RHEUMATOL, V17, P1582; PLANT MJ, 1994, J RHEUMATOL, V21, P1808; Rich E, 1999, J RHEUMATOL, V26, P259; SANY J, 1991, J RHEUMATOL, V18, P1323; SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816; SHARP JT, 1985, ARTHRITIS RHEUM, V28, P1326, DOI 10.1002/art.1780281203; SHARP JT, 1971, ARTHRITIS RHEUM-US, V14, P706, DOI 10.1002/art.1780140605; Tak PP, 1996, ARTHRITIS RHEUM, V39, P1077, DOI 10.1002/art.1780390702; VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM-US, V35, P26; vanLeeuwen MA, 1997, J RHEUMATOL, V24, P20; WEINBLATT, 1993, ARTHRITIS RHEUM, V36, P1028; WEINBLATT ME, 1993, ARTHRITIS RHEUM-US, V36, P613, DOI 10.1002/art.1780360507; WEINBLATT ME, 1992, ARTHRITIS RHEUM, V35, P129, DOI 10.1002/art.1780350202; WEINBLATT ME, 1988, ARTHRITIS RHEUM, V31, P167, DOI 10.1002/art.1780310203; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; WIKSKE KR, 1989, J RHEUMATOL, V16, P565; Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1571, DOI 10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R	34	1427	1501	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2000	343	22					1586	1593		10.1056/NEJM200011303432201	http://dx.doi.org/10.1056/NEJM200011303432201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JT	11096165				2022-12-28	WOS:000165511000001
J	Robins, AH; Sellars, SL				Robins, AH; Sellars, SL			Oscar Wilde's terminal illness: reappraisal after a century	LANCET			English	Review									Univ Cape Town, Sch Med, Dept Pharmacol, ZA-7925 Observatory, South Africa; Univ Cape Town, Dept Otolaryngol, ZA-7925 Observatory, South Africa; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa	University of Cape Town; University of Cape Town; University of Cape Town	Robins, AH (corresponding author), Univ Cape Town, Sch Med, Dept Pharmacol, ZA-7925 Observatory, South Africa.							[Anonymous], CAMBRIDGE COMPANION; CAWTHORN.T, 1966, ANN OTO RHINOL LARYN, V75, P657, DOI 10.1177/000348946607500306; CRITCHLEY M, 1990, MED HLTH ANN, P191; Ellmann Richard, 1987, O WILDE; Hart-Davis Rupert., 1962, LETT O WILDE; HOLLAND VB, 1954, SON O WILDE, P156; LYONS JB, 1995, IRISH STUDIES REV, V11, P24; RANSOME A, 1912, O WILDE, P199; SELLARS SL, 1974, S AFR MED J, V48, P234; WILDE WR, 1953, PRACTICAL OBSERVATIO	10	7	7	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1841	1843		10.1016/S0140-6736(00)03245-1	http://dx.doi.org/10.1016/S0140-6736(00)03245-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117929				2022-12-28	WOS:000165545700042
J	Ganachaud, A; Wunsch, C				Ganachaud, A; Wunsch, C			Improved estimates of global ocean circulation, heat transport and mixing from hydrographic data	NATURE			English	Article							LARGE-SCALE CIRCULATION; WATER; PACIFIC; NO	Through its ability to transport large amounts of heat, fresh water and nutrients, the ocean is an essential regulator of climate(1,2). The pathways and mechanisms of this transport and its stability are critical issues in understanding the present state of climate and the possibilities of future changes. Recently, global high-quality hydrographic data have been gathered in the World Ocean Circulation Experiment (WOCE), to obtain an accurate picture of the present circulation. Here we combine the new data from high-resolution trans-oceanic sections and current meters with climatological wind fields, biogeochemical balances and improved a priori error estimates in an inverse model, to improve estimates of the global circulation and heat fluxes. Our solution resolves globally vertical mixing across surfaces of equal density, with coefficients in the range (3-12) x 10(-4) m(2) s(-1). Net deepwater production rates amount to (15 +/- 12) x 10(6) m(3) s(-1) in the North Atlantic Ocean and (21 +/- 6) x 10(6) m(3) s(-1) in the Southern Ocean. Our estimates provide a new reference state for future climate studies with rigorous estimates of the uncertainties.	MIT 54 1517, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Ganachaud, A (corresponding author), IFREMER, Lab Phys Oceans, F-29280 Plouzane, France.		Ganachaud, Alexandre S/B-7556-2013					ANDERSON LA, 1994, GLOBAL BIOGEOCHEM CY, V8, P65, DOI 10.1029/93GB03318; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Broecker WS, 1999, SCIENCE, V286, P1132, DOI 10.1126/science.286.5442.1132; BROECKER WS, 1974, EARTH PLANET SC LETT, V23, P100, DOI 10.1016/0012-821X(74)90036-3; BRYDEN HL, 1991, DEEP-SEA RES, V38, P297, DOI 10.1016/0198-0149(91)90070-V; da Silva A.M., 1994, ATLAS SURFACE MARINE, V6; De las Heras MM, 1999, J GEOPHYS RES-OCEANS, V104, P15515, DOI 10.1029/1999JC900102; GANACHAUD A, 1999, THESIS MIT WOODS HOL; GANACHAUD A, UNPUB GLOB BIOGEOCHE; GANACHAUD A, IN PRESS J GEOPHYS R; GARNIER E, IN PRESS INT J CLIMA; Gleckler PJ, 1997, J CLIMATE, V10, P2764, DOI 10.1175/1520-0442(1997)010<2764:UIGOSH>2.0.CO;2; Gordon AL, 1999, GEOPHYS RES LETT, V26, P3325, DOI 10.1029/1999GL002340; Jackett DR, 1997, J PHYS OCEANOGR, V27, P237, DOI 10.1175/1520-0485(1997)027<0237:ANDVFT>2.0.CO;2; Josey SA, 1999, J CLIMATE, V12, P2856, DOI 10.1175/1520-0442(1999)012<2856:NIITOH>2.0.CO;2; KEITH DW, 1995, TELLUS A, V47, P30, DOI 10.1034/j.1600-0870.1995.00002.x; Macdonald AM, 1998, PROG OCEANOGR, V41, P281, DOI 10.1016/S0079-6611(98)00020-2; Macdonald AM, 1996, NATURE, V382, P436, DOI 10.1038/382436a0; Manabe S, 1988, J CLIMATE, V1, P841, DOI 10.1175/1520-0442(1988)001<0841:TSEOAC>2.0.CO;2; MAROTZKE J, 1996, DECADAL CLIMATE VARI, V1, P44; McDougall T.J, 1991, PARAMETERIZING MIXIN, P355; MCDOUGALL TJ, 1987, J PHYS OCEANOGR, V17, P1950, DOI 10.1175/1520-0485(1987)017<1950:NS>2.0.CO;2; Munk W, 1998, DEEP-SEA RES PT I, V45, P1977, DOI 10.1016/S0967-0637(98)00070-3; Orsi AH, 1999, PROG OCEANOGR, V43, P55, DOI 10.1016/S0079-6611(99)00004-X; Polzin KL, 1997, SCIENCE, V276, P93, DOI 10.1126/science.276.5309.93; ROEMMICH D, 1989, PROG OCEANOGR, V22, P171, DOI 10.1016/0079-6611(89)90005-0; SCHMITZ WJ, 1993, REV GEOPHYS, V31, P29, DOI 10.1029/92RG02583; Stammer D, 1996, J GEOPHYS RES-OCEANS, V101, P25779, DOI 10.1029/96JC01754; Toggweiler JR, 1998, J PHYS OCEANOGR, V28, P1832, DOI 10.1175/1520-0485(1998)028<1832:OTOSLS>2.0.CO;2; TRENBERTH KE, 1994, CLIM DYNAM, V10, P107, DOI 10.1007/BF00210625; Wunsch C., 1996, OCEAN CIRCULATION IN, P437	31	770	792	4	176	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					453	457		10.1038/35044048	http://dx.doi.org/10.1038/35044048			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100723				2022-12-28	WOS:000165429800043
J	Ranganathan, R; Cannon, SC; Horvitz, HR				Ranganathan, R; Cannon, SC; Horvitz, HR			MOD-1 is a serotonin-gated chloride channel that modulates locomotory behaviour in C. elegans	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; NICOTINIC ACETYLCHOLINE-RECEPTOR; CAENORHABDITIS-ELEGANS; MEDICINAL LEECH; ION CURRENTS; NEURONS; EXPRESSION; MUTATIONS; GENETICS; SUBUNIT	The neurotransmitter and neuromodulator serotonin (5-HT) functions by binding either to metabotropic G-protein-coupled receptors (for example, 5-HT1, 5-HT2, 5-HT4 to 5-HT7), which mediate 'slow' modulatory responses through numerous second messenger pathways(1), or to the ionotropic 5-HT3 receptor, a non-selective cation channel that mediates 'fast' membrane depolarizations(2). Here we report that the gene mod-1 (for modulation of locomotion defective) from the nematode Caenorhabditis elegans encodes a new type of ionotropic 5-HT receptor, a 5-HT-gated chloride channel. The predicted MOD-1 protein is similar to members of the nicotinic acetylcholine receptor family of ligand-gated ion channels, in particular to GABA (gamma -aminobutyric acid)- and glycine-gated chloride channels. The MOD-1 channel has distinctive ion selectivity and pharmacological properties. The reversal potential of the MOD-1 channel is dependent on the concentration of chloride ions but not of cations. The MOD-1 channel is not blocked by calcium ions or 5-HT3a-specific antagonists but is inhibited by the metabotropic 5-HT receptor antagonists mianserin and methiothepin. mod-1 mutant animals are defective in a 5-HT-mediated experience-dependent behaviour(3) and are resistant to exogenous 5-HT, confirming that MOD-1 functions as a 5-HT receptor in vivo.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Horvitz, HR (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, Room 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	horvitz@mit.edu	Cannon, Stephen/V-5343-2019	Cannon, Stephen/0000-0001-8428-3690				Adelsberger H, 2000, EUR J PHARMACOL, V394, P163, DOI 10.1016/S0014-2999(00)00164-3; Aizenberg D, 1997, CLIN NEUROPHARMACOL, V20, P210, DOI 10.1097/00002826-199706000-00004; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cooper J.R., 1996, BIOCH BASIS NEUROPHA, Vseventh; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; DOWNIE DL, 1994, NEUROPHARMACOLOGY, V33, P473, DOI 10.1016/0028-3908(94)90078-7; Granas C, 1999, EUR J PHARMACOL, V380, P171, DOI 10.1016/S0014-2999(99)00520-8; HARDIE RC, 1989, NATURE, V339, P704, DOI 10.1038/339704a0; Hayward LJ, 1996, J GEN PHYSIOL, V107, P559, DOI 10.1085/jgp.107.5.559; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Krause RM, 1998, MOL PHARMACOL, V53, P283, DOI 10.1124/mol.53.2.283; LESSMANN V, 1991, J NEUROSCI, V11, P800; LESSMANN V, 1995, J NEUROSCI, V15, P1496; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; MCCLINTOCK TS, 1989, P NATL ACAD SCI USA, V86, P8137, DOI 10.1073/pnas.86.20.8137; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Morrill JA, 1999, J PHYSIOL-LONDON, V520, P321, DOI 10.1111/j.1469-7793.1999.00321.x; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; Weber WM, 1999, BBA-BIOMEMBRANES, V1421, P213, DOI 10.1016/S0005-2736(99)00135-2	30	169	181	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	2000	408	6811					470	475		10.1038/35044083	http://dx.doi.org/10.1038/35044083			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100728				2022-12-28	WOS:000165429800048
J	Scully, R; Livingston, DM				Scully, R; Livingston, DM			In search of the tumour-suppressor functions of BRCA1 and BRCA2	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; DNA-DAMAGE; MEIOTIC CELLS; GENE BRCA1; STRAND; REPAIR; BREAST; ATM; PHOSPHORYLATION; PRODUCT	Hereditary breast and ovarian cancer syndromes can be caused by loss-of-function germline mutations in one of two tumour-suppressor genes, BRCA1 and BRCA2 (ref. 1). Each gene product interacts with recombination/DNA repair proteins in pathways that participate in preserving intact chromosome structure. However, it is unclear to what extent such functions specifically suppress breast and ovarian cancer. Here we analyse what is known of BRCA gene function and highlight some unanswered questions in the field.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Livingston, DM (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Scully, Ralph/F-5008-2013		NCI NIH HHS [K01 CA079576-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA079576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brown EJ, 2000, GENE DEV, V14, P397; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x; FORNACE AJ, 1983, NATURE, V304, P552, DOI 10.1038/304552a0; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Henikoff S, 1997, CURR OPIN CELL BIOL, V9, P388, DOI 10.1016/S0955-0674(97)80012-9; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Le Page F, 2000, CANCER RES, V60, P5548; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; SCULLY R, IN PRESS ONCOGENE; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; TIBBETTS RS, IN PRESS GENES DEV; TOKUNAGA M, 1979, J NATL CANCER I, V62, P1347; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wolden SL, 1998, J CLIN ONCOL, V16, P536, DOI 10.1200/JCO.1998.16.2.536; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	42	518	550	1	77	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					429	432		10.1038/35044000	http://dx.doi.org/10.1038/35044000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100717	Green Accepted			2022-12-28	WOS:000165429800037
J	Shah, SG; Brooker, JC; Williams, CB; Thapar, C; Saunders, BP				Shah, SG; Brooker, JC; Williams, CB; Thapar, C; Saunders, BP			Effect of magnetic endoscope imaging on colonoscopy performance: a randomised controlled trial	LANCET			English	Article							COLORECTAL-CANCER; COLONIC DISEASE; LEARNING-CURVE; BARIUM ENEMA; DIFFICULT; FLUOROSCOPY; TRAINEES; FAILURE; SKILLS	Background Colonoscopy can be technically challenging because of unpredictable colonoscope looping. Without imaging, straightening the colonoscope is sometimes difficult since the endoscopist has to guess where the tip is. Magnetic endoscope imaging (MEI), a new non-radiographical technique for picturing the colonoscope shaft in real time, could facilitate loop straightening and thus improve performance. Methods We assessed trainees and endoscopists with much experience of routine outpatient colonoscopy. In group 1, trainees examined 113 consecutive patients. MEI views were recorded in all examinations, but procedures were randomised to be done by two trainees, either with the endoscopist and endoscopy assistants viewing the imager display (n=58), or without the imager view (n=55). In group 2, two skilled endoscopists were randomised las with group 1) to undertake consecutive examinations (n=183) either with (n=92) or without (n=91) the MEI view. MEI views of ail procedures were analysed retrospectively. Findings in both groups, intubation times were shorter (median 11.8 min [4.3-31.5] vs 15.3 min [4-67] [group 1]; 8.0 min [2.6-40.8] vs 9.3 min [2.5-52.6] [group 2]) and number of attempts at straightening the colonoscope fewer (median 5 [0-20] vs 12 [0-57] [group 1]; 7 [0-55] vs 10 [0-80] [group 2]), when the endoscopist was able to see the imager view. In group 1, colonoscopy completion rates were also higher (100% [58] vs 89% [49]) and duration of looping was reduced (median 3 min [0-18.8] vs 5.4 min [0-44.5]) when the imager could be seen. Abdominal hand pressure was more effective when the endoscopist and endoscopy assistant could see the imager view. Interpretation MEI significantly improves performance of colonoscopy, particularly when used by trainees, or by experts in technically difficult cases; loops were straightened or controlled effectively, resulting in quick intubation times and high completion rates.	St Marks Hosp, Wolfson Unit Endocopy, Harrow HA1 3UJ, Middx, England	Imperial College London	Saunders, BP (corresponding author), St Marks Hosp, Wolfson Unit Endocopy, Harrow HA1 3UJ, Middx, England.	b.saunders@ic.ac.uk	Saunders, Brian/AAP-4137-2020					Bell GD, 2000, GUT, V46, pA30; Bell GD, 1999, MED BIOL ENG COMPUT, V37, P605, DOI 10.1007/BF02513355; BLADEN JS, 1993, LANCET, V341, P719, DOI 10.1016/0140-6736(93)90487-2; BOWLE SCJA, 2000, COMMUNICATION    APR; CASS OW, 1993, ANN INTERN MED, V118, P40, DOI 10.7326/0003-4819-118-1-199301010-00008; Chak A, 1996, GASTROINTEST ENDOSC, V44, P54, DOI 10.1016/S0016-5107(96)70229-8; Cirocco WC, 1996, SURG ENDOSC-ULTRAS, V10, P1080, DOI 10.1007/s004649900244; COTTON PB, 1996, PRACTICAL GASTROINES; DURDEY P, 1987, LANCET, V2, P549; HANCOCK JH, 1995, INT J COLORECTAL DIS, V10, P140, DOI 10.1007/BF00298535; Haseman JH, 1997, GASTROINTEST ENDOSC, V45, P451, DOI 10.1016/S0016-5107(97)70172-X; HULL T, 1994, SURG ENDOSC-ULTRAS, V8, P784, DOI 10.1007/BF00593441; HUNT RH, 1981, COLONOSCOPY TECHNIQU, P109; Jowell PS, 1996, GASTROINTEST ENDOSC, V43, P95; LINDSAY DC, 1988, BRIT MED J, V296, P167, DOI 10.1136/bmj.296.6616.167; MARSHALL JB, 1995, GASTROINTEST ENDOSC, V42, P287, DOI 10.1016/S0016-5107(95)70123-0; Miller BJ, 1998, AUST NZ J SURG, V68, P331, DOI 10.1111/j.1445-2197.1998.tb04765.x; NIVATVONGS S, 1982, GASTROINTEST ENDOSC, V28, P140; Painter J, 1999, ENDOSCOPY, V31, P227, DOI 10.1055/s-1999-13673; PARRY BR, 1991, AUST NZ J SURG, V61, P419, DOI 10.1111/j.1445-2197.1991.tb00254.x; RAUH SM, 1989, AM J SURG, V55, P569; Rex DK, 1997, GASTROENTEROLOGY, V112, P17, DOI 10.1016/S0016-5085(97)70213-0; ROGERS BHG, 1990, GASTROINTEST ENDOSC, V36, P71; SAUNDERS BP, 1995, GUT, V36, P913, DOI 10.1136/gut.36.6.913; Shah SG, 2000, GASTROINTEST ENDOSC, V52, P1, DOI 10.1067/mge.2000.107296; TREWBY PN, 1993, GUT, V34, P1290, DOI 10.1136/gut.34.9.1290; WAYE JD, 1991, GASTROINTEST ENDOSC, V37, P152, DOI 10.1016/S0016-5107(91)70674-3; WEBB WA, 1991, AM SURGEON, V57, P178; WILLIAMS C, 1993, LANCET, V341, P724, DOI 10.1016/0140-6736(93)90489-4; WILLIAMS CB, 1982, ENDOSCOPY, V14, P74, DOI 10.1055/s-2007-1021584	30	77	82	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 18	2000	356	9243					1718	1722		10.1016/S0140-6736(00)03205-0	http://dx.doi.org/10.1016/S0140-6736(00)03205-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095259				2022-12-28	WOS:000165462300010
J	Tuveri, M; Generini, S; Matucci-Cerinic, M; Aloe, L				Tuveri, M; Generini, S; Matucci-Cerinic, M; Aloe, L			NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis	LANCET			English	Article							NERVE GROWTH-FACTOR	Vasculitic necrosis and ulceration of the skin are frequent complications of connective tissue diseases and are very difficult to heal. We treated chronic vasculitic leg ulcers in rheumatoid arthritis and systemic sclerosis by topical application of nerve growth factor (NGF). In all patients with rheumatoid arthritis, NGF led to rapid healing, whereas less striking results were obtained in patients with systemic sclerosis. The efficacy of NGF could be due to its promoting activity on keratinocytes proliferation and vascular neoangiogenisis. We suggest that topical application of NGF could represent a powerful pharmacological tool for the treatment of vasculitic ulcers.	Natl Res Council, Inst Neurobiol, I-00137 Rome, Italy; Univ Florence, Dept Med, Div Rheumatol, I-50121 Florence, Italy	University of Florence	Aloe, L (corresponding author), Natl Res Council, Inst Neurobiol, I-00137 Rome, Italy.		CERINIC, marco MATUCCI/AAO-2769-2020					Bernabei R, 1999, LANCET, V354, P307, DOI 10.1016/S0140-6736(99)02784-1; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; Lambiase A, 1998, NEW ENGL J MED, V338, P1174, DOI 10.1056/NEJM199804233381702; Matsuda H, 1998, J EXP MED, V187, P297, DOI 10.1084/jem.187.3.297; Wilkinson D I, 1994, Exp Dermatol, V3, P239, DOI 10.1111/j.1600-0625.1994.tb00283.x	5	85	89	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1739	1740		10.1016/S0140-6736(00)03212-8	http://dx.doi.org/10.1016/S0140-6736(00)03212-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095266				2022-12-28	WOS:000165462300017
J	Chamberlin, RV				Chamberlin, RV			Mean-field cluster model for the critical behaviour of ferromagnets	NATURE			English	Article							SUPERCOOLED LIQUIDS; GLASS	Two separate theories are often used to characterize the paramagnetic properties of ferromagnetic materials. At temperatures T well above the Curie temperature, T-C (where the transition from paramagnetic to ferromagnetic behaviour occurs), classical mean-field theory(1) yields the Curie-Weiss law for the magnetic susceptibility: chi (T) proportional to 1/(T - Theta), where Theta is the Weiss constant. Close to T-C, however, the standard mean-field approach breaks down so that better agreement with experimental data is provided by critical scaling theory(2,3): chi (T) proportional to 1/(T -T-C)(gamma) , where gamma is a scaling exponent. But there is no known model capable of predicting the measured values of g nor its variation among different substances(4). Here I use a mean-field cluster model(5) based on finite-size thermostatistics(6,7) to extend the range of mean-field theory, thereby eliminating the need for a separate scaling regime. The mean-field approximation is justified by using a kinetic-energy term to maintain the microcanonical ensemble(8). The model reproduces the Curie-Weiss law at high temperatures, but the classical Weiss transition at T-C = Theta is suppressed by finite-size effects. Instead, the fraction of clusters with a specific amount of order diverges at T-C, yielding a transition that is mathematically similar to Bose-Einstein condensation. At all temperatures above T-C, the model matches the measured magnetic susceptibilities of crystalline EuO, Gd, Co and Ni, thus providing a unified picture for both the critical-scaling and Curie-Weiss regimes.	Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Chamberlin, RV (corresponding author), Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA.							[Anonymous], 1987, STAT MECH; ARAJS S, 1961, J APPL PHYS, V32, pS336, DOI 10.1063/1.2000459; ARAJS S, 1965, J APPL PHYS, V36, P1136, DOI 10.1063/1.1714136; BALLY D, 1968, NEUTRON INELASTIC SC, V2, P75; Chamberlin RV, 1998, PHASE TRANSIT, V65, P169, DOI 10.1080/01411599808209287; CHAMBERLIN RV, 1991, PHYS REV LETT, V67, P1606, DOI 10.1103/PhysRevLett.67.1606; Chamberlin RV, 1999, PHYS REV LETT, V83, P5134, DOI 10.1103/PhysRevLett.83.5134; Chamberlin RV, 1999, PHYS REV LETT, V82, P2520, DOI 10.1103/PhysRevLett.82.2520; Collins MF., 1989, MAGNETIC CRITICAL SC; COLVIN RV, 1965, J PHYS CHEM SOLIDS, V26, P435, DOI 10.1016/0022-3697(65)90174-5; CREUTZ M, 1986, ANN PHYS-NEW YORK, V167, P62, DOI 10.1016/S0003-4916(86)80006-9; FALLOT M, 1944, J PHYS RAD, V8, P153; GELDART DJW, 1989, PHYS REV LETT, V62, P2728, DOI 10.1103/PhysRevLett.62.2728; GUGGENHEIM EA, 1945, J CHEM PHYS, V13, P253, DOI 10.1063/1.1724033; Hill TL, 1998, P NATL ACAD SCI USA, V95, P12779, DOI 10.1073/pnas.95.22.12779; Hill TL, 1994, THERMODYNAMICS SMA 1; Hill TL, 1994, THERMODYNAMICS SMA 2; HUANG CC, 1975, PHYS REV B, V12, P5255, DOI 10.1103/PhysRevB.12.5255; KORENMAN V, 1985, J APPL PHYS, V57, P3000, DOI 10.1063/1.335195; MENYUK N, 1971, PHYS REV B, V3, P1689, DOI 10.1103/PhysRevB.3.1689; MEZEI F, 1989, PHYSICA B, V156, P226, DOI 10.1016/0921-4526(89)90638-8; NAKAGAWA Y, 1956, J PHYS SOC JPN, V11, P855, DOI 10.1143/JPSJ.11.855; NIGH HE, 1963, PHYS REV, V132, P1092, DOI 10.1103/PhysRev.132.1092; Onsager L, 1944, PHYS REV, V65, P117, DOI 10.1103/PhysRev.65.117; ROWLINSO.JS, 1973, NATURE, V244, P414, DOI 10.1038/244414a0; Schiener B, 1996, SCIENCE, V274, P752, DOI 10.1126/science.274.5288.752; Smart J. S, 1966, EFFECTIVE FIELD THEO; SOULETIE J, 1983, SOLID STATE COMMUN, V48, P407, DOI 10.1016/0038-1098(83)90842-6; Stanley HE, 1999, REV MOD PHYS, V71, pS358, DOI 10.1103/RevModPhys.71.S358; Stanley HE., 1971, PHASE TRANSITIONS CR; WEGNER FJ, 1972, PHYS REV B, V5, P4529, DOI 10.1103/PhysRevB.5.4529; Weiss P, 1907, J PHYS, V6, P661, DOI [10.1051/jphystap:019070060066100, DOI 10.1051/JPHYSTAP:019070060066100]	32	77	77	2	52	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					337	339		10.1038/35042534	http://dx.doi.org/10.1038/35042534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099035				2022-12-28	WOS:000165296000038
J	Hasty, R; Hawthorne-Allen, AM; Averett, T; Barkhuff, D; Beck, DH; Beise, EJ; Blake, A; Breuer, H; Carr, R; Covrig, S; Danagoulian, A; Dodson, G; Dow, K; Farkhondeh, M; Filippone, BW; Gao, J; Herda, MC; Ito, TM; Jones, CE; Korsch, W; Kramer, K; Kowalski, S; Lee, P; McKeown, RD; Mueller, B; Pitt, M; Ritter, J; Roche, J; Savu, V; Spayde, DT; Tieulent, R; Tsentalovich, E; Wells, SP; Yang, B; Zwart, T				Hasty, R; Hawthorne-Allen, AM; Averett, T; Barkhuff, D; Beck, DH; Beise, EJ; Blake, A; Breuer, H; Carr, R; Covrig, S; Danagoulian, A; Dodson, G; Dow, K; Farkhondeh, M; Filippone, BW; Gao, J; Herda, MC; Ito, TM; Jones, CE; Korsch, W; Kramer, K; Kowalski, S; Lee, P; McKeown, RD; Mueller, B; Pitt, M; Ritter, J; Roche, J; Savu, V; Spayde, DT; Tieulent, R; Tsentalovich, E; Wells, SP; Yang, B; Zwart, T			Strange magnetism and the anapole structure of the proton	SCIENCE			English	Article							PARITY NONCONSERVATION; SCATTERING; NUCLEON; MOMENT; WEAK	The violation of mirror symmetry in the weak force provides a powerful tool to study the internal structure of the proton. Experimental results have been obtained that address the role of strange quarks in generating nuclear magnetism. The measurement reported here provides an unambiguous constraint on strange quark contributions to the proton's magnetic moment through the electron-proton weak interaction. We also report evidence for the existence of a parity-violating electromagnetic effect known as the anapole moment of the proton. The proton's anapole moment is not yet well understood theoretically, but it could have important implications for precision weak interaction studies in atomic systems such as cesium.	Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; CALTECH, Kellogg Radiat Lab, Pasadena, CA 91125 USA; MIT, Nucl Sci Lab, Bates Linear Accelerator Ctr, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA; Virginia Polytech Inst & State Univ, Dept Phys, Blacksburg, VA 24061 USA; Univ Kentucky, Dept Phys & Astron, Lexington, KY 40506 USA; Argonne Natl Lab, Div Phys, Argonne, IL 60439 USA; Louisiana Tech Univ, Dept Phys, Ruston, LA 71272 USA; Coll William & Mary, Dept Phys, Williamsburg, VA 23187 USA	University System of Maryland; University of Maryland College Park; University of Illinois System; University of Illinois Urbana-Champaign; California Institute of Technology; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Virginia Polytechnic Institute & State University; University of Kentucky; United States Department of Energy (DOE); Argonne National Laboratory; University of Louisiana System; Louisiana Technical University; William & Mary	Beise, EJ (corresponding author), Univ Maryland, Dept Phys, College Pk, MD 20742 USA.	beise@physics.umd.edu	Averett, Todd D/A-2969-2011; Savu, Veronica/C-6069-2009; Lee, Patricia/B-6146-2012	Roche, Julie/0000-0003-1913-3308; Tieulent, Raphael/0000-0002-2106-5415				Groom DE, 2000, EUR PHYS J C, V15, P1; HADJIMICHAEL E, 1992, PHYS REV C, V45, P2666, DOI 10.1103/PhysRevC.45.2666; HAXTON WC, 1989, PHYS REV LETT, V63, P949, DOI 10.1103/PhysRevLett.63.949; HEIL W, 1989, NUCL PHYS B, V327, P1, DOI 10.1016/0550-3213(89)90284-8; Hemmert TR, 1998, PHYS LETT B, V437, P184, DOI 10.1016/S0370-2693(98)00889-2; KAPLAN DB, 1988, NUCL PHYS B, V310, P527, DOI 10.1016/0550-3213(88)90090-9; Liesenfeld A, 1999, PHYS LETT B, V468, P20, DOI 10.1016/S0370-2693(99)01204-6; MCKEOWN RD, 1989, PHYS LETT B, V219, P140, DOI 10.1016/0370-2693(89)90364-X; MILLER G, 1972, PHYS REV D, V5, P528, DOI 10.1103/PhysRevD.5.528; Mueller B, 1997, PHYS REV LETT, V78, P3824, DOI 10.1103/PhysRevLett.78.3824; MUSOLF MJ, 1990, PHYS LETT B, V242, P461, DOI 10.1016/0370-2693(90)91794-C; OKA T, 1983, PHYS REV D, V27, P523, DOI 10.1103/PhysRevD.27.523; Spayde DT, 2000, PHYS REV LETT, V84, P1106, DOI 10.1103/PhysRevLett.84.1106; Wood CS, 1997, SCIENCE, V275, P1759, DOI 10.1126/science.275.5307.1759; ZelDovich I. B., 1957, J EXP THEOR PHYS+, V33, P1531; Zhu SL, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.033008	17	146	148	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	2000	290	5499					2117	2119		10.1126/science.290.5499.2117	http://dx.doi.org/10.1126/science.290.5499.2117			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118140	Green Published, Green Submitted			2022-12-28	WOS:000165870600048
J	Traver, D; Akashi, K; Manz, M; Merad, M; Miyamoto, T; Engleman, EG; Weissman, IL				Traver, D; Akashi, K; Manz, M; Merad, M; Miyamoto, T; Engleman, EG; Weissman, IL			Development of CD8 alpha-positive dendritic cells from a common myeloid progenitor	SCIENCE			English	Article							MOUSE BONE-MARROW; T-CELLS; IN-VIVO; LYMPHOID ORGANS; B-CELLS; EXPRESSION; MARKERS; SPLEEN	Dendritic cells (DCs) are critical in both initiating adaptive immune responses and maintaining tolerance to self antigens. These apparently contradictory roles have been suggested to depend on different subsets of DCs that arise from either myeloid or Lymphoid hematopoietic origins, respectively, Although DC expression of CD8 alpha is attributed to a lymphoid origin, here we show that both CD8 alpha (+) and CD8 alpha (-) DCs can arise from clonogenic common myeloid progenitors in both thymus and spleen. Thus, expression of CD8 alpha is not indicative of a lymphoid origin, and phenotypic and functional differences among DC subsets are likely to reflect maturation status rather than ontogeny.	Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Stanford University; Stanford University; Harvard University; Dana-Farber Cancer Institute	Manz, M (corresponding author), Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.		Manz, Markus G/C-7588-2011	Manz, Markus/0000-0002-4676-7931	NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER; NCI NIH HHS [CA42551] Funding Source: Medline; NIAID NIH HHS [5T32 AI-07290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; Ardavin C, 1997, IMMUNOL TODAY, V18, P350, DOI 10.1016/S0167-5699(97)01090-6; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brocker T, 1997, J EXP MED, V185, P541, DOI 10.1084/jem.185.3.541; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; Guerriero A, 2000, BLOOD, V95, P879, DOI 10.1182/blood.V95.3.879.003k13_879_885; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Leenen PJM, 1998, J IMMUNOL, V160, P2166; Merad M, 2000, BLOOD, V96, P1865, DOI 10.1182/blood.V96.5.1865.h8001865_1865_1872; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rodewald HR, 1999, P NATL ACAD SCI USA, V96, P15068, DOI 10.1073/pnas.96.26.15068; Shortman K, 1997, STEM CELLS, V15, P409, DOI 10.1002/stem.150409; Shreedhar V, 1999, IMMUNITY, V11, P625, DOI 10.1016/S1074-7613(00)80137-5; Steinman RM, 1999, J LEUKOCYTE BIOL, V66, P205, DOI 10.1002/jlb.66.2.205; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; Vremec D, 1997, J IMMUNOL, V159, P565; WEISSMAN IL, 1994, IMMUNITY, V1, P529, DOI 10.1016/1074-7613(94)90042-6; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4	24	303	312	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2152	2154		10.1126/science.290.5499.2152	http://dx.doi.org/10.1126/science.290.5499.2152			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118150				2022-12-28	WOS:000165870600058
J	Dahl, JL				Dahl, JL			Improving the practice of pain management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EDUCATION; OUTCOMES; BARRIERS		Univ Wisconsin, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dahl, JL (corresponding author), Univ Wisconsin, Sch Med, Madison, WI 53706 USA.							[Anonymous], [No title captured]; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Drayer RA, 1999, J PAIN SYMPTOM MANAG, V17, P434, DOI 10.1016/S0885-3924(99)00022-6; Jacox A, 1994, AHCPR PUBLICATION; Joranson D E, 1998, Semin Oncol Nurs, V14, P158, DOI 10.1016/S0749-2081(98)80022-3; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; *PAIN POL STUD GRO, 2000, GUID EV ACH BAL FED; Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885-3924(99)00097-4; Stross JK, 1999, ANN INTERN MED, V131, P304, DOI 10.7326/0003-4819-131-4-199908170-00009; Weissman DE, 1996, J PAIN SYMPTOM MANAG, V12, P364, DOI 10.1016/S0885-3924(96)00185-6	10	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2785	2785		10.1001/jama.284.21.2785	http://dx.doi.org/10.1001/jama.284.21.2785			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105189	hybrid			2022-12-28	WOS:000165509500036
J	Henney, JE				Henney, JE			Microwave therapy warning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2711	2711		10.1001/jama.284.21.2711-c	http://dx.doi.org/10.1001/jama.284.21.2711-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105160				2022-12-28	WOS:000165509500004
J	Cohen, BA; Swindle, TD; Kring, DA				Cohen, BA; Swindle, TD; Kring, DA			Support for the lunar cataclysm hypothesis from lunar meteorite impact melt ages	SCIENCE			English	Article							ASTEROID IMPACTS; NOBLE-GAS; MAC88105; HISTORY; HIGHLANDS; EVOLUTION; SPECTRA; CRUST	Lunar meteorites represent a more random sampling of Lunar material than the Apollo or Luna collections and, as such, Lunar meteorite impact melt ages are the most important data in nearly 30 years with which to reexamine the Lunar cataclysm hypothesis. Within the lunar meteorite breccias MAC 88105, QUE 93069, DaG 262, and DaG 400, seven to nine different impact events are represented with 40Ar-39Ar ages between 2.76 and 3.92 billion years ago (Ca). The Lack of impact melt older than 3.92 Ca supports the concept of a short, intense period of bombardment in the Earth-moon system at similar to3.9 Ca. This was an anomalous spike of impact activity on the otherwise declining impact-frequency curve.	Univ Arizona, Tucson, AZ 85721 USA	University of Arizona	Cohen, BA (corresponding author), Univ Tennessee, Dept Geol Sci, Knoxville, TN 37996 USA.	bcohen@utk.edu						Bischoff A, 1998, METEORIT PLANET SCI, V33, P1243, DOI 10.1111/j.1945-5100.1998.tb01309.x; CADOGAN PH, 1977, PHILOS T R SOC A, V284, P167, DOI 10.1098/rsta.1977.0007; COHEN BA, 2000, THESIS U ARIZONA; Culler TS, 2000, SCIENCE, V287, P1785, DOI 10.1126/science.287.5459.1785; DALRYMPLE GB, 1993, J GEOPHYS RES-PLANET, V98, P13085, DOI 10.1029/93JE01222; Dalrymple GB, 1996, J GEOPHYS RES-PLANET, V101, P26069, DOI 10.1029/96JE02806; DEUTSCH A, 1994, METEORITICS, V29, P301, DOI 10.1111/j.1945-5100.1994.tb00595.x; DOGARD DD, 1995, METEORITICS, V30, P244; EUGSTER O, 1991, GEOCHIM COSMOCHIM AC, V55, P3139, DOI 10.1016/0016-7037(91)90478-N; Gladman BJ, 1995, ICARUS, V118, P302, DOI 10.1006/icar.1995.1193; GRINSPOON DH, 1989, THESIS U ARIZONA; HARTMANN WK, 1975, ICARUS, V24, P181, DOI 10.1016/0019-1035(75)90095-0; Hartung J. B., 1974, METEORITICS, V9, P349; Hohenberg C.M., 1978, P LUNAR PLANET SCI C, P2311; Jolliff BL, 2000, J GEOPHYS RES-PLANET, V105, P4197, DOI 10.1029/1999JE001103; Kring DA, 2000, GSA TODAY, V10, P1; KRING DA, 2000, LUNAR PLANETARY SCI, V31; McKay D. S., 1991, LUNAR SOURCEBOOK, P285, DOI DOI 10.1006/ICAR.1999.6165; Mojzsis SJ, 2000, GSA TODAY, V10, P1; NISHIIZUMI K, 1991, GEOCHIM COSMOCHIM AC, V55, P3149, DOI 10.1016/0016-7037(91)90479-O; NYQUIST LE, 1992, GEOCHIM COSMOCHIM AC, V56, P2213, DOI 10.1016/0016-7037(92)90185-L; Pierazzo E, 1999, METEORIT PLANET SCI, V34, P909, DOI 10.1111/j.1945-5100.1999.tb01409.x; Renne PR, 1998, CHEM GEOL, V145, P117, DOI 10.1016/S0009-2541(97)00159-9; RYDER G, 2000, EOS, V81, pS76; Scherer P, 1998, METEORIT PLANET SCI, V33, pA135; SLEEP NH, 1989, NATURE, V342, P139, DOI 10.1038/342139a0; Sleep NH, 1998, J GEOPHYS RES-PLANET, V103, P28529, DOI 10.1029/98JE01809; STOFFLER D, 1985, J GEOPHYS RES, V90, pC449, DOI 10.1029/JB090iS02p0C449; SWINDLE TD, 1991, P LUNAR PLANET SCI, V21, P167; SWINDLE TD, 1988, METEORITES EARLY SOL, P535; TAYLOR GJ, 1991, GEOCHIM COSMOCHIM AC, V55, P3031, DOI 10.1016/0016-7037(91)90471-G; TURNER G, 1979, P LUNAR PLANET SCI C, V10, P1917; Turner G., 1973, P LUNAR PLANET SCI C, P1889; WARREN PH, 1994, ICARUS, V111, P338, DOI 10.1006/icar.1994.1149; WARREN PH, 1991, GEOCHIM COSMOCHIM AC, V55, P3123, DOI 10.1016/0016-7037(91)90477-M; Wilhelms D.E., 1987, 1348 US GEOL SURV, P302, DOI DOI 10.3133/PP1348; Zappala V, 1998, ICARUS, V134, P176, DOI 10.1006/icar.1998.5946	38	200	205	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	2000	290	5497					1754	1756		10.1126/science.290.5497.1754	http://dx.doi.org/10.1126/science.290.5497.1754			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099411				2022-12-28	WOS:000165632400039
J	Hastings, PJ; Bull, HJ; Klump, JR; Rosenberg, SM				Hastings, PJ; Bull, HJ; Klump, JR; Rosenberg, SM			Adaptive amplification: An inducible chromosomal instability mechanism	CELL			English	Article							STATIONARY-PHASE MUTATION; ESCHERICHIA-COLI; GENE AMPLIFICATION; MISMATCH REPAIR; FRAMESHIFT MUTATION; LAC OPERON; EVOLUTION; TRANSIENT; MUTATORS; HYPERMUTATION	Adaptive mutation is an induced response to environmental stress in which mutation rates rise, producing permanent genetic changes that can adapt cells to stress. This contrasts with neo-Darwinian views of genetic change rates blind to environmental conditions. DNA amplification is a flexible, reversible genomic change that has long been postulated to be adaptive. We report the discovery of adaptive amplification at the lac operon in Escherichia coli. Additionally, we find that adaptive amplification is separate from, and does not lead to, adaptive point mutation. This contradicts a prevailing alternative hypothesis whereby adaptive mutation is normal mutability in amplified DNA. Instead, adaptive mutation and amplification are parallel routes of inducible genetic instability allowing rapid evolution under stress, and escape from growth inhibition.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Hastings, PJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	hastings@bcm.tmc.edu		Rosenberg, Susan M./0000-0003-1444-473X	NIAID NIH HHS [R01-AI43917] Funding Source: Medline; NIGMS NIH HHS [R01-GM53158] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053158] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson DI, 1998, SCIENCE, V282, P1133, DOI 10.1126/science.282.5391.1133; BRODEUR GM, 1998, GENETIC BASIS HUMAN, P161; Bull HJ, 2000, GENETICS, V154, P1427; CAIMS J, 1991, GENETICS, V128, P695; CAIMS J, 1988, NATURE, V335, P142; Darwin C., 1877, ORIGIN SPECIES; DELBRUCK M, 1946, COLD SPRING HARB SYM, V11, P33; Dickinson WJ, 1999, NATURE, V399, P30, DOI 10.1038/19894; ECHOLS H, 1981, CELL, V25, P1, DOI 10.1016/0092-8674(81)90223-3; Foster PL, 1999, ANNU REV GENET, V33, P57, DOI 10.1146/annurev.genet.33.1.57; FOSTER PL, 1995, P NATL ACAD SCI USA, V92, P5487, DOI 10.1073/pnas.92.12.5487; Foster PL, 1996, GENETICS, V142, P25; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; FOSTER PL, 1994, GENETICS, V138, P253; GALITSKI T, 1995, SCIENCE, V268, P421, DOI 10.1126/science.7716546; Godoy VG, 2000, GENETICS, V154, P49; HALL BG, 1990, GENETICS, V126, P5; Harris RS, 1999, MUTAT RES-REV MUTAT, V437, P51; Harris RS, 1996, GENETICS, V142, P681; Harris RS, 1997, GENE DEV, V11, P2426, DOI 10.1101/gad.11.18.2426; HORIUCHI T, 1963, GENETICS, V48, P151; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LOEB LA, 1991, CANCER RES, V51, P3075; Lombardo MJ, 1999, J GENET, V78, P13, DOI 10.1007/BF02994698; Longerich S, 1995, P NATL ACAD SCI USA, V92, P12017, DOI 10.1073/pnas.92.26.12017; Luria SE, 1943, GENETICS, V28, P491; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; Matic I, 1997, SCIENCE, V277, P1833, DOI 10.1126/science.277.5333.1833; Mayr E., 1982, GROWTH BIOL THOUGHT; MCCLINTOCK B, 1978, STADLER GENET S, V10, P25; McKenzie GJ, 1998, GENETICS, V149, P1163; McKenzie GJ, 2000, P NATL ACAD SCI USA, V97, P6646, DOI 10.1073/pnas.120161797; Metzgar D, 2000, CELL, V101, P581, DOI 10.1016/S0092-8674(00)80869-7; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NINIO J, 1991, GENETICS, V129, P957; ONO S, 1970, EVOLUTION GENE DUPLI; Prival MJ, 1996, GENETICS, V144, P1337; Radman M, 1975, Basic Life Sci, V5A, P355; Reynolds TY, 1996, CANCER RES, V56, P5754; Rosche WA, 1999, P NATL ACAD SCI USA, V96, P6862, DOI 10.1073/pnas.96.12.6862; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; Rosenberg SM, 1998, GENETICS, V148, P1559; ROTH JR, 1996, ESCHERICHIA COLI SAL, P2256; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; TLSTY TD, 1984, CELL, V37, P217, DOI 10.1016/0092-8674(84)90317-9; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; Von Borstel R C, 1978, Methods Cell Biol, V20, P1, DOI 10.1016/S0091-679X(08)62005-1; WHORISKEY SK, 1987, GENE DEV, V1, P227, DOI 10.1101/gad.1.3.227; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X	51	120	125	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					723	731		10.1016/S0092-8674(00)00176-8	http://dx.doi.org/10.1016/S0092-8674(00)00176-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114329	Bronze			2022-12-28	WOS:000165433100005
J	Martinelli, P				Martinelli, P			Holmes-Adie syndrome	LANCET			English	Editorial Material									Univ Bologna, Dept Neurol Sci, I-40123 Bologna, Italy	University of Bologna	Martinelli, P (corresponding author), Univ Bologna, Dept Neurol Sci, Via U Foscola 7, I-40123 Bologna, Italy.	pmartin@neuro.unibo.it						Adie WJ, 1931, BRIT MED J, V1931, P928, DOI 10.1136/bmj.1.3673.928; Holmes G. M., 1931, T OPHTHAL SOC UK, V51, P209; LOEWENFELD IE, 1967, AM J OPHTHALMOL, V63, P46, DOI 10.1016/0002-9394(67)90579-X; LOWENFIELD IE, 1993, PUPIL ANATOMY PHYSL, V1, P1085; Martinelli P, 1999, NEUROPHYSIOL CLIN, V29, P255, DOI 10.1016/S0987-7053(99)80061-6; Thomson HS, 1979, TOPICS NEUROOPHTHALM, P95; ULRICH J, 1980, EUR NEUROL, V19, P390, DOI 10.1159/000115179	7	28	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 18	2000	356	9243					1760	1761		10.1016/S0140-6736(00)03216-5	http://dx.doi.org/10.1016/S0140-6736(00)03216-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095273				2022-12-28	WOS:000165462300039
J	Tetley, M				Tetley, M			Instinctive sleeping and resting postures: an anthropological and zoological approach to treatment of low back and joint pain	BRITISH MEDICAL JOURNAL			English	Article											Tetley, M (corresponding author), 27 Cunningham Hill Rd, St Albans AL1 5B, England.							ROSEN SI, 1974, INTRO PRIMATES LIVIN, P20	1	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1616	1618		10.1136/bmj.321.7276.1616	http://dx.doi.org/10.1136/bmj.321.7276.1616			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124203	Green Published			2022-12-28	WOS:000166134500039
J	Pugh, J; Clarke, L; Gray, J; Haveman, J; Lawler, P; Bonner, S				Pugh, J; Clarke, L; Gray, J; Haveman, J; Lawler, P; Bonner, S			Presence of relatives during testing for brain stem death: questionnaire study	BRITISH MEDICAL JOURNAL			English	Article									S Cleveland Hosp, Intens Care Unit, Middlesbrough TS4 3BW, Cleveland, England; Univ Teesside, Ctr Hlth & Med Res, Middlesbrough TS1 3BA, Cleveland, England	University of Teesside	Bonner, S (corresponding author), S Cleveland Hosp, Intens Care Unit, Middlesbrough TS4 3BW, Cleveland, England.			gray, joanne/0000-0001-6157-230X				Black D, 1997, J ROY COLL PHYS LOND, V31, P260; COLLICAN MB, 1994, CRIT CARE NURS CLIN, V6, P607; Pallis C., 1996, ABC BRAINSTEM DEATH; Robinson SM, 1998, LANCET, V352, P614, DOI 10.1016/S0140-6736(97)12179-1; Swinburn JMA, 1999, BMJ-BRIT MED J, V318, P1753	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	2000	321	7275					1505	+		10.1136/bmj.321.7275.1505	http://dx.doi.org/10.1136/bmj.321.7275.1505			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118177	Bronze, Green Published			2022-12-28	WOS:000165994700026
J	Rogina, B; Reenan, RA; Nilsen, SP; Helfand, SL				Rogina, B; Reenan, RA; Nilsen, SP; Helfand, SL			Extended life-span conferred by cotransporter gene mutations in Drosophila	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; LONGEVITY; DIAPAUSE; STRESS; MUTANT	Aging is genetically determined and environmentally modulated. In a study of Longevity in the adult fruit fly, Drosophila melanogaster, we found that five independent P-element insertional mutations in a single gene resulted in a near doubling of the average adult Life-span without a decline in fertility or physical activity. Sequence analysis revealed that the product of this gene, named Indy (for I'm not dead yet), is most closely related to a mammalian sodium dicarboxylate cotransporter-a membrane protein that transports Krebs cycle intermediates. Indy was most abundantly expressed in the fat body, midgut, and oenocytes: the principal sites of intermediary metabolism in the fly. Excision of the P element resulted in a reversion to normal Life-span. These mutations may create a metabolic state that mimics caloric restriction, which has been shown to extend Life-span.	Univ Connecticut, Ctr Hlth, Sch Med, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut	Helfand, SL (corresponding author), Univ Connecticut, Ctr Hlth, Sch Med, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	shelfand@neuron.uchc.edu		Rogina, Blanka/0000-0003-1195-905X	NIA NIH HHS [R37 AG016667, AG14532, AG16667] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG014532, R37AG016667, R01AG016667] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bartke A, 2000, RES PRO CEL, V29, P181; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOYNTON S, 1992, GENETICS, V131, P655; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Hekimi S, 2000, RES PRO CEL, V29, P81; HELFAND SL, 1995, GENETICS, V140, P549; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Pajor AM, 1996, AM J PHYSIOL-RENAL, V270, pF642, DOI 10.1152/ajprenal.1996.270.4.F642; Pajor AM, 1999, ANNU REV PHYSIOL, V61, P663, DOI 10.1146/annurev.physiol.61.1.663; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; SOHAL RS, 1981, EXP GERONTOL, V16, P157, DOI 10.1016/0531-5565(81)90040-1; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SONDERGAARD L, 1993, TRENDS GENET, V9, P193, DOI 10.1016/0168-9525(93)90113-V; Wigglesworth VB, 1972, PRINCIPLES INSECT PH	26	356	389	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	2000	290	5499					2137	2140		10.1126/science.290.5499.2137	http://dx.doi.org/10.1126/science.290.5499.2137			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118146				2022-12-28	WOS:000165870600054
J	Ferriman, A				Ferriman, A			GMC decides on a new structure	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1434	1434		10.1136/bmj.321.7274.1434/a	http://dx.doi.org/10.1136/bmj.321.7274.1434/a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110733				2022-12-28	WOS:000165852300022
J	Wilcock, GK; Lilienfeld, S; Gaens, E				Wilcock, GK; Lilienfeld, S; Gaens, E		Galantamine International-1 Study	Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CHOLINERGIC HYPOTHESIS; APOLIPOPROTEIN-E; DONEPEZIL; GENOTYPE; RIVASTIGMINE; TOLERABILITY; METRIFONATE; INHIBITORS	Objective To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer's disease. Design Randomised, double blind, parallel group, placebo controlled trial. Setting 86 outpatient clinics in Europe and Canada. Participants 653 patients with mild to moderate Alzheimer's disease. Intervention Patients randomly assigned to galantamine had their daily dose escalated over three to four weeks to maintenance doses of 24 or 32 mg. Main outcome measures Scores on the 11 item cognitive subscale of the Alzheimer's disease assessment scale, the clinician's interview based impression of change plus caregiver input, and the disability assessment for dementia scale. The effect of apolipoprotein E4 genotype on response to treatment was also assessed. Results At six months, patients who received galantamine had a significantly better outcome on the 11 item cognitive subscale of the Alzheimer's disease assessment scale than patients in the placebo group (mean treatment effect 2.9 points for lower dose and 3.1 for higher dose, intention to tr eat analysis, P < 0.001 for both doses). Galantamine was more effective than placebo on the clinician's interview based impression of change plus caregiver input (P < 0.05 for both doses v placebo). At six months, patients in the higher dose galantamine group had significantly better scores on the disability assessment for dementia scale than patients in the placebo group (mean treatment effect 3.4 points, P < 0.05). Apolipoprotein E genotype had no effect on the efficacy of galantamine. 80% (525) of patients completed the study. Conclusion Galantamine is effective and well tolerated in Alzheimer's disease. As galantamine slowed the decline of functional ability as well as cognition, its effects are likely to be clinically relevant.	Univ Bristol, Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England; Janssen Res Fdn, B-2340 Beerse, Belgium	University of Bristol; Johnson & Johnson	Wilcock, GK (corresponding author), Univ Bristol, Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England.							Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; ALLEN NHP, 1995, J PSYCHOPHARMACOL, V9, P43, DOI 10.1177/026988119500900108; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bentham P, 1999, BRIT MED J, V319, P640, DOI 10.1136/bmj.319.7210.640a; Bores GM, 1996, J PHARMACOL EXP THER, V277, P728; Burns A, 1999, DEMENT GERIATR COGN, V10, P237, DOI 10.1159/000017126; *COMM PROP MED PRO, 1997, NOT GUID MED PROD TR; COREYBLOOM J, 1998, INT J GERIATR PSYCHO, V1, P55; Dubois B, 1999, INT J GERIATR PSYCH, V14, P973, DOI 10.1002/(SICI)1099-1166(199911)14:11<973::AID-GPS58>3.0.CO;2-U; Farlow MR, 1999, NEUROLOGY, V53, P2010, DOI 10.1212/WNL.53.9.2010; Farlow MR, 1998, NEUROLOGY, V50, P669, DOI 10.1212/WNL.50.3.669; *FDA, 1989, PER CENTR NERV SYST, P277; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Gelinas I, 1999, AM J OCCUP THER, V53, P471, DOI 10.5014/ajot.53.5.471; Higgins GA, 1997, PHARMACOL BIOCHEM BE, V56, P675, DOI 10.1016/S0091-3057(96)00420-0; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; Lawrence AD, 1998, NEUROCHEM RES, V23, P787, DOI 10.1023/A:1022419712453; Macgowan SH, 1998, INT J GERIATR PSYCH, V13, P625, DOI 10.1002/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2; MCDOWELL I, 1994, CAN J AGING, V13, P470; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOHS RC, 1997, ALZ DIS ASSOC DIS, V11, P13; Nordberg A, 1998, DRUG SAFETY, V19, P465, DOI 10.2165/00002018-199819060-00004; Pryse-Phillips W, 1999, ARCH NEUROL-CHICAGO, V56, P735, DOI 10.1001/archneur.56.6.735-a; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Schneider LS, 1996, J CLIN PSYCHIAT, V57, P30; SCHNEIDER LS, 1997, ALZ DIS ASSOC DIS, V11, P22; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; VASILENKO E T, 1974, Biokhimiya, V39, P701; WENDHAM PR, 1991, LANCET, V337, P1158	35	430	445	0	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1445	1449		10.1136/bmj.321.7274.1445	http://dx.doi.org/10.1136/bmj.321.7274.1445			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110737	Bronze, Green Published			2022-12-28	WOS:000165852300027
J	Shen, JN; Wenger, N; Glaspy, J; Hays, RD; Albert, PS; Choi, C; Shekelle, PG				Shen, JN; Wenger, N; Glaspy, J; Hays, RD; Albert, PS; Choi, C; Shekelle, PG			Electroacupuncture for control of myeloablative chemotherapy-induced emesis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER-CHEMOTHERAPY; ACUPUNCTURE; CYCLOPHOSPHAMIDE; ONDANSETRON; ENKEPHALIN; CISPLATIN; NAUSEA	Context High-dose chemotherapy poses considerable challenges to emesis management. Although prior studies suggest that acupuncture may reduce nausea and emesis, it is unclear whether such benefit comes from the nonspecific effects of attention and clinician-patient interaction. Objective To compare the effectiveness of electroacupuncture vs minimal needling and mock electrical stimulation or antiemetic medications alone in controlling emesis among patients undergoing a highly emetogenic chemotherapy regimen. Design Three-arm, parallel-group, randomized controlled trial conducted from March 1996 to December 1997, with a 5-day study period and a 9-day follow-up. Setting Oncology center at a university medical center. Patients One hundred four women (mean age, 46 years) with high-risk breast cancer. Interventions Patients were randomly assigned to receive low-frequency electroacupuncture at classic antiemetic acupuncture points once daily for 5 days (n=37), minimal needling at control points with mock electrostimulation on the same schedule (n=33); or no adjunct needling (n=34). All patients received concurrent triple antiemetic pharmacotherapy and high-dose chemotherapy (cyclophosphamide, cisplatin, and carmustine). Main Outcome Measures Total number of emesis episodes occurring during the 5-day study period and the proportion of emesis-free days, compared among the 3 groups. Results The number of emesis episodes occurring during the 5 days was lower for patients receiving electroacupuncture compared with those receiving minimal needling or pharmacotherapy alone (median number of episodes, 5, 10, and 15, respectively; P<.001). The electroacupuncture group had fewer episodes of emesis than the minimal needling group (P<.001), whereas the minimal needling group had fewer episodes of emesis than the antiemetic pharmacotherapy alone group (P=.01), The differences among groups were not significant during the 9-day follow-up period (P=.18), Conclusions in this study of patients with breast cancer receiving high-dose chemotherapy, adjunct electroacupuncture was more effective in controlling emesis than minimal needling or antiemetic pharmacotherapy alone, although the observed effect had limited duration.	NIAAA, Clin Studies Lab, Brain Electrophysiol & Imaging Sect, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90024 USA; RAND Corp, Santa Monica, CA USA; NCI, Biometr Res Branch, NIH, Bethesda, MD 20892 USA; W Los Angeles Vet Affairs Med Ctr, Dept Med, Vet Affairs Hlth Serv REs & Dev Serv, Los Angeles, CA 90073 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Shen, JN (corresponding author), NIAAA, Clin Studies Lab, Brain Electrophysiol & Imaging Sect, NIH, Room 6 S-240,Mail Stop 1610,10 Ctr Dr,Bldg 10, Bethesda, MD 20892 USA.		Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X	BHP HRSA HHS [PE19001-09] Funding Source: Medline	BHP HRSA HHS		AGLIETTI L, 1990, CANCER CHEMOTH PHARM, V26, P239, DOI 10.1007/BF02897209; BUCINSKAITE V, 1994, BRAIN RES, V666, P128, DOI 10.1016/0006-8993(94)90294-1; Cagnoni PJ, 1999, BONE MARROW TRANSPL, V24, P1, DOI 10.1038/sj.bmt.1701832; CHENG RSS, 1989, SCI BASES ACUPUNCTUR, P119; DUNDEE JW, 1987, LANCET, V1, P1083; DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508; EPSTEIN BS, 1993, HDB NAUSEA VOMITING, P93; Frigerio C, 1996, LANCET, V347, P1484, DOI 10.1016/S0140-6736(96)91720-1; Gilbert CJ, 1998, CANCER CHEMOTH PHARM, V42, P497, DOI 10.1007/s002800050851; Gralla RJ, 1999, J CLIN ONCOL, V17, P2971, DOI 10.1200/JCO.1999.17.9.2971; GRALLA RJ, 1991, EUR J CANCER, V27, pS5; GRUNBERG SM, 1993, NEW ENGL J MED, V329, P1790; HAN JS, 1984, NEUROPHARMACOLOGY, V23, P1; HARRIS AL, 1982, LANCET, V1, P714; JENKINS M, 1980, ACUPUNCT MED, V7, P21; KOBRINSKY NL, 1988, AM J PEDIAT HEMATOL, V10, P209; LAO L, 1997, P DEP DEF BREAST CAN, V3, P861; Lee A, 1999, ANESTH ANALG, V88, P1362, DOI 10.1097/00000539-199906000-00031; LESLIE RA, 1992, COLLOQ INSE, V223, P19; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MORROW G, 1992, BR J CANC S19, V66, pS60; MORROW GR, 1992, BRIT J CANCER, V66, pS54; Navari RM, 1999, NEW ENGL J MED, V340, P190, DOI 10.1056/NEJM199901213400304; OCONNOR J, 1981, ACUPUNCTURE COMPREHE, P557; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Rudd JA, 1999, EUR J PHARMACOL, V374, P77, DOI 10.1016/S0014-2999(99)00285-X; Tonato M, 1996, SUPPORT CARE CANCER, V4, P281, DOI 10.1007/BF01358880; VACCAGALLOWAY LL, 1985, PEPTIDES, V6, P177, DOI 10.1016/0196-9781(85)90029-4; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602	31	206	222	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2755	2761		10.1001/jama.284.21.2755	http://dx.doi.org/10.1001/jama.284.21.2755			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105182	Bronze			2022-12-28	WOS:000165509500030
J	Bulstrode, C; Hunt, V				Bulstrode, C; Hunt, V			What is mentoring?	LANCET			English	Editorial Material									Royal Coll Surg, Dept Educ, Edinburgh, Midlothian, Scotland; Univ Oxford, Sch Med, Oxford OX3 9DW, England	University of Oxford	Bulstrode, C (corresponding author), Royal Coll Surg, Dept Educ, Edinburgh, Midlothian, Scotland.							Andrews M, 1999, J ADV NURS, V29, P201, DOI 10.1046/j.1365-2648.1999.00884.x; Connor MP, 2000, MED EDUC, V34, P747; Djerassi C, 1999, NATURE, V397, P291, DOI 10.1038/16786; EGAN G, 1990, SKILLED HELPER; FREEMAN R, 1998, MENTORING GEN PRACTI; Johnson JC, 1999, ACAD MED, V74, P376, DOI 10.1097/00001888-199904000-00029; LUNDIN F, 1978, HARVARD BUS REV, V7, P89; Rieu E. V., 1991, HOMER ODYSSEY; *STAND COMM POSTGR, 1998, ENQ MENT SUPP DOCT D	9	14	14	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1788	1788		10.1016/S0140-6736(00)03229-3	http://dx.doi.org/10.1016/S0140-6736(00)03229-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	377UY	11117909				2022-12-28	WOS:000165545700008
J	Dowdall, N				Dowdall, N			"Is there a doctor on the aircraft?" Top 10 in-flight medical emergencies	BRITISH MEDICAL JOURNAL			English	Article									British Airways Hlth Serv, Harmondsworth UP7 0GB, England		Dowdall, N (corresponding author), British Airways Hlth Serv, POB 365, Harmondsworth UP7 0GB, England.								0	75	77	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1336	1337		10.1136/bmj.321.7272.1336	http://dx.doi.org/10.1136/bmj.321.7272.1336			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090520	Green Published			2022-12-28	WOS:000165561600034
J	Reisz, RR; Sues, HD				Reisz, RR; Sues, HD			Palaeontology the 'feathers' of Longisquama	NATURE			English	Article									Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada; Royal Ontario Museum, Dept Palaeobiol, Toronto, ON M5S 2C6, Canada	University of Toronto; University Toronto Mississauga; Royal Ontario Museum	Reisz, RR (corresponding author), Univ Toronto, Dept Biol, 3359 Mississauga Rd, Mississauga, ON L5L 1C6, Canada.							Feduccia A., 1996, ORIGIN EVOLUTION BIR; Jones TD, 2000, SCIENCE, V288, P2202, DOI 10.1126/science.288.5474.2202; SHAROV AG, 1970, PALEONTOL ZH, P127	3	17	18	0	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					428	428		10.1038/35044204	http://dx.doi.org/10.1038/35044204			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100716	Bronze			2022-12-28	WOS:000165429800035
J	Fukai, S; Nureki, O; Sekine, S; Shimada, A; Tao, JS; Vassylyev, DG; Yokoyama, S				Fukai, S; Nureki, O; Sekine, S; Shimada, A; Tao, JS; Vassylyev, DG; Yokoyama, S			Structural basis for double-sieve discrimination of L-valine from L-isoleucine and L-threonine by the complex of tRNA(Val) and valyl-tRNA synthetase	CELL			English	Article							ANGSTROM CRYSTAL-STRUCTURE; AMINO-ACID DISCRIMINATION; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; BAKERS-YEAST; ZINC ION; AMINOACYLATION; ADENYLATE; MECHANISM; DETERMINANTS	Valyl-tRNA synthetase (ValRS) strictly discriminates the cognate L-valine from the larger L-isoleucine and the isosteric L-threonine by the tRNA-dependent "double sieve" mechanism. In this study, we determined the 2.9 Angstrom crystal structure of a complex of Thermus thermophilus ValRS, tRNA(Val), and an analog of the Val-adenylate intermediate. The analog is bound in a pocket, where Pro(41) allows accommodation of the Val and Thr moieties but precludes the lie moiety (the first sieve), on the aminoacylation domain, The editing domain, which hydrolyzes incorrectly synthesized Thr-tRNA(Val), is bound to the 3' adenosine of tRNA(Val). A contiguous pocket was found to accommodate the Thr moiety, but not the Val moiety (the second sieve). Furthermore, another Thr binding pocket for Thr-adenylate hydrolysis was suggested on the editing domain.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan; SPring 8, Riken Harima Inst, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; Cubist Pharmaceut Inc, Cambridge, MA 02139 USA	University of Tokyo; Japan Synchrotron Radiation Research Institute; RIKEN	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Sekine, Shun-ichi/N-5450-2015; Fukai, Shuya/X-4838-2018; Vassylyev, Dmitry/A-9005-2008; Yokoyama, Shigeyuki/N-6911-2015	Sekine, Shun-ichi/0000-0001-8174-8704; Fukai, Shuya/0000-0002-1241-1443; Yokoyama, Shigeyuki/0000-0003-3133-7338; Shimada, Atsushi/0000-0002-4108-770X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Farrow MA, 1999, BIOCHEMISTRY-US, V38, P16898, DOI 10.1021/bi9920782; FERSHT A, 1985, ENZYME STRUCTURE MEC, P1; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1238, DOI 10.1021/bi00574a019; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P818, DOI 10.1021/bi00649a014; FREIST W, 1985, BIOCHEMISTRY-US, V24, P7014, DOI 10.1021/bi00345a040; FREIST W, 1994, EUR J BIOCHEM, V220, P745, DOI 10.1111/j.1432-1033.1994.tb18675.x; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hale SP, 1996, P NATL ACAD SCI USA, V93, P2755, DOI 10.1073/pnas.93.7.2755; IGLOI GL, 1977, BIOCHEMISTRY-US, V16, P1696, DOI 10.1021/bi00627a027; JAKUBOWSKI H, 1980, BIOCHEMISTRY-US, V19, P5071, DOI 10.1021/bi00563a021; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHDA D, 1984, FEBS LETT, V174, P20, DOI 10.1016/0014-5793(84)81069-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin L, 1996, BIOCHEMISTRY-US, V35, P5596, DOI 10.1021/bi960011y; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Mechulam Y, 1999, J MOL BIOL, V294, P1287, DOI 10.1006/jmbi.1999.3339; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Nomanbhoy TK, 2000, P NATL ACAD SCI USA, V97, P5119, DOI 10.1073/pnas.090102197; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; Sankaranarayanan R, 2000, NAT STRUCT BIOL, V7, P461; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Sugiura I, 2000, STRUCTURE, V8, P197, DOI 10.1016/S0969-2126(00)00095-2; SUSSMAN JL, 1976, SCIENCE, V192, P853, DOI 10.1126/science.775636; TAMURA K, 1994, J BIOL CHEM, V269, P22173; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627	44	233	240	1	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 22	2000	103	5					793	803		10.1016/S0092-8674(00)00182-3	http://dx.doi.org/10.1016/S0092-8674(00)00182-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114335	Bronze			2022-12-28	WOS:000165433100011
J	Nygard, J; Cobden, DH; Lindelof, PE				Nygard, J; Cobden, DH; Lindelof, PE			Kondo physics in carbon nanotubes	NATURE			English	Article							SINGLE-ELECTRON TRANSISTOR; QUANTUM WIRES; TRANSPORT; ROPES; DOT	The connection of electrical leads to wire-like molecules is a logical step in the development of molecular electronics, but also allows studies of fundamental physics. For example, metallic carbon nanotubes(1) are quantum wires that have been found to act as one-dimensional quantum dots(2,3), Luttinger liquids(4,5), proximity-induced superconductors(6,7) and ballistic(8) and diffusive(9) one-dimensional metals. Here we report that electrically contacted single-walled carbon nanotubes can serve as powerful probes of Kondo physics, demonstrating the universality of the Kondo effect. Arising in the prototypical case from the interaction between a localized impurity magnetic moment and delocalized electrons in a metallic host, the Kondo effect has been used to explain(10) enhanced low-temperature scattering from magnetic impurities in metals, and also occurs in transport through semiconductor quantum dots(11-18). The far greater tunability of dots (in our case, nanotubes) compared with atomic impurities renders new classes of Kondo-like effects(19,20) accessible. Our nanotube devices differ from previous systems in which Kondo effects have been observed, in that they are one-dimensional quantum dots with three-dimensional metal (gold) reservoirs. This allows us to observe Kondo resonances for very large electron numbers (N) in the dot, and approaching the unitary limit (where the transmission reaches its maximum possible value). Moreover, we detect a previously unobserved Kondo effect, occurring for even values of N in a magnetic field.	Univ Warwick, Dept Phys, Coventry CV4 7AL, W Midlands, England; Niels Bohr Inst, Orsted Lab, DK-2100 Copenhagen, Denmark	University of Warwick; University of Copenhagen; Niels Bohr Institute	Cobden, DH (corresponding author), Univ Warwick, Dept Phys, Coventry CV4 7AL, W Midlands, England.		Nygård, Jesper/F-5113-2014	Nygård, Jesper/0000-0002-4639-5314				Bachtold A, 1999, NATURE, V397, P673, DOI 10.1038/17755; Bockrath M, 1999, NATURE, V397, P598, DOI 10.1038/17569; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Cobden DH, 1998, PHYS REV LETT, V81, P681, DOI 10.1103/PhysRevLett.81.681; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Frank S, 1998, SCIENCE, V280, P1744, DOI 10.1126/science.280.5370.1744; Glazman LI, 2000, J LOW TEMP PHYS, V118, P247, DOI 10.1023/A:1004654129125; GLAZMAN LI, 1988, JETP LETT+, V47, P452; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Goldhaber-Gordon D, 1998, PHYS REV LETT, V81, P5225, DOI 10.1103/PhysRevLett.81.5225; Hewson A C, 1993, KONDO PROBLEM HEAVY; Kasumov AY, 1999, SCIENCE, V284, P1508, DOI 10.1126/science.284.5419.1508; MEIR Y, 1993, PHYS REV LETT, V70, P2601, DOI 10.1103/PhysRevLett.70.2601; Morpurgo AF, 1999, SCIENCE, V286, P263, DOI 10.1126/science.286.5438.263; NG TK, 1988, PHYS REV LETT, V61, P1768, DOI 10.1103/PhysRevLett.61.1768; Nygard J, 1999, APPL PHYS A-MATER, V69, P297, DOI 10.1007/s003390051004; Pustilnik M, 2000, PHYS REV LETT, V84, P1756, DOI 10.1103/PhysRevLett.84.1756; Sasaki S, 2000, NATURE, V405, P764, DOI 10.1038/35015509; Schmid J, 1998, PHYSICA B, V256, P182, DOI 10.1016/S0921-4526(98)00533-X; Simmel F, 1999, PHYS REV LETT, V83, P804, DOI 10.1103/PhysRevLett.83.804; Soh HT, 1999, APPL PHYS LETT, V75, P627, DOI 10.1063/1.124462; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V394, P761, DOI 10.1038/29494; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	26	581	584	2	135	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					342	346		10.1038/35042545	http://dx.doi.org/10.1038/35042545			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099037	Green Submitted			2022-12-28	WOS:000165296000040
J	Smith, R				Smith, R			How not to give a presentation	BRITISH MEDICAL JOURNAL			English	Article																			0	6	7	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1570	1571		10.1136/bmj.321.7276.1570	http://dx.doi.org/10.1136/bmj.321.7276.1570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124179	Green Published, Bronze			2022-12-28	WOS:000166134500017
J	Mayle, FE; Burbridge, R; Killeen, TJ				Mayle, FE; Burbridge, R; Killeen, TJ			Millennial-scale dynamics of southern Amazonian rain forests	SCIENCE			English	Article							REGION; BOLIVIA; RECORD; CLIMATE; BP	Amazonian rain forest-savanna boundaries are highly sensitive to climatic change and may also play an important role in rain forest speciation. However, their dynamics over millennial time scales are poorly understood. Here, we present late Quaternary pollen records from the southern margin of Amazonia, which show that the humid evergreen rain forests of eastern Bolivia have been expanding southward over the past 3000 years and that their present-day Limit represents the southernmost extent of Amazonian rain forest over at Least the past 50,000 years. This rain forest expansion is attributed to increased seasonal Latitudinal migration of the Intertropical Convergence Zone, which can in turn be explained by Milankovitch astronomic forcing.	Univ Leicester, Dept Geog, Leicester LE1 7RH, Leics, England; Conservat Int, Ctr Appl Biodivers Sci, Washington, DC 20037 USA; Museo Hist Nat Noel Kempff Mercado, Santa Cruz De La Sierra, Santa Cruz, Bolivia	University of Leicester; Conservation International	Mayle, FE (corresponding author), Univ Leicester, Dept Geog, Leicester LE1 7RH, Leics, England.			Mayle, Francis/0000-0001-9208-0519				Abbott MB, 1997, QUATERNARY RES, V47, P169, DOI 10.1006/qres.1997.1881; ABSY M L, 1976, Acta Amazonica, V6, P293; ABSY ML, 1991, CR ACAD SCI II, V312, P673; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; BURBRIDGE R, UNPUB; COLINVAUX P, 1999, AMAZON PLLEN MANUAL; Colinvaux PA, 2000, QUATERNARY SCI REV, V19, P141, DOI 10.1016/S0277-3791(99)00059-1; Cross SL, 2000, HOLOCENE, V10, P21, DOI 10.1191/095968300671452546; DEFREITAS HA, IN PRESS QUAT RES; Faegri K, 1975, TXB POLLEN ANAL; KILLEEN T, 1998, HUANCHACA PLATEAU NO; KILLEEN TJ, 1992, J TROP ECOL, V8, P389, DOI 10.1017/S0266467400006714; Killeen TJ, 1998, J TROP ECOL, V14, P803, DOI 10.1017/S0266467498000583; KILLEEN TJ, UNPUB; Latrubesse E., 1994, QUATERN INT, V21, P163; Litherland M., 1989, J S AM EARTH SCI, V2, P1, DOI [DOI 10.1016/0895-9811(89)90023-0, 10.1016/0895-9811(89)90023-0]; Martin L, 1997, QUATERNARY RES, V47, P117, DOI 10.1006/qres.1996.1866; MAYLE FE, UNPUB; Pessenda LCR, 1998, HOLOCENE, V8, P599, DOI 10.1191/095968398673187182; Pessenda LCR, 1998, RADIOCARBON, V40, P1013, DOI 10.1017/S0033822200018981; Smith TB, 1997, SCIENCE, V276, P1855, DOI 10.1126/science.276.5320.1855; Soubies F., 1979, CAH ORSTOM G, V1, P133; SOUBIES F, 1991, B IG USP PUBL ESP, V8, P233; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858; Turcq B, 1998, AMBIO, V27, P139; VANDERHAMMEN T, 1994, PALAEOGEOGR PALAEOCL, V109, P247, DOI 10.1016/0031-0182(94)90178-3; WIRRMANN D, 1995, QUATERNARY RES, V43, P344, DOI 10.1006/qres.1995.1040; WRIGHT HE, 1967, J SEDIMENT PETROL, V27, P957	29	351	366	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2291	+		10.1126/science.290.5500.2291	http://dx.doi.org/10.1126/science.290.5500.2291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125139	Green Published			2022-12-28	WOS:000165995800039
J	Huh, GS; Boulanger, LM; Du, HP; Riquelme, PA; Brotz, TM; Shatz, CJ				Huh, GS; Boulanger, LM; Du, HP; Riquelme, PA; Brotz, TM; Shatz, CJ			Functional requirement for class I MHC in CNS development and plasticity	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; LONG-TERM POTENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; CENTRAL-NERVOUS-SYSTEM; SYNAPTIC PLASTICITY; GENE-EXPRESSION; MICE; RETINOGENICULATE; SEGREGATION; SYNAPSES	Class I major histocompatibility complex (class I MHC) molecules, known to be important for immune responses to antigen, are expressed also by neurons that undergo activity-dependent, Long-term structural and synaptic modifications. Here, we show that in mice genetically deficient for cell surface class I MHC or for a class I MHC receptor component, CD3 zeta, refinement of connections between retina and central targets during development is incomplete. In the hippocampus of adult mutants, N-methyl-D-aspartate receptor-dependent Long-term potentiation (LTP) is enhanced, and Long-term depression (LTD) is absent. Specific class I MHC messenger RNAs are expressed by distinct mosaics of neurons, reflecting a potential for diverse neuronal functions. These results demonstrate an important role for these molecules in the activity-dependent remodeling and plasticity of connections in the developing and mature mammalian central nervous system (CNS).	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Huh, GS (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.		Brotz, Tilmann M/R-6599-2016	Brotz, Tilmann M/0000-0001-8212-459X; Boulanger, Lisa/0000-0002-6578-7890	NEI NIH HHS [EY06912, F32 EY007016-02, F32 EY007016, F32 EY007016-03, 1F32EY07016] Funding Source: Medline; NIMH NIH HHS [MH48108] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY007016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGGELOPOULOS N, 1989, ANAT EMBRYOL, V180, P243, DOI 10.1007/BF00315883; Amadou C, 1999, IMMUNOL REV, V167, P211, DOI 10.1111/j.1600-065X.1999.tb01394.x; Amsen D, 1998, IMMUNOL REV, V165, P209, DOI 10.1111/j.1600-065X.1998.tb01241.x; BEAR MF, 1995, NEURON, V15, P1, DOI 10.1016/0896-6273(95)90056-X; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CAMPBELL G, 1992, J NEUROSCI, V12, P1847; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Crair MC, 1999, CURR OPIN NEUROBIOL, V9, P88, DOI 10.1016/S0959-4388(99)80011-7; Deisseroth K, 1995, CURR BIOL, V5, P1334, DOI 10.1016/S0960-9822(95)00262-4; Dorfman JR, 1997, J IMMUNOL, V159, P5219; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Feldman DE, 1999, J NEUROBIOL, V41, P92, DOI 10.1002/(SICI)1097-4695(199910)41:1<92::AID-NEU12>3.0.CO;2-U; GODEMENT P, 1984, J COMP NEUROL, V230, P552, DOI 10.1002/cne.902300406; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; JACKSON MR, 1993, ANNU REV CELL BIOL, V9, P207, DOI 10.1146/annurev.cb.09.110193.001231; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; LIEBERMAN AR, 1974, J NEUROCYTOL, V3, P677, DOI 10.1007/BF01097191; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Neumann H, 1997, J EXP MED, V185, P305, DOI 10.1084/jem.185.2.305; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; RAFOLS JA, 1973, J COMP NEUROL, V150, P303, DOI 10.1002/cne.901500305; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; SO KF, 1990, J EXP BIOL, V153, P85; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Wong ROL, 1999, ANNU REV NEUROSCI, V22, P29, DOI 10.1146/annurev.neuro.22.1.29; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	37	618	635	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2155	2159		10.1126/science.290.5499.2155	http://dx.doi.org/10.1126/science.290.5499.2155			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118151	Green Accepted			2022-12-28	WOS:000165870600059
J	Chang, HY; Ready, DF				Chang, HY; Ready, DF			Rescue of photoreceptor degeneration in rhodopsin-null Drosophila mutants by activated Rac1	SCIENCE			English	Article							SMALL GTPASES; ACTIN CYTOSKELETON; CYTOCHALASIN-D; RHO GTPASES; G-PROTEINS; MORPHOGENESIS; GENE; DISRUPTION; MICE; ROD	Rhodopsin is essential for photoreceptor morphogenesis; photoreceptors lacking rhodopsin degenerate in humans, mice, and Drosophila. Here we report that transgenic expression of a dominant-active Drosophila Rho guanosine triphosphatase, Drac1, rescued photoreceptor morphogenesis in rhodopsin-null mutants; expression of dominant-negative Drac1 resulted in a phenotype similar to that seen in rhodopsin-null mutants. Drac1 was localized in a specialization of the photoreceptor cortical actin cytoskeleton, which was lost in rhodopsin-null mutants. Thus, rhodopsin appears to organize the actin cytoskeleton through Drac1, contributing a structural support-essential for photoreceptor morphogenesis.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Ready, DF (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.				NEI NIH HHS [EY10306] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010306] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; Edwards KA, 1997, DEV BIOL, V191, P103, DOI 10.1006/dbio.1997.8707; Fan SS, 1997, DEVELOPMENT, V124, P1497; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harden N, 1999, J CELL SCI, V112, P273; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Kumar JP, 1997, DEV BIOL, V188, P43, DOI 10.1006/dbio.1997.8636; Kumar JP, 1995, DEVELOPMENT, V121, P4359; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; LEONARD DS, 1992, J NEUROBIOL, V23, P605, DOI 10.1002/neu.480230602; LONGLEY R, UNPUB; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Magie CR, 1999, DEVELOPMENT, V126, P5353; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; PAULSEN R, 1979, BIOCHIM BIOPHYS ACTA, V557, P385, DOI 10.1016/0005-2736(79)90336-5; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; VAUGHAN DK, 1989, INVEST OPHTH VIS SCI, V30, P339; WILLIAMS DS, 1991, BIOESSAYS, V13, P171, DOI 10.1002/bies.950130405; WILLIAMS DS, 1992, J CELL SCI, V103, P183; WILLIAMS DS, 1988, J COMP NEUROL, V272, P161, DOI 10.1002/cne.902720202	23	101	101	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1978	1980		10.1126/science.290.5498.1978	http://dx.doi.org/10.1126/science.290.5498.1978			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110667				2022-12-28	WOS:000165810000050
J	Malin, MC; Edgett, KS				Malin, MC; Edgett, KS			Sedimentary rocks of early Mars	SCIENCE			English	Article							LAYERED DEPOSITS; VALLES-MARINERIS; GLOBAL SURVEYOR; ASTRONOMICAL THEORY; MARTIAN HIGHLANDS; RECENT VOLCANISM; EVOLUTION; SURFACE; CHANNELS; ORIGIN	Layered and massive outcrops on Mars, some as thick as 4 kilometers, display the geomorphic attributes and stratigraphic relations of sedimentary rock. Repeated beds in some locations imply a dynamic depositional environment during early martian history. Subaerial (such as eolian, impact, and volcaniclastic) and subaqueous processes may have contributed to the formation of the layers. Affinity for impact craters suggests dominance of lacustrine deposition; alternatively, the materials were deposited in a dry, subaerial setting in which atmospheric density, and variations thereof mimic a subaqueous depositional environment. The source regions and transport paths for the materials are not preserved.	Malin Space Sci Syst, San Diego, CA 92191 USA		Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.			Edgett, Kenneth/0000-0001-7197-5751				BLANEY DL, 1989, J GEOPHYS RES-SOLID, V94, P10159, DOI 10.1029/JB094iB08p10159; Blasius K. R., 1977, Journal of Geophysical Research, V82, P4067, DOI 10.1029/JS082i028p04067; Cabrol NA, 1999, ICARUS, V142, P160, DOI 10.1006/icar.1999.6191; Carr MH, 2000, ICARUS, V146, P366, DOI 10.1006/icar.2000.6428; CHAPMAN CR, 1974, ICARUS, V22, P272, DOI 10.1016/0019-1035(74)90177-8; CHAPMAN CR, 1968, ASTRON J, V74, P1039; CHRISTENSEN PR, 1988, J GEOPHYS RES-SOLID, V93, P7611, DOI 10.1029/JB093iB07p07611; Christensen PR, 2000, J GEOPHYS RES-PLANET, V105, P9623, DOI 10.1029/1999JE001093; Christensen PR, 1998, SCIENCE, V279, P1692, DOI 10.1126/science.279.5357.1692; CHRISTENSEN PR, 1986, J GEOPHYS RES, V91, P496; CRADDOCK RA, 1990, J GEOPHYS RES-SOLID, V95, P14265, DOI 10.1029/JB095iB09p14265; CRADDOCK RA, 1993, J GEOPHYS RES-PLANET, V98, P3453, DOI 10.1029/92JE02508; CUTTS JA, 1973, J GEOPHYS RES, V78, P4231, DOI 10.1029/JB078i020p04231; Edgett KS, 1997, GEOPHYS RES LETT, V24, P2897, DOI 10.1029/97GL02840; FANALE FP, 1976, ICARUS, V28, P179, DOI 10.1016/0019-1035(76)90032-4; Farmer JD, 1999, J GEOPHYS RES-PLANET, V104, P26977, DOI 10.1029/1998JE000540; Fisher R.V., 1984, PYROCLASTIC ROCKS, P186, DOI [10.1007/978-3-642-74864-6_8, DOI 10.1007/978-3-642-74864-6_8, DOI 10.1007/978-3-642-74864-6_10]; Hartmann WK, 1999, METEORIT PLANET SCI, V34, P167, DOI 10.1111/j.1945-5100.1999.tb01743.x; Hartmann WK, 2000, J GEOPHYS RES-PLANET, V105, P15011, DOI 10.1029/1999JE001189; Hartmann WK, 1999, NATURE, V397, P586, DOI 10.1038/17545; HARTMANN WK, 1966, ICARUS, V5, P565, DOI 10.1016/0019-1035(66)90071-6; HARTMANN WK, 1971, ICARUS, V15, P410, DOI 10.1016/0019-1035(71)90119-9; HARTMANN WK, 1973, J GEOPHYS RES, V78, P4096, DOI 10.1029/JB078i020p04096; HARTMANN WK, 1981, BASALTIC VOLCANISM T, P1050; JONES KL, 1974, J GEOPHYS RES, V79, P3917, DOI 10.1029/JB079i026p03917; KERRIDGE JF, 1995, NASA SPEC PUBL NASA; Keszthelyi L, 2000, J GEOPHYS RES-PLANET, V105, P15027, DOI 10.1029/1999JE001191; KOMATSU G, 1993, J GEOPHYS RES-PLANET, V98, P11105, DOI 10.1029/93JE00537; LEIGHTON RB, 1966, SCIENCE, V153, P136, DOI 10.1126/science.153.3732.136; LEIGHTON RB, 1965, SCIENCE, V149, P627, DOI 10.1126/science.149.3684.627; Lucchitta B. K., 1992, MARS, P453; MALIN MC, 1992, J GEOPHYS RES-PLANET, V97, P7699, DOI 10.1029/92JE00340; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; Malin MC, 1999, NATURE, V397, P589, DOI 10.1038/17551; MALIN MC, 1999, 5 INT C MARS LUN PLA; MALIN MC, 1976, THESIS CALTECH PASAD, pCH3; McCauley J. F., 1977, US GEOL SURV INTERAG, V81; MCCAULEY JF, 1978, US GEOL SURV MISC I, V897; McEwen AS, 1999, NATURE, V397, P584, DOI 10.1038/17539; MCKAY CP, 1989, REV GEOPHYS, V27, P189, DOI 10.1029/RG027i002p00189; MELLON MT, IN PRESS ICARUS; NEDELL SS, 1987, ICARUS, V70, P409, DOI 10.1016/0019-1035(87)90086-8; NEUKUM G, 1981, J GEOPHYS RES, V86, P3097, DOI 10.1029/JB086iB04p03097; NEUKUM G, 1976, SCIENCE, V194, P1381, DOI 10.1126/science.194.4272.1381; OPIK EJ, 1965, IR ASTRON J, V7, P473; PIERI D, 1976, ICARUS, V27, P25, DOI 10.1016/0019-1035(76)90182-2; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; SCOTT DH, 1986, US GEOL SURV MISC IN; SELIVANOV AS, 1989, NATURE, V341, P593, DOI 10.1038/341593a0; SHARP RP, 1975, GEOL SOC AM BULL, V86, P593, DOI 10.1130/0016-7606(1975)86<593:COM>2.0.CO;2; SHARP RP, 1963, J GEOL, V71, P617, DOI 10.1086/626936; SHARP RP, 1973, J GEOPHYS RES, V78, P4073, DOI 10.1029/JB078i020p04073; SHOEMAKER EM, 1962, MOON S, V14, P289; SODERBLOM LA, 1974, ICARUS, V22, P239, DOI 10.1016/0019-1035(74)90175-4; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; SQUYRES SW, 1989, ICARUS, V79, P229, DOI 10.1016/0019-1035(89)90078-X; TANAKA KL, 1986, J GEOPHYS RES-SOLID, V91, pE139, DOI 10.1029/JB091iB13p0E139; TANAKA KL, 1992, P LUNAR PLANET SCI, V22, P73; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; WARD WR, 1974, J GEOPHYS RES, V79, P3387, DOI 10.1029/JC079i024p03387; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; Wentworth CK, 1922, J GEOL, V30, P377, DOI 10.1086/622910; Wilhelms D.E., 1990, PLANETARY MAPPING, P208; Zimbelman J.R., 1990, LUNAR PLANET SCI, V21, P1375; [No title captured]	65	572	582	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1927	1937		10.1126/science.290.5498.1927	http://dx.doi.org/10.1126/science.290.5498.1927			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110654				2022-12-28	WOS:000165810000037
J	Phillips, KA; Shlipak, MG; Coxson, P; Heidenreich, PA; Hunink, MGM; Goldman, PA; Williams, LW; Weinstein, MC; Goldman, L				Phillips, KA; Shlipak, MG; Coxson, P; Heidenreich, PA; Hunink, MGM; Goldman, PA; Williams, LW; Weinstein, MC; Goldman, L			Health and economic benefits of increased beta-blocker use following myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; QUALITY-OF-LIFE; COOPERATIVE CARDIOVASCULAR PROJECT; RANDOMIZED CLINICAL-TRIALS; COST-EFFECTIVENESS; UNITED-STATES; PRACTICE GUIDELINES; ELDERLY PATIENTS; DRUG-TREATMENT; POLICY MODEL	Context beta -Blockers are underused in patients who have myocardial infarction (MI), despite the proven efficacy of these agents. New evidence indicates that beta -blockers can have benefit in patients with conditions that have been considered relative contraindications, Understanding the consequences of underuse of beta -blockers is important because of the implications for current policy debates over quality-of-care measures and Medicare prescription drug coverage, Objective To examine the potential health and economic impact of increased use of beta -blockers in patients who have had MI. Design and Setting We used the Coronary Heart Disease (CHD) Policy Model, a computer-simulation Markov model of CHD in the US population, to estimate the epidemiological impact and cost-effectiveness of increased beta -blocker use from current to target levels among survivors of MI aged 35 to 84 years. Simulations included 1 cohort of MI survivors in 2000 followed up for 20 years and 20 successive annual cohorts of all first-MI survivors in 2000-2020. Mortality and morbidity from CHD were derived from published meta-analyses and recent studies. This analysis used a societal perspective. Main Outcome Measures Prevented Mis, CHD mortality, life-years gained, and cost per quality-adjusted life-year (QALY) gained in 2000-2020, Results Initiating beta -blocker use for all MI survivors except those with absolute contraindications in 2000 and continuing treatment for 20 years would result in 4300 fewer CHD deaths, 3500 Mis prevented, and 45000 life-years gained compared with current use. The incremental cost per QALY gained would be $4500, If this increase in beta -blocker use were implemented in all first-MI survivors annually over 20 years, beta -blockers would save $18 million and result in 72000 fewer CHD deaths, 62000 Mis prevented, and 447000 life-years gained. Sensitivity analyses demonstrated that the cost-effectiveness of beta -blocker therapy would always be less than $11000 per QALY gained, even under unfavorable assumptions, and may even be cost saving, Restricting beta -blockers only to ideal patients (those without absolute or relative contraindications) would reduce the epidemiological impact of beta -blocker therapy by about 60%, Conclusions Our simulation indicates that increased use of beta -blockers after MI would lead to impressive gains in health and would be potentially cost saving.	Univ Calif San Francisco, Sch Pharm, Inst Hlth Policy Studies, Dept Clin Pharm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Excellence Hlth Care Markets & Managed Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; San Francisco Vet Affairs Med Ctr, San Francisco, CA USA; Stanford Univ, Palo Alto VA Hlth Care Syst, Palo Alto, CA 94304 USA; Stanford Univ, Dept Med, Palo Alto, CA 94304 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Erasmus Univ, Med Ctr, Rotterdam, Netherlands	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; Stanford University; Stanford University; Harvard University; Harvard T.H. Chan School of Public Health; Erasmus University Rotterdam; Erasmus MC	Phillips, KA (corresponding author), Univ Calif San Francisco, Sch Pharm, Inst Hlth Policy Studies, Dept Clin Pharm, 3333 Calif St,Room 420,Box 0613, San Francisco, CA 94143 USA.		Heidenreich, Paul/AAU-6864-2021	Heidenreich, Paul/0000-0001-7730-8490				AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; Bradford WD, 1999, PHARMACOECONOMICS, V15, P257, DOI 10.2165/00019053-199915030-00005; BRAND DA, 1995, J AM COLL CARDIOL, V26, P1432, DOI 10.1016/0735-1097(95)00362-2; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Cleophas TJM, 1996, INT J CLIN PHARM TH, V34, P312; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P408; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; Gattis WA, 1999, ARCH INTERN MED, V159, P1939, DOI 10.1001/archinte.159.16.1939; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GOLDMAN L, 1989, CIRCULATION, V80, P254, DOI 10.1161/01.CIR.80.2.254; GOLDMAN L, 1993, AM J CARDIOL, V72, pD75, DOI 10.1016/0002-9149(93)90015-5; Goldman L, 1999, J AM COLL CARDIOL, V34, P768, DOI 10.1016/S0735-1097(99)00260-0; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; Grimm RH, 1997, ARCH INTERN MED, V157, P638, DOI 10.1001/archinte.157.6.638; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; HJALMARSON A, 1981, LANCET, V2, P823; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Jackson G, 1999, INT J CLIN PRACT, V53, P363; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; *MED EC CO, 1998, DRUG TOP RED BOOK; *NAT COMM QUAL ASS, 1999, STAT MAN CAR QUAL RE; *NAT COMM QUAL ASS, 1997, WID QUAL CIRC 1996 A; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Phillips BG, 1996, AM HEART J, V131, P872, DOI 10.1016/S0002-8703(96)90167-2; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; Siegel D, 1997, JAMA-J AM MED ASSOC, V278, P1745, DOI 10.1001/jama.278.21.1745; SIEGEL J, 1996, COST EFFECTIVENESS H, pCH9; SIM I, 1999, SOC MED DEC MAK C OC; Soumerai SB, 1999, ARCH INTERN MED, V159, P2013, DOI 10.1001/archinte.159.17.2013; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Stinett AA, 1996, COST EFFECTIVENESS H, P349; Tosteson ANA, 1997, CIRCULATION, V95, P24, DOI 10.1161/01.CIR.95.1.24; TOSTESON ANA, 1990, AM J PUBLIC HEALTH, V80, P1481, DOI 10.2105/AJPH.80.12.1481; TSEVAT J, 1995, J AM COLL CARDIOL, V26, P914, DOI 10.1016/0735-1097(95)00284-1; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; TSEVAT J, 1992, AM J MED, V93, pS43, DOI 10.1016/0002-9343(92)90627-N; Wang TJ, 1998, ARCH INTERN MED, V158, P1901, DOI 10.1001/archinte.158.17.1901; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	51	80	82	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2748	2754		10.1001/jama.284.21.2748	http://dx.doi.org/10.1001/jama.284.21.2748			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105180	Bronze			2022-12-28	WOS:000165509500029
J	Cheng, CHF; Sanders, GD; Hlatky, MA; Heidenreich, P; McDonald, KM; Lee, BK; Larson, MS; Owens, DK				Cheng, CHF; Sanders, GD; Hlatky, MA; Heidenreich, P; McDonald, KM; Lee, BK; Larson, MS; Owens, DK			Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia	ANNALS OF INTERNAL MEDICINE			English	Article							NODAL REENTRANT TACHYCARDIA; QUALITY-OF-LIFE; SUPRA-VENTRICULAR TACHYCARDIA; PARKINSON-WHITE-SYNDROME; SLOW PATHWAY ABLATION; LONG-TERM EFFICACY; CATHETER ABLATION; ATRIOVENTRICULAR NODE; CARDIAC-ARRHYTHMIAS; ACCESSORY PATHWAYS	Background: Radiofrequency ablation is an established but expensive treatment option for many forms of supraventricular tachycardia. Most cases of supraventricular tachycardia are not life-threatening; the goal of therapy is therefore to improve the patient's quality of life. Objective: To compare the cost-effectiveness of radiofrequency ablation with that of medical management of supraventricular tachycardia. Design: Markov model. Data Sources: Costs were estimated from a major academic hospital and the literature, and treatment efficacy was estimated from reports from clinical studies at major medical centers. Probabilities of clinical outcomes were estimated from the literature. To account for the effect of radiofrequency ablation on quality of life, assessments by patients who had undergone the procedure were used. Target Population: Cohort of symptomatic patients who experienced 4.6 unscheduled visits per year to an emergency department or a physician's office while receiving long-term drug therapy for supraventricular tachycardia. Time Horizon: Patient lifetime. Perspective: Societal. Interventions: Initial radiofrequency ablation, long-term antiarrhythmic drug therapy, and treatment of acute episodes of arrhythmia with antiarrhythmic drugs. Outcome Measures: costs, quality-adjusted life-years, life-years, and marginal cost-effectiveness ratios. Results of Base-Case Analysis: Among patients who have monthly episodes of supraventricular tachycardia, radiofrequency ablation was the most effective and least expensive therapy and therefore dominated the drug therapy options. Radiofrequency ablation improved quality-adjusted life expectancy by 3.10 quality-adjusted life-years and reduced lifetime medical expenditures by $27 900 compared with long-term drug therapy. Long-term drug therapy was more effective and had lower costs than episodic drug therapy. Results of Sensitivity Analysis: The findings were highly robust over substantial variations in assumptions about the efficacy and complication rate of radiofrequency ablation, including analyses in which the complication rate was tripled and efficacy was decreased substantially. Conclusions: Radiofrequency ablation substantially improves quality of life and reduces costs when it is used to treat highly symptomatic patients. Although the benefit of radiofrequency ablation has not been studied in less symptomatic patients, a small improvement in quality of life is sufficient to give preference to radiofrequency ablation over drug therapy.	Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Yale University	Owens, DK (corresponding author), Stanford Univ, Ctr Primary Care & Outcomes Res, 179 Encina Commons, Stanford, CA 94305 USA.	owens@stanford.edu	Heidenreich, Paul/AAU-6864-2021	Heidenreich, Paul/0000-0001-7730-8490; Hlatky, Mark/0000-0003-4686-9441	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008362] Funding Source: NIH RePORTER; AHRQ HHS [HS 08362] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM MED ASS, 1998, CURR PROC TERM; ANDERSON JL, 1992, AM J CARDIOL, V70, pA11, DOI 10.1016/0002-9149(92)91072-C; ANDERSON JL, 1988, AM J CARDIOL, V62, pD62; BAKER JH, 1994, AM J CARDIOL, V73, P765, DOI 10.1016/0002-9149(94)90878-8; Basta Magdy, 1997, Cardiology Clinics, V15, P587; Basta MN, 1997, AM J CARDIOL, V80, P155, DOI 10.1016/S0002-9149(97)00310-X; Bathina MN, 1998, AM J CARDIOL, V82, P589, DOI 10.1016/S0002-9149(98)00416-0; BERNSTEIN AD, 1994, PACE, V17, P1714, DOI 10.1111/j.1540-8159.1994.tb03738.x; Bubien RS, 1996, CIRCULATION, V94, P1585, DOI 10.1161/01.CIR.94.7.1585; Calkins H, 1996, J CARDIOVASC ELECTR, V7, P704, DOI 10.1111/j.1540-8167.1996.tb00578.x; Calkins H, 1999, CIRCULATION, V99, P262, DOI 10.1161/01.CIR.99.2.262; Chen SA, 1996, AM J CARDIOL, V77, P41; CLAIR WK, 1992, CLIN PHARMACOL THER, V51, P562, DOI 10.1038/clpt.1992.63; COBBE SM, 1995, CIRCULATION, V92, P2550; DEBUITLEIR M, 1990, AM J CARDIOL, V66, P189, DOI 10.1016/0002-9149(90)90586-P; DIMICH I, 1970, AM HEART J, V79, P811, DOI 10.1016/0002-8703(70)90368-6; Dorian P, 1996, AM J CARDIOL, V77, pA89, DOI 10.1016/S0002-9149(97)89123-0; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; FISHER JD, 1994, J AM COLL CARDIOL, V24, P828, DOI 10.1016/0735-1097(94)90036-1; GANZ LI, 1995, NEW ENGL J MED, V332, P162, DOI 10.1056/NEJM199501193320307; Gold MR, 1996, COST EFFECTIVENESS H; GRAVES EJ, 1990, DETAILED DIAGNOSES P, V113; GRAVES EJ, 1996, DETAILED DIAGNOSES P, V138; HARNER AW, 1993, PACING CLIN ELECTROP, V16, P1394; HARRIS A, 1966, AM J CARDIOL, V18, P431, DOI 10.1016/0002-9149(66)90066-X; HENTHORN RW, 1991, CIRCULATION, V83, P119, DOI 10.1161/01.CIR.83.1.119; Hindricks G, 1996, EUR HEART J, V17, P82; HINDRICKS G, 1993, EUR HEART J, V14, P1644, DOI 10.1093/eurheartj/14.12.1644; HOGENHUIS W, 1993, CIRCULATION, V88, P437; HUYCKE EC, 1989, J AM COLL CARDIOL, V13, P538, DOI 10.1016/0735-1097(89)90589-5; Iesaka Y, 1996, JPN HEART J, V37, P759; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; KALBFLEISCH SJ, 1993, J AM COLL CARDIOL, V21, P567, DOI 10.1016/0735-1097(93)90086-G; KALBFLEISCH SJ, 1992, J AM COLL CARDIOL, V19, P1583, DOI 10.1016/0735-1097(92)90621-S; KAY GN, 1993, J CARDIOVASC ELECTR, V4, P371, DOI 10.1111/j.1540-8167.1993.tb01277.x; KERTES PJ, 1993, AUST NZ J MED, V23, P433, DOI 10.1111/j.1445-5994.1993.tb01458.x; KLEIN GJ, 1988, AM J CARDIOL, V61, pA77, DOI 10.1016/0002-9149(88)90745-X; KLEIN GJ, 1990, PACE, V13, P1516, DOI 10.1111/j.1540-8159.1990.tb04032.x; Krikler D M, 1988, Prog Clin Biol Res, V275, P301; KUBIK MM, 1986, CURR MED RES OPIN, V10, P215, DOI 10.1185/03007998609110441; Kugler JD, 1997, AM J CARDIOL, V80, P1438, DOI 10.1016/S0002-9149(97)00736-4; Larson MS, 1999, AM J CARDIOL, V84, P471, DOI 10.1016/S0002-9149(99)00338-0; LAU CP, 1995, PACE, V18, P424, DOI 10.1111/j.1540-8159.1995.tb02541.x; LEATHER RA, 1991, AM J CARDIOL, V68, P1651, DOI 10.1016/0002-9149(91)90324-E; Lee KL, 1997, CLIN CARDIOL, V20, P372, DOI 10.1002/clc.4960200414; LESH MD, 1992, J AM COLL CARDIOL, V19, P1303, DOI 10.1016/0735-1097(92)90338-N; Lin JL, 1998, J AM COLL CARDIOL, V31, P855, DOI 10.1016/S0735-1097(98)00015-1; MAN KC, 1993, AM J CARDIOL, V72, P1323, DOI 10.1016/0002-9149(93)90308-Y; MANKIW NG, 2001, PRINCIPLES EC, P519; MANOLIS AS, 1994, ANN INTERN MED, V121, P452, DOI 10.7326/0003-4819-121-6-199409150-00010; MARGOLIS B, 1980, AM J CARDIOL, V45, P621, DOI 10.1016/S0002-9149(80)80014-2; MARKELL RL, 1995, PACE, V18, P1474, DOI 10.1111/j.1540-8159.1995.tb06733.x; MAURITSON DR, 1982, ANN INTERN MED, V96, P409, DOI 10.7326/0003-4819-96-4-409; *MED EC, 1998, RED BOOK; MEHTA D, 1995, BRIT HEART J, V74, P671; Morady F, 1999, NEW ENGL J MED, V340, P534, DOI 10.1056/NEJM199902183400707; NEUSS H, 1988, AM J CARDIOL, V62, pD56; Orejarena LA, 1998, J AM COLL CARDIOL, V31, P150, DOI 10.1016/S0735-1097(97)00422-1; OWENS DK, 1990, MED INFORMATICS COMP, P70; PRITCHETT ELC, 1983, AM J CARDIOL, V52, P1007, DOI 10.1016/0002-9149(83)90521-0; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; PRITCHETT ELC, 1988, AM J CARDIOL, V62, pD1; Prystowsky EN, 1997, PACE, V20, P552, DOI 10.1111/j.1540-8159.1997.tb06210.x; PRYSTOWSKY EN, 1994, CLIN CARDIOL S2, V17, P117; Sakurada H, 1996, JPN HEART J, V37, P751; SCHEINMAN M, 1994, CLIN CARDIOL, V117, P11; SCHEINMAN MM, 1992, PACE, V15, P715, DOI 10.1111/j.1540-8159.1992.tb06835.x; SCHEINMAN MM, 1993, PACE, V16, P671, DOI 10.1111/j.1540-8159.1993.tb01641.x; Scheinman MM, 2000, PACE, V23, P1020, DOI 10.1111/j.1540-8159.2000.tb00891.x; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stevenson WG, 1997, AM J CARDIOL, V80, pG56, DOI 10.1016/S0002-9149(97)00714-5; STRICKBERGER SA, 1993, AM J CARDIOL, V71, P473; SUNG RJ, 1994, PACE, V17, P1413, DOI 10.1111/j.1540-8159.1994.tb02461.x; SZEKELY P, 1966, AM J CARDIOL, V18, P426, DOI 10.1016/0002-9149(66)90065-8; Talwar K K, 1996, Indian Heart J, V48, P685; THAKUR RK, 1994, CAN J CARDIOL, V10, P835; TROHMAN RG, 1994, AM HEART J, V128, P586, DOI 10.1016/0002-8703(94)90635-1; *US PREV SERV TASK, 1996, REP US PREV SERV TAS, P861; Van Wijck EEE, 1998, MED DECIS MAKING, V18, P400, DOI 10.1177/0272989X9801800407; WINNIFORD MD, 1984, AM J CARDIOL, V54, P1138, DOI 10.1016/S0002-9149(84)80162-9; YEH SJ, 1983, AM J CARDIOL, V52, P271, DOI 10.1016/0002-9149(83)90121-2; ZEECHENG CS, 1988, AM J CARDIOL, V62, pD23	83	55	57	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					864	876		10.7326/0003-4819-133-11-200012050-00010	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103056				2022-12-28	WOS:000165585800005
J	van den Engh, G; Nelson, P; Roach, J				van den Engh, G; Nelson, P; Roach, J			Analytical dynamics - Numismatic gyrations	NATURE			English	Article									Inst Syst Biol, Seattle, WA 98105 USA; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Utah, Salt Lake City, UT 84132 USA	Institute for Systems Biology (ISB); University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah	van den Engh, G (corresponding author), Inst Syst Biol, Seattle, WA 98105 USA.								0	31	33	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					540	540		10.1038/35046209	http://dx.doi.org/10.1038/35046209			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117733				2022-12-28	WOS:000165548600105
J	Bossuyt, PMM; Lijmer, JG; Mol, BWJ				Bossuyt, PMM; Lijmer, JG; Mol, BWJ			Randomised comparisons of medical tests: sometimes invalid, not always efficient	LANCET			English	Editorial Material							CONTROLLED TRIAL; IMPACT		Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Bossuyt, PMM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021; Mol, Ben/I-4526-2012	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; 				BONADIO WA, 1988, CLIN PEDIATR, V27, P601, DOI 10.1177/000992288802701207; Bossuyt P M, 1999, Acad Radiol, V6 Suppl 1, pS77, DOI 10.1016/S1076-6332(99)80092-0; DOERN GV, 1994, J CLIN MICROBIOL, V32, P1757, DOI 10.1128/JCM.32.7.1757-1762.1994; ELIA S, 1992, EUR J CARDIO-THORAC, V6, P361, DOI 10.1016/1010-7940(92)90173-U; FREEDMAN LS, 1987, BRIT J RADIOL, V60, P1071, DOI 10.1259/0007-1285-60-719-1071; FRYBACK DG, 1991, MED DECIS MAKING, V11, P88, DOI 10.1177/0272989X9101100203; GUYATT GH, 1986, J CHRON DIS, V39, P295, DOI 10.1016/0021-9681(86)90051-2; Hall S, 2000, BMJ-BRIT MED J, V320, P407, DOI 10.1136/bmj.320.7232.407; Hudson ER, 1996, RADIOLOGY, V198, P61, DOI 10.1148/radiology.198.1.8539407; Lawson K, 1996, J MED GENET, V33, P856, DOI 10.1136/jmg.33.10.856; Nienhuis SJ, 1997, ULTRASOUND OBST GYN, V9, P6, DOI 10.1046/j.1469-0705.1997.09010006.x; Oei SG, 1998, BRIT MED J, V317, P502; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Rothman K., 1998, MODERN EPIDEMIOLOGY; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; van der Post JAM, 1998, LANCET, V351, P913, DOI 10.1016/S0140-6736(05)70333-0; van Loon AJ, 1997, LANCET, V350, P1799, DOI 10.1016/S0140-6736(97)05431-7; WALTER SD, 1977, AM J EPIDEMIOL, V105, P387, DOI 10.1093/oxfordjournals.aje.a112395; WATSON A, 1994, FERTIL STERIL, V61, P470	19	158	163	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1844	1847		10.1016/S0140-6736(00)03246-3	http://dx.doi.org/10.1016/S0140-6736(00)03246-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117930				2022-12-28	WOS:000165545700043
J	Greenberg, JE; Lynn, M; Kirsner, RS; Hanly, AJ				Greenberg, JE; Lynn, M; Kirsner, RS; Hanly, AJ			Mucocutaneous pigmentation due to zinc deposition	LANCET			English	Article									Univ Miami, Dept Pathol, Miami, FL 33136 USA; Univ Miami, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA; Univ Miami, Ctr Adv Microscopy, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Greenberg, JE (corresponding author), Univ Miami, Dept Pathol, Miami, FL 33136 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1817	1817		10.1016/S0140-6736(00)03235-9	http://dx.doi.org/10.1016/S0140-6736(00)03235-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117915				2022-12-28	WOS:000165545700014
J	Kahn, RS; Wise, PH; Kennedy, BP; Kawachi, I				Kahn, RS; Wise, PH; Kennedy, BP; Kawachi, I			State income inequality, household income, and maternal mental and physical health: cross sectional national survey	BRITISH MEDICAL JOURNAL			English	Article							SELF-RATED HEALTH; UNITED-STATES; ALAMEDA-COUNTY; MORTALITY; PATHWAYS	Objective To examine the association of state income inequality and individual household income with the mental and physical health of women with young children. Design Cross sectional study. Individual level data (outcomes, income, and other sociodemographic covariates) from a 1991 follow up survey of a birth cohort established in 1988. State level income inequality calculated from the income distribution of each state from 1990 US census. Setting United States, 1991. Participants Nationally representative stratified random sample of 8060 women who gave birth in 1988 and were successfully contacted (89%) in 1991. Main outcome measures Depressive symptoms (Center for Epidemiologic Studies depression score >15) and self rated health Results 19% of women reported depressive symptoms, and 7.5% reported fair or poor health. Compared with women in the highest fifth of distribution of household income, women in the lowest fifth were more likely to report depressive symptoms (33% v 9% P<0.001) and fair or poor health (15% v 2% P<0.001). Compared with low income women in states with low income inequality, low income women in states wit high income inequality had a higher risk of depressive symptoms (odds ratio 1.6, 95% confidence interval 1.0 to 2.6) and fair or poor health (1.8, 0.9 to 3.5). Conclusions High income inequality confers an increased risk of poor mental and physical health, particularly among the poorest women. Both income inequality and household income are important for health in this population.	Childrens Hosp, Med Ctr, Div Gen & Community Pediat, Cincinnati, OH 45229 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Med Ctr, Boston, MA 02118 USA; Harvard Univ, Sch Publ Hlth, Div Publ Hlth Practice, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA	Cincinnati Children's Hospital Medical Center; Boston University; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kahn, RS (corresponding author), Childrens Hosp, Med Ctr, Div Gen & Community Pediat, CH-1,3333 Burnet, Cincinnati, OH 45229 USA.							BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; Federman M, 1996, MON LABOR REV, V119, P3; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; Gravelle H, 1998, BMJ-BRIT MED J, V316, P382, DOI 10.1136/bmj.316.7128.382; HIL IT, 1990, HLTH CARE FINANCING, V11, P75; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; KALTON G, 1993, INTRO SURVEY SAMPLIN; Kaplan GA, 1996, BRIT MED J, V313, P1207, DOI 10.1136/bmj.313.7066.1207; Kaplan GA, 1996, BRIT MED J, V312, P999; Kaplan GA, 1996, INT J HEALTH SERV, V26, P507, DOI 10.2190/4CUU-7B3G-G4XR-0K0B; Kawachi I, 1999, SOC SCI MED, V48, P21, DOI 10.1016/S0277-9536(98)00286-X; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; Kawachi I, 1999, HEALTH SERV RES, V34, P215; Kennedy BP, 1996, BRIT MED J, V313, P1207, DOI 10.1136/bmj.313.7066.1207a; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kennedy BP, 1998, BRIT MED J, V317, P917; Lynch JW, 1997, NEW ENGL J MED, V337, P1889, DOI 10.1056/NEJM199712253372606; Lynch JW, 1998, AM J PUBLIC HEALTH, V88, P1074, DOI 10.2105/AJPH.88.7.1074; Marmot M, 1997, SOC SCI MED, V44, P901, DOI 10.1016/S0277-9536(96)00194-3; Moffitt R, 1998, J PUBLIC ECON, V68, P421, DOI 10.1016/S0047-2727(98)00017-6; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; SHAPIRO I, 1999, WIDENING INCOME GULF; SHORT K, 1995, POVERTY EXTENDED MEA; SMEEDING TM, 1998, FOCUS, V19, P15; Soobader MJ, 1999, SOC SCI MED, V48, P733, DOI 10.1016/S0277-9536(98)00401-8; WEINBERG D, 1996, BRIEF LOOK POSTWAR I; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wolfson M, 1999, BRIT MED J, V319, P953, DOI 10.1136/bmj.319.7215.953; Yen IH, 1999, AM J EPIDEMIOL, V149, P898	31	245	252	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1311	1315		10.1136/bmj.321.7272.1311	http://dx.doi.org/10.1136/bmj.321.7272.1311			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	378BK	11090512	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000165561600023
J	McArdle, C				McArdle, C			ABC of colorectal cancer - Effectiveness of follow up	BRITISH MEDICAL JOURNAL			English	Review							RADICAL SURGERY		Royal Infirm, Dept Surg, Edinburgh, Midlothian, Scotland	Royal Infirmary of Edinburgh	McArdle, C (corresponding author), Royal Infirm, Dept Surg, Edinburgh, Midlothian, Scotland.							BRUINVELS DJ, 1994, ANN SURG, V219, P174, DOI 10.1097/00000658-199402000-00009; Kjeldsen BJ, 1997, BRIT J SURG, V84, P666; MAKELA JT, 1995, ARCH SURG-CHICAGO, V130, P1062; OHLSSON B, 1995, DIS COLON RECTUM, V38, P619, DOI 10.1007/BF02054122; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2	5	34	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1332	1335		10.1136/bmj.321.7272.1332	http://dx.doi.org/10.1136/bmj.321.7272.1332			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090519	Green Published			2022-12-28	WOS:000165561600033
J	Karels, TJ; Boonstra, R				Karels, TJ; Boonstra, R			Concurrent density dependence and independence in populations of arctic ground squirrels	NATURE			English	Article							SNOWSHOE HARE CYCLE; BOREAL FOREST; PREDATION; FOOD; SIZE	No population increases without limit. The processes that prevent this can operate in either a density-dependent way (acting with increasing severity to increase mortality rates or decrease reproductive rates as density increases), a density-independent way, or in both ways simultaneously(1-3). However, ecologists disagree for two main reasons about the relative roles and influences that density-dependent and density-independent processes have in determining population size(4,5). First, empirical studies showing both processes operating simultaneously are rare(6). Second, time-series analyses of long-term census data sometimes overestimate dependence(7,8). By using a density-perturbation experiment(9-12) on arctic ground squirrels, we show concurrent density-dependent and density-independent declines in weaning rates, followed by density-dependent declines in overwinter survival during hibernation. These two processes result in strong, density-dependent convergence of experimentally increased populations to those of control populations that had been at low, stable levels.	Univ Toronto, Div Life Sci, Scarborough, ON M1C 1A4, Canada	University of Toronto; University Toronto Scarborough	Boonstra, R (corresponding author), Univ Toronto, Div Life Sci, 1265 Mil Trail, Scarborough, ON M1C 1A4, Canada.							ANUFRIEV AI, 1990, SOV J ECOL+, V21, P279; BATZLI GO, 1980, ARCTIC ALPINE RES, V12, P501, DOI 10.2307/1550497; BOUTIN S, 1995, OIKOS, V74, P69, DOI 10.2307/3545676; Buck CL, 1999, J MAMMAL, V80, P1264, DOI 10.2307/1383177; Byrom AE, 1999, CAN J ZOOL, V77, P1048, DOI 10.1139/cjz-77-7-1048; Cappuccino N, 1996, FRONTIERS OF POPULATION ECOLOGY, P53; CARL EA, 1971, ECOLOGY, V52, P395, DOI 10.2307/1937623; Florant GL, 1998, AM ZOOL, V38, P331; Green J. E., 1977, THESIS U BRIT COLUMB; Harrison Susan, 1995, P131, DOI 10.1016/B978-012159270-7/50008-7; Hubbs AH, 1997, J ANIM ECOL, V66, P527, DOI 10.2307/5947; Karels TJ, 2000, J ANIM ECOL, V69, P235, DOI 10.1046/j.1365-2656.2000.00387.x; KARELS TJ, 2000, THESIS U TORONTO; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; LACEY EA, 1997, ANIM BEHAV, V53, P565; Leirs H, 1997, NATURE, V389, P176, DOI 10.1038/38271; Lewellen RH, 1998, ECOL MONOGR, V68, P571, DOI 10.1890/0012-9615(1998)068[0571:TEODDA]2.0.CO;2; MAY RM, 1973, AM NAT, V107, P621, DOI 10.1086/282863; MURDOCH WW, 1970, ECOLOGY, V51, P497, DOI 10.2307/1935385; Murray BG, 1999, OIKOS, V84, P148, DOI 10.2307/3546875; OSTFELD RS, 1993, NATURE, V366, P259, DOI 10.1038/366259a0; POLLOCK KH, 1990, WILDLIFE MONOGR, P1; RISCH TS, 1995, ECOLOGY, V76, P1643, DOI 10.2307/1938165; Shenk TM, 1998, ECOL MONOGR, V68, P445, DOI 10.1890/0012-9615(1998)068[0445:SVEODD]2.0.CO;2; Sinclair A.R.E., 1989, P197; Sinclair ARE, 1996, OIKOS, V75, P164, DOI 10.2307/3546240; Strong D.R., 1984, P313; Turchin Peter, 1995, P19, DOI 10.1016/B978-012159270-7/50003-8	28	53	60	0	26	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					460	463		10.1038/35044064	http://dx.doi.org/10.1038/35044064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100725	Green Published			2022-12-28	WOS:000165429800045
J	Robbiani, DF; Finch, RA; Jager, D; Muller, WA; Sartorelli, AC; Randolph, GJ				Robbiani, DF; Finch, RA; Jager, D; Muller, WA; Sartorelli, AC; Randolph, GJ			The leukotriene C-4 transporter MRP1 regulates CCL19 (MIP-3 beta, ELC)-dependent mobilization of dendritic cells to lymph nodes	CELL			English	Article							RESISTANCE PROTEIN MRP; MOUSE BONE-MARROW; P-GLYCOPROTEIN; T-LYMPHOCYTES; MICE LACKING; EXPORT PUMP; IN-VIVO; CHEMOKINE; GLUTATHIONE; EXPRESSION	Adaptive immune responses begin after antigen-bearing dendritic cells (DCs) traffic from peripheral tissues to lymph nodes. Here, we show that DC migration from skin to lymph nodes utilizes the leukotriene C-4 (LTC4) transporter multidrug resistance-associated protein 1 (MRP1). DC mobilization from the epidermis and trafficking into lymphatic vessels was greatly reduced in MRP1(-/-) mice, but migration was restored by exogenous cysteinyl leukotrienes LTC4 or LTD,. In vitro, these cysteinyl leukotrienes promoted optimal chemotaxis to the chemokine CCL19, but not to other related chemokines. Antagonism of CCL19 in vivo prevented DC migration out of the epidermis. Thus, MRP-1 regulates DC migration to lymph nodes, apparently by transporting LTC4, which in turn promotes chemotaxis to CCL19 and mobilization of DCs from the epidermis.	Cornell Univ, Program Immunol, New York, NY USA; Cornell Univ, Weill Med Coll, New York, NY USA; Cornell Univ, Weill Med Coll, New York, NY USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Krankenhaus Nordwest, Med Klin Hamatol Onkol, Frankfurt, Germany; Cornell Univ, Dept Pathol, New York, NY USA	Cornell University; Cornell University; Cornell University; Yale University; Krankenhaus Nordwest; Cornell University	Randolph, GJ (corresponding author), CUNY Mt Sinai Sch Med, Inst Gene Therapy & Mol Med, 1425 Madison Ave,Box 1496, New York, NY 10029 USA.	gwendalyn.randolph@mssm.edu	Robbiani, Davide F./AAF-7662-2019	Robbiani, Davide F./0000-0001-7379-3484				CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CROCKER PR, 1986, J EXP MED, V164, P1862, DOI 10.1084/jem.164.6.1862; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; Drach J, 1996, BLOOD, V88, P1747, DOI 10.1182/blood.V88.5.1747.bloodjournal8851747; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Gosling J, 2000, J IMMUNOL, V164, P2851, DOI 10.4049/jimmunol.164.6.2851; Gretz JE, 1997, IMMUNOL REV, V156, P11, DOI 10.1111/j.1600-065X.1997.tb00955.x; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JOHNSTON MG, 1983, PROSTAG OTH LIPID M, V25, P85, DOI 10.1016/0090-6980(83)90138-7; JORIS I, 1987, AM J PATHOL, V126, P19; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; LEACH L, 1993, J CELL SCI, V104, P1073; LEIER I, 1994, J BIOL CHEM, V269, P27807; LEVEILLEWEBSTER CR, 1995, J MEMBRANE BIOL, V143, P89; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Loe DW, 1998, CANCER RES, V58, P5130; Lohoff M, 1998, J CLIN INVEST, V101, P703, DOI 10.1172/JCI824; Lorico A, 1997, CANCER RES, V57, P5238; Lukas M, 1996, J INVEST DERMATOL, V106, P1293, DOI 10.1111/1523-1747.ep12349010; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Lynch KR, 1999, NATURE, V399, P789; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; Nuessler V, 1997, Eur J Med Res, V2, P159; Ortner U, 1996, J IMMUNOL METHODS, V193, P71, DOI 10.1016/0022-1759(96)00058-0; Randolph DA, 1999, SCIENCE, V286, P2159, DOI 10.1126/science.286.5447.2159; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; Rappa G, 1997, CANCER RES, V57, P5232; Saeki H, 1999, J IMMUNOL, V162, P2472; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sato K, 1998, J IMMUNOL, V161, P6835; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; SPANBROEK R, 2000, IN PRESS BLOOD; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Vellenga E, 1999, BRIT J PHARMACOL, V127, P441, DOI 10.1038/sj.bjp.0702577; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	48	379	403	2	16	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 22	2000	103	5					757	768		10.1016/S0092-8674(00)00179-3	http://dx.doi.org/10.1016/S0092-8674(00)00179-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114332	Bronze			2022-12-28	WOS:000165433100008
J	Lubsen, J; Hoes, A; Grobbee, D				Lubsen, J; Hoes, A; Grobbee, D			Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained	LANCET			English	Editorial Material								Consider a physician advising a patient to start antihypertensive treatment. He has the unenviable task of presenting often conflicting trial data in a comprehensible manner. He must justly represent the known risks and benefits such that his patient can make a reasonably informed choice. Should the physician cite the number needed to treat or the average duration of life gained to clarify his explanations?.	Univ Utrecht, Med Ctr, Julius Ctr Gen Practice & Patient Oriented Res, NL-3508 GA Utrecht, Netherlands; Erasmus Univ, Fac Hlth Sci, Dept Epidemiol & Biostat, Rotterdam, Netherlands; SOCAR Res SA, Nyon, Switzerland	Utrecht University; Erasmus University Rotterdam	Grobbee, D (corresponding author), Univ Utrecht, Med Ctr, Julius Ctr Gen Practice & Patient Oriented Res, D 01-335,POB 85500, NL-3508 GA Utrecht, Netherlands.	D.E.Grobbee@jc.azu.nl	Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; [Anonymous], 1988, LANCET, V2, P349; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; de Craen AJM, 1998, LANCET, V351, P310, DOI 10.1016/S0140-6736(05)78341-0; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Smeeth L, 1999, BMJ-BRIT MED J, V318, P1548, DOI 10.1136/bmj.318.7197.1548; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Tan LB, 1999, LANCET, V354, P1378, DOI 10.1016/S0140-6736(98)11472-1; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	9	42	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 18	2000	356	9243					1757	1759		10.1016/S0140-6736(00)03215-3	http://dx.doi.org/10.1016/S0140-6736(00)03215-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095272				2022-12-28	WOS:000165462300038
J	Naqvi, SWA; Jayakumar, DA; Narvekar, PV; Naik, H; Sarma, VVSS; D'Souza, W; Joseph, S; George, MD				Naqvi, SWA; Jayakumar, DA; Narvekar, PV; Naik, H; Sarma, VVSS; D'Souza, W; Joseph, S; George, MD			Increased marine production of N2O due to intensifying anoxia on the Indian continental shelf	NATURE			English	Article							GULF-OF-MEXICO; NITROUS-OXIDE; ARABIAN SEA; DENITRIFICATION; OXYGEN; HYPOXIA; MONSOON; WATER; CO2	Eutrophication of surface waters and hypoxia in bottom waters has been increasing in many coastal areas(1-4), leading to very large depletions of marine life in the affected regions(4). These areas of high surface productivity and low bottom-water oxygen concentration are caused by increasing runoff of nutrients from land. Although the local ecological and socio-economic effects have received much attention(2-4), the potential contribution of increasing hypoxia to global-change phenomena is unknown. Here we report the intensification of one of the largest low-oxygen zones in the ocean, which develops naturally over the western Indian continental shelf during late summer and autumn. We also report the highest accumulations yet observed of hydrogen sulphide (H2S) and nitrous oxide (N2O) in open coastal waters. Increased N2O production is probably caused by the addition of anthropogenic nitrate and its subsequent denitrification, which is favoured by hypoxic conditions. We suggest that a global expansion of hypoxic zones may lead to an increase in marine production and emission of N2O, which, as a potent greenhouse gas, could contribute significantly to the accumulation of radiatively active trace gases in the atmosphere(5).	Natl Inst Oceanog, Dona Paula 403004, Goa, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Institute of Oceanography (NIO)	Naqvi, SWA (corresponding author), Natl Inst Oceanog, Dona Paula 403004, Goa, India.		Sarma, VVSS/B-5087-2008; Joseph, Sudheer/N-8662-2016	Joseph, Sudheer/0000-0002-9163-3027				Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; BANGE HW, IN PRESS GLOBAL BIOG; BANSE K, 1968, DEEP-SEA RES, V15, P45, DOI 10.1016/0011-7471(68)90028-4; Banse K., 1959, J MAR BIOL ASSOC IND, V1, P33; CALVERT SE, 1971, DEEP-SEA RES, V18, P505, DOI 10.1016/0011-7471(71)90074-X; CARRUTHERS JN, 1959, NATURE, V183, P1084, DOI 10.1038/1831084a0; Codispoti L.A., 1992, OCEANOGRAPHY INDIAN, P271; CODISPOTI LA, 1980, J MAR RES, V38, P453; CODISPOTI LA, 1986, SCIENCE, V233, P1200, DOI 10.1126/science.233.4769.1200; Diaz RJ, 1995, OCEANOGR MAR BIOL, V33, P245; FIRESTONE MK, 1979, APPL ENVIRON MICROB, V38, P673, DOI 10.1128/AEM.38.4.673-679.1979; GOREAU TJ, 1980, APPL ENVIRON MICROB, V40, P526, DOI 10.1128/AEM.40.3.526-532.1980; Hansen H., 1983, METHODS SEAWATER ANA, P347; JAYAKUMAR DA, IN PRESS MAR CHEM; Justic D, 1996, LIMNOL OCEANOGR, V41, P992, DOI 10.4319/lo.1996.41.5.0992; Kitoh A, 1997, J METEOROL SOC JPN, V75, P1019, DOI 10.2151/jmsj1965.75.6_1019; LAW CS, 1990, NATURE, V346, P826, DOI 10.1038/346826a0; Liss P.S., 1986, ROLE AIR SEA EXCHANG, P113, DOI [10.1007/978-94-009-4738-2_5, DOI 10.1007/978-94-009-4738-2_5]; Malakoff D, 1998, SCIENCE, V281, P190, DOI 10.1126/science.281.5374.190; NAQVI SWA, 1987, J MAR RES, V45, P1049, DOI 10.1357/002224087788327118; Naqvi SWA, 1998, NATURE, V394, P462, DOI 10.1038/28828; NAQVI SWA, 1991, DEEP-SEA RES, V38, P871, DOI 10.1016/0198-0149(91)90023-9; Rabalais N.N., 2000, OXYGEN DEPLETION COA; Redfield A. C, 1963, SEA, P26, DOI DOI 10.1016/J.ORGGEOCHEM.2014.06.002; SHETYE SR, 1990, J MAR RES, V48, P359, DOI 10.1357/002224090784988809; TURNER RE, 1994, NATURE, V368, P619, DOI 10.1038/368619a0; *UNDP FAO PEL FISH, 1973, 3 UNDPFAO PEL FISH P, P1; WANNINKHOF R, 1992, J GEOPHYS RES-OCEANS, V97, P7373, DOI 10.1029/92JC00188; WEISS RF, 1980, MAR CHEM, V8, P347, DOI 10.1016/0304-4203(80)90024-9; YOH M, 1983, NATURE, V301, P327, DOI 10.1038/301327a0	30	445	462	5	123	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					346	349		10.1038/35042551	http://dx.doi.org/10.1038/35042551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099038				2022-12-28	WOS:000165296000041
J	Sousa, MC; Trame, CB; Tsuruta, H; Wilbanks, SM; Reddy, VS; McKay, DB				Sousa, MC; Trame, CB; Tsuruta, H; Wilbanks, SM; Reddy, VS; McKay, DB			Crystal and solution structures of an HsIUV protease-chaperone complex	CELL			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI HOMOLOG; CELL-DIVISION INHIBITOR; 20S PROTEASOME; PROTEOLYTIC ACTIVITY; HSLVU PROTEASE; BETA-SUBUNITS; PROTEINS; DEGRADATION; SCATTERING	HslUV is a "prokaryotic proteasome" composed of the HslV protease and the HslU ATPase, a chaperone of the Clp/Hsp100 family. The 3.4 a crystal structure of an HslUV complex is presented here. Two hexameric ATP binding rings of HslU bind intimately to opposite sides of the HslV protease; the HslU "intermediate domains" extend outward from the complex. The solution structure of HslUV, derived from small angle X-ray scattering data under conditions where the complex is assembled and active, agrees with this crystallographic structure. When the complex forms, the carboxy-terminal helices of HslU distend and bind between subunits of HslV, and the apical helices of HsIV shift substantially, transmitting a conformational change to the active site region of the protease.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Scripps Research Institute	McKay, DB (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	dave.mckay@stanford.edu		Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NCRR NIH HHS [RR12255] Funding Source: Medline; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Huang HC, 1997, J BIOL CHEM, V272, P21364, DOI 10.1074/jbc.272.34.21364; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kanemori M, 1999, J BACTERIOL, V181, P3674, DOI 10.1128/JB.181.12.3674-3680.1999; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuwald AF, 1999, GENOME RES, V9, P27; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Seol JH, 1997, EUR J BIOCHEM, V247, P1143, DOI 10.1111/j.1432-1033.1997.01143.x; Seong IS, 1999, FEBS LETT, V456, P211, DOI 10.1016/S0014-5793(99)00935-7; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1991, J APPL CRYSTALLOGR, V24, P485, DOI 10.1107/S0021889891001280; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Yoo SJ, 1997, BIOCHEM BIOPH RES CO, V238, P581, DOI 10.1006/bbrc.1997.7341; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	45	253	257	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 10	2000	103	4					633	643		10.1016/S0092-8674(00)00166-5	http://dx.doi.org/10.1016/S0092-8674(00)00166-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106733	Bronze			2022-12-28	WOS:000165348000008
J	Chapman, S; Morrell, S				Chapman, S; Morrell, S			Barking mad? Another lunatic hypothesis bites the dust	BRITISH MEDICAL JOURNAL			English	Article							FULL MOON; CYCLE	Objective To assess whether dog bites requiring hospital admission occur more at the full moon. Design Review of dates of admission for dog bites to accident and emergency departments,June 1997 to June 1998, compared with dates of the full moon. Setting All public hospitals in Australia. Main outcome measures Admissions for dog bites. Results 12 peak clusters of admissions were unrelated to the time of the full moon. Conclusion Dog bites are no more frequent on full moons than at any other time of the month. Sceptics rejoice.	Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia	University of Sydney	Chapman, S (corresponding author), Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia.							BUCKLEY NA, 1993, MED J AUSTRALIA, V159, P786, DOI 10.5694/j.1326-5377.1993.tb141350.x; Chapman S, 2000, BRIT MED J, V320, P1512, DOI 10.1136/bmj.320.7248.1512; COATES W, 1989, ANN EMERG MED, V18, P763, DOI 10.1016/S0196-0644(89)80014-9; COHENMANSFIELD J, 1989, J CLIN PSYCHOL, V45, P611, DOI 10.1002/1097-4679(198907)45:4<611::AID-JCLP2270450417>3.0.CO;2-F; DECASTRO JM, 1995, PHYSIOL BEHAV, V57, P439, DOI 10.1016/0031-9384(94)00232-T; Ghiandoni G, 1998, EUR J OBSTET GYN R B, V77, P47, DOI 10.1016/S0301-2115(97)00226-1; Laverty WH, 1998, PERCEPT MOTOR SKILL, V86, P299, DOI 10.2466/pms.1998.86.1.299; LAW SP, 1986, ACTA OBSTET GYN SCAN, V65, P45, DOI 10.3109/00016348609158228; LIEBER AL, 1978, J CLIN PSYCHIAT, V39, P385; MATHEW VM, 1991, PSYCHOL REP, V68, P927, DOI 10.2466/PR0.68.3.927-930; Myers Daniel E., 1995, Journal of Emergency Medicine, V13, P529; ODERDA GM, 1983, J TOXICOL-CLIN TOXIC, V20, P487, DOI 10.3109/15563658308990614; Owen C, 1998, AUST NZ J PSYCHIAT, V32, P496, DOI 10.1046/j.1440-1614.1998.00442.x; Raison CL, 1999, J AFFECT DISORDERS, V53, P99, DOI 10.1016/S0165-0327(99)00016-6; SANDS JM, 1991, PSYCHOL REP, V69, P959, DOI 10.2466/PR0.69.7.959-962; THAKUR CP, 1984, BRIT MED J, V289, P1789, DOI 10.1136/bmj.289.6460.1789; Thompson DA, 1996, AM J EMERG MED, V14, P161, DOI 10.1016/S0735-6757(96)90124-2; Wilkinson G, 1997, INT J SOC PSYCHIATR, V43, P29, DOI 10.1177/002076409704300103	18	25	25	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1561	1563		10.1136/bmj.321.7276.1561	http://dx.doi.org/10.1136/bmj.321.7276.1561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	387RA	11124174	Bronze, Green Published			2022-12-28	WOS:000166134500012
J	Ness, G; Macaskill, N				Ness, G; Macaskill, N			Near drowning: self therapy in situ	BRITISH MEDICAL JOURNAL			English	Article							POSTTRAUMATIC-STRESS-DISORDER		Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; Leeds Community Mental Hlth Trust, Leeds LS6 4QB, W Yorkshire, England	University of Sheffield	Ness, G (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.							BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Marks I, 1998, ARCH GEN PSYCHIAT, V55, P317, DOI 10.1001/archpsyc.55.4.317; Mayou RA, 2000, BRIT J PSYCHIAT, V176, P589, DOI 10.1192/bjp.176.6.589; Meichenbaum D, 1975, HELPING PEOPLE CHANG, P357	6	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1604	1606		10.1136/bmj.321.7276.1604	http://dx.doi.org/10.1136/bmj.321.7276.1604			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124197	Green Published			2022-12-28	WOS:000166134500033
J	Marlow, JR; Lange, CB; Wefer, G; Rosell-Mele, A				Marlow, JR; Lange, CB; Wefer, G; Rosell-Mele, A			Upwelling intensification as part of the Pliocene-Pleistocene climate transition	SCIENCE			English	Article							WALVIS RIDGE; ATLANTIC; ALKENONES; DEGRADATION; CIRCULATION; EVOLUTION; MARINE; DIATOM	A deep-sea sediment core underlying the Benguela upwelling system off southwest Africa provides a continuous time series of sea surface temperature (SST) for the past 4.5 million years. Our results indicate that temperatures in the region have declined by about 10 degreesC since 3.2 million years ago, Records of paleoproductivity suggest that this cooling was associated with an increase in wind-driven upwelling tied to a shift from relatively stable global warmth during the mid-Pliocene to the high-amplitude glacial-interglacial cycles of the Late Quaternary, These observations imply that Atlantic Ocean surface water circulation was radically different during the mid-Pliocene.	Newcastle Univ, Dept Fossil Fuels & Environm Geochem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Calif San Diego, Scripps Inst Oceanog, Geosci Res Div, La Jolla, CA 92093 USA; Univ Bremen, Dept Earth Sci FB5, D-28334 Bremen, Germany; Univ Durham, Dept Geog, Durham DH1 3LE, England	Newcastle University - UK; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Bremen; Durham University	Marlow, JR (corresponding author), Newcastle Univ, Dept Fossil Fuels & Environm Geochem, Drummond Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	J.R.Marlow@ncl.ac.uk	Gerold, Wefer/S-2291-2016; Lange, Carina/AHC-2015-2022; Rosell-Melé, Antoni/B-3433-2013	Gerold, Wefer/0000-0002-6803-2020; Lange, Carina/0000-0002-2916-4207; Rosell-Melé, Antoni/0000-0002-5513-2647				ABELMANN A, 1990, NATO ADV SCI I C-MAT, V308, P729; BARRON JA, 1989, LIFE SCI R, V44, P341; Berger W.H., 1998, P ODP INIT REP, V175, P505, DOI [10.2973/odp.proc.ir. 175.117.1998, DOI 10.2973/ODP.PROC.IR.175.117.1998]; Berger WH, 1996, SOUTH ATLANTIC, P363; Billups K, 1998, PALEOCEANOGRAPHY, V13, P84, DOI 10.1029/97PA02995; BRASSELL SC, 1986, NATURE, V320, P129, DOI 10.1038/320129a0; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; Diester-Haass L., 1992, GEOLOGICAL SOC LONDO, V63, P331; Dowsett H, 1996, MAR MICROPALEONTOL, V27, P13, DOI 10.1016/0377-8398(95)00050-X; Dowsett H, 1996, MAR MICROPALEONTOL, V27, P181, DOI 10.1016/0377-8398(95)00059-3; DOWSETT HJ, 1990, MAR MICROPALEONTOL, V16, P1, DOI 10.1016/0377-8398(90)90026-I; Emeis K.-C., 1995, P OCEAN DRILL PROGRA, V138, P605; FranceLanord C, 1997, NATURE, V390, P65, DOI 10.1038/36324; Gong C, 1999, GEOCHIM COSMOCHIM AC, V63, P405, DOI 10.1016/S0016-7037(98)00283-X; Haug GH, 1998, NATURE, V393, P673, DOI 10.1038/31447; Haug GH, 1999, NATURE, V401, P779, DOI 10.1038/44550; Hay W.W., 1992, GEOL SOC SPEC PUBL L, P463, DOI DOI 10.1144/GSL.SP.1992.064.01.31; Herbert T.D., 1998, P OCEAN DRILLING PRO, V159T, P17, DOI [10.2973/odp.proc.sr.159T.063.1998, DOI 10.2973/ODP.PROC.SR.159T.063.1998]; Herbert TD, 1998, PALEOCEANOGRAPHY, V13, P263, DOI 10.1029/98PA00069; Hodell David A., 1992, Antarctic Research Series, V56, P265; Hoefs MJL, 1998, PALEOCEANOGRAPHY, V13, P42, DOI 10.1029/97PA02893; HOVAN SA, 1991, P OC DRILL PROGR SCI, V0121; Lange CB, 1999, MAR GEOL, V161, P93, DOI 10.1016/S0025-3227(99)00081-X; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; LUTJEHARMS JRE, 1987, S AFR J MARINE SCI, V5, P35, DOI 10.2989/025776187784522612; MARLOWE IT, 1990, CHEM GEOL, V88, P349, DOI 10.1016/0009-2541(90)90098-R; Miller KG, 1987, PALEOCEANOGRAPHY, V2, P1, DOI 10.1029/PA002i001p00001; Muller PJ, 1997, PALAEOGEOGR PALAEOCL, V135, P71, DOI 10.1016/S0031-0182(97)00018-7; Muller PJ, 1998, GEOCHIM COSMOCHIM AC, V62, P1757, DOI 10.1016/S0016-7037(98)00097-0; Pflaumann U., 1998, P OCEAN DRILLING PRO, V159T, P3; Raymo ME, 1996, MAR MICROPALEONTOL, V27, P313, DOI 10.1016/0377-8398(95)00048-8; Reed KE, 1997, J HUM EVOL, V32, P289, DOI 10.1006/jhev.1996.0106; Rind D, 1998, J GEOPHYS RES-ATMOS, V103, P5943, DOI 10.1029/97JD03649; ROSELLMELE A, 1994, THESIS U BRISTOL UK; Ruddiman WF, 1989, PALEOCEANOGRAPHY, V4, P353, DOI 10.1029/PA004i004p00353; RUDDIMAN WF, 1989, P OCEAN DRILLING PRO, V0108; Shackleton N.J., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P337, DOI 10.2973/odp.proc.sr.138.117.1995; *SHIPB SCI PART, 1998, P ODP IN REP, V175, P339; Sloan LC, 1996, MAR MICROPALEONTOL, V27, P51, DOI 10.1016/0377-8398(95)00063-1; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; Treppke UF, 1996, J MAR RES, V54, P991, DOI 10.1357/0022240963213655; Watson AJ, 1995, DAHL WS ENV, V18, P321	42	266	279	2	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	2000	290	5500					2288	+						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125138				2022-12-28	WOS:000165995800038
J	Meininger, ME; Kendler, JS				Meininger, ME; Kendler, JS			Trousseau's sign.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									New York Hosp, Cornell Med Ctr, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital	Meininger, ME (corresponding author), New York Hosp, Cornell Med Ctr, New York, NY 10021 USA.								0	8	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1855	1855		10.1056/NEJM200012213432506	http://dx.doi.org/10.1056/NEJM200012213432506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117978				2022-12-28	WOS:000165940400006
J	Yonekura, K; Maki, S; Morgan, DG; DeRosier, DJ; Vonderviszt, F; Imada, K; Namba, K				Yonekura, K; Maki, S; Morgan, DG; DeRosier, DJ; Vonderviszt, F; Imada, K; Namba, K			The bacterial flagellar cap as the rotary promoter of flagellin self-assembly	SCIENCE			English	Article							HOOK-ASSOCIATED PROTEINS; SALMONELLA-TYPHIMURIUM; ANGSTROM RESOLUTION; EXPORT APPARATUS; FILAMENT; HAP2; COMPONENTS; MICROSCOPY; EXCRETION; LOCATIONS	The growth of the bacterial flagellar filament occurs at its distal end by self-assembly of flagellin transported from the cytoplasm through the narrow central channel. The cap at the growing end is essential for its growth, remaining stably attached while permitting the flagellin insertion. In order to understand the assembly mechanism, we used electron microscopy to study the structures of the cap-filament complex and isolated cap dimer. Five log-like anchor domains of the pentameric cap flexibly adjusted their conformations to keep just one flagellin binding site open, indicating a cap rotation mechanism to promote the flagellin self-assembly. This represents one of the most dynamic movements in protein structures.	JST, ERATO, Proton Nanomachine Project, Kyoto 6190237, Japan; Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02254 USA; Univ Veszprem, Dept Phys, H-8201 Veszprem, Hungary; Matsushita Elect Ind Co Ltd, Adv Technol Res Labs, Kyoto 6190237, Japan	Japan Science & Technology Agency (JST); Boston University; Brandeis University; Harvard University; Harvard Medical School; University of Pannonia; Panasonic	Namba, K (corresponding author), JST, ERATO, Proton Nanomachine Project, 3-4 Hikaridai, Kyoto 6190237, Japan.		Morgan, David Gene/W-3429-2019; Vonderviszt, Ferenc/GLR-5618-2022; YONEKURA, Koji/N-5060-2015	Vonderviszt, Ferenc/0000-0002-6498-8172; Yonekura, Koji/0000-0001-5520-4391; Imada, Katsumi/0000-0003-1342-8885				BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; Caspar D L, 1990, Adv Biophys, V26, P157, DOI 10.1016/0065-227X(90)90011-H; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; Fan F, 1997, MOL MICROBIOL, V26, P1035, DOI 10.1046/j.1365-2958.1997.6412010.x; FLANK J, 1996, J STRUCT BIOL, V116, P190; HOMMA M, 1985, J BACTERIOL, V162, P183, DOI 10.1128/JB.162.1.183-189.1985; HOMMA M, 1984, J BACTERIOL, V159, P1056, DOI 10.1128/JB.159.3.1056-1059.1984; HOMMA M, 1985, J BACTERIOL, V164, P1370, DOI 10.1128/JB.164.3.1370-1372.1985; IINO T, 1969, J GEN MICROBIOL, V56, P227, DOI 10.1099/00221287-56-2-227; IKEDA T, 1985, J MOL BIOL, V184, P735, DOI 10.1016/0022-2836(85)90317-1; Ikeda T, 1996, J MOL BIOL, V259, P679, DOI 10.1006/jmbi.1996.0349; IKEDA T, 1987, J BACTERIOL, V169, P1168, DOI 10.1128/jb.169.3.1168-1173.1987; Imada K, 1998, J MOL BIOL, V277, P883, DOI 10.1006/jmbi.1998.1662; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; Maki S, 1998, J MOL BIOL, V277, P771, DOI 10.1006/jmbi.1998.1663; MIMORI Y, 1995, J MOL BIOL, V249, P69, DOI 10.1006/jmbi.1995.0281; MimoriKiyosue Y, 1997, J MOL BIOL, V270, P222, DOI 10.1006/jmbi.1997.1111; Minamino T, 1999, J BACTERIOL, V181, P1388, DOI 10.1128/JB.181.5.1388-1394.1999; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; Namba K, 1997, Q REV BIOPHYS, V30, P1, DOI 10.1017/S0033583596003319; NAMBA K, 1986, SCIENCE, V231, P1401, DOI 10.1126/science.3952490; Owen CH, 1996, J STRUCT BIOL, V116, P167, DOI 10.1006/jsbi.1996.0027; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; SUZUKI T, 1978, J BACTERIOL, V133, P904, DOI 10.1128/JB.133.2.904-915.1978; THOMAS D, 1999, THESIS BRANDEIS U; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; VONDERVISZT F, 1989, J MOL BIOL, V209, P127, DOI 10.1016/0022-2836(89)90176-9; Vonderviszt F, 1998, J MOL BIOL, V284, P1399, DOI 10.1006/jmbi.1998.2274; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YAMASHITA I, 1995, J MOL BIOL, V253, P547, DOI 10.1006/jmbi.1995.0572; Yamashita I, 1998, NAT STRUCT BIOL, V5, P125	32	152	157	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2148	2152		10.1126/science.290.5499.2148	http://dx.doi.org/10.1126/science.290.5499.2148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118149				2022-12-28	WOS:000165870600057
J	Gubitz, G; Sandercock, P				Gubitz, G; Sandercock, P			Prevention of ischaemic stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CAROTID-ENDARTERECTOMY; SECONDARY PREVENTION; ACETYLSALICYLIC-ACID; MORTALITY; TRIAL; DIPYRIDAMOLE; WARFARIN; ASPIRIN; DRUGS; RISK		Queen Elizabeth II Med Ctr, Div Neurol, Halifax, NS B3H 3A7, Canada; Western Gen Hosp NHS Trust, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland	Queen Elizabeth II Health Sciences Centre; University of Edinburgh	Gubitz, G (corresponding author), Queen Elizabeth II Med Ctr, Div Neurol, Halifax, NS B3H 3A7, Canada.	ggubitz@IS.Dal.Ca	sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Mubarak N, 2000, STROKE, V31, P292; ALBERTS M, 1988, NEUROLOGY S3, V51, P53; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Benavente O, 1998, BMJ-BRIT MED J, V317, P1477, DOI 10.1136/bmj.317.7171.1477; BRAND MB, 1999, COCHRANE LIB; BROWN M, 1999, CEREBROVASC DIS, V9, P21; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; CINA C, 1999, COCHRANE LIB; *COCHR STROK GROUP, 2000, COCHR LIB; COLLINS R, 1999, STROKE, V30, P1304; DESCHRYVER ELL, 1998, CEREBROVASC DIS, V8, P83; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; DOWNS JR, 1995, AM J CARDIOL, V75, P1130; Franke CL, 1997, ANN NEUROL, V42, P857; GODLEE F, 1999, CLIN EVIDENCE; GOLDSTEIN L, 2000, 25 INT STROK C NEW O; Gorelick PB, 1999, JAMA-J AM MED ASSOC, V281, P1112, DOI 10.1001/jama.281.12.1112; GOUGH M, GEN VERS LOC AN CAR; Gueyffier F, 1997, STROKE, V28, P2557, DOI 10.1161/01.STR.28.12.2557; Hankey GJ, 1999, LANCET, V354, P1457, DOI 10.1016/S0140-6736(99)04407-4; HANKEY GJ, 1999, COCHRANE LIB; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Hillbom M, 1999, J CARDIOVASC RISK, V6, P223; LIU M, 1999, COCHRANE LIB; Lurbe E, 1996, J HYPERTENS, V14, P41; MACMAHON S, 1994, HYPERTENS RES, V17, P23; MOHR JP, 1995, CEREBROVASC DIS, V5, P156, DOI 10.1159/000107841; Morocutti C, 1997, STROKE, V28, P1015, DOI 10.1161/01.STR.28.5.1015; Mulrow C, 1999, CLIN EVIDENCE, P524; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; SANDERCOCK P, 2000, COCHRANE LIB; SANDERCOCK P, IN PRESS STROKE PRAC; SIGAL R, 1999, CLIN EVIDENCE, P32; Taylor DW, 1999, LANCET, V353, P2179, DOI 10.1016/S0140-6736(99)05388-X; Wannamethee SG, 1999, J CARDIOVASC RISK, V6, P213; Wardlaw JM, 1999, COCHRANE LIB; Wilterdink JL, 1999, ARCH NEUROL-CHICAGO, V56, P1087, DOI 10.1001/archneur.56.9.1087; Yusuf S, 2000, NEW ENGL J MED, V342, P145	43	26	31	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	2000	321	7274					1455	1459		10.1136/bmj.321.7274.1455	http://dx.doi.org/10.1136/bmj.321.7274.1455			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11110741	Green Published			2022-12-28	WOS:000165852300033
J	Cheung, AT; Dayanandan, B; Lewis, JT; Korbutt, GS; Rajotte, RV; Bryer-Ash, M; Boylan, MO; Wolfe, MM; Kieffer, TJ				Cheung, AT; Dayanandan, B; Lewis, JT; Korbutt, GS; Rajotte, RV; Bryer-Ash, M; Boylan, MO; Wolfe, MM; Kieffer, TJ			Glucose-dependent insulin release from genetically engineered K cells	SCIENCE			English	Article							GASTROINTESTINAL-TRACT; POLYPEPTIDE GIP; GENE-EXPRESSION; REVERSAL; HORMONE; MICE	Genetic engineering of non-beta cells to release insulin upon feeding could be a therapeutic modality for patients with diabetes. A tumor-derived K-cell line was induced to produce human insulin by providing the cells with the human insulin gene linked tb the 5'-regulatory region of the gene encoding glucose-dependent insulinotropic polypeptide (GIP). Mice expressing this transgene produced human insulin specifically in gut K cells. This insulin protected the mice from developing diabetes and maintained glucose tolerance after destruction of the native insulin-producing beta cells.	Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Surg, Edmonton, AB T6G 2S2, Canada; enGene Inc, Edmonton, AB T6G 2T5, Canada; Univ Tennessee, Dept Med, Memphis, TN 38103 USA; Boston Med Ctr, Gastroenterol Sect, Boston, MA 02118 USA	University of Alberta; University of Alberta; University of Alberta; University of Tennessee System; University of Tennessee Health Science Center; Boston Medical Center	Kieffer, TJ (corresponding author), Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada.	tim.kieffer@ualberta.ca						Bartlett RJ, 1997, TRANSPLANT P, V29, P2199, DOI 10.1016/S0041-1345(97)00294-7; Bochan MR, 1999, TRANSPLANT P, V31, P690, DOI 10.1016/S0041-1345(98)01611-X; Boylan MO, 1997, J BIOL CHEM, V272, P17438, DOI 10.1074/jbc.272.28.17438; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATALAND S, 1974, J CLIN ENDOCR METAB, V39, P223, DOI 10.1210/jcem-39-2-223; CHEUNG ASC, UNPUB; Croyle MA, 1998, GENE THER, V5, P645, DOI 10.1038/sj.gt.3300645; Falqui L, 1999, HUM GENE THER, V10, P1753, DOI 10.1089/10430349950017437; FERRI GL, 1983, GASTROENTEROLOGY, V84, P777; Goldfine ID, 1997, NAT BIOTECHNOL, V15, P1378, DOI 10.1038/nbt1297-1378; HENNING SJ, 1997, ADV DRUG DELIV REV, V17, P341; KIEFFER TJ, 1994, AM J PHYSIOL-ENDOC M, V267, pE489, DOI 10.1152/ajpendo.1994.267.4.E489; KOLODKA TM, 1995, P NATL ACAD SCI USA, V92, P3293, DOI 10.1073/pnas.92.8.3293; Lipes MA, 1996, P NATL ACAD SCI USA, V93, P8595, DOI 10.1073/pnas.93.16.8595; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; RINDI G, 1990, AM J PATHOL, V136, P1349; Sandstrom O, 1999, MECH AGEING DEV, V108, P39, DOI 10.1016/S0047-6374(98)00154-7; SIMON PB, 2000, CARCINOGENESIS, V21, P469; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Thule PM, 2000, GENE THER, V7, P205, DOI 10.1038/sj.gt.3301076; TSENG CC, 1994, AM J PHYSIOL, V266, pG887, DOI 10.1152/ajpgi.1994.266.5.G887; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wolfe MM, 1999, CONT ENDOCRINOL, V8, P439; Yeung CM, 1999, MOL CELL ENDOCRINOL, V154, P161, DOI 10.1016/S0303-7207(99)00106-9	24	216	241	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1959	1962		10.1126/science.290.5498.1959	http://dx.doi.org/10.1126/science.290.5498.1959			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110661				2022-12-28	WOS:000165810000044
J	Denke, MA; Adams-Huet, B; Nguyen, AT				Denke, MA; Adams-Huet, B; Nguyen, AT			Individual cholesterol variation in response to a margarine- or butter-based diet - A study in families	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; FATTY-ACID-COMPOSITION; SERUM-CHOLESTEROL; LOWERING DIET; PLASMA-CHOLESTEROL; APOLIPOPROTEIN-E; RESPONSIVENESS; WEIGHT; ESTERS; MEN	Context The effectiveness of dietary modification in reducing low-density lipoprotein cholesterol (LDL-C) levels can be reliably predicted for populations, but not for individuals. Objective To determine whether individual variation in cholesterol response to dietary modification is a familial trait. Design Two-period, outpatient crossover trial conducted from September 1997 to September 1999, Setting and Participants Fifty-six families from the Dallas-Ft Worth, Tex, area with 2 biological parents and at least 2 children aged 5 years or older volunteered; 46 families (n=92 adults and n=134 children) completed the study. Intervention All families followed two 5-week dietary regimens that included individualized daily dietary prescriptions and emphasized a low-saturated fat diet supplemented with specially manufactured baked goods and spreadable fat. One regimen used butter only and the other used margarine only. Main Outcome Measure Mean LDL-C levels during the last 2 weeks of each dietary period. Results Margarine intake compared with butter intake lowered LDL-C levels 11% in adults (95% confidence interval [CI], -13% to -9%) and 9% in children (95% CI, -12% to -6%) (P<.001 for both adults and children). The distribution of individual responses were peaked around the mean response. For adults and children together, family membership accounted for 19% of variability in response (P=.007). In children, family membership accounted for 40% of variability in response of percent change in LDL-C levels (P=.002). Body mass index and change in cholesterol ester (CE) 18, 2/18:1 ratio accounted for 26% of variation, leaving 26% still attributable to family membership. In all participants, BMI predicted response-heavier individuals had higher LDL-C levels, less excursion in CE fatty acids, and less LDL-C response to dietary change. Conclusions Our results suggest that individual variation in response to a cholesterol-lowering diet is a familial trait. Body weight is an important modifiable factor that influences response.	Univ Texas, SW Med Ctr, Ctr Human Nutr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Denke, MA (corresponding author), Univ Texas, SW Med Ctr, Ctr Human Nutr, Dept Internal Med, 5323 Harry Hines Blvd,Room Y3-234, Dallas, TX 75390 USA.	mdenke@mednet.swmed.edu			NCRR NIH HHS [MO1-RR00633] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ascherio A, 1997, AM J CLIN NUTR, V66, P1006, DOI 10.1093/ajcn/66.4.1006S; BAKER BM, 1968, CIRCULATION, V37, P1; BEYNEN AC, 1987, ADV LIPID RES, V22, P115; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; COLE TG, 1992, AM J CLIN NUTR, V55, P385, DOI 10.1093/ajcn/55.2.385; DENKE MA, 1994, ARCH INTERN MED, V154, P1977, DOI 10.1001/archinte.154.17.1977; DENKE MA, 1993, AM J MED, V94, P626, DOI 10.1016/0002-9343(93)90215-B; DENKE MA, 1993, ARCH INTERN MED, V153, P1093, DOI 10.1001/archinte.153.9.1093; DENKE MA, 1994, ARCH INTERN MED, V154, P401, DOI 10.1001/archinte.154.4.401; DENKE MA, 1994, ARCH INTERN MED, V154, P317, DOI 10.1001/archinte.154.3.317; DOLE VP, 1960, J BIOL CHEM, V235, P2595; Hannah JS, 1997, INT J OBESITY, V21, P445, DOI 10.1038/sj.ijo.0800427; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HIXSON JE, 1990, J LIPID RES, V31, P545; HUDGINS LC, 1991, AM J CLIN NUTR, V53, P1372, DOI 10.1093/ajcn/53.6.1372; JACOBS DR, 1983, ARTERIOSCLEROSIS, V3, P349, DOI 10.1161/01.ATV.3.4.349; Jansen S, 1998, J NUTR, V128, P1144, DOI 10.1093/jn/128.7.1144; Judd JT, 1998, AM J CLIN NUTR, V68, P768, DOI 10.1093/ajcn/68.4.768; KANG KW, 1976, LIPIDS, V11, P722, DOI 10.1007/BF02533045; KATAN MB, 1988, J LIPID RES, V29, P883; KEYS A, 1957, LANCET, V2, P959; KNUIMAN JT, 1980, ATHEROSCLEROSIS, V37, P617, DOI 10.1016/0021-9150(80)90068-4; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; LEHTIMAKI T, 1990, J LIPID RES, V31, P487; LEPAGE G, 1986, J LIPID RES, V27, P114; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lichtenstein AH, 1999, NEW ENGL J MED, V340, P1933, DOI 10.1056/NEJM199906243402501; LITTELL RC, 1986, SAS SYSTEM MIXED MOD; MA J, 1995, AM J CLIN NUTR, V62, P564, DOI 10.1093/ajcn/62.3.564; MCCOMBS RJ, 1994, NEW ENGL J MED, V331, P706, DOI 10.1056/NEJM199409153311104; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MOILANEN T, 1983, ATHEROSCLEROSIS, V48, P49, DOI 10.1016/0021-9150(83)90016-3; Ordovas JM, 1999, P NUTR SOC, V58, P171, DOI 10.1079/PNS19990023; QUIVERS ES, 1992, PEDIATRICS, V89, P925; ROTTERDAM EP, 1987, CLIN CHEM, V33, P1913; SARKKINEN ES, 1994, AM J CLIN NUTR, V59, P364, DOI 10.1093/ajcn/59.2.364; SHENBERGER DM, 1992, J AM DIET ASSOC, V92, P441; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Tall A, 1997, ARTERIOSCL THROM VAS, V17, P3326, DOI 10.1161/01.ATV.17.11.3326; TIKKANEN MJ, 1990, ARTERIOSCLEROSIS, V10, P285, DOI 10.1161/01.ATV.10.2.285; TONSTAD S, 1995, ARTERIOSCL THROM VAS, V15, P1009, DOI 10.1161/01.ATV.15.8.1009; WALD ER, 1995, CLIN UPDATES PEDIAT, V1, P1; Wang JP, 1998, J CLIN INVEST, V101, P1283, DOI 10.1172/JCI1343; XU CF, 1987, GENET EPIDEMIOL, V126, P202; YU SM, 1995, AM J CLIN NUTR, V61, P1129, DOI 10.1093/ajcn/61.5.1129; Zock PL, 1997, ATHEROSCLEROSIS, V131, P7, DOI 10.1016/S0021-9150(96)06063-7; Zock PL, 1997, AM J EPIDEMIOL, V145, P1114, DOI 10.1093/oxfordjournals.aje.a009074	48	53	53	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2740	2747		10.1001/jama.284.21.2740	http://dx.doi.org/10.1001/jama.284.21.2740			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105179	Bronze			2022-12-28	WOS:000165509500028
J	Morice, AH				Morice, AH			Helium/oxygen and severe COPD	LANCET			English	Editorial Material							PRESSURE		Castle Hill Hosp, Acad Dept Med, Cottingham HU16 5JQ, East Yorkshire, England	University of Hull	Morice, AH (corresponding author), Castle Hill Hosp, Acad Dept Med, Cottingham HU16 5JQ, East Yorkshire, England.							PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; SASSOON CSH, 1991, AM REV RESPIR DIS, V143, P469, DOI 10.1164/ajrccm/143.3.469; Tassaux D, 2000, CRIT CARE MED, V28, P2721, DOI 10.1097/00003246-200008000-00006	3	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1785	1786		10.1016/S0140-6736(00)03226-8	http://dx.doi.org/10.1016/S0140-6736(00)03226-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117906				2022-12-28	WOS:000165545700005
J	Desiraju, GR				Desiraju, GR			The all-chemist - Linus Pauling set the agenda for a century of chemical research	NATURE			English	Editorial Material									Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India	University of Hyderabad	Desiraju, GR (corresponding author), Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India.		Desiraju, Gautam R./AAQ-6388-2021; Desiraju, Gautam R/B-1565-2009						0	10	10	1	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					407	407		10.1038/35044150	http://dx.doi.org/10.1038/35044150			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100703				2022-12-28	WOS:000165429800020
J	Hoshi, E; Tanji, J				Hoshi, E; Tanji, J			Integration of target and body-part information in the premotor cortex when planning action	NATURE			English	Article							SUPERIOR PARIETAL LOBULE; NEURONAL-ACTIVITY; PRIMATE PREMOTOR; PREFRONTAL CORTEX; MACAQUE MONKEY; MOTOR; MOVEMENT; AREA; ORGANIZATION; DIRECTION	To plan an action, we must first select an object to act on and the body part (or parts) to use to accomplish our intention. To plan the motor task of reaching, we specify both the target to reach for and the arm to use. In the process of planning and preparing a motor task, information about the motor target and the arm to use must be integrated before a motor program can be formulated to generate the appropriate limb movement. One of the structures in the brain that is probably involved in integrating these two sets of information is the premotor area in the cerebral cortex of primates(1-5). The lateral sector of the dorsal premotor cortex is known to receive both visual and somatosensory input(6-8), and we show here that neurons in this area gather information about both the target and the body part, while subsequent activity specifies the planned action.	Tohoku Univ, Sch Med, Dept Physiol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Core Res Evolut Sci & Technol Program, Kawaguchi 3320012, Japan	Tohoku University; Japan Science & Technology Agency (JST)	Tanji, J (corresponding author), Tohoku Univ, Sch Med, Dept Physiol, Aoba Ku, 2-1 Seiryo Cho, Sendai, Miyagi 9808575, Japan.	tanjij@mail.cc.tohoku.ac.jp						BOUSSAOUD D, 1993, EXP BRAIN RES, V95, P15, DOI 10.1007/BF00229650; Caminiti R, 1996, CEREB CORTEX, V6, P319, DOI 10.1093/cercor/6.3.319; DIPELLEGRINO G, 1993, J NEUROSCI, V13, P1227; DUM RP, 1991, LIFE SCI R, V50, P383; Fogassi L, 1999, EXP BRAIN RES, V128, P194, DOI 10.1007/s002210050835; HALSBAND V, 1982, BRAIN RES, V240, P368; Hoshi E, 2000, J NEUROPHYSIOL, V83, P2355, DOI 10.1152/jn.2000.83.4.2355; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; KURATA K, 1985, EXP BRAIN RES, V60, P188; KURATA K, 1994, BEHAV BRAIN RES, V61, P135, DOI 10.1016/0166-4328(94)90154-6; KURATA K, 1993, J NEUROPHYSIOL, V69, P187, DOI 10.1152/jn.1993.69.1.187; KURATA K, 1988, EXP BRAIN RES, V69, P327; Matelli M, 1998, J COMP NEUROL, V402, P327; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; PASSINGHAM RE, 1988, EXP BRAIN RES, V70, P590; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PETRIDES M, 1985, BEHAV BRAIN RES, V16, P95, DOI 10.1016/0166-4328(85)90085-3; RIEHLE A, 1989, J NEUROPHYSIOL, V61, P534, DOI 10.1152/jn.1989.61.3.534; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; Shen LM, 1997, J NEUROPHYSIOL, V77, P1195, DOI 10.1152/jn.1997.77.3.1195; Tokuno H, 2000, NEUROSCI RES, V36, P335, DOI 10.1016/S0168-0102(99)00133-9; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245	23	191	192	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					466	470		10.1038/35044075	http://dx.doi.org/10.1038/35044075			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100727				2022-12-28	WOS:000165429800047
J	Modvig, J; Pagaduan-Lopez, J; Rodenburg, J; Salud, CMD; Cabigon, RV; Panelo, CIA				Modvig, J; Pagaduan-Lopez, J; Rodenburg, J; Salud, CMD; Cabigon, RV; Panelo, CIA			Torture and trauma in post-conflict East Timor	LANCET			English	Editorial Material									Int Rehabil Council Torture Victims, Copenhagen K, Denmark		Modvig, J (corresponding author), Int Rehabil Council Torture Victims, Copenhagen K, Denmark.								0	46	46	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1763	1763		10.1016/S0140-6736(00)03218-9	http://dx.doi.org/10.1016/S0140-6736(00)03218-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095275				2022-12-28	WOS:000165462300041
J	Neven, P				Neven, P			Local levonorgestrel to prevent tamoxifen-related endometrial lesions	LANCET			English	Editorial Material							INTRAUTERINE SYSTEM; WOMEN		Algemene Klin St Jan, B-1000 Brussels, Belgium		Neven, P (corresponding author), Algemene Klin St Jan, Broekstr 104, B-1000 Brussels, Belgium.							BALLARD P, 1998, BRIT J OBSTET GY S17, V105; Berezowsky J., 1994, Obstetrics and Gynecology, V84, P727; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Berliere M, 1998, OBSTET GYNECOL, V91, P40, DOI 10.1016/S0029-7844(97)00591-7; Brechin S, 2000, HUM REPROD, V15, P650, DOI 10.1093/humrep/15.3.650; Cohen I, 1996, INT J GYNECOL PATHOL, V15, P17, DOI 10.1097/00004347-199601000-00003; Critchley HOD, 1998, HUM REPROD, V13, P1210, DOI 10.1093/humrep/13.5.1210; Elkas J, 2000, OBSTET GYNECOL, V95, P697, DOI 10.1016/S0029-7844(99)00660-2; Elkas J, 1998, OBSTET GYNECOL, V91, P45, DOI 10.1016/S0029-7844(97)00549-8; Gardner FJE, 2000, LANCET, V356, P1711, DOI 10.1016/S0140-6736(00)03204-9; Kennedy MM, 1999, INT J GYNECOL PATHOL, V18, P130, DOI 10.1097/00004347-199904000-00006; Neven P, 2000, DRUG SAFETY, V22, P1, DOI 10.2165/00002018-200022010-00001; Neven P, 1998, LANCET, V351, P155, DOI 10.1016/S0140-6736(05)78216-7; PEKONEN F, 1992, J CLIN ENDOCR METAB, V75, P660, DOI 10.1210/jc.75.2.660; Powles TJ, 1998, BRIT J CANCER, V78, P272, DOI 10.1038/bjc.1998.477; Rose PG, 1999, INT J GYNECOL CANCER, V9, P362, DOI 10.1046/j.1525-1438.1999.99041.x; Suvanto-Luukkonen E, 1999, FERTIL STERIL, V72, P161, DOI 10.1016/S0015-0282(99)00162-4; Thijs I, 2000, Eur J Cancer, V36 Suppl 4, P108, DOI 10.1016/S0959-8049(00)00263-X	18	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1698	1699		10.1016/S0140-6736(00)03197-4	http://dx.doi.org/10.1016/S0140-6736(00)03197-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095251				2022-12-28	WOS:000165462300002
J	Smith, J				Smith, J			Nice work - but is it science?	NATURE			English	Editorial Material									Winfrith Technol Ctr, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, Dorset, England	UK Centre for Ecology & Hydrology (UKCEH)	Smith, J (corresponding author), Winfrith Technol Ctr, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, Dorset, England.		Smith, Jim/G-7716-2011	Smith, Jim/0000-0002-0808-2739				PETERS RH, 1991, CRITIQUE ECOLOGY; Popper K. R., 1963, CONJECTURES REFUTAT	2	8	9	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					293	293		10.1038/35042642	http://dx.doi.org/10.1038/35042642			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099020	Bronze			2022-12-28	WOS:000165296000021
J	Gogos, JA; Osborne, J; Nemes, A; Mendelsohn, M; Axel, R				Gogos, JA; Osborne, J; Nemes, A; Mendelsohn, M; Axel, R			Genetic ablation and restoration of the olfactory topographic map	CELL			English	Article							BROMIDE-INDUCED LESION; ADULT MAMMALIAN BRAIN; NEURAL STEM-CELL; TOXIN-A-CHAIN; TRANSGENIC MICE; SUBVENTRICULAR ZONE; MARKER PROTEIN; SENSORY MAP; EXPRESSION; BULB	In the olfactory sensory system, neurons expressing a given odorant receptor project with precision to two of 1800 spatially invariant glomeruli creating a topographic map within the olfactory bulb. Olfactory sensory neurons have a half-life of about 90 days and are continually renewing. This poses the problem of how this precise spatial map is maintained throughout the life of the organism. We have developed a genetic approach to effect the synchronous ablation of subpopulations of neurons expressing a given receptor. The axons of newly generated neurons can then be followed as they enter the brain and converge on glomerular targets during adult life. The observation that following neuronal cell killing, the spatial map is faithfully restored, demonstrates that the information necessary for the establishment of the sensory map persists throughout the life of the organism.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Axel, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076				ATTARDI DG, 1963, EXP NEUROL, V7, P46, DOI 10.1016/0014-4886(63)90093-1; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; BURD GD, 1993, MICROSC RES TECHNIQ, V24, P195, DOI 10.1002/jemt.1070240302; CAGGIANO M, 1994, NEURON, V13, P339, DOI 10.1016/0896-6273(94)90351-4; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Costanzo RM, 2000, CHEM SENSES, V25, P199, DOI 10.1093/chemse/25.2.199; Cummings DM, 2000, J COMP NEUROL, V421, P362; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; Galizia CG, 1999, NAT NEUROSCI, V2, P473, DOI 10.1038/8144; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAZIADEI PPC, 1978, DEV SENSORY SYSTEMS, P55; HINDS JW, 1984, ANAT REC, V210, P375, DOI 10.1002/ar.1092100213; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Koster NL, 1996, BRAIN RES, V724, P117, DOI 10.1016/0006-8993(96)00281-8; Lee P, 1998, P NATL ACAD SCI USA, V95, P11371, DOI 10.1073/pnas.95.19.11371; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Luskin MB, 1997, MOL CELL NEUROSCI, V8, P351, DOI 10.1006/mcne.1996.0592; MACKAYSIM A, 1991, EUR J NEUROSCI, V3, P209, DOI 10.1111/j.1460-9568.1991.tb00081.x; MACKAYSIM A, 1991, J NEUROSCI, V11, P979; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MAXWELL IH, 1986, CANCER RES, V46, P4660; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Royal SJ, 1999, J NEUROSCI, V19, P9856; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Schwob JE, 1999, J COMP NEUROL, V412, P439, DOI 10.1002/(SICI)1096-9861(19990927)412:3<439::AID-CNE5>3.0.CO;2-H; SCHWOB JE, 1995, J COMP NEUROL, V359, P15, DOI 10.1002/cne.903590103; STROTMANN J, 1994, CELL TISSUE RES, V276, P429; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VERHAAGEN J, 1990, J NEUROSCI RES, V26, P31, DOI 10.1002/jnr.490260105; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WANG F, 1998, THESIS COLUMBIA U NE; Whitlock KE, 1998, J NEUROSCI, V18, P8919; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; Yee KK, 1998, CHEM SENSES, V23, P513, DOI 10.1093/chemse/23.5.513; YEE KK, 1995, PHYSIOL BEHAV, V58, P959, DOI 10.1016/0031-9384(95)00159-G; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X	50	109	112	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 10	2000	103	4					609	620		10.1016/S0092-8674(00)00164-1	http://dx.doi.org/10.1016/S0092-8674(00)00164-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106731	Bronze			2022-12-28	WOS:000165348000006
J	Keeley, PW; Foster, G; Whitelaw, L				Keeley, PW; Foster, G; Whitelaw, L			Hear my song: auditory hallucinations with tramadol hydrochloride	BRITISH MEDICAL JOURNAL			English	Article							MUSICAL HALLUCINATIONS; CHRONIC PAIN		Strathcarron Hospice, Denny FK6 5HJ, Stirlingshire, Scotland		Keeley, PW (corresponding author), Strathcarron Hospice, Denny FK6 5HJ, Stirlingshire, Scotland.			Keeley, Paul/0000-0002-3169-8187				BUDD K, 1994, DRUGS, V47, P33, DOI 10.2165/00003495-199400471-00006; Evans M, 1997, BRIT MED J, V314, P1869, DOI 10.1136/bmj.314.7098.1869; GILBERT GJ, 1993, NEUROLOGY, V43, P1621, DOI 10.1212/WNL.43.8.1621; LEE CR, 1993, DRUGS, V46, P313, DOI 10.2165/00003495-199346020-00008; Medicines Control Agency, 1996, CURR PROBL PHARMACOV, V22, P11; Pasquini F, 1997, J GERIATR PSYCH NEUR, V10, P11, DOI 10.1177/089198879701000103; 1994, DRUG THER B, V32, P85	7	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1608	1608		10.1136/bmj.321.7276.1608	http://dx.doi.org/10.1136/bmj.321.7276.1608			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124199	Green Published			2022-12-28	WOS:000166134500035
J	Loudon, I				Loudon, I			Why are (male) surgeons still addressed as Mr?	BRITISH MEDICAL JOURNAL			English	Article											Loudon, I (corresponding author), Mill House,Locks Lane, Wantage OX12 9EH, England.							Aronson J, 2000, BRIT MED J, V320, P357, DOI 10.1136/bmj.320.7231.357; COOKE AM, 1972, HIST ROYAL COLL PHYS, V3, P844; Cope Z., 1959, ROYAL COLL SURG ENGL; GUTHRIE GJ, 1934, PARLIAMENTARY PAPE 2, V13, pQ4842; GUTHRIE GJ, 1934, PARLIAMENTARY PAPE 2, V13, pQ4731; LOUDON I, 1992, DEATH CHILDBIRTH INT, P183; LOUDON I, 1995, HIST MED ED BRITAIN, P229; Loudon Irvine, 1986, MED CARE GEN PRACTIT, P152; *ROYAL SOC MED LON, 1912, NOT JG CROSS NORW, V285, pG11	9	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1589	1591		10.1136/bmj.321.7276.1589	http://dx.doi.org/10.1136/bmj.321.7276.1589			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124190	Green Published			2022-12-28	WOS:000166134500027
J	Suenaga, K; Tence, M; Mory, C; Colliex, C; Kato, H; Okazaki, T; Shinohara, H; Hirahara, K; Bandow, S; Iijima, S				Suenaga, K; Tence, M; Mory, C; Colliex, C; Kato, H; Okazaki, T; Shinohara, H; Hirahara, K; Bandow, S; Iijima, S			Element-selective single atom imaging	SCIENCE			English	Article							DETECTION LEVEL	Electron energy-loss spectroscopy (EELS) is widely used to identify elemental compositions of materials studied by microscopy. We demonstrate that the sensitivity and spatial resolution of EELS can be extended to the single-atom Limit. A chemical map for gadolinium (Cd) clearly reveals the distribution of Cd atoms inside a single chain of metallofullerene molecules (Gd@C-82) generated within a single-wall carbon nanotube, This characterization technique thus provides the "eyes" to see and identify individual atoms in nanostructures. It is likely to find broad application in nanoscale science and technology research.	Univ Paris 11, Phys Solides Lab, CNRS, UMR 8502, F-91405 Orsay, France; Univ Paris 11, Aime Cotton Lab, CNRS, UPR 3321, F-91405 Orsay, France; Meijo Univ, Japan Sci & Technol Corp, Nanotubul Project, Nagoya, Aichi 4688502, Japan; Nagoya Univ, Dept Chem, Nagoya, Aichi 4648602, Japan; NEC Corp Ltd, Tsukuba, Ibaraki 3058501, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Japan Science & Technology Agency (JST); Meijo University; Nagoya University; NEC Corporation	Suenaga, K (corresponding author), Univ Paris 11, Phys Solides Lab, CNRS, UMR 8502, Batiment 510, F-91405 Orsay, France.	suenaga@meijo-u.ac.jp	Okazaki, Toshiya/H-9545-2018; Okazaki, Toshiya/U-6757-2019; Suenaga, Kazu/E-2339-2014; Hirahara, Kaori/C-5286-2014	Okazaki, Toshiya/0000-0002-5958-0148; Okazaki, Toshiya/0000-0002-5958-0148; Suenaga, Kazu/0000-0002-6107-1123; Hirahara, Kaori/0000-0002-7776-4493				Colliex C, 1999, J ELECTRON MICROSC, V48, P995; CREWE AV, 1970, SCIENCE, V168, P1338, DOI 10.1126/science.168.3937.1338; Egerton R.F., 1996, ELECT ENERGY LOSS SP, P245; HIRAHARA K, IN PRESS PHYS REV LE; IIJIMA S, 1977, OPTIK, V47, P437; ISAACSON M, 1975, ULTRAMICROSCOPY, V1, P33, DOI 10.1016/S0304-3991(75)80006-4; KRIVANEK OL, 1991, MICROSC MICROANAL M, V2, P257, DOI 10.1051/mmm:0199100202-3025700; MORY C, 1989, ULTRAMICROSCOPY, V28, P339, DOI 10.1016/0304-3991(89)90321-5; Tanaka N, 1996, THIN SOLID FILMS, V281, P613, DOI 10.1016/0040-6090(96)08693-2	9	258	262	4	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	2000	290	5500					2280	+		10.1126/science.290.5500.2280	http://dx.doi.org/10.1126/science.290.5500.2280			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11125135				2022-12-28	WOS:000165995800035
J	Lester, SJ; Baggott, M; Welm, S; Schiller, NB; Jones, RT; Foster, E; Mendelson, J				Lester, SJ; Baggott, M; Welm, S; Schiller, NB; Jones, RT; Foster, E; Mendelson, J			Cardiovascular effects of 3,4-methylenedioxymethamphetamine - A double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							AMBIENT-TEMPERATURE; HEALTHY-VOLUNTEERS; MDMA; ECSTASY; AMPHETAMINE; RATS; MDE	Background: The psychoactive stimulant 3,4-methylenedioxymethamphetamine (MDMA), also known as "ecstasy," is widely used in nonmedical settings. Little is known about its cardiovascular effects. Objective: To evaluate the acute cardiovascular effects of MDMA by using transthoracic two-dimensional and Doppler echocardiography. Design: Four-session, ascending-dose, double-blind, placebo-controlled trial. Setting: Urban hospital. Patients: Eight healthy adults who self-reported MDMA use. Intervention: Echocardiographic effects of dobutamine (5, 20, and 40 mug/kg of body weight per minute) were measured in a preliminary session. Oral MDMA (0.5 and 1.5 mg/kg of body weight) or placebo was administered 1 hour before echocardiographic measurements in three weekly sessions. Measurements: Heart rate and blood pressure were measured at regular intervals before and after MDMA administration. Echocardiographic measures of stroke volume, ejection fraction, cardiac output, and meridional wall stress were obtained 1 hour after MDMA administration and during dobutamine infusions. Results: At a dose of 1.5 mg/kg, MDMA increased mean heart rate (by 28 beats/min), systolic blood pressure (by 25 mm Hg), diastolic blood pressure (by 7 mm Hg), and cardiac output (by 2 L/min). The effects of MDMA were similar to those of dobutamine, 20 and 40 mug/kg per minute. Inotropism, measured by using meridional wall stress corrected for ejection fraction, decreased after administration of dobutamine, 40 mug/kg per minute, but did not change after either dose of MDMA. Conclusions: Modest oral doses of MDMA increase heart rate, blood pressure, and myocardial oxygen consumption in a magnitude similar to dobutamine, 20 to 40 mug/kg per minute. In contrast to dobutamine, MDMA has no measurable inotropic effects.	Univ Calif San Francisco, Langley Porter Psychiat Inst, Drug Dependence Res Ctr, San Francisco, CA 94143 USA; Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA; Univ Calif San Francisco, Dept Med, John Henry Mills Echocardiog Lab, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Mayo Clinic; Mayo Clinic Phoenix; University of California System; University of California San Francisco	Mendelson, J (corresponding author), Univ Calif San Francisco, Langley Porter Psychiat Inst, Drug Dependence Res Ctr, 401 Parnassus Ave,Box CPR-0984, San Francisco, CA 94143 USA.	jemmd@itsa.ucsf.edu		Baggott, Matthew/0000-0003-1000-194X	NCRR NIH HHS [RR-00079] Funding Source: Medline; NIDA NIH HHS [DA00053, DA01696] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA001696] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CALLAWAY CW, 1992, NEUROPSYCHOPHARMACOL, V7, P113; Cami J, 2000, J CLIN PSYCHOPHARM, V20, P455, DOI 10.1097/00004714-200008000-00010; DAFTERS RI, 1995, PHYSIOL BEHAV, V58, P877, DOI 10.1016/0031-9384(95)00136-7; DAVIS W M, 1984, Substance and Alcohol Actions-Misuse, V5, P105; FITZGERALD JL, 1994, J PHARM PHARMACOL, V46, P826, DOI 10.1111/j.2042-7158.1994.tb03738.x; Gouzoulis-Mayfrank E, 1999, PSYCHOPHARMACOLOGY, V142, P41, DOI 10.1007/s002130050860; Grob CS, 1996, BEHAV BRAIN RES, V73, P103; HEGADOREN KM, 1995, PSYCHOPHARMACOLOGY, V118, P295, DOI 10.1007/BF02245958; Helmlin HJ, 1996, J ANAL TOXICOL, V20, P432, DOI 10.1093/jat/20.6.432; HERMLE L, 1993, NEUROPSYCHOPHARMACOL, V8, P171, DOI 10.1038/npp.1993.19; JOHNSTON LD, 1998, NIH PUBL; Malberg JE, 1998, J NEUROSCI, V18, P5086; OBERLENDER R, 1988, PSYCHOPHARMACOLOGY, V95, P71; REICHEK N, 1982, CIRCULATION, V65, P99, DOI 10.1161/01.CIR.65.1.99; RUSSELL ARB, 1992, ARCH DIS CHILD, V67, P1114, DOI 10.1136/adc.67.9.1114; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Topp L, 1999, DRUG ALCOHOL DEPEN, V55, P105, DOI 10.1016/S0376-8716(99)00002-2; Vollenweider FX, 1998, NEUROPSYCHOPHARMACOL, V19, P241, DOI 10.1016/S0893-133X(98)00013-X	18	87	90	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					969	973		10.7326/0003-4819-133-12-200012190-00012	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119398				2022-12-28	WOS:000165952300005
J	Walley, T; Earl-Slater, A; Haycox, A; Bagust, A				Walley, T; Earl-Slater, A; Haycox, A; Bagust, A			An integrated national pharmaceutical policy for the United Kingdom?	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Dept Pharmacol & Therapeut, Prescribing Res Grp, Liverpool L69 3GF, Merseyside, England; Univ Birmingham, Dept Commerce, Birmingham B15 2TT, W Midlands, England	University of Liverpool; University of Birmingham	Walley, T (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Prescribing Res Grp, Liverpool L69 3GF, Merseyside, England.							COLLIER J, 1999, GUARDIAN        1013; *COMM DEP HLTH AG, 1999, NAT MED POL 2000; DAVIS P, 1997, MANAGING MED PUBLIC; Dent THS, 1997, BMJ-BRIT MED J, V315, P1248, DOI 10.1136/bmj.315.7118.1248; *DEP HLTH, 1998, 1 CLASS SERV; *DEP HLTH, 1999, PHARM PRIC REG SCHEM; *DEP HLTH, 1998, INT GUID VIAGR ISS; DYER C, 1997, BRIT MED J, V315, P143; Earl-Slater A, 1998, J Manag Med, V12, P5, DOI 10.1108/02689239810225210; EarlSlater A, 1997, BRIT MED J, V314, P365, DOI 10.1136/bmj.314.7077.365; Klein R, 1998, BMJ-BRIT MED J, V317, P959, DOI 10.1136/bmj.317.7164.959; Ludlam CA, 1997, BRIT MED J, V314, P749, DOI 10.1136/bmj.314.7082.749; MORGAN O, 1999, OBSERVER        1010; *NAT I CLIN EXC, 1999, NAT I CLIN EX GUID Z; *NAT I CLIN EXC, 2000, TAX APP PAN DEC; *NHS EX, 1999, QUAL PERF NHS HIGH L; *ROYAL COLL PHYS W, 2000, PRESCR COSTL MED; Walley T, 2000, BRIT MED J, V320, P131, DOI 10.1136/bmj.320.7228.131; *WHO, 2000, ESS DRUGS MD POL	19	20	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	2000	321	7275					1523	1526		10.1136/bmj.321.7275.1523	http://dx.doi.org/10.1136/bmj.321.7275.1523			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118184	Green Published			2022-12-28	WOS:000165994700036
J	Thurn-Albrecht, T; Schotter, J; Kastle, CA; Emley, N; Shibauchi, T; Krusin-Elbaum, L; Guarini, K; Black, CT; Tuominen, MT; Russell, TP				Thurn-Albrecht, T; Schotter, J; Kastle, CA; Emley, N; Shibauchi, T; Krusin-Elbaum, L; Guarini, K; Black, CT; Tuominen, MT; Russell, TP			Ultrahigh-density nanowire arrays grown in self-assembled diblock copolymer templates	SCIENCE			English	Article							ANODIC ALUMINA; ELECTRIC-FIELD; THIN-FILMS; FABRICATION; MICROSTRUCTURE; ALIGNMENT; PARTICLES	We show a simple, robust, chemical route to the fabrication of ultrahigh-density arrays of nanopores with high aspect ratios using the equilibrium self-assembled morphology of asymmetric diblock copolymers. The dimensions and Lateral density of the array are determined by segmental interactions and the copolymer molecular weight. Through direct current electrodeposition, we fabricated vertical arrays of nanowires with densities in excess of 1.9 x 10(11) wires per square centimeter. We found markedly enhanced coercivities with ferromagnetic cobalt nanowires that point toward a route to ultrahigh-density storage media. The copolymer approach described is practical, parallel, compatible with current Lithographic processes, and amenable to multilayered device fabrication.	Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA; Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA; IBM Corp, Thomas J Watson Res Ctr, Yorktown Heights, NY 10598 USA; Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; International Business Machines (IBM); United States Department of Energy (DOE); Los Alamos National Laboratory	Russell, TP (corresponding author), Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA.		Tuominen, Mark/A-6129-2012; Russell, Thomas Paul/ADL-3689-2022; Shibauchi, Takasada/B-9349-2008	Russell, Thomas Paul/0000-0001-6384-5826; Shibauchi, Takasada/0000-0001-5831-4924; Thurn-Albrecht, Thomas/0000-0002-7618-0218				AMUNDSON K, 1994, MACROMOLECULES, V27, P6559, DOI 10.1021/ma00100a047; AMUNDSON K, 1993, MACROMOLECULES, V26, P2698, DOI 10.1021/ma00063a010; Bard A. J., 1980, ELECTROCHEMICAL METH; Bertotti G., 1998, HYSTERESIS MAGNETISM; Braun PV, 1999, NATURE, V402, P603, DOI 10.1038/45137; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Chou SY, 1997, P IEEE, V85, P652, DOI 10.1109/5.573754; Fan SS, 1999, SCIENCE, V283, P512, DOI 10.1126/science.283.5401.512; Fasol G, 1997, SCIENCE, V275, P941, DOI 10.1126/science.275.5302.941; FOSS CA, 1994, J PHYS CHEM-US, V98, P2963, DOI 10.1021/j100062a037; Fruchart O, 1999, PHYS REV LETT, V83, P2769, DOI 10.1103/PhysRevLett.83.2769; Garcia JM, 1999, J APPL PHYS, V85, P5480, DOI 10.1063/1.369868; Garcia-Otero J, 2000, PHYS REV LETT, V84, P167, DOI 10.1103/PhysRevLett.84.167; Hehn M, 1996, SCIENCE, V272, P1782, DOI 10.1126/science.272.5269.1782; Heremans J, 1999, PHYS REV B, V59, P12579, DOI 10.1103/PhysRevB.59.12579; Huczko A, 2000, APPL PHYS A-MATER, V70, P365, DOI 10.1007/s003390051050; Hulteen JC, 1996, J CHEM SOC FARADAY T, V92, P4029, DOI 10.1039/ft9969204029; Hulteen JC, 1997, J MATER CHEM, V7, P1075, DOI 10.1039/a700027h; HYLTON TL, 1995, APPL PHYS LETT, V67, P1154, DOI 10.1063/1.114992; KAWAI S, 1987, S EL TECHNOLOGY ELEC; Li AP, 1998, J APPL PHYS, V84, P6023, DOI 10.1063/1.368911; Li AP, 1999, ADV MATER, V11, P483, DOI 10.1002/(SICI)1521-4095(199904)11:6<483::AID-ADMA483>3.0.CO;2-I; Madou M., 1997, FUNDAMENTALS MICROFA; MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466; Masuda H, 1997, APPL PHYS LETT, V71, P2770, DOI 10.1063/1.120128; Morkved TL, 1996, SCIENCE, V273, P931, DOI 10.1126/science.273.5277.931; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; Routkevitch D, 1996, J PHYS CHEM-US, V100, P14037, DOI 10.1021/jp952910m; Strijkers GJ, 1999, J APPL PHYS, V86, P5141, DOI 10.1063/1.371490; Sun L, 1999, APPL PHYS LETT, V74, P2803, DOI 10.1063/1.124019; Thurn-Albrecht T, 2000, ADV MATER, V12, P787, DOI 10.1002/(SICI)1521-4095(200006)12:11<787::AID-ADMA787>3.0.CO;2-1; Thurn-Albrecht T, 2000, MACROMOLECULES, V33, P3250, DOI 10.1021/ma991896z; Weller D, 1999, IEEE T MAGN, V35, P4423, DOI 10.1109/20.809134; WHITNEY TM, 1993, SCIENCE, V261, P1316, DOI 10.1126/science.261.5126.1316; Wirth S, 1999, J APPL PHYS, V85, P5249, DOI 10.1063/1.369957; Wong J, 1999, J APPL PHYS, V85, P5489, DOI 10.1063/1.369871; Zeng H, 2000, J APPL PHYS, V87, P4718, DOI 10.1063/1.373137	37	1957	2078	14	748	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2126	2129		10.1126/science.290.5499.2126	http://dx.doi.org/10.1126/science.290.5499.2126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118143				2022-12-28	WOS:000165870600051
J	Vision, TJ; Brown, DG; Tanksley, SD				Vision, TJ; Brown, DG; Tanksley, SD			The origins of genomic duplications in Arabidopsis	SCIENCE			English	Article							MONOCOT-DICOT DIVERGENCE; NUCLEOTIDE SUBSTITUTION; HIGHER-PLANTS; THALIANA; SEQUENCE; DNA; CHROMOSOME-4; GENERATION; PREDICTION; BRASSICA	Large segmental duplications cover much of the Arabidopsis thaliana genome. Little is known about their origins. We show that they are primarily due to at Least four different Large-scale duplication events that occurred 100 to 200 million years ago. a formative period in the diversification of the angiosperms. A better understanding of the complex structural history of angiosperm genomes is necessary to make full use of Arabidopsis as a genetic model for other plant species.	USDA ARS, Ctr Agr Bioinformat, Ithaca, NY 14853 USA; Whitehead Inst MIT Ctr Genome Res, Cambridge, MA 02141 USA; Cornell Univ, Dept Plant Breeding, Ithaca, NY 14853 USA; Cornell Univ, Dept Plant Pathol, Ithaca, NY 14853 USA	United States Department of Agriculture (USDA); Massachusetts Institute of Technology (MIT); Whitehead Institute; Cornell University; Cornell University	Vision, TJ (corresponding author), USDA ARS, Ctr Agr Bioinformat, 604 Rhodes Hall, Ithaca, NY 14853 USA.		Vision, Todd J/B-4867-2010	Vision, Todd J/0000-0002-6133-2581; Brown, Dan/0000-0002-5205-5762				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arumuganathan K, 1991, PLANT MOL BIOL REP, V9, P208, DOI DOI 10.1007/BF02672069; Bancroft I, 2000, YEAST, V17, P1, DOI 10.1002/(SICI)1097-0061(200004)17:1<1::AID-YEA3>3.0.CO;2-V; Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15; Blanc G, 2000, PLANT CELL, V12, P1093, DOI 10.1105/tpc.12.7.1093; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; CORMEN TH, 1990, INTRO ALGORITHMS, P536; Devos KM, 1999, GENOME RES, V9, P825, DOI 10.1101/gr.9.9.825; FELLER W, 1957, INTRO PROBABILITY TH, P238; Gaut BS, 1998, EVOL BIOL, V30, P93; Grant D, 2000, P NATL ACAD SCI USA, V97, P4168, DOI 10.1073/pnas.070430597; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Koch M, 1999, PLANT BIOLOGY, V1, P529, DOI 10.1055/s-2007-978548; KOWALSKI SP, 1994, GENETICS, V138, P499; Ku HM, 2000, P NATL ACAD SCI USA, V97, P9121, DOI 10.1073/pnas.160271297; Lan TH, 2000, GENOME RES, V10, P776, DOI 10.1101/gr.10.6.776; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LYNCH M, 1997, GENETICS ANAL QUANTI, P359; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; MCGRATH JM, 1993, THEOR APPL GENET, V86, P880, DOI 10.1007/BF00212616; McLysaght A, 2000, COMP GENOMICS, P47; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Muse SV, 2000, PLANT MOL BIOL, V42, P25, DOI 10.1023/A:1006319803002; Paterson AH, 2000, PLANT CELL, V12, P1523, DOI 10.1105/tpc.12.9.1523; Paterson AH, 1996, NAT GENET, V14, P380, DOI 10.1038/ng1296-380; Semple C, 1999, J MOL EVOL, V48, P555, DOI 10.1007/PL00006498; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; SOMERVILLE CC, COMMUNICATION; Terryn N, 1999, FEBS LETT, V445, P237, DOI 10.1016/S0014-5793(99)00097-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Dodeweerd AM, 1999, GENOME, V42, P887, DOI 10.1139/gen-42-5-887; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; Yang YW, 1999, J MOL EVOL, V48, P597, DOI 10.1007/PL00006502; Yang Z., 2000, PHYLOGENETIC ANAL MA	37	759	793	3	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2114	2117		10.1126/science.290.5499.2114	http://dx.doi.org/10.1126/science.290.5499.2114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11118139				2022-12-28	WOS:000165870600047
J	Choe, W; Mehlman, D				Choe, W; Mehlman, D			Mediastinal abnormalities in systemic sclerosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NW Mem Hosp, Chicago, IL 60611 USA	Northwestern Memorial Hospital	Choe, W (corresponding author), NW Mem Hosp, Chicago, IL 60611 USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1771	1771		10.1056/NEJM200012143432405	http://dx.doi.org/10.1056/NEJM200012143432405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11114316				2022-12-28	WOS:000165812000005
J	Danovaro-Holliday, MC; LeBaron, CW; Allensworth, C; Raymond, R; Borden, TG; Murray, AB; Ieenogle, JP; Reef, SE				Danovaro-Holliday, MC; LeBaron, CW; Allensworth, C; Raymond, R; Borden, TG; Murray, AB; Ieenogle, JP; Reef, SE			A large rubella outbreak with spread from the workplace to the community	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINATION LEVELS; UNITED-STATES; SYNDROME CRS; CHILDREN; PRESCHOOL; PROGRAM	Context Childhood vaccination has reduced rubella disease to low levels in the United States, but outbreaks continue to occur. The largest outbreak in the past 5 years occurred in Nebraska in 1999. Objectives To examine risk factors for disease, susceptibility of the risk population, role of vaccine failure, and the need for new vaccination strategies in response to the Nebraska rubella outbreak. Design, Setting, and Patients Investigation of 83 confirmed rubella cases occurring in Douglas County, Nebraska, between March 23 and August. 24, 1999; serosurvey of 413 pregnant women in the outbreak locale between October 1998 and March 1999 (prior to outbreak) and April and November 1999 (during and after outbreak). Main Outcome Measures Case characteristics, compared with that of the general county population; area childhood rubella vaccination rates; and susceptibility among pregnant women before vs during and after the outbreak. Results All 83 rubella cases were unvaccinated or had unknown vaccination status and fell into 3 groups: (1) 52 (63%) were young adults (median age, 26 years), 83% of whom were born in Latin American countries where rubella vaccination was not routine. They were either employed in meatpacking plants or were their household contacts. Attack rates in the plants were high (14.4 per 1000 vs 0.19 per 1000 for general county population); (2) 16 (19%), including 14 children (9 of whom were aged <12 months) and 2 parents, were US-born and non-Hispanic, who acquired the disease through contacts at 2 day care facilities (attack rate, 88.1 per 1000); and (3) 15 (18%) were young adults (median age, 22 years) whose major disease risk was residence in population-dense census tracts where meatpacking-related cases resided (R-2=0.343; P<.001); 87% of these persons were born in Latin America. Among pregnant women, susceptibility rates were 13% before the outbreak and 11% during and after the outbreak. Six (25%) of 24 susceptible women tested were seropositive for rubella IgM. Rubella vaccination rates were 90.2% for preschool children and 99.8% for school-aged children. Conclusions A large rubella outbreak occurred among unvaccinated persons in a community with high immunity levels. Crowded working and living conditions facilitated transmission, but vaccine failure did not. Workplace vaccination could be considered to prevent similar outbreaks.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA; Douglas Cty Hlth Dept, Omaha, NE USA; Nebraska Hlth & Human Serv Syst, Lincoln, NE USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Danovaro-Holliday, MC (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, 1600 Clifton Rd NE,Mail Stop E-61, Atlanta, GA 30333 USA.	mmd9@cdc.gov						ANDERSON RM, 1986, J HYG-CAMBRIDGE, V96, P305, DOI 10.1017/S0022172400066079; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; CHERRY JD, 1992, TXB PEDIATRIC INFECT, P1792; Cutts FT, 1999, INT J EPIDEMIOL, V28, P1176, DOI 10.1093/ije/28.6.1176; DYKEWICZ CA, 1997, 37 INT C ANT AG CHEM; HESELTINE PNR, 1985, INFECT CONT HOSP EP, V6, P371, DOI 10.1017/S0195941700063347; Hethcote HW, 1989, APPL MATH ECOLOGY, P119, DOI DOI 10.1007/978-3-642-61317-3{\_}5; Hoekstra EJ, 1998, JAMA-J AM MED ASSOC, V280, P1143, DOI 10.1001/jama.280.13.1143; Johnson CE, 1996, PEDIATR INFECT DIS J, V15, P687, DOI 10.1097/00006454-199608000-00010; Lamphere L., 1994, NEWCOMERS WORKPLACE; Langmuir A D, 1980, Ann N Y Acad Sci, V353, P35; LeBaron CW, 1996, AM J PUBLIC HEALTH, V86, P1551, DOI 10.2105/AJPH.86.11.1551; LEBARON CW, 1997, 37 INT C ANT AG CHEM; LEHANE DE, 1970, J AMER MED ASSOC, V213, P2236, DOI 10.1001/jama.213.13.2236; LINDEGREN ML, 1991, EPIDEMIOL REV, V13, P341, DOI 10.1093/oxfordjournals.epirev.a036077; *NATL CTR HLTH STA, 1999, HLTH PEOPL 2000 REV, P204; ORENSTEIN WA, 1984, JAMA-J AM MED ASSOC, V251, P1988, DOI 10.1001/jama.251.15.1988; PLOTKIN SA, 1998, VACCINES, P409; Rangel Maria C., 1999, Ethnicity and Disease, V9, P230; REEF S, 1999, MANUAL SURVEILLANCE; Robertson SE, 1997, B WORLD HEALTH ORGAN, V75, P69; SCHLENKER TL, 1992, JAMA-J AM MED ASSOC, V267, P823, DOI 10.1001/jama.267.6.823; Schluter WW, 1998, J INFECT DIS, V178, P636, DOI 10.1086/515384; *SECR HLTH MEX, 2000, B EP 1994 1998; *US BUR CENS, 1998, POP EST DOUGL COUNT; *US NAT IMM SURV, 1998, EST VACC COV IND VAC; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1999, MMWR MORB MORTAL WKL, V48, P1	28	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2733	2739		10.1001/jama.284.21.2733	http://dx.doi.org/10.1001/jama.284.21.2733			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105178	Bronze			2022-12-28	WOS:000165509500027
J	Shelton, JD				Shelton, JD			The harm of "First, do no harm"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600	1	6	6	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2687	2688		10.1001/jama.284.21.2687	http://dx.doi.org/10.1001/jama.284.21.2687			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105155				2022-12-28	WOS:000165509500001
J	Wang, Q; Khillan, J; Gadue, P; Nishikura, K				Wang, Q; Khillan, J; Gadue, P; Nishikura, K			Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis	SCIENCE			English	Article							DSRNA-ADENOSINE-DEAMINASE; SUBUNIT GLUR-B; 2 FORMS; ENZYME; CELLS; MICE	The members of the ADAR (adenosine deaminase acting on RNA) gene family are involved in site-selective RNA editing that changes adenosine residues of target substrate RNAs to inosine, Analysis of staged chimeric mouse embryos with a high contribution from embryonic stem cells with a functional null allele for ADAR1 revealed a heterozygous embryonic-lethal phenotype. Most ADAR1(+/-) chimeric embryos died before embryonic day 14 with defects in the hematopoietic system. Our results suggest the importance of regulated Levels of ADAR1 expression, which is critical for embryonic erythropoiesis in the liver.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Nishikura, K (corresponding author), Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.	kazuko@wistar.upenn.edu						Bass BL, 1997, RNA, V3, P947; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gerber A, 1997, RNA, V3, P453; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Hu NP, 1997, CANCER RES, V57, P4123; Joyner AL, 1993, GENE TARGETING PRACT; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Lai F, 1997, J NEUROCHEM, V69, P43; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Polson AG, 1996, NATURE, V380, P454; RAILSKIN O, UNPUB; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Wang QD, 2000, J NEUROCHEM, V74, P1290; WANG Y, 1995, J MOL BIOL, V254, P184, DOI 10.1006/jmbi.1995.0610	28	337	358	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	2000	290	5497					1765	1768		10.1126/science.290.5497.1765	http://dx.doi.org/10.1126/science.290.5497.1765			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099415				2022-12-28	WOS:000165632400043
J	Zha, JP; Weiler, S; Oh, KJ; Wei, MC; Korsmeyer, SJ				Zha, JP; Weiler, S; Oh, KJ; Wei, MC; Korsmeyer, SJ			Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis	SCIENCE			English	Article							CYTOCHROME-C RELEASE; PROTEIN; DEATH; MEMBRANES; SURVIVAL; PATHWAY; BCL-2; DNA	Many apoptotic molecules relocate subcellularly in cells undergoing apoptosis. The pro-apoptotic protein BID underwent posttranslational (rather than classic cotranslational) N-myristoylation when cleavage by caspase 8 caused exposure of a glycine residue. N-myristoylation enabled the targeting of a complex of p7 and myristoylated p15 fragments of BID to artificial membranes bearing the Lipid composition of mitochondria, as well as to intact mitochondria. This post-proteolytic N-myristoylation serves as an activating switch, enhancing BID-induced release of cytochrome c and cell death.	Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst,Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst,Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Korsmeyer, SJ (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst,Howard Hughes Med Inst, Boston, MA 02115 USA.			OH, KYOUNG JOON/0000-0002-4729-9674	NATIONAL CANCER INSTITUTE [K01CA082231, R37CA050239, T32CA072320, R01CA050239] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA82231, T32 CA72320-01A1, CA50239-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Blobel G, 1995, COLD SPRING HARB SYM, V60, P1; Borgese N, 1996, J CELL BIOL, V135, P1501, DOI 10.1083/jcb.135.6.1501; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Wei MC, 2000, GENE DEV, V14, P2060; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	24	458	488	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1761	1765		10.1126/science.290.5497.1761	http://dx.doi.org/10.1126/science.290.5497.1761			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099414				2022-12-28	WOS:000165632400042
J	Chen, HW; Lanzetta, KM; Pascarelle, S; Yahata, N				Chen, HW; Lanzetta, KM; Pascarelle, S; Yahata, N			Unusual spectral energy distribution of a galaxy previously reported to be at redshift 6.68	NATURE			English	Article								Observations of distant galaxies are important both for understanding how galaxies form and for probing the physical conditions of the Universe at early times. It is, however, very difficult to identify galaxies at redshifts z> 5, because they are so faint and have few spectral characteristics. We previously reported(1) the probable identification of a galaxy at z = 6.68, based on one line and an apparent break in the spectrum just shortwards of that, which we interpreted as Lyman alpha emission and the Lyman alpha break, where photons with shorter wavelengths are absorbed by the intervening neutral hydrogen gas. Here we present optical photometry that shows moderate detections of light in the B- and V-band images, which are inconsistent with the expected absence of flux shortwards of the Lyman alpha break for a galaxy at z> 5, and inconsistent with the previous flux measurement. Moreover, the spectral energy distribution for this object cannot readily be fitted by any known galaxy spectral template at any redshift, so the redshift is undetermined.	Carnegie Inst Washington Observ, Pasadena, CA 91101 USA; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA	Carnegie Institution for Science; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Chen, HW (corresponding author), Carnegie Inst Washington Observ, 813 Santa Barbara St, Pasadena, CA 91101 USA.			Chen, Hsiao-Wen/0000-0001-8813-4182				Chen MC, 1999, TRANSPLANTATION, V68, P586, DOI 10.1097/00007890-199908270-00026; Fernandez-Soto A, 1999, ASTROPHYS J, V513, P34, DOI 10.1086/306847; HOLTZMAN JA, 1995, PUBL ASTRON SOC PAC, V107, P1065, DOI 10.1086/133664; Puetter RC, 1999, ASTR SOC P, V172, P307; Yahata N, 2000, ASTROPHYS J, V538, P493, DOI 10.1086/309143	6	9	9	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					562	564		10.1038/35046031	http://dx.doi.org/10.1038/35046031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117738	Green Submitted			2022-12-28	WOS:000165548600111
J	Thakar, R; Stanton, S				Thakar, R; Stanton, S			Regular review - Management of urinary incontinence in women	BRITISH MEDICAL JOURNAL			English	Review							GENUINE STRESS-INCONTINENCE; RANDOMIZED CONTROLLED TRIAL; ELECTRICAL-STIMULATION; PELVIC FLOOR; URGE INCONTINENCE; VAGINAL CONES; BLADDER; INSTABILITY; MULTICENTER		St Georges Hosp, London SW17 0QT, England	St Georges University London	Thakar, R (corresponding author), St Georges Hosp, London SW17 0QT, England.							ABRAMS P, 1988, NEUROUROL URODYNAM, V7, P403, DOI 10.1002/nau.1930070502; Appell RA, 1997, UROLOGY, V50, P90, DOI 10.1016/S0090-4295(97)00599-2; Atala A, 2000, BJU Int, V85 Suppl 3, P24; Awad SA, 1998, BRIT J UROL, V81, P569; Bo K, 1999, BMJ-BRIT MED J, V318, P487, DOI 10.1136/bmj.318.7182.487; BO K, 1994, NEUROUROL URODYNAM, V13, P374; Bosch J L, 1998, Curr Opin Urol, V8, P287, DOI 10.1097/00042307-199807000-00005; BOSCH JLH, 1997, NEUROUROL URODYNAM, V16, P426; Brubaker L, 1997, AM J OBSTET GYNECOL, V177, P536, DOI 10.1016/S0002-9378(97)70142-X; BURCH JC, 1961, AM J OBSTET GYNECOL, V81, P281, DOI 10.1016/S0002-9378(16)36367-0; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Burton G., 1999, Neurourology and Urodynamics, V18, P295; CAMMU H, 1991, UROLOGY, V38, P332, DOI 10.1016/0090-4295(91)80146-X; Cammu H, 1997, Int Urogynecol J Pelvic Floor Dysfunct, V8, P297, DOI 10.1007/BF02765489; CARDOZO LD, 1978, BRIT J UROL, V50, P521, DOI 10.1111/j.1464-410X.1978.tb06204.x; CARSON CC, 1989, UROL CLIN N AM, V16, P139; *CONT FDN, 2000, MAK CAS INV INT CONT; Davila GW, 1999, OBSTET GYNECOL, V93, P938, DOI 10.1016/S0029-7844(99)00240-9; *DEP HLTH, 2000, GOOD PRACT CONT SERV; Elliott D S, 1998, Int Urogynecol J Pelvic Floor Dysfunct, V9, P409, DOI 10.1007/BF02199579; Elliott DS, 1998, J UROLOGY, V159, P1206, DOI 10.1016/S0022-5347(01)63557-2; ERIKSEN BC, 1989, NEUROUROL URODYNAM, V8, P219, DOI 10.1002/nau.1930080305; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; FERRIE BG, 1984, BRIT J UROL, V56, P482; Gorton E, 1999, BJU INT, V84, P966; JARVIS GJ, 1994, BRIT J OBSTET GYNAEC, V101, P371, DOI 10.1111/j.1471-0528.1994.tb11907.x; Jarvis GJ, 1999, INCONTINENCE, P637; KAITAM MM, 1999, UROGYNECOLOGY RECONS; NORTON C, 1996, COMMISSIONING COMPRE; OBRIEN J, 1995, BRIT MED J, V311, P1208, DOI 10.1136/bmj.311.7014.1208; PEATTIE AB, 1988, BRIT J OBSTET GYNAEC, V95, P1049, DOI 10.1111/j.1471-0528.1988.tb06512.x; PERRY S, 2000, J PUBLIC HEALTH MED, V22, P3; Pieber D, 1995, INT UROGYNECOL J, V6, P14; Royal College of Physicians, 1995, INC CAUS MAN PROV SE; SAND PK, 1995, AM J OBSTET GYNECOL, V173, P72, DOI 10.1016/0002-9378(95)90172-8; Seim A, 1996, BRIT MED J, V312, P1459, DOI 10.1136/bmj.312.7044.1459; *SIF RES CONS AB, 1998, MULT TRACK SURV OV B; Staskin D, 1996, UROLOGY, V47, P629, DOI 10.1016/S0090-4295(96)00003-9; Su TH, 1997, ACTA OBSTET GYN SCAN, V76, P576, DOI 10.3109/00016349709024588; Tincello DG, 2000, OBSTET GYNECOL, V95, P417, DOI 10.1016/S0029-7844(99)00579-7; Ulmsten U, 1999, BRIT J OBSTET GYNAEC, V106, P345, DOI 10.1111/j.1471-0528.1999.tb08272.x	41	41	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1326	1331		10.1136/bmj.321.7272.1326	http://dx.doi.org/10.1136/bmj.321.7272.1326			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090517	Green Published			2022-12-28	WOS:000165561600028
J	Ichimura, Y; Kirisako, T; Takao, T; Satomi, Y; Shimonishi, Y; Ishihara, N; Mizushima, N; Tanida, I; Kominami, E; Ohsumi, M; Noda, T; Ohsumi, Y				Ichimura, Y; Kirisako, T; Takao, T; Satomi, Y; Shimonishi, Y; Ishihara, N; Mizushima, N; Tanida, I; Kominami, E; Ohsumi, M; Noda, T; Ohsumi, Y			A ubiquitin-like system mediates protein lipidation	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; AUTOPHAGY; YEAST; DEGRADATION; APG7P/CVT2P; PEPTIDES; VACUOLE	Autophagy is a dynamic membrane phenomenon for bulk protein degradation in the lysosome/vacuole(1,2). Apg8/Aut7 is an essential factor for autophagy in yeast(3-5). We previously found that the carboxy-terminal arginine of nascent Apg8 is removed by Apg4/Aut2 protease, leaving a glycine residue at the C terminus(6). Apg8 is then converted to a form (Apg8-X) that is tightly bound to the membrane(6). Here we report a new mode of protein lipidation. Apg8 is covalently conjugated to phosphatidylethanolamine through an amide bond between the C-terminal glycine and the amino group of phosphatidylethanolamine. This lipidation is mediated by a ubiquitination-like system. Apg8 is a ubiquitin-like protein that is activated by an E1 protein, Apg7 (refs 7, 8), and is transferred subsequently to the E2 enzymes Apg3/Aut1 (ref. 9). Apg7 activates two different ubiquitin-like proteins, Apg12 (ref. 10) and Apg8, and assigns them to specific E2 enzymes, Apg10 (ref. 11) and Apg3, respectively. These reactions are necessary for the formation of Apg8-phosphatidylethanolamine. This lipidation has an essential role in membrane dynamics during autophagy(6).	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; JST, PRESTO, Kawaguchi 3320012, Japan; Teikyo Univ Sci & Technol, High Tech Res Ctr, Dept Biosci, Yamanashi 4090193, Japan; Juntendo Univ, Sch Med, Dept Biochem, Tokyo 1138421, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Osaka University; Japan Science & Technology Agency (JST); Juntendo University	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.		Ohsumi, Yoshinori/C-6449-2009; Noda, Takeshi/B-7240-2008; Tanida, Isei/C-8277-2009; Kominami, Eiki/D-3802-2009; Mizushima, Noboru/C-3635-2009	Ohsumi, Yoshinori/0000-0003-2384-2166; Noda, Takeshi/0000-0003-3581-7961; Mizushima, Noboru/0000-0002-6258-6444; Tanida, Isei/0000-0001-8999-3990; Ishihara, Naotada/0000-0002-6305-7149; Satomi, Yoshinori/0000-0002-8991-1040				BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Fernandez-de-Cossio J, 1998, RAPID COMMUN MASS SP, V12, P1867, DOI 10.1002/(SICI)1097-0231(19981215)12:23<1867::AID-RCM407>3.0.CO;2-S; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; JOHNSON RS, 1987, ANAL CHEM, V59, P2621, DOI 10.1021/ac00148a019; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Rose MD., 1990, METHODS YEAST GENETI; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Sambrook J., 2002, MOL CLONING LAB MANU; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264	28	1457	1523	3	209	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2000	408	6811					488	492		10.1038/35044114	http://dx.doi.org/10.1038/35044114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375YD	11100732				2022-12-28	WOS:000165429800052
J	Roll-Mecak, A; Cao, C; Dever, TE; Burley, SK				Roll-Mecak, A; Cao, C; Dever, TE; Burley, SK			X-ray structures of the universal translation initiation factor IF2/elF5B: Conformational changes on GDP and GTP binding	CELL			English	Article							ELONGATION-FACTOR TU; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; FACTOR IF2; FACTOR-II; EF-TU; RNA; DIFFRACTION; RESOLUTION; HYDROLYSIS	X-ray structures of the universal translation initiation factor IF2/eIF5B have been determined in three stales: free enzyme, inactive IF2/eIF5B.GDP, and active IF2/eIF5B.GTP. The "chalice-shaped" enzyme is a GTPase that facilitates ribosomal subunit joining and Met-tRNA(i) binding to ribosomes in all three kingdoms of life. The conserved core of IF2/eIF5B consists of an N-terminal G domain (I) plus an EF-Tu-type beta barrel (II), followed by a novel alpha/beta/alpha -sandwich (III) connected via an alpha helix to a second EF-Tu-type beta barrel (IV). Structural comparisons reveal a molecular lever, which amplifies a modest conformational change in the Switch 2 region of the G domain induced by Mg2+/GTP binding over a distance of 90 Angstrom from the G domain active center to domain IV. Mechanisms of GTPase function and ribosome binding are discussed.	Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Burley, SK (corresponding author), Rockefeller Univ, Lab Mol Biophys, 1230 York Ave, New York, NY 10021 USA.	burley@rockvax.rockefeller.edu	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678; Roll-Mecak, Antonina/0000-0003-2621-7307; Burley, Stephen K./0000-0002-2487-9713	NIGMS NIH HHS [GM61262] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061262] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEVARSSON A, 1994, EMBO J, V13, P1669; Battiste JL, 2000, MOL CELL, V5, P109, DOI 10.1016/S1097-2765(00)80407-4; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOILEAU G, 1983, BIOCHEMISTRY-US, V22, P3162, DOI 10.1021/bi00282a020; Brock S, 1998, MOL MICROBIOL, V29, P409, DOI 10.1046/j.1365-2958.1998.00893.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrera P, 2000, MOL CELL, V5, P181, DOI 10.1016/S1097-2765(00)80414-1; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; Choi SK, 2000, MOL CELL BIOL, V20, P7183, DOI 10.1128/MCB.20.19.7183-7191.2000; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KOLAKOFSKY D, 1968, NATURE, V220, P244, DOI 10.1038/220244a0; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P3726, DOI 10.1073/pnas.95.7.3726; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; Luchin S, 1999, J BIOL CHEM, V274, P6074, DOI 10.1074/jbc.274.10.6074; Meunier S, 2000, EMBO J, V19, P1918, DOI 10.1093/emboj/19.8.1918; MOAZED D, 1995, J MOL BIOL, V248, P207, DOI 10.1016/S0022-2836(95)80042-5; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Sette M, 1997, EMBO J, V16, P1436, DOI 10.1093/emboj/16.6.1436; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wilson SA, 1999, BIOCHEM J, V342, P97, DOI 10.1042/0264-6021:3420097; Wu XQ, 1996, EMBO J, V15, P4734, DOI 10.1002/j.1460-2075.1996.tb00850.x	39	189	191	0	8	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 22	2000	103	5					781	792		10.1016/S0092-8674(00)00181-1	http://dx.doi.org/10.1016/S0092-8674(00)00181-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	375ZJ	11114334	Bronze			2022-12-28	WOS:000165433100010
J	Gardner, FJE; Konje, JC; Abrams, KR; Brown, LJR; Khanna, S; Al-Azzawi, F; Bell, SC; Taylor, DJ				Gardner, FJE; Konje, JC; Abrams, KR; Brown, LJR; Khanna, S; Al-Azzawi, F; Bell, SC; Taylor, DJ			Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial	LANCET			English	Article							BREAST-CANCER PATIENTS; PATIENTS RECEIVING TAMOXIFEN; HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; SONOGRAPHIC DEPICTION; MENOPAUSAL WOMEN; ABNORMALITIES; PREVENTION; PAIN; RISK	Introduction Tamoxifen is currently the most commonly used adjuvant treatment for breast cancer, however, it frequently causes episodes of unscheduled uterine bleeding, which could be associated with proliferative changes of the endometrium, or even endometrial cancer. We aimed to assess whether a levonorgestrel intrauterine system could modulate the uterine responses to tamoxifen. We also aimed to assess women's tolerance of the screening procedures, the insertion, removal, and potential side-effects of the device. Methods We did a randomised controlled trial, in which postmenopausal women who had had at least 1 year of adjuvant tamoxifen treatment and who were undergoing regular follow-up for breast cancer were randomly assigned to either endometrial surveillance alone, or endometrial surveillance before and after insertion of the levonorgestrel intrauterine system for 12 months. We assessed tolerance of the surveillance procedures and the device with visual analogue scales. Findings Baseline assessment showed only benign uterine changes in all women (n=122). Hysteroscopic assessment indicated a uniform decidual response (confirmed histologically in 40 of 41 cases) in all women fitted with the intrauterine system; there were no new polyps in these women and 13% had fewer fibroids than in controls. Both screening procedures and device were well tolerated. There was an excess of bleeding in the women fitted with intrauterine systems but this resolved to a baseline similar to those receiving surveillance only. Interpretation The levonorgestrel-releasing intrauterine system had a protective action against the uterine effects of tamoxifen. The effectiveness of this device in preventing uterine changes in the endometrium needs to be assessed in the context of decreasing the need for repeated investigations of postmenopausal bleeding in women taking tamoxifen.	Univ Leicester, Dept Obstet & Gynaecol, Leicester LE2 7LX, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE2 7LX, Leics, England; Leicester Royal Infirm NHS Trust, Dept Histopathol, Leicester LE1 5WW, Leics, England; Leicester Royal Infirm NHS Trust, Dept Clin Oncol, Leicester LE1 5WW, Leics, England	University of Leicester; University of Leicester	Gardner, FJE (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Obstet & Gynaecol, POB 65, Leicester LE2 7LX, Leics, England.		Abrams, Keith/AAA-2557-2020	Abrams, Keith/0000-0002-7557-1567				AKKAD AA, 1995, OBSTET GYNECOL, V86, P330, DOI 10.1016/0029-7844(95)00172-N; ANDERSSON K, 1992, OBSTET GYNECOL, V79, P963; Assikis VJ, 1996, EUR J CANCER, V32A, P1464, DOI 10.1016/0959-8049(96)00184-0; Clarke M, 1998, LANCET, V351, P1451; DOWNES E, 1993, EUR J OBSTET GYN R B, V48, P37, DOI 10.1016/0028-2243(93)90051-D; *EARL BREAST CANC, 1992, LANCET, V339, P1; Eells T P, 1990, Cytopathology, V1, P263, DOI 10.1111/j.1365-2303.1990.tb00359.x; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FLEISCHER AC, 1986, ULTRASOUND MED BIOL, V12, P271, DOI 10.1016/0301-5629(86)90336-4; FLEISCHER AC, 1986, J ULTRAS MED, V5, P445; Gardner F J, 1998, Climacteric, V1, P180, DOI 10.3109/13697139809085539; GARDNER FJE, 1998, EUR J ULTRASOUND S7, V8; GOLDSTEIN SR, 1994, AM J OBSTET GYNECOL, V170, P447, DOI 10.1016/S0002-9378(94)70209-8; *IARC, 1996, SOM PHARM DRUGS, P253; ISMAIL SM, 1994, J CLIN PATHOL, V47, P827, DOI 10.1136/jcp.47.9.827; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; KRISTENSEN B, 1994, J CLIN ONCOL, V12, P992, DOI 10.1200/JCO.1994.12.5.992; LAHTI E, 1994, GYNECOL ONCOL, V55, P410, DOI 10.1006/gyno.1994.1314; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; LUUKKAINEN T, 1995, CONTRACEPTION, V52, P269, DOI 10.1016/0010-7824(95)00210-2; McGonigle KF, 1998, AM J OBSTET GYNECOL, V178, P1145, DOI 10.1016/S0002-9378(98)70315-1; More Ian A. R., 1995, P365; Neven P, 1998, LANCET, V351, P155, DOI 10.1016/S0140-6736(05)78216-7; NILSSON CG, 1982, CLIN ENDOCRINOL, V17, P529, DOI 10.1111/j.1365-2265.1982.tb01625.x; Panay N, 1997, HUM REPROD UPDATE, V3, P159, DOI 10.1093/humupd/3.2.159; Powles T, 1998, LANCET, V352, P98; Powles TJ, 1998, BRIT J CANCER, V78, P272, DOI 10.1038/bjc.1998.477; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; ROSSNER S, 1984, ATHEROSCLEROSIS, V52, P339, DOI 10.1016/0021-9150(84)90064-9; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; Veronesi U, 1998, LANCET, V352, P93; WHITEHEAD MI, 1990, OBSTETRICS GYNECOL S, V75, P59	35	86	99	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1711	1717		10.1016/S0140-6736(00)03204-9	http://dx.doi.org/10.1016/S0140-6736(00)03204-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095258				2022-12-28	WOS:000165462300009
J	Gonczy, P; Echeverri, C; Oegema, K; Coulson, A; Jones, SJM; Copley, RR; Duperon, J; Oegema, J; Brehm, M; Cassin, E; Hannak, E; Kirkham, M; Pichler, S; Flohrs, K; Goessen, A; Leidel, S; Alleaume, AM; Martin, C; Ozlu, N; Bork, P; Hyman, AA				Gonczy, P; Echeverri, C; Oegema, K; Coulson, A; Jones, SJM; Copley, RR; Duperon, J; Oegema, J; Brehm, M; Cassin, E; Hannak, E; Kirkham, M; Pichler, S; Flohrs, K; Goessen, A; Leidel, S; Alleaume, AM; Martin, C; Ozlu, N; Bork, P; Hyman, AA			Functional genomic analysis of cell division in C-elegans using RNAi of genes on chromosome III	NATURE			English	Article							CAENORHABDITIS-ELEGANS; MICROTUBULE ORGANIZATION; CYTOPLASMIC DYNEIN; SPINDLE FORMATION; GERM-LINE; PROTEIN; EMBRYOS; POLARITY; RAN; CYTOKINESIS	Genome sequencing projects generate a wealth of information; however, the ultimate goal of such projects is to accelerate the identification of the biological function of genes. This creates a need for comprehensive studies to fill the gap between sequence and function. Here we report the results of a functional genomic screen to identify genes required for cell division in Caenorhabditis elegans. We inhibited the expression of similar to 96% of the similar to2,300 predicted open reading frames on chromosome III using RNA-mediated interference (RNAi). By using an in vivo time-lapse differential interference contrast microscopy assay, we identified 133 genes (similar to6%) necessary for distinct cellular processes in early embryos. Our results indicate that these genes represent most of the genes on chromosome III that are required for proper cell division in C. elegans embryos. The complete data set, including sample time-lapse recordings, has been deposited in an open access database. We found that similar to 47% of the genes associated with a differential interference contrast phenotype have clear orthologues in other eukaryotes, indicating that this screen provides putative gene functions for other species as well.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Sanger Ctr, Cambridge CB10 1SA, England; British Columbia Canc Res Ctr, Genome Sequence Ctr, Vancouver, BC V5Z 4E6, Canada; Max Planck Inst Cell Biol & Genet, D-01307 Dresden, Germany	European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute; British Columbia Cancer Agency; Max Planck Society	Gonczy, P (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.	Pierre.Gonczy@isrec.unil.ch; hyman@EMBL-Heidelberg.de	Hyman, Anthony A/B-3917-2017; Kirkham, Matthew/I-5458-2012; Bork, Peer/F-1813-2013; Jones, Steven J/C-3621-2009; Leidel, Sebastian/K-9507-2019; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Bork, Peer/0000-0002-2627-833X; Jones, Steven J/0000-0003-3394-2208; Leidel, Sebastian/0000-0002-0523-6325; Kirkham, Matthew/0000-0003-0920-5355; Gonczy, Pierre/0000-0002-6305-6883; Ozlu, Nurhan/0000-0002-5157-8780; Alleaume, Anne-Marie/0000-0001-7881-1880				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Boxem M, 1999, DEVELOPMENT, V126, P2227; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; CARTER PW, 1990, MOL GEN GENET, V221, P72, DOI 10.1007/BF00280370; Chase D, 2000, GENESIS, V26, P26, DOI 10.1002/(SICI)1526-968X(200001)26:1<26::AID-GENE6>3.0.CO;2-O; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Furuta T, 2000, MOL BIOL CELL, V11, P1401, DOI 10.1091/mbc.11.4.1401; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; Gonczy P, 1999, J CELL BIOL, V144, P927, DOI 10.1083/jcb.144.5.927; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Hung TJ, 1999, DEVELOPMENT, V126, P127; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nicolas FJ, 1997, J CELL SCI, V110, P3019; Pichler S, 2000, DEVELOPMENT, V127, P2063; Powers J, 1998, CURR BIOL, V8, P1133, DOI 10.1016/S0960-9822(98)70470-1; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; Rappleye CA, 1999, GENE DEV, V13, P2838, DOI 10.1101/gad.13.21.2838; Rose LS, 1998, DEVELOPMENT, V125, P1337; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Shelton CA, 1999, J CELL BIOL, V146, P439, DOI 10.1083/jcb.146.2.439; Skop AR, 1998, CURR BIOL, V8, P1110, DOI 10.1016/S0960-9822(98)70465-8; Snel B, 1999, NAT GENET, V21, P108, DOI 10.1038/5052; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; Swan A, 1999, NAT CELL BIOL, V1, P444, DOI 10.1038/15680; Swan KA, 1998, J CELL SCI, V111, P2017; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Willins DA, 1997, MOL GEN GENET, V255, P194, DOI 10.1007/s004380050489; Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429	44	683	771	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	2000	408	6810					331	336		10.1038/35042526	http://dx.doi.org/10.1038/35042526			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099034				2022-12-28	WOS:000165296000037
J	Kreiman, G; Koch, C; Fried, I				Kreiman, G; Koch, C; Fried, I			Imagery neurons in the human brain	NATURE			English	Article							INFERIOR TEMPORAL CORTEX; VISUAL-IMAGERY; OBJECT RECOGNITION; PREFRONTAL CORTEX; MENTAL-IMAGERY; MEMORY; PERCEPTION; REPRESENTATION; DISSOCIATION; ORGANIZATION	Vivid visual images can be voluntarily generated in our minds in the absence of simultaneous visual input. While trying to count the number of flowers in Van Gogh's Sunflowers, understanding a description or recalling a path, subjects report forming an image in their "mind's eye''(1). Whether this process is accomplished by the same neuronal mechanisms as visual perception has long been a matter of debate(1-3). Evidence from functional imaging(1.4-8), psychophysics(1.9), neurological studies(2) and monkey electrophysiology(10-12) suggests a common process, yet there are patients with deficits in one but not the other(3,13). Here we directly investigated the neuronal substrates of visual recall by recording from single neurons in the human medial temporal lobe(14,15) while the subjects were asked to imagine previously viewed images. We found single neurons in the hippocampus, amygdala, entorhinal cortex and parahippocampal gyrus that selectively altered their firing rates depending on the stimulus the subjects were imagining. Of the neurons that fired selectively during both vision and imagery, the majority (88%) had identical selectivity. Our study reveals single neuron correlates of volitional visual imagery in humans and suggests a common substrate for the processing of incoming visual information and visual recall.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biobehav Sci, Los Angeles, CA 90095 USA; CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; California Institute of Technology	Fried, I (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, 740 Westwood Plaza, Los Angeles, CA 90095 USA.			Kreiman, Gabriel/0000-0003-3505-8475; Koch, Christof/0000-0001-6482-8067				Bartolomeo P, 1998, NEUROPSYCHOLOGIA, V36, P239, DOI 10.1016/S0028-3932(97)00103-6; BEHRMANN M, 1992, NATURE, V359, P636, DOI 10.1038/359636a0; Chelazzi L, 1998, J NEUROPHYSIOL, V80, P2918, DOI 10.1152/jn.1998.80.6.2918; DEsposito M, 1997, NEUROPSYCHOLOGIA, V35, P725, DOI 10.1016/S0028-3932(96)00121-2; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; FARAH MJ, 1988, PSYCHOL REV, V95, P307, DOI 10.1037/0033-295X.95.3.307; FRIED I, 1982, BRAIN, V105, P349, DOI 10.1093/brain/105.2.349; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Frith C, 1997, PHILOS T R SOC B, V352, P1221, DOI 10.1098/rstb.1997.0104; GREEN DM, 1966, SIGNAL DETECTION THE; ISHAI A, 1995, SCIENCE, V268, P1772, DOI 10.1126/science.7792605; Kanwisher N, 2000, COGN NEUROPSYCHOL, V17, P1, DOI 10.1080/026432900380454; Kosslyn S. M., 1994, IMAGE BRAIN; Kosslyn SM, 1997, NEUROIMAGE, V6, P320, DOI 10.1006/nimg.1997.0295; Kreiman G, 2000, NAT NEUROSCI, V3, P946, DOI 10.1038/78868; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; Meunier M, 1996, J NEUROPHYSIOL, V75, P1190, DOI 10.1152/jn.1996.75.3.1190; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; OCRAVEN K, IN PRESS J COG NEURO; OJEMANN G, 1979, SCIENCE, V205, P1401, DOI 10.1126/science.472757; Penfield W, 1954, EPILEPSY FUNCTIONAL; Rainer G, 1999, J NEUROSCI, V19, P5493; ROLAND PE, 1994, TRENDS NEUROSCI, V17, P281, DOI 10.1016/0166-2236(94)90057-4; Rolls E T, 1991, Curr Opin Neurobiol, V1, P274, DOI 10.1016/0959-4388(91)90090-T; Suzuki WA, 1996, SEMIN NEUROSCI, V8, P3, DOI 10.1006/smns.1996.0002; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; [No title captured]	30	227	231	2	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					357	361		10.1038/35042575	http://dx.doi.org/10.1038/35042575			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099042				2022-12-28	WOS:000165296000045
J	Aronson, JK				Aronson, JK			Autopathography: the patient's tale	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Aronson, JK (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.							ARONSON JK, 2000, PATIENTS TALES ANNOT; Campbell R., 1989, PSYCHIAT DICT; CLOW B, IN PRESS SOCIAL HIST; Cooter R., 1780, SCI SENSIBILITY GEND, P144; Goldbeck R, 1997, J PSYCHOSOM RES, V43, P575, DOI 10.1016/S0022-3999(97)00168-2; Greenhalgh T, 1998, NARRATIVE BASED MED, P3; Hawkins Anne Hunsaker, 1999, RECONSTRUCTING ILLNE; LAWSON M, 1999, WISDENS CRICHETERS A, P1435; WILDEVUUR SE, 2000, 136 REUT FDN	9	43	43	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1599	1602		10.1136/bmj.321.7276.1599	http://dx.doi.org/10.1136/bmj.321.7276.1599			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124195	Green Published			2022-12-28	WOS:000166134500031
J	Greaves, D				Greaves, D			The obsessive pursuit of health and happiness	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales, Ctr Philosophy & Hlth Care, Sch Hlth Sci, Swansea SA2 8PP, W Glam, Wales	Swansea University	Greaves, D (corresponding author), Univ Wales, Ctr Philosophy & Hlth Care, Sch Hlth Sci, Swansea SA2 8PP, W Glam, Wales.							BENTALL RP, 1992, J MED ETHICS, V18, P94, DOI 10.1136/jme.18.2.94; BOYD KM, 2000, MED HUMANITIES, V26, P14	2	2	2	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1576	1576		10.1136/bmj.321.7276.1576	http://dx.doi.org/10.1136/bmj.321.7276.1576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124184	Green Published			2022-12-28	WOS:000166134500021
J	Bouchard, C				Bouchard, C			Inhibition of food intake by inhibitors of fatty acid synthase.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Bouchard, C (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.		Bouchard, Claude/AAE-2035-2019; Bouchard, Claude/A-7637-2009	Bouchard, Claude/0000-0002-0048-491X				Bray GA, 1998, HDB HLTH CARE; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527	4	38	42	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1888	1889		10.1056/NEJM200012213432511	http://dx.doi.org/10.1056/NEJM200012213432511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117983				2022-12-28	WOS:000165940400011
J	Haller, CA; Benowitz, NL				Haller, CA; Benowitz, NL			Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAFFEINE; PHENYLPROPANOLAMINE; VASCULITIS; HEMORRHAGE; INGESTION; TOXICITY	Background: Dietary supplements that contain ephedra alkaloids (sometimes called ma huang) are widely promoted and used in the United States as a means of losing weight and increasing energy. In the light of recently reported adverse events related to use of these products, the Food and Drug Administration (FDA) has proposed limits on the dose and duration of use of such supplements. The FDA requested an independent review of reports of adverse events related to the use of supplements that contained ephedra alkaloids to assess causation and to estimate the level of risk the use of these supplements poses to consumers. Methods: We reviewed 140 reports of adverse events related to the use of dietary supplements containing ephedra alkaloids that were submitted to the FDA between June 1, 1997, and March 31, 1999. A standardized rating system for assessing causation was applied to each adverse event. Results: Thirty-one percent of cases were considered to be definitely or probably related to the use of supplements containing ephedra alkaloids, and 31 percent were deemed to be possibly related. Among the adverse events that were deemed definitely, probably, or possibly related to the use of supplements containing ephedra alkaloids, 47 percent involved cardiovascular symptoms and 18 percent involved the central nervous system. Hypertension was the single most frequent adverse effect (17 reports), followed by palpitations, tachycardia, or both (13); stroke (10); and seizures (7). Ten events resulted in death, and 13 events produced permanent disability, representing 26 percent of the definite, probable, and possible cases. Conclusions: The use of dietary supplements that contain ephedra alkaloids may pose a health risk to some persons. These findings indicate the need for a better understanding of individual susceptibility to the adverse effects of such dietary supplements. (N Engl J Med 2000;343:1833-8.) (C) 2000, Massachusetts Medical Society.	Univ Calif San Francisco, Dept Med, Div Clin Pharmacol & Expt Therapeut, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Calif Poison Control Syst, San Francisco Div, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Benowitz, NL (corresponding author), Univ Calif San Francisco, Dept Med, Div Clin Pharmacol & Expt Therapeut, Box 1220, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA012393, R01DA002277, R37DA002277] Funding Source: NIH RePORTER; NIDA NIH HHS [DA12393, DA02277] Funding Source: Medline; NIGMS NIH HHS [T32GM07546] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnes J, 1998, BRIT J CLIN PHARMACO, V45, P496, DOI 10.1046/j.1365-2125.1998.00715.x; BENOWITZ NL, 1990, ANNU REV MED, V41, P277, DOI 10.1146/annurev.me.41.020190.001425; BLANC S, 1979, CLIN PHARMACOL THER, V25, P493; BROWN NJ, 1991, CLIN PHARMACOL THER, V50, P363, DOI 10.1038/clpt.1991.152; BRUNO A, 1993, NEUROLOGY, V43, P1313, DOI 10.1212/WNL.43.7.1313; Chyka PA, 2000, DRUG SAFETY, V23, P87, DOI 10.2165/00002018-200023010-00006; COSTELLO JF, 1975, BR J CLIN PHARM, V2, P180; DREW CDM, 1978, BRIT J CLIN PHARMACO, V6, P221, DOI 10.1111/j.1365-2125.1978.tb04588.x; FALLIS RJ, 1985, NEUROLOGY, V35, P405, DOI 10.1212/WNL.35.3.405; *FDC, 2000, FDC REP; Gurley BJ, 2000, AM J HEALTH-SYST PH, V57, P963, DOI 10.1093/ajhp/57.10.963; Josefson D, 1996, BRIT MED J, V312, P1378, DOI 10.1136/bmj.312.7043.1378c; Perrotta DM, 1996, JAMA-J AM MED ASSOC, V276, P1711; ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403; Theoharides TC, 1997, J CLIN PSYCHOPHARM, V17, P437, DOI 10.1097/00004714-199710000-00025; TO LB, 1980, MED J AUSTRALIA, V2, P35, DOI 10.5694/j.1326-5377.1980.tb131811.x; Vahedi K, 2000, J NEUROL NEUROSUR PS, V68, P112, DOI 10.1136/jnnp.68.1.112; White LM, 1997, J CLIN PHARMACOL, V37, P116, DOI 10.1002/j.1552-4604.1997.tb04769.x; WIENER I, 1990, CATHETER CARDIO DIAG, V20, P51, DOI 10.1002/ccd.1810200113; WOOTEN MR, 1983, ANN NEUROL, V13, P337, DOI 10.1002/ana.410130321; Zaacks SM, 1999, J TOXICOL-CLIN TOXIC, V37, P485, DOI 10.1081/CLT-100102440; Zahn KA, 1999, J EMERG MED, V17, P289, DOI 10.1016/S0736-4679(98)00194-2	22	607	636	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1833	1838		10.1056/NEJM200012213432502	http://dx.doi.org/10.1056/NEJM200012213432502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117974	Bronze			2022-12-28	WOS:000165940400002
J	Katz, SJ; Kabeto, M; Langa, KM				Katz, SJ; Kabeto, M; Langa, KM			Gender disparities in the receipt of home care for elderly people with disability in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-General-Internal-Medicine	MAY 05-06, 2000	BOSTON, MASSACHUSETTS	Soc Gen Internal Med			INFORMAL CARE; PREDICTORS; PATTERNS; PARENTS; HELP	Context Projected demographic shifts in the US population over the next 50 years will cause families, health care practitioners, and policymakers to confront a marked increase in the number of people with disabilities living in the community. Concerns about the adequacy of community support are particularly salient to women, who make up a disproportionate number of disabled elderly people and who may be particularly vulnerable because they are more likely to live alone with limited financial resources. Objective To address gender differences in receipt of informal and formal home care. Design, Setting, and Participants Nationally representative survey conducted in 1993 among 7443 noninstitutionalized people (4538 women and 2905 men) aged 70 years or older. Main Outcome Measure Number of hours per week of informal (generally unpaid) and formal (generally paid) home care received by survey participants who reported any activity of daily living (ADL) or instrumental activity of daily living (IADL) impairment (n = 3109) com pared by gender and living arrangement and controlling for other factors. Results Compared with disabled men, disabled women were much more likely to be living alone (45.4% vs 16.8%, P<.001) and much less likely to be living with a spouse (27.8% vs 73.6%, P<.001). Overall, women received fewer hours of informal care per week than men (15.7 hours; 95% confidence interval [CI], 14.5-16.9 vs 21.2 hours; 95% CI, 19.7-22.8). Married disabled women received many fewer hours per week of informal home care than married disabled men (14.8 hours; 95% CI, 13.7-15.8 vs 26.2 hours; 95% CI, 24.6-27.9). Children (>80% women) were the dominant caregivers for disabled women while wives were the dominant caregivers of disabled men. Gender differences in formal home care were small (2.8 hours for women; 95% CI, 2.5-3.1 vs 2.1 hours for men; 95% CI, 1.7-2.4). Conclusion Large gender disparities appear to exist in the receipt of informal home care for disabled elderly people in the United States, even within married households, Programs providing home care support for disabled elderly people need to consider these large gender disparities and the burden they impose on families when developing intervention strategies in the community.	Univ Michigan, Dept Med, Div Gen Med, Ann Arbor, MI 48109 USA; Univ Michigan, Vet Affairs Ctr Practice Management & Outcomes Re, Ann Arbor, MI 48109 USA; Univ Michigan, CHOICES, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Social Res, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Katz, SJ (corresponding author), Univ Michigan, Dept Med, Div Gen Med, 300 N Ingalls,Suite 7E12,Box 0429, Ann Arbor, MI 48109 USA.		KATZ, STEVEN/ABH-8886-2020	Langa, Kenneth/0000-0002-2798-1836	NIA NIH HHS [U01 AG009740] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG009740] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson GF, 2000, HEALTH AFFAIR, V19, P191, DOI 10.1377/hlthaff.19.3.191; BARER BM, 1994, INT J AGING HUM DEV, V38, P29, DOI 10.2190/MCH0-VTER-DL6G-LECR; Boaz RF, 1997, J GERONTOL B-PSYCHOL, V52, pS317, DOI 10.1093/geronb/52B.6.S317; BURTON L, 1995, GERONTOLOGIST, V35, P744, DOI 10.1093/geront/35.6.744; *COLL STAT, 1999, STATA REF MAN; Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; *HLTH CAR FIN ADM, 1998, NAT HLTH CAR EXP PRO; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Hopp FP, 1999, GERONTOLOGIST, V39, P167, DOI 10.1093/geront/39.2.167; IngersollDayton B, 1996, GERONTOLOGIST, V36, P483, DOI 10.1093/geront/36.4.483; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; KEMPER P, 1992, HEALTH SERV RES, V27, P421; Langa KM, 2000, J GEN INTERN MED, V15, P79; LANGA KM, IN PRESS MED CARE; LEE GR, 1993, J GERONTOL, V48, pS9, DOI 10.1093/geronj/48.1.S9; Merlis M, 2000, HEALTH AFFAIR, V19, P141, DOI 10.1377/hlthaff.19.3.141; MILLER B, 1992, GERONTOLOGIST, V32, P498, DOI 10.1093/geront/32.4.498; Norgard TM, 1997, J GERONTOL B-PSYCHOL, V52, P93, DOI 10.1093/geronb/52B.Special_Issue.93; PENNING MJ, 1994, J GERONTOL, V49, P5202; Soldo BJ, 1997, J GERONTOL B-PSYCHOL, V52, P1, DOI 10.1093/geronb/52B.Special_Issue.1; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; STOLLER EP, 1993, GERONTOLOGIST, V33, P31, DOI 10.1093/geront/33.1.31; Stump TE, 1997, J GERONTOL B-PSYCHOL, V52, P49, DOI 10.1093/geronb/52B.Special_Issue.49; Wolf DA, 1997, J GERONTOL B-PSYCHOL, V52, P102, DOI 10.1093/geronb/52B.Special_Issue.102	24	126	127	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3022	3027		10.1001/jama.284.23.3022	http://dx.doi.org/10.1001/jama.284.23.3022			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	382VC	11122589	Bronze			2022-12-28	WOS:000165847200027
J	Muscat, JE; Malkin, MC; Thompson, S; Shore, RE; Stellman, SD; McRee, D; Neugut, AI; Wynder, EL				Muscat, JE; Malkin, MC; Thompson, S; Shore, RE; Stellman, SD; McRee, D; Neugut, AI; Wynder, EL			Handheld cellular telephone use and risk of brain cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	International Workshop on Mobil Phone and Tumors of Brain, Head and Neck	NOV 13, 1999	BEIDELBERY, GERMANY				CENTRAL-NERVOUS-SYSTEM; FIELD EXPOSURE; TUMORS; HEAD; EPIDEMIOLOGY; MORTALITY; RADIATION; PHONES; NECK	Context A relative paucity of data exist on the possible health effects of using cellular telephones. Objective To test the hypothesis that using handheld cellular telephones is related to the risk of primary brain cancer. Design and Setting Case-control study conducted in 5 US academic medical centers between 1994 and 1998 using a structured questionnaire. Patients A total of 469 men and women aged 18 to 80 years with primary brain cancer and 422 matched controls without brain cancer. Main Outcome Measure Risk of brain cancer compared by use of handheld cellular telephones, in hours per month and years of use. Results The median monthly hours of use were 2.5 for cases and 2.2 for controls. Compared with patients who never used handheld cellular telephones, the multivariate odds ratio (OR) associated with regular past or current use was 0.85 (95% confidence interval [CI], 0.6-1.2). The OR for infrequent users (<0.72 h/mo) was 1.0 (95% CI, 0.5-2.0) and for frequent users (>10.1 h/mo) was 0.7 (95% CI, 0.3-1.4). The mean duration of use was 2.8 years for cases and 2.7 years for controls; no association with brain cancer was observed according to duration of use (P=.54), In cases, cerebral tumors occurred more frequently on the same side of the head where cellular telephones had been used (26 vs 15 cases; P=.06), but in the cases with temporal lobe cancer a greater proportion of tumors occurred in the contralateral than ipsilateral side (9 vs 5 cases; P=.33). The OR was less than 1.0 for all histologic categories of brain cancer except for uncommon neuroepitheliomatous cancers (OR, 2.1; 95% CI, 0.9-4.7). Conclusions Our data suggest that use of handheld cellular telephones is not associated with risk of brain cancer, but further studies are needed to account for longer induction periods, especially for slow-growing tumors with neuronal features.	Amer Hlth Fdn, Div Epidemiol, Valhalla, NY 10595 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; NYU, Dept Environm Med, New York, NY 10016 USA; Wireless Technol Res Inc, Raleigh, NC USA; Columbia Univ, Sch Publ Hlth, New York, NY USA	American Health Foundation; Memorial Sloan Kettering Cancer Center; New York University; Columbia University	Muscat, JE (corresponding author), Amer Hlth Fdn, Div Epidemiol, 1 Dana Rd, Valhalla, NY 10595 USA.	jmuscat2@earthlink.net		Shore, Roy/0000-0002-6842-2248	NCPDCID CDC HHS [NCI68384, NCI17613, NCI32617] Funding Source: Medline	NCPDCID CDC HHS		Adey WR, 1999, RADIAT RES, V152, P293, DOI 10.2307/3580329; Adey WR, 2000, CANCER RES, V60, P1857; BALZANO Q, 1995, IEEE T VEH TECHNOL, V44, P390, DOI 10.1109/25.406605; Brusick D, 1998, ENVIRON MOL MUTAGEN, V32, P1; Cardis E, 1999, RADIAT PROT DOSIM, V83, P179, DOI 10.1093/oxfordjournals.rpd.a032657; Davidson JA, 1998, MED J AUSTRALIA, V168, P48, DOI 10.5694/j.1326-5377.1998.tb123359.x; Dimbylow PJ, 1999, RADIAT PROT DOSIM, V83, P139, DOI 10.1093/oxfordjournals.rpd.a032648; Dreyer NA, 1999, JAMA-J AM MED ASSOC, V282, P1814, DOI 10.1001/jama.282.19.1814-a; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Elwood JM, 1999, ENVIRON HEALTH PERSP, V107, P155, DOI 10.2307/3434480; Funch DP, 1996, EPIDEMIOLOGY, V7, P299, DOI 10.1097/00001648-199605000-00014; Gandhi OP, 1996, IEEE T MICROW THEORY, V44, P1884, DOI 10.1109/22.539947; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; Guy AW, 1997, HUM ECOL RISK ASSESS, V3, P25, DOI 10.1080/10807039709383666; Hardell L, 1999, INT J ONCOL, V15, P113; HARDELL L, 2000, CASE CONTROL STUDY R; Hocking B, 1998, MED J AUSTRALIA, V168, P48, DOI 10.5694/j.1326-5377.1998.tb123360.x; Inskip PD, 1999, RADIAT PROT DOSIM, V86, P45, DOI 10.1093/oxfordjournals.rpd.a032924; Inskip PD, 1995, EPIDEMIOL REV, V17, P382; Jauchem JR, 1998, J MICROWAVE POWER EE, V33, P263; Johansen C, 1999, RADIAT PROT DOSIM, V83, P155, DOI 10.1093/oxfordjournals.rpd.a032652; Juutilainen J, 1998, SCAND J WORK ENV HEA, V24, P245, DOI 10.5271/sjweh.317; Katzman GL, 1999, JAMA-J AM MED ASSOC, V282, P36, DOI 10.1001/jama.282.1.36; KELLER JJ, 1993, WALL STREET J   0125, pB; KLEIHUES P, 1997, TUMORS NERVOUS SYSTE, P1; KUSTER N, 1992, IEEE T VEH TECHNOL, V41, P17, DOI 10.1109/25.120141; LAI H, 1995, BIOELECTROMAGNETICS, V16, P207, DOI 10.1002/bem.2250160309; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Malyapa RS, 1998, RADIAT RES, V149, P637, DOI 10.2307/3579911; MCKINLAY A, 1999, RADIOL PROTECTION B, V187, P9; Morris HH, 1998, EPILEPSIA, V39, P307, DOI 10.1111/j.1528-1157.1998.tb01378.x; Moulder JE, 1999, RADIAT RES, V151, P513, DOI 10.2307/3580028; PrestonMartin S, 1996, NEUROL CLIN, V14, P273, DOI 10.1016/S0733-8619(05)70256-5; Quinn B, 1998, AM J SURG PATHOL, V22, P550, DOI 10.1097/00000478-199805000-00005; Redelmeier DA, 1997, NEW ENGL J MED, V336, P453, DOI 10.1056/NEJM199702133360701; Repacholi MH, 1997, ENVIRON HEALTH PERSP, V105, P1565, DOI 10.2307/3433671; Rothman KJ, 1996, EPIDEMIOLOGY, V7, P291, DOI 10.1097/00001648-199605000-00013; Rothman KJ, 1996, EPIDEMIOLOGY, V7, P303, DOI 10.1097/00001648-199605000-00015; Royal Society of Canada, 1999, REV POT HLTH RISKS R; *SAS I INC, 1985, SAS IML US GUID VERS; Smirniotopoulos JG, 1999, NEUROIMAG CLIN N AM, V9, P595; Stewart W., 2000, REPORT INDEPENDENT E, P1; Stuchly MA, 1998, CRIT REV BIOMED ENG, V26, P117, DOI 10.1615/CritRevBiomedEng.v26.i1-2.20; Valberg PA, 1997, CANCER CAUSE CONTROL, V8, P323, DOI 10.1023/A:1018449003394; Verschaeve L, 1998, MUTAT RES-REV MUTAT, V410, P141, DOI 10.1016/S1383-5742(97)00037-9; Violanti JM, 1998, ACCIDENT ANAL PREV, V30, P519, DOI 10.1016/S0001-4575(97)00094-8	46	184	202	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3001	3007		10.1001/jama.284.23.3001	http://dx.doi.org/10.1001/jama.284.23.3001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	382VC	11122586	Green Published			2022-12-28	WOS:000165847200024
J	Ladher, RK; Anakwe, KU; Gurney, AL; Schoenwolf, GC; Francis-West, PH				Ladher, RK; Anakwe, KU; Gurney, AL; Schoenwolf, GC; Francis-West, PH			Identification of synergistic signals initiating inner ear development	SCIENCE			English	Article							DEVELOPING CHICK LIMB; PRIMITIVE STREAK; EXPRESSION; HINDBRAIN; INDUCTION; XENOPUS; PATTERN; GENE; PROTOONCOGENE; ORGANIZATION	Tissue manipulation experiments in amphibians more than 50 years ago showed that induction of the inner ear requires two signals: a mesodermal signal followed by a neural signal. However, the molecules mediating this process have remained elusive. We present evidence for mesodermal initiation of otic development in higher Vertebrates and show that the mesoderm can direct terminal differentiation of the inner ear in rostral ectoderm. Furthermore, we demonstrate the synergistic interactions of the extracellular polypeptide ligands FGF-19 and Wnt-8c as mediators of mesodermal and neural signals, respectively, initiating inner ear development.	Kings Coll, Dept Craniofacial Dev, London SE1 9RT, England; Genentech Inc, Dept Mol Biol, San Francisco, CA USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA	University of London; King's College London; Roche Holding; Genentech; Utah System of Higher Education; University of Utah	Francis-West, PH (corresponding author), Kings Coll, Dept Craniofacial Dev, London SE1 9RT, England.		Ladher, Raj/B-3001-2008	Ladher, Raj/0000-0002-3613-9456				BARTOLAMI S, 1991, J COMP NEUROL, V314, P777, DOI 10.1002/cne.903140410; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; DEITCHER DL, 1994, J NEUROSCI, V14, P486; FERRARI D, 1995, MECH DEVELOP, V52, P257, DOI 10.1016/0925-4773(95)98113-O; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Groves AK, 2000, DEVELOPMENT, V127, P3489; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Herbrand H, 1998, DEVELOPMENT, V125, P645; HUME CR, 1993, DEVELOPMENT, V119, P1147; JACOBSON AG, 1966, SCIENCE, V152, P25, DOI 10.1126/science.152.3718.25; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LaBonne C, 1998, DEVELOPMENT, V125, P2403; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; McGrew LL, 1997, MECH DEVELOP, V69, P105, DOI 10.1016/S0925-4773(97)00160-3; Muhr J, 1999, NEURON, V23, P689, DOI 10.1016/S0896-6273(01)80028-3; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; SECHRIST J, 1994, DEVELOPMENT, V120, P1777; Torres M, 1998, MECH DEVELOP, V71, P5, DOI 10.1016/S0925-4773(97)00155-X; Uusitalo M, 1999, EXP CELL RES, V253, P336, DOI 10.1006/excr.1999.4710; Vendrell V, 2000, DEVELOPMENT, V127, P2011; Yuan SP, 1998, DEVELOPMENT, V125, P201	23	202	207	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1965	1967		10.1126/science.290.5498.1965	http://dx.doi.org/10.1126/science.290.5498.1965			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110663				2022-12-28	WOS:000165810000046
J	van Gastel, R; Somfai, E; van Saarloos, W; Frenken, JWM				van Gastel, R; Somfai, E; van Saarloos, W; Frenken, JWM			A giant atomic slide-puzzle - Atoms crammed tightly together in metal crystal surfaces are surprisingly mobile.	NATURE			English	Article							STEPPED CU(100) SURFACE; MOBILITIES		Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands; Leiden Univ, Inst Lorentz, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	van Gastel, R (corresponding author), Leiden Univ, Kamerlingh Onnes Lab, POB 9504, NL-2300 RA Leiden, Netherlands.		Frenken, Joost/AAA-7272-2020; Somfai, Ellák/A-9277-2009	Frenken, Joost/0000-0002-2486-7720; Somfai, Ellák/0000-0002-2218-8855				BREEMAN M, 1993, SURF SCI, V287, P881, DOI 10.1016/0039-6028(93)91092-4; BREEMAN M, 1992, PHYS REV B, V46, P1703, DOI 10.1103/PhysRevB.46.1703; BRUMMELHUIS MJAM, 1988, J STAT PHYS, V53, P249, DOI 10.1007/BF01011556; Hoogeman MS, 1998, REV SCI INSTRUM, V69, P2072, DOI 10.1063/1.1148901	4	54	54	0	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					665	665		10.1038/35047156	http://dx.doi.org/10.1038/35047156			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130057				2022-12-28	WOS:000165815200031
J	Faber-Langendoen, K; Lanken, PN; Lo, B; Abrahm, J; Block, S; Breitbart, W; Byock, IR; Faber-Langendoen, K; Kitchens, LW; Lanken, P; Lynn, J; Meier, D; Quill, TE; Thibault, G; Tulsky, JA; Snyder, L; Karlawish, J				Faber-Langendoen, K; Lanken, PN; Lo, B; Abrahm, J; Block, S; Breitbart, W; Byock, IR; Faber-Langendoen, K; Kitchens, LW; Lanken, P; Lynn, J; Meier, D; Quill, TE; Thibault, G; Tulsky, JA; Snyder, L; Karlawish, J		ACP ASIM End Life Care Consensus	Dying patients in the intensive care unit: Forgoing treatment, maintaining care	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; ADVANCE DIRECTIVES; END; EXPERIENCE; WITHDRAWAL; DIALYSIS; SUPPORT; PREFERENCES; PREDICTION; MANAGEMENT	End-of-life care of patients in the intensive care unit (ICU) often requires dramatic shifts in attitudes and interventions, from traditional intensive rescue care to intensive palliative care. The care of patients dying in ICUs raises both clinical and ethical difficulties, Because fewer ICU patients are able to make decisions about withdrawing treatment, careful attention must be paid to previously expressed preferences and surrogate input Cultural and spiritual values of patients and families may differ markedly from those of clinicians. Although prognostic models are increasingly able to predict mortality rates for groups of ICU patients, their usefulness in guiding specific decisions to forgo treatment has not been established. When a decision to forgo treatment is made, the focus should be on specifying the patient's goals of care and assessing all treatments in light of these goals; interventions that do not contribute to the patient's goals should be discontinued. Symptoms accompanying withdrawal of life support can almost always be controlled with appropriate palliative measures. After ICU interventions are forgone, patient comfort must be the paramount objective. Whether in the ICU or elsewhere, hospitals have an ethical obligation to provide settings that offer dignified, compassionate, and skilled care.	SUNY Upstate Med Univ, Ctr Bioeth & Humanities, Syracuse, NY USA; Univ Penn, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Snyder, L (corresponding author), Amer Soc Internal Med, Amer Coll Phys, Ctr Eth & Professionalism, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	lsnyder@mail.acponline.org						American Thoracic Society, 1991, Ann Intern Med, V115, P478; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Burns JP, 2000, CRIT CARE MED, V28, P3060, DOI 10.1097/00003246-200008000-00064; Byock I, 1997, DYING WELL PROSPECT; Campbell ML, 1997, CRIT CARE MED, V25, P197, DOI 10.1097/00003246-199701000-00034; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; Carlson RW, 1996, CHEST, V109, P852, DOI 10.1378/chest.109.3.852-b; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; CHRISTAKIS NA, 1995, J GEN INTERN MED, V10, P491, DOI 10.1007/BF02602399; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; Doyle D, 1998, OXFORD TXB PALLIATIV; Eidelman LA, 1998, INTENS CARE MED, V24, P162, DOI 10.1007/s001340050539; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1996, AM J RESP CRIT CARE, V153, pS4; Field MJ, 1997, APPROACHING DEATH IM; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GIANAKOS D, 1995, CHEST, V108, P1405, DOI 10.1378/chest.108.5.1405; Gilligan T, 1996, CRIT CARE MED, V24, P352, DOI 10.1097/00003246-199602000-00028; GRENVIK A, 1983, CRIT CARE MED, V11, P394, DOI 10.1097/00003246-198305000-00019; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; King P A, 1991, Law Med Health Care, V19, P76; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOCH KA, 1994, CRIT CARE MED, V22, P233, DOI 10.1097/00003246-199402000-00013; Lanken PN, 1997, AM J RESP CRIT CARE, V156, P1282; LEE DKP, 1994, JAMA-J AM MED ASSOC, V271, P1358, DOI 10.1001/jama.271.17.1358; Leggat JE, 1997, J AM SOC NEPHROL, V8, P1755; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; LUCE JM, 1992, CHEST, V101, P1185, DOI 10.1378/chest.101.5.1185; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; LYNN J, 1983, HASTINGS CENT REP, V13, P17, DOI 10.2307/3560572; Miles S H, 1987, Theor Med, V8, P293, DOI 10.1007/BF00489465; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; QUILL TE, 1994, AM J CARDIOL, V74, P205, DOI 10.1016/0002-9149(94)90107-4; Reitemeier PJ, 1997, HASTINGS CENT REP, V27, P24, DOI 10.2307/3528022; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; TERES D, 1987, CRIT CARE MED, V15, P208, DOI 10.1097/00003246-198703000-00005; THIBAULT GE, 1997, APPROACHING DEATH IM, P363; TRUOG RD, 1994, J CLIN ETHIC, V5, P39	48	72	74	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					886	893		10.7326/0003-4819-133-11-200012050-00013	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	378LL	11103059				2022-12-28	WOS:000165585800008
J	Ward, E; King, M; Lloyd, M; Bower, P; Sibbald, B; Farrelly, S; Gabbay, M; Tarrier, N; Addington-Hall, J				Ward, E; King, M; Lloyd, M; Bower, P; Sibbald, B; Farrelly, S; Gabbay, M; Tarrier, N; Addington-Hall, J			Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: Clinical effectiveness	BRITISH MEDICAL JOURNAL			English	Article							DISORDER; EFFICACY	Objective To compare the clinical effectiveness of general practitioner care and two general practice based psychological therapies for depressed patients. Design Prospective, controlled trial with randomised and patient preference allocation arms. Setting General practices in London and greater Manchester. Participants 464 of 627 patients presenting with depression or mixed anxiety and depression were suitable for inclusion. Interventions Usual general practitioner care or up to 12 sessions of non-directive counselling or cognitive-behaviour therapy provided by therapists. Main outcome measures Beck depression inventory scores, other psychiatric symptoms, social functioning, and satisfaction with treatment measured at baseline and at 4 and 12 months. Results 197 patients were randomly assigned to treatment, 137 chose their treatment, and 130 were randomised only between the two psychological therapies. All groups improved significantly over time. At four months, patients randomised to non-directive counselling or cognitive-behaviour therapy improved more in terms of the Beck depression inventory (mean (SD) scores 12.9 (9.3) and 14.3 (10.8) respectively) than those randomised to usual general practitioner care (18.3 (12.4)). However, there was no significant difference between the two therapies. There were no significant differences between the three treatment groups at 12 months (Beck depression scores 11.8 (9.6), 11.4 (10.8), and 12.1(10.3) for non-directive counselling, cognitive-behaviour therapy, and general practitioner care). Conclusions Psychological therapy was a more effective treatment for depression than usual general practitioner care in the short term, but after one year there was no difference in outcome.	Kings Coll London, Sch Med & Dent, Dept Palliat Care & Policy, London, England; UCL, Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England; Univ Manchester, NPCRDC, Manchester M13 9PL, Lancs, England; Univ Liverpool, Dept Primary Care, Liverpool L69 3BX, Merseyside, England; Univ Manchester, Sch Psychiat & Behav Sci, Dept Clin Psychol, Manchester M13 9PL, Lancs, England	University of London; King's College London; University of London; University College London; University of Manchester; University of Liverpool; University of Manchester	King, M (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England.	m.king@rfc.ucl.ac.uk	Bower, Peter/A-1508-2011; King, Michael B/D-7477-2011	Bower, Peter/0000-0001-9558-3349; King, Michael B/0000-0003-4715-7171; Gabbay, Mark/0000-0002-0126-8485				Beck A.T., 1987, BECK DEPRESSION INVE; BLACKBURN IM, 1981, BRIT J PSYCHIAT, V139, P181, DOI 10.1192/bjp.139.3.181; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; COOPER P, 1982, BRIT J PSYCHIAT, V141, P68, DOI 10.1192/bjp.141.1.68; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR., 1992, BRIEF SYMPTOM INVENT; DOBSON KS, 1989, J CONSULT CLIN PSYCH, V57, P414, DOI 10.1037/0022-006X.57.3.414; DOBSON KS, 1985, BRIT J CLIN PSYCHOL, V24, P295, DOI 10.1111/j.2044-8260.1985.tb00662.x; ELLIOTT R, 1988, BRIT J MED PSYCHOL, V61, P141, DOI 10.1111/j.2044-8341.1988.tb02773.x; Fairhurst K, 1996, J Health Serv Res Policy, V1, P77; Friedli K, 1997, LANCET, V350, P1662, DOI 10.1016/S0140-6736(97)05298-7; Greenberger D, 1995, MIND OVER MOOD; Greenberger D., 1995, CLIN GUIDE MIND MOOD; Harvey I, 1998, BRIT J GEN PRACT, V48, P1043; Hemmings A, 1997, PATIENT EDUC COUNS, V32, P219, DOI 10.1016/S0738-3991(97)00035-9; LEWIS G, 1988, PSYCHOL MED, V18, P737, DOI 10.1017/S0033291700008448; ROGERS C, 1967, PERSON THERAPISTS VI; Roth A., 1996, WHAT WORKS WHOM CRIT; SCOTT A, 1990, BRIT MED J, V304, P883; Scott C, 1997, BRIT J PSYCHIAT, V171, P131, DOI 10.1192/bjp.171.2.131; SIBBALD B, 1993, BMJ-BRIT MED J, V306, P29, DOI 10.1136/bmj.306.6869.29; SIBBALD B, 1996, ROLE COUNSELLORS GEN; TEASDALE JD, 1984, BRIT J PSYCHIAT, V144, P400, DOI 10.1192/bjp.144.4.400; Torgerson DJ, 1998, BRIT MED J, V316, P360, DOI 10.1136/bmj.316.7128.360; WHO, 1993, ICD 10 CLASS MENT BE	25	202	204	0	28	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1383	1388		10.1136/bmj.321.7273.1383	http://dx.doi.org/10.1136/bmj.321.7273.1383			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	380TT	11099284	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000165720100027
J	Sargent, P				Sargent, P			Too many memories - Sit down and tell me your story. I'm listening.	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					525	525		10.1038/35046173	http://dx.doi.org/10.1038/35046173			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117723	Bronze			2022-12-28	WOS:000165548600094
J	Oesterle, SN; Sanborn, TA; Ali, N; Resar, J; Ramee, SR; Heuser, R; Dean, L; Knopf, W; Schofield, P; Schaer, GL; Reeder, G; Masden, R; Yeung, AC; Burkhoff, D				Oesterle, SN; Sanborn, TA; Ali, N; Resar, J; Ramee, SR; Heuser, R; Dean, L; Knopf, W; Schofield, P; Schaer, GL; Reeder, G; Masden, R; Yeung, AC; Burkhoff, D			Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial	LANCET			English	Article							MYOCARDIAL REVASCULARIZATION; REFRACTORY ANGINA; MEDICAL THERAPY; BLOOD-FLOW; ANGIOGENESIS	Background Percutaneous transmyocardial laser revascularisation (PTMR) is a proposed catheter-based therapy for refractory angina pectoris when bypass surgery or angioplasty is not possible. We undertook a randomised trial to assess the safety and efficacy of this technique. Methods 221 patients with reversible ischaemia of Canadian Cardiovascular Society angina class 111 (61%) or IV (39%) and incomplete response to other therapies were recruited from 13 centres. Patients were randomly assigned PTMR with a holmium:YAG laser plus continued medical treatment (n=110) or continued medical treatment only (n=111). The primary endpoint was the exercise tolerance at 12 months. Analyses were by intention to treat. Findings 11 patients died and 19 withdrew; 92 PTMR-group and 99 medical-treatment-group patients completed the study. Exercise tolerance at 12 months had increased by a median of 89.0 s (IQR -15 to 183) with PTMR compared with 12.5 s (-67 to 125) with medical treatment only (p=0.008). On masked assessment, angina class was II or lower in 34.1% of PTMR patients compared with 13.0% of those medically treated. All indices of the Seattle angina questionnaire improved more with PTMR than with medical care only. By 12 months there had been eight deaths in the PTMR group and three in the medical treatment group, with similar survival in the two groups. Interpretation PTMR was associated with increased exercise tolerance time, low morbidity, lower angina scores assessed by masked reviewers, and improved quality of life. Although there is controversy about the mechanism of action, and the contribution of the placebo effect cannot be quantified, this unmasked study suggests that this palliative procedure provides some clinical benefits in the defined population of patients.	Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; New York Presbyterian Hosp, New York, NY USA; Baylor Univ VA Hosp, Houston, TX USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; Oschner Clin, New Orleans, LA USA; Columbia Hosp, Phoenix, AZ USA; Univ Alabama Birmingham, Birmingham, AL USA; St Josephs Hosp, Atlanta, GA USA; Papworth Hosp, Cambridge CB3 8RE, England; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Mayo Clin, Rochester, MN USA; Jewish Hosp, Louisville, KY USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Columbia Univ, New York, NY USA	Harvard University; Massachusetts General Hospital; NewYork-Presbyterian Hospital; Johns Hopkins University; Johns Hopkins Medicine; Ochsner Health System; University of Alabama System; University of Alabama Birmingham; Papworth Hospital; Rush University; Mayo Clinic; Stanford University; Columbia University	Oesterle, SN (corresponding author), Massachusetts Gen Hosp, Div Cardiol, Bulfinch 105,55 Fruit St, Boston, MA 02114 USA.	oesterle.stephen@mgh.harvard.edu	Burkhoff, Daniel/D-7674-2011	Dean, Larry/0000-0001-6462-3571				Al-Sheikh T, 1999, CIRCULATION, V100, P135, DOI 10.1161/01.CIR.100.2.135; Allen KB, 1999, NEW ENGL J MED, V341, P1029, DOI 10.1056/NEJM199909303411403; Burkhoff D, 1999, J AM COLL CARDIOL, V34, P55, DOI 10.1016/S0735-1097(99)00162-X; Burkhoff D, 1999, LANCET, V354, P885, DOI 10.1016/S0140-6736(99)08113-1; Frazier OH, 1999, NEW ENGL J MED, V341, P1021, DOI 10.1056/NEJM199909303411402; Kim CB, 1997, CATHETER CARDIO DIAG, V40, P223, DOI 10.1002/(SICI)1097-0304(199702)40:2<223::AID-CCD26>3.0.CO;2-Q; Kohmoto T, 1997, BASIC RES CARDIOL, V92, P45; Kohmoto T, 1997, ANN THORAC SURG, V63, P1275, DOI 10.1016/S0003-4975(97)00102-1; Kohmoto T, 1997, CIRCULATION, V95, P1585; Kohmoto T, 1996, ANN THORAC SURG, V61, P861, DOI 10.1016/0003-4975(95)01134-X; Kwong KF, 1997, J THORAC CARDIOV SUR, V114, P883, DOI 10.1016/S0022-5223(97)70001-1; Kwong KF, 1998, CIRCULATION, V98, pII67; Lauer B, 1999, J AM COLL CARDIOL, V34, P1663, DOI 10.1016/S0735-1097(99)00419-2; MIRHOSEINI M, 1988, ANN THORAC SURG, V45, P415, DOI 10.1016/S0003-4975(98)90015-7; Mukherjee D, 1999, AM J CARDIOL, V84, P598, DOI 10.1016/S0002-9149(99)00387-2; Nagele H, 1998, EUR HEART J, V19, P1525, DOI 10.1053/euhj.1998.1152; Oesterle SN, 1998, AM J CARDIOL, V82, P659, DOI 10.1016/S0002-9149(98)00384-1; Schofield PM, 1999, LANCET, V353, P519, DOI 10.1016/S0140-6736(98)11478-2; SPERTUS JA, 1995, J AM COLL CARDIOL, V25, P333, DOI 10.1016/0735-1097(94)00397-9; Yamamoto N, 1998, J AM COLL CARDIOL, V31, P1426, DOI 10.1016/S0735-1097(98)00086-2	20	131	136	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 18	2000	356	9243					1705	1710		10.1016/S0140-6736(00)03203-7	http://dx.doi.org/10.1016/S0140-6736(00)03203-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095257				2022-12-28	WOS:000165462300008
J	Salignon, P; Cabrol, JC; Liu, J; Legros, D; Brown, V; Ford, N				Salignon, P; Cabrol, JC; Liu, J; Legros, D; Brown, V; Ford, N			Health and war in Congo-Brazzaville	LANCET			English	Editorial Material									Med Sans Frontieres & Epictr, Paris, France		Salignon, P (corresponding author), Med Sans Frontieres & Epictr, 8 Rue St Sabin, Paris, France.							*MED SANS FRONT, 1999, CONG BRAZZ WAR CLOS	1	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1762	1762		10.1016/S0140-6736(00)03217-7	http://dx.doi.org/10.1016/S0140-6736(00)03217-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095274				2022-12-28	WOS:000165462300040
J	Guo, S; Yamaguchi, Y; Schilbach, S; Wada, T; Lee, J; Goddard, A; French, D; Handa, H; Rosenthal, A				Guo, S; Yamaguchi, Y; Schilbach, S; Wada, T; Lee, J; Goddard, A; French, D; Handa, H; Rosenthal, A			A regulator of transcriptional elongation controls vertebrate neuronal development	NATURE			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; SPT5; DSIF; PROTEIN; GENES; EXPRESSION; ZEBRAFISH; CELLS	The development of distinct vertebrate neurons is defined by the unique profiles of genes that neurons express. It is accepted that neural genes are regulated at the point of transcription initiation, but the role of messenger RNA elongation in neural gene regulation has not been examined(1-3). Here we describe the mutant foggy, identified in a genetic screen for mutations that affect neuronal development in zebrafish(4), that displayed a reduction of dopamine-containing neurons and a corresponding surplus of serotonin-containing neurons in the hypothalamus. Positional cloning disclosed that Foggy is a brain-enriched nuclear protein that is structurally related to the transcription elongation factor Spt5 (refs 5-12). Foggy is not part of the basic transcription apparatus but a phosphorylation-dependent, dual regulator of transcription elongation. The mutation disrupts its repressive but not its stimulatory activity. Our results provide molecular, genetic and biochemical evidence that negative regulators of transcription elongation control key aspects of neuronal development.	Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA; Tokyo Inst Technol, Dept Biol Informat, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Yokohama, Kanagawa 2268501, Japan	Roche Holding; Genentech; Roche Holding; Genentech; Tokyo Institute of Technology; Tokyo Institute of Technology	Rosenthal, A (corresponding author), Genentech Inc, Dept Mol Biol, 1 DNA Way, S San Francisco, CA 94080 USA.		Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X				Anderson D, 1997, MOL CELLULAR APPROAC, P26; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Guo S, 1999, DEV BIOL, V208, P473, DOI 10.1006/dbio.1999.9204; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Higashijima S, 1997, DEV BIOL, V192, P289, DOI 10.1006/dbio.1997.8779; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; Kyrpides NC, 1996, TRENDS BIOCHEM SCI, V21, P425, DOI 10.1016/S0968-0004(96)30036-4; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; SWANSON MS, 1992, GENETICS, V132, P325; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yamaguchi Y, 1998, GENES CELLS, V3, P9, DOI 10.1046/j.1365-2443.1998.00162.x; Zorick TS, 1999, DEVELOPMENT, V126, P1397	25	130	131	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					366	369		10.1038/35042590	http://dx.doi.org/10.1038/35042590			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099044				2022-12-28	WOS:000165296000047
J	Spence, K				Spence, K			Ancient Egyptian chronology and the astronomical orientation of pyramids	NATURE			English	Article								The ancient Egyptian pyramids at Giza have never been accurately dated, although we know that they were built approximately around the middle of the third millennium BC. The chronologies of this period have been reconstructed from surviving lists of kings and the lengths of their reigns, but the lists are rare, seldom complete and contain known inconsistencies and errors. As a result, the existing chronologies for that period (the Old Kingdom) can be considered accurate only to about +/- 100 years, a figure that radiocarbon dating cannot at present improve. Here I use trends in the orientation of Old Kingdom pyramids to demonstrate that the Egyptians aligned them to north by using the simultaneous transit of two circumpolar stars. Modelling the precession of these stars yields a date for the start of construction of the Great Pyramid that is accurate to +/- 5 yr, thereby providing an anchor for the Old Kingdom chronologies.	Univ Cambridge, Fac Oriental Studies, Cambridge CB3 9DA, England	University of Cambridge	Spence, K (corresponding author), Univ Cambridge, Fac Oriental Studies, Sidgwick Ave, Cambridge CB3 9DA, England.							ARNOLD D, 1987, PYRAMIDENBEZIRK KONI, V3; Arnold D., 1991, BUILDING EGYPT PHARA; ARNOLD D, 1988, PYRAMID SENWOSRET, V1; Baines J., 1989, ATLAS ANCIENT EGYPT; Dorner J., 1981, THESIS U INNSBRUCK; DORNER J, 1986, DTSCH ARCHAOLOGISC K, V42, P43; EDWARDS IES, 1993, PYRAMIDS EGYPT; ISLER M, 1989, J AM RES CTR EGYPT, V26, P191; KITCHEN KA, 1991, WORLD ARCHAEOL, V23, P201, DOI 10.1080/00438243.1991.9980172; Krauss R, 1996, J EGYPT ARCHAEOL, V82, P43, DOI 10.2307/3822113; MARRIOTT C, 1999, SKYMAP PRO VERSION 6; Petrie, 1883, PYRAMIDS TEMPLES GIZ; PETRIE WMF, 1982, MEDUM; STADELMANN R, 1990, GROSSEN PYRAMIDEN GI; STADELMANN R, 1986, MDAIK, V43, P229; VONBECKERATH J, 1997, CHRONOLOGIE PHARONIS; ZABA Z, 1953, ORIENTATION ASTRONOM	17	59	61	0	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					320	324		10.1038/35042510	http://dx.doi.org/10.1038/35042510			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099032				2022-12-28	WOS:000165296000035
J	Siegert, R; Leroux, MR; Scheufler, C; Hartl, FU; Moarefi, I				Siegert, R; Leroux, MR; Scheufler, C; Hartl, FU; Moarefi, I			Structure of the molecular chaperone prefoldin: Unique interaction of multiple coiled coil tentacles with unfolded proteins	CELL			English	Article							FOLDING IN-VIVO; CRYSTAL-STRUCTURE; SUBSTRATE-BINDING; POLYPEPTIDE-BINDING; ARCHAEAL CHAPERONIN; TRIGGER FACTOR; GROEL; COMPLEX; DNAK; PEPTIDE	Prefoldin (GimC) is a hexameric molecular chaperone complex built from two related classes of subunits and present in all eukaryotes and archaea. Prefoldin interacts with nascent polypeptide chains and, in vitro, can functionally substitute for the Hsp70 chaperone system in stabilizing non-native proteins for subsequent folding in the central cavity of a chaperonin. Here, we present the crystal structure and characterization of the prefoldin hexamer from the archaeum Methanobacterium thermoautotrophicum. Prefoldin has the appearance of a jellyfish: its body consists of a double beta barrel assembly with six long tentacle-like coiled coils protruding from it. The distal regions of the coiled coils expose hydrophobic patches and are required for multivalent binding of nonnative proteins.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Hartl, FU (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	uhartl@biochem.mpg.de; ismail@moarefi.com	Hartl, F. Ulrich/Y-8206-2019	Scheufler, Clemens/0000-0002-3693-3529				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Coyle JE, 1999, NAT STRUCT BIOL, V6, P683; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Gribaldo S, 1999, J BACTERIOL, V181, P434, DOI 10.1128/JB.181.2.434-443.1999; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; Kobayashi N, 1999, J MOL BIOL, V292, P181, DOI 10.1006/jmbi.1999.3042; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Leroux MR, 1999, EMBO J, V18, P6730, DOI 10.1093/emboj/18.23.6730; Leroux MR, 2000, CURR BIOL, V10, pR260, DOI 10.1016/S0960-9822(00)00432-2; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Saibil H, 2000, CURR OPIN STRUC BIOL, V10, P251, DOI 10.1016/S0959-440X(00)00074-9; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schoehn G, 2000, J MOL BIOL, V296, P813, DOI 10.1006/jmbi.2000.3505; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	63	246	252	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 10	2000	103	4					621	632		10.1016/S0092-8674(00)00165-3	http://dx.doi.org/10.1016/S0092-8674(00)00165-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	374MB	11106732	Bronze			2022-12-28	WOS:000165348000007
J	Armour, RH				Armour, RH			Manufacture and use of home made ophthalmoscopes: a 150th anniversary tribute to Helmholtz	BRITISH MEDICAL JOURNAL			English	Article								Objective To produce a simple, effective, and inexpensive training ophthalmoscope. Design Case study. Setting A coffee table in a sitting room and an eye clinic. Participants 10 friends and relatives, several patients, and a cooperative Persian cat. Interventions Direct ophthalmoscopy with instrument made with easily available material and tools from art and office equipment shops. Main outcome measures Efficiency, clarity of view, and price of ophthalmoscope. Results The instrument was readily made; of the 50 manufactured two thirds gave a good view; and each cost less than pound1 to make. Conclusion The ophthalmoscope is fun to make, works well, and anyone can make one.	Lister Hosp, Dept Surg, Stevenage SG1 4AB, Herts, England	Lister Hospital	Armour, RH (corresponding author), Lister Hosp, Dept Surg, Stevenage SG1 4AB, Herts, England.							DUKEELDER WS, 1938, TSB OPHTHALMOLOGY 2, V1, P1159; DUKEELDER WS, 1954, PARSONS DIS EYE, P90; FELDMANN H, 1995, LARYNGO RHINO OTOL, V74, P707, DOI 10.1055/s-2007-997830; HELMHOLTZ HV, 1951, BESCHREIBUNG AUGENSP; JONES RG, 1997, SMALL ANIMAL OPHTHAL, P51; TREVORROPER PD, 1984, EYE ITS DISORDER, P225	6	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1557	1559		10.1136/bmj.321.7276.1557	http://dx.doi.org/10.1136/bmj.321.7276.1557			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124172	Bronze, Green Published			2022-12-28	WOS:000166134500009
J	Norton, SA				Norton, SA			Tokelau on Naboo	BRITISH MEDICAL JOURNAL			English	Article											Norton, SA (corresponding author), 7506 Tarrytown Rd, Chevy Chase, MD 20815 USA.							BRADBURY R, 1986, MARTIAN CHRONICLES, P50; DAFONSECA O, 1972, ESSAYS TROPICAL DERM, P339; Fox T., 1874, LANCET, V2, P304; Hay R J, 1988, Curr Top Med Mycol, V2, P55; Heyerdahl Thor, 1950, KON TIKI PACIFIC RAF; Hildebrand M., 1985, P38; MACGREGOR G, 1937, ETHNOLOGY TOKELAU IS, P72; MANSON P, 1892, BRIT J DERMATOL, V4, P5; Manson P, 1878, MED REPORTS, V16, P1; REYNOLDS D, 1999, STAR WARS EPISODE 1, P36; VONDANIKEN E, 1973, GOLD GODS, P166; WELLS HG, 1960, WAR WORLDS, P188; WILKES C, 1845, NARRATIVE US EXPLORI, V5, P104	13	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1619	1620		10.1136/bmj.321.7276.1619	http://dx.doi.org/10.1136/bmj.321.7276.1619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124204	Green Published			2022-12-28	WOS:000166134500040
J	Shapin, S; Martyn, C				Shapin, S; Martyn, C			How to live forever: lessons of history	BRITISH MEDICAL JOURNAL			English	Article									Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England; Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA	University of Southampton; University of California System; University of California San Diego	Martyn, C (corresponding author), Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England.							ALMOND PC, 1999, ADAM EVE 17 CENTURY, P19; [Anonymous], GENESIS; CALMAN K, 1998, NUTR ASPECTS DEV CAN; Feudtner C, 2000, WESTERN J MED, V173, P64, DOI 10.1136/ewjm.173.1.64; GRMEK MD, 1958, MONOGRAPHIAE BIOL, V5; GRUMAN GJ, 1966, T AM PHIL SOC, V56; HAWKES N, 2000, TIMES           0411; Martyn, 1999, BMJ, V319, P1012; MONTAIGNE M, 1965, COMPLETE ESSAYS MONT, P815; Schneiderman LJ, 1995, WRONG MED DOCTORS PA; Shapin S, 2000, BRIT J HIST SCI, V33, P131, DOI 10.1017/S000708749900391X; SHAW GB, 1957, DOCTORS DILEMMA, P86; TRIMMER EJ, 1638, HIST LIFE DEATH, P188; Trimmer Eric J., 1967, REJUVENATION HIST ID; Webster Ch., 1975, GREAT INSTAURATION S, P246; LIFE DEATH 21 CENTUR	16	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1580	1582		10.1136/bmj.321.7276.1580	http://dx.doi.org/10.1136/bmj.321.7276.1580			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124187	Green Published, Green Submitted			2022-12-28	WOS:000166134500024
J	Bhatnagar, D; Morgan, J; Siddiq, S; Mackness, MI; Miller, JP; Durrington, PN				Bhatnagar, D; Morgan, J; Siddiq, S; Mackness, MI; Miller, JP; Durrington, PN			Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia	BRITISH MEDICAL JOURNAL			English	Article							SERUM LIPOPROTEIN(A); REGRESSION; DIAGNOSIS	Objectives To assess the feasibility of detecting new cases of heterozygous familial hypercholesterolaemia by using a nurse led genetic register. Design Case finding among relatives of patients with familial hypercholesterolaemia. Setting Two lipid clinics in central and south Manchester. Subjects 259 (137 men and 122 women) probands and 285 first degree relatives. Results Of the 200 first degree relatives tested, 121 (60%) had inherited familial hypercholesterolaemia. The newly diagnosed patients were younger than the probands and were generally detected before they had clinically overt atherosclerosis. Concentrations of serum cholesterol were, respectively, 8.4 (1.7 SD) mmol/l and 8.1 (1.9 SD) mmol/l in affected men and women and 5.6 (1.0 SD) mmol/l and 5.6 (1.1 SD) mmol/l in unaffected men and women. Screening for risk factors as recommended in recent guidelines for coronary heart disease prevention would have failed to identify most of the affected relatives in whom hypertension, diabetes mellitus, cigarette smoking, and obesity were uncommon. Conclusions By performing cholesterol tests on 200 relatives, 121 new patients with familial hypercholesterolaemia were discovered. Because 1 in 500 people in the United Kingdom affected by this condition, to detect a similar number by population screening over 60 000 tests would be required, and only a few of` these patients would have been detected had cholesterol testing been restricted to those with other risk factors for coronary heart disease. A case exists for organising a genetic register approach, linking lipid clinics nationally.	Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Univ S Manchester Hosp, Dept Gastroenterol, Manchester M20 2LR, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Durrington, PN (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England.							Andersen LK, 1997, ARCH INTERN MED, V157, P553, DOI 10.1001/archinte.157.5.553; BHATNAGAR D, 1995, LANCET, V345, P405; DEFESCHE JC, 1993, HUM GENET, V92, P567, DOI 10.1007/BF00420940; DONG W, 1996, HLTH SURVEY ENGLAND, P369; DURRINGTON PN, 1995, HYPERLIPIDAEMIA DIAG; GOLDMAN L, 1993, AM J CARDIOL, V72, pD75, DOI 10.1016/0002-9149(93)90015-5; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; HEIBERG A, 1977, BRIT MED J, V2, P493, DOI 10.1136/bmj.2.6085.493; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HUGGINS GS, 1996, ATHEROSCLEROSIS CORO, P835; Humphries SE, 1997, QJM-INT J MED, V90, P169, DOI 10.1093/qjmed/90.3.169; IRVINE MJ, 1994, J CLIN EPIDEMIOL, V47, P131; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; Laker M, 1991, Health Trends, V23, P147; MACKNESS MI, 1992, LIPOPROTEIN ANAL PRA; MBEWU AD, 1991, ARTERIOSCLER THROMB, V11, P940, DOI 10.1161/01.ATV.11.4.940; Neil HAW, 1999, ATHEROSCLEROSIS, V142, P105; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; TALMUD P, 1991, ATHEROSCLEROSIS, V89, P137, DOI 10.1016/0021-9150(91)90053-6; THOMPSON GR, 1995, LANCET, V345, P811, DOI 10.1016/S0140-6736(95)92961-4; THOROGOOD M, 1991, BRIT MED J, V303, P893; VONROGGREN FG, 1991, HUM GENET, V88, P204; WILLIAMS RR, 1993, AM J CARDIOL, V72, pD18, DOI 10.1016/0002-9149(93)90006-X; Wood D, 1998, HEART, V80, pS1	24	80	80	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	2000	321	7275					1497	1500A		10.1136/bmj.321.7275.1497	http://dx.doi.org/10.1136/bmj.321.7275.1497			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118175	Bronze, Green Published			2022-12-28	WOS:000165994700024
J	Stammers, T				Stammers, T			For and against - Doctors should advise adolescents to abstain from sex	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ABSTINENCE		Univ London St Georges Hosp, Sch Med, Dept Gen Practice, London SW17 0RE, England	St Georges University London	Stammers, T (corresponding author), Church Lane Practice, London SW19 3NY, England.	stammtg@globalnet.co.uk						Beitz J M, 1998, Holist Nurs Pract, V12, P27; CHALKE S, 1996, SEX MATTERS; COHEN MW, 1995, PEDIATR ANN, V24, P324, DOI 10.3928/0090-4481-19950601-10; *DEP HLTH, 1999, TEEN PREGN; DiIoro C, 1999, J ADOLESCENT HEALTH, V24, P181, DOI 10.1016/S1054-139X(98)00115-3; GENUIS SJ, 1995, LANCET, V345, P240, DOI 10.1016/S0140-6736(95)90229-5; Jemmott JB, 1998, JAMA-J AM MED ASSOC, V279, P1529, DOI 10.1001/jama.279.19.1529; KAY LE, 1995, POSTGRAD MED, V97, P121, DOI 10.1080/00325481.1995.11946008; POLLARD N, 1998, WHY DO THEY DO THAT; StuartSmith S, 1996, BRIT MED J, V312, P390; Wight D, 2000, BRIT MED J, V320, P1243, DOI 10.1136/bmj.320.7244.1243; WILLIAMS ES, 1995, BRIT MED J, V311, P807	12	10	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2000	321	7275					1520	1521		10.1136/bmj.321.7275.1520	http://dx.doi.org/10.1136/bmj.321.7275.1520			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118183	Green Published			2022-12-28	WOS:000165994700033
J	Anderson, JS; Lampl, I; Gillespie, DC; Ferster, D				Anderson, JS; Lampl, I; Gillespie, DC; Ferster, D			The contribution of noise to contrast invariance of orientation tuning in cat visual cortex	SCIENCE			English	Article							STOCHASTIC RESONANCE; SIMPLE CELLS; SELECTIVITY; NEURONS; PSYCHOPHYSICS; MODEL; INPUT	Feedforward models of visual cortex appear to be inconsistent with a well-known property of cortical cells: contrast invariance of orientation tuning. The models' fixed threshold broadens orientation tuning as contrast increases, whereas in real cells tuning width is invariant with contrast. We have compared the orientation tuning of spike and membrane potential responses in single cells. Both are contrast invariant, yet a threshold-linear relation applied to the membrane potential accurately predicts the orientation tuning of spike responses. The key to this apparent paradox lies in the noisiness of the membrane potential. Responses that are subthreshold on average are still capable of generating spikes on individual trials. Unlike the iceberg effect, contrast invariance remains intact even as threshold narrows orientation selectivity. Noise may, by extension, smooth the average relation between membrane potential and spike rate throughout the brain.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Northwestern University	Ferster, D (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, 2153 N Campus Dr, Evanston, IL 60208 USA.			Lampl, Ilan/0000-0002-9380-0730; Anderson, Jeffrey/0000-0002-9669-3846	NATIONAL EYE INSTITUTE [R01EY004726] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY04726] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alonso JM, 1996, NATURE, V383, P815, DOI 10.1038/383815a0; Anderson J, 2000, NAT NEUROSCI, V3, P617, DOI 10.1038/75797; BENYISHAI R, 1995, P NATL ACAD SCI USA, V92, P3844, DOI 10.1073/pnas.92.9.3844; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; BULSARA A, 1991, J THEOR BIOL, V152, P531, DOI 10.1016/S0022-5193(05)80396-0; Carandini M, 2000, J NEUROSCI, V20, P470, DOI 10.1523/JNEUROSCI.20-01-00470.2000; Chung S, 1998, NEURON, V20, P1177, DOI 10.1016/S0896-6273(00)80498-5; Ferster D, 2000, ANNU REV NEUROSCI, V23, P441, DOI 10.1146/annurev.neuro.23.1.441; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P427, DOI 10.1017/S095252380001124X; Ho N, 2000, J NEUROPHYSIOL, V84, P1488, DOI 10.1152/jn.2000.84.3.1488; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; Lampl I, 1999, NEURON, V22, P361, DOI 10.1016/S0896-6273(00)81096-X; LI CY, 1984, PFLUG ARCH EUR J PHY, V401, P304; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Reich DS, 1997, J NEUROPHYSIOL, V77, P2836, DOI 10.1152/jn.1997.77.5.2836; SCLAR G, 1982, EXP BRAIN RES, V46, P457; SKOTTUN BC, 1987, J NEUROPHYSIOL, V57, P773, DOI 10.1152/jn.1987.57.3.773; SOMERS DC, 1995, J NEUROSCI, V15, P5448; Sompolinsky H, 1997, CURR OPIN NEUROBIOL, V7, P514, DOI 10.1016/S0959-4388(97)80031-1; Troyer TW, 1998, J NEUROSCI, V18, P5908; Volgushev M, 2000, EUR J NEUROSCI, V12, P257, DOI 10.1046/j.1460-9568.2000.00909.x; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	23	305	310	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1968	1972		10.1126/science.290.5498.1968	http://dx.doi.org/10.1126/science.290.5498.1968			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11110664				2022-12-28	WOS:000165810000047
J	Kamisago, M; Sharma, SD; DePalma, SR; Solomon, S; Sharma, P; McDonough, B; Smoot, L; Mullen, MP; Woolf, PK; Wigle, ED; Seidman, JG; Seidman, CE				Kamisago, M; Sharma, SD; DePalma, SR; Solomon, S; Sharma, P; McDonough, B; Smoot, L; Mullen, MP; Woolf, PK; Wigle, ED; Seidman, JG; Seidman, CE			Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-LINKED GENE; HYPERTROPHIC CARDIOMYOPATHY; HEART-FAILURE; TROPONIN-C; MYOSIN; LOCUS; FREQUENCY; LINKAGE; DOMAIN; SYSTEM	Background: The molecular basis of idiopathic dilated cardiomyopathy, a primary myocardial disorder that results in reduced contractile function, is largely unknown. Some cases of familial dilated cardiomyopathy are caused by mutations in cardiac cytoskeletal proteins; this finding implicates defects in contractile-force transmission as one mechanism underlying this disorder. To elucidate this important cause of heart failure, we investigated other genetic causes of dilated cardiomyopathy. Methods: Clinical evaluations were performed in 21 kindreds with familial dilated cardiomyopathy. A genome-wide linkage study prompted a search of the genes encoding beta -myosin heavy chain, troponin T, troponin I, and alpha -tropomyosin for disease-causing mutations. Results: A genetic locus for mutations associated with dilated cardiomyopathy was identified at chromosome 14q11.2-13 (maximal lod score, 5.11; theta =0), where the gene for cardiac beta -myosin heavy chain is encoded. Analyses of this and other genes for sarcomere proteins identified disease-causing dominant mutations in four kindreds. Cardiac beta -myosin heavy-chain missense mutations (Ser532Pro and Phe764Leu) and a deletion in cardiac troponin T (Delta Lys210) caused early-onset ventricular dilatation (average age at diagnosis, 24 years) and diminished contractile function and frequently resulted in heart failure. Affected persons had neither antecedent cardiac hypertrophy (average maximal left-ventricular-wall thickness, 8.5 mm) nor histopathological findings characteristic of hypertrophy. Conclusions: Mutations in sarcomere protein genes account for approximately 10 percent of cases of familial dilated cardiomyopathy and are particularly prevalent in families with early-onset ventricular dilatation and dysfunction. Because distinct mutations in sarcomere proteins cause either dilated or hypertrophic cardiomyopathy, the effects of mutant sarcomere proteins on muscle mechanics must trigger two different series of events that remodel the heart. (N Engl J Med 2000;343:1688-96.) (C) 2000, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Div Cardiovasc, Boston, MA 02114 USA; New York Med Coll, Westchester Cty Med Ctr, Dept Pediat, Valhalla, NY 10595 USA; Univ Toronto, Toronto Gen Hosp, Dept Med, Toronto, ON M5G 1L7, Canada	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; New York Medical College; Westchester Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Seidman, CE (corresponding author), Harvard Univ, Sch Med, Dept Genet, Alpert Bldg,Rm 533,200 Longwood Ave, Boston, MA 02115 USA.			DePalma, Steven/0000-0002-0381-5016				Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Cohn JN, 1997, CIRCULATION, V95, P766; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; DAdamo P, 1997, AM J HUM GENET, V61, P862, DOI 10.1086/514886; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; DURAND JB, 1995, CIRCULATION, V92, P3387, DOI 10.1161/01.CIR.92.12.3387; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; HINA K, 1993, CLIN CARDIOL, V16, P403, DOI 10.1002/clc.4960160507; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Jha PK, 1996, BIOCHEMISTRY-US, V35, P16573, DOI 10.1021/bi9622433; Jung M, 1998, CIRCULATION, V98, P246; Kobayashi T, 1999, BIOCHEMISTRY-US, V38, P5386, DOI 10.1021/bi981320m; KRAJINOVIC M, 1995, AM J HUM GENET, V57, P846; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; Mestroni L, 1999, EUR HEART J, V20, P93, DOI 10.1053/euhj.1998.1145; Mestroni L, 1999, J AM COLL CARDIOL, V34, P181, DOI 10.1016/S0735-1097(99)00172-2; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RUSS AP, 1993, HUM MOL GENET, V2, P609, DOI 10.1093/hmg/2.5.609; SEIDMAN CE, 1999, MOL BASIS CARDIOVASC, P251; Siu BL, 1999, CIRCULATION, V99, P1022, DOI 10.1161/01.CIR.99.8.1022; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Towbin JA, 1999, NAT MED, V5, P266, DOI 10.1038/6474; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; TOWNSEND PJ, 1994, GENOMICS, V21, P311, DOI 10.1006/geno.1994.1271; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680	37	497	521	2	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2000	343	23					1688	1696		10.1056/NEJM200012073432304	http://dx.doi.org/10.1056/NEJM200012073432304			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380PX	11106718				2022-12-28	WOS:000165711900004
J	Paulson, S; Helser, A; Nardelli, MB; Taylor, RM; Falvo, M; Superfine, R; Washburn, S				Paulson, S; Helser, A; Nardelli, MB; Taylor, RM; Falvo, M; Superfine, R; Washburn, S			Tunable resistance of a carbon nanotube-graphite interface	SCIENCE			English	Article							CONTACT RESISTANCE	The transfer of electrons from one material to another is usually described in terms of energy conservation, with no attention being paid to momentum conservation. Here we present results on the junction resistance between a carbon nanotube and a graphite substrate and show that details of momentum conservation also can change the contact resistance. By changing the angular alignment of the atomic lattices, we found that contact resistance varied by more than an order of magnitude in a controlled and reproducible fashion, indicating that momentum conservation, in addition to energy conservation, can dictate the junction resistance in graphene systems such as carbon nanotube junctions and devices.	Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA; N Carolina State Univ, Dept Phys, Raleigh, NC 27695 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University	Falvo, M (corresponding author), Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA.		Nardelli, Marco Buongiorno/AAO-8938-2020; Superfine, Richard/A-1968-2012; Nardelli, Marco Buongiorno/C-9089-2009	Nardelli, Marco Buongiorno/0000-0003-0793-5055; Superfine, Richard/0000-0002-2569-071X; 				Bachtold A, 1999, NATURE, V397, P673, DOI 10.1038/17755; Bachtold A, 2000, PHYS REV LETT, V84, P6082, DOI 10.1103/PhysRevLett.84.6082; Bockrath M, 1999, NATURE, V397, P598, DOI 10.1038/17569; BUONGIORNO M, 1999, PHYS REV B, V60; Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801; Crespi VH, 1997, PHYS REV LETT, V79, P2093, DOI 10.1103/PhysRevLett.79.2093; Dai HJ, 1996, SCIENCE, V272, P523, DOI 10.1126/science.272.5261.523; Delaney P, 1999, APPL PHYS LETT, V75, P4028, DOI 10.1063/1.125527; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Falvo MR, 2000, PHYS REV B, V62, P10665, DOI 10.1103/PhysRevB.62.R10665; Falvo MR, 1999, NATURE, V397, P236, DOI 10.1038/16662; Frank S, 1998, SCIENCE, V280, P1744, DOI 10.1126/science.280.5370.1744; Fuhrer MS, 2000, SCIENCE, V288, P494, DOI 10.1126/science.288.5465.494; Maarouf AA, 2000, PHYS REV B, V61, P11156, DOI 10.1103/PhysRevB.61.11156; MINTMIRE JW, 1992, PHYS REV LETT, V68, P631, DOI 10.1103/PhysRevLett.68.631; Schonenberger C, 1999, APPL PHYS A-MATER, V69, P283, DOI 10.1007/s003390051003; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Tersoff J, 1999, APPL PHYS LETT, V75, P4030, DOI 10.1063/1.125529; Tersoff J, 1999, APPL PHYS LETT, V74, P2122, DOI 10.1063/1.123776; WALLACE PR, 1947, PHYS REV, V71, P622, DOI 10.1103/PhysRev.71.622; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	21	103	125	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1742	1744		10.1126/science.290.5497.1742	http://dx.doi.org/10.1126/science.290.5497.1742			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11099407				2022-12-28	WOS:000165632400035
J	Cyranoski, D				Cyranoski, D			Japan sets sights on success in nanotechnology	NATURE			English	Article																			0	3	3	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 30	2000	408	6812					624	624		10.1038/35046299	http://dx.doi.org/10.1038/35046299			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	377WE	11117757				2022-12-28	WOS:000165548600136
J	Catchpole, MA; McGarrigle, CA; Rogers, PA; Jordan, LF; Mercey, D; Gill, ON				Catchpole, MA; McGarrigle, CA; Rogers, PA; Jordan, LF; Mercey, D; Gill, ON			Serosurveillance of prevalence of undiagnosed HIV-1 infection in homosexual men with acute sexually transmitted infection	BRITISH MEDICAL JOURNAL			English	Article							GENITOURINARY MEDICINE CLINICS; ATTENDERS; ENGLAND		Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV STI Sect, London NW9 5EQ, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Stat Unit, London NW9 5EQ, England; UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England	Public Health England; Public Health England; University of London; University College London; UCL Medical School	Catchpole, MA (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV STI Sect, London NW9 5EQ, England.	mcatchpole@phls.nhs.uk	McGarrigle, Christine/J-8331-2017	McGarrigle, Christine/0000-0001-5814-5673				Catchpole M, 1997, GENITOURIN MED, V73, P457; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; *HIV SURV STEER GR, 1999, PREV HIV UK DAT END; NARDONE A, 1995, AIDS RES WORKSH ABST, P5; Simms I, 1999, SEX TRANSM INFECT, V75, P332, DOI 10.1136/sti.75.5.332	5	10	10	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1319	1320		10.1136/bmj.321.7272.1319	http://dx.doi.org/10.1136/bmj.321.7272.1319			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090514	Bronze, Green Published			2022-12-28	WOS:000165561600025
J	Rothman, KJ				Rothman, KJ			Epidemiological evidence on health risks of cellular telephones	LANCET			English	Review							CANCER INCIDENCE; BRAIN-TUMORS; TELEVISION TRANSMITTERS; GREAT-BRITAIN; MORTALITY; EXPOSURE; MICROWAVE; RADIO; RADIOFREQUENCY	It Is too soon for a verdict on the health risks from cellular telephones, especially in view of changing technology. From the Interphone project and some other large studies in progress, beater information may emerge. Based on the epidemiological evidence available now, the main public-health concern is clearly motor vehicle collisions, a behavioural effect rather than an effect of radiofrequency exposure as such. Neither the several studies of occupational exposure to radiofrequencies nor the few of cellular telephone users offer any clear evidence of an association with brain tumours or other malignancies. Even If the studies In progress were to find large relative effects for brain cancer, the absolute increase in risk would probably be much smaller than the risk stemming from motor vehicle collisions. Cellular telephones affect the quality of our lives in myriad ways, for good and ill; the health risk is just one part of a picture that is slowly coming into focus.	Epidemiol Res Inst, Newton Lower Falls, MA 02462 USA		Rothman, KJ (corresponding author), Epidemiol Res Inst, 1 Newton Execut Pk, Newton Lower Falls, MA 02462 USA.	KRothman@aol.com		Rothman, Kenneth/0000-0003-2398-1705				Ahlbom A, 1999, INT J ONCOL, V15, P1045; Blettner M, 2000, Epidemiology, V11, P609, DOI 10.1097/00001648-200009000-00020; Dolk H, 1997, AM J EPIDEMIOL, V145, P10, DOI 10.1093/oxfordjournals.aje.a009026; Dolk H, 1997, AM J EPIDEMIOL, V145, P1, DOI 10.1093/oxfordjournals.aje.a009025; Dreyer NA, 1999, JAMA-J AM MED ASSOC, V282, P1814, DOI 10.1001/jama.282.19.1814-a; Dreyer NA, 1999, RADIAT PROT DOSIM, V83, P159, DOI 10.1093/oxfordjournals.rpd.a032653; Funch DP, 1996, EPIDEMIOLOGY, V7, P299, DOI 10.1097/00001648-199605000-00014; GANDHI OP, 1995, RADIO SCI, V30, P161, DOI 10.1029/94RS01158; Grayson JK, 1996, AM J EPIDEMIOL, V143, P480, DOI 10.1093/oxfordjournals.aje.a008768; Hardell L, 1999, INT J ONCOL, V15, P113; Hayes DL, 1997, NEW ENGL J MED, V336, P1473, DOI 10.1056/NEJM199705223362101; HILL D, 1988, THESIS J HOPKINS U B; Hocking B, 1996, MED J AUSTRALIA, V165, P601, DOI 10.5694/j.1326-5377.1996.tb138661.x; Inskip PD, 1999, RADIAT PROT DOSIM, V86, P45, DOI 10.1093/oxfordjournals.rpd.a032924; Lamble D, 1999, ACCIDENT ANAL PREV, V31, P617, DOI 10.1016/S0001-4575(99)00018-4; LILIENFELD AM, PB28816O NTIS; LIPMAN RM, 1988, SURV OPHTHALMOL, V33, P200, DOI 10.1016/0039-6257(88)90088-4; Maskarinec Gertraud, 1994, Journal of Environmental Pathology Toxicology and Oncology, V13, P33; MILHAM S, 1988, AM J EPIDEMIOL, V127, P50, DOI 10.1093/oxfordjournals.aje.a114790; Morgan RW, 2000, EPIDEMIOLOGY, V11, P118, DOI 10.1097/00001648-200003000-00007; Occhetta E, 1999, PACE, V22, P983, DOI 10.1111/j.1540-8159.1999.tb00561.x; Redelmeier DA, 1997, NEW ENGL J MED, V336, P453, DOI 10.1056/NEJM199702133360701; ROBINETTE CD, 1980, AM J EPIDEMIOL, V112, P39, DOI 10.1093/oxfordjournals.aje.a112975; Rothman KJ, 1996, EPIDEMIOLOGY, V7, P291, DOI 10.1097/00001648-199605000-00013; Rothman KJ, 1996, EPIDEMIOLOGY, V7, P303, DOI 10.1097/00001648-199605000-00015; SELVIN S, 1992, SOC SCI MED, V34, P769, DOI 10.1016/0277-9536(92)90364-V; Stewart W., 2000, INDEPENDENT EXPERT G; Szmigielski S, 1996, SCI TOTAL ENVIRON, V180, P9, DOI 10.1016/0048-9697(95)04915-0; Van Leeuwen GMJ, 1999, PHYS MED BIOL, V44, P2367, DOI 10.1088/0031-9155/44/10/301	29	68	69	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 25	2000	356	9244					1837	1840		10.1016/S0140-6736(00)03244-X	http://dx.doi.org/10.1016/S0140-6736(00)03244-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117928				2022-12-28	WOS:000165545700041
J	Grevemeyer, I; Herber, R; Essen, HH				Grevemeyer, I; Herber, R; Essen, HH			Microseismological evidence for a changing wave climate in the northeast Atlantic Ocean	NATURE			English	Article							TEMPERATURE; SURFACE; HEIGHT; WINTER	One possible consequence of a change in climate over the past several decades is an increase in wave heights, potentially threatening coastal areas as well as the marine industry(1-4). But the difficulties in observing wave heights exacerbates a general problem of climate-change detection: inhomogeneities in long-term observational records owing to changes in the instruments or techniques used, which may cause artificial trends(5,6). Ground movements with periods of 4-16 seconds, known as microseisms, are associated with ocean waves and coastal surf(7-10), and have been recorded continuously since the early days of seismology. Here we use such a 40-year record of wintertime microseisms from Hamburg, Germany, to reconstruct the wave climate in the northeast Atlantic Ocean. For the period 1954-77, we detect an average of seven days per month with strong microseismic activity, without a significant trend. This number increases significantly in the second half of the record, reaching approximately 14 days of strong microseisms per month. The implied increase in northeast Atlantic wave height over the past 20 years parallels increased surface air temperatures(11) and storminess(12) in this region, suggesting a common forcing.	Univ Bremen, Dept Earth Sci, D-28359 Bremen, Germany; Univ Hamburg, Geophys Observ, D-21075 Hamburg, Germany; Univ Hamburg, Inst Oceanog, D-22529 Hamburg, Germany	University of Bremen; University of Hamburg; University of Hamburg	Grevemeyer, I (corresponding author), Univ Bremen, Dept Earth Sci, Klagenfurter Str Bldg GEO, D-28359 Bremen, Germany.		Grevemeyer, Ingo/E-5162-2016	Grevemeyer, Ingo/0000-0002-6807-604X				Alexandersson H., 1998, GLOBAL ATMOSPHERE OC, V6, P97; [Anonymous], 1904, GERL BEITR GEOPHYS; BATH M, 1949, 14 ROYAL U UPPS; Berz G., 1994, ECODECISION, V12, P65; BERZ GA, 1993, INTERDISCIPL SCI REV, V18, P120; Bijl W, 1997, CLIMATE RES, V8, P45, DOI 10.3354/cr008045; Bouws E, 1996, B AM METEOROL SOC, V77, P2275, DOI 10.1175/1520-0477(1996)077<2275:TIWHIT>2.0.CO;2; Bromirski PD, 1999, J GEOPHYS RES-OCEANS, V104, P20753, DOI 10.1029/1999JC900156; Carretero JC, 1998, B AM METEOROL SOC, V79, P741, DOI 10.1175/1520-0477(1998)079<0765:TSERBD>2.0.CO;2; CARTER DJT, 1988, NATURE, V332, P494, DOI 10.1038/332494a0; Conrad V., 1962, METHODS CLIMATOLOGY; DARBYSHIRE J, 1990, PHYS EARTH PLANET IN, V63, P181, DOI 10.1016/0031-9201(90)90017-R; ESSEN HH, 1999, GERM J HYDROGR, V51, P33; GUNTHER H, 1998, GLOBAL ATMOS OCEAN S, V6, P121; GUTENBERG B, 1947, J METEOROL, V4, P21, DOI 10.1175/1520-0469(1947)004<0021:MAWF>2.0.CO;2; GUTENBERG B, 1921, VEROFF ZENTR BUR INT, P106; HASSELMANN K, 1963, REV GEOPHYS, V1, P177, DOI 10.1029/RG001i002p00177; Jones P, 1995, ANALYSIS OF CLIMATE VARIABILITY, P53; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; KARL TR, 1993, J CLIMATE, V6, P1481, DOI [10.1175/1520-0442(1993)006<1481:DCVACN>2.0.CO;2, 10.1175/1520-0442(1993)006&lt;1481:DCVACN&gt;2.0.CO;2]; LONGUETHIGGINS MS, 1948, NATURE, V162, P700, DOI 10.1038/162700a0; LONGUETHIGGINS MS, 1950, PHILOS TR R SOC S-A, V243, P1, DOI 10.1098/rsta.1950.0012; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; Rodwell MJ, 1999, NATURE, V398, P320, DOI 10.1038/18648; Santer BD, 1996, NATURE, V382, P39, DOI 10.1038/382039a0; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; STOUFFER RJ, 1994, NATURE, V367, P634, DOI 10.1038/367634a0; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164; *WASA GROUP, 1994, T R I NAVAL ARCH, V137, P107	29	102	104	0	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					349	352		10.1038/35042558	http://dx.doi.org/10.1038/35042558			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11099039				2022-12-28	WOS:000165296000042
J	Bassler, D; Antes, G; Egger, M				Bassler, D; Antes, G; Egger, M			Non-English reports of medical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Freiburg, German Cochrane Ctr, Freiburg, Germany; Univ Bristol, Dept Social Med, Bristol, Avon, England	University of Freiburg; University of Bristol	Bassler, D (corresponding author), Univ Freiburg, German Cochrane Ctr, Freiburg, Germany.			Bassler, Dirk/0000-0003-2358-4419; Egger, Matthias/0000-0001-7462-5132				Bauder FH, 2000, Z GEBURTSH NEONATOL, V204, P68, DOI 10.1055/s-2000-10199; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Egger M, 1998, BRIT MED J, V316, P140; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417	5	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					2996	2997		10.1001/jama.284.23.2996	http://dx.doi.org/10.1001/jama.284.23.2996			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122582				2022-12-28	WOS:000165847200019
J	Wilson, DR				Wilson, DR			Gender vs sex	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Creighton Univ, Dept Psychiat, Omaha, NE 68178 USA; Creighton Univ, Dept Anthropol, Omaha, NE 68178 USA	Creighton University; Creighton University	Wilson, DR (corresponding author), Creighton Univ, Dept Psychiat, Omaha, NE 68178 USA.							Paglia Camille, 1990, SEXUAL PERSONAE; Simpson JL, 2000, JAMA-J AM MED ASSOC, V284, P1568, DOI 10.1001/jama.284.12.1568; WILSON DR, 1994, ACTA BIOTHEOR, V42, P49, DOI 10.1007/BF00706839	3	7	7	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					2997	2998		10.1001/jama.284.23.2997	http://dx.doi.org/10.1001/jama.284.23.2997			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122583				2022-12-28	WOS:000165847200021
J	Burger, GT; Swauger, JE				Burger, GT; Swauger, JE			Health consequences of eclipse cigarettes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									RJ Reynolds Tobacco Co, Winston Salem, NC 27102 USA	R. J. Reynolds Tobacco Company	Burger, GT (corresponding author), RJ Reynolds Tobacco Co, Winston Salem, NC 27102 USA.							Borgerding MF, 1998, FOOD CHEM TOXICOL, V36, P169, DOI 10.1016/S0278-6915(97)00108-7; Environmental Protection Agency (EPA), 1991, PUBL US EPA; Stephenson J, 2000, JAMA-J AM MED ASSOC, V283, P2507, DOI 10.1001/jama.283.19.2507; Swauger JE, 2000, INHAL TOXICOL, V12, P1071; Swauger JE, 1999, CANCER EPIDEM BIOMAR, V8, P835; WAGNER BM, 2000, INHAL TOXICOL S5, V12, P1	6	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					2995	2996		10.1001/jama.284.23.2995	http://dx.doi.org/10.1001/jama.284.23.2995			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382VC	11122579				2022-12-28	WOS:000165847200017
